0001802768-21-000006.txt : 20210224 0001802768-21-000006.hdr.sgml : 20210224 20210224090206 ACCESSION NUMBER: 0001802768-21-000006 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 89 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210224 DATE AS OF CHANGE: 20210224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Royalty Pharma plc CENTRAL INDEX KEY: 0001802768 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39329 FILM NUMBER: 21668962 BUSINESS ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 883-0200 MAIL ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 10-K 1 rprx-20201231.htm 10-K rprx-20201231
00018027682020FYFALSEus-gaap:AccountingStandardsUpdate201601Memberus-gaap:AccountingStandardsUpdate201613Member200180200200200180180180Related to the pro rata portion of RPIFT's outstanding debt repaid by the Legacy Investors PartnershipsRelated to the achievement of a sales-based milestone that was not paid as of December 31, 2020. 00018027682020-01-012020-12-31iso4217:USD00018027682020-06-30xbrli:shares0001802768us-gaap:CommonClassAMember2021-02-190001802768us-gaap:CommonClassBMember2021-02-190001802768rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember2020-11-012020-11-3000018027682020-12-3100018027682019-12-31iso4217:USDxbrli:shares0001802768us-gaap:CommonClassAMember2020-12-310001802768us-gaap:CommonClassAMember2019-12-310001802768us-gaap:CommonClassBMember2019-12-310001802768us-gaap:CommonClassBMember2020-12-31iso4217:GBPxbrli:shares0001802768rprx:ClassRRedeemableStockMember2020-12-310001802768rprx:ClassRRedeemableStockMember2019-12-310001802768rprx:FinancialRoyaltyAssetsMember2020-01-012020-12-310001802768rprx:FinancialRoyaltyAssetsMember2019-01-012019-12-310001802768rprx:FinancialRoyaltyAssetsMember2018-01-012018-12-310001802768rprx:IntangibleRoyaltyAssetsMember2020-01-012020-12-310001802768rprx:IntangibleRoyaltyAssetsMember2019-01-012019-12-310001802768rprx:IntangibleRoyaltyAssetsMember2018-01-012018-12-310001802768rprx:RoyaltyIncomeOtherMember2020-01-012020-12-310001802768rprx:RoyaltyIncomeOtherMember2019-01-012019-12-310001802768rprx:RoyaltyIncomeOtherMember2018-01-012018-12-3100018027682019-01-012019-12-3100018027682018-01-012018-12-310001802768rprx:UnitholdersContributionsMember2017-12-310001802768us-gaap:RetainedEarningsMember2017-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2017-12-310001802768us-gaap:NoncontrollingInterestMember2017-12-310001802768us-gaap:TreasuryStockMember2017-12-3100018027682017-12-310001802768us-gaap:RetainedEarningsMember2018-01-012018-12-310001802768us-gaap:NoncontrollingInterestMember2018-01-012018-12-3100018027682017-01-012017-12-310001802768srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2017-12-310001802768srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2017-12-310001802768srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2017-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2018-01-012018-12-310001802768rprx:UnitholdersContributionsMember2018-12-310001802768us-gaap:RetainedEarningsMember2018-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2018-12-310001802768us-gaap:NoncontrollingInterestMember2018-12-310001802768us-gaap:TreasuryStockMember2018-12-3100018027682018-12-310001802768us-gaap:RetainedEarningsMember2019-01-012019-12-310001802768us-gaap:NoncontrollingInterestMember2019-01-012019-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2019-01-012019-12-310001802768us-gaap:TreasuryStockMember2019-01-012019-12-310001802768rprx:UnitholdersContributionsMember2019-12-310001802768us-gaap:RetainedEarningsMember2019-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2019-12-310001802768us-gaap:NoncontrollingInterestMember2019-12-310001802768us-gaap:TreasuryStockMember2019-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2019-12-310001802768us-gaap:CommonClassBMemberus-gaap:CommonStockMember2019-12-310001802768rprx:ClassRRedeemableStockMemberus-gaap:CommonStockMember2019-12-310001802768rprx:DeferredSharesMember2019-12-310001802768us-gaap:AdditionalPaidInCapitalMember2019-12-310001802768rprx:ShareholdersContributionsMember2020-01-012020-12-310001802768us-gaap:NoncontrollingInterestMember2020-01-012020-12-310001802768srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2019-12-310001802768srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310001802768us-gaap:RetainedEarningsMember2020-01-012020-12-310001802768rprx:ClassRRedeemableStockMemberus-gaap:CommonStockMember2020-01-012020-12-310001802768us-gaap:RetainedEarningsMember2020-01-012020-06-170001802768us-gaap:NoncontrollingInterestMember2020-01-012020-06-1700018027682020-01-012020-06-170001802768us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-01-012020-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-01-012020-12-310001802768rprx:DeferredSharesMember2020-01-012020-12-310001802768us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2020-01-012020-12-310001802768us-gaap:TreasuryStockMember2020-01-012020-12-310001802768us-gaap:RetainedEarningsMember2020-06-182020-12-310001802768us-gaap:NoncontrollingInterestMember2020-06-182020-12-3100018027682020-06-182020-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-12-310001802768us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-12-310001802768rprx:ClassRRedeemableStockMemberus-gaap:CommonStockMember2020-12-310001802768rprx:DeferredSharesMember2020-12-310001802768us-gaap:AdditionalPaidInCapitalMember2020-12-310001802768rprx:ShareholdersContributionsMember2020-12-310001802768us-gaap:RetainedEarningsMember2020-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001802768us-gaap:NoncontrollingInterestMember2020-12-310001802768us-gaap:TreasuryStockMember2020-12-31xbrli:pure0001802768rprx:LegacyInvestorsPartnershipsMemberrprx:ExchangeOfferTransactionMember2020-02-112020-02-110001802768rprx:RoyaltyPharmaInvestmentsOldRPIMemberrprx:ExchangeOfferTransactionMember2020-02-110001802768rprx:RoyaltyPharmaCollectionTrustMember2020-02-110001802768rprx:RoyaltyPharmaCollectionTrustMemberrprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember2020-02-110001802768rprx:LegacyInvestorsPartnershipsMemberrprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Memberus-gaap:SecuredDebtMember2020-02-110001802768rprx:RPI2019IntermediateFinanceMemberrprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Memberus-gaap:SecuredDebtMember2020-02-110001802768rprx:OldCreditFacilityMemberus-gaap:SecuredDebtMember2020-02-112020-02-110001802768rprx:RPI2019IntermediateFinanceMemberrprx:RPIFTSeniorSecuredCreditFacilitiesMemberus-gaap:SecuredDebtMember2020-02-112020-02-110001802768us-gaap:IPOMemberus-gaap:CommonClassAMember2020-06-182020-06-180001802768us-gaap:IPOMemberus-gaap:CommonClassAMember2020-06-180001802768us-gaap:CommonClassAMemberrprx:IPOSharesFromCompanyMember2020-06-182020-06-180001802768rprx:IPOSharesFromSellingShareholdersMemberus-gaap:CommonClassAMember2020-06-182020-06-180001802768us-gaap:IPOMember2020-06-182020-06-180001802768us-gaap:CommonClassAMember2020-06-012020-06-300001802768us-gaap:CommonClassBMemberrprx:IPOContinuingInvestorsPartnershipsMember2020-06-012020-06-300001802768rprx:LegacyInvestorsPartnershipsMemberrprx:RoyaltyPharmaInvestmentsOldRPIMember2020-02-29rprx:partnership0001802768rprx:ContinuingInvestorsPartnershipMemberrprx:RPHoldingsMember2020-12-310001802768srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2019-12-310001802768srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2019-01-012019-12-310001802768rprx:VertexMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:FinanceReceivablesMember2020-01-012020-12-310001802768rprx:VertexMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:FinanceReceivablesMember2019-01-012019-12-31rprx:segment0001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Member2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForwardContractsMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForwardContractsMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember2020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel2Member2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2020-12-310001802768rprx:ImmunomedicsMember2020-01-012020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2019-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2019-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2019-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2019-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Member2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2019-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMember2019-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel2Member2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2019-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForwardContractsMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForwardContractsMember2019-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember2019-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2019-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001802768us-gaap:AvailableforsaleSecuritiesMember2019-12-310001802768us-gaap:AvailableforsaleSecuritiesMember2018-12-310001802768us-gaap:AvailableforsaleSecuritiesMember2020-01-012020-12-310001802768us-gaap:AvailableforsaleSecuritiesMember2019-01-012019-12-310001802768us-gaap:AvailableforsaleSecuritiesMember2020-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:AvailableforsaleSecuritiesMember2020-01-012020-12-310001802768us-gaap:ForwardContractsMember2019-12-310001802768us-gaap:ForwardContractsMember2020-01-012020-12-310001802768us-gaap:ForwardContractsMember2020-12-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-12-310001802768rprx:ValuationTechniqueBlackDermanTroyMemberus-gaap:FairValueInputsLevel3Memberrprx:ChangeOfControlProbabilityMember2019-12-310001802768rprx:ValuationTechniqueBlackDermanTroyMemberrprx:LikelihoodOfFDAApprovalMemberus-gaap:FairValueInputsLevel3Membersrt:MinimumMember2019-12-310001802768rprx:ValuationTechniqueBlackDermanTroyMemberrprx:LikelihoodOfFDAApprovalMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMember2019-12-310001802768rprx:LikelihoodOfFDAApprovalAtEndOfAnyGivenQuarterBy2024Memberrprx:ValuationTechniqueBlackDermanTroyMemberus-gaap:FairValueInputsLevel3Membersrt:MinimumMember2019-12-310001802768rprx:LikelihoodOfFDAApprovalAtEndOfAnyGivenQuarterBy2024Memberrprx:ValuationTechniqueBlackDermanTroyMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMember2019-12-310001802768us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-310001802768us-gaap:SeriesBPreferredStockMember2020-01-012020-12-310001802768us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2020-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-12-310001802768us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2019-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2019-12-310001802768us-gaap:PreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMembersrt:MaximumMember2019-04-052019-04-050001802768us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember2020-01-012020-12-310001802768rprx:InterestRateSwapDueNovember2020Member2019-12-310001802768rprx:InterestRateSwapDueMarch20231Member2019-12-310001802768rprx:InterestRateSwapDueMarch20232Member2019-12-310001802768rprx:InterestRateSwapDueMarch20233Member2019-12-310001802768rprx:InterestRateSwapDueMarch20234Member2019-12-310001802768us-gaap:InterestRateSwapMember2020-01-012020-12-310001802768us-gaap:InterestRateSwapMember2019-01-012019-12-310001802768us-gaap:InterestRateSwapMember2018-01-012018-12-310001802768us-gaap:InterestRateSwapMember2019-12-310001802768rprx:EpizymeIncMember2019-11-300001802768rprx:EpizymeIncMember2019-11-012019-11-300001802768rprx:EpizymeCommonStockWarrantMember2019-11-300001802768rprx:EpizymeCommonStockWarrantMemberrprx:EpizymeIncMember2019-11-300001802768rprx:EpizymeIncMemberus-gaap:PutOptionMember2019-11-012019-11-300001802768rprx:EpizymeIncMemberus-gaap:PutOptionMember2019-11-300001802768us-gaap:ForwardContractsMember2019-12-310001802768us-gaap:WarrantMember2020-12-310001802768us-gaap:WarrantMember2019-12-310001802768us-gaap:WarrantMember2020-01-012020-12-310001802768us-gaap:WarrantMember2019-01-012019-12-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2019-04-052019-04-050001802768us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2019-04-050001802768us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:GainLossOnDerivativeInstrumentsMember2020-01-012020-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:GainLossOnDerivativeInstrumentsMember2019-01-012019-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:GainLossOnDerivativeInstrumentsMember2018-01-012018-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2020-01-012020-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2019-01-012019-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2018-01-012018-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:NondesignatedMember2020-01-012020-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:NondesignatedMember2019-01-012019-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:NondesignatedMember2018-01-012018-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMemberus-gaap:NondesignatedMember2020-01-012020-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMemberus-gaap:NondesignatedMember2019-01-012019-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMemberus-gaap:NondesignatedMember2018-01-012018-12-310001802768us-gaap:WarrantMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:NondesignatedMember2020-01-012020-12-310001802768us-gaap:WarrantMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:NondesignatedMember2019-01-012019-12-310001802768us-gaap:WarrantMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:NondesignatedMember2018-01-012018-12-310001802768us-gaap:ForwardContractsMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:NondesignatedMember2020-01-012020-12-310001802768us-gaap:ForwardContractsMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:NondesignatedMember2019-01-012019-12-310001802768us-gaap:ForwardContractsMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:NondesignatedMember2018-01-012018-12-310001802768us-gaap:PreferredStockMember2020-12-310001802768us-gaap:PreferredStockMember2019-12-310001802768us-gaap:SeriesAPreferredStockMember2019-04-052019-04-050001802768us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2020-08-072020-08-070001802768us-gaap:SeriesBPreferredStockMember2020-08-072020-08-070001802768rprx:RoyaltyPharmaInvestmentFinancialTrustMember2018-01-012018-12-310001802768rprx:RoyaltyPharmaInvestmentFinancialTrustMemberrprx:TecfideraMember2018-12-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMembersrt:MaximumMember2019-04-052019-04-050001802768us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember2019-04-052019-04-050001802768us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember2020-08-072020-08-070001802768us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember2020-08-072020-08-070001802768rprx:CysticFibrosisFranchiseMember2020-12-310001802768rprx:TysabriMember2020-12-310001802768rprx:ImbruvicaMember2020-12-310001802768rprx:XtandiMember2020-12-310001802768rprx:PromactaMember2020-12-310001802768rprx:EvrysdiMember2020-12-310001802768rprx:OtherFinancialRoyaltyAssetMember2020-12-310001802768rprx:CysticFibrosisFranchiseMember2019-12-310001802768rprx:TysabriMember2019-12-310001802768rprx:ImbruvicaMember2019-12-310001802768rprx:XtandiMember2019-12-310001802768rprx:PromactaMember2019-12-310001802768rprx:CrysvitaMember2019-12-310001802768rprx:OtherFinancialRoyaltyAssetMember2019-12-310001802768rprx:CysticFibrosisFranchiseMembersrt:MinimumMember2019-11-012019-11-300001802768rprx:CysticFibrosisFranchiseMembersrt:MaximumMember2019-11-012019-11-300001802768rprx:CysticFibrosisFranchiseMember2019-01-012019-12-310001802768rprx:DPPIVPatentsMember2020-12-310001802768rprx:DPPIVPatentsMember2019-12-310001802768rprx:DPPIVPatentsMember2020-01-012020-12-310001802768rprx:IndividualLicenseesConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-12-310001802768rprx:IndividualLicenseesConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-01-012019-12-310001802768rprx:IndividualLicenseesConcentrationRiskMemberus-gaap:SalesRevenueNetMember2018-01-012018-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-02-110001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-01-012020-12-310001802768rprx:AvillionEntitiesMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-01-012020-12-310001802768rprx:AvillionEntitiesMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2019-01-012019-12-310001802768rprx:AvillionEntitiesMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2018-01-012018-12-310001802768rprx:AvillionIMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-01-012020-12-310001802768rprx:AvillionIMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2019-01-012019-12-310001802768rprx:MerckAssetPhaseIIClinicalTrialMemberrprx:AvillionIIMember2019-12-310001802768rprx:MerckAssetPhaseIIClinicalTrialMemberrprx:AvillionIIMember2017-03-310001802768rprx:AvillionIIMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-01-012020-12-310001802768rprx:AZAssetPhaseIIAndPhaseIIIClinicalTrialMemberrprx:AvillionIIMember2018-05-310001802768rprx:AvillionEntitiesMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-12-310001802768rprx:AvillionEntitiesMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2019-12-310001802768rprx:FundingAgreementsWithSanofiMember2020-01-012020-12-310001802768rprx:FundingAgreementsWithSanofiMember2019-01-012019-12-310001802768rprx:FundingAgreementsWithPfizerMember2019-01-012019-12-310001802768rprx:FundingAgreementsWithSanofiMember2018-01-012018-12-310001802768rprx:FundingAgreementsWithPfizerMember2018-01-012018-12-310001802768rprx:FundingAgreementWithImmunomedicsMember2018-01-012018-12-310001802768rprx:FundingAgreementWithBiohavenMember2018-01-012018-12-310001802768rprx:FundingAgreementsWithSanofiMember2020-12-310001802768rprx:PointSevenFivePercentSeniorNotesDue2023Memberus-gaap:UnsecuredDebtMember2020-01-012020-12-310001802768rprx:PointSevenFivePercentSeniorNotesDue2023Memberus-gaap:UnsecuredDebtMember2020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:OnePointTwoZeroPercentSeniorNotesDue2025Member2020-01-012020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:OnePointTwoZeroPercentSeniorNotesDue2025Member2020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:OnePointSevenFivePercentSeniorNotesDue2027Member2020-01-012020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:OnePointSevenFivePercentSeniorNotesDue2027Member2020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member2020-01-012020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member2020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member2020-01-012020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member2020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointFiveFivePercentSeniorNotesDue2050Member2020-01-012020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointFiveFivePercentSeniorNotesDue2050Member2020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:RPIFTSeniorSecuredCreditFacilitiesMember2020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:RPIFTSeniorSecuredCreditFacilitiesMember2019-12-310001802768us-gaap:LondonInterbankOfferedRateLIBORMemberrprx:RPIFTSeniorSecuredCreditFacilitiesTrancheB6Memberus-gaap:SecuredDebtMember2019-01-012019-12-310001802768rprx:RPIFTSeniorSecuredCreditFacilitiesTrancheB6Memberus-gaap:SecuredDebtMember2019-12-310001802768us-gaap:LondonInterbankOfferedRateLIBORMemberrprx:RPIFTSeniorSecuredCreditFacilitiesTrancheA4Memberus-gaap:SecuredDebtMember2019-01-012019-12-310001802768rprx:RPIFTSeniorSecuredCreditFacilitiesTrancheA4Memberus-gaap:SecuredDebtMember2019-12-310001802768us-gaap:UnsecuredDebtMember2020-12-310001802768us-gaap:SecuredDebtMember2019-12-310001802768us-gaap:UnsecuredDebtMemberrprx:TheNotesMember2020-09-020001802768us-gaap:UnsecuredDebtMemberrprx:TheNotesMember2020-12-310001802768us-gaap:UnsecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberrprx:TheNotesMember2020-09-022020-09-020001802768us-gaap:UnsecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberrprx:TheNotesMember2020-09-022020-09-020001802768us-gaap:UnsecuredDebtMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2020-09-182020-09-180001802768us-gaap:UnsecuredDebtMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2020-09-180001802768us-gaap:UnsecuredDebtMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberrprx:OvernightBankFundingRateMemberus-gaap:RevolvingCreditFacilityMember2020-09-182020-09-180001802768us-gaap:UnsecuredDebtMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberus-gaap:FederalFundsPurchasedMemberus-gaap:RevolvingCreditFacilityMember2020-09-182020-09-180001802768us-gaap:UnsecuredDebtMemberus-gaap:LondonInterbankOfferedRateLIBORMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2020-09-182020-09-180001802768rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Memberus-gaap:SecuredDebtMember2020-02-110001802768rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Memberus-gaap:SecuredDebtMember2020-02-110001802768us-gaap:LondonInterbankOfferedRateLIBORMemberrprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Memberus-gaap:SecuredDebtMember2020-02-112020-02-110001802768us-gaap:LondonInterbankOfferedRateLIBORMemberrprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Memberus-gaap:SecuredDebtMember2020-02-112020-02-110001802768rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Memberus-gaap:SecuredDebtMember2020-09-012020-09-300001802768rprx:RPIFTSeniorSecuredCreditFacilitiesMemberus-gaap:SecuredDebtMember2020-02-012020-02-290001802768rprx:RPIFTSeniorSecuredCreditFacilitiesMemberus-gaap:SecuredDebtMember2019-12-310001802768us-gaap:UnsecuredDebtMemberrprx:TheNotesMemberus-gaap:FairValueInputsLevel2Member2020-12-310001802768rprx:SecondaryOfferingMemberus-gaap:CommonClassAMember2020-10-012020-10-310001802768rprx:SecondaryOfferingMemberus-gaap:CommonClassAMember2020-10-310001802768rprx:IPOContinuingInvestorsPartnershipsMemberrprx:SecondaryOfferingMemberus-gaap:CommonClassAMember2020-10-012020-10-310001802768rprx:SecondaryOfferingMemberrprx:ContinuingInvestorsPartnershipMemberus-gaap:CommonClassAMember2020-10-012020-10-310001802768us-gaap:CommonClassBMemberrprx:SecondaryOfferingMemberrprx:ContinuingInvestorsPartnershipMember2020-10-012020-10-310001802768rprx:ClassRRedeemableStockMember2020-01-012020-12-31rprx:noncontrolling_interest0001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2019-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2019-12-310001802768rprx:ContinuingInvestorsPartnershipMemberus-gaap:NoncontrollingInterestMember2019-12-310001802768rprx:EPAHoldingsMemberus-gaap:NoncontrollingInterestMember2019-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2020-01-012020-12-310001802768rprx:ContinuingInvestorsPartnershipMemberus-gaap:NoncontrollingInterestMember2020-01-012020-12-310001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2020-01-012020-12-310001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2020-01-012020-06-170001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2020-01-012020-06-170001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2020-06-182020-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2020-06-182020-12-310001802768rprx:ContinuingInvestorsPartnershipMemberus-gaap:NoncontrollingInterestMember2020-06-182020-12-310001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2020-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2020-12-310001802768rprx:ContinuingInvestorsPartnershipMemberus-gaap:NoncontrollingInterestMember2020-12-310001802768rprx:EPAHoldingsMemberus-gaap:NoncontrollingInterestMember2020-12-310001802768rprx:RPHoldingsMember2020-12-310001802768rprx:A2020EquityIncentivePlanMemberus-gaap:CommonClassAMember2020-06-150001802768rprx:A2020EquityIncentivePlanMemberus-gaap:CommonClassAMember2020-12-310001802768us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001802768us-gaap:RestrictedStockUnitsRSUMember2020-12-310001802768us-gaap:CommonClassAMember2020-01-012020-12-310001802768rprx:ClassBHoldersMember2020-01-012020-12-310001802768rprx:LegacyInvestorsPartnershipsAndRPSFTMember2020-01-012020-12-310001802768rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember2017-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2017-12-310001802768us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2017-12-310001802768us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310001802768rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember2018-01-012018-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-01-012018-12-310001802768us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2018-01-012018-12-310001802768srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberrprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember2017-12-310001802768srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2017-12-310001802768srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2017-12-310001802768rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember2018-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-12-310001802768us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2018-12-310001802768us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001802768rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember2019-01-012019-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-01-012019-12-310001802768us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2019-01-012019-12-310001802768rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember2019-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310001802768us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2019-12-310001802768us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001802768rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember2020-01-012020-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-12-310001802768us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-01-012020-12-310001802768us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001802768rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember2020-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310001802768us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-12-310001802768us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001802768us-gaap:InterestIncomeMember2020-01-012020-12-310001802768rprx:OperatingAndPersonnelPaymentsMembersrt:ManagementMember2020-12-310001802768rprx:OperatingAndPersonnelPaymentsMembersrt:ManagementMember2020-01-012020-12-310001802768rprx:FormerOperatingAndPersonnelPaymentsMembersrt:ManagementMember2020-01-012020-12-310001802768rprx:FormerOperatingAndPersonnelPaymentsMembersrt:ManagementMember2019-01-012019-12-310001802768rprx:FormerOperatingAndPersonnelPaymentsMembersrt:ManagementMember2018-01-012018-12-310001802768srt:AffiliatedEntityMemberrprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember2020-12-310001802768srt:AffiliatedEntityMemberrprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember2020-12-310001802768rprx:BristolMyersSquibbMembersrt:AffiliatedEntityMemberrprx:AssignmentAgreementBenefitOfPaymentStreamMember2017-12-082017-12-080001802768rprx:BristolMyersSquibbMembersrt:AffiliatedEntityMemberrprx:AssignmentAgreementFundingObligationsMember2017-12-082017-12-080001802768rprx:BristolMyersSquibbMember2020-01-012020-12-310001802768rprx:BristolMyersSquibbMember2019-01-012019-12-310001802768rprx:BristolMyersSquibbMemberrprx:PaymentsToRelatedPartyFundedByAcquisitionsMember2020-01-012020-12-310001802768rprx:BristolMyersSquibbMemberrprx:PaymentsToRelatedPartyFundedByAcquisitionsMember2019-01-012019-12-310001802768rprx:BristolMyersSquibbMembersrt:AffiliatedEntityMemberrprx:AssignmentAgreementFundingObligationsMember2020-12-310001802768rprx:BristolMyersSquibbMembersrt:AffiliatedEntityMemberrprx:AssignmentAgreementFundingObligationsMember2019-12-310001802768srt:ChiefExecutiveOfficerMemberrprx:PurchasingAndDonatingVentilatorsMember2020-01-012020-12-310001802768srt:AffiliatedEntityMemberrprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember2020-01-012020-12-310001802768srt:AffiliatedEntityMemberrprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMemberus-gaap:TreasuryStockMember2020-01-012020-12-310001802768srt:AffiliatedEntityMemberrprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMemberus-gaap:NoncontrollingInterestMember2020-01-012020-12-310001802768srt:AffiliatedEntityMemberrprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMemberus-gaap:NoncontrollingInterestMember2019-01-012019-12-310001802768rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember2020-08-072020-08-070001802768rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember2019-11-012019-11-300001802768rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember2020-01-012020-01-310001802768rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMembersrt:ScenarioForecastMember2021-11-012021-11-300001802768us-gaap:SubsequentEventMember2021-01-012021-01-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2020
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 001-39329
Royalty Pharma plc
(Exact name of registrant as specified in its charter)
England and Wales
98-1535773
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
110 East 59th Street
New York, New York 10022
(Address of principal executive offices and Zip Code)
(212) 883-0200
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A ordinary shares, par value $0.0001
RPRXThe Nasdaq Global Select Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes  ☐    No  ☒

Indicate by check mark whether the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐     No ☒ 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐ 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes  ☒   No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer  
☒
Smaller reporting company
☐
Emerging growth company
☐
                
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes  ☐     No  ☒

The aggregate market value of the voting and non-voting ordinary shares held by non-affiliates of the registrant as of June 30, 2020, the last business day of the registrant's most recently completed second fiscal quarter, was approximately $4.2 billion based upon the closing price reported for such date on the Nasdaq Global Select Market. This determination of affiliate status is not necessarily a conclusive determination for any other purposes.

As of February 19, 2021, Royalty Pharma plc had 388,134,040 Class A ordinary shares outstanding and 218,976,830 Class B ordinary shares outstanding.

DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement relating to the Annual Meeting of Shareholders, or Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2020. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof.





ROYALTY PHARMA PLC
PART I
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
PART II
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
PART III
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
PART IV
Item 15.
Item 16.











Special Note Regarding Forward-Looking Statements

This Annual Report on Form 10-K contains statements reflecting our views about our future performance that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about us, our current and prospective assets, our industry, our beliefs and our assumptions. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed in Part I under Item 1A. “Risk Factors” in this Annual Report on Form 10-K.

These risks and uncertainties include factors related to:
•sales risks of biopharmaceutical products on which we receive royalties;
•the ability of RP Management, LLC (the “Manager”) to locate suitable assets for us to acquire;
•uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add development-stage product candidates and late stage funding opportunities to our product portfolio;
•the assumptions underlying our business model;
•our ability to successfully execute our royalty acquisition strategy;
•our ability to leverage our competitive strengths;
•actual and potential conflicts of interest with the Manager and its affiliates;
•the ability of the Manager or its affiliates to attract and retain highly talented professionals;
•the effect of changes to tax legislation and our tax position; and
•the risks, uncertainties and other factors we identify elsewhere in this Annual Report on Form 10-K and in our other filings with the SEC.

Although we believe the expectations reflected in the forward-looking statements are reasonable, any of those expectations could prove to be inaccurate, and as a result, the forward-looking statements based on those expectations also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this Annual Report on Form 10-K should not be regarded as a representation by us that our plans and business objectives will be achieved. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. We are under no duty to update any of these forward-looking statements after the date of this Annual Report on Form 10-K to conform our prior statements to actual results or revised expectations.






PART I     
Item 1.         BUSINESS

Overview

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, which includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

Our capital-efficient business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, including long product life cycles, significant barriers to entry and non-cyclical revenues, but with substantially reduced exposure to many common industry challenges such as early stage development risk, therapeutic area constraints, high research and development costs, and high fixed manufacturing and marketing costs. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies across the biopharmaceutical industry.

The success of our business has been the result of a focused strategy of actively identifying and tracking the development and commercialization of key new therapies, allowing us to move quickly to make acquisitions when opportunities arise. We acquire royalties on approved products, often in the early stages of their commercial launches, and development-stage product candidates with strong proof of concept data, mitigating development risk and expanding our opportunity set. From 1996 through 2020, we have deployed more than $20 billion of cash to acquire biopharmaceutical royalties, representing approximately 50% of all royalty transactions during this period. From 2012, when we began acquiring royalties on development-stage product candidates, through 2020, we have deployed more than $15 billion of cash to acquire biopharmaceutical royalties, representing approximately 60% of all royalty transactions during this period.

In 2020, we generated cash from operating activities of $2.03 billion, Adjusted Cash Receipts (as defined in “—Non-GAAP Financial Results”) of $1.80 billion and Adjusted Cash Flow (as defined in “—Non-GAAP Financial Results”) of $1.48 billion. We deployed $2.3 billion of cash in 2020 for royalties and related assets.

Portfolio Overview

Our current portfolio includes royalties on more than 45 commercial products and five development-stage product candidates. Growth Products are defined as royalties with a duration beyond December 31, 2020. We define all other royalties on approved products as Mature Products. We believe that end market sales of the therapies in our portfolio are important drivers of our financial performance as a substantial portion of our royalties are based on end market sales. In addition, end market sales are a strong indicator of the importance of the therapies to both patients and the marketers. The following table provides an overview of our current portfolio of royalties:

1

Product(s)Marketer(s)Product Detail2020 Royalty Receipts (in millions)
2020 End Market Sales (in millions)(1)
Growth Portfolio (Approved Products)
Cystic fibrosis
franchise (2)
Vertex Portfolio of therapies for the treatment of cystic fibrosis $551.3 $6,203 
TysabriBiogen Therapy for the treatment of relapsing forms of multiple sclerosis345.81,946 
ImbruvicaAbbVie,
Johnson & Johnson 		Therapy for the treatment of hematological malignancies and chronic GVHD322.16,612 
HIV franchise (3)
Gilead, others Portfolio of therapies for the treatment and prevention of HIV 293.816,890 
XtandiPfizer, Astellas
Therapy for the treatment of prostate cancer
146.44,170 
Januvia, Janumet, Other DPP-IVsMerck, others
Portfolio of therapies for the treatment of diabetes
143.89,007 
PromactaNovartis Therapy for the treatment of chronic ITP and aplastic anemia 143.71,738 
Farxiga/OnglyzaAstraZeneca Therapies for the treatment of diabetes25.0 2,434 
PrevymisMerck Therapy for prophylaxis of CMV in adult recipients of stem cell transplant21.5281 
EmgalityEli Lilly Therapy for the treatment of migraine prevention & episodic cluster headache9.5363 
CrysvitaUltragenyx, Kyowa Kirin Therapy for the treatment of X-linked hypophosphatemia 9.5398 
ErleadaJohnson & Johnson Therapy for the treatment of prostate cancer7.9760 
IDHIFABristol Myers SquibbTherapy for the treatment of relapsed/refractory AML with an IDH2 mutation6.1Not Disclosed
TrodelvyGilead Therapy for the treatment of metastatic triple-negative breast cancer 3.0 137 
Nurtec ODTBiohaven Therapy for the treatment of migraine 0.764 
TazverikEpizyme Therapy for the treatment for epithelioid sarcoma and follicular lymphoma 0.512 
EvrysdiRoche Therapy for the treatment of spinal muscular atrophy 0.3 61 
OrladeyoBioCryst
Therapy for the treatment of hereditary angioedema prophylaxis
 Approved Dec 2020
Other Growth Products (4)(5)
246.59,848 
Total Royalty Receipts - Growth Products$2,277.4 $60,924 
Mature Portfolio (Approved Products)
LetairisGilead, GlaxoSmithKlineTherapy for the treatment of pulmonary arterial hypertension$40.2 $493 
LyricaPfizer Therapy for the treatment of neuropathic pain22.9 1,425 
Other Mature Products (6)
3.9 65 
Total Mature Portfolio (Approved Products)$67.0 $1,983 
Development Stage Product Candidates
ZavegepantBiohaven Potential therapy for the treatment and prevention of migraine (Phase III)— — 
PT027Astrazeneca Potential therapy for the treatment of asthma (Phase III) — — 
Seltorexant (7)
Johnson & Johnson Potential therapy for the treatment of MDD with insomnia symptoms (Phase III)— — 
Omecamtiv mercarbil (8)
Cytokinetics Potential therapy for the treatment of heart failure (Phase III)— — 
BCX9930BioCryst Potential therapy for the treatment of PNH (Phase I)— — 
GVHD is Graft Versus Host Disease, ITP is Immune Thrombocytopenic Purpura, CMV is Cytomegalovirus, AML is Acute Myelogenous Leukemia, MDD is Major Depressive Disorder and PNH is Paroxysmal Nocturnal Hemoglobinuria.
Notes:
(1)     Represents end market sales for calendar year 2020 as reported by respective product marketers or based on EvaluatePharma projections where marketers have not reported. Sales shown for Crysvita represent EMEA only. Royalty receipts lag product performance by one quarter and can be estimated by applying our publicly disclosed royalty rate to the preceding quarter’s marketer-announced net revenues on a product-by-product basis.
(2)     The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio.
(3)     The HIV franchise includes the following approved products: Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza and Biktarvy; royalties are received on the emtricitabine portion of sales only.
(4)     Excludes duplicate end-market sales where we have multiple royalties on the same product: Kombiglyze, Nesina, Onglyza and Soliqua.
(5)     Other Growth Products include royalties on the following products: Bosulif, Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy and Soliqua. Other Growth Products also include contributions from the Legacy SLP Interest, a distribution from Avillion in respect of the Merck KGaA’s anti-IL 17 nanobody M1095 (the “Merck KGaA Asset”), for which development ceased in 2020 and a payment from Biohaven in respect of an expired option to exercise additional funding of the Biohaven Series A Preferred Shares.
(6)     Other Mature Products primarily include royalties on the following products: Prezista and Thalomid.
(7)     Royalty was acquired in January 2021.
(8)     The financial royalty asset associated with omecamtiv mercarbil was written off in the three months ended December 31, 2020 given the uncertainty around the future of omecamtiv.
2


Biopharmaceutical Industry and the Role of Royalties

Our business is supported by significant growth and unprecedented innovation within the biopharmaceutical industry. Global prescription pharmaceutical sales are expected to grow from approximately $0.9 trillion in 2020 to approximately $1.3 trillion in 2025, representing a CAGR of 7% according to EvaluatePharma despite nearly $125 billion in cumulative sales being lost to expected patent expiries during the same period. The growth of the biopharmaceutical industry is driven by global secular trends, including population growth, increasing life expectancy and growth of the middle classes in emerging markets. In addition, a dramatic acceleration of medical research in recent years has led to a better understanding of the molecular origins of disease and identification of potential targets for therapeutic intervention. This has created research and development opportunities for new drugs. The significant pace of biopharmaceutical innovation coupled with the proliferation of new biotechnology companies and the increasing cost of drug development has created a significant capital need over recent years that we believe will provide a sustainable tailwind for our business.

Royalties play a fundamental and growing role in the biopharmaceutical industry. As a result of the increasing cost and complexity of drug development, the creation of a new drug today typically involves a number of industry participants. Academia and other research institutions conduct basic research and license new technologies to industry for further development. Biotechnology companies typically in-license these new technologies, add value through applied research and early-stage clinical development, and then either out-license the resulting development-stage product candidates to large biopharmaceutical companies for late-stage clinical development and commercialization, or commercialize the products themselves. As new drugs are transferred along this value chain, royalties are created as compensation for the licensing or selling institutions. Biotechnology companies are also increasingly creating royalties on existing products within their portfolios, known as synthetic royalties, in order to provide a source of non-dilutive capital to fund their businesses. As a result of this industry paradigm, the development of a single new drug can lead to the creation of multiple royalties. Given our leadership position within the biopharmaceutical royalty sector, we are able to capitalize on the growing volumes of royalties that are created as new therapies are developed to address unmet medical needs.

Our Business Model

We believe that the following elements of our business and product portfolio provide a unique and compelling proposition to investors seeking exposure to the biopharmaceutical sector.

Our portfolio provides direct exposure to a broad array of blockbuster therapies. In 2020, our portfolio included royalties on 20 therapies that each generated end-market sales of more than $1 billion, including seven therapies that each generated end-market sales of more than $3 billion. The therapies within our royalty portfolio are marketed by leading global biopharmaceutical companies for whom these products are important sources of revenue. Given the marketers’ significant focus on and investment in these products, they are motivated to invest substantial resources in driving continued sales growth.

Our portfolio is highly diversified across products, therapeutic areas and marketers. Our portfolio consists of royalties on more than 45 marketed biopharmaceutical therapies which address a wide range of therapeutic areas, including rare diseases, cancer, neurology, HIV, cardiology and diabetes. In the year ended December 31, 2020, no individual therapy accounted for more than 15% of our royalty receipts, no therapeutic area accounted for more than 24% of our royalty receipts and no marketer represented more than 24% of our royalty receipts. The royalties in our portfolio entitle us to payments based directly on the top-line sales of the associated therapies, rather than the profits of these therapies. As such, the diversification of our profits directly reflects the diversification of our royalty receipts, rather than varying levels of product-level profitability, as would typically be expected within a biopharmaceutical company. The graphic below shows the diversification within our 2020 royalty receipts by product, therapeutic area and marketer.
3

rprx-20201231_g1.jpg

Notes:
(1)    Comprised of royalty receipts from Truvada, Genvoya, Biktarvy and several other emtricitabine products.
(2)    Comprised of royalty receipts from Januvia, Janumet and several other DPP-IVs.

The key growth-driving royalties in our portfolio are protected by long patent lives. The estimated weighted average royalty duration of our portfolio is approximately 15 years based on projected cumulative cash royalty receipts. Our largest marketed royalty in 2020 was on Vertex’s cystic fibrosis franchise, and existing patent applications covering Trikafta, the most significant product in that franchise, are expected to provide exclusivity through 2037. Our right to receive royalties is perpetual, but we expect that the 2037 patent expiration for Trikafta may result in potential sales declines based on potential generic entry. Several of our marketed royalties have unlimited durations and could provide cash flows for many years after key patents have expired.

Simple and efficient operating model generates substantial cash flow for reinvestment in new biopharmaceutical royalties. Our capital-efficient operating model requires limited operating expenses and no material capital investment in fixed assets or infrastructure in order to support the ongoing growth of our business. As a result, we generate high Adjusted Cash Flow relative to our Adjusted Cash Receipts and we convert the vast majority of our Adjusted Cash Flow into operating cash flow. In 2020, we generated cash from operating activities of $2.0 billion, Adjusted Cash Receipts of $1.8 billion and Adjusted Cash Flow of $1.5 billion. We deployed $2.3 billion of cash in 2020 for new royalties and related assets. Our high cash flow conversion provides us with significant capital that we can deploy for new royalty acquisitions, while also growing our dividend to shareholders.

Our business model captures many of the most attractive aspects of the biopharmaceutical industry, but with reduced exposure to many common industry challenges. The biopharmaceutical industry benefits from a number of highly attractive characteristics, including long product life cycles, significant barriers to entry and non-cyclical revenues. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies from across the biopharmaceutical industry. We focus on the acquisition of royalties on approved products or development-stage product candidates that have generated strong proof of concept data, avoiding the risks associated with early stage research and development. By acquiring royalties, we are able to realize payments based directly on the top-line sales of leading biopharmaceutical therapies, without the costs associated with fixed research and development, manufacturing and commercial infrastructure.

Our unique role in the biopharmaceutical ecosystem positions us to benefit from multiple compounding growth drivers. As a result of our significant scale and highly flexible business model, we believe that we are uniquely positioned to capitalize on multiple compounding growth drivers: an accelerating understanding of the molecular origins of disease, technological innovation leading to the creation of new treatment modalities, increasing number of biopharmaceutical industry participants with significant capital needs, competitive industry dynamics which reward companies that can rapidly execute broad clinical development programs, increasing FDA drug approvals which reached an all-time high in 2018 and the potential for multiple royalties to be created from each new drug that reaches the market.

4

We have the ability to access innovation from across the biopharmaceutical ecosystem. Our approach is to first assess innovative science in areas of significant unmet medical need and then evaluate how to acquire royalties on therapies that we believe are attractive. We closely follow a broad range of therapeutic areas and treatment modalities and are therefore able to move quickly when we identify compelling opportunities to acquire new royalties.

We have deep access to attractively priced investment grade debt that provides a significant cost of capital advantage. We believe that we have an attractive cost of capital that enables us to acquire high-quality biopharmaceutical royalties at competitive prices while still creating value for our shareholders. As of December 31, 2020, we had an aggregate principal amount of $6.0 billion of senior unsecured notes outstanding with a weighted average coupon of 2.125% and a weighted-average maturity of approximately 12 years. In addition, we have an undrawn $1.5 billion five-year unsecured revolving credit facility (the “Revolving Credit Facility”) that we entered into on September 18, 2020.

We have a talented, long-tenured team with extensive experience and deep industry relationships. Our team has significant experience identifying, evaluating and acquiring royalties on biopharmaceutical therapies. Together they have been responsible for $20 billion of acquisitions of biopharmaceutical royalties and related assets. Our acquisitions have included many of the industry’s leading therapies across the past three decades, such as Humira, Imbruvica, Trikafta, Lyrica, Tecfidera, Xtandi, Neupogen and Rituxan, among others. Our long history of collaboration has resulted in deep relationships with a broad range of participants across the biopharmaceutical industry.

We are the leader in acquiring biopharmaceutical royalties. We are the leader within the space, having executed transactions with an aggregate transaction value of $20 billion of cash. We estimate this to represent an estimated market share of more than 50% by value. This compares to our next nearest competitor, which we believe has executed $2.4 billion of transactions, which we estimate to represent market share of 6%. Given the scale of our business relative to our competitors, we have a particularly strong leadership position within large royalty transactions. Since 1996, there have been 15 transactions with an aggregate value of more than $500 million each. From 1996 through December 31, 2020, we executed 13 of the 15 royalty transactions, for a total aggregate transaction value of $13.5 billion of cash and estimated market share of more than 80%, in this transaction size range. The charts below show our market share since 1996 across all transaction sizes and in royalty transactions with an aggregate value of more than $500 million.
rprx-20201231_g2.jpg


5

Our Strategic Plan to Grow the Portfolio

We intend to grow our business by continuing to partner with constituents across the biopharmaceutical value chain to fund innovation. The three key pillars of our growth strategy are summarized below.

• Acquisition of royalties on approved products which provide dependable cash flows. We intend to continue capturing a leading share of royalties on approved products, particularly those that are early in their life cycles, so that we can participate in the growth that is generated as they penetrate their markets, and enter new indications or geographies.

• Acquisition of royalties on attractive development-stage product candidates. We intend to supplement our diverse portfolio of royalties on approved products with acquisitions of royalties on development-stage product candidates that have generated strong clinical proof of concept data, we can minimize risk while providing attractive upside potential.

• Acquisition of royalties in connection with merger and acquisition (M&A) transactions. We acquire royalties in connection with M&A transactions in a number of ways: by purchasing non-strategic assets following the closing of acquisitions, by partnering with biopharmaceutical companies to acquire other biopharmaceutical companies that own significant royalties, or in select circumstances, by seeking to acquire biopharmaceutical companies on our own that have significant royalties or products that could be out-licensed to create royalties.

We acquire royalties in a number of ways including by acquiring existing royalties, acquiring new synthetic royalties and by funding R&D in exchange for future royalties. During the early years of our business, we focused our acquisitions on royalties on approved biopharmaceutical products. However, as we grew and diversified our business, we began acquiring royalties on development-stage product candidates that had demonstrated strong clinical proof of concept. These development-stage transactions have broadened our landscape of potential opportunities where we are able to leverage our scientific expertise and financial strength.

From 2012 through December 31, 2020, we deployed $7.0 billion of cash to acquire royalties on development-stage product candidates. Products underlying $6.3 billion of these acquisitions have already been approved, representing a success rate of 90%, while products underlying $0.4 billion were not approved and products underlying $0.2 billion are still in development.
rprx-20201231_g3.jpg

Notes:
(1)     Reflects cash deployed for royalty acquisitions from 2012 through 2020.
(2)     Includes Epizyme equity investment; Tazverik not yet approved in Japan.
(3)     Includes $100 million Cytokinetics/omecamtiv investment; includes $16 million in R&D funding for Merck KGaA’s anti-IL 17 nanobody M1095, for which we received a cash payment of 1.25 times upon termination of development.


6

In recent years, we have increased the scope of our investments beyond royalties to include additional assets such as equity investments and the acquisition of businesses with significant royalty assets. Our broad scope maximizes our total addressable market and has allowed us to provide a broad range of solutions to our partners across the biopharmaceutical ecosystem.
Our approach is to first assess innovative science in areas of significant unmet medical need and then evaluate how to acquire royalties on therapies that we believe are attractive. We have a strong base of institutional knowledge of important therapeutic areas and key industry trends. Our team of scientific experts actively monitors the evolving treatment landscape across many therapeutic areas and treatment modalities in order to identify new opportunities. We analyze a wide range of scientific data and stay in constant communication with leading physicians, scientists, biopharmaceutical executives and venture capital firms. This allows us to quickly assess and gain conviction in the value of assets when acquisition opportunities arise.

We take a disciplined approach in assessing opportunities and seek to acquire exposure to therapies based on the following key product characteristics:

• Clinically validated: therapies that have received regulatory approval or have strong clinical proof-of-concept data that gives us confidence in the clinical and commercial profile.

• High unmet need: therapies that address areas of significant unmet medical need that also represent large commercial opportunities.

• Significant benefits to patients: therapies that have potential to disrupt or significantly enhance the treatment paradigm for patients and physicians based on compelling clinical data.

• Unique competitive positioning: therapies that are well-positioned to be leaders in their respective categories and are expected to maintain a competitive advantage in the long-term.

• Growth potential: therapies where we see strong long-term potential, based on our in-depth evaluation and in-house expertise.

• Strong marketer: therapies marketed by biopharmaceutical companies that have the resources, capabilities and commitment to successfully develop them and maximize their commercial potential.

• IP: therapies that have strong patent portfolios and offer durable, long-term cash flows.

• Attractive value proposition: therapies that we believe provide value-add to the healthcare system.

Our focus is to create significant long-term value for our shareholders by acquiring both approved and development-stage product candidates through a variety of structures. In evaluating these acquisition opportunities, we focus on the following financial characteristics:

• Long duration cash flows: we prioritize long-duration assets over short-duration assets that may boost near-term financial performance. The durability of our cash flows also allows us to add leverage to our portfolio, enhancing returns and providing capital that we can use to acquire additional assets.

• Attractive risk-adjusted returns: we focus on generating attractive returns on our investments on a risk-adjusted basis. We do not target the same return for all assets and evaluate opportunities across the risk spectrum.

• Growth and scale: we seek assets that are accretive to our long-term growth profile and additive to our overall scale.

7

We conduct extensive due diligence when evaluating potential new opportunities. We have end-to-end capabilities that span clinical and commercial analysis, valuation and transaction structuring. We have a highly focused and experienced team that conducts proprietary primary market research, forms its own views on the clinical and commercial outlook for the product, and builds its own financial models, allowing us to generate direct insights and allowing us to take significant accountability and ownership for our investments. We invest significant time and resources across all levels of the organization, including senior leadership, in the evaluation of potential opportunities.

Our Portfolio

Commercial Products

The key royalties in our marketed portfolio related to approved products include the ones listed below. Descriptions of estimated royalty expiration dates are based on our estimates of patent expiry dates (which may include estimated patent term extensions) or estimates of the dates on which the royalties otherwise expire and are based on each product’s key geographies; duration may differ in other geographies. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. In addition, the royalties in our portfolio are subject to the underlying contractual agreements from which they arise and may be subject to reductions or other adjustments in accordance with the terms of such agreements.

Cystic fibrosis franchise

Our cystic fibrosis franchise consists of our right to receive royalty payments on the sale of various products marketed by Vertex for use in the treatment of cystic fibrosis, including Kalydeco (ivacaftor), Orkambi (lumacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor and ivacaftor) and Trikafta/Kaftrio (elexacaftor, tezacaftor and ivacaftor). Vertex’s cystic fibrosis franchise represents the leading treatments for cystic fibrosis, providing treatment options for approximately 90% of cystic fibrosis patients.

We added the cystic fibrosis franchise to our portfolio in November 2014 and purchased an additional residual royalty interest in November 2020. Our right to receive royalties is perpetual, but we expect that the 2037 patent expiration for Trikafta may result in potential sales declines based on potential generic entry. Total global end market sales for the cystic fibrosis franchise during 2020 were $6.2 billion and we collected $551 million in related royalty receipts over the same period. Global end market sales of the cystic fibrosis franchise are projected to grow to approximately $10.1 billion in 2026, according to EvaluatePharma.

Tysabri

Tysabri (natalizumab) is a monoclonal antibody marketed by Biogen for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Tysabri competes in the high efficacy segment of the multiple sclerosis market, often reserved for patients with aggressive disease at onset and patients who have failed front-line therapies.

We added Tysabri to our portfolio in February 2017. Our right to receive royalties is perpetual. Total global end market sales for Tysabri during 2020 were $1.9 billion and we collected $346 million in related royalty receipts over the same period. Global end market sales of Tysabri are projected to be approximately $1.5 billion in 2026, according to EvaluatePharma.

Imbruvica

Imbruvica (ibrutinib) is a first-in-class small molecule Bruton’s tyrosine kinase inhibitor marketed by AbbVie and Janssen, a subsidiary of Johnson & Johnson, that is the leading therapy in chronic lymphocytic leukemia, relapsed/refractory mantle cell lymphoma and other blood cancers. A robust clinical program supports Imbruvica's use across a wide range of patient populations and cancer types, including 11 FDA approvals in six distinct indications with more than 200,000 patients treated globally.

We added Imbruvica to our portfolio in July 2013. We estimate that our royalties will substantially end from 2027-2029. Total global end market sales for Imbruvica during 2020 were $6.6 billion and we collected $322 million in related royalty receipts over the same period. Global end market sales of Imbruvica are projected to grow to approximately $10.0 billion in 2026, according to EvaluatePharma.
8


HIV franchise

Our HIV franchise consists of our right to receive royalty payments on the sale of various products, including Atripla, Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Symtuza and Truvada, which have been approved for the treatment and prevention of human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV). Gilead is the primary marketer for the products in our HIV franchise.

We added the HIV franchise to our portfolio starting in July 2005. We estimate that our royalties will substantially end in 2021. Total global end market sales for the products in the HIV franchise during 2020 were $16.9 billion and we collected $294 million in related royalty receipts over the same period.

Xtandi

Xtandi (enzalutamide) is an oral, small molecule androgen receptor inhibitor marketed by Pfizer and Astellas for the treatment of non-metastatic and metastatic castration-resistant prostate cancer as well as metastatic castration sensitive prostate cancer.

We added Xtandi to our portfolio in March 2016. We estimate that our royalties will substantially end from 2027-2028. Total global end market sales for Xtandi during 2020 were approximately $4.2 billion and we collected $146 million in related royalty receipts over the same period. Global end market sales of Xtandi are projected to grow to approximately $6.2 billion in 2026, according to EvaluatePharma.

Januvia, Janumet, other DPP-IVs

We hold patents covering the DPP-IV inhibitors which entitle us to royalty payments on the sale of various products, including Januvia (sitagliptin) / Janumet (sitagliptin and metformin) marketed by Merck; Onglyza (saxagliptin) / Kombiglyze (saxagliptin and metformin) and Qtern (dapagliflozin and saxagliptin), which are marketed by AstraZeneca; Novartis’ Galvus (vildagliptin) / Eucreas (vildagliptin and metformin); Tradjenta (linagliptin) / Jentadueto (linagliptin and metformin) marketed by Boehringer Ingelheim and Eli Lilly; and Nesina (alogliptin) marketed by Takeda, which have been approved for the treatment of Type 2 diabetics in substitution of, or in addition to, insulin therapy.

We added the DPP-IV inhibitors to our portfolio in June 2011. Our royalties on Januvia and Janumet will expire in 2022 and royalties on the other DPP IVs have substantially ended. Total global end market sales for the DPP-IV inhibitors during 2020 were $9.0 billion and we collected $144 million in related royalty receipts over the same period.

Promacta

Promacta (eltrombopag) is an oral, small molecule activator of the thrombopoietin receptor used to increase the number of platelets in the blood, marketed by Novartis for the treatment of chronic immune thrombocytopenia and aplastic anemia.

We added Promacta to our portfolio in March 2019. We estimate that our royalties will substantially end from 2025-2027. Total global end market sales for Promacta during 2020 were $1.7 billion and we collected $144 million in related royalty receipts over the same period. Global end market sales of Promacta are projected to be approximately $0.6 billion in 2026, according to EvaluatePharma.

Prevymis

Prevymis (letermovir) is a first-in-class prophylactic marketed by Merck for the prophylaxis of cytomegalovirus infection and disease in adults who have received an allogeneic hematopoietic stem cell transplant.

We added Prevymis to our portfolio in the second quarter of 2020. We estimate that our royalties will substantially end in 2029. Total global end market sales for Prevymis during 2020 were $281 million and we collected $21 million in related royalty receipts over the same period. Global end market sales of Prevymis are projected to grow to approximately $0.9 billion in 2026, according to EvaluatePharma.
9


Emgality

Emgality (galcanezumab-gnlm) is a monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of migraine and for the treatment of episodic cluster headache.

We added Emgality to our portfolio in March 2019. We estimate that our royalties will substantially end in 2033. Total global end market sales for Emgality during 2020 were $363 million and we collected $10 million in related royalty receipts over the same period. Global end market sales of Emgality are projected to grow to approximately $1.1 billion in 2026, according to EvaluatePharma.

Crysvita

Crysvita (burosumab) is a monoclonal antibody against fibroblast growth factor 23 that has received European conditional marketing authorization for the treatment of X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons. In October 2020, this authorization was expanded to include older adolescents and adults.

We added a royalty on Crysvita sales in Europe to our portfolio in December 2019. Our royalties expire when we receive aggregate royalties equal to $608 million if that happens prior to December 31, 2030, and otherwise when we receive aggregate royalties of $800 million. We estimate that our royalties will substantially end from 2033-2038. Total global end market sales for Crysvita during 2020 were approximately $398 million and we collected approximately $9 million in related royalty receipts over the same period. Global end market sales of Crysvita are projected to grow to approximately $2.0 billion in 2026, according to EvaluatePharma.

Erleada

Erleada (apalutamide) is an oral, small molecule androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer and for the treatment of patients with metastatic castration sensitive prostate cancer.

We added Erleada to our portfolio in February 2019. We estimate that our royalties will substantially end in 2032. Total global end market sales for Erleada during 2020 were $760 million and we collected approximately $8 million in related royalty receipts over the same period. Global end market sales of Erleada are expected to grow to approximately $2.2 billion in 2026, according to EvaluatePharma.

IDHIFA

IDHIFA (enasidenib) is an oral, targeted therapy approved by the FDA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation. It is marketed by Bristol Myers Squibb.

We added IDHIFA to our portfolio in June 2020. We estimate that our royalties will substantially end from 2033-2037. End market sales for IDHIFA are not disclosed by Bristol Myers Squibb, but we collected approximately $6 million in related royalty receipts in 2020. We also hold rights to receive up to $55 million in outstanding regulatory milestone payments from Bristol Myers Squibb.

Trodelvy

Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate approved by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer. Trodelvy was initially developed by Immunomedics and is now marketed by Gilead following the acquisition of Immunomedics in 2020. Gilead is exploring monotherapy and combinations of Trodelvy across numerous cancer indications and lines of therapy.

10

We added Trodelvy to our portfolio in January 2018. Our right to receive royalties is perpetual. Total global end market sales for Trodelvy during 2020 were $137 million and we collected approximately $3 million in related royalty receipts over the same period. Global end market sales of sacituzumab govitecan are expected to grow to approximately $2.4 billion in 2026, according to EvaluatePharma.

Nurtec ODT

Nurtec ODT (rimegepant) is an oral, small molecule CGRP receptor antagonist marketed by Biohaven Pharmaceuticals for the acute treatment of migraine.

We added Nurtec ODT to our portfolio in June 2018 and purchased an additional interest as part of our expanded funding agreement with Biohaven in August 2020. We estimate that our royalties will substantially end from 2034-2036. Total global end market sales for Nurtec ODT during 2020 were approximately $64 million and we collected less than $1 million in related royalty receipts over the same period. Global end market sales of Nurtec ODT are projected to grow to approximately $1.6 billion in 2026, according to EvaluatePharma.

Tazverik

Tazverik (tazemetostat) is a first-in-class, oral EZH2 inhibitor marketed by Epizyme that was granted accelerated approval for the treatment of epithelioid sarcoma and follicular lymphoma.

We added Tazverik to our portfolio in November 2019. We estimate that our royalties will substantially end in 2034. Total global end market sales for Tazverik during 2020 were $12 million and we collected less than $1 million in related royalty receipts over the same period. Global end market sales of Tazverik are projected to grow to approximately $1.0 billion in 2026, according to EvaluatePharma.

Evrysdi

Evrysdi (risdiplam) is a survival motor neuron 2 (SMN2) splicing modifier marketed by Roche, and is the first oral treatment approved for infants, children and adults with all types of spinal muscular atrophy.

We added Evrysdi to our portfolio in July 2020. Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion. Total global end market sales for Evrysdi during 2020 were approximately $61 million and we collected less than $1 million in related royalty receipts over the same period. Global end market sales of Evrysdi are expected to grow to approximately $2.0 billion in 2026, according to EvaluatePharma.

Orladeyo

Orladeyo (berotralstat) is a first-in-class oral inhibitor of plasma kallikrein marketed by BioCryst for the prevention of hereditary angioedema attacks.

We added Orladeyo to our portfolio in December 2020. Our right to receive royalties is perpetual, but we expect that the 2035-2039 patent expirations for Orladeyo may result in potential sales declines based on potential generic entry. Global end market sales of Orladeyo are expected to grow to approximately $0.4 billion in 2026, according to EvaluatePharma.

Development-Stage Product Candidates

Our current portfolio includes five development-stage product candidates. These development-stage product candidates have not yet been approved, and therefore have not generated any royalties (and we have not collected any related royalty receipts) to date.

Zavegepant

Zavegepant is a small molecule CGRP receptor antagonist in clinical development by Biohaven Pharmaceuticals for the acute treatment and prevention of migraines.
11


We added zavegepant to our portfolio in June 2018. We estimate that our royalties will substantially end from 2034-2036. As a result of an additional transaction in 2020, we are also entitled to success-based milestone payments that range from 0.6 times to 2.95 times of the funded amount, depending on the number of regulatory approvals achieved for zavegepant (including 1.9 times for the first zavegepant migraine regulatory approval) that would be paid over a ten-year period.

PT027

PT027 is an investigational fixed dose combination of the inhaled corticosteroid, budesonide and albuterol, a short-acting beta-2 agonist for the treatment of asthma.

In 2018, we agreed to fund up to approximately $105 million over multiple years to fund a portion of the costs for Phase III clinical trials of Avillion II, who simultaneously entered into a co-development agreement with AstraZeneca to advance PT027 through a global clinical development program in exchange for a series of deferred payments and success-based milestones. We estimate that our royalties will substantially end in 2030.

Seltorexant

Seltorexant is a selective orexin 2 receptor antagonist currently in Phase III development for the treatment of major depressive disorder (MDD) with insomnia symptoms by Janssen, a subsidiary of Johnson & Johnson.

We added seltorexant to our portfolio in January 2021.

Omecamtiv mecarbil

Omecamtiv mecarbil is an oral, small molecule cardiac myosin activator in Phase III clinical development by Amgen and Cytokinetics for the treatment of heart failure with reduced ejection fraction.

We added omecamtiv mecarbil to our portfolio in 2017. In November 2020, results from the Phase III GALACTIC-HF trial of omecamtiv mecarbil in patients with heart failure showed that the trial met the primary composite endpoint of reduction in cardiovascular death or heart failure events, but did not meet the secondary endpoint of reduction in cardiovascular death. Cytokinetics subsequently regained global rights to develop and commercialize omecamtiv mercarbil when Amgen and Servier elected to terminate their collaboration agreement effective, May 2021. Following the Phase III results and termination of the collaboration announced in 2020, we recognized an impairment charge of $65 million related to the write-off of the associated financial royalty asset of $90 million and its associated provision of $25 million, given the uncertainty around the future of omecamtiv.

BCX9930

BCX9930 is an oral Factor D inhibitor in Phase I clinical development by BioCryst Pharmaceuticals as monotherapy for paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases.

We added BCX9930 to our portfolio in December 2020. Our right to receive royalties is perpetual.
Our Portfolio Products and Product Candidates

The table below provides a summary of the estimated royalty expiration and the royalty rates for our key products:


12

ProductTherapeutic Area
Estimated Royalty 
Expiration(1)
Royalty Rate(5)
Cystic fibrosis franchiseRare disease
2037(3)
For combination therapies, sales are allocated equally to each of the active pharmaceutical ingredients; tiered royalties ranging from single digit to subteen percentages on annual worldwide net sales of ivacaftor, lumacaftor and tezacaftor, and mid-single digit percentages on annual worldwide net sales of elexacaftor
TysabriNeurologyPerpetualContingent payments of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales above $2.0 billion
ImbruvicaCancer2027-2029Tiered royalties in the mid-single digits on annual worldwide net sales
HIV franchiseInfectious disease
2021(4)
Royalties in the single digit percentages on annual worldwide net sales varying by product depending on contribution of emtricitabine to the total
Januvia and JanumetDiabetes2022Royalties in the low single digit percentages on annual worldwide net sales
XtandiCancer2027-2028Royalties slightly less than 4% on annual worldwide net sales
PromactaHematology2025-2027Tiered royalty ranging from 4.7% to 9.4% on annual worldwide net sales
PrevymisInfectious disease2029Low double-digit royalty on annual worldwide net sales up to $300 million
EmgalityNeurology2033Low single-digit royalties on annual worldwide net sales
CrysvitaRare disease
2033-2038(5)
10% royalty on annual EU, U.K. and Switzerland net sales
ErleadaCancer2032Low single-digit royalties on annual worldwide net sales
IDHIFA Cancer
2033-2037(6)
Tiered royalties in the low double-digits to mid-teens based on annual worldwide sales
TrodelvyCancerPerpetual4.15% royalty on annual worldwide net sales up to $2 billion, declining stepwise based on sales tiers to 1.75% on annual worldwide net sales above $6 billion
Nurtec ODT and ZavegepantNeurology2034-20362.1% royalty on annual combined worldwide net sales up to $1.5 billion and 1.5% on annual combined worldwide net sales above $1.5 billion. 0.4% incremental royalty on all Nurtec ODT worldwide net sales and up to a 3.0% incremental royalty on zavegepant worldwide net sales
TazverikCancer
2034(7)
Royalties in the mid-teen percentages on annual worldwide net sales, stepping down on annual worldwide net sales above certain sales thresholds
EvrysdiNeurology
2030-2035(8)
Total royalties are tiered at 8% on worldwide net sales up to $500 million, 11% on net sales between $500 million and $1 billion, 14% on net sales between $1 billion and $2 billion, 16% on net sales over $2 billion; Royalty Pharma is entitled to approximately 43% of total royalties
OrladeyoRare disease
2035-2039(9)
8.75% on direct annual net sales of up to $350 million, 2.75% on sales between $350 million and $550 million, no royalty on sales over $550 million; tiered percentage of sublicense revenue in certain territories
PT027Respiratory
2030(10)
Tiered royalties in the low-single digits on annual worldwide net sales(11)
Seltorexant Neurology—Mid single-digit royalty on worldwide net sales
Omecamtiv mecarbilCardiology2032-20334.5% royalty on annual worldwide net sales
BCX9930Rare diseasePerpetual1.0% royalty on annual worldwide net sales

Notes:
(1)     Dates shown represent our estimates of when a royalty will substantially end, which may depend on patent expiration dates (which may include patent term extensions) or other factors and may vary by geography. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. There can be no assurances that our royalties will expire when expected.
(2)     The royalties in our portfolio are subject to the underlying contractual agreements from which they arise and may be subject to reductions or other adjustments in accordance with the terms of such agreements.
(3)     Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on generic entry.
(4)     Represents patent expiration date in the United States as patents in major jurisdictions outside the United States have expired.
(5)     Royalties expire when we receive aggregate royalties equal to $608 million if that happens prior to December 31, 2030, and otherwise when we receive aggregate royalties of $800 million.
(6)     Represents estimated patent expiration dates in the United States and Europe, respectively.
(7)     Represents the estimated patent expiration date in the United States.
(8)     Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
(9)     Royalty is perpetual; years shown represent estimated United States patent expiration for Orladeyo and potential sales decline based on generic entry.
(10)     AstraZeneca is entitled to certain buyout rights which, if exercised, would result in earlier expiration.
(11)     Represents the portion of the royalties owed to Avillion II attributable to our minority ownership stake in Avillion II.


There can be no assurance that patents covering the products generating our royalties will expire when expected. Any reduction in the expected patent term or any other expected period in which we are entitled to receive royalties may adversely affect our financial condition and results of operation. See “Risk Factors” in Item 1A, Risk Factors for further information.

13

Competition

We face competition from other entities that acquire biopharmaceutical royalties, including competitors to the Manager that are in the similar business of acquiring biopharmaceutical royalties. There are a limited number of suitable and attractive acquisition opportunities available in the market. Therefore, competition to acquire such assets is intense. The Manager is subject to competition from other potential royalty buyers, including from the companies that market the products on which royalties are paid, financial institutions and other entities. These potential royalty buyers may be larger and better capitalized than us. The Manager may not be able to identify and obtain a sufficient number of asset acquisition opportunities to invest the full amount of capital that may be available to us. There can be no assurance that we will continue to acquire biopharmaceutical products and companies that hold biopharmaceutical royalties that are acceptable to us.

The products that provide the basis for the cash flows of the biopharmaceutical products in which we invest are also subject to intense competition. The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product’s commercial life cannot be predicted. There can be no assurance that one or more products will not be rendered obsolete or non-competitive by new products or improvements made to existing products, either by the current marketer of such products or by another marketer. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which serve as the security or other support for the payments due under the biopharmaceutical products that we hold.

Competitive factors affecting the market position and success of each product include:
• effectiveness;
• safety and side effect profile;
• price, including third-party insurance reimbursement policies;
• timing and introduction of the product;
• efficacy of marketing strategy;
• governmental regulation;
• availability of lower-cost generics and/or biosimilars;
• treatment innovations that eliminate or minimize the need for a product; and
• product liability claims.

If a product for which we have a royalty receivable or other interest is rendered obsolete or non-competitive by new products, including generics and/or biosimilars, or improvements on existing therapies or governmental or regulatory action, such developments could have a material adverse effect on the ability of the payor with respect to a biopharmaceutical asset to make payments to us, and consequently could materially adversely affect our business, financial condition and results of operations. If additional side effects or complications are discovered with respect to a product, and such product’s market acceptance is impaired or it is withdrawn from the market, continuing payments with respect to biopharmaceutical products, including royalty payments and payments of interest on and repayment of the principal, relating to such product may not be made on time or at all.

Corporate Responsibility

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharma industry. We play an important role in providing capital to the biopharma ecosystem and thereby positively impact human health. Our responsibility to stakeholders is based around three key areas: integrity (maintaining the highest ethical standards), culture (promoting an inclusive and diverse workforce) and taking responsibility (being a responsible citizen). We do not directly conduct biopharma R&D or manufacture or market the biopharmaceutical assets in which we participate, and thus our environmental impact is minimal. Despite the passive nature of our business, we strive to invest in novel therapies that address unmet patient needs and to support ethical business practices that drive innovation, competition and patient choice.

Integrity

We maintain the highest standards of integrity and trust in our role as investors and partners to the biopharma industry. This is recognized in our market-leading position and the high esteem with which we believe we are held in the industry. We conduct thorough diligence and monitoring with all of our investment positions. The biopharmaceutical companies and academic and non-profit institutions with which we work typically have well-developed and transparent environmental, social and governance (ESG) policies, which seek to benefit wider society through sustainable and ethical business practices.
14


Culture

A diverse, talented and motivated workforce is essential to maintain our competitive advantages and to successfully execute our business strategy. We consider it highly important to strive for an appropriate gender balance: currently approximately 51% of our workforce are women. We take employee engagement and retention very seriously and are proud that on average our workforce has been employed with us for approximately 4.5 years. We are committed to our employees’ health, well-being and job satisfaction and to ensuring that people find purpose in their careers. Opportunities for career enhancement and progression are regularly reviewed.

Responsibility

We are committed to good corporate citizenship and actively supports the work of a number of patient advocacy groups and medical research foundations, including the American Heart Association, the Alliance for Lupus Research, Children of Bellevue, the Melanoma Research Alliance, the National Multiple Sclerosis Society and the Prostate Cancer Foundation. Over one-third (by value) of the transactions we have completed since our founding have been with leading academic and non-profit institutions. By partnering with these institutions, we have provided capital which has been used to further scientific research (for example with the Cystic Fibrosis Foundation) or to help fund capital projects. Our commitment to responsibility starts with our Chief Executive Officer who is a founding member of Boston Children’s Hospital Medical Research Council and serves on the Board of Governors of the New York Academy of Sciences, as well as the Boards of Trustees of Rockefeller University, the Hospital for Special Surgery, the Pasteur Foundation (the U.S. affiliate of the French Institute Pasteur) and the Open Medical Institute. Mr. Legorreta was the founder and is currently Honorary Chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities. Since its foundation in 2010, AMSA has provided over 500 scholarships to Mexican and Latin American doctors and healthcare providers to study abroad. Mr. Legorreta is also a founding member of Mount Sinai’s Institute for Health Equity Research, created in part as a response to the health inequities made apparent by COVID-19. These diverse organizations are united in their quest to advance science, the careers of scientists and human health around the globe.

Employees

Our directors and executive officers will manage our operations and activities. However, we do not currently have any employees or any officers other than our executive officers. Pursuant to the management agreement entered into in connection with our initial public offering (the “Management Agreement”) with the Manager, the Manager will perform corporate and administration services for us.

As of December 31, 2020, the Manager had 51 employees. None of these employees are represented by labor unions or covered by any collective bargaining agreement. We believe that the Manager’s relations with its employees are satisfactory.

Human Capital Resources

Because we are “externally managed,” we do not employ our own personnel, but instead depend upon the Manager and its executive officers and employees for virtually all of the services we require. Under the Management Agreement, the Manager manages the assets of our business and sources and evaluates royalty acquisitions. Accordingly, our success is largely dependent upon the expertise and services of the executive officers and other personnel provided to us through the Manager. The Manager is responsible for the selection of these executive officers and other personnel, and our Board of Directors reviews personnel with the Manager with the objective of evaluating the Manager’s internal capabilities. The Management Agreement requires the Manager’s executives to devote substantially all of their time to managing us and any legacy vehicles related to Royalty Pharma Investments, an Irish Unit Trust (“Old RPI”) or Royalty Pharma Investments 2019 ICAV (“RPI”) unless otherwise approved by our Board of Directors. The Management Agreement also provides for the development of succession plans for the senior management of the Manager by the Management Development and Compensation Committee of our Board of Directors in consultation with the Manager.

15

Governmental Regulation and Environmental Matters

Our business has been and will continue to be subject to numerous laws and regulations. Failure to comply with these laws and regulations could subject us to administrative and legal proceedings and actions by various governmental bodies. See “Risk Factors” in Item 1A, Risk Factors for further information. Our compliance with these laws and regulations has not had a material impact on our capital expenditures, earnings, financial condition or competitive position in excess of those affecting
others in our industry.

We believe that there are no compliance issues with laws and regulations that have been enacted or adopted regulating the discharge of materials into the environment, or otherwise relating to the protection of the environment, that have adversely affected, or are reasonably expected to adversely affect, our business, financial condition and results of operations, and we do
not currently anticipate material capital expenditures arising from environmental regulation. We believe that climate change could present risks to our business. Some of the potential impacts of climate change to our business include increased operating costs due to additional regulatory requirements and the risk of disruptions to our business. We do not believe these risks are material to our business at this time.

U.S. Investment Company Act Status

We intend to conduct our business so as not to become regulated as an investment company under the U.S. Investment Company Act. An entity generally will be determined to be an investment company for purposes of the U.S. Investment Company Act if, absent an applicable exemption, (i) it is or holds itself out as being engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (ii) it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis, which we refer to as the ICA 40% Test.

We do not hold ourselves out as being engaged primarily, or propose to engage primarily, in the business of investing, reinvesting or trading in securities, and believe that we are not engaged primarily in the business of investing, reinvesting or trading in securities. We believe that, for U.S. Investment Company Act purposes, we are engaged primarily, through one or more of our subsidiaries, in the business of purchasing or otherwise acquiring certain obligations that represent part or all of the sales price of merchandise. Our subsidiaries that are so engaged rely on Section 3(c)(5)(A) of the U.S. Investment Company Act, which, according to certain SEC staff interpretations, generally may be available to an issuer who invests at least 55% of its assets in “notes, drafts, acceptances, open accounts receivable, and other obligations representing part or all of the sales price of merchandise, insurance, and services,” which we refer to as ICA Exception Qualifying Assets and not to issue any redeemable securities, face-amount certificates of the installment type or periodic payment plan certificates.

In a no-action letter, dated August 13, 2010, to our predecessor, the SEC staff promulgated an interpretation that royalties that entitle an issuer to collect royalty receivables that are directly based on the sales price of specific biopharmaceutical assets that use intellectual property covered by specific license agreements are ICA Exception Qualifying Assets under Section 3(c)(5)(A). We rely on this no-action letter for the position that royalty receivables relating to biopharmaceutical assets that we hold are ICA Exception Qualifying Assets under Section 3(c)(5)(A) and Section 3(c)(6), which is described below.

As the parent of one or more subsidiaries that rely on Section 3(c)(5)(A), we currently are excepted from registration as an investment company based on Section 3(a)(1)(C) and/or Section 3(c)(6) of the U.S. Investment Company Act. To ensure that we are not obligated to register as an investment company, we must not exceed the thresholds provided by the ICA 40% Test. For purposes of the ICA 40% Test, the term “investment securities” does not include U.S. government securities or securities issued by majority-owned subsidiaries that are not themselves investment companies and are not relying on Section 3(c)(1) or Section 3(c)(7) of the U.S. Investment Company Act, such as majority-owned subsidiaries that rely on Section 3(c)(5)(A). We also may rely on Section 3(c)(6), which, based on SEC staff interpretations, requires us to invest, either directly or through majority-owned subsidiaries, at least 55% of our assets in, as relevant here, businesses relying on Section 3(c)(5)(A). For a subsidiary to be “majority-owned,” a parent entity must own a majority of the voting securities of the applicable security. Therefore, the assets that we and our subsidiaries hold and acquire are limited by the provisions of the U.S. Investment Company Act and the rules and regulations promulgated thereunder.

16

If the SEC or its staff in the future adopts a contrary interpretation to that provided in the no-action letter to Royalty Pharma or otherwise restricts the conclusions in the SEC staff’s no-action letter such that royalties are no longer treated as ICA Exception Qualifying Assets for purposes of Section 3(c)(5)(A) and Section 3(c)(6), or the SEC or its staff in the future determines that the no-action letter does not apply to some or all types of royalty receivables relating to biopharmaceutical assets, our business will be materially and adversely affected. In particular, we would be required either to convert to a corporation formed under the laws of the United States or a state thereof (which would likely result in our being subject to U.S. federal corporate income taxation) and to register as an investment company, or to stop all business activities in the United States until such time as the SEC grants an application to register us as an investment company formed under non-U.S. law. It is unlikely that such an application would be granted and, even if it were, requirements imposed by the Investment Company Act, including limitations on our capital structure, our ability to transact business with affiliates and our ability to compensate key employees, could make it impractical for us to continue our business as currently conducted. Our no longer qualifying for an exemption from registration as an investment company would materially and adversely affect the value of your Class A ordinary shares and our ability to pay dividends in respect of our Class A ordinary shares.

Corporate Information

Our predecessor was founded in 1996 and we were incorporated under the laws of England and Wales on February 6, 2020. We are a holding company, and our principal asset is a controlling equity interest in Royalty Pharma Holdings Ltd. (“RP Holdings”). Our principal executive offices are located at 110 East 59th Street, New York, NY 10022, and our telephone number is (212) 883-0200. Our Internet site is www.royaltypharma.com. Our website and the information contained therein or connected thereto is not incorporated into this Annual Report on Form 10-K. Our agent for service in the United States is CSC North America located at 251 Little Falls Drive, Wilmington, Delaware, 19808.

Available Information

Our reports filed with or furnished to the SEC pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available, free of charge, on the Investors section of our website at https://royaltypharma.com as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a website at http://www.sec.gov that contains reports, and other information regarding us and other companies that file materials with the SEC electronically. We use the Investor section of our website as a means of disclosing material information. Accordingly, investors should monitor our website, in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Item 1A.    RISK FACTORS

Described below are certain risks that we believe apply to our business. You should carefully consider the following information about these risks, together with the other information contained in this Annual Report on Form 10-K, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business.

Summary of Risk Factors

Our business is subject to a number of risks, including risks that may adversely affect our business, financial condition and results of operations. These risks are discussed more fully below and include, but are not limited to, risks related to:

Risks Relating to Our Business

•sales risks of biopharmaceutical products on which we receive royalties;
•the growth of the royalty market;
•the ability of the Manager to identify suitable assets for us to acquire;
•uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add development-stage product candidates and late-stage funding opportunities to our product portfolio;
•potential strategic acquisitions of biopharmaceutical companies;
17

•our use of leverage in connection with our capital deployment;
•our reliance on the Manager for all services we require;
•our reliance on key members of the Manager’s senior advisory team;
•our ability to successfully execute our royalty acquisition strategy;
•our ability to leverage our competitive strengths;
•actual and potential conflicts of interest with the Manager and its affiliates;
•interest rate and foreign exchange fluctuations;
•the assumptions underlying our business model;
•our reliance on a limited number of products;
•the ability of the Manager or its affiliates to attract and retain highly talented professionals;
•the competitive nature of the biopharmaceutical industry;
Risks Relating to Our Organization and Structure

•our organizational structure, including our status as a holding company;
Risks Relating to Our Class A Ordinary Shares

•volatility of the market price of our Class A ordinary shares;
•our incorporation under English law;
Risks Relating to Taxation

•the effect of changes to tax legislation and our tax position; and
General Risk Factors

•the impact of COVID-19 on our operations.
Risks Relating to Our Business

Biopharmaceutical products are subject to sales risks.

Biopharmaceutical product sales may be lower than expected due to a number of reasons, including pricing pressures, insufficient demand, product competition, failure of clinical trials, lack of market acceptance, obsolescence, loss of patent protection, the impact of the COVID-19 global pandemic or other factors and development-stage product candidates may fail to reach the market. Unexpected side effects, safety or efficacy concerns can arise with respect to a product, leading to product recalls, withdrawals or declining sales. As a result, payments of our royalties may be reduced or cease. In addition, these payments may be delayed, causing our near-term financial performance to be weaker than expected.

18

The royalty market may not grow at the same rate as it has in the past, or at all, and we may not be able to acquire sufficient royalties to sustain the growth of our business.

We have been able to grow our business over time by acquiring numerous royalties, including those relating to many of the industry’s leading therapies. We may not be able to identify and acquire a sufficient number of royalties, or royalties of sufficient scale, to invest the full amount of capital that may be available to us in the future, which could prevent us from executing our growth strategy and negatively impact our results of operations. Changes in the royalty market, including its structure and participants, or a reduction in the growth of the biopharmaceutical industry, could lead to diminished opportunities for us to acquire royalties, fewer royalties (or royalties of significant scale) being available, or increased competition for royalties. Even if we continue to acquire royalties, they may not generate a meaningful return for a period of several years, if at all, due to the price we pay for such royalties or other factors relating to the underlying products. As a result, we may not be able to continue to grow as we have in the past, or at all.

Acquisitions of royalties from development-stage biopharmaceutical product candidates are subject to a number of uncertainties.

We may continue to and in the future acquire more royalties on development-stage product candidates that have not yet received marketing approval by any regulatory authority. There can be no assurance that the FDA, the EMA or other regulatory authorities will approve such products or that such products will be brought to market timely or at all, or that the market will be receptive to such products. For example, in January 2016, we partnered with Pfizer to provide up to $300 million in funding for Pfizer’s ongoing Phase III clinical trials, the PALLAS and PENELOPE-B trials, of Ibrance (palbociclib) for the adjuvant treatment of breast cancer. On May 29, 2020, Pfizer reported that the independent data monitoring committee for the PALLAS trial had concluded after the recent interim analysis that the PALLAS trial is “unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival.” Subsequently on October 9, 2020, Pfizer announced that the Phase III PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival in women with hormone receptor-positive (HR+), human epidermal growth factor-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy. If the FDA, the EMA or other regulatory authority approves a development-stage product candidate that generates our royalties, the labeling, packaging, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The subsequent discovery of previously unknown problems with the product, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the product, and could include withdrawal of the product from the market.

In addition, the developers of these development-stage product candidates may not be able to raise additional capital to continue their discovery, development and commercialization activities, which may cause them to delay, reduce the scope of, or eliminate one or more of their clinical trials or research and development programs. If other product developers introduce and market products that are more effective, safer or less expensive than the relevant products that generate our royalties, or if such developers introduce their products prior to the competing products underlying our royalties, such products may not achieve commercial success and thereby result in a loss for us.

Further, the developers of such products may not have sales, marketing or distribution capabilities. If no sales, marketing or distribution arrangements can be made on acceptable terms or at all, the affected product may not be able to be successfully commercialized, which will result in a loss for us. Losses from such assets could adversely affect our business, financial condition and results of operations.

We intend to continue, and may increase, this strategy of acquiring development-stage product candidates. While we believe that we can readily evaluate and gain conviction about the likelihood of a development-stage product candidate’s approval and achieving significant sales, there can be no assurance that our assumptions will prove correct, that regulatory authorities will approve such development-stage product candidates, that such development-stage product candidates will be brought to market timely or at all, or that such products will achieve commercial success.

19

Our strategy of acquiring royalty interests in development-stage product candidates, including by co-funding clinical development and acquiring securities of biopharmaceutical companies, is subject to risks and uncertainties.

We intend to continue to provide capital to innovators to co-fund clinical development of a product candidate in exchange for a share of the future revenues of that asset and when we do so, we do not control its clinical development. In these situations, the innovators may not complete activities on schedule or in accordance with our expectations or in compliance with applicable laws and regulations. Failure by one or more of these third parties to meet their obligations, comply with applicable laws or regulations or any disruption in the relationships between us and these third parties, could delay or prevent the development, approval, manufacturing or commercialization of the development-stage product candidate for which we have provided funding.
We seek to further expand our market opportunity by acquiring securities issued by biopharmaceutical companies. Where we may acquire equity securities as all or part of the consideration for business development activities, the value of those securities will fluctuate, and may depreciate in value. We will likely not control the company in which we acquire securities, and as a result, we may have limited ability to determine its management, operational decisions and policies. Further, while we may seek to mitigate the risks and liabilities of such transactions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. In addition, as a result of our activities we receive material non-public information about other companies from time to time. Where such information relates to a company whose equity securities we hold, we may be delayed or prevented from selling such securities when we would otherwise choose to do so, and such delay or prohibition may result in a loss or reduced gain on such securities.
We may undertake strategic acquisitions of biopharmaceutical companies with significant royalty assets. Our failure to realize expected benefits of such acquisitions or our incurrence of unanticipated liabilities, could adversely affect our share price, operating results and results of operations.
We may acquire companies with significant royalty assets or where we believe we could create significant synthetic royalties. These acquired or created royalty assets may not perform as we project. Moreover, the acquisition of operating biopharmaceutical companies will result in the assumption of, or exposure to, liabilities of the acquired business that are not inherent in our other royalty acquisitions, such as direct exposure to product liability claims, high fixed costs and an expansion of our operations and expense structure, thereby potentially decreasing our profitability. The diversion of our management’s attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our on-going business operations. Despite our business, financial and legal due diligence efforts, we have limited experience in assessing acquisition opportunities, and we ultimately may be unsuccessful in ascertaining or evaluating all risks associated with such acquisitions. Moreover, we may need to raise additional funds through public or private debt or equity financing to acquire any businesses or products, which may result in dilution for shareholders or the incurrence of indebtedness. As a result, our acquisition of biopharmaceutical companies could adversely affect our business, financial condition and results of operations.
We use leverage in connection with our capital deployment, which magnifies the potential for loss if the royalties acquired do not generate sufficient income to us.
We use borrowed funds to finance a significant portion of our deployed capital. The use of leverage creates an opportunity for an increased return but also increases the risk of loss if our assets do not generate sufficient income to us. The interest expense and other costs incurred in connection with such borrowings may not be covered by our cash flow. In addition, leverage may inhibit our operating flexibility and reduce cash flow available for dividends to our shareholders. The level of our indebtedness could limit our ability to respond to changing business conditions. The various agreements relating to our borrowings may impose operating and financial restrictions on us which could affect the number and size of the royalties that we may pursue. Therefore, no assurance can be given that we will be able to take advantage of favorable conditions or opportunities as a result of any restrictive covenants under our indebtedness. There can also be no assurance that additional debt financing, either to replace or increase existing debt financing, will be available when needed or, if available, will be obtainable on terms that are commercially reasonable. Additional risks related to our leverage include:
• our royalties may be used as collateral for our borrowings;
• in the event of a default under secured borrowings, if any, one or more of our creditors or their assignees could obtain control of our royalties and, in the event of a distressed sale, these creditors could dispose of these royalties for significantly less value than we could realize for them;
20

• we have to comply with various financial covenants in the agreements that govern our debt, including requirements to maintain certain leverage ratios and coverage ratios, which may affect our ability to achieve our business objectives;
• our ability to pay dividends to our shareholders may be restricted;
• to the extent that interest rates at which we borrow increase, our borrowing costs will increase and our leveraging strategy will become more costly, which could lead to diminished net profits; and
• because our Revolving Credit Facility utilizes LIBOR as a factor in determining the applicable interest rate, the expected discontinuation and transition away from LIBOR may increase the cost of servicing debt, lead to higher borrowing costs and adversely affect our results of operations and cash flows.
We do not employ our own personnel and are entirely dependent upon the Manager for all the services we require.
Because we are “externally managed,” we do not employ our own personnel but instead depend upon the Manager, its executive officers and its employees for virtually all of the services we require. The Manager selects and manages the acquisition of royalties and similar payment streams that meet our investment criteria and provides all of our other administrative services. Accordingly, our success is largely dependent upon the expertise and services of the executive officers and other personnel provided to us through the Manager. The Management Agreement has an initial term of ten years, after which it can be renewed for an additional term of three years, unless either we or the Manager provides notice of non-renewal 180 days prior the expiration of the initial term or renewal term. The Manager may not be removed during the initial or any renewal term without cause. While our agreement with the Manager requires its executives to devote substantially all of their time to managing us and any legacy vehicles related to Old RPI or RPI unless otherwise approved by Board, such resources may prove to be inadequate to meet our needs.
The success of our business depends upon key members of the Manager’s senior advisory team who may not continue to work for the Manager.
We depend on the expertise, skill and network of business contacts of the advisory professionals of the Manager, who evaluate, negotiate, structure, execute, monitor and service our assets in accordance with the terms of the Management Agreement between us and the Manager. Our future success depends to a significant extent on the continued service and coordination of the senior advisory professionals of the Manager, particularly Mr. Legorreta. Pursuant to the Management Agreement, executives of the Manager must devote substantially all of their business time to managing us, unless otherwise approved by the Board. Despite this, Mr. Legorreta and other key advisory professionals may have other demands on their time now and in the future, and we cannot assure you that they will continue to be actively involved in our business. Each of these individuals is an employee of the Manager and is not subject to an employment contract with us. The departure of any of these individuals or competing demands on their time in the future could impact our ability to achieve our business objectives. This could adversely affect our financial condition and results of operations.
The senior advisory professionals of the Manager have relationships with participants in the biopharmaceutical industry, financial institutions and other advisory professionals, which we rely upon to source potential asset acquisition opportunities. If the senior advisory professionals of the Manager fail to maintain such relationships, or to develop new relationships with other sources, we will not be able to grow our current asset portfolio. In addition, we can offer no assurance that these relationships, even if maintained, will generate asset acquisition opportunities for us in the future.
There can be no assurance that the policies and procedures we have established to mitigate conflicts of interest will be effective in doing so.
Pursuant to the Management Agreement, the Manager cannot manage another entity that invests in or acquires royalties other than any legacy vehicle related to Old RPI or RPI. Every executive of our Manager is subject to a non-compete agreement that is effective for 18 months following termination of their employment with the Manager for any reason. We are a beneficiary of this agreement. In addition, executives of the Manager must devote substantially all of their business time to managing us and any legacy vehicle related to Old RPI or RPI, unless otherwise approved by the Board. Despite this, the ability of our Manager and its officers and employees to engage in other business activities, subject to the terms of our Management Agreement, may reduce the amount of time our Manager, its officers or other employees spend managing us.
21

Furthermore, there could be conflicts of interest between us and our senior advisory personnel. For instance, Mr. Legorreta, our Chief Executive Officer, is also a co-founder of and has significant influence over Pharmakon Advisors, which shares physical premises with the Manager. Pharmakon manages BioPharma Credit PLC (LSE: BPCR) and other investment vehicles that collectively are leading providers of debt capital to the biopharmaceutical industry. Mr. Legorreta has a substantial investment in BioPharma Credit. Even though he has the involvement with Pharmakon and BioPharma Credit PLC described above, Mr. Legorreta does not have any material constraints on the time he has available to devote to us and the Manager. From time to time, the Manager and Pharmakon may pursue similar investment opportunities for their respective clients, although we believe that actual conflicts of interest are rare due to the differing investment strategies of Pharmakon and us, and the fact that royalty holders, rather than the Pharmakon and us, determine the type of transaction they seek. Under arrangements with Pharmakon, the Manager subleases office space to Pharmakon, and the parties may provide research, business development, legal, compliance, financial and administrative services to one another. The Manager and Pharmakon reimburse each other to the extent that one of them provides materially more services to the other than they receive in return. In consideration of the support provided to Pharmakon by the Manager, certain employees of the Manager receive compensation from Pharmakon. In addition, Mr. Legorreta has founded and participates in two foundations that provide medical research funding.
In addition, the structure of our Manager’s compensation arrangements may have unintended consequences for us. We have agreed to pay our Manager the Operating and Personnel Payments (as defined below), a portion of which is based on the mark-to-market value of security investments, including equity securities and derivative financial instruments, at the end of each quarter and is payable to the Manager regardless of whether we realize any gain on the security investments when sold. Consequently, the Manager may be incentivized to have us make security investments regardless of our expected gain on such investments, which may not align with our or our shareholders’ long-term interests.
To service our indebtedness and meet our other ongoing liquidity needs, we will require a significant amount of cash. Our ability to generate cash depends on many factors beyond our control. If we cannot generate the required cash, we may not be able to make the required payments under our indebtedness.
As of December 31, 2020, our total principal amount of Notes outstanding was $6.0 billion. In addition, we have up to $1.5 billion of available revolving commitments under our Revolving Credit Facility. Our ability to make payments on our indebtedness, including the Notes, and to fund our planned capital expenditures and our other ongoing liquidity needs will depend on our financial condition and operating performance, which are subject to prevailing economic and competitive conditions and to financial, business, legislative, regulatory and other factors beyond our control. Except for RP Holdings, our subsidiaries that do not guarantee the Notes will have no obligation, contingent or otherwise, to pay amounts due under the Notes or to make any funds available to pay those amounts, whether by dividend, distribution, loan or other payment. We cannot assure you that our business will generate sufficient cash flow from operations to enable us to pay our indebtedness or to fund our other liquidity needs.
Absent sufficient cash flow and the ability to refinance, we could also be forced to sell assets to make up for any shortfall in our payment obligations. However, the terms of our Revolving Credit Facility and the indenture that governs the Notes will limit, our and our subsidiaries’ ability to sell assets and also restrict the use of proceeds from such a sale. Accordingly, we may not be able to sell assets quickly enough or for sufficient amounts to enable us to meet our obligations on our indebtedness.

Our business is subject to interest rate and foreign exchange risk.
We are subject to interest rate fluctuation exposure through any borrowings under our Revolving Credit Facility and our investments in money market accounts and marketable securities, the majority of which bear a variable interest rate. To the extent that interest rates generally increase, our borrowing costs will increase and our leveraging strategy will become more costly, leading to diminished net profits.
Certain products pay royalties in currencies other than U.S. dollars, which creates foreign currency risk primarily with respect to the Euro, Canadian Dollar, Swiss Franc and Japanese Yen, as our functional and reporting currency is the U.S. dollar. In addition, our results of operations are subject to foreign currency exchange risk through transactional exposure resulting from movements in exchange rates between the time we recognize royalty income or royalty revenue and the time at which the transaction settles, or we receive the royalty payment. Because we are entitled to royalties on worldwide sales for various products, there is an underlying exposure to foreign currency as the marketer converts payment amounts from local currencies to U.S. dollars using a quarterly average exchange rate. Therefore, cash received may differ from the estimated receivable based on fluctuations in currency. As a result, significant changes in foreign exchange rates can impact our results.
22

Information about the biopharmaceutical products underlying the royalties we buy available to us may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited.
We may have limited information concerning the products generating the royalties we are evaluating for acquisition. Often, the information we have regarding products following our acquisition of a royalty may be limited to the information that is available in the public domain. Therefore, there may be material information that relates to such products that we would like to know but do not have and may not be able to obtain. For example, we do not always know the results of studies conducted by marketers of the products or others or the nature or amount of any complaints from doctors or users of such products. In addition, the market data that we obtain independently may also prove to be incomplete or incorrect. Due to these and other factors, the actual cash flow from a royalty may be significantly lower than our estimates.
Our future income is dependent upon numerous royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns.
Our business model is based on multiple-year internal and external forecasts regarding product sales and numerous product-specific assumptions in connection with each royalty acquisition, including where we have limited information regarding the product. There can be no assurance that the assumptions underlying our financial models, including those regarding product sales or competition, patent expirations or license terminations for the products underlying our portfolio, are accurate. These assumptions involve a significant element of subjective judgment and may be and in the past have been adversely affected by post-acquisition changes in market conditions and other factors affecting the underlying product. Our assumptions regarding the financial stability or operational or marketing capabilities of the partner obligated to pay us royalties may also prove and in the past have proven to be incorrect. Due to these and other factors, the assets in our current portfolio or future assets may not generate expected returns or returns in line with our historical financial performance or in the time periods we expect. This could negatively impact our results of operation for a given period.
We make assumptions regarding the royalty duration for terms that are not contractually fixed, and a shortened royalty term could result in a reduction in the effective interest rate, a decline in income from royalties, significant reductions in royalty payments compared to expectations, or a permanent impairment.
In accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we classify most royalty assets that we acquire as financial assets that are measured at amortized cost using the prospective effective interest method described in ASC 835-30. The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount, net of any purchased receivables. A critical component of such forecast is our assumptions regarding duration of the royalty.
The royalty duration is important for purposes of accurately measuring interest income over the life of a royalty. In making assumptions around the royalty duration for terms that are not contractually fixed, we consider the strength of existing patent protection, expected entry of generics, geographical exclusivity periods and potential patent term extensions tied to the underlying product.
The duration of a royalty usually varies on a country-by-country basis and can be based on a number of factors, such as patent expiration dates, regulatory exclusivity, years from first commercial sale of the patent-protected product, the entry of competing generic or biosimilar products, or other terms set out in the contracts governing the royalty. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen positive or negative developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing for the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles, and industry consolidations.
An unexpected shortening of a royalty term has not caused a permanent impairment in recent years. However, if an unexpected shortening of a royalty term were to occur, it could result in a reduction in the effective interest rate, a decline in income from royalties, a significant reduction in royalty payments compared to expectations, or a permanent impairment.
23

Our reliance on a limited number of products may adversely affect our business, financial condition and results of operation.
While our current asset portfolio includes royalties relating to over 45 marketed therapies and five development-stage product candidates, the top five therapies accounted for 61% of our royalty receipts in the year ended December 31, 2020. In addition, our asset portfolio may not be fully diversified by geographic region or other criteria. Any significant deterioration in the cash flows from the top products in our asset portfolio could adversely affect our business, financial condition and results of operations.
We face competition in acquiring assets and locating suitable assets to acquire.
There are a limited number of suitable and attractive opportunities to acquire high-quality royalties available in the market. Therefore, competition to acquire such royalties is intense and may increase. We compete with other potential acquirers for these opportunities, including companies that market the products on which royalties are paid, financial institutions and others. These competitors may be able to access lower cost capital, may be larger than us, may have relationships that provide them access to opportunities before us, or may be willing to acquire royalties for lower projected returns than we are.
Biopharmaceutical products are subject to substantial competition.
The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product’s commercial life cannot be predicted with certainty. There can be no assurance that one or more products on which we are entitled to a royalty will not be rendered obsolete or non-competitive by new products or improvements on which we are not entitled to a royalty made to existing products, either by the current marketer of such products or by another marketer. Current marketers of products may undertake these development efforts in order to improve their products or to avoid paying our royalty. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which generate our royalties.
Competitive factors affecting the market position and success of each product include:
• effectiveness;
• safety and side effect profile;
• price, including third-party insurance reimbursement policies;
• timing and introduction of the product;
• effectiveness of marketing strategy and execution;
• governmental regulation;
• availability of lower-cost generics and/or biosimilars;
• treatment innovations that eliminate or minimize the need for a product; and
• product liability claims.
Products on which we have a royalty may be rendered obsolete or non-competitive by new products, including generics and/or biosimilars, improvements on existing products or governmental or regulatory action. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies using gene editing and new curative modalities, such as cell and gene therapy, products on which we have a royalty may become obsolete. These developments could adversely affect the sales of the biopharmaceutical products that generate our royalties, and consequently could adversely affect our business, financial condition and results of operations.
24

Marketers of products that generate our royalties are outside of our control.
In the case of our royalty receivables, our cash flow consists primarily of payments supported by royalties paid by marketers. These marketers may have interests that are different from our interests. For example, these marketers may be motivated to maximize income by allocating resources to other products and, in the future, may decide to focus less attention on the products generating our royalties or by allocating resources to develop products that do not generate royalties to us. There can be no assurance that any marketer or person with whom the marketer has a working relationship has adequate resources and motivation to continue to produce, market and sell the products generating our royalties. Aside from any limited audit rights relating to the activities of the marketers that we may have in certain circumstances pursuant to the terms of our arrangements with the licensor, we do not have oversight rights with respect to the marketers’ operations and do not have rights allowing us to direct their operations or strategy nor do our agreements contain performance standards for their operations. We also have limited information on the marketers’ operations.
In these circumstances, while we may be able to receive certain information relating to sales of products through the exercise of audit rights and review of royalty reports we receive from the licensor, we will not have the right to review or receive certain information relating to products that the marketers may have, including the results of any studies conducted by the marketers or others, or complaints from doctors or users of products. The market performance of the products generating our royalties may therefore be diminished by any number of factors relating to the marketers that are outside of our control.
The marketers of biopharmaceutical products are, generally, entirely responsible for the ongoing regulatory approval, commercialization, manufacturing and marketing of products.
Generally, the holders of royalties on products have granted exclusive regulatory approval, commercialization, manufacturing and marketing rights to the marketers of such products. The marketers have full control over those efforts and sole discretion to determine the extent and priority of the resources they will commit to their program for a product. Accordingly, the successful commercialization of a product depends on the marketer’s efforts and is beyond our control. If a marketer does not devote adequate resources to the ongoing regulatory approval, commercialization and manufacture of a product, or if a marketer engages in illegal or otherwise unauthorized practices, the product’s sales may not generate sufficient royalties, or the product’s sales may be suspended, and consequently, could adversely affect our business.
License agreements relating to products may, in some instances, be unilaterally terminated or disputes may arise which may affect our royalties.
License agreements relating to the products generating our royalties may be terminated, which may adversely affect sales of such products and therefore the payments we receive. For example, under certain license agreements, marketers retain the right to unilaterally terminate the agreements with the licensors. When the last patent covering a product expires or is otherwise invalidated in a country, a marketer may be economically motivated to terminate its license agreement, either in whole or with respect to such country, in order to terminate its payment and other obligations. In the event of such a termination, a licensor may no longer receive all of the payments it expected to receive from the licensee and may also be unable to find another company to continue developing and commercializing the product on the same or similar terms as those under the license agreement that has been terminated.
In addition, license agreements may fail to provide significant protection for the licensor in case of the licensee’s failure to perform or in the event of disputes. License agreements which relate to the products underlying our royalties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what the licensor believes to be the scope of its rights to the relevant intellectual property or technology, or decrease the licensee’s financial or other obligations under the relevant agreement, any of which could in turn impact the value of our royalties and adversely affect our business, financial condition and results of operations. If a marketer were to default on its obligations under a license agreement, the licensor’s remedy may be limited either to terminating certain licenses related to certain countries or to generally terminate the license agreement with respect to such country. In such cases, we may not have the right to seek to enforce the rights of the licensor and we may be required to rely on the resources and willingness of the licensor to enforce its rights against the licensee.
In any of these situations, if the expected payments under the license agreements do not materialize, this could result in a significant loss to us and adversely affect our business, financial condition and results of operations.
25

The insolvency of a marketer could adversely affect our receipt of cash flows on the related royalties that we hold.
If a marketer were to become insolvent and seek to reorganize under Chapter 11 of Title 11 of the U.S. Code, as amended, or the Bankruptcy Code, or liquidate under Chapter 7 of the Bankruptcy Code (or foreign equivalent), such event could delay or impede the payment of the amounts due under a license agreement, pending a resolution of the insolvency proceeding. Any unpaid royalty payments due for the period prior to the filing of the bankruptcy proceeding would be unsecured claims against the marketer, which might not be paid in full or at all. While royalty payments due for periods after the filing may qualify as administrative expenses entitled to a higher priority, the actual payment of such post-filing royalty payments could be delayed for a substantial period of time and might not be in the full amount due under the license agreement. The licensor would be prevented by the automatic stay from taking any action to enforce its rights without the permission of the bankruptcy court. In addition, the marketer could elect to reject the license agreement, which would require the licensor to undertake a new effort to market the applicable product with another distributor. Such proceedings could adversely affect the ability of a payor to make payments with respect to a royalty, and could consequently adversely affect our business, financial condition and results of operations.
Unsuccessful attempts to acquire new royalties could result in significant costs and negatively impact subsequent attempts to locate and acquire other assets.
The investigation of each specific target royalty and the negotiation, drafting and execution of relevant agreements, disclosure and other documents requires substantial management time and attention and results in substantial costs for accountants, attorneys and others. If a decision is made not to complete a specific acquisition, the costs incurred for the proposed transaction would not be recoverable from a third party. Furthermore, even if an agreement is reached relating to a specific target asset, we may fail to consummate the acquisition for any number of reasons, including, in the case of an acquisition of a royalty through a business combination with a public company, approval by the target company’s public shareholders. Multiple unsuccessful attempts to acquire new royalties could hurt our reputation, result in significant costs and waste the Manager’s time. The opportunity cost of diverting management and financial resources could negatively impact our ability to locate and acquire other assets.
Most of our royalties are classified as financial assets that are measured at amortized cost using the effective interest method of accounting as a result of which our U.S. GAAP results of operations can be volatile and unpredictable.
In accordance with U.S. GAAP, most of the royalty assets we acquire are treated as investments in cash flow streams and are thus classified as financial assets. Under this classification, our financial royalty assets are treated as having a yield component that resembles loans measured at amortized cost under the effective interest accounting methodology. Under this accounting methodology, we calculate the effective interest rate on each financial royalty asset using a forecast of the expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. The yield, which is calculated at the end of each reporting period and applied prospectively, is then recognized via accretion into our income at the effective rate of return over the expected life of the financial royalty asset.
As a result of applying the effective interest method of accounting, our income statement activity in respect of many of our royalties can be volatile and unpredictable as a result of non-cash charges associated with the provision. Small declines in sell-side equity research analysts’ consensus forecasts over a multi-year period can result in an immediate non-cash income statement expense recognition, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014 we acquired the cystic fibrosis franchise royalty, which was treated as a financial royalty asset. Beginning in the second quarter of 2015, declines in near-term sales forecasts of sell-side equity research analysts caused us to build up a provision for this financial royalty asset. Over the course of 10 quarters, we recognized non-cash charges to the income statement as a result of these changes in forecasts, ultimately accumulating a peak cumulative provision of $1.3 billion by September 30, 2017, including a non-cash expense of $743.2 million in 2016 related to this financial royalty interest. With the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts’ consensus forecasts increased to reflect the larger addressable market and the increase in the expected duration of the Trikafta royalty. While small reductions in the cumulative provision for the royalties related to our cystic fibrosis franchise were recognized in 2018, there remained a $1.1 billion cumulative provision balance that was fully offset by a $1.1 billion credit to the provision in 2019 as a result of an increase in sell-side equity research analysts’ consensus forecasts from the Trikafta approval. The financial statement impact caused by the application of the effective interest accounting methodology could result in a negative perception of our results in a given period.
26

Sales of the products that generate our royalties are subject to uncertainty related to healthcare reimbursement policies, managed care considerations and pricing pressures.
In both the U.S. and non-U.S. markets, sales of medical, biopharmaceutical products, and the success of such products, depends in part on the availability and extent of coverage and reimbursement from third-party payors, including government healthcare programs and private insurance plans.
In the United States, pharmaceutical product pricing is subject to enhanced government regulation, public scrutiny and calls for reforms. Some states have implemented, and other states are considering, pharmaceutical price controls or patient access constraints under their Medicaid program. There have also been recent state legislative efforts that have generally focused on increasing transparency around drug costs or limiting drug prices. In addition, the growth of large managed care organizations and prescription benefit managers, as well as the prevalence of generic substitution, has hindered price increases for prescription drugs. Continued intense public scrutiny of the price of drugs, together with government and payor dynamics, may limit the ability of producers and marketers to set or adjust the price of products based on their value. There can be no assurance that new or proposed products will be considered cost-effective or that adequate third-party reimbursement will be available to enable the producer or marketer of such product to maintain price levels sufficient to realize an appropriate return. Outside the United States, numerous major markets, including the EU, Japan and China, have pervasive government involvement in funding healthcare, and, in that regard, fix the pricing and reimbursement of pharmaceutical products. Consequently, in those markets, the products generating our royalties are subject to government decision-making and budgetary actions.
These pricing pressures may adversely affect our current royalties and the attractiveness of future acquisitions of royalties.
The products that generate our royalties are subject to uncertainty related to the regulation of the healthcare industry.
The U.S. healthcare industry is highly regulated and subject to frequent and substantial changes. For example, the U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (the “ACA”) was enacted by Congress in March 2010 and established a major expansion of healthcare coverage, financed in part by a number of new rebates, discounts, and taxes that had a significant effect on the expenses and profitability on the companies that manufacture the products that generate our royalties. These companies and their products face uncertainty due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA.
Other U.S. federal or state legislative or regulatory action and/or policy efforts could adversely affect the healthcare industry, including, among others, general budget control actions, changes in patent laws, the importation of prescription drugs from outside the United States at prices that are regulated by governments of various foreign countries, revisions to reimbursement of biopharmaceutical products under government programs, restrictions on U.S. direct-to-consumer advertising or limitations on interactions with healthcare professionals. No assurances can be provided that these laws and regulations will not adversely affect our business, financial condition and results of operations.
In addition, many of the products in our portfolio benefit from regulatory exclusivity. If, in an effort to regulate pricing, regulatory exclusivity is not maintained, our business, financial condition and results of operations may be adversely impacted.
The biopharmaceutical industry may be negatively affected by federal government deficit reduction policies, which could reduce the value of the royalties that we hold.
In an effort to contain the U.S. federal deficit, the pharmaceutical industry could be considered a potential source of savings via legislative proposals. Government action to reduce federal spending on entitlement programs, including Medicare, Medicaid or other publicly funded or subsidized health programs, or to lower drug spending, may affect payment for the products that generate our royalties. These and any other cost controls and/or any significant additional taxes or fees that may be imposed on the biopharmaceutical industry as part of deficit reduction efforts could reduce cash flows from our royalties and therefore adversely affect our business, financial condition and results of operations.
27

Sales of products that generate our royalties are subject to regulatory approvals and actions in the United States and foreign jurisdictions that could harm our business.
The procedures to approve biopharmaceutical products for commercialization vary among countries and can involve additional testing and time. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval and many include additional risks, such as pricing approval.
There can be no assurance that any of these regulatory approvals will be granted or not be revoked or restricted in a manner that would adversely affect the sales of such products and on the ability of payors to make payments with respect to such royalties to us.
The manufacture and distribution of a biopharmaceutical product may be interrupted by regulatory agencies or supplier deficiencies.
The manufacture of products generating our royalties is typically complex and is highly regulated. In particular, biopharmaceutical products are manufactured in specialized facilities that require the approval of, and ongoing regulation by, the FDA in the United States and, if manufactured outside of the United States, both the FDA and non-U.S. regulatory agencies, such as the EMA. With respect to a product, to the extent that operational standards set by such agencies are not adhered to, manufacturing facilities may be closed or production interrupted until such time as any deficiencies noted by such agencies are remedied. Any such closure or interruption may interrupt, for an indefinite period of time, the manufacture and distribution of a product and therefore the cash flows from the related biopharmaceutical asset may be significantly less than expected.
In addition, manufacturers of a product may rely on third parties for selected aspects of product development, such as packaging or to supply bulk raw material used in the manufacture of such product. In the United States, the FDA requires that all suppliers of pharmaceutical bulk materials and all manufacturers of pharmaceuticals for sale in or from the United States adhere to the FDA’s current “Good Manufacturing Practice” regulations and guidelines and similar requirements that exist in jurisdictions outside the United States. Licensees generally rely on a small number of key, highly specialized suppliers, manufacturers and packagers. Any interruptions, however minimal, in the operation of these manufacturing and packaging facilities could adversely affect production and product sales and therefore adversely affect our business, financial condition and results of operations.
Product liability claims may diminish the returns on biopharmaceutical products.
The developer, manufacturer or marketer of a product could become subject to product liability claims. A product liability claim, regardless of its merits, could adversely affect the sales of the product and the amount of any related royalty payments, and consequently, could adversely affect the ability of a payor to make payments with respect to a royalty.
Although we believe that we will not bear responsibility in the event of a product liability claim against the developer, manufacturer, marketer or other seller of the product that generates our royalty, such claims could adversely affect our business, financial condition and results of operations due to the lower than expected cash flows from the royalty.
We are typically not involved in maintaining, enforcing and defending patent rights on products that generate our royalties.
Our right to receive royalties generally depends on the existence of valid and enforceable claims of registered and/or issued patents in the United States and elsewhere in the world. The products on which we receive payments are dependent on patent protection and on the fact that the manufacturing, marketing and selling of such products do not infringe, misappropriate or otherwise violate intellectual property rights of third parties. Typically, we have no ability to control the prosecution, maintenance, enforcement or defense of patent rights, but must rely on the willingness and ability of our partners or their marketers to do so. While we believe that these third parties are in the best position and have the requisite business and financial motivation to do so, there can be no assurance that these third parties will vigorously prosecute, maintain, enforce or defend such rights. Even if such third parties seek to prosecute, maintain, enforce or defend such rights, they may not be successful.
28

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. Furthermore, changes in patent laws or interpretation of patent laws in the United States and in other jurisdictions could increase the uncertainties surrounding the successful prosecution of patent applications and the successful enforcement or defense of issued patents by our partners, all of which could diminish the value of patent protection relating to the biopharmaceutical assets. As a result, the issuance, scope, validity, enforceability and commercial value of the patent rights of our partners and their marketers are highly uncertain. In addition, such third parties’ pending and future patent applications may not result in patents being issued which protect their products, development-stage product candidates and technologies or which effectively prevent others from commercializing competitive products, development-stage product candidates and technologies. Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance.
Even if the patent applications our partners and their marketers license or own do issue as patents, they may not issue in a form that will provide them with any meaningful protection, prevent competitors or other third parties from competing with them or otherwise provide them with any competitive advantage. Competitors or other third parties may be able to circumvent patents of our partners and their marketers by developing similar or alternative products in a non-infringing manner. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit the ability of our partners and their marketers from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of their products, development-stage product candidates and technologies.
Any loss or reduction in the scope or duration of patent protection for any product that generates our royalties, or any failure to successfully prosecute, maintain, enforce or defend any patents that protect any such product may result in a decrease in the sales of such product and any associated royalties payable to us. Any such event would adversely affect the ability of the payor to make payments of royalties to us or may otherwise reduce the value of our royalty interest, and could consequently adversely affect our business, financial condition and results of operations. In cases where our contractual arrangements with our partner permit us to do so, we could participate in patent suits brought by third parties but this could result in substantial litigation costs, divert management’s attention from our core business and there can be no assurance that such suits would be successful.
The existence of third-party patents in relation to products may result in additional costs for the marketer and reduce the amount of royalties paid to us.
The commercial success of a product depends, in part, on avoiding infringement, misappropriation or other violations of the intellectual property rights and proprietary technologies of others. Third-party issued patents or patent applications claiming subject matter necessary to manufacture and market a product could exist or issue in the future. Such third-party patents or patent applications may include claims directed to the mechanism of action of a product. There can be no assurance that a license would be available to marketers for such subject matter if such infringement were to exist or, if offered, would be offered on reasonable and/or commercially feasible terms. Without such a license, it may be possible for third parties to assert infringement or other intellectual property claims against the marketer of such product based on such patents or other intellectual property rights.
Even if the marketer was able to obtain a license, it could be non-exclusive, thereby giving its competitors and other third parties access to the same technologies. In addition, if a marketer of a product that generates our royalties is required to obtain a license from a third party, the marketer may, in some instances, have the right to offset the licensing and royalty payments to such third party against royalties that would be owed to our partner, which may ultimately reduce the value of our royalty interest. An adverse outcome in infringement or other intellectual property-related proceedings could subject a marketer to significant liabilities to third parties, require disputed rights to be licensed from third parties or require the marketer to cease or modify its manufacturing, marketing and distribution of any affected product, any of which could reduce the amount of cash flow generated by the affected products and any associated royalties payable to us and therefore adversely affect our business, financial condition and results of operations.
29

Disclosure of trade secrets of marketers of products could negatively affect the competitive position of the products underlying our biopharmaceutical assets.
The marketers of the products that generate our royalties depend, in part, on trade secrets, know-how and technology, which are not protected by patents, to maintain the products’ competitive position. This information is typically protected through confidentiality agreements with parties that have access to such information, such as collaborative partners, licensors, employees and consultants. Any of these parties may breach the agreements and disclose the confidential information or competitors might independently develop or learn of the information in some other way, which could harm the competitive position of the products and therefore reduce the amount of cash flow generated by our royalty interest.
The internal computer systems of our partners may fail or suffer security breaches, which could result in a significant disruption of their ability to operate their business effectively, adversely affect the cash flow generated by the related biopharmaceutical products, and adversely affect our business and operating results.
The internal computer systems and cloud-based computing services of our partners and those of their current and any future collaborators and other contractors or consultants are vulnerable to damage or interruption from computer viruses, data corruption, cyber-based attacks, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in their operations, it could result in a disruption of their development and commercialization programs and business operations, whether due to a loss of trade secrets or other proprietary information or other similar disruptions. To the extent that any disruption or security breach were to result in a loss of, or damage to, a partner’s data or applications, or inappropriate disclosure of confidential or proprietary information, our partners’ operations may be harmed and the development and commercialization of their products, development-stage product candidates and technologies could be delayed. Such an event may reduce the amount of cash flow generated by the related biopharmaceutical products and therefore adversely affect our business, financial condition and results of operations.
Our ability to pay periodic dividends to our shareholders may be limited by applicable provisions of English law and contractual restrictions and obligations.
Subject to the terms of our indebtedness or other contractual obligations, the approval and payment of any interim dividends are at the sole discretion of our board of directors, which may change our dividend policy at any time and the payment of any final dividends will be subject to majority approval by holders of Class A ordinary and Class B ordinary shares and in each case will be paid out of profits available for that purpose under English law. There can be no assurance that any dividends, whether quarterly or otherwise, will or can be paid. Our ability to pay dividends to our shareholders depends on a number of factors, including among other things, general economic and business conditions, our strategic plans and prospects, our business and acquisition opportunities, our financial condition and operating results, working capital requirements and anticipated cash needs, contractual restrictions and obligations, including fulfilling our current and future capital commitments, legal, tax and regulatory restrictions, restrictions and other implications on the payment of dividends by us to our shareholders and such other factors as our board of directors may deem relevant.
Our Articles of Association authorize the board of directors to approve interim dividends without shareholder approval to the extent that such dividends appear justified by profits available for such purpose. The board of directors may also recommend final dividends be approved and declared by shareholders at an annual general meeting. No such dividend may exceed the amount recommended by the board of directors.
Under English law, dividends and distributions may only be made out of profits available for that purpose. Profits available for distribution are accumulated, realized profits, to the extent that they have not been previously utilized by distribution or capitalization, less its accumulated, realized losses, to the extent that they have not been previously written off in a reduction or reorganization of capital duly made. The amount of our distributable reserves is a cumulative calculation. We may be profitable in a single financial year but unable to pay a dividend if our accumulated, realized profits do not offset all previous years’ accumulated, realized losses. Additionally, we may only make a distribution if our net assets are not less than the amount of our aggregate called-up share capital and distributable reserves, and if, and to the extent that, the distribution does not reduce the amount of those assets to less than that aggregate.
A shareholder who receives a distribution under circumstances where he or she knows or has reasonable grounds for believing that the distribution is unlawful in the circumstances is obliged to repay such distribution (or that part of it, as the case may be) to us.
30

If we were determined to be an investment company under the U.S. Investment Company Act of 1940, applicable restrictions could make it impractical for us to continue our business as contemplated and could adversely affect our business, financial condition and results of operations.
We intend to conduct our business so as not to become regulated as an investment company under the U.S. Investment Company Act. An entity generally will be determined to be an investment company for purposes of the U.S. Investment Company Act if, absent an applicable exemption, (i) it is or holds itself out as being engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities; or (ii) it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis, which we refer to as the ICA 40% Test.
We do not hold ourselves out as being engaged primarily, or propose to engage primarily, in the business of investing, reinvesting or trading in securities, and believe that we are not engaged primarily in the business of investing, reinvesting or trading in securities. We believe that, for U.S. Investment Company Act purposes, we are engaged primarily, through one or more of our subsidiaries, in the business of purchasing or otherwise acquiring certain obligations that represent part or all of the sales price of merchandise. Our subsidiaries that are so engaged rely on Section 3(c)(5)(A) of the U.S. Investment Company Act, which, as interpreted by the SEC staff, requires each such subsidiary to invest at least 55% of its assets in “notes, drafts, acceptances, open accounts receivable, and other obligations representing part or all of the sales price of merchandise, insurance, and services,” which we refer to as the ICA Exception Qualifying Assets.
In a no-action letter, dated August 13, 2010, to our predecessor, the SEC staff promulgated an interpretation that royalty interests that entitle an issuer to collect royalty receivables that are directly based on the sales price of specific biopharmaceutical assets that use intellectual property covered by specific license agreements are ICA Exception Qualifying Assets under Section 3(c)(5)(A). We rely on this no-action letter for the position that royalty receivables relating to biopharmaceutical assets that we hold are ICA Exception Qualifying Assets under Section 3(c)(5)(A) and Section 3(c)(6), which is described below.
To ensure that we are not obligated to register as an investment company, we must not exceed the thresholds provided by the ICA 40% Test. For purposes of the ICA 40% Test, the term investment securities does not include U.S. government securities or securities issued by majority-owned subsidiaries that are not themselves investment companies and are not relying on Section 3(c)(1) or Section 3(c)(7) of the U.S. Investment Company Act, such as majority-owned subsidiaries that rely on Section 3(c)(5)(A). We also may rely on Section 3(c)(6), which, based on SEC staff interpretations, requires us to invest, either directly or through majority-owned subsidiaries, at least 55% of our assets in, as relevant here, businesses relying on Section 3(c)(5)(A). Therefore, the assets that we and our subsidiaries hold and acquire are limited by the provisions of the U.S. Investment Company Act and the rules and regulations promulgated thereunder.
If the SEC or its staff in the future adopts a contrary interpretation to that provided in the no-action letter to Royalty Pharma or otherwise restricts the conclusions in the SEC staff’s no-action letter such that royalty interests are no longer treated as ICA Exception Qualifying Assets for purposes of Section 3(c)(5)(A) and Section 3(c)(6), or the SEC or its staff in the future determines that the no-action letter does not apply to some or all types of royalty receivables relating to biopharmaceutical assets, our business will be materially and adversely affected. In particular, we would be required either to convert to a corporation formed under the laws of the United States or a state thereof (which would likely result in our being subject to U.S. federal corporate income taxation) and to register as an investment company, or to stop all business activities in the United States until such time as the SEC grants an application to register us as an investment company formed under non-U.S. law. It is unlikely that such an application would be granted and, even if it were, requirements imposed by the Investment Company Act, including limitations on our capital structure, our ability to transact business with affiliates and our ability to compensate key employees, could make it impractical for us to continue our business as currently conducted. Our ceasing to qualify for an exemption from registration as an investment company could materially and adversely affect the value of our Class A ordinary shares and our ability to pay dividends in respect of our Class A ordinary shares.
31

The equity performance awards payable to an affiliate of the Manager may create incentives that are not fully aligned with the interests of our shareholders.
Subject to certain conditions, at the end of each fiscal quarter, an affiliate of the Manager is entitled to a distribution in the form of equity from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The right to Equity Performance Awards may create an incentive for the Manager to make riskier or more speculative asset acquisitions than would be the case absent such Equity Performance Awards. In addition, the Manager may cause us to incur more debt or otherwise use more leverage in connection with asset acquisitions, as generally the use of leverage can increase the rate of return on an investment and therefore our profits. This Equity Performance Awards structure may encourage the Manager to cause us to borrow money to finance additional asset acquisitions or to maintain leverage which poses higher risks for our business when it would otherwise be appropriate to not use such leverage. Under certain circumstances, the use of borrowed money may increase the likelihood of default, which would disfavor our shareholders. In addition, there is no correlation between our profits and the obligation of our board of directors to pay dividends to shareholders. Consequently, you may receive limited or no dividends while an affiliate of the Manager remains entitled to Equity Performance Awards based on our Net Economic Profit. In addition, even though Equity Performance Awards are payable on a portfolio-by-portfolio basis (with portfolios comprised of investments made during sequential two-year periods) in order to reduce the risks that affiliates of the Manager will be paid Equity Performance Awards on individual investments even though our overall portfolio of investments is not performing well, Equity Performance Awards may nevertheless be payable to affiliates of the Manager when our overall portfolio of investments is not performing as well as the individual portfolios that are used as the basis for measuring the Equity Performance Awards.
Our board of directors may make decisions with respect to the cash generated from our operations that may result in no dividends paid to our shareholders.
Our board of directors is under no obligation to pay dividends to our shareholders, and it may decide to use cash to fund asset acquisitions or operations in lieu of paying dividends. We will pay Equity Performance Awards to an affiliate of the Manager based on our Net Economic Profit regardless of whether any dividends are made to our shareholders. Our board’s decisions with respect to our cash may result in no dividends to our shareholders. Furthermore, our board’s decisions with respect to dividends may adversely affect the market price of our Class A ordinary shares. In the event that we generate positive income, but pay limited or no dividends, holders of Class A ordinary shares may, if they have made certain elections for U.S. federal income tax purposes with respect to their Class A ordinary shares, have a tax liability on our income in excess of the actual cash dividends received by such holders. If our board of directors decides to approve limited or no dividends, the primary remedy for holders of Class A ordinary shares will be to sell their at prevailing market prices, including at a loss, which prices may be low due to unfavorable or inconsistent dividends.
The royalties that we acquire may fall outside the biopharmaceutical industry, and any such assets, and the cash flows therefrom, may not resemble the assets in our current portfolio.
We have discretion as to the types of healthcare assets that we may acquire. While we expect the Manager to acquire assets that primarily fall within the biopharmaceutical industry, we are not obligated to do so and may acquire other types of healthcare assets that are peripheral to or outside of the biopharmaceutical industry. Consequently, our asset acquisitions in the future, and the cash flows from such assets, may not resemble those of the assets in our current portfolio. There can be no assurance that assets acquired in the future will have returns similar to the returns expected of the assets in our current portfolio or be profitable at all.
The Manager may be the subject of a change of control resulting in a disruption in our operations that could adversely affect our business, financial condition and results of operations.
There could be a change of control of the Manager and, in such a case, the new controlling party may have a different philosophy, employ advisory professionals who are less experienced, be unsuccessful in identifying asset acquisition opportunities or have a track record that is not as successful as that of the Manager prior to such a change of control. If the foregoing were to occur, we could experience difficulty in making new asset acquisitions, and the value of our existing assets, our business, financial condition and results of operations could materially suffer.
32

The Manager’s liability is limited under the Management Agreement, and we have agreed to indemnify the Manager against certain liabilities. As a result, we could experience unfavorable operating results or incur losses for which the Manager would not be liable.
Pursuant to the Management Agreement, the Manager does not assume any responsibility other than to render the services called for thereunder. Under the terms of the Management Agreement, the Manager and its affiliates (including RPI EPA Holdings, LP (“EPA Holdings”)) and their respective officers, directors, stockholders, members, employees, agents and partners, and any other person who is entitled to indemnification (each, an “Indemnitee”) is not liable to us, any subsidiary of ours, our directors, our stockholders or any subsidiary’s stockholders or partners for acts or omissions performed in accordance with and pursuant to the Management Agreement, except those resulting from acts constituting fraud, bad faith, willful misconduct, gross negligence (as such concept is interpreted under the laws of the State of New York) and a material breach of the Management Agreement that is not cured in accordance with its terms or a violation of applicable securities laws.
In addition, to the fullest extent permitted by law, we have agreed to indemnify the Indemnitees from and against any and all claims, liabilities, damages, losses, penalties, actions, judgments, costs and expenses (including amounts paid in satisfaction of judgments, in compromises and settlements, as fines and penalties and legal or other costs and reasonable expenses of investigating or defending against any claim or alleged claim) of any nature whatsoever, known or unknown, liquidated or unliquidated that are incurred by any Indemnitee or to which such Indemnitee may be subject by reason of its activities on behalf of us or any of our subsidiaries to the extent that such Indemnitee’s conduct did not constitute fraud, bad faith, willful misconduct, gross negligence (as such concept is interpreted under the laws of the State of New York), material breach of the Management Agreement that is not cured in accordance with the terms of the Management Agreement or a violation of applicable securities laws. As a result, we could experience unfavorable operating results or incur losses for which the Manager would not be liable.
Operational risks may disrupt our businesses, result in losses or limit our growth.
We and the Manager rely heavily on our respective financial, accounting, information and other data processing systems and cloud computing services, as well as those of our current and future collaborators, contractors or consultants. Such systems are vulnerable to damage or interruption from computer viruses, data corruption, cyber-based attacks, unauthorized access, natural disasters, pandemics, such as the current COVID-19 pandemic, terrorism, war and telecommunication and electrical failures. If any of these events occur and such systems do not operate properly or are disabled or if there is any unauthorized disclosure of data, whether as a result of tampering, a breach of network security systems, a cyber-incident or attack or otherwise, we could suffer substantial financial loss, increased costs, a disruption of our business, loss of trade secrets or other proprietary information, liability to us, regulatory intervention or reputational damage.
Furthermore, federal, state and international laws and regulations relating to data privacy and protection, such as the European Union’s General Data Protection Regulation, which took effect in May 2018, and the California Consumer Privacy Act, which took effect in January 2020, can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties and significant legal liability, if our information technology security efforts or data privacy and protection compliance efforts fail. In addition, we operate a business that is highly dependent on information systems and technology. Our information systems and technology and that of the Manager may not continue to be able to accommodate our growth, and the cost of maintaining such systems may increase from its current level. Such a failure to accommodate growth, or an increase in costs related to such information systems, could adversely affect our business, financial condition and results of operations.
A disaster or a disruption in the public infrastructure that supports our business, including a disruption involving electronic communications or other services used by us or third parties with whom we conduct business, could adversely affect our ability to continue to operate our business without interruption. Our disaster recovery programs and those of the Manager may not be sufficient to mitigate the harm that may result from such a disaster or disruption. In addition, insurance and other safeguards might only partially reimburse us for our losses, if at all.
In addition, sustaining our growth may require us or the Manager to commit additional management, operational and financial resources to identify new professionals to join the team and to maintain appropriate operational and financial systems to adequately support expansion. Due to the fact that the market for hiring talented professionals is competitive, we may not be able to grow at the pace we desire.
33

We are subject to the U.K. Bribery Act, the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations.
Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010 (“Bribery Act”), the U.S. Foreign Corrupt Practices Act of 1977, as amended the (“FCPA”), the U.S. domestic bribery statute contained in 18 U.S.C. §201, the U.S. Travel Act, and other anti-corruption laws that apply in countries where we do business. The Bribery Act, the FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We and the marketers of products that generate our royalties operate in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.
We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws.
There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by the United Kingdom, United States or other authorities could also have an adverse impact on our reputation, our business, financial condition and results of operations.
Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities or our business arrangements with third parties could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices or the business practices of the marketers of products that generate our royalties may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations or the operations of the marketers of products that generate are royalties are found to be in violation of any of these laws or any other governmental regulations, we or marketers of products that generate our royalties may be subject to significant criminal, civil and administrative sanctions, including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we or marketers of products that generate our royalties become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we or marketers of products that generate our royalties may be required to curtail or restructure operations, any of which could adversely affect our ability to operate our business and our results of operations.
The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.
34

The EU directive on alternative investment fund managers (the “AIFM Directive”) may significantly increase our compliance costs.
The AIFM Directive has been implemented into the national law of the majority of member states of the European Economic Area and the United Kingdom (each an “AIFM state”). The AIFM Directive sets out minimum conditions related to the marketing of interests in alternative investment funds (such as our Class A ordinary shares) in the AIFM states and may impact our ability to attract investors in the AIFM states and may significantly increase our and the Manager’s compliance costs. Such conditions include requirements for us to register with the competent authority in the relevant AIFM in order to market the Class A ordinary shares to investors, state requirements to file periodic reports with the competent authority in the relevant AIFM state and requirements to comply with disclosure and reporting obligations in respect of investors in the relevant AIFM state. Such reports and disclosures may become publicly available. While such conditions are met in relation to the AIFM states where our Class A ordinary shares will be marketed, there can be no guarantee that this will continue to be the case. The AIFM Directive does not, however, prohibit an investor in such AIFM state from subscribing for our Class A ordinary shares at their own initiative in circumstances where such Class A ordinary shares have not been marketed in such AIFM state and we may issue our Class A ordinary shares to such investors, as long as they have provided us and the Manager with representations that they have done so at their own initiative.
In each AIFM state, our Class A ordinary shares may only be offered to investors in accordance with local measures implementing the AIFM Directive. Investors, together with any person making or assisting in the decision to invest in us, who are situated, domiciled or who have a registered office, in an AIFM state where our Class A ordinary shares are not being offered pursuant to private placement rules implementing the AIFM Directive may invest, or effect an investment in our Class A ordinary shares, but only in circumstances where they do so at their own initiative. Any investor acquiring our Class A ordinary shares at their own initiative in such AIFM state should note that as we have not been registered for marketing in that AIFM state, no reports will be filed with the competent authority in the relevant AIFM state by or in respect of us and no investor shall be entitled to receive any disclosure or report that is mandated in respect of an alternative investment fund being marketed pursuant to the AIFM Directive.
Risks Relating to Our Organization and Structure
We are a holding company with no operations and rely on our subsidiaries to provide us with funds necessary to meet our financial obligations and to pay dividends.
We are a holding company with no material direct operations. Our principal asset is our controlling equity interest in RP Holdings. As a result, we are dependent on loans, dividends and other payments from our subsidiaries to generate the funds necessary to meet our financial obligations and to pay dividends on our ordinary shares. Our subsidiaries are legally distinct from us and may be prohibited or restricted from paying dividends or otherwise making funds available to us under certain conditions. If the cash we receive from our subsidiaries pursuant to dividend payments is insufficient for us to fund our obligations, or if a subsidiary is unable to pay dividends to us, provided that we have sufficient distributable profits, our net assets exceed the total of our called-up share capital and distributable reserves and any dividend would not reduce our net assets to less than such total, we may be required to raise cash through the incurrence of debt, the issuance of equity or the sale of assets to fund the payment of the dividends. However, there is no assurance that we would be able to raise cash by these means. If the ability of any of our subsidiaries to pay dividends or make other distributions or payments to us is materially restricted by regulatory or legal requirements, bankruptcy or insolvency, or our need to maintain our financial strength ratings, or is limited due to operating results or other factors, it could adversely affect our ability to pay our operating costs and other corporate expenses and we may be unable to, or our board may exercise its discretion not to, pay dividends.
Our structure will result in tax distributions to the owner of the RP Holdings Class C Special Interest.
RP Holdings is treated as a partnership for U.S. federal income tax purposes and has owners that are subject to U.S. federal income taxation. To the extent permitted by applicable law, RP Holdings is required to make cash distributions, or tax distributions, to the owner of the RP Holdings Class C Special Interest, calculated using an assumed tax rate that is generally uniform for all recipients regardless of their tax status. Funds used by RP Holdings to satisfy its tax distribution obligations will not be available for reinvestment in our business.
35

Risks Relating to Our Class A Ordinary Shares
The market price of our Class A ordinary shares may be volatile, which could cause the value of your investment to decline.
The market price of our Class A ordinary shares may be highly volatile and could be subject to wide fluctuations. Securities markets worldwide experience significant price and volume fluctuations. This market volatility, as well as general economic, market or political conditions, could reduce the market price of Class A ordinary shares in spite of our operating performance. In addition to the factors discussed in this Annual Report on Form 10-K, our operating results could be below the expectations of public market analysts and investors due to a number of potential factors, including:
• market conditions in the broader stock market in general, or in our industry in particular; including as a result of impacts of the ongoing COVID-19 pandemic;
• variations in our quarterly operating results or dividends to shareholders;
• additions or departures of key management personnel at the Manager;
• failure to meet analysts’ earnings estimates;
• publication of research reports about our industry;
• third-party healthcare reimbursement policies and practices;
• litigation and government investigations;
• changes or proposed changes in laws or regulations or differing interpretations or enforcement thereof affecting our business;
• no results, or projected results, from marketers of products that generate our royalties;
• results from, and any delays to, the clinical trial programs of development-stage product candidates underlying our biopharmaceutical assets or other issues relating to such products, including regulatory approval or commercialization;
• adverse market reaction to any indebtedness that we may incur or securities we may issue in the future;
• changes in market valuations of similar companies or speculation in the press or investment community;
• announcements by our competitors of significant contracts, acquisitions, dispositions, strategic partnerships, joint ventures or capital commitments;
• litigation;
• economic and political conditions or events; and
• adverse publicity about us or the industries in which we participate or individual scandals.
These and other factors may cause the market price of and demand for our Class A ordinary shares to fluctuate significantly, which may limit or prevent our existing shareholders from reselling their Class A ordinary shares at or above the purchase price.
The stock market in general has from time to time experienced extreme price and volume fluctuations, including in recent months. In addition, in the past, following periods of volatility in the overall market and the market price of a company’s securities, securities class action litigation has often been instituted against public companies. This type of litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources.
36

Our Articles of Association provide that the courts of England and Wales will be the exclusive forum for the resolution of all shareholder complaints other than complaints asserting a cause of action arising under the Securities Act and the Exchange Act, and that the U.S. federal district courts will be the exclusive forum for the resolution of any shareholder complaint asserting a cause of action arising under the Securities Act and the Exchange Act.
Our Articles of Association provide that the courts of England and Wales will be the exclusive forum for resolving all shareholder complaints other than shareholder complaints asserting a cause of action arising under the Securities Act and the Exchange Act, and that the U.S. federal district courts will be the exclusive forum for resolving any shareholder complaint asserting a cause of action arising under the Securities Act and the Exchange Act. This choice of forum provision may limit a shareholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits. If a court were to find either choice of forum provision contained in our Articles of Association to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition.
U.S. investors may have difficulty enforcing civil liabilities against our company, our directors or members of senior management and the experts named herein.
We are a public limited company with our registered office in England and our subsidiaries are incorporated in various jurisdictions, including jurisdictions outside the United States. One of our directors is not a resident of the United States, and a substantial portion of our assets and the assets of this director are located outside the United States. As a result, it may be difficult for investors to effect service of process on this director in the United States or to enforce in the United States judgments obtained in U.S. courts against us or this director based on the civil liability provisions of the U.S. securities laws or otherwise. Even if you are successful in bringing an action of this kind, the laws of England may render you unable to enforce a judgment against our assets or the assets of our directors and executive officers. In addition, it is doubtful whether English courts would enforce certain civil liabilities under U.S. securities laws in original actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in the United Kingdom. An award for monetary damages under the U.S. securities laws would likely be considered punitive if it does not seek to compensate the claimant for loss or damage suffered and is intended to punish the defendant. The enforceability of any judgment in the United Kingdom will depend on the particular facts of the case as well as the laws and treaties in effect at the time. The United States and the United Kingdom do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. As a result of the above, public holders of our Class A ordinary shares may have more difficulty in protecting their interest through actions against our management, directors or major shareholders than they would as shareholders of a U.S. public company.
The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation and these differences may make our Class A ordinary shares less attractive to investors.
We are incorporated under English law. The rights of holders of our Class A ordinary shares are governed by English law, including the provisions of the Companies Act 2006 (the “U.K. Companies Act”), and by our Articles of Association. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations and these differences may make our Class A ordinary shares less attractive to investors.
The City Code on Takeovers and Mergers (the “Takeover Code”) applies, among other things, to an offer for a public company whose registered office is in the United Kingdom (or the Channel Islands or the Isle of Man) and whose securities are not admitted to trading on a regulated market in the United Kingdom (or the Channel Islands or the Isle of Man) if the company is considered by the Panel on Takeovers and Mergers (the “Takeover Panel”) to have its place of central management and control in the United Kingdom (or the Channel Islands or the Isle of Man). This is known as the “residency test.” The test for central management and control under the Takeover Code is different from that used by the U.K. tax authorities. Under the Takeover Code, the Takeover Panel will determine whether we have our place of central management and control in the United Kingdom by looking at various factors, including the structure of our board of directors, the functions of the directors and where they are resident.
If at the time of a takeover offer the Takeover Panel determines that we have our place of central management and control in the United Kingdom, we would be subject to a number of rules and restrictions, including but not limited to the following: (i) our ability to enter into deal protection arrangements with a bidder would be extremely limited; (ii) we might not, without the approval of our shareholders, be able to perform certain actions that could have the effect of frustrating an offer, such as issuing shares or carrying out acquisitions or disposals; and (iii) we would be obliged to provide equality of information to all bona fide competing bidders.
37

Given that our central management and control is currently not situated within, and our current intention is not to have it in the future situated within the United Kingdom (or the Channel Islands or the Isle of Man), but to have such management and control situated within the United States, we do not currently envisage that the Takeover Code will apply to an offer for us.
Under English law, and whether or not we are subject to the Takeover Code, an offeror for us that has acquired (i) 90% in value of; and (ii) 90% of the voting rights carried by the shares to which the offer relates may exercise statutory squeeze-out rights to compulsorily acquire the shares of the non-assenting minority. However, if an offer for us is conducted by way of a scheme of arrangement the threshold for the offeror obtaining 100% of Company shares comprises two components (i) approval by a majority in number of each class of Company shareholders present and voting at the shareholder meeting; and (ii) approval of Company shareholders representing 75% or more in value of each class of Company shareholders present and voting at that meeting.
As an English public limited company, certain capital structure decisions will require shareholder approval, which may limit our flexibility to manage our capital structure.
We are a public limited company incorporated under the laws of England and Wales. English law provides that a board of directors may only allot shares (or rights to subscribe for or convert into shares) with the prior authorization of shareholders, such authorization stating the aggregate nominal amount of shares that it covers and valid for a maximum period of five years, each as specified in the articles of association or relevant shareholder resolution. We have obtained authority from our shareholders to allot additional shares for a period expiring on May 31, 2025, which authorization will need to be renewed upon expiration (i.e., at least every five years) but may be sought more frequently for additional five-year terms (or any shorter period).
English law also generally provides shareholders with preemptive rights when new shares are issued for cash. However, it is possible for the articles of association, or for shareholders to pass a special resolution at a general meeting, being a resolution passed by at least 75% of the votes cast, to disapply preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the disapplication is contained in the articles of association, or from the date of the shareholder special resolution, if the disapplication is by shareholder special resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every five years). We have obtained authority from our shareholders to disapply preemptive rights for a period expiring on May 31, 2025, which disapplication will need to be renewed upon expiration (i.e., at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).
English law also generally prohibits a public company from repurchasing its own shares without the prior approval of shareholders by ordinary resolution, being a resolution passed by a simple majority of votes cast, and other formalities. Such approval may be for a maximum period of up to five years.
The United Kingdom’s vote in favor of withdrawing from the European Union may have a negative effect on global economic conditions, financial markets and our business, which could reduce the market price of our Class A ordinary shares.
The withdrawal of the United Kingdom from the European Union (commonly referred to as “Brexit”) took effect on January 31, 2020 (the “Exit Day”). A post-Brexit transition period started on the Exit Day and expired on December 31, 2020. In December 2020, the United Kingdom and the European Union agreed on a trade and cooperation agreement that will apply provisionally after the end of the transition period until it is ratified by the parties to the agreement. On December 31, 2020, the United Kingdom passed legislation giving effect to the trade and cooperation agreement, with the E.U. expected to formally adopt the agreement in early 2021. The trade and cooperation agreement covers the general objectives and framework of the relationship between the United Kingdom and the European Union, including as it related to trade, transport, visas, judicial, law enforcement and security matters, and provides for continued participation in community programs and mechanisms for dispute resolution. Notably, under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire EU single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the United Kingdom and the European Union. Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, the impact on the regulatory regime with respect to obtaining marketing approval of our development-stage product candidates in the United Kingdom remains unclear. The United Kingdom will no longer be covered by the centralized procedures for obtaining European Union-wide marketing authorization from the EMA and, unless a specific agreement is entered into, a separate process for authorization of drug products will be required in the United Kingdom. Depending on the outcome of these developments, we could face new regulatory costs and challenges that could adversely affect our operations and the market price of our Class A ordinary shares.
38

If our Class A ordinary shares are not eligible for deposit and clearing within the facilities of DTC, then transactions in our securities may be disrupted.
The facilities of The Depository Trust Company (“DTC”) are a widely-used mechanism that allow for rapid electronic transfers of securities between the participants in the DTC system, which include many large banks and brokerage firms. While our Class A ordinary shares are eligible for deposit and clearing within the DTC system and DTC has agreed to accept our Class A ordinary shares for deposit and clearing within its facilities in certain specified circumstances, DTC will generally have discretion to cease to act as a depository and clearing agency for the Class A ordinary shares, including to the extent that any changes in U.K. law (including changes as a result of the U.K.’s withdrawal from the EU, which could affect the stamp duty or stamp duty reserve tax (“SDRT”) position) change the stamp duty or SDRT position in relation to the Class A ordinary shares. If DTC determined at any time that the shares were not eligible for continued deposit and clearance within its facilities, then we believe the shares would not be eligible for continued listing on a U.S. securities exchange and trading in the shares would be disrupted. While we would pursue alternative arrangements to preserve our listing and maintain trading, any such disruption could adversely affect the market price of our Class A ordinary shares.
The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain qualified board members.
As a public entity, we are subject to the reporting requirements of the U.S. Securities Exchange Act of 1934, as amended (“U.S. Exchange Act”), the requirements of the U.S. Sarbanes-Oxley Act of 2002 (“U.S. Sarbanes-Oxley Act”), and the requirements of the U.K. Companies Act and, if applicable, the Takeover Code. The requirements of these rules and regulations increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources. We are obligated to file with the SEC annual and quarterly information and other reports that are specified in the Exchange Act, and therefore will need to have the ability to prepare financial statements that are compliant with all SEC reporting requirements on a timely basis. In addition, we are subject to other reporting and corporate governance requirements, including certain requirements of Nasdaq and certain provisions of the Sarbanes-Oxley Act and the regulations promulgated thereunder, which will impose significant compliance obligations upon us. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal controls for financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required, and management’s attention may be diverted from other business concerns.
Our compliance with the requirements under the U.S. Exchange Act, the U.S. Sarbanes-Oxley Act, the U.K. Companies Act and, if applicable, the Takeover Code and the rules and regulations thereunder increases our legal and financial compliance costs and makes some activities more time consuming and costly. These rules and regulations have made it more difficult and more expensive for us to obtain directors’ and officers’ liability insurance, and we may in the future be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers. We may not be able to predict or estimate accurately the amount of additional costs we may incur or the timing of such costs.
Failure to establish and maintain effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could adversely affect our business, reputation and the trading price of our Class A ordinary shares.
Prior to our initial public offering, we were not required to comply with the requirements of the U.S. Sarbanes–Oxley Act, including the internal controls evaluation and certification requirements of Section 404 of that statute. Accordingly, our internal controls over financial reporting do not currently meet all of the standards contemplated by Section 404 that we will eventually be required to meet. We are required to meet these standards in the course of preparing our financial statements as of and for the year ended December 31, 2021, which will be the second annual report that we file with the SEC. We are in the process of addressing our internal controls over financial reporting and are establishing formal policies, processes and practices related to financial reporting and to the identification of key financial reporting risks, assessment of their potential effect and linkage of those risks to specific areas and activities within our organization.
Additionally, we have begun the process of documenting our internal controls procedures to satisfy the requirements of Section 404, which requires annual management assessments of the effectiveness of our internal controls over financial reporting and a report by our independent registered public accounting firm addressing these assessments. During the course of our ongoing evaluation and integration of the internal controls over financial reporting, we may identify areas requiring improvement, and we may have to design enhanced processes and controls to address issues identified through this review. For example, we anticipate that the Manager will hire additional administrative and accounting personnel to conduct our financial reporting.
39

Because we do not currently have comprehensive documentation of our internal controls over financial reporting and have not yet tested our internal controls over financial reporting in accordance with Section 404, we cannot conclude in accordance with Section 404 that we do not have a material weakness in our internal controls over financial reporting or a combination of significant deficiencies that could result in the conclusion that we have a material weakness in our internal controls over financial reporting. As a public entity, we are required to complete our initial assessment in a timely manner. If we are not able to implement the requirements of Section 404 in a timely manner or with adequate compliance, our financial reporting could be adversely affected. We may be unable to report our financial information on a timely or reliable basis, which may subject us to adverse regulatory consequences, including sanctions by the SEC or violations of applicable stock exchange listing rules, and result in a breach of the covenants under the agreements governing any of our financing arrangements. There could also be a negative reaction in the financial markets due to a loss of investor confidence in us and the reliability of our financial statements. Confidence in the reliability of our financial statements could also suffer if our independent registered public accounting firm were to report a material weakness in our internal controls over financial reporting. This could adversely affect our business and lead to a decline in the trading price of our Class A ordinary shares.
Risks Relating to Taxation
Our structure involves complex provisions of tax law for which no clear precedent or authority may be available. Our structure also is subject to potential legislative, judicial or administrative change and differing interpretations, possibly on a retroactive basis.
The tax treatment of shareholders and us (including the Irish, U.K. and U.S. federal income tax treatment) depends in some instances on determinations of fact and interpretations of complex provisions of applicable tax law for which no clear precedent or authority may be available. You should be aware that our tax position is not free from doubt, and that applicable tax rules are generally subject to ongoing review by legislative and administrative bodies and relevant tax authorities, as well as by the Organization for Economic Co-operation and Development (“OECD”), which is continuously considering recommendations for changes to existing tax rules. These review processes could result in revised interpretations of established concepts, statutory changes, revisions to regulations and other modifications and interpretations. The present tax treatment of an investment in our Class A ordinary shares and of our operations may be modified by administrative, legislative or judicial interpretation at any time, and any such action may affect investments and commitments previously made. No ruling will be sought from the relevant tax authority regarding any of the tax issues discussed herein, and no assurance can be given that the relevant tax authorities will not challenge any of our tax positions and that such challenge would not succeed. If any such position is successfully challenged, our tax liabilities could materially increase, which would have an adverse effect on our profitability, cash flows and the value of our Class A ordinary shares.
There have been significant changes both made and proposed to international tax laws that increase the complexity, burden and cost of tax compliance for all multinational groups. We expect to continue to monitor these and other developments in international tax law.
We expect to be classified as a passive foreign investment company for U.S. federal income tax purposes, which could subject U.S. holders of our Class A ordinary shares to adverse U.S. federal income tax consequences.
We expect to be classified as a passive foreign investment company (“PFIC”) for U.S. federal income tax purposes. A foreign corporation is generally a PFIC if either at least 75% of its gross income is “passive income,” or 50% of the gross value of its assets is attributable to assets that produce, or are held for the production of, passive income. We generally expect that our income, which consists primarily of passive income, and our assets, which consist primarily of assets that produce passive income, will satisfy these tests and result in our treatment as a PFIC for the current taxable year and any future taxable year. U.S. holders of our Class A ordinary shares who do not make a qualified electing fund (“QEF”) election with respect to us or a mark-to-market election with respect to our Class A ordinary shares will be subject to potentially material adverse tax consequences, including (i) the treatment of any gain on disposition of our Class A ordinary shares as ordinary income and (ii) the application of a deferred interest charge on such gain and the receipt of certain distributions on our Class A ordinary shares. In addition, regardless of whether a QEF or mark-to-market election is made with respect to us, a U.S. holder of our Class A ordinary shares will be required to file an annual report on IRS Form 8621 containing such information with respect to its interest in a PFIC as the IRS may require. Failure to file IRS Form 8621 for each applicable taxable year may result in substantial penalties and result in the U.S. holder’s taxable years being open to audit by the IRS until after such Forms are properly filed. Further, if we are a PFIC for any taxable year during which a U.S. holder holds our Class A ordinary shares, we generally would continue to be treated as a PFIC with respect to that U.S. holder for all succeeding years during which the U.S. holder holds our Class A ordinary shares, even if we ceased to meet the threshold requirements for PFIC status, unless the U.S. holder makes a special “purging” election on IRS Form 8621. The effect of these adverse tax consequences could be materially adverse to you.
40

If you are a U.S. holder and make a valid, timely QEF election for us, the potentially adverse tax consequences discussed above may be mitigated, but you could still recognize taxable income in a taxable year with respect to our Class A ordinary shares in excess of any distributions that we make to you in that year, thus giving rise to so-called “phantom income” and to a potential tax liability in excess of actual cash received. In addition, U.S. holders will also need to make the QEF election with respect to any PFIC owned by us in order to avoid being subject to the adverse tax consequences described above. We expect to provide information to all electing shareholders needed to comply with the QEF election, including with respect to any of our subsidiaries that may be classified as a PFIC. However, no assurance can be given that we will be able to provide information necessary to make QEF elections with respect to any subsidiary that is a PFIC and that we will not control. As a result, even if a U.S. holder validly makes a timely QEF election with respect to our Class A ordinary shares, the U.S. holder may continue to be subject to the adverse tax consequences described above with respect to its indirect interest in any of our subsidiaries that are PFICs and that we will not control. U.S. holders should consult their tax advisors as to the availability and desirability of a QEF election, as well as the impact of such election on interests in any lower-tier PFICs.
If you are a U.S. holder and make a valid, timely mark-to-market election with respect to our Class A ordinary shares, you will recognize as ordinary income or loss in each year that we are a PFIC an amount equal to the difference between your basis in our Class A ordinary shares and the fair market value of the Class A ordinary shares, thus also possibly giving rise to phantom income and a potential tax liability in excess of actual cash received. Ordinary loss generally is recognized only to the extent of net mark-to-market gains previously included in income. U.S. holders should also be aware that there is no provision in the U.S. Internal Revenue Code, Treasury regulations or other published authority that would allow them to make the mark-to-market election with respect to any of our subsidiaries that are PFICs (because shares in such subsidiaries are not expected to be publicly traded), potentially rendering such election less beneficial to U.S. holders than the QEF election.
Distributions that we pay to individual and other non-corporate U.S. holders will not be eligible for taxation at reduced rates, which could potentially adversely affect the value of your Class A ordinary shares.
Distributions made to non-corporate U.S. holders will not be eligible for taxation at reduced tax rates generally applicable to dividends paid by certain U.S. corporations and “qualified foreign corporations” because of our expected status as a PFIC. The more favorable rates applicable to qualifying corporate dividends could cause individuals to perceive investment in our Class A ordinary shares to be relatively less attractive than investment in the shares of other corporations, and this perception could adversely affect the value of our Class A ordinary shares.
We could be liable for significant taxes due to changes in our eligibility for certain income tax treaty benefits or challenges to our tax positions with respect to the application of income tax treaties.
Our subsidiaries expect to receive revenue from both U.S. and non-U.S. sources. We expect that our subsidiaries generally will be eligible for benefits under the applicable income tax treaties between Ireland and the jurisdictions where income is sourced. However, no assurances can be provided in this regard, and it is possible that a taxing authority could successfully assert that any of our subsidiaries does not qualify for treaty benefits as a result of its failure to satisfy the applicable requirements to be eligible to claim treaty benefits. If a taxing authority were to challenge our position regarding the application of an applicable income tax treaty, we could become subject to increased withholding taxes, and such taxes could be significant.
41

Specifically, with respect to certain U.S.-source income, we expect that our subsidiaries will be eligible for benefits under the U.S.-Ireland income tax treaty (the “Treaty”), and, under that Treaty, will not be subject to any U.S. withholding taxes on such U.S.-source payments. Our current treaty position with respect to U.S.-source payments relies in part on U.S. citizens or tax residents (as defined for purposes of the Treaty) owning, directly or indirectly, at least 50% of the beneficial interest in, or at least 50% of the aggregate vote and value of, each of our subsidiaries that earns U.S.-source income. Our treaty position is based on the current U.S. status of the majority of the existing indirect investors in RP Holdings and Old RPI. Subject to certain exceptions, the existing indirect U.S. investors in RP Holdings have the right to exchange their interests for our publicly traded Class A ordinary shares. Such publicly traded Class A ordinary shares could be further transferred on the public market to other persons. Therefore, it is possible that over time U.S. persons will own indirectly in the aggregate less than 50% of the interests in our subsidiaries. We currently expect that our Class A ordinary shares and other existing indirect interests in RP Holdings and Old RPI in the aggregate will continue to be owned in sufficient amount by U.S. citizens or tax residents, and that we will be able to establish such ownership, for purposes of satisfying the 50% ownership requirement under the Treaty. However, there is no assurance that RP Holdings and Old RPI will continue to be owned directly or indirectly by sufficient U.S. citizens or residents or that we will be able to establish to the IRS’ satisfaction such ownership for purposes of satisfying the 50% U.S. ownership requirement under the Treaty. It is possible that if the indirect U.S. ownership in our subsidiaries becomes lower than 50% (or we cannot establish such ownership) we may in the future be able to qualify for another applicable exemption from U.S. withholding under the Treaty, but there can be no assurance in this regard. A substantial portion of our revenue is, and is expected to continue to be, derived from U.S.-source royalties. Therefore, if our subsidiaries failed to qualify for an exemption from U.S. withholding tax under the Treaty (by satisfying either the 50% U.S. ownership requirement or an alternative Treaty exemption) and such royalties were subject to a 30% U.S. withholding tax, our financial position and profitability, and the value of your investment in our Class A ordinary shares could be materially and adversely affected.
Furthermore, on August 25, 2016, the Irish Department of Finance announced that, in the context of the publication by the United States Treasury Department of a revised U.S. Model Income Tax Convention in February 2016, discussions have begun with the United States Treasury on updating certain elements of the Treaty. It is at this time not clear what elements of the Treaty may be updated, or when any such updates would go into effect. However, certain elements of the revised U.S. Model Income Tax Convention could, if included in an update to the Treaty, result in our subsidiaries being unable to qualify for the benefits of the Treaty or eliminate or reduce the benefits of the Treaty that otherwise would have been available to us. If our subsidiaries are unable to qualify for the benefits of the Treaty, or if any benefits of the Treaty that otherwise would have been available to us are eliminated or reduced, then all or a portion of our income may become subject to increased withholding taxes, and such taxes could be very significant and materially and adversely affect our financial position, profitability and cash flows.
If we were to become subject to increased withholding taxes, we potentially could reorganize Royalty Pharma plc and/or RPI and its wholly-owned subsidiaries, but no assurance can be provided that any such reorganization transaction could be implemented without triggering any taxable gains to us and/or our shareholders, and such taxable gains could be material.
We could be liable for significant U.S. taxation if our subsidiaries are considered to be engaged in a U.S. trade or business.
In general, if a foreign corporation, such as Royalty Pharma plc, is considered to be engaged in a U.S. trade or business, such corporation’s share of any income that is effectively connected with such U.S. trade or business will be subject to regular U.S. federal income taxation (currently imposed at a maximum rate of 21%) on a net basis and, potentially, an additional 30% U.S. “branch profits” tax on distributions attributable to income that is effectively connected with such U.S. trade or business. In addition, it is possible that such corporation could be subject to taxation on a net basis by state or local jurisdictions within the United States. We intend to conduct our activities, through our subsidiaries, such that no income realized by us will be effectively connected with the conduct of a U.S. trade or business or otherwise subject to regular U.S. federal income taxation on a net basis. If we are able to conduct our activities in this way, income or gains realized by us will not be subject to U.S. net federal income taxation. However, no assurance can be provided in this regard. The proper characterization of our income and gains for U.S. tax purposes is not certain, and it is possible that all or a portion of our income and gains could be characterized as income that is “effectively connected” with the conduct of a U.S. trade or business. If our income and gains were characterized as effectively connected with a U.S. trade or business, we would be subject to significant U.S. taxes plus interest and possible penalties, and our financial position, cash flows and profitability could be materially and adversely affected.
42

Transfers of our Class A ordinary shares outside DTC may be subject to stamp duty or SDRT, in the U.K., which would increase the cost of dealing in our Class A ordinary shares.
Except for Class A ordinary shares received by a holder deemed to be an affiliate of us for purposes of U.S. securities laws, our Class A ordinary shares have been issued to a nominee for DTC, and corresponding book-entry interests credited in the facilities of DTC. On the basis of current law, no charges to U.K. stamp duty or SDRT are expected to arise on the issue of Class A ordinary shares into DTC’s facilities or on transfers of book-entry interests in Class A ordinary shares within DTC’s facilities and you are strongly encouraged to hold your Class A ordinary shares in book-entry form through the facilities of DTC.
A transfer of title in the Class A ordinary shares from within the DTC system to a purchaser out of DTC and any subsequent transfers that occur entirely outside the DTC system, will generally result in a charge to stamp duty at a rate of 0.5% (rounded up to the nearest £5) of any consideration, which is payable by the transferee of the ordinary shares. Any such duty must be paid (and the relevant transfer document, if any, stamped by HM Revenue & Customs) before the transfer can be registered in our company books. However, if those Class A ordinary shares are redeposited into DTC, the redeposit will generally attract stamp duty or SDRT at the rate of 1.5% to be paid by the transferor.
We have put in place arrangements to require that our Class A ordinary shares held in certificated form or otherwise outside the DTC system cannot be transferred into the DTC system until the transferor of the Class A ordinary shares has first delivered the ordinary shares to a depositary specified by us so that stamp duty (and/or SDRT) may be collected in connection with the initial delivery to the depositary. Any such ordinary shares are evidenced by a receipt issued by the depositary. Before the transfer can be registered in our books, the transferor will also be required to put funds in the depositary to settle the resultant liability to stamp duty (and/or SDRT), which will be charged at a rate of 1.5% of the value of the shares.
We expect to operate, and expect that RP Holdings will operate, so as to be treated solely as a resident of the U.K. for tax purposes, but changes to our management and organizational structure and/or to the tax residency laws of other jurisdictions where we operate may cause the relevant tax authorities to treat us or RP Holdings as also being a resident of another jurisdiction for tax purposes.
Under current U.K. tax law, a company that is incorporated in the U.K. is regarded as resident for tax purposes in the U.K. unless (i) it is concurrently treated as resident for tax purposes in another jurisdiction (applying the rules of that other jurisdiction for determining tax residency) that has a double tax treaty with the U.K. and (ii) there is a residency tie-breaker provision in that tax treaty which allocates tax residence to that other jurisdiction.
Based upon our anticipated management and organizational structure, we believe that we and RP Holdings should be regarded as tax resident solely in the U.K. However, because this analysis is highly factual and may depend on future changes in our management and organizational structure, as well as future changes in the tax residency laws of other jurisdictions where we operate, there can be no assurance regarding the determination of our tax residence in the future.
As U.K. tax resident companies, we and RP Holdings will be subject to U.K. corporation tax on our worldwide taxable profits and gains. Should we (or RP Holdings) be treated as resident in a jurisdiction other than the U.K., we (or RP Holdings, as applicable) could be subject to taxation in that jurisdiction and may be required to comply with a number of material and formal tax obligations, including withholding tax and/or reporting obligations provided under the relevant tax law, which could result in additional costs and expenses.
We believe that we should not be subject to material U.K. corporation tax in respect of certain profits of our non-U.K. tax resident subsidiaries as a result of the U.K.’s “controlled foreign companies” rules but it cannot be guaranteed that this will continue to be the case.
As U.K. tax resident companies, we and RP Holdings will be subject to the U.K.’s “controlled foreign companies” rules (the “U.K. CFC Rules”). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the “Controlled Foreign Company”) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. The types of profits of a Controlled Foreign Company that can potentially be subject to a U.K. corporation tax charge under the U.K. CFC Rules include business profits of the Controlled Foreign Company that are attributable to assets or risks that are managed by activities in the U.K., or certain finance profits of the Controlled Foreign Company that arise from capital or other assets contributed, directly or indirectly, to the Controlled Foreign Company from a connected U.K. tax resident company.
43

Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings), will be Controlled Foreign Companies for U.K. tax purposes. We and RP Holdings will therefore be required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets or our financing arrangements, however no assurances can be given that this will continue to be the case. The U.K. CFC Rules are highly complex and fact-dependent, and changes to, or adverse interpretations of, these rules, or changes in the future activities of RPI or other non-U.K. companies in which we hold an interest, directly or indirectly, may alter this position and could impact our group’s effective tax rate.
We believe that dividends received by us and RP Holdings should be exempt from U.K. corporation tax, but it cannot be guaranteed that this will continue to be the case.
U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. However, a number of conditions must be met in order for such dividends to qualify for this tax exemption, including (in respect of dividends paid by RPI, which are tax resident in Ireland) conditions relating to the application of Irish tax law. As such, it cannot be guaranteed that these conditions for the U.K. tax exemption in respect of distributions will continue at all times to be satisfied. If distributions received by us or by RP Holdings were not to fall within an exempt class, such distributions would likely be subject to U.K. corporation tax at the then prevailing corporation tax rate.
Even where distributions fall within an exempt class, certain anti-avoidance and recharacterization rules may also apply. For instance, if RPI were to constitute an “offshore fund” for U.K. tax purposes that has at any time in an accounting period more than 60% by market value of its investments in debt securities, money placed at interest (other than cash awaiting investment), certain contracts for differences, or in holdings in other offshore funds with, broadly, more than 60% of their investments similarly invested, RP Holdings’ shareholding in RPI may be subject to U.K. corporation tax as a deemed “loan relationship”, with the result that dividends received by RP Holdings from RPI could be subject to U.K. tax as deemed interest and RP Holdings may be subject to U.K. corporation tax on increases in the fair market value of its shareholding in RPI. The term “offshore fund” is defined for U.K. tax purposes through a characteristics-based approach and, broadly, can include arrangements constituted by a non-U.K. resident body corporate in which a reasonable investor would expect to be able to realize their investment entirely, or almost entirely, by reference to net asset value. We believe and have been advised that RP Holdings’ shareholding in RPI should not fall within these rules, however no guarantee can be offered that this will continue to be the case. Changes to, or adverse interpretations of, the offshore funds rules, or changes in the nature of our investments, may alter this position and could impact our group’s effective rate.

General Risk Factors

Cyber-attacks or other failures in telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations.
We utilize information technology systems and networks to process, transmit and store electronic information in connection with our business activities. As use of digital technologies has increased, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our systems and networks and the confidentiality, availability and integrity of our data. We have been subject to these attacks in the past and expect to be subject to them in the future. There can be no assurance that we will be successful in preventing cyber-attacks or mitigating their effects. Any cyber-attack or destruction or loss of data could adversely affect our business. In addition, we may suffer reputational harm or face litigation as a result of cyber-attacks or other data security breaches and may incur significant additional expense to implement further data protection measures.
Changes in the application of accounting standards issued by the U.S. Financial Accounting Standards Board or other standard-setting bodies may adversely affect our financial statements.
Our financial statements are prepared in accordance with U.S. GAAP, which are periodically revised, interpreted and/or expanded. From time to time, we are required to adopt new or revised accounting standards issued by recognized authoritative bodies. It is possible that future accounting standards we are required to adopt may require changes to the current accounting treatment that we apply to our consolidated financial statements and may require us to make significant changes to our systems. Such changes could adversely affect our financial condition and results of operations.
44

The current outbreak of the novel coronavirus, or COVID-19, or the future outbreak of any other highly infectious or contagious diseases, could materially and adversely affect our results of operations, financial condition and cash flows. Further, the spread of the COVID-19 outbreak has caused severe disruptions in the U.S. and global economy and financial markets and could potentially create widespread business continuity issues of an as yet unknown magnitude and duration.
In December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in Wuhan, China. COVID-19 has since spread to over 100 countries, including every state in the United States. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020 the United States declared a national emergency with respect to COVID-19.
The outbreak of COVID-19 has severely impacted global economic activity and caused significant volatility and negative pressure in financial markets. The global impact of the outbreak has been rapidly evolving and many countries, including the United States, have reacted by instituting quarantines, mandating business and school closures and restricting travel. Many experts predict that the outbreak will trigger a period of global economic slowdown or a global recession. COVID-19 or another pandemic could have material and adverse effects on us due to, among other factors:
• a general decline in business activity;
• the destabilization of the markets could negatively impact our partners in the biopharmaceutical industry and the sales of products generating our royalties;
• difficulty accessing the capital and credit markets on favorable terms, or at all, and a severe disruption and instability in the global financial markets, or deteriorations in credit and financing conditions which could affect our access to capital necessary to fund business operations or address maturing liabilities on a timely basis;
• the potential negative impact on the health of our Manager’s highly qualified personnel, especially if a significant number of them are impacted;
• a deterioration in our ability to ensure business continuity during a disruption;
• interruptions, shortages, delivery delays and potential discontinuation of supply to our partners, which could (i) delay the clinical trials of the development-stage product candidates underlying our assets and result in a loss of our market share for products generating our royalties or development-stage product candidates underlying our assets, if approved, and (ii) hinder our partners’ ability to timely distribute products generating our royalties and satisfy customer demand;
• travel restrictions, shelter-in-place policies or restrictions and other disruptions, which could cause or continue to cause delays and other direct impacts at our partners’ manufacturing sites, which could impact the ability of our partners to manufacture development-stage product candidates underlying our biopharmaceutical assets and products generating our royalties; and
• potential interruptions to our partners’ clinical trial programs of development-stage product candidates underlying our biopharmaceutical assets, including: (i) the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns; (ii) changes in hospital or research institution policies or government regulations, which could delay or adversely impact our partners’ ability to conduct their clinical trials; and (iii) pauses to or delays of trial procedures (particularly any procedures that may be deemed non-essential), patient dosing, shipment of our partners’ development-stage product candidates, distribution of clinical trial materials, study monitoring, site inspections and data analysis due to reasons related to the pandemic, each of which could cause or continue to cause a disruption or delay to the development or the approval of development-stage product candidates underlying our biopharmaceutical assets.
The rapid development and fluidity of this situation makes it impossible to predict the ultimate adverse impact of COVID-19. Nevertheless, COVID-19 presents material uncertainty which could adversely affect our results of operations, financial condition and cash flows.
45

Legal claims and proceedings could adversely affect our business.
We may be subject to a wide variety of legal claims and proceedings. Regardless of their merit, these claims can require significant time and expense to investigate and defend. Since litigation is inherently uncertain, there is no guarantee that we will be successful in defending ourselves against such claims or proceedings, or that our assessment of the materiality of these matters, including any reserves taken in connection therewith, will be consistent with the ultimate outcome of such matters. The resolution of, or increase in the reserves taken in connection with, one or more of these matters could adversely affect our business, financial condition and results of operations.

Item 1B.    UNRESOLVED STAFF COMMENTS

None.

Item 2.        PROPERTIES

Our executive offices are located at 110 East 59th Street, New York, NY 10022, and are provided by the Manager. We believe that our office facilities are suitable and adequate for our business as it is contemplated to be conducted.

Item 3.         LEGAL PROCEEDINGS

From time to time, we or the Manager may be a party to various claims, charges and litigation matters arising in the ordinary course of business. Management and legal counsel regularly review the probable outcome of such proceedings. While we cannot feasibly predict the outcome of these matters with certainty, we believe, based on examination of these matters, experience to date and discussions with counsel, that the ultimate liability, individually or in the aggregate, will not adversely affect our business, financial condition or results of operations.

Item 4.        MINE SAFETY DISCLOSURES

Not applicable.

PART II.     

Item 5.        MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our Class A ordinary shares are traded in the Nasdaq Global Select Market under the symbol “RPRX”. Our Class B ordinary shares are not listed on any stock exchange nor traded on any public market. As of February 24, 2021, there were 5 shareholders of record of our Class A ordinary shares and 2 shareholders of record of our Class B ordinary shares. The number of record holders does not include persons who held our Class A ordinary shares in nominee or “street name” accounts through brokers or other institutions on behalf of shareholders.

Use of Proceeds

On June 15, 2020, our registration statement on Form S-1 (File No. 333-238632), as amended, was declared effective by the SEC for our Initial Public Offering (“the IPO”) of our Class A ordinary shares. There has been no material change in the planned use of proceeds from our IPO as described in the prospectus relating to the offering.

Dividends

Subsequent to our IPO, we declared and paid two quarterly cash dividends for an aggregate amount of $112.5 million, or $0.15 per share to holders of our Class A ordinary shares during the year ended December 31, 2020. Future dividends are subject to declaration by the Board of Directors. To the extent approved and payable, we intend to pay dividends on or about March 15, June 15, September 15 and December 15 to holders of record on or about the twentieth day of each such prior month.

46

Securities Authorized for Issuance Under Equity Compensation Plans

See Item 12, “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” for information regarding securities authorized for issuance.

Stock Performance Graph

The graph below compares the cumulative total stockholder return, calculated on a dividend-reinvested basis, on our Class A ordinary shares, the Standard & Poor’s 500 Index (“S&P 500”) and the Nasdaq Composite Index (“Nasdaq Composite”). The graph assumes an initial investment of $100 in our Class A ordinary shares at the market close on June 16, 2020, which was our initial trading day and its relative performance is tracked through December 31, 2020. The comparisons in the graph below are based upon historical data and are not indicative of, nor intended to forecast, future performance of our Class A ordinary shares.

rprx-20201231_g4.jpg

The above performance graph shall not be deemed soliciting material or to be filed with the SEC for purposes of Section 18 of the Exchange Act, nor shall such information be incorporated by reference into any of our other filings under the Exchange Act or the Securities Act.

Recent Sales of Unregistered Securities

The following is a description of all securities sold or issued by the predecessors to the registrant in 2020. No underwriters were involved in these sales. There was no general solicitation of investors or advertising, and we did not pay or give, directly or indirectly, any commission or other remuneration, in connection with the offering of these shares.

On February 6, 2020, RPI US Partners 2019, LP and RPI International Partners 2019, LP formed Royalty Pharma Ltd., a private limited company organized under the laws of England and Wales (“RP Ltd.”), which issued one Class B ordinary share and one Class R redeemable share to each of RPI US Partners 2019, LP and RPI International Partners 2019, LP in exchange for a nominal capital contribution. On February 10, 2020, RP Ltd. formed RP Holdings, which issued one Class A ordinary share to RP Ltd. in exchange for a nominal capital contribution. In connection with our IPO, each of RPI US Partners 2019, LP and RPI International Partners 2019, LP transferred their shares of Royalty Pharma Investments 2019 ICAV to RP Holdings in exchange for the issuance by RP Holdings of 226,704,600 and 308,678,380 Class B shares (or depository receipts representing such shares), respectively, to each of RPI US Partners 2019, LP and RPI International Partners 2019, LP and one Class C ordinary share to EPA Holdings.

47

On March 25, 2020, RPI US Partners 2019, LP and RPI International Partners 2019, LP each subscribed for an aggregate of 24,999 Class R redeemable shares of RP Ltd. for an aggregate purchase price of £24,999. On April 22, 2020, RP Ltd. was re-registered as Royalty Pharma plc.

The offers, sales and issuances of the securities described above were deemed to be exempt from registration under the
Securities Act in reliance upon Section 4(a)(2) of the Securities Act as transactions by an issuer not involving any public offering. The recipients in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof.

Issuer Purchases of Equity Securities

None.
48

Item 6.         SELECTED FINANCIAL DATA

We have elected to voluntarily comply with Item 301, as amended in a final rule issued by the SEC which is effective for filings on or after February 10, 2021, and eliminate the Selected Financial Data section.

Item 7.         MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand our results of operations and financial condition, cash flows and other changes in financial condition. MD&A is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements and the accompanying notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Special Note Regarding Forward-Looking Statements and the section titled “Risk Factors” in Part I, Item 1A.

Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the IPO of our Class A ordinary shares that was completed in June 2020. “Royalty Pharma,” “Royalty Pharma Investments,” “RPI,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Exchange Offer Transactions (as defined below) and execution of the New Management Agreement (as defined below) (collectively, the “Reorganization Transactions”) in February 2020 and before the consummation of the IPO, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma Investments 2019 ICAV. Prior to the Reorganization Transactions, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma Investments, an Irish Unit Trust (“Old RPI”).

Business Overview

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, which includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

Our capital-efficient business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, including long product life cycles, significant barriers to entry and noncyclical revenues, but with substantially reduced exposure to many common industry challenges such as early stage development risk, therapeutic area constraints, high research and development costs, and high fixed manufacturing and marketing costs. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies across the biopharmaceutical industry.

We classify our royalty acquisitions by the approval status of the therapy at the time of acquisition:

•Approved Products – We acquire royalties in approved products that generate predictable cash flows and may offer upside potential from unapproved indications. Since inception in 1996 through 2020, we have deployed $13.2 billion of cash to acquire royalties on approved products. From 2012 through 2020, we have acquired $8.4 billion of royalties on approved products.

•Development-Stage Product Candidates – We acquire royalties on development-stage product candidates that have demonstrated strong clinical proof of concept. From 2012, when we began acquiring royalties on development-stage product candidates, through 2020, we have deployed $7.0 billion to acquire royalties on development-stage product candidates.

49

While we classify our acquisitions in these two broad segments, several of our acquisitions of royalties on approved products were driven by the long-term potential of these products in other, unapproved indications. Similarly, some of our royalty acquisitions in development-stage product candidates are for products that are approved in other indications.

We acquire product royalties in a variety of ways that can be tailored to the needs of our partners. We classify our product royalty acquisitions by the following structures:

•Third-party Royalties – A royalty is the contractual right to a percentage of top-line sales from a licensee’s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties.

•Synthetic / Hybrid Royalties – A synthetic royalty is the contractual right to a percentage of top-line sales created by the developer and/or marketer of a therapy in exchange for funding. In many of our synthetic royalties, we also make investments in the public equity of the company, where the main value driver of the company is the product for which we concurrently acquired a royalty.

•R&D Funding – We fund R&D, typically for large biopharmaceutical companies, in exchange for future royalties and/or milestones if the product or indication we are funding is approved.

•M&A – We acquire royalties in connection with mergers and acquisitions (“M&A”) transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.

Background and Format of Presentation

In connection with our IPO, we consummated an exchange offer on February 11, 2020 (the “Exchange Date”). Through the exchange offer, investors representing 82% of the aggregate limited partnership in the various partnerships owned by Old RPI (the “Legacy Investors Partnerships”), exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, (together, the “Continuing Investors Partnerships”). The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under a new credit facility and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”

Following our IPO, we operate and control the business affairs of Royalty Pharma Holdings Ltd, (“RP Holdings”) through our controlling ownership of RP Holdings’ Class A ordinary shares and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). We include RP Holdings and its subsidiaries in our consolidated financial statements. RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV, which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions.

As a result of the Exchange Offer Transactions, we own, through our wholly-owned subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”), an 82% economic interest in Old RPI. Through our 82% indirect ownership of Old RPI, we are legally entitled to 82% of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”).

The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish Unit trust. From the Exchange Date until the expiration of the Legacy Investors Partnerships’ investment period on June 30, 2020 (“the Legacy Date”), the Legacy Investors Partnerships had the option to participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI has ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Following the Legacy Date, we have made and will continue to make new investments solely through our wholly-owned subsidiaries, including RPI Intermediate FT.

50

Following management’s determination that a high degree of common ownership exists in RPI both before and after the Exchange Date, RPI recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date. Old RPI is our predecessor for financial reporting purposes. The references in the following discussion to all periods ending on and prior to December 31, 2019 refer to the financial results of Old RPI for the same periods.

Understanding Our Financial Reporting

In accordance with generally accepted accounting principles in the United States (“GAAP”), most of the royalties we acquire are treated as investments in cash flow streams and are thus classified as financial assets. These investments have yield components that most closely resemble loans measured at amortized cost under the effective interest method accounting methodology. Under this accounting methodology, we calculate the effective interest rate on each financial royalty asset using a forecast of the expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. The yield, which is calculated at the end of each reporting period and applied prospectively, is then recognized via accretion into our income at the effective rate of return over the expected life of the financial royalty asset.

The preparation of our financial statements in this manner requires the use of estimates, judgments and assumptions that affect both our reported assets and liabilities and our income and revenue and expenses. The most significant judgments and estimates applied by management are associated with the measurement of income derived from our financial royalty assets, including management’s judgment in forecasting the expected future cash flows of the underlying royalties and the expected duration of the financial royalty asset. Our cash flow forecasts are generated and updated each reporting period by manually compiling sell-side equity research analysts’ consensus estimates for each of the products in which we own royalties. We then calculate our expected royalty cash flows using these consensus forecasts. In any given reporting period, any decline in the expected future cash flows associated with a financial royalty asset is recognized as a provision which is expensed through our income statement as a non-cash charge.

As a result of the non-cash charges associated with applying the effective interest method accounting methodology, our income statement activity in respect of many of our royalties can be volatile and unpredictable. Small declines in sell-side equity research analysts’ consensus forecasts over a long time horizon can result in an immediate non-cash income statement expense recognition, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014 we acquired the cystic fibrosis franchise royalty, which was classified as a financial royalty asset. Beginning in the second quarter of 2015, declines in near-term sales forecasts of sell-side equity research analysts caused us to build up a provision for this financial royalty asset. Over the course of 10 quarters, we recognized non-cash charges to the income statement as a result of these changes in forecasts, ultimately accumulating a peak cumulative non-cash provision of $1.30 billion by September 30, 2017, including non-cash provision expense of $743.2 million in 2016 related to this financial royalty asset. With the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts’ consensus forecasts increased to reflect the larger addressable market and the increase in the expected duration of the Trikafta royalty. While small reductions in the cumulative provision for the cystic fibrosis franchise were recognized in 2017 and 2018, there remained a $1.10 billion cumulative provision balance that was fully offset by a $1.10 billion credit to the provision in 2019 as a result of an increase in sell-side equity research analysts’ consensus forecasts associated with the Trikafta approval. This example illustrates the volatility caused by our accounting model. Therefore, management believes investors should not look to income from royalties or the associated provision for changes in future cash flows as a measure of our near-term financial performance or as a source for predicting future income or growth trends.

Our operations have historically been financed primarily with cash flows generated by our royalties. Due to the nature of our accounting methodology for our financial royalty assets, there is no direct correlation between our income from royalties and our royalty cash receipts. As noted above, income from such royalties is measured at amortized cost under the effective interest method accounting methodology. Given the importance of cash flows to management’s operation of the business and their predictability, management uses royalty receipts as the primary measure of our operating performance. Royalty receipts refer to the summation of the following line items from our GAAP Statement of Cash Flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections and Distributions from non-consolidated affiliates (which line item is included in both Net cash provided by operating activities and Net cash used in investing activities).

In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. The closest comparable GAAP measure to each of the non-GAAP measures that management review is Net cash provided by operating activities. The key non-GAAP metrics we focus on are Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow, each of which is further discussed in the section titled “Non-GAAP Financial Results.”

51

Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of the strength of the Company and the performance of the business. Management uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income used by companies in the biopharmaceutical industry. Adjusted EBITDA, which is derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants.

Refer to the section titled “Non-GAAP Reconciliations” for additional discussion of management’s use of non-GAAP measures as supplemental financial measures.

Portfolio Overview

Our portfolio consists of royalties on more than 45 marketed therapies and five development-stage product candidates. The therapies in our portfolio address therapeutic areas such as rare disease, oncology, neurology, infectious disease, cardiology and diabetes, and are delivered to patients across both primary and specialty care settings. The table below includes royalty cash receipts for the years ended December 31, 2020, 2019 and 2018 grouped by Growth Products and Mature Products. “Growth Products” are defined as royalties with a duration beyond December 31, 2020. We define all other royalties as “Mature Products.”

Royalty receipts
(in thousands)Years Ended December 31,
MarketerTherapeutic area202020192018
Growth Products
Cystic fibrosis franchise (1)VertexRare disease$551,338 $424,741 $224,214 
TysabriBiogenNeurology345,845 332,816 338,697 
ImbruvicaAbbVie/Johnson & JohnsonCancer322,071 270,558 209,171 
HIV franchise (2)Gilead, othersInfectious disease293,808 262,939 224,321 
XtandiPfizer, AstellasCancer146,374 120,096 105,958 
Januvia, Janumet, Other DPP-IVs (3)Merck, othersDiabetes143,754 143,298 106,689 
PromactaNovartisHematology143,741 86,266 — 
Farxiga/Onglyza AstraZenecaDiabetes25,004 — — 
PrevymisMerckInfectious disease21,492 — — 
EmgalityEli LillyNeurology9,529 2,440 — 
CrysvitaUltragenyx, Kyowa KirinRare disease9,454 — — 
ErleadaJohnson & JohnsonCancer7,876 2,683 — 
IDHIFACelgene, Bristol-Myers SquibbCancer6,111 — — 
TrodelvyGileadCancer3,031 — — 
Nurtec ODTBiohavenNeurology667 — — 
TazverikEpizymeCancer522 — — 
EvrysdiRocheNeurology273 — — 
Other Growth Products (4)246,545 205,043 192,241 
Total Royalty Receipts - Growth Products$2,277,435 $1,850,880 $1,401,291 
Mature Products
Tecfidera (5)BiogenNeurology$— $150,000 $750,000 
LetairisGileadCardiology40,170 112,656 130,078 
LyricaPfizerNeurology22,850 128,246 126,916 
RemicadeJohnson & Johnson, MerckImmunology— 6,068 121,055 
HumiraAbbVieImmunology— — 499,055 
Other mature products (6)3,944 21,047 45,450 
Total Royalty Receipts - Mature Products$66,964 $418,017 $1,672,554 

52

(1) The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio.
(2) The HIV franchise includes the following approved products: Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza and Biktarvy. Royalties are received on the emtricitabine portion of sales only.
(3) Januvia, Janumet, Other DPP-IVs include the following approved products: Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas and Nesina. The Other DPP-IVs are marketed by Boehringer Ingelheim, AstraZeneca, Novartis and Takeda.
(4) Other Growth Products include royalties on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion, for which receipts are presented as Distributions from non-consolidated affiliates on the Statement of Cash Flows), Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy and Soliqua. Other Growth Products for 2020 also include contributions from the Legacy SLP Interest, a payment from Biohaven in respect of an expired option to exercise additional funding of the Biohaven Series A Preferred Shares which is presented as Proceeds from available for sale debt securities on the Statement of Cash Flows, and a distribution from Avillion in respect of the Merck KGaA Asset, for which development ceased in 2020, and for which the receipt is presented as Distributions from non-consolidated affiliates in both the operating and investing section of the Statement of Cash Flows.
(5) Receipts from Tecfidera milestone payments are presented as Proceeds from available for sale debt securities on the Statement of Cash Flows.
(6) Other Mature Products primarily include royalties on the following products: Prezista, Rotateq and Thalomid.

Financial Overview

Financial highlights

•Net cash provided by operating activities totaled $2.0 billion, $1.7 billion and $1.6 billion for the years ended December 31, 2020, 2019 and 2018, respectively. Net cash provided by operating activities is the closest comparable GAAP financial measure to the supplemental non-GAAP liquidity measures that follow.
•Adjusted Cash Receipts (a non-GAAP metric) totaled $1.8 billion, $2.1 billion and $2.8 billion for the years ended December 31, 2020, 2019 and 2018, respectively.
•Adjusted EBITDA (a non-GAAP metric) totaled $1.6 billion, $2.0 billion and $2.7 billion for the years ended December 31, 2020, 2019 and 2018, respectively.
•Adjusted Cash Flow (a non-GAAP metric) totaled $1.5 billion, $1.6 billion and $2.4 billion for the years ended December 31, 2020, 2019 and 2018, respectively.

Understanding Our Results of Operations

In connection with our IPO, Royalty Pharma plc became a holding company whose principal asset is a controlling equity interest in RP Holdings, which is the sole equity owner of Royalty Pharma Investments 2019 ICAV, an entity that is included in our consolidated financial statements. We report non-controlling interests related to four minority interests in our subsidiaries held by third parties.

1.     The first minority interest is attributable to the Legacy Investors Partnerships’ 18% ownership interest in Old RPI. The value of this non-controlling interest will decline over time as the assets in Old RPI expire.
2.     The second minority interest is attributable to the RP Holdings Class C Special Interests held by EPA Holdings, an affiliate of the Manager. Income will not be allocated to this non-controlling interest until certain conditions are met, which we do not expect to occur for several years.
3.     The third minority interest is attributable to the RP Holdings Class B Interests held indirectly by the Continuing Investors, which represent an approximate 36% ownership interest in RP Holdings as of December 31, 2020 and are exchangeable for Class A ordinary shares. The value of this non-controlling interest will decline over time if the investors who indirectly own the RP Holdings Class B Interests exchange those shares for our Class A ordinary shares.
4.     The fourth minority interest is attributable to a de minimis interest in RPCT held by certain legacy investors as a result of a 2011 reorganization transaction that created a prior legacy entity. The value of this non-controlling interest will decline over time as the assets in RPCT expire and is expected to be substantially eliminated by the end of 2022.

53

The fourth non-controlling interest related to ownership in RPCT held by Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), is the only non-controlling interest that existed prior to the Reorganization Transactions and is reflected in our historical financial statements for periods through December 31, 2019 and discussed in this MD&A. The non-controlling interest related to the Legacy Investors Partnerships’ 18% ownership interest in Old RPI exists from the Exchange Date and is reflected in our financial statements from the first quarter of 2020. The other two non-controlling interests are reflected in our financial statements from and after the date of our IPO. All of the results of operations of RP Holdings, Old RPI and RPCT are consolidated into our financial statements.

Following the IPO, EPA Holdings is entitled to receive Equity Performance Awards through its RP Holdings Class C Special Interests. Equity Performance Awards owed to EPA Holdings will be recognized as an equity transaction when the obligation becomes due and will impact the income allocated to non-controlling interests related to the RP Holdings Class C Special Interests at that time.

Total income and other revenues

Total income and other revenues is primarily comprised of income from our financial royalty assets, royalty revenue from our intangible royalty assets, and royalty income arising from successful commercialization of products developed through joint R&D funding arrangements. Most of our royalties on both approved products and development-stage product candidates are classified as financial royalty assets as our ownership rights are generally passive in nature. In instances in which we acquire a royalty that does include more substantial rights or ownership of the underlying intellectual property, we classify such royalties as intangible royalty assets.

We recognize interest income related to our financial royalty assets. Royalty revenue relates solely to revenue from our DPP-IV patent estate for which the patent rights have been licensed to various counterparties. For the years ended December 31, 2020, 2019 and 2018, the royalty payors accounting for greater than 10% of our total income and other revenues in any one year are shown in the table below:

Years Ended December 31,
Royalty payorProduct(s)202020192018
VertexCystic fibrosis franchise29 %23 %22 %
AbbVieImbruvica19 %19 %17 %
GileadHIV franchise, Letairis, Trodelvy (1)14 %19 %12 %
BiogenTysabri10 %12 %12 %

(1) We did not recognize any income related to Trodelvy prior to 2020.

Income from financial royalty assets

Our financial royalty assets represent investments in cash flow streams with yield components that most closely resemble loans measured at amortized cost under the effective interest method. We calculate the effective interest rate using forecasted expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. Interest income is recognized at the effective rate of return over the expected life of the asset, which is calculated at the end of each reporting period and applied prospectively. As changes in sell-side equity research analysts’ consensus estimates are updated on a quarterly basis, the effective rate of return changes. For example, if sell-side equity research analysts’ consensus forecasts increase, the yield to derive income on a financial royalty asset will increase and result in higher income for subsequent periods.

Variables affecting the recognition of interest income from financial royalty assets on individual products under the prospective effective interest method include any one of the following: (1) additional acquisitions, (2) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts’ consensus forecasts, (3) regulatory approval of additional indications leading to new cash flow streams, (4) changes to the duration of the royalty (i.e., patent expiration date) and (5) amounts and timing of royalty receipts. Our financial royalty assets are directly linked to sales of underlying pharmaceutical products whose life cycle typically peaks at a point in time, followed frequently by declining sales trends due to the entry of generic competition, resulting in natural declines in the asset balance and periodic interest income over the life of our royalties. The recognition of income from royalties requires management to make estimates and assumptions around many factors, including those impacting the variables noted above.

54

Revenue from intangible royalty assets

Revenue from intangible royalty assets is derived from our Januvia, Janumet and other DPP-IV patents classified as intangible royalty assets.

Other royalty income

Other royalty income primarily includes income from former royalties for which the asset balances have been fully amortized and royalty income from synthetic royalties arising out of R&D funding arrangements. Occasionally, a royalty asset may be amortized on an accelerated basis due to collectability concerns, which, if resolved, may result in future cash collections when no financial royalty asset remains. Similarly, we may continue to collect royalties on a financial royalty asset beyond the estimated patent expiration date by which the financial royalty asset was amortized in full. In each scenario where a financial royalty asset no longer remains, such income is recognized as other royalty income.

R&D funding expense

R&D funding expense consists of (1) upfront R&D payments we have made to counterparties to acquire royalties on development-stage product candidates and (2) ongoing R&D payments to fund development-stage product candidates undergoing clinical trials with our partners in exchange for royalties if the products are successfully developed and commercialized. These expenditures relate to the activities performed by our counterparties to develop and test new products, to test existing products for treatment in new indications, and to ensure product efficacy and regulatory compliance prior to launch.

Below is a summary of the ongoing R&D agreements in place, upfront R&D funding completed, and the associated R&D funding expense during the years ended December 31, 2020, 2019 and 2018:

(in thousands)Years Ended December 31,
Partner/ CounterpartyProductCurrent stage of development202020192018
ImmunomedicsTrodelvy (sacituzumab govitecan-hziy)The FDA approved Trodelvy (sacituzumab govitecan-hziy) in April 2020$— $— $181,428 
BiohavenNurtec ODT (rimegepant) and ZavegepantThe FDA approved Nurtec ODT (rimegepant) in February 2020— — 103,011 
PfizerPalbociclib/ IbranceNo longer in Phase III clinical trial for adjuvant breast cancer; approved for other indications— 62,796 99,265 
OtherVariousVarious26,289 20,240 8,905 
Total R&D funding expense$26,289 $83,036 $392,609 

Provision for changes in expected cash flows from financial royalty assets

The provision for changes in expected future cash flows from financial royalty assets includes the following activities:

•the movement in the cumulative allowance for changes in expected future cash flows; and
•the movement in the allowance for credit losses subsequent to adoption of ASU 2016-13 on January 1, 2020.

The provision for changes in expected cash flows is the current period activity resulting from adjustments to the cumulative allowance for changes in expected cash flows, which is a netted against the balance sheet account Financial royalty assets, net balance on the consolidated balance sheets. As discussed above, income is accreted on our financial royalty assets using the effective interest method. As we update our forecasted cash flows on a periodic basis and recalculate the present value of the remaining future cash flows, any shortfall when compared to the carrying value of the financial royalty asset is recorded directly to the income statement through the line item Provision for changes in expected future cash flows from financial royalty assets. If, in a subsequent period, there is an increase in expected cash flows or if actual cash flows are greater than cash flows previously expected, we reduce the cumulative allowance previously established for a financial royalty asset for the incremental increase in the present value of cash flows expected to be collected. This results in a credit to provision expense.

55

Most of the same variables and management’s estimates affecting the recognition of interest income on our financial royalty assets also impact the provision. In any period, we will recognize provision income (i.e., a credit to the provision) or expense as a result of the following factors: (1) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts’ consensus forecasts, (2) regulatory approval of additional indications which leads to new cash flow streams, (3) changes to the duration of the royalty (i.e., patent expiration date) and (4) amounts and timing of royalty receipts.

Upon the adoption on January 1, 2020 of ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), we recorded a cumulative adjustment to Retained earnings of $192.7 million to recognize an allowance for current expected credit losses on our portfolio of financial royalty assets. The Provision for changes in expected cash flows from financial royalty assets reflects the activity for the period that relates to the change in estimates applied to calculate the allowance for current expected credit losses, namely any new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts used in the effective interest model to measure income from our financial royalty assets.

General and administrative expenses

General and administrative (“G&A”) expenses primarily include Operating and Personnel Payments, bad debt expense, legal reserves, other expenses for professional services, and share-based compensation.

Beginning in 2020, the Operating and Personnel Payments paid to our Manager have been significantly higher than they were in historical periods. Prior to the Reorganization Transactions, the Operating and Personnel Payments were fixed, growing at 5% annually, and not linked to any financial line item. Under the management agreement which is effective from the Exchange Date (“New Management Agreement”), Operating and Personnel Payments for RPI are calculated as 6.5% of the Adjusted Cash Receipts for each quarter and 0.25% of the GAAP value of our security investments as of the end of each quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in our net income, is payable in equal quarterly installments and is calculated as the greater of $1 million per quarter and 0.3125% of Royalty Investments (as defined in the New Management Agreement). The expenses incurred in respect of RPI’s Operating and Personnel Payments are expected to comprise the most significant component of G&A expenses on an ongoing basis.

Equity in (earnings)/loss of non-consolidated affiliates

Legacy SLP Interest

In connection with the Exchange Offer Transactions, we acquired a new equity method investment from the Continuing Investors Partnerships in the form of a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) in exchange for issuing shares in our subsidiary. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and a performance income allocation on a similar basis. The performance income allocation attributable to us is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships.

As the Legacy Investors Partnerships are no longer participating in investment opportunities, the value of the Legacy SLP Interest is expected to decline over time. Our equity method investee, the Legacy Investors Partnerships, also owns a non-controlling interest in Old RPI.

The Avillion Entities

During 2014, we entered into an agreement with our equity method investee Avillion Financing I, LP (“Avillion I”) to invest up to $46.0 million over three years to fund a portion of the costs of a pivotal Phase III study for Pfizer’s Bosulif (bosutinib) to expand its label into front-line chronic myeloid leukemia. The FDA approved a supplemental New Drug Application (“sNDA”) for Pfizer’s Bosulif (bosutinib) in December 2017, which triggered a series of contractual fixed payments from Pfizer to Avillion I over a 10-year period, which we recognize through receipt of distributions from non-consolidated affiliates on the Statement of Cash Flows.

56

In March 2017, we entered into an agreement with BAv Financing II, LP (“Avillion II”, or, together with Avillion I, the “Avillion Entities”), amended in December 2019, to fund up to $19.0 million of the costs of a clinical trial for the use of the Merck KGaA Asset for the treatment of psoriasis in exchange for certain milestone and royalty payments. Development for the Merck KGaA Asset ceased in 2020 and we do not expect to record significant earnings or losses in the future related to this investment.

In 2018, we agreed to fund up to approximately $105 million over multiple years to fund a portion of the costs for Phase II and III clinical trials of Avillion II, who simultaneously entered into a co-development agreement with AstraZeneca to advance PT027 (the “AZ Asset”) through a global clinical development program for the treatment of asthma in exchange for a series of deferred payments and success-based milestones.

The business model of the Avillion Entities includes partnering with global biopharmaceutical companies to perform R&D in exchange for success-based milestones and/or royalties once products are commercialized.

Other (income)/expense, net

Other (income)/expense, net primarily includes the change in fair market value of our equity securities, the unrealized gains or losses on our derivatives and non-derivative forwards, losses on extinguishment of debt and interest income.

Net income attributable to non-controlling interest

Prior to the Exchange Date, the net income attributable to non-controlling interest related to RPSFT’s 20% share of earnings in RPCT, which is a consolidated subsidiary of Old RPI.

As of and following the Exchange Date, the net income attributable to non-controlling interest also includes the Legacy Investors Partnerships’ approximately 18% share of earnings in Old RPI. As the Legacy Investors Partnerships are no longer participating in investment opportunities of RPI, the related net income attributable to this non-controlling interest is expected to decline over time.
In connection with our IPO, this line item also includes net income attributable to the RP Holdings Class B Interests held by the Continuing Investors Partnerships, and will include net income attributable to the Class C Special Interests held by EPA Holdings once certain conditions have been met. Net income attributable to the non-controlling interest related to the RP Holdings Class B Interests held by the Continuing Investors Partnerships will decline over time if the investors who indirectly own the RP Holdings Class B Interests exchange those shares for our Class A ordinary shares.

Results of Operations

For the Years Ended December 31, 2020, 2019 and 2018

The comparison of our historical results of operations for the years ended December 31, 2020, 2019 and 2018 is as follows:

57

(in thousands)Years Ended December 31,2020 vs. 20192019 vs. 2018
202020192018$ % $ %
Income and other revenues:
     Income from financial royalty assets $1,959,975 $1,648,837 $1,524,816 $311,138 18.9 %$124,021 8.1 %
     Revenue from intangible royalty assets 143,382 145,775 134,118 (2,393)(1.6)%11,657 8.7 %
     Other royalty income 18,996 19,642 135,960 (646)(3.3)%(116,318)(85.6)%
Total income and other revenues 2,122,353 1,814,254 1,794,894 308,099 17.0 %19,360 1.1 %
Operating expenses:
     Research and development funding expense 26,289 83,036 392,609 (56,747)(68.3)%(309,573)(78.9)%
     Provision for changes in expected cash flows from financial royalty assets 230,839 (1,019,321)(57,334)1,250,160 (122.6)%(961,987)1,677.9 %
     Amortization of intangible royalty assets 23,058 23,924 33,267 (866)(3.6)%(9,343)(28.1)%
     General and administrative expenses 181,715 103,439 61,906 78,276 75.7 %41,533 67.1 %
     Other operating expenses65,053 — — 65,053 — %— — %
Total operating expenses 526,954 (808,922)430,448 1,335,876 (165.1)%(1,239,370)(287.9)%
Operating income 1,595,399 2,623,176 1,364,446 (1,027,777)(39.2)%1,258,730 92.3 %
Other (income)/expense:
     Equity in (earnings)/loss of non-consolidated affiliates (44,459)32,517 7,023 (76,976)(236.7)%25,494 363.0 %
     Interest expense 157,059 268,573 279,956 (111,514)(41.5)%(11,383)(4.1)%
     Realized gain on available for sale debt securities— — (419,481)— — %419,481 (100.0)%
     Other income, net (219,155)(139,333)(20,907)(79,822)57.3 %(118,426)566.4 %
Total other (income)/expenses, net (106,555)161,757 (153,409)(268,312)(165.9)%315,166 (205.4)%
Consolidated net income 1,701,954 2,461,419 1,517,855 (759,465)(30.9)%943,564 62.2 %
     Less: Net income attributable to non-controlling interest (726,914)(112,884)(140,126)(614,030)543.9 %27,242 (19.4)%
Net income attributable to controlling interest $975,040 $2,348,535 $1,377,729 $(1,373,495)(58.5)%$970,806 70.5 %


Total income and revenues

Income from financial royalty assets

Income from financial royalty assets by product for our top products for the years ended December 31, 2020, 2019 and 2018 is as follows, in order of contribution to income for the year ended December 31, 2020.

(in thousands)Years Ended December 31,2020 vs. 20192019 vs. 2018
202020192018$ % $ %
Cystic fibrosis franchise$611,948 $422,618 $400,375 $189,330 44.8 %$22,243 5.6 %
Imbruvica396,285 349,210 298,740 47,075 13.5 %50,470 16.9 %
HIV franchise244,268 253,837 197,211 (9,569)(3.8)%56,626 28.7 %
Tysabri218,370 226,554 213,929 (8,184)(3.6)%12,625 5.9 %
Xtandi102,791 99,933 106,567 2,858 2.9 %(6,634)(6.2)%
Tazverik56,464 — — 56,464 — %— — %
Other329,849 296,685 307,994 33,164 11.2 %(11,309)(3.7)%
Total income from financial royalty assets$1,959,975 $1,648,837 $1,524,816 $311,138 18.9 %$124,021 8.1 %

Years ended December 31, 2020 and 2019

Income from financial royalty assets increased by $311.1 million, or 18.9%, in 2020 compared to 2019, primarily driven by increased income from the cystic fibrosis franchise and Imbruvica. Additionally, we recorded $51.7 million in income in 2020 related to new assets acquired in 2020, primarily Evrysdi and Prevymis. Also, a full year of income related to Crysvita and income from Tazverik following its FDA approval date in January 2020, both of which were acquired in the fourth quarter of 2019, contributed to the increase. The increased income was partially offset by declines from maturing assets, such as Lyrica and Letairis.

58

Years ended December 31, 2019 and 2018

Income from financial royalty assets increased by $124.0 million, or 8.1%, in 2019 compared to 2018, primarily due to increased income from the following royalty assets: Imbruvica, HIV franchise, cystic fibrosis franchise, Letairis, Promacta and Emgality, the latter two of which were newly acquired in 2019. Imbruvica, the HIV franchise and cystic fibrosis franchise generated increased income as a result of strong product performance. We extended the duration of our Letairis royalty as a result of new information, which resulted in increased income from Letairis for the year. Partially offsetting the increase in income from financial royalty assets was a significant decline in income related to Humira, which expired in 2018.

Revenue from intangible royalty assets

Years ended December 31, 2020 and 2019

Revenue from intangible royalty interests decreased by $2.4 million, or 1.6%, in 2020 compared to 2019, primarily driven by the Januvia and Janumet royalties approaching maturity, and the maturity of the other DPP-IVs.

Years ended December 31, 2019 and 2018

Revenue from intangible royalty assets increased $11.7 million, or 8.7%, due to a full year of royalties earned on the Januvia and Janumet products marketed by Merck & Co. In 2016, we entered into a contractual amendment to our license agreement and a settlement with Merck & Co. (the “Merck Settlement”) that provided for a cumulative catch-up payment for past-due royalties on Januvia and Janumet products between 2014 and 2016 of $297.5 million in exchange for a five-quarter payment holiday that began in January 2017. In 2018, we only earned royalties on product sales during the last three quarters of the year, following the expiration of the holiday period.

Other royalty income

Years ended December 31, 2020 and 2019

Other royalty income decreased by $0.6 million, or 3.3%, in 2020 compared to 2019, primarily due to the loss of royalty income from Remicade, which expired in 2018, but for which we continued collecting royalties through the three months ended March 31, 2019, as well as the expiration of our Prezista royalty in 2019. The decrease was offset by higher royalty income in 2020 related to Soliqua, the product we co-funded with Sanofi on which we are entitled to royalties indefinitely, and royalty income related to Trodelvy, the product for which we provided upfront R&D funding to Immunomedics in 2018 and which was approved by the FDA in 2020.

Years ended December 31, 2019 and 2018

Other royalty income of $19.6 million in 2019 primarily included income from our final royalties on Remicade and royalty income from Soliqua.

Other royalty income of $136.0 million in 2018 primarily included income from our Remicade and Prezista royalties of $93.7 million and $35.6 million, respectively, after the financial royalty assets were amortized.

R&D funding expense

Years ended December 31, 2020 and 2019

R&D funding expense decreased by $56.7 million, or 68.3%, in 2020 as compared to 2019, due to the completion of our funding requirements in the three months ended December 31, 2019 under our agreement with Pfizer. In 2019, we recorded $62.8 million in R&D funding expense under our agreement with Pfizer.

59

Years ended December 31, 2019 and 2018

R&D funding expense decreased by $309.6 million, or 78.9%, in 2019 compared to 2018, primarily due to the royalty acquisitions from Immunomedics and Biohaven that occurred in 2018, which resulted in upfront development-stage funding expense of $181.4 million and $103.0 million, respectively. We did not have upfront development-stage funding expense in 2019.

Provision for changes in expected cash flows from financial royalty assets

The breakdown of our provision for changes in expected cash flows includes the
(1) provision for current expected credit losses upon adoption of ASU 2016-13 on January 1, 2020; and
(2) income and expense activity for financial royalty assets whose cash flow forecasts have changed from the prior period.
As the latter activity is a combination of income and expense items, the provision breakdown by product, exclusive of the provision for current expected credit losses, is as follows, based on the largest contributors to each year’s provision income or expense:

(in thousands)
Product2020Product2019Product2018
IDHIFA$87,835 Cystic fibrosis franchise$(1,101,675)Imbruvica$(45,577)
Imbruvica46,872 Tysabri(66,451)Tysabri(43,355)
Tysabri40,931 Emgality38,262 Cystic fibrosis franchise(40,287)
Soliqua32,735 Soliqua42,002 Letairis(31,888)
Xtandi(187,059)Xtandi76,568 Xtandi63,442 
Other53,339 Other(8,027)Other40,331 
Total provision, exclusive of provision for credit losses74,653 Total provision, exclusive of provision for credit losses(1,019,321)Total provision, exclusive of provision for credit losses(57,334)
Provision for current expected credit losses156,186 Provision for current expected credit losses— Provision for current expected credit losses— 
Total provision$230,839 Total provision$(1,019,321)Total provision$(57,334)

Years ended December 31, 2020, 2019 and 2018

In 2020, we recorded provision expense of $230.8 million for changes in expected cash flows in comparison to provision income of $1.0 billion for 2019. The provision expense for 2020 is primarily driven by current expected credit losses of $156.2 million as a result of our adoption of the new accounting standard in 2020 and for which we did not have comparable activity in 2019. The 2020 provision for current expected credit losses was predominantly driven by increases to our portfolio of financial royalty assets during 2020, such as the additional tranche of Tazverik acquired from Epizyme and our acquisition of the zavegepant royalty from Biohaven.

In 2020, we recognized provision expense of $87.8 million related to IDHIFA, which was acquired in 2020. In addition, we recorded provision expenses of $46.9 million and $40.9 million related to Imbruvica and Tysabri, respectively, due to decreases in sell-side research analysts’ consensus forecasts during 2020. The provision expense was partially offset by the reversal of the cumulative allowance for Xtandi of $187.1 million due to increases in sell-side research analysts’ consensus forecasts during 2020.

In 2019, we recognized provision income of $1.0 billion primarily driven by the full reversal of the remaining provision of $1.1 billion recorded against the cystic fibrosis franchise as a result of the approval of the Vertex triple combination therapy, Trikafta, in October 2019. Upon the approval, we began including sell-side equity research analysts’ consensus forecasts for Trikafta in the consensus forecasts for the franchise and also extended the duration of our expected cash flows from the cystic fibrosis franchise to reflect the longer patent duration of Trikafta. In addition, we recognized provision income for Tysabri of $66.5 million due to increases in sell-side research analysts’ consensus forecasts. The provision income was offset by provision expenses recorded for Xtandi, Soliqua and Emgality totaling $156.8 million, which were all driven by declines in sell-side equity research analysts’ consensus forecasts.

60

In 2018, we recognized provision income of $57.3 million. The cumulative allowance for Imbruvica of $45.6 million was fully reversed in 2018 due to an increase in sell-side equity research analyst consensus forecasts. In 2018, we partially reversed $43.4 million of cumulative allowance related to Tysabri as Tysabri sales did not decline as quickly as sell-side equity research analysts expected and we saw a subsequent increase in sell-side equity research analyst consensus forecasts in 2018. In addition, we recorded provision income of $31.9 million for Letairis in 2018 due to the delayed entry of generics that was initially expected in the third quarter of 2018, which caused a partial reversal of a previously recognized cumulative provision against this asset. While the cystic fibrosis franchise generated provision income in 2018, this was primarily the result of variability in the consensus forecasts during both years and not representative of any significant underlying driver in franchise product sales.

Throughout 2017, we recorded significant provision expense for Xtandi as consensus forecasts for future years dropped significantly in 2017, contributing to declines in analyst consensus compared to forecasts from prior periods. Product sales and sell-side equity research analyst consensus forecasts improved for Xtandi in 2018, resulting in a partial reversal of the cumulative allowance in late 2018, and net expense of $63.4 million for the year.

G&A expenses

Years ended December 31, 2020 and 2019

G&A expenses increased $78.3 million, or 75.7%, in 2020 compared to 2019, primarily due to a $39.1 million increase in Operating and Personnel Payments under the New Management Agreement and an increase of $26.2 million in fees related to our debt refinancing in 2020, for which there was no comparable activity in 2019. We also incurred non-recurring professional services costs in connection with the IPO, two full quarters of expense associated with the directors and officers liability insurance policy and $5.7 million of share-based compensation expense, which further contributed to the increased G&A expenses in 2020.

Years ended December 31, 2019 and 2018

G&A expenses increased $41.5 million, or 67.1%, during 2019 compared to 2018, primarily due to a $26.4 million increase in costs for consulting and professional services related to our Reorganization Transactions. In addition, the 2018 reversal of an $8.7 million legal reserve from a dispute related to one of our DPP-IV products contributed to the increase year over year in 2019.

Other operating expenses

Years ended December 31, 2020, 2019 and 2018

Other operating expenses was $65.1 million in 2020 due to the recognition of a non-cash impairment charge related to the write-off of our omecamtiv financial royalty asset balance of $90.2 million, net of cumulative allowance of $25.2 million. During the three months ended December 31, 2020, it was announced that omecamtiv, a development stage product did not meet the clinical trial objectives. We did not have comparable activity in 2019 or 2018.

Equity in (earnings)/loss of non-consolidated affiliates

Years ended December 31, 2020 and 2019

Equity in earnings of non-consolidated affiliates was $44.5 million in 2020 and was comprised of equity in earnings from the Legacy SLP Interest and equity in losses from the Avillion Entities. Equity in earnings from the Legacy SLP Interest, an investment which arose through the Exchange Offer Transactions, was $62.0 million in 2020.

Equity in losses of the Avillion Entities was $17.6 million and $32.5 million during 2020 and 2019, respectively. Equity in losses of the Avillion Entities was lower in 2020 compared to 2019 primarily driven by a gain related to Avillion II’s completion of the development program for the Merck KGaA Asset during the second quarter of 2020, which triggered a distribution to us in 2020.

61

Years ended December 31, 2019 and 2018

Equity in losses of non-consolidated affiliates was not material in 2019 or in 2018 and related solely to our investment in the Avillion Entities.

Interest expense

Years ended December 31, 2020 and 2019

Interest expense decreased by $111.5 million, or 41.5%, in 2020 as compared to 2019, due to the Reorganization Transactions and refinancing of RPIFT’s prior senior secured credit facilities that occurred in February 2020 through the issuance of senior secured credit facilities (“Senior Secured Credit Facilities”) at lower interest rates. The Senior Secured Credit Facilities were subsequently refinanced through the $6.0 billion senior unsecured notes offering completed in September 2020 (the “Notes”). The Notes were issued at a weighted average interest rate of 2.125%, which is lower than the weighted average interest rate on RPIFT’s prior senior secured credit facilities of 3.69% that was applicable in 2019.
Refer to the “Liquidity and Capital Resources” section for additional discussion of the Notes and the refinanced senior secured credit facilities.

Years ended December 31, 2019 and 2018

Interest expense remained relatively consistent between 2019 and 2018, as expected.

Realized gain on available for sale debt securities

Years ended December 31, 2019 and 2018

We did not record any realized gains on available for sale debt securities subsequent to December 31, 2018 because our contractual agreement in respect of Tecfidera milestones was satisfied as of December 31, 2018. In 2018, four Tecfidera milestones totaling $600.0 million were triggered, with an associated cost basis of $180.5 million.

Other income, net

Years ended December 31, 2020, 2019 and 2018

Other income was $219.2 million in 2020 and was primarily comprised of realized and unrealized gains on equity securities of $247.1 million. We recognized a gain of $292.3 million related to an increase in the share price of Immunomedics common stock as a result of its acquisition by Gilead in the fourth quarter of 2020 and a $66.0 million unrealized gain related to an increase in share price of our investment in Biohaven common stock. These gains were partially offset by an unrealized loss of $120.1 million related to a decrease in share price of our investment in Epizyme common stock. We also recorded income of $18.6 million related to the movement in fair value of our commitment to acquire the Series B Biohaven Preferred Shares (“Series B Forwards”), for which we did not have comparable activity in 2019. We also recorded a loss on debt extinguishment of $30.5 million in 2020 due to unamortized loan issuance costs and original issue discount related to our credit facilities written off as a result of the 2020 debt refinancings, for which we did not have comparable activity in 2019.

Other income was $139.3 million in 2019 and was primarily comprised of the movement in fair market value of equity securities purchased in 2019. As part of our transaction with Epizyme in November 2019, we acquired common stock and warrants with an initial fair value of $87.8 million. By the end of 2019, the market value of the common stock and warrants of Epizyme had increased by $107.0 million to $194.8 million. We also recorded unrealized gains of $67.0 million for the increases in market value of our investment in common stock of Biohaven and Immunomedics. Finally, we recognized an unrealized loss of $72.6 million on our interest rate swaps due to adverse movements in the LIBOR curve.

62

Other income was $20.9 million in 2018 primary due to the adoption of ASU 2016-01, which resulted in the recognition of $13.9 million in unrealized losses on equity securities in earnings. Unrealized gains and losses on equity securities were previously recorded as a component of accumulated other comprehensive income. This loss was offset by increased interest income compared to prior periods due to carrying a significantly larger cash and cash equivalents balance over the year, on which we earned interest.

Net income attributable to non-controlling interest

Years ended December 31, 2020 and 2019

Net income attributable to the Legacy Investors Partnerships and the Continuing Investors Partnerships was $321.0 million and $317.0 million, respectively, in 2020. The net income attributable to non-controlling interest in 2020 was larger than in 2019 as a result of ownership changes related to the Exchange Offer Transactions and the IPO. As a result of the Exchange Offer Transactions, a new non-controlling interest exists related to the ownership in Old RPI by the Legacy Investors Partnerships of approximately 18%. As a result of the IPO, holders of our Class B ordinary shares also represent a non-controlling interest through the respective holders’ Class B Interests in RP Holdings. We now have four different components of non-controlling interest and total ownership by non-controlling interest of 51% as of December 31, 2020 compared to ownership by non-controlling interest related solely to RPSFT in the prior year period of less than 1% as of December 31, 2019.

During 2020 and 2019, we recorded net income attributable to RPSFT of $88.9 million and $112.9 million, respectively. Income attributable to RPSFT is expected to continue to decline as the assets held by RPCT mature.

Years ended December 31, 2019 and 2018

Net income attributable to RPSFT declined by $27.2 million, or 19.4%, in 2019 compared to 2018, primarily due to declines in expired and maturing royalty assets held by RPCT.

Key recent developments and upcoming events relating to our portfolio

The key developments impacting our cash receipts and income and revenue from our royalty interests are discussed below:

Commercial Products

•Cystic fibrosis franchise. In October 2019, Vertex received approval from the FDA for Trikafta for the treatment of patients with cystic fibrosis ages 12 years and older who have at least one copy of the F508del mutation.

In November 2019, Vertex announced that it reached an agreement with France’s Economic Committee of Health Care Products for a national reimbursement deal for Orkambi. As a result, we experienced a reduction in our royalty receipts in 2020 of approximately $41 million, to reflect a true-up related to prior periods where we collected royalties on sales in France of Orkambi at a higher selling price. In October 2019, Vertex announced that it reached an agreement with England’s National Health Service, where eligible patients will receive access to Orkambi and Symkevi, and access to Kalydeco will be expanded.

In August 2020, Vertex announced that the European Commission had granted marketing authorization of Kaftrio in a combination regimen with ivacaftor for the treatment of patients with cystic fibrosis ages 12 years and older with one F508del mutation and one minimal function mutation, or two F508del mutations in the CFTR gene.

In December 2020, the FDA expanded the eligibility for Trikafta to include people with cystic fibrosis ages 12 and older with certain mutations that are responsive to Trikafta based on in vitro data.

In January 2021, Vertex announced that the FDA accepted a supplemental New Drug Application (sNDA) for Trikafta for the treatment of children with cystic fibrosis ages 6 to 11 who have at least one F508del mutation or have certain mutations that are responsive to Trikafta based on in vitro data. The FDA granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 8, 2021.

63

•Tysabri. In January 2019, Biogen announced the start of the two-year global Phase IIIb NOVA study evaluating the efficacy and safety of extended interval dosing for natalizumab compared to standard interval dosing in patients with relapsing multiple sclerosis. Data from the study is expected to readout in 2021.

In June 2020, Biogen submitted a Supplemental Biologics License Application for a subcutaneous formulation of Tysabri to the FDA. This followed a regulatory submission for a subcutaneous formulation of Tysabri to the European Medicines Agency in March 2020. Biogen expects US and EU approvals for the subcutaneous formulation of Tysabri in mid-2021.

•Imbruvica. In April 2020, Imbruvica received FDA approval for use in combination with rituximab for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

In August 2020, the European Commission granted marketing authorization for Imbruvica in combination with rituximab for the treatment of adult patients with previously untreated CLL. This milestone marked the 11th FDA approval for Imbruvica since it was first approved in 2013 and sixth in CLL.

The primary completion date for the Phase III SHINE trial for treatment of frontline mantle cell lymphoma is expected to be June 2021 and AbbVie has indicated that approval could occur in 2022.

The primary completion date for the Phase III GLOW trial of Imbruvica in combination with Venetoclax for treatment of frontline CLL and SLL is expected to be February 2021 and AbbVie has indicated that approval could occur in 2022.

•Xtandi. In October 2018, the European Commission approved Xtandi for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer. Xtandi was previously approved by the EC for the treatment of adult men with metastatic CRPC.

In December 2019, Astellas and Pfizer announced that the FDA approved Xtandi for the treatment of patients with metastatic castration sensitive prostate cancer. Xtandi is currently under review by the European Medicines Agency for the treatment of patients with metastatic castration sensitive prostate cancer.

Astellas and Pfizer have indicated that there could be a potential readout of the Phase III EMBARK trial for high-risk non-metastatic prostate cancer in 2021, with a primary trial completion date anticipated in 2023.

•Trodelvy. In April 2020, Immunomedics announced that the FDA granted accelerated approval of Trodelvy for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.

In September 2020, Gilead and Immunomedics announced that Gilead would acquire Immunomedics for approximately $21 billion in cash and the transaction closed in October 2020. In 2018, we entered into a partnership with Immunomedics whereby we acquired a tiered sales-based royalty on Trodelvy for $175.0 million and acquired 4,373,178 shares of Immunomedics common stock for $75.0 million. Gilead’s acquisition of Immunomedics closed in October, resulting in gross cash proceeds upon redemption of our Immunomedics common stock of approximately $385 million.

In September 2020, Immunomedics presented results from the confirmatory Phase III ASCENT study that showed that Trodelvy significantly extended overall survival and improved overall response rate and clinical benefit rate, compared to treatment of choice standard single-agent chemotherapy in brain metastases-negative patients with metastatic triple negative breast cancer who had previously received at least two prior therapies for metastatic disease.

In December 2020, Gilead filed two supplemental biologics license applications with the FDA for full approval of Trodelvy as a treatment for adult patients with metastatic triple-negative breast cancer and accelerated approval of Trodelvy for metastatic urothelial carcinoma. Gilead anticipates potential approval for both indications in the first half of 2021.

64

In January 2021, Gilead also announced that progression-free survival data from the Phase III TROPiCS-02 trial testing Trodelvy versus physician’s choice in hormone receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer who have previously failed at least two, and no more than four, prior chemotherapy regimens for metastatic disease was expected in the second half of 2021.

In February 2021, Gilead announced that the company expects to submit a European Medicines Agency filing for Trodelvy for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease in the first half of 2021.

•Nurtec ODT. In February 2020, Biohaven announced that the FDA approved Nurtec ODT for the acute treatment of migraine in adults. The FDA approval of Nurtec ODT triggered a redemption provision related to our investment in Biohaven’s Series A Preferred Shares, which entitles us to receive a fixed payment amount of $250.0 million payable in nominal quarterly payments from March 31, 2021 through December 31, 2024.

In October 2020, Biohaven announced that the FDA had filed and accepted for review its recently submitted supplemental new drug application for Nurtec ODT for the preventive treatment of migraine. The PDUFA target date for completion of the FDA review of the preventive application for Nurtec ODT is in the second quarter of 2021.

•Evrysdi. In August 2020, the FDA approved Evrysdi, the first at-home, orally administered treatment for spinal muscular atrophy in adults and children ages 2 months and older. In August 2020, the European Medicines Agency accepted the filing for Evrysdi for the treatment of spinal muscular atrophy.

The European Medicines Agency’s Committee for Medicinal Products for Human Use opinion for Evrysdi is expected in the first half of 2021, and priority review of the Japanese New Drug Application is ongoing.

•Orladeyo. In December 2020, BioCryst announced that Orladeyo was approved by the FDA for prophylaxis to prevent attacks of hereditary angioedema in patients ages 12 years and older.

In January 2021, Orladeyo was approved in Japan, becoming the first and only prophylactic HAE medication approved in the region.

The European Medicines Agency validated BioCryst’s application for Orladeyo and formal review is underway. BioCryst expects a decision from the European Medicines Agency in the second quarter of 2021.

•Tecfidera. We continued collecting milestone receipts quarterly throughout 2018; however, our contractual agreement covering our milestones on cumulative sales of Tecfidera ended in 2018, and therefore receipts from Tecfidera ceased after the final milestone was collected in the first quarter of 2019.

•Humira. Our royalties on Humira expired in June 2018.

•Remicade. The patents covering our royalties on Remicade expired in September 2018.

Development-Stage Product Candidates

•Zavegepant. In December 2019, Biohaven announced positive topline results from the Phase II/III trial of intranasal zavegepant for the acute treatment of migraine.

In October 2020, Biohaven commenced a Phase III pivotal trial of intranasal zavegepant for the acute treatment of migraine.

In October 2020, Biohaven also began a one-year long-term safety trial of zavegepant. Biohaven expects a potential NDA filing at the end of 2021 if the pivotal acute trial proves to be positive.

65

•Omecamtiv mecarbil. In November 2020, Amgen, Cytokinetics and Servier presented the results of GALACTIC-HF study, a Phase III trial of omecamtiv mecarbil in patients with heart failure, at the American Heart Association Scientific Sessions. The trial met the primary composite endpoint of reduction in cardiovascular death or heart failure events, but did not meet the secondary endpoint of reduction in cardiovascular death. Cytokinetics subsequently regained global rights to develop and commercialize omecamtiv mercarbil when Amgen and Servier elected to terminate their collaboration agreement effective, May 2021. Following the Phase III results and termination of the collaboration, we recorded a $90 million write-off to the royalty investment given the uncertainty around the future of omecamtiv.

•Ibrance. In May 2020, Pfizer reported that the independent data monitoring committee for the PALLAS trial had concluded after the interim analysis that the PALLAS trial was “unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival.” In October 2020, Pfizer announced that the Phase III PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival in women with hormone receptor-positive, human epidermal growth factor-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy. As a result, we will not be entitled to any royalties or milestone payments from our R&D funding arrangement.


Non-GAAP Financial Results

In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. There is no direct correlation between income from financial royalty assets and royalty receipts due to the nature of the accounting methodology applied for financial royalty assets. Further, income from financial royalty assets and the provision for changes in expected cash flows related to these financial royalty assets can be volatile and unpredictable. As a result, management places importance on royalty receipts as they are predictable and we use them as a measure of our operating performance. Refer to section titled “Non-GAAP Reconciliations” for additional discussion of management’s use of non-GAAP measures as supplemental financial measures and reconciliations from the most directly GAAP comparable measures of Net cash provided by operating activities.

Adjusted Cash Receipts is a measure calculated with inputs directly from the Statement of Cash Flows and includes (1) royalty receipts by product: (i) Cash collections from royalty assets (financial assets and intangible assets), (ii) Other royalty cash collections, (iii) Distributions from non-consolidated affiliates and (iv) Proceeds from available for sale debt securities; less Distributions to non-controlling interest, which represents distributions to our historical non-controlling interest attributable to a de minimis interest in RPCT held by certain legacy investors and to a new non-controlling interest that was created as a result of the Exchange Offer Transactions in February 2020 related to the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI. Adjusted Cash Receipts is most directly comparable to the GAAP measure of Net cash provided by operating activities.

Adjusted EBITDA and Adjusted Cash Flow are similar non-GAAP liquidity measures that are both most closely comparable to the GAAP measure, Net cash provided by operating activities. Adjusted EBITDA is important to our lenders and is defined under the Credit Agreement as Adjusted Cash Receipts less payments for operating and professional costs. Operating and professional costs are comprised of Payments for operating and professional costs and Payments for rebates from the Statement of Cash Flows.

Adjusted Cash Flow is defined as Adjusted EBITDA less (1) Ongoing development-stage funding payments, (2) Interest paid, net, (3) Swap collateral (posted) or received, net, (4) Swap termination payments and (5) Investment in non-consolidated affiliates, and plus (1) Contributions from non-controlling interest- R&D, all directly reconcilable to the Statement of Cash Flows.

Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of the strength of the Company and the performance of the business. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income used by companies in the biopharmaceutical industry. Adjusted EBITDA, as derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants.

The table below includes the royalty receipts for the years ended December 31, 2020, 2019 and 2018 by product for our Growth Products and Mature Products, as defined in “—Portfolio Overview” above.
66

(in thousands)Years Ended December 31,2020 vs. 20192019 vs. 2018
202020192018$ % $ %
Growth Products
Cystic fibrosis franchise$551,338 $424,741 $224,214 $126,597 29.8 %$200,527 89.4 %
Tysabri345,845 332,816 338,697 13,029 3.9 %(5,881)(1.7)%
Imbruvica322,071 270,558 209,171 51,513 19.0 %61,387 29.3 %
HIV franchise293,808 262,939 224,321 30,869 11.7 %38,618 17.2 %
Xtandi146,374 120,096 105,958 26,278 21.9 %14,138 13.3 %
Januvia, Janumet, Other DPP-IVs143,754 143,298 106,689 456 0.3 %36,609 34.3 %
Promacta143,741 86,266 — 57,475 66.6 %86,266 — 
Farxiga/Onglyza25,004 — — 25,004 — — — 
Prevymis21,492 — — 21,492 — — — 
Emgality9,529 2,440 — 7,089 290.5 %2,440 — 
Crysvita9,454 — — 9,454 — — — 
Erleada7,876 2,683 — 5,193 193.6 %2,683 — 
IDHIFA6,111 — — 6,111 — — — 
Trodelvy3,031 — — 3,031 — — — 
Nurtec ODT667 — — 667 — — — 
Tazverik522 — — 522 — — — 
Evrysdi273 — — 273 — — — 
Other Growth Products (1)246,545 205,043 192,241 41,502 20.2 %12,802 6.7 %
     Total Royalty Receipts - Growth Products$2,277,435 $1,850,880 $1,401,291 $426,555 23.0 %$449,589 32.1 %
Mature Products
Tecfidera (2)$— $150,000 $750,000 $(150,000)(100.0)%$(600,000)(80.0)%
Letairis40,170 112,656 130,078 (72,486)(64.3)%(17,422)(13.4)%
Lyrica22,850 128,246 126,916 (105,396)(82.2)%1,330 1.0 %
Remicade— 6,068 121,055 (6,068)(100.0)%(114,987)(95.0)%
Humira— — 499,055 — — (499,055)(100.0)%
Other Mature Products (3)3,944 21,047 45,450 (17,103)(81.3)%(24,403)(53.7)%
     Total Royalty Receipts - Mature Products$66,964 $418,017 $1,672,554 $(351,053)(84.0)%$(1,254,537)(75.0)%
Distributions to non-controlling interest(543,952)(154,084)(268,693)(389,868)253.0 %114,609 (42.7)%
Adjusted Cash Receipts (non-GAAP)$1,800,447 $2,114,813 $2,805,152 $(314,366)(14.9)%$(690,339)(24.6)%
Payments for operating and professional costs(179,709)(88,524)(72,660)(91,185)103.0 %(15,864)21.8 %
Adjusted EBITDA (non-GAAP)$1,620,738 $2,026,289 $2,732,492 $(405,551)(20.0)%$(706,203)(25.8)%
Ongoing development-stage funding payments(20,479)(83,036)(108,163)62,557 (75.3)%25,127 (23.2)%
Interest paid, net(95,492)(234,828)(243,216)139,336 (59.3)%8,388 (3.4)%
Swap collateral received or (posted), net45,252 (45,270)2,957 90,522 (200.0)%(48,227)(1630.9)%
Swap termination payments(35,448)— — (35,448)— %— — 
Investment in non-consolidated affiliates(40,155)(27,042)(24,173)(13,113)48.5 %(2,869)11.9 %
Contributions from non-controlling interest- R&D8,482 — — 8,482 — %— — 
Adjusted Cash Flow (non-GAAP)$1,482,898 $1,636,113 $2,359,897 $(153,215)(9.4)%$(723,784)(30.7)%
Fully diluted shares outstanding607,111 n/an/a

67

(1) Other Growth Products include royalties on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion, for which receipts are presented as Distributions from non-consolidated affiliates on the Statement of Cash Flows), Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy and Soliqua. Other Growth Products for 2020 also include contributions from the Legacy SLP Interest, a payment from Biohaven in respect of an expired option to exercise additional funding of the Biohaven Series A Preferred Shares which is presented as Proceeds from available for sale debt securities on the Statement of Cash Flows, and a distribution from Avillion in respect of the Merck KGaA Asset, for which development ceased in 2020, and for which the receipt is presented as Distributions from non-consolidated affiliates in both the operating and investing section of the Statement of Cash Flows.
(2) Receipts from our Tecfidera milestone payments are presented as Proceeds from available for sale debt securities on the Statement of Cash Flows.
(3) Other Mature Products primarily include royalties on the following products: Prezista, Rotateq and Thalomid.

Adjusted Cash Receipts (non-GAAP)

Years ended December 31, 2020 and 2019

Adjusted Cash Receipts declined by $314.4 million to $1.8 billion in 2020 compared to 2019, primarily driven by increased distributions to non-controlling interest as a result of a new non-controlling interest created related to the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI following our Exchange Offer Transactions in February 2020. The decline in Adjusted Cash Receipts was further attributable to a decline in royalty receipts related to Mature Products, the most significant of which was Tecfidera. The decline was offset by an increase in royalty receipts from our Growth Products of $426.6 million in 2020 compared to 2019, driven primarily by the performance of cystic fibrosis franchise, Imbruvica and the 2019 acquisition of Promacta. Below we discuss the key drivers of royalty receipts from our Growth Products.

Growth Products

•Cystic fibrosis franchise – Royalty receipts from the cystic fibrosis franchise, which includes Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio, all approved for patients with certain mutations causing cystic fibrosis, increased by $126.6 million in 2020 compared to 2019, primarily driven by the highly successful launch of Trikafta in the United States.

•Tysabri – Royalty receipts from Tysabri, which is marketed by Biogen for the treatment of multiple sclerosis, increased by $13.0 million in 2020 compared to 2019.

•Imbruvica – Royalty receipts from Imbruvica, which is marketed by AbbVie and Johnson & Johnson for the treatment of blood cancers and chronic graft versus host disease, increased by $51.5 million in 2020 compared to 2019, driven by continued penetration in patients with chronic lymphocytic leukemia.

•HIV franchise – Royalty receipts from the HIV franchise, which is based on products marketed by Gilead that contain emtricitabine, including Biktarvy, Genvoya and Truvada, among others, increased by $30.9 million in 2020 compared to 2019. This increase was driven by strong performance of Biktarvy offset by decreases in sales of other combination products.

•Januvia, Janumet, Other DPP-IVs – Royalty receipts from the DPP-IVs for type 2 diabetes, which includes Januvia and Janumet, both marketed by Merck, was relatively consistent in 2020 compared to 2019.

•Xtandi – Royalty receipts from Xtandi, which is marketed by Pfizer and Astellas for the treatment of prostate cancer, increased by $26.3 million in 2020 compared to 2019, driven by demand across various prostate cancer indications.

•Promacta – Royalty receipts from Promacta, which is marketed by Novartis for the treatment of chronic immune thrombocytopenia and aplastic anemia, increased by $57.5 million in 2020 compared to 2019. We acquired the Promacta royalty in March 2019 and did not record royalty receipts for Promacta until the second quarter of 2019. We saw overall global growth of Promacta driven by increased use in chronic immune thrombocytopenia and further acceptance as first-line treatment for severe aplastic anemia in the United States.

68

Mature Products

The decline in our royalty receipts from Mature Products was primarily related to Tecfidera. Our contractual agreement covering our milestones on cumulative sales of Tecfidera up to $20 billion ended in 2018 and therefore, receipts from Tecfidera ceased after the final milestone was collected in the first quarter of 2019. We also saw declines in receipts from the losses of exclusivity for Lyrica and Letairis.

Distributions to Non-Controlling Interest

Distributions to non-controlling interest increased by $389.9 million to $544.0 million in 2020 compared to 2019, which negatively impacts Adjusted Cash Receipts. This increase is due to the additional 18% contractual non-controlling interest held by the Legacy Investors Partnerships that arose in the Exchange Offer Transactions. The increased distributions related to the Legacy Investors Partnerships were partially offset by a decline in distributions related to RPSFT from the maturation of several royalties held by RPCT, including Humira and Remicade.

Years ended December 31, 2019 and 2018
Adjusted Cash Receipts declined by $690.3 million in 2019 compared to 2018, primarily as a result of a decline in royalty receipts related to Mature Products, specifically Tecfidera. Our Growth Products increased by $449.6 million in 2019 compared to 2018, driven by the cystic fibrosis franchise, Imbruvica and Promacta, a royalty we acquired in 2019. Below we discuss the key drivers of royalty receipts from our Growth Products.

Growth Products

•     Cystic fibrosis franchise – Royalty receipts from the cystic fibrosis franchise increased by $200.5 million in 2019 compared to 2018, driven by continued growth of Symdeko. In addition, we started collecting 100% of the royalties on cystic fibrosis franchise products in the third quarter of 2018, after a pre-existing capped royalty was repaid. For the first three quarters of 2018, we only collected cash receipts from the cystic fibrosis franchise equal to the residual royalty of 25%.

•     Tysabri – Royalty receipts from Tysabri declined by $5.9 million in 2019 compared to 2018, driven by competition from new products approved to treat multiple sclerosis. Despite increased competition, Tysabri has shown resilience, highlighting the important role Tysabri plays in the multiple sclerosis treatment paradigm.

•     Imbruvica – Royalty receipts from Imbruvica increased by $61.4 million in 2019 compared to 2018, driven by continued penetration in patients with chronic lymphocytic leukemia.

•     HIV franchise – Royalty receipts from the HIV franchise increased by $38.6 million in 2019 compared to 2018. This increase was driven by strong performance of Truvada and Biktarvy in the United States, offset by decreases in sales of other combination products and decreased royalties on sales outside the United States.

•     Januvia, Janumet, Other DPP-IVs – Royalty receipts from the DPP-IVs increased by $36.6 million in 2019 compared to 2018, driven by increased royalties from Januvia and Janumet. As part of the Merck Settlement, we agreed to forgo royalties on Januvia and Janumet for a period that expired in the quarter ending March 31, 2018. The increase reflects a full year of royalty receipts from Januvia and Janumet in 2019, compared to only a partial year of royalty receipts in 2018.

•     Xtandi – Royalty receipts from Xtandi increased by $14.1 million in 2019 compared to 2018, driven by demand in metastatic castration-resistant prostate cancer and non-metastatic castration-resistant prostate cancer.

•     Promacta – Royalty receipts from Promacta were $86.3 million in 2019. We acquired the Promacta royalty in March 2019 and recorded no royalty receipts for Promacta in 2018.

69

Mature Products

The declines in our royalty receipts from Mature Products were primarily related to Tecfidera, Humira and Remicade. As sales-based performance targets that trigger our milestones on Tecfidera were met, we continued collecting $150 million in milestone receipts quarterly throughout 2018, with a double milestone collected in the first quarter of 2018. Our contractual agreement covering our milestones on cumulative sales of Tecfidera up to $20 billion ended in 2018 and therefore, receipts from Tecfidera ceased after the final milestone was collected in the first quarter of 2019. We recorded receipts from Tecfidera of $150 million in 2019 compared to $750 million in 2018, a reduction of $600 million. Our Humira and Remicade royalties also matured in June and September 2018, respectively, resulting in a reduction in royalty receipts of $499.1 million and $115.0 million, respectively, compared to 2018.

Distributions to Non-Controlling Interest

Distributions to non-controlling interest decreased by $114.6 million in 2019 compared to 2018, which impacts Adjusted Cash Receipts. This decrease reflects a decline in royalty assets held by RPCT, driven by the maturation of several royalties due to RPSFT, including Humira and Remicade.

Adjusted EBITDA (non-GAAP)

Years ended December 31, 2020 and 2019

Adjusted EBITDA declined by $405.6 million to $1.6 billion in 2020 compared to 2019 as a result of the factors noted above in “Adjusted Cash Receipts (Non-GAAP).” Payments for operating and professional costs, the only adjustment between Adjusted Cash Receipts and Adjusted EBITDA, increased in 2020 as a result of higher costs for Operating and Personnel Payments under the terms of our New Management Agreement and increased costs for professional services paid in connection with the Reorganization Transactions, our IPO and our Notes issuance.

Years ended December 31, 2019 and 2018

Adjusted EBITDA declined by $706.2 million in 2019 compared to 2018 also as a result of the factors noted above in “Adjusted Cash Receipts (Non-GAAP).” Payments for operating and professional costs, the only adjustment between Adjusted Cash Receipts and Adjusted EBITDA, increased in 2019 as a result of higher costs for professional services in connection with the Reorganization Transactions and preparation for our IPO.

Adjusted Cash Flow (non-GAAP)

Years ended December 31, 2020 and 2019

Adjusted Cash Flow declined by $153.2 million to $1.5 billion in 2020 compared to 2019 primarily for the same reasons noted above in “Adjusted Cash Receipts (Non-GAAP).” In 2020, we paid $35.4 million to terminate our interest rate swaps executed in connection with the Reorganization Transactions, which was offset by the return of collateral, lower ongoing development stage funding payments and lower interest payments on our refinanced debt.

Years ended December 31, 2019 and 2018

Adjusted Cash Flow declined by $723.8 million in 2019 compared to 2018 for the same reasons noted above. Adjusted Cash Flow is also impacted by ongoing development-stage funding payments, which declined slightly in 2019 as co-funding arrangements are coming to an end, and offset by a large net swap collateral posted in 2019 as compared to prior year due primarily to adverse movements in the LIBOR curve.

70

Non-GAAP Reconciliations

Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow are non-GAAP measures presented as supplemental measures to our GAAP financial performance. These non-GAAP financial measures exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. In each case, because our operating performance is a function of our liquidity, the non-GAAP measures used by management are presented and defined as supplemental liquidity measures. We caution readers that amounts presented in accordance with our definitions of Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow may not be the same as similar measures used by other companies. Not all companies and analysts calculate the non-GAAP measures we use in the same manner. We compensate for these limitations by using non-GAAP financial measures as supplements to GAAP financial measures and by presenting the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures, in each case being Net cash provided by operating activities.

We believe that Adjusted Cash Receipts and Adjusted Cash Flow provide meaningful information about our operating performance because the business is heavily reliant on its ability to generate consistent cash flows and these measures reflect the core cash collections and cash charges comprising our operating results. Management strongly believes that our significant operating cash flow is one of the attributes that attracts potential investors to our business.

In addition, we believe that Adjusted Cash Receipts and Adjusted Cash Flow help identify underlying trends in the business and permit investors to more fully understand how management assesses the performance of the Company, including planning and forecasting for future periods. Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of the Company’s ability to generate cash from operations. Both measures are an indication of the strength of the Company and the performance of the business. Management uses Adjusted Cash Receipts and Adjusted Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, voluntary debt repayments, dividends and other discretionary investments. Further, these non-GAAP financial measures help management, the audit committee and investors evaluate our ability to generate liquidity from operating activities.

Management believes that Adjusted EBITDA is an important non-GAAP measure in analyzing our liquidity and is a key component of certain material covenants contained within the Company’s credit agreement. Noncompliance with the interest coverage ratio and leverage ratio covenants under the credit agreement could result in our lenders requiring the Company to immediately repay all amounts borrowed. If we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the assessment of our liquidity.

Management uses Adjusted Cash Flow to evaluate its ability to generate cash and performance of the business and to evaluate the Company’s performance as compared to its peer group. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income measures used by many companies in the biopharmaceutical industry, even though each company may customize its own calculation and therefore one company’s metric may not be directly comparable to another’s. We believe that non-GAAP financial measures, including Adjusted Cash Flow, are frequently used by securities analysts, investors and other interested parties to evaluate companies in our industry.

The non-GAAP financial measures used in this Annual Report on Form 10-K have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of our results as reported under GAAP. We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, in each case being Net cash provided by operating activities below.

71

To arrive at Adjusted Cash Receipts, we start with the GAAP line item, Net cash provided by operating activities, and adjust for the following items from the Statement of Cash Flows: to add back (1) Proceeds from available for sale debt securities (primarily Tecfidera milestone payments), which are cash inflows that management believes are derived from royalties and form part of our core business strategy, (2) Distributions from non-consolidated affiliates classified as Cash used in investing activities, (3) Interest paid, net of Interest received, (4) Development-stage funding payments, (5) Payments for operating and professional costs, (6) Payments for rebates and (7) Swap termination payments, and to deduct (1) Distributions to non-controlling interest, which represents distributions to our historical non-controlling interest attributable to a de minimis interest in RPCT held by certain legacy investors and to a new non-controlling interest that was created as a result of the Exchange Offer Transactions in February 2020 related to the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI and (2) Swap collateral posted or (received), net, both of which are excluded when management assesses its operating performance through cash collections, or, Adjusted Cash Receipts.

To arrive at Adjusted EBITDA, we start with Net cash provided by operating activities and adjust for the following items from the Statement of Cash Flows: to add back (1) Proceeds from available for sale debt securities (primarily Tecfidera milestone payments), (2) Distributions from non-consolidated affiliates classified as Cash used in investing activities, (3) Interest paid, net of Interest received and (4) Development-stage funding payments and (5) Swap termination payments, and to deduct (1) Distributions to non-controlling interest and (2) Swap collateral posted or (received), net.

To arrive at Adjusted Cash Flow, we start with Net cash provided by operating activities and adjust for the following items from the Statement of Cash Flows: to add back (1) Proceeds from available for sale debt securities (primarily Tecfidera milestone payments), (2) Distributions from non-consolidated affiliates classified as Cash used in investing activities, (3) Upfront development-stage funding payments and (4) Contributions from non-controlling interest- R&D, and to deduct (1) Distributions to non-controlling interest and (2) Investment in non-consolidated affiliates. This is intended to present an Adjusted Cash Flow measure that is representative of cash generated from the broader business strategy of acquiring royalty-generating assets that are available for reinvestment and for discretionary purposes.

72

(in thousands)Years Ended December 31,
202020192018
Net cash provided by operating activities (GAAP)$2,034,629 $1,667,239 $1,618,317 
Adjustments:
Proceeds from available for sale debt securities (1)3,000 150,000 750,000 
Distributions from non-consolidated affiliates - investing (2)15,084 — — 
Interest paid, net (2)95,492 234,828 243,216 
Ongoing development-stage funding payments (3)20,479 83,036 108,163 
Upfront development-stage funding payments (3)5,810 — 284,446 
Payments for operating and professional costs179,709 88,524 72,535 
Payments for rebates— — 125 
Swap termination payments35,448 — — 
Distributions to non-controlling interest (2)(543,952)(154,084)(268,693)
Swap collateral (received) or posted, net (2)(45,252)45,270 (2,957)
Adjusted Cash Receipts (non-GAAP)$1,800,447 $2,114,813 $2,805,152 
Net cash provided by operating activities (GAAP) $2,034,629 $1,667,239 $1,618,317 
Adjustments:
Proceeds from available for sale debt securities (1)3,000 150,000 750,000 
Distributions from non-consolidated affiliates - investing (2)15,084 — — 
Interest paid, net (2)95,492 234,828 243,216 
Ongoing development-stage funding payments (3)20,479 83,036 108,163 
Upfront development-stage funding payments (3)5,810 — 284,446 
Swap termination payments35,448 — — 
Distributions to non-controlling interest (2)(543,952)(154,084)(268,693)
Swap collateral (received) or posted, net (2)(45,252)45,270 (2,957)
Adjusted EBITDA (non-GAAP)$1,620,738 $2,026,289 $2,732,492 
Net cash provided by operating activities (GAAP) $2,034,629 $1,667,239 $1,618,317 
Adjustments:
Proceeds from available for sale debt securities (1)3,000 150,000 750,000 
Distributions from non-consolidated affiliates - investing (2)15,084 — — 
Upfront development-stage funding payments (3)5,810 — 284,446 
Distributions to non-controlling interest (2)(543,952)(154,084)(268,693)
Investment in non-consolidated affiliates (2), (4)(40,155)(27,042)(24,173)
Contributions from non-controlling interests-R&D (2)8,482 — — 
Adjusted Cash Flow (non-GAAP)$1,482,898 $1,636,113 $2,359,897 

73

(1) Receipts from our Tecfidera milestone payments are presented as Proceeds from available for sale debt securities on the Statement of Cash Flows. In 2020, amount includes a payment from Biohaven in respect of an expired option to exercise additional funding of the Biohaven Series A Preferred Shares.
(2) The table below shows the line item for each adjustment and the direct location for such line item on the Statement of Cash Flows.
Reconciling adjustmentStatement of Cash Flows classification
Investments in non-consolidated affiliatesInvesting activities
Distributions to non-controlling interestFinancing activities
Interest paid, net
Operating activities (Interest paid less Interest received)
Swap collateral (received) or posted, net
Operating activities (Swap collateral received less Swap collateral posted)
Contributions from non-controlling interest- R&DFinancing activities
Distributions from non-consolidated affiliates - investingInvesting activities
(3) Our lenders consider all payments made to support R&D activities for products undergoing late-stage development similar to asset acquisitions as these funds are expected to generate operational returns in the future. All ongoing and upfront development-stage funding payments are reported in R&D funding expense in net income and are added back in aggregate to Net cash provided by operating activities to arrive at Adjusted Cash Receipts and Adjusted EBITDA. As a result, Adjusted Cash Receipts and Adjusted EBITDA capture the full add-back for R&D funding payments while Adjusted Cash Flow only reflects the add-back for the upfront portion of development-stage funding payments due to the fact that ongoing development-stage funding payments are considered an ongoing business expense.
(4) We consider all payments to fund our operating joint ventures that are performing R&D activities for products undergoing late stage development similar to asset acquisitions as these funds are expected to generate operational returns in the future. As a result, amounts funded through capital calls by our equity method investees, the Avillion Entities, are deducted to arrive at Adjusted Cash Flow, but are not deducted in Adjusted EBITDA.

Investments Overview

Ongoing investment in new royalties is fundamental to the long-term prospects of our business. New investments provide a source of growth for our royalty receipts, supplementing growth within our existing portfolio and offsetting declines for products in our portfolio that have lost market exclusivity. We evaluate an array of royalty acquisition opportunities on a continuous basis and expect to continue to make acquisitions in the ordinary course of our business. Our team has established a strong track record of identifying, evaluating and investing in royalties tied to leading products across therapeutic areas and treatment modalities. We invest in approved products and development-stage product candidates that have generated robust proof of concept data. We invest in these therapies through the purchase of royalties, by making hybrid investments and by acquiring businesses with significant existing royalty assets or the potential for the creation of such assets.

For the year ended December 31, 2020, we invested $2.3 billion in royalties and related assets, including nine new investments. While volatility exists in the quantum of our new acquisitions on a year-to-year basis due to the unpredictable timing of new investment opportunities, we have consistently deployed significant amounts of cash when measured over multi-year periods. Our approach is rooted in a highly disciplined evaluation process that is not dictated by a minimum annual investment threshold.

Included below is a table of investment activity over each of the last nine years based on the type of investment at the acquisition date. Amounts presented in the table below reflect cash paid at the acquisition date; any associated contractual payments are reflected in the period in which cash was paid.

74

(in thousands)
Average202020192018201720162015201420132012
Approved / marketed royalties$928,943 $1,404,221 $1,848,711 $269,554 $2,200,480 $1,197,210 $337,882 $468,427 $510,000 $124,000 
Development-stage royalties (1) (2)772,846 894,469 445,699 569,592 220,093 99,242 120,285 3,428,530 391,287 786,417 
Totals$1,701,789 $2,298,690 $2,294,410 $839,146 $2,420,573 $1,296,452 $458,167 $3,896,957 $901,287 $910,417 
Number of new investments (3)5986321624
(1) Development stage royalties include: direct R&D funding arrangements and funding arrangements executed through our joint venture partnership with the Avillion Entities, investments in development-stage product candidates, and investments in securities primarily made in connection with royalty acquisitions from the seller.
(2) In 2014, acquisitions of development-stage royalties included $3.3 billion for the acquisition of royalties on the cystic fibrosis franchise. At the time of the investment, Kalydeco was the only approved product in the franchise, while the vast majority of the value of our investment was tied to development-stage product candidates.
(3) Excludes continued investments in development-stage product candidates, such as funding paid over time, and subsequent tranches of an accelerated royalty.

Summary of royalty acquisition activity

•In January 2021, we acquired royalty interests in seltorexant from Minerva Neurosciences, Inc. for an upfront payment of $60 million and up to $95 million in additional milestone payments, contingent on the achievement of certain clinical, regulatory and commercialization milestones. Seltorexant is currently in Phase III development for the treatment of major depressive disorder (MDD) with insomnia symptoms by Janssen Pharmaceutica, N.V., a subsidiary of Johnson & Johnson.

•In December 2020, we acquired royalty interests from BioCryst Pharmaceuticals, Inc. on (1) ORLADEYO (betrotralstat) to support the launch of the product in hereditary angioedema (HAE) and (2) its development stage Factor D inhibitor BCX9930 in exchange for an upfront cash payment of $125 million.

•In October 2020, we acquired the residual royalty interest in Vertex’s cystic fibrosis franchise owned by the Cystic Fibrosis Foundation. The agreement includes an upfront payment of $575 million and a potential milestone payment of $75 million.

•In August 2020, we entered into an expanded agreement with Biohaven Pharmaceuticals for up to $450 million to fund the development of zavegepant and the commercialization of Nurtec ODT. Biohaven received an upfront payment of $150 million and will receive an additional $100 million payment upon the start of the oral zavegepant Phase III program. We will receive a royalty on Nurtec ODT and zavegepant and success-based milestone payments based on zavegepant regulatory approvals. We will also provide further support for the ongoing launch of Nurtec ODT through the purchase of committed, non-contingent Commercial Launch Preferred Equity for a total of $200 million payable between 2021 and 2024. In return, Biohaven will pay a series of equal fixed payments between 2025 and 2030.

•In July 2020, we acquired a royalty on risdiplam, a development-stage product for the treatment of Types 1, 2 and 3 spinal muscular atrophy (SMA) from PTC Therapeutics, Inc. in exchange for an upfront payment of $650 million. Evrysdi (risdiplam) was subsequently approved by the FDA in August 2020, representing the first, oral treatment approved for infants, children and adults with all SMA types.

•In the second quarter of 2020, we acquired a royalty on (1) Prevymis, an approved product to prevent cytomegalovirus (CMV) infection in stem cell transplants, from AiCuris Anti-infective Cures GmbH in exchange for an upfront payment of $220 million and (2) IDHIFA, an approved product for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation, from Agios Pharmaceuticals, Inc. in exchange for an upfront payment of $255 million.

75

•In the first quarter of 2020, we acquired a royalty on Entyvio, an approved product for the treatment of ulcerative colitis and Crohn’s disease, from The General Hospital Corporation in exchange for an upfront payment of $86.6 million.

•In the fourth quarter of 2019, we agreed to pay $320 million to acquire from Ultragenyx Pharmaceutical, Inc. a royalty on the European sales of Crysvita, an approved product for the treatment of XLH, a rare genetic orphan disease that has a profound impact on bone development in adults and children, subject to certain caps.

•In the fourth quarter of 2019, we agreed to pay up to $330 million to purchase a royalty owned by Eisai Co., Ltd (“Eisai”), on future worldwide sales outside Japan of Tazerik (tazemetostat), a novel targeted therapy in late-stage clinical development with the potential to be approved in several cancer indications. We acquired a portion Eisai’s future worldwide royalties on net sales by Epizyme of Tazerik outside Japan, for an upfront payment of $110 million plus up to an additional $220 million for the remainder of the royalty upon FDA approval of Tazverik for certain indications. The FDA approved Tazverik in January 2020 for epithelioid sarcoma which triggered our obligation to fund the second $110 million tranche in November 2020. In June 2020, the FDA approval of additional indications triggered our recognition of a liability for the final tranche payment of $110.0 million in November 2021.

•In the fourth quarter of 2019, we made a $100 million investment in Epizyme. In exchange for an upfront payment of $100 million, we received (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5 million shares of Epizyme common stock at $20 per share over a three-year term and (3) Epizyme’s royalty on sales of Tazverik in Japan payable by Eisai. We also lowered Epizyme’s royalty on Tazverik above certain sales thresholds and granted Epizyme an 18-month put option to sell an additional $50 million of its common stock to RPIFT at then-prevailing prices, not to exceed $20 per share. Epizyme exercised its put option on December 30, 2019, which resulted in Epizyme issuing RPIFT 2.5 million shares on settlement in February 2020.

•In the first quarter of 2019, we entered into a preferred share purchase agreement with Biohaven through which we purchased $125 million in Series A Preferred Shares, providing us with a fixed return on redemption of two times our investment on FDA approval of Biohaven’s pipeline product, Nurtec ODT, for migraine treatment. The FDA approved Nurtec ODT for the acute treatment of migraine in adults in February 2020.

•In the first quarter of 2019, we acquired the following: (1) a royalty on Promacta, an approved product for the treatment of chronic immune thrombocytopenia and aplastic anemia, from Ligand Pharmaceuticals in exchange for an upfront payment of $827 million, (2) a royalty on Eli Lilly’s Emgality, an approved product for the treatment of migraine, from Atlas Ventures and Orbimed for $260 million and (3) a royalty on Johnson & Johnson’s Erleada, an approved product for the treatment of prostate cancer, from the Regents of the University of California for $105.4 million and potential future milestones.

•In 2018, we acquired (1) from Zealand Pharma, future royalty streams and $85 million of potential commercial milestones on Sanofi’s Lixisenatide franchise in exchange for $205 million up front, (2) from Biohaven, rights to future cash flows on Nurtec ODT and zavegepant, development-stage product candidates, in exchange for $100 million in up-front R&D funding and a payment of $50 million for Biohaven’s common stock and (3) from Immunomedics, a tiered, sales-based royalty on Trodelvy, which was at the time a development-stage product candidate, in exchange for an up-front payment of $175 million for R&D funding and a payment of $75 million for Immunomedics’ common stock, acquired at a premium.

Liquidity and Capital Resources

Overview

Our primary source of liquidity is cash provided by operations. For the years ended December 31, 2020, 2019 and 2018, we generated $2.0 billion, $1.7 billion and $1.6 billion, respectively, in Net cash provided by operating activities. We believe that our existing capital resources, cash provided by operating activities and our Revolving Credit Facility will continue to allow us to meet our operating and working capital requirements, to fund planned strategic acquisitions, and contractually obligated equity and R&D funding arrangements, and to meet our debt service obligations for the foreseeable future. We have historically operated at a low level of fixed operating costs. Our primary cash operating expenses, other than R&D funding commitments, include interest expense, our Operating and Personnel Payments, and legal and professional fees.

76

We have access to substantial sources of funds in the capital markets and we may, from time to time, seek additional capital through a combination of additional debt or equity financings. In June 2020, we completed our IPO and received net proceeds of approximately $1.9 billion from the IPO after deducting underwriting discounts and commissions of approximately $86.3 million. In September 2020, we refinanced our syndicated term loan facilities with $6.0 billion of Notes. Additionally, we entered into a $1.5 billion Revolving Credit Facility in September 2020. The Revolving Credit Facility remains undrawn and available to us as of December 31, 2020. Our ability to satisfy our working capital needs, debt service and other obligations, and to comply with the financial covenants under our financing agreements depends on our future operating performance and cash flow, which are in turn subject to prevailing economic conditions and other factors, many of which are beyond our control.
We have historically funded our acquisition program through free cash flow, equity contributions and debt. Our low operating costs coupled with a lack of capital expenditures and low taxes have contributed to our strong financial profile, resulting in high operating leverage and high conversion of our Adjusted Cash Receipts to Adjusted Cash Flow. We expect to continue funding our current and planned operating costs (excluding acquisitions) principally through our cash flow from operations and our acquisition program through cash flow and issuances of equity and debt. In the past, we have supplemented our available cash and cash equivalents on hand with attractive debt capital to fund certain strategic acquisitions.

As of December 31, 2020, we had total long-term debt outstanding of $5.8 billion. As of December 31, 2019, we had total long-term debt outstanding of $6.0 billion. In February 2020, in connection with the Exchange Offer Transactions, we repaid our outstanding debt held by RPIFT in full and issued new long-term debt at RPI Intermediate FT. In September 2020, we repaid in full our Senior Secured Credit facilities entered into in February 2020 using the proceeds of the Notes in addition to cash on hand.

Cash flows

The following table summarizes our cash flow activities:

(in thousands)Years Ended December 31,
202020192018
Cash provided by (used in):
     Operating activities$2,034,629 $1,667,239 $1,618,317 
     Investing activities$(2,759,320)$(2,153,625)$303,424 
     Financing activities$1,487,172 $(1,191,626)$(1,379,101)

Analysis of Cash Flow Changes

Operating activities

Years ended December 31, 2020 and 2019

Cash provided by operating activities increased by $367.4 million in 2020 compared to 2019. The primary drivers were an increase in cash collections from financial royalty assets of $187.8 million and a decrease in interest paid of $151.8 million. The decrease in interest paid was driven by lower interest rates under the refinanced senior secured credit facilities and a semi-annual interest payment schedule on the Notes, which resulted in no interest payments made on the Notes in 2020. Further contributing to the increased cash from operations was a decline in ongoing development-stage funding payments of $62.6 million due to the completion of our co-funding arrangement with Pfizer in 2019. Partially offsetting these increases were increased payments for operating and professional costs of $91.2 million primarily due to the higher Operating and Personnel Payments under the New Management Agreement and increased costs for professional services in connection with the Reorganization Transactions.

77

Years ended December 31, 2019 and 2018

Cash provided by operating activities increased by $48.9 million in 2019 compared to 2018, primarily as a result of a smaller amount of upfront payments related to development stage funding. In 2018, we paid $284.4 million to acquire royalties on development-stage product candidates of Biohaven and Immunomedics. Partially offsetting the impact of these reduced payments in the current year was a reduction of $179.6 million on cash collections from royalty assets and other royalty cash collections primarily due to the expiration of royalties on Humira and Remicade. The declines in Mature Products were partially offset by increases in cash collections from royalties primarily on the cystic fibrosis franchise, Promacta, Imbruvica and the HIV franchise. We also posted collateral of $45.6 million in 2019 related to our interest rate swaps compared to $0.5 million in 2018 as a result of unfavorable movements in LIBOR.

Investing activities
Years ended December 31, 2020 and 2019

Cash used in investing activities increased by $605.7 million in 2020 compared to 2019, primarily due to using more cash to purchase marketable securities and to acquire financial royalty assets in 2020. The increase in cash used to purchase marketable securities and acquire financial royalty assets was partially offset by an increase of $90.4 million in proceeds from sales and maturities of marketable securities and $384.8 million in proceeds received from the full redemption of our investment in Immunomedics common stock upon its acquisition by Gilead in the fourth quarter of 2020. We also purchased available for sale debt securities of $125.1 million in 2019 and made the Tysabri milestone payment of $250.0 million in 2019, for which there was not comparable activity in 2020.

Years ended December 31, 2019 and 2018

Cash used in investing activities in 2019 was $2.2 billion, compared to cash provided by investing activities of $303.4 million in 2018. In 2019, we made several acquisitions of financial royalty assets, totaling $2.0 billion. We also spent $213.0 million on investments in securities and warrants in 2019, compared to $152.8 million in 2018. As our Tecfidera agreement came to an end with the last milestone earned in December 31, 2018, we collected cash receipts on Tecfidera of $150.0 million in 2019 compared to $750.0 million for 2018.

Financing activities

Years ended December 31, 2020 and 2019

Cash provided by financing activities in 2020 was $1.5 billion compared to cash used in financing activities of $1.2 billion in 2019. The proceeds from the issuance of Class A ordinary shares upon our IPO in June 2020 provided cash of $1.9 billion, net of offering costs paid. The repayment of RPIFT’s outstanding debt in February 2020, including through amounts contributed by a non-controlling interest, and subsequent Note issuances yielded net proceeds of $727.9 million. The proceeds from these 2020 financing activities were partially offset by an increase of $571.0 million in cash distributions to non-controlling interest in 2020 due to the new contractual non-controlling interest held by the Legacy Investors Partnerships and dividends paid to shareholders of our Class A ordinary shares of $112.5 million.

Years ended December 31, 2019 and 2018

Cash used in financing activities in 2019 declined by $187.5 million in 2019 compared to 2018, primarily due to decreases in distributions to non-controlling interest and to unitholders. Distributions to non-controlling interest declined as products held by the RPCT are maturing.

78

Sources of Capital

As of December 31, 2020, our cash and cash equivalents and marketable securities totaled $1.0 billion and $983.3 million, respectively. As of December 31, 2019, our cash and cash equivalents and our marketable securities totaled $246.2 million and $94.5 million, respectively. We intend to fund short-term and long-term financial obligations as they mature through cash and cash equivalents, sales of short-term marketable securities, future cash flows from operations or the issuance of additional debt. Our ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the sales of the underlying pharmaceutical products in which we hold royalties, deterioration in our key financial ratios or credit ratings, or other material unfavorable changes in business conditions. Currently, we believe that we have sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support our growth objectives.

Borrowings

Senior Unsecured Notes

On September 2, 2020, we issued $6.0 billion of Notes with a weighted average coupon rate of 2.125% and requiring interest payments of approximately $127.5 million on an annual basis, paid semi-annually. The Notes consist of the following:
•$1.0 billion principal amount of 0.750% senior notes due 2023, issued at 99.322% of par;
•$1.0 billion principal amount of 1.200% senior notes due 2025, issued at 98.875% of par;
•$1.0 billion principal amount of 1.750% senior notes due 2027, issued at 98.284% of par;
•$1.0 billion principal amount of 2.200% senior notes due 2030, issued at 97.760% of par;
•$1.0 billion principal amount of 3.300% senior notes due 2040, issued at 95.556% of par; and
•$1.0 billion principal amount of 3.550% senior notes due 2050, issued at 95.306% of par.

The indenture governing the Notes contains certain covenants which we were in compliance with as of December 31, 2020. We used the net proceeds from the Notes offering, together with available cash on hand, to repay in full the Senior Secured Credit Facilities.
Revolving Credit Facility

On September 18, 2020, RP Holdings, as borrower, entered into a five-year Revolving Credit Facility which provides for borrowing capacity up to $1.5 billion for general corporate purposes. Our revolving credit agreement includes certain customary financial covenants with which we were in compliance as of December 31, 2020. The Revolving Credit Facility remains undrawn and available to us as of December 31, 2020.

Senior Secured Credit Facilities

On February 11, 2020, in connection with the Exchange Offer Transactions and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement (the “Senior Secured Credit Agreement”) with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. In September 2020, we repaid in whole the outstanding principal amounts of term loans under Senior Secured Credit Facilities governed by the Senior Secured Credit Agreement with net proceeds from the Notes.
We had the following indebtedness outstanding at December 31, 2020 and 2019:


79

(in thousands)MaturityInterest rateDecember 31, 2020December 31, 2019
Senior Unsecured Notes:
Senior unsecured notes (issued at 99.322% of par)9/20230.750%$1,000,000 $— 
Senior unsecured notes (issued at 98.875% of par)9/20251.200%1,000,000 — 
Senior unsecured notes (issued at 98.284% of par)9/20271.750%1,000,000 — 
Senior unsecured notes (issued at 97.760% of par)9/20302.200%1,000,000 — 
Senior unsecured notes (issued at 95.556% of par)9/20403.300%1,000,000 — 
Senior unsecured notes (issued at 95.306% of par)9/20503.550%1,000,000 — 
RPIFT Senior Secured Credit Facilities:
   Term Loan B Facility(1)LIBOR + 200 bps— 4,123,000 
   Term Loan A Facility(1)LIBOR + 150 bps— 2,150,000 
Total senior secured debt6,000,000 6,273,000 
Unamortized debt discount and issuance costs(183,416)(34,878)
Total long-term debt, including current portion$5,816,584 $6,238,122 

(1) In February 2020, the outstanding principal amounts of RPIFT’s prior term loan facilities were repaid in full with net proceeds from our Senior Secured Credit Facilities which we subsequently repaid in full in September 2020 with net proceeds from the Notes and available cash on hand.

RPIFT Senior Secured Credit Facilities

The RPIFT Senior Secured Credit Facilities (the “Prior Credit Facility”) was issued by our wholly-owned subsidiary, RPIFT and was investment grade rated. RPIFT used interest rate swap agreements to fix a portion of its floating rate debt. In February 2020, in connection with the Exchange Offer Transactions, the Prior Credit Facility was repaid in full and new long-term debt was issued by RPI Intermediate FT.

Guarantor Financial Information
Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary (the “Guarantor Subsidiary”). Our remaining subsidiaries (the “Non-Guarantor Subsidiaries”) do not guarantee the Notes. Under the terms of the indenture governing the Notes, Royalty Pharma plc and the Guarantor Subsidiary each fully and unconditionally, jointly and severally, guarantee the payment of interest, principal and premium, if any, on the Notes. The par value and carrying value of the total outstanding and guaranteed Notes was $6.0 billion and $5.8 billion, respectively as of December 31, 2020.

The following tables present condensed combined summarized financial information for Royalty Pharma plc and RP Holdings. All intercompany balances and transactions between Royalty Pharma plc and RP Holdings are eliminated in the presentation of the combined financial statements. RP Holdings’ most significant asset is its investment in operating subsidiaries, which has been eliminated in the table below to exclude investments in Non-Guarantor Subsidiaries. As a result, our ability to make required payments on the Notes depends on the performance of our operating subsidiaries and their ability to distribute funds to us. There are no material restrictions on distributions from the operating subsidiaries. Amounts presented below do not represent our total consolidated amounts as of December 31, 2020 and for the year then ended.

80

Summarized Balance Sheet
(in thousands)As of
December 31, 2020
Current assets$51,625 
Current interest receivable on intercompany notes due from Non-Guarantor Subsidiaries15,709 
Non-current assets 4,558 
Non-current intercompany notes receivable due from Non-Guarantor Subsidiaries2,101,656 
Current liabilities44,161 
Current interest payables on intercompany notes due to Non-Guarantor Subsidiaries15,709 
Current intercompany payables due to Non-Guarantor Subsidiaries1,182 
Non-current liabilities5,816,133 
Non-current intercompany notes payable due to non-Guarantor Subsidiaries2,101,656 

Summarized Statement of Comprehensive Income
(in thousands)For the year ended
December 31, 2020
Interest income on intercompany notes receivable from Non-Guarantor Subsidiaries$17,727 
Expenses74,458 
Interest expense on intercompany notes payable with Non-Guarantor Subsidiaries17,727 
Net loss74,458 

Uses of Capital

Acquisitions of royalties

We acquire product royalties in a variety of ways that can be tailored to the needs of our partners. We classify our product royalty acquisitions by the following structures:

•Third-party Royalties – A royalty is the contractual right to a percentage of top-line sales from a licensee’s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties.

•Synthetic / Hybrid Royalties – A synthetic royalty is the contractual right to a percentage of top-line sales created by the owner of a therapy in exchange for funding. In many of our synthetic royalties, we also make investments in the public equity of the company, where the main value driver of the company is the product for which we concurrently acquired a royalty.

•R&D Funding – We fund R&D, typically for large biopharmaceutical companies, in exchange for future royalties and/or milestones if the product or indication we are funding is approved.

•M&A - We acquire royalties in connection with M&A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.

Distributions to Shareholders/Unitholders

We made distributions of $285.4 million to shareholders prior to the IPO in June 2020. We paid dividends to holders of our Class A ordinary shares of $112.5 million in 2020 subsequent to the IPO. We do not have a legal obligation to pay a quarterly dividend or dividends at any specified rate or at all.

We made distributions of $739.3 million and $814.4 million to unitholders in 2019 and 2018, respectively.

81

Commercial Launch Preferred Equity and Other Funding Arrangements

On August 7, 2020, we entered into a Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven to purchase up to 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”), for a total of $200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024.

We have other funding arrangements where we are contractually obligated to fund R&D activities performed by our development partners and to provide additional capital related to our equity method investment in the Avillion entities. As our committed capital requirements are based on phases of development, the completion of which is highly uncertain, only the capital required to fund the current stage of development under such funding arrangements is considered committed capital requirements which approximate $68.2 million as of December 31, 2020.

Debt service

The future principal and interest payments under our Notes as of December 31, 2020, over the next five years and thereafter are as follows:

(in thousands)
YearPrincipal PaymentsInterest Payments
2021$— $127,500 
2022— 127,500 
20231,000,000 127,500 
2024— 120,000 
20251,000,000 120,000 
Thereafter4,000,000 1,527,500 
Total (1)$6,000,000 $2,150,000 

(1) Excludes unamortized discount and loan issuance costs on long-term debt of $183.4 million at December 31, 2020, which are amortized through interest expense over the remaining life of the underlying debt obligations.

Commitments, Contingencies and Guarantees

We are involved in certain legal proceedings arising in the ordinary course of business and, as required, accrue an estimate of the probable costs for resolution of those claims for which the occurrence of loss is probable and the amount can be reasonably estimated. In general, estimates are developed in consultation with counsel and are based upon an analysis of potential results, assuming a combination of litigation and settlement strategies. It is possible, however, that future results of operations for any particular period could be materially affected by changes in our assumptions or the effectiveness of our strategies related to these proceedings.

Amounts related to contingent milestone payments are not considered contractual obligations and are excluded from the table below, as they are contingent on the successful achievement of certain development, regulatory approval or commercial milestones. Amounts we expect to fund based on contingent milestones in the next twelve months primarily relate to $100.0 million due to Biohaven upon the start of the oral zavegepant Phase III program. As of December 31, 2020, we recognized a current liability of $18.6 million related to a sales-based milestone for Erleada that was achieved in the three months ended December 31, 2020.

The table below summarizes our contractual obligations at December 31, 2020 and the effect that such obligations are expected to have on our liquidity and cash flows in future periods.

82

(in thousands)
Total<1 year1-3 years3-5 years>5 years
Long-term debt:
Principal payments on Notes$6,000,000 $— $1,000,000 $1,000,000 $4,000,000 
Interest payments on Notes2,150,000 127,500 255,000 240,000 1,527,500 
Commercial Launch Preferred Equity funding200,000 70,442 93,938 35,620 — 
Purchase obligation (1)110,000 110,000 — — — 
Funding commitments (2)68,225 49,225 8,000 8,000 3,000 
Operating and Personnel Payments (3)Refer to footnote (2) belowRefer to footnote (2) belowRefer to footnote (2) belowRefer to footnote (2) belowRefer to footnote (2) below
Total (4)$8,528,225 $357,167 $1,356,938 $1,283,620 $5,530,500 
(1)    Under the terms of our funding agreement with Eisai, we are obligated to fund the third and final tranche of the Tazverik royalty for $110.0 million in November 2021, following the FDA approval of additional indications of Tazverik in June 2020. The purchase obligation is recorded within current liabilities on the consolidated balance sheet at December 31, 2020.
(2)    Funding commitments include amounts we are contractually obligated to fund in respect of R&D funding arrangements with our development partners and committed capital related to our equity method investment in the Avillion entities. As our committed capital requirements are based on phases of development, the completion of which is highly uncertain, only the capital required to fund the current stage of development is included in the above table.
(3)    Under the Management Agreement that became effective in February 2020, RPI will pay quarterly operating and personnel payments in respect of operating and personnel expenses to the Manager or its affiliates (the “Operating and Personnel Payments”) equal to 6.5% of the Adjusted Cash Receipts for such quarter and 0.25% of the GAAP value of our security investments, including equity securities and derivative financial instruments, as of the end of such quarter. Because the fee is variable and based on projected cash receipts, no amounts are fixed.
(4)    Excluded from the table are amounts related to various obligations with no specific contractual commitment or maturity.


Other off-balance sheet arrangements

We do not have relationships with structured finance or special purpose entities that were established to facilitate off-balance sheet arrangements. Therefore, we are not exposed to any financing, liquidity, market or credit risk that may arise if we had engaged in such relationships. We consolidate variable interest entities when we are the primary beneficiary.

Critical Accounting Policies and Use of Estimates

The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses. Certain of these policies are considered critical as they have the most significant impact on our financial condition and results of operations and require the most difficult, subjective, or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain. On an ongoing basis, we evaluate our estimates that are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The result of these evaluations forms the basis for making judgments about the carrying values of assets and liabilities and the reported amount of expenses that are not readily apparent from other sources. Because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

Our most critical accounting policies relate to our royalties and the full descriptions can be found in Note 2–Summary of Significant Accounting Policies to the consolidated financial statements. Similarly, the most significant judgments and estimates applied by management are associated with the measurement of our financial royalty assets. The application of the prospective approach to measure income from our financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties. These estimates and judgments arise because of the inherent uncertainty in predicting future events.

83

Income and provision recognition from financial royalty assets can be impacted by management’s assumptions around (1) product growth rates and sales trends in outer years, (2) the geographical allocation of annual sales data from sell-side equity research analysts’ models, (3) product and pricing mix for franchised products, (4) the strength of patent protection, including anticipated entry of generics and (5) estimates of the duration of the royalty. The amounts and duration of forecasted expected future cash flows are largely influenced by sell-side equity research analyst coverage, commercial performance of the product and the royalty duration.

For example, based on the level of detail in sell-side equity research analyst models, management may be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for development-stage product candidates or indications. When royalty-bearing pharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst estimates are not available for the full term of our royalty, particularly for the later years in a product’s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, publicly available information for the marketer, industry data and market trends, and management’s own expertise.

The royalty duration is important for purposes of accurately measuring interest income over the life of a financial royalty asset. In making assumptions around the royalty duration for terms that are not contractually fixed, management considers the strength of existing patent protection, expected entry of generics, geographical exclusivity periods and potential patent term extensions tied to the underlying product. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen positive or negative developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing for the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles and industry consolidations.

A shortened royalty term can result in a reduction in the effective interest rate, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Changes in sell-side equity research analyst consensus forecasts directly impact future interest income and recognition of any provision income or expense in the same manner.

Recent Accounting Pronouncements

See Note 2–Summary of Significant Accounting Policies to our consolidated financial statements for additional information on recently issued accounting standards.

Item 7A.     QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market Risk

We are subject to certain risks which may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates and interest rate movements. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the nature of the marketable securities we hold. Although we currently do not have any interest rate swaps or foreign currency forward contracts in place, we have historically managed the impact of foreign currency exchange rate and interest rate risk through various financial instruments and derivative instruments. We only use derivatives strategically to hedge existing interest rate exposure and to minimize volatility in cash flow and earnings arising from our exposure to foreign currency risk. We do not enter into derivative instruments for trading or speculative purposes. The counterparties to these contracts are all major financial institutions.

84

Foreign Currency Exchange Risk

Our results of operations are subject to foreign currency exchange risk through transactional exposure resulting from movements in exchange rates between the time we recognize royalty income or royalty revenue and the time at which the transaction settles, or we receive the royalty payment. The current portion of Financial royalty assets, net and Accrued royalty receivable account for the most common types of transactional exposure. Because we are entitled to royalties on worldwide sales for various products, there is an underlying exposure to foreign currency as the marketer converts payment amounts from local currencies to U.S. dollars using a quarterly average exchange rate. Therefore, cash received may differ from the estimated receivable based on fluctuations in currency. In addition, certain products pay royalties in currencies other than U.S. dollars, which also creates foreign currency risk primarily with respect to the Euro, Canadian Dollar, Swiss Franc and Japanese Yen, as our functional and reporting currency is the U.S. dollar. To manage foreign currency exchange risk, we may periodically utilize non-deliverable forward exchange contracts. We do not currently have any foreign exchange contracts in place.

Interest Rate Risk

We are subject to interest rate fluctuation exposure through our investments in money market accounts and marketable securities, the majority of which bear a variable interest rate. As of December 31, 2020, we held cash and cash equivalents of $1.0 billion, of which $832.7 million was cash, $151.7 million was invested in commercial paper and certificates of deposit and $24.3 million was invested in interest-bearing money market funds. We also held $983.3 million in marketable securities at December 31, 2020 invested in corporate debt securities, commercial paper and certificates of deposit.

As of December 31, 2019, we had cash and cash equivalents of $246.2 million, of which $19.9 million was cash, $222.3 million was invested in interest-bearing money market funds and $4.0 million was invested in certificates of deposit. In addition, as of December 31, 2019 we had $94.5 million in marketable securities invested in U.S. government securities, commercial paper and certificates of deposit.
The objectives of our investment policy are the preservation of capital and fulfillment of liquidity needs. In order to maximize income without assuming significant market risk, we maintain our excess cash and cash equivalents in money market funds and marketable securities, largely composed of investment grade, short to intermediate term fixed income and debt securities. Because of the short term maturities of our cash equivalents and the short term nature of our marketable securities, we do not believe that a decrease in interest rates would have any material negative impact on the fair value of our cash equivalents or marketable securities.

Our debt portfolio is managed on a consolidated basis and management makes financing decisions to achieve the lowest cost of debt capital and to maximize portfolio objectives. Following the Notes issuance in September 2020, 100% of our outstanding debt became fixed with a total weighted average coupon rate of 2.125% as of December 31, 2020. In September 2020, we also entered into a five-year $1.5 billion Revolving Credit Facility with a variable interest rate that remained undrawn as of December 31, 2020. We are subject to interest rate fluctuation exposure related to the Revolving Credit Facility, if drawn. As of December 31, 2019, 33% of our debt was effectively fixed with a total weighted average interest rate of 3.69% across the portfolio. In connection with the Reorganization Transactions, we terminated all of our interest rate swaps and currently do not have in place any derivative hedging our debt.

Credit and Counterparty Risk

We are exposed to credit risk related to the counterparties with which we do business. We are subject to credit risk from our royalty assets, our receivables and our derivative contracts. The majority of our royalty assets and receivables arise from contractual royalty agreements that pay royalties on the sales of underlying pharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading biopharmaceutical industry participants, including, among others, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Gilead, Johnson & Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche/Genentech and Vertex. The individual marketers making up the largest balance of our current portion of Financial royalty assets, net were Vertex as of December 31, 2020 and Biogen as of December 31, 2019, accounting for 27% and 18%, respectively. Refer to “—Understanding Our Results of Operations” within this MD&A for a discussion of the marketers or royalty payors accounting for greater than 10% of our total income and other revenues for the years ended December 31, 2020 and 2019.

85

We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements and to our derivative contracts so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets or on the settlement of our derivative contracts. Of the $2.1 billion of notional interest rate swaps agreements in effect at December 31, 2019, the maximum exposure with any single counterparty accounted for 29% of our total interest rate swap portfolio. If a counterparty becomes bankrupt, or otherwise fails to perform its obligations under a derivative contract due to financial difficulties, we may experience significant delays in obtaining any recovery under the derivative contract in a bankruptcy or other reorganization proceeding.

86

Item 8.         Financial Statements and Supplementary Data

ROYALTY PHARMA PLC
Index to Audited Consolidated Financial Statements


87

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Royalty Pharma plc

Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Royalty Pharma plc (the “Company”) as of December 31, 2020 and 2019, the related consolidated statements of comprehensive income, shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.


88

Valuation of Financial Royalty Assets
Description of the Matter
As disclosed in Note 6, the Company’s total financial royalty assets, net, were carried at $12,955,277 thousand as of December 31, 2020. For the year ended December 31, 2020 the Company recognized income from financial royalty assets of $1,959,975 thousand. As explained in Note 2 to the consolidated financial statements, the Company’s financial royalty assets are measured at amortized cost using the prospective effective interest rate method. The effective interest rate (“EIR”) is calculated by forecasting the expected future cash flows to be received over the life of the asset relative to the initial invested amount. Income from financial royalty assets is calculated by multiplying the carrying value of the royalty asset by the EIR. The EIR is reviewed and adjusted quarterly as differences between expected and actual cash flows are realized and for any other changes to the future cash flows.
Auditing the valuation of the financial royalty assets and related interest income was complex because the assumptions used by Management to forecast the expected cash flows from the underlying royalties are judgmental and subject to estimation uncertainty. The key assumptions in the determination of the expected cash flows are product growth rates applied to forecasted sales in the later years in the royalty life, the percentage of sales which will bear royalties, and royalty duration. As more fully described in Note 2, these assumptions are based on a number of factors.
How We Addressed the Matter in Our Audit
To test the valuation of the financial royalty assets and related interest income, our audit procedures included, among others, evaluating the methodology and completeness and accuracy of the data used to develop the key assumptions identified above. We assessed the reasonableness of product growth rates and royalty bearing sales adjustments by considering explanations from the Company’s internal research team, corroborated by discussion with Management and inspection of relevant evidence to support the conclusions reached. For royalty duration, we compared Management’s assessment of the likely date of expiry of the Company’s cash flows against original purchase documentation and independently corroborated this with available published information sources such as those from regulatory bodies, counterparties, and product marketers.
We also performed sensitivity analyses over these assumptions. We assessed the historical accuracy of Management’s estimates by comparing expected cash flows to actual cash receipts. We also evaluated the related disclosures in the consolidated financial statements.

/s/ Ernst & Young

We have served as the Company’s auditor since 2003.

Dublin, Ireland
February 24, 2021
89



ROYALTY PHARMA PLC
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
As of December 31,
20202019
Assets
Current Assets
Cash and cash equivalents$1,008,680 $246,199 
Marketable securities983,279 94,455 
Financial royalty assets587,193 452,560 
Accrued royalty receivable33,155 33,525 
Available for sale debt securities69,984 — 
Other royalty income receivable6,011 5,241 
Other current assets8,596 92 
Total current assets2,696,898 832,072 
Financial royalty assets, net12,368,084 10,842,052 
Intangible royalty assets, net28,666 51,724 
Equity securities298,689 380,756 
Available for sale debt securities144,416 131,280 
Derivative financial instruments5,439 42,315 
Investments in non-consolidated affiliates454,936 124,061 
Other assets23,158 45,635 
Total assets$16,020,286 $12,449,895 
Liabilities and equity
Current liabilities
Distribution payable to non-controlling interest$126,366 $31,041 
Accounts payable and accrued expenses10,775 11,177 
Interest payable42,146 — 
Accrued purchase obligation110,000 — 
Milestone payable18,600 — 
Current portion of long-term debt— 281,984 
Derivative financial instruments— 9,215 
Total current liabilities307,887 333,417 
Long-term debt5,816,584 5,956,138 
Derivative financial instruments— 18,902 
Total liabilities6,124,471 6,308,457 
Commitments and contingencies
Shareholders’/Unitholders’ equity
Shareholders’ contributions— 3,282,516 
Class A ordinary shares, $0.0001 par value; 388,135 and 0 issued and outstanding, respectively
39 — 
Class B shares, $0.000001 par value; 218,976 and 0 issued and outstanding, respectively
— — 
Class R redeemable shares, £1 par value; 50 and 0 issued and outstanding, respectively
63 — 
Deferred shares, $0.000001 par value, 316,407 and 0 issued and outstanding, respectively
— — 
Additional paid-in capital2,865,964 — 
Retained earnings1,920,635 2,825,212 
Non-controlling interest5,077,036 35,883 
Accumulated other comprehensive income34,395 2,093 
Treasury interests(2,317)(4,266)
Total shareholders’/unitholders’ equity9,895,815 6,141,438 
Total liabilities and shareholders’/unitholders’ equity$16,020,286 $12,449,895 
See accompanying notes to these consolidated financial statements.
90



ROYALTY PHARMA PLC
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands, except per share amounts)
For the Years Ended December 31,
202020192018
Total income and revenues
Income from financial royalty assets$1,959,975 $1,648,837 $1,524,816 
Revenue from intangible royalty assets143,382 145,775 134,118 
Other royalty income18,996 19,642 135,960 
Total income and other revenues2,122,353 1,814,254 1,794,894 
Operating expenses
Research and development funding expense26,289 83,036 392,609 
Provision for changes in expected cash flows from financial royalty assets230,839 (1,019,321)(57,334)
Amortization of intangible assets23,058 23,924 33,267 
General and administrative expenses181,715 103,439 61,906 
Other operating expenses65,053 — — 
Total operating expenses, net526,954 (808,922)430,448 
Operating income1,595,399 2,623,176 1,364,446 
Other (income)/expense
Equity in (earnings)/loss of non-consolidated affiliates(44,459)32,517 7,023 
Interest expense157,059 268,573 279,956 
Realized gain on available for sale debt securities— — (419,481)
Unrealized loss/(gain) on derivative financial instruments42,076 39,138 (11,923)
(Gain)/loss on equity securities(247,073)(155,749)13,939 
Unrealized gain on forwards(18,600)— — 
Interest income(28,379)(22,329)(24,441)
Other non-operating expense/(income), net32,821 (393)1,518 
Total other (income)/expense, net(106,555)161,757 (153,409)
Consolidated net income before tax1,701,954 2,461,419 1,517,855 
Income tax expense— — — 
Consolidated net income1,701,954 2,461,419 1,517,855 
Less: Net income attributable to non-controlling interest(726,914)(112,884)(140,126)
Net income attributable to controlling interest975,040 2,348,535 1,377,729 
Other comprehensive income/(loss)
Reclassification of loss on interest rate swaps4,066 6,189 8,003 
Unrealized gain/(loss) on available for sale debt securities83,120 6,159 (402,502)
Reclassification of unrealized gain on available for sale debt securities(20,551)— — 
Other comprehensive income/(loss)66,635 12,348 (394,499)
Comprehensive income1,041,675 2,360,883 983,230 
Less: Other comprehensive income attributable to non-controlling interest(12,873)— — 
Comprehensive income attributable to controlling interest$1,028,802 $2,360,883 $983,230 
Earnings per Class A ordinary share (1):
     Basic$1.32 N/AN/A
     Diluted$1.32 N/AN/A
Weighted average Class A ordinary shares outstanding (1):
     Basic375,444 N/AN/A
     Diluted375,455 N/AN/A
(1) Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020, the period following our initial public offering (see Note 13).


See accompanying notes to these consolidated financial statements.
91

ROYALTY PHARMA PLC
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(In thousands)
Unitholders’ ContributionsRetained EarningsAccumulated Other Comprehensive Income/(Loss)Non-Controlling InterestTreasury InterestsTotal Equity
Balance at December 31, 2017$3,282,516 $655,446 $381,381 $141,203 $— $4,460,546 
Distributions— (814,359)— (217,464)— (1,031,823)
Cumulative adjustment for adoption of ASU 2016-01— (2,863)2,863 — — — 
Net income— 1,377,729 — 140,126 — 1,517,855 
Other comprehensive income/(loss):
Unrealized loss on available for sale debt securities— — (402,502)— — (402,502)
Reclassification of loss on interest rate swaps— — 8,003 — — 8,003 
Balance at December 31, 2018$3,282,516 $1,215,953 $(10,255)$63,865 $— $4,552,079 
Distributions— (739,276)— (140,866)— (880,142)
Net income— 2,348,535 — 112,884 — 2,461,419 
Other comprehensive income/(loss):
Unrealized gain on available for sale debt securities— — 6,159 — — 6,159 
Reclassification of loss on interest rate swaps— — 6,189 — — 6,189 
Purchase of treasury interests— — — — (4,266)(4,266)
Balance at December 31, 2019$3,282,516 $2,825,212 $2,093 $35,883 $(4,266)$6,141,438 














See accompanying notes to these consolidated financial statements.
92


ROYALTY PHARMA PLC
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(In thousands)
Class A Ordinary SharesClass B Ordinary SharesClass R Redeemable SharesDeferred SharesAdditional Paid-In CapitalShareholders’ ContributionsRetained EarningsAccumulated Other Comprehensive Income/(Loss)Non-Controlling InterestTreasury InterestsTotal Equity
SharesAmountSharesAmountSharesAmountSharesAmount
Balance at December 31, 2019— $— — $— — $— — $— $— $3,282,516 $2,825,212 $2,093 $35,883 $(4,266)$6,141,438 
Contributions— — — — — — — — — 307,646 — — 1,174,676 — 1,482,322 
Transfer of interests— — — — — — — — — (1,037,161)— — 1,037,161 — — 
Cumulative adjustment for adoption of ASU 2016-13— — — — — — — — — — (192,705)— — — (192,705)
Distributions— — — — — — — — — — (313,408)— (792,357)— (1,105,765)
Initial share issuance upon registration of Royalty Pharma plc— — — — 50 63 — — — — — — — — 63 
Net income prior to IPO— — — — — — — — — — 479,842 — 145,043 — 624,885 
Issuance of Class B shares to Continuing Investors Partnerships— — 535,383 1 — — — — — — — — — — 1 
Effect of exchange by Continuing Investors of Class B shares for Class A ordinary shares and reallocation of historical equity294,176 30 (294,176)(1)— — 294,176 — 1,402,762 (2,553,001)(1,261,014)(24,022)2,433,098 2,147 (1)
Issuance of Class A ordinary shares sold in IPO, net of offering costs71,652 7 — — — — — — 1,150,383 — — — 758,354 — 1,908,744 
Share-based compensation and related issuance of Class A ordinary shares76 — — — — — — — 5,428 — — — — — 5,428 
Other exchanges22,231 2 (22,231)— — — 22,231 — 307,391 — — 2,562 (309,566)(198)191 
Dividends— — — — — — — — — — (112,490)— — — (112,490)
Net income subsequent to IPO— — — — — — — — — — 495,198 — 581,871 — 1,077,069 
Other comprehensive income:
Reclassification of loss on interest rate swaps— — — — — — — — — — — 4,066 — — 4,066 
Unrealized gain on available for sale debt securities— — — — — — — — — — — 60,617 22,503 — 83,120 
Reclassification of unrealized gain on available for sale debt securities— — — — — — — — — — — (10,921)(9,630)— (20,551)
Balance at December 31, 2020388,135$39 218,976$— 50$63 316,407$— $2,865,964 $— $1,920,635 $34,395 $5,077,036 $(2,317)$9,895,815 






See accompanying notes to these consolidated financial statements.
93

ROYALTY PHARMA PLC
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
For the Years Ended December 31,
202020192018
Cash flows from operating activities:
Cash collections from financial royalty assets$2,121,923 $1,934,092 $2,052,592 
Cash collections from intangible royalty assets143,753 143,298 106,689 
Other royalty cash collections18,305 27,448 125,162 
Distributions from non-consolidated affiliates42,334 14,059 39,402 
Interest received7,704 20,136 24,441 
Swap collateral received45,252 360 3,467 
Swap collateral posted— (45,630)(510)
Swap termination payments(35,448)— — 
Ongoing development-stage funding payments(20,479)(83,036)(108,163)
Upfront development-stage funding payments(5,810)— (284,446)
Payments for operating and professional costs(179,709)(88,524)(72,535)
Payments for rebates— — (125)
Interest paid(103,196)(254,964)(267,657)
Net cash provided by operating activities2,034,629 1,667,239 1,618,317 
Cash flows from investing activities:
Distributions from non-consolidated affiliates15,084 — — 
Purchases of available for sale debt securities— (125,121)— 
Purchase of warrants— (8,840)— 
Purchases of equity securities(50,000)(78,999)(152,810)
Proceeds from available for sale debt securities3,000 150,000 750,000 
Purchases of marketable securities(1,705,283)(817,402)— 
Proceeds from sales and maturities of marketable securities815,440 725,070 — 
Proceeds from equity securities384,840 — — 
Investments in non-consolidated affiliates(40,155)(27,042)(24,173)
Acquisitions of financial royalty assets(2,182,246)(1,721,291)(269,593)
Milestone payments— (250,000)— 
Net cash (used in)/provided by investing activities(2,759,320)(2,153,625)303,424 
Cash flows from financing activities:
Distributions to shareholders/unitholders(285,353)(739,276)(814,359)
Distributions to non-controlling interest(543,952)(154,084)(268,693)
Distributions to non-controlling interest- other(181,135)— — 
Dividends to shareholders(112,490)— — 
Contributions from non-controlling interest- R&D8,482 — — 
Contributions from non-controlling interest- other58,957 — — 
Scheduled repayments of long-term debt(94,200)(294,000)(294,000)
Repayments of long-term debt(11,116,196)— — 
Proceeds from issuance of long-term debt11,891,030 — — 
Debt issuance costs and other(46,715)— (2,049)
Purchase of treasury interests— (4,266)— 
Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs1,908,744 — — 
Net cash provided by/(used in) financing activities1,487,172 (1,191,626)(1,379,101)
Net change in cash and cash equivalents762,481 (1,678,012)542,640 
Cash and cash equivalents, beginning of year246,199 1,924,211 1,381,571 
Cash and cash equivalents, end of year$1,008,680 $246,199 $1,924,211 

See accompanying notes to these consolidated financial statements.
94
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS


1. Organization and Purpose

Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (the “IPO”) of our Class A ordinary shares that was completed in June 2020.

Following our IPO, we control Royalty Pharma Holdings Ltd. (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K. tax resident through our ownership of RP Holdings’ Class A ordinary shares (the “RP Holdings Class A Interests”) and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our consolidated financial statements.

RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV, which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish Unit Trust (“Old RPI”), for accounting and financial reporting purposes. RP Holdings is owned directly by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, (together, the “Continuing Investors Partnerships”), and Royalty Pharma plc. Old RPI is a unit trust established in August 2011 under the laws of Ireland and authorized by the Central Bank of Ireland pursuant to the Unit Trusts Act, 1990. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”).

RP Management, LLC (the “Manager”), a Delaware limited liability company, is an external adviser which is responsible for our management. RP Management (Ireland) Ltd. (“RP Ireland”), is the manager of Old RPI and equivalent to the board of directors of a company or general partner of a partnership and is responsible for the day to day operations of Old RPI. Its functions can be delegated to third parties. RP Ireland delegated responsibility for investment management of Old RPI to its parent company, the Manager, in accordance with the investment objectives and policies of Old RPI.

“Royalty Pharma,” “Royalty Pharma Investments,” “RPI,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Reorganization Transactions (defined below) and before the consummation of the IPO, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma Investments 2019 ICAV. Prior to the Reorganization Transactions, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Old RPI.
We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

Reorganization Transactions

In connection with our IPO, we consummated an exchange offer on February 11, 2020 (the “Exchange Date”). Through the exchange offer, investors representing 82% of the aggregate limited partnership in the Legacy Investors Partnerships, exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under a new credit facility and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”

95
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



As a result of the Exchange Offer Transactions, we own, through our wholly-owned subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”), an 82% economic interest in Old RPI. Through our 82% indirect ownership of Old RPI, we are legally entitled to 82% of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish Unit trust. From the Exchange Date until the expiration of the Legacy Investors Partnerships’ investment period on June 30, 2020 (the “Legacy Date”), the Legacy Investors Partnerships were offered to participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI has ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Following the Legacy Date, we have made and will continue to make new investments through our subsidiaries, including RPI Intermediate FT.
As part of the Exchange Offer Transactions, the Legacy Investors Partnerships and RPI Intermediate FT entered into new credit facilities in the amount of $1.3 billion and $6.0 billion, respectively, the proceeds of which were primarily used to repay the $6.3 billion outstanding debt of RPIFT as of the Exchange Date and, in the case of RPI Intermediate FT, was also available to be used to fund investments. As part of the new credit facilities, RPI Intermediate FT repaid $5.2 billion, its pro rata portion of RPIFT’s outstanding debt and accrued interest. RPIFT also terminated all outstanding interest rate swaps in connection with the debt refinancing.
Prior to, and as a condition precedent to the closing of the IPO, various reorganization transactions became effective, including the following:
•the Exchange Offer Transactions (as described above); and
•the execution of a new management agreement with the Manager (the “New Management Agreement”).

We refer to these transactions collectively as the “Reorganization Transactions.”

As Old RPI is our predecessor for financial reporting purposes, we have recorded Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date. The references in the following notes for the periods prior to the Exchange Date refer to the financial results of Old RPI for the same periods.
IPO

In June 2020, we completed our IPO, in which we issued 89,334 thousand shares of Class A ordinary shares at a price to the public of $28.00 per share, of which 71,652 thousand and 17,682 thousand shares were offered by the Company and selling shareholders, respectively. The Company received net proceeds of approximately $1.9 billion from the IPO after deducting underwriting discounts and commissions. The Class A ordinary shares began trading on the Nasdaq Global Select Market under the ticker symbol “RPRX” on June 16, 2020. We used the net proceeds from the IPO to acquire the RP Holdings Class A Interests shortly after completion of the IPO. As a result, we own 100% of RP Holdings Class A Interests.

In connection with the IPO, pursuant to the Exchange Offer Transactions, certain of the Continuing Investor Partnerships agreed to exchange, upon consummation of the IPO, interests in the Continuing Investors Partnerships represented by their ownership of 294,176 thousand RP Holdings Class B Interests into an aggregate of 294,176 thousand Class A ordinary shares of the Company. Upon completion of the exchange, Royalty Pharma plc indirectly owned 294,176 thousand RP Holdings Class B Interests. The remaining investors in the Continuing Investors Partnerships who did not elect to exchange into Class A ordinary shares held 241,207 thousand newly issued Class B ordinary shares of Royalty Pharma plc. As a result, the Continuing Investors Partnerships held a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests indirectly held by them at such time which are exchangeable on a one-for-one basis for Class A ordinary shares of Royalty Pharma plc. Our Class B ordinary shares will not be publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. However, the RP Holdings Class B Interests will be entitled to dividends and distributions from RP Holdings. Our Class A ordinary and Class B ordinary shares will vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law, with each share entitled to one vote.

96
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



2. Summary of Significant Accounting Policies

Basis of preparation and use of estimates

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.

The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, the pandemic has not materially impacted our financial performance and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.

Basis of consolidation

The consolidated financial statements include the accounts of Royalty Pharma plc and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record Net income attributable to non-controlling interest in our consolidated statements of comprehensive income equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

Following management’s determination that a high degree of common ownership existed in RPI both before and after the Exchange Date, RPI recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date.

Prior to the Exchange Offer Transactions, our only historical non-controlling interest was attributable to a de minimis interest in RPCT held by RPSFT. As a result of the Exchange Offer Transactions in February 2020, a new non-controlling interest was created related to the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI.

Following the consummation of our IPO in June 2020, two new non-controlling interests were created: (1) a non-controlling interest related to the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, which amounted to approximately 36% as of December 31, 2020, and (2) a non-controlling interest attributable to the RP Holdings Class C Special Interest held by EPA Holdings, an affiliate of the Manager. Income will not be allocated to the latter non-controlling interest until certain conditions are met, which we do not expect to occur for several years.

All intercompany transactions and balances have been eliminated in consolidation.

Adjustment to prior period presentation

In connection with the preparation of our condensed consolidated interim financial statements for the three months ended September 30, 2020, we identified an adjustment to the classification of our short-term investments on our consolidated balance sheets, as of December 31, 2019, based on the original maturity dates of the investments. The adjustment resulted in an increase of $37.5 million to Marketable securities and a corresponding decrease to Cash and cash equivalents on the consolidated balance sheet as of December 31, 2019. In addition, the adjustment resulted in an increase of $388.0 million and $350.5 million in cash activity related to Purchases of marketable securities and Proceeds from sales and maturities of marketable securities, respectively, within Net cash used in investing activities for the year ended December 31, 2019, with a net impact on net cash flow from investing of $37.5 million. The adjustment had no effect on our reported total income and revenues, consolidated net income, total assets, or shareholders’ equity for any period. In addition, the adjustment does not impact net cash provided by operating activities in any period. We evaluated the adjustment and determined that, based on quantitative and qualitative analysis, it was not material to the consolidated financial statements as of and for the year ended December 31, 2019.
97
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Concentrations of credit risk
Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2020 and 2019 were held with State Street, Deutsche Bank and Bank of America. Our primary operating accounts significantly exceed the FDIC limits.

The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Abbott, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Gilead, Johnson & Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche/ Genentech and Vertex. For the years ended December 31, 2020 and 2019, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise products, accounted for 27% and 17% of our current portion of Financial royalty assets, respectively.

We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.

Segment information

Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.

Royalty assets

An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.

In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.

Financial royalty assets, net

Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (“ASC”), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 Imputation of Interest.

98
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty assets is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as Provision for changes in expected future cash flows from financial royalty assets and the carrying value of Financial royalty assets, net is presented net of the cumulative allowance for changes in expected future cash flows.

The application of the prospective approach to measure financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties.
The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product and royalty duration, each discussed in further detail below.

•Analyst coverage. Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to derive annual sales projections for each financial royalty asset by applying the median growth rates calculated from consensus forecasts among sell-side equity research analysts currently reporting on a product to the corresponding periods for which we are entitled to royalties. Growth rates inherent in these forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst estimates are not available for the full term of the royalty, particularly for the later years in a product’s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management’s own expertise. Further, based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms and rates are then applied to the adjusted sales projections to calculate the expected royalty payments over the term of the financial royalty asset’s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.

•Commercial performance. The approval of a product for use in new indications can extend the date through which we are entitled to royalties on that product. Likewise, for certain royalties, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in sales projections. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts’ forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product’s performance in the market can materially affect our forecast of expected future cash flows over the royalty term.

99
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



•Royalty duration. The duration of a royalty can be based on a number of factors, such as patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product’s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation outcomes. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.

As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) product growth rates and sales trends in outer years, (2) the geographical allocation of annual sales data from sell-side equity research analysts’ models, (3) the product and pricing mix for franchised products, (4) the strength of patent protection, including anticipated entry of generics and (5) estimates of the duration of the royalty. The most sensitive of these assumptions relates to management’s estimate of the royalty duration in the final years of an asset’s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows.

A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.

The current portion of Financial royalty assets, net represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears.

Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets

We evaluate financial royalty assets for impairment on an individual basis at each reporting date by comparing the effective interest rate to that of the prior period. If the current period effective interest rate is lower than the prior period, and if the gross cash flows have declined (expected and collected), management records a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset’s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period’s effective interest rate. The amount recognized as provision expense increases the financial royalty asset’s cumulative allowance, which reduces the net carrying value of the financial royalty asset.

100
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. Management also recalculates the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.

Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the Financial royalty assets, net line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset’s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either Provision for changes in expected cash flows from financial royalty assets or as Income from financial royalty assets on the consolidated statements of comprehensive income.

Income from financial royalty assets

We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.

When royalties continue to be collected for financial royalty assets that have been fully amortized, such income is recognized as Other royalty income.

Allowance for current expected credit losses

On January 1, 2020, we adopted ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of Financial royalty assets, net on the consolidated balance sheets. Any subsequent routine movement in the allowance for credit losses is recorded as part of the Provision for changes in expected future cash flows from financial royalty assets on the consolidated statements of comprehensive income.

Refer to Note 7—Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for further information.

Intangible royalty assets, net

Currently, our only intangible royalty assets are the Januvia and Janumet (“DPP-IV”) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, which terminate at various dates until 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.

101
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10, Property, Plant, and Equipment - Overall. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product’s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty’s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.

Revenue from intangible royalty assets and Accrued royalty receivable

We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue on DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts’ projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.

Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.

Milestone payments

Certain acquisition agreements provide for future contingent payments based on the financial performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts’ consensus forecasts. Milestones based on regulatory approval are not reflected in the expected future cash flows until such approval is achieved.

Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.

Financial instruments

Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than Financial royalty assets, net are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 3–Fair Value Measurements and Financial Instruments.

Cash and cash equivalents and Marketable securities

Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value.

102
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Equity securities and Available for sale debt securities

Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities, including our investment in the Biohaven Series A Preferred Shares, are measured at fair value and unrealized gains and losses are included in accumulated other comprehensive income/(loss) (“AOCI”). Unrealized gains and losses are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows.

A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management’s assessment.

We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.

Derivatives

All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements.

Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of comprehensive income as part of Unrealized gain/(loss) on derivative financial instruments.

Investment in non-consolidated affiliates

Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at cost. Subsequently, we recognize through earnings our proportionate share of the investee’s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of these entities one quarter in arrears within Equity in (earnings)/loss of non-consolidated affiliates in the consolidated statements of comprehensive income. The investment is reflected as Investments in non-consolidated affiliates on the consolidated balance sheet.

We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the “Avillion entities”). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.

103
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets.

Research and development funding expense

We enter into transactions where we agree to fund a portion of the research and development (“R&D”) for products undergoing late-stage clinical trials in exchange for future royalties if the products are successfully developed and commercialized. In accordance with ASC 730 Research and Development, we account for the funded amounts as R&D expense when we have the ability to obtain the results of the R&D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval.

Royalty payments owed to the Company on successfully commercialized products generated from R&D agreements are recognized as Other royalty income in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria (i.e., typically the achievement of agreed upon sales thresholds) for products arising out of our R&D arrangements are also recognized as Other royalty income in the period that the commercial sales threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed and we have no further performance obligations.

Income taxes

We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (“the Code”) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.

While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments.

Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes.

We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI.

104
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



We are also subject to the U.K.’s “controlled foreign companies” rules (the “U.K. CFC Rules”). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the “Controlled Foreign Company”) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings), will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes.

Earnings per share

Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares and restricted share units (“RSUs”) issued under our 2020 Independent Director Equity Incentive Plan (“Equity Incentive Plan”). We use the “if-converted” method to determine the potentially dilutive effect of Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.

There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information has been presented for any period prior to that date.

Recently adopted accounting standards

In May 2014, the Financial Accounting Standard Board (“FASB”) issued a new revenue standard under ASC Topic 606 (ASU 2014-09). ASU 2014-09 applies to all contracts with customers. Based on management’s assessment, income from financial royalty assets which are accounted for in accordance with ASC 310, Receivables, is not subject to the application of ASU 2014-09. As a result, management believes that financial royalty assets represent contractual rights and obligations that continue to be within the scope of Topic 310 and therefore specifically exempted from the new revenue standard. The provisions of ASU 2014-09 became effective for us on January 1, 2018, including interim reporting periods. Our revenues are primarily derived from intangible royalty assets, which fall under the sales-based royalties exception in the new standard. Therefore, we did not recognize any adjustment upon adoption of the new revenue standard.

In January 2016, the FASB issued revised guidance for the accounting and reporting of financial instruments (ASU 2016-01) and in 2018 issued related technical corrections (ASU 2018-03). The new guidance requires that equity investments with readily determinable fair values currently classified as available for sale be measured at fair value with changes in fair value recognized in net income. The new guidance also changed certain disclosure requirements. We adopted ASU 2016-01 as of January 1, 2018 using a modified retrospective approach. We recorded a cumulative-effect adjustment upon adoption that decreased retained earnings by $2.9 million as a result of accumulated other comprehensive income previously recognized on its available for sale equity securities. ASU 2018-03 was also adopted as of January 1, 2018 on a prospective basis and did not result in any additional impact upon adoption.

In August 2016, the FASB issued revised guidance which makes eight targeted changes to how royalty receipts and cash payments are presented and classified in the Statement of Cash Flows (ASU 2016-15). Among the updates, the standard allows companies to elect the “cumulative earnings” approach or the “nature-of-the-distribution” approach in distinguishing whether distributions received from equity method investees are returns of investment, which should be classified as cash flows from investing activities, and returns on investment, which should be classified as cash flows from operating activities. We made a policy election to use the “cumulative earnings” approach and adopted ASU 2016-15 for the year ended December 31, 2018.

105
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to Retained earnings of $192.7 million to recognize an allowance for current expected credit losses on our financial royalty assets.

In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.

3. Fair Value Measurements and Financial Instruments

Fair value measurements

The summary below presents information about our assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020 and 2019, and the valuation techniques we utilized to determine such fair value.

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Our Level 1 assets consist of equity securities with readily determinable fair values and money market funds.
•Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. Our Level 2 assets generally include marketable securities, warrants, derivatives and our interest rate swap contracts, which may be in an asset or liability position.
•Level 3: Prices or valuation that requires inputs that are both significant to the fair value measurement and unobservable. Our Level 3 assets consist of our investments in the Series A Biohaven Preferred Shares and the Series B Forwards and, historically, our investment in Tecfidera. See Note 5––Available for Sale Debt Securities for a description of our investments in the Biohaven Preferred Shares.

For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety.

106
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Fair value hierarchy

The following is a summary of the inputs used to value our financial assets and liabilities measured at fair value as of December 31, 2020 and 2019 (in thousands):
As of December 31, 2020
Level 1Level 2Level 3Total
Assets:
Cash equivalents
Money market funds$24,302 $— $— $24,302 
Commercial paper— 77,176 — 77,176 
Certificates of deposit— 74,502 — 74,502 
Marketable securities
Corporate debt securities— 32,754 — 32,754 
Commercial paper— 444,554 — 444,554 
Certificates of deposit— 505,971 — 505,971 
Available for sale debt securities— — 69,984 69,984 
Total current assets$24,302 $1,134,957 $69,984 $1,229,243 
Equity securities (1)298,689 — — 298,689 
Available for sale debt securities— — 144,416 144,416 
Forwards (2)— — 18,600 18,600 
Warrants (3)— 5,439 — 5,439 
Total non-current assets$298,689 $5,439 $163,016 $467,144 
(1)Upon Gilead’s acquisition of Immunomedics, our investment in Immunomedics common stock was redeemed in full in the fourth quarter of 2020, resulting in a gain of $292.3 million recognized within (Gain)/loss on equity securities in the year ended December 31, 2020.
(2)The Series B Forwards, recorded within Other assets in the consolidated balance sheet as of December 31, 2020, relate to our obligation to fund the acquisition of the Series B Biohaven Preferred Shares.
(3)Related to Epizyme transaction as described in Note 4–Derivative Instruments and recorded in the non-current asset portion of Derivative financial instruments in the consolidated balance sheet as of December 31, 2020.

The net unrealized gain or loss recognized on equity securities still held as of December 31, 2020 was a loss of $45.2 million, a gain of $125.6 million and a loss of $7.8 million for the years ended December 31, 2020, 2019 and 2018, respectively.
107
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



As of December 31, 2019
Level 1Level 2Level 3Total
Assets:
Cash equivalents
Money market funds$222,326 $— $— $222,326 
Certificates of deposit— 4,000 — 4,000 
Marketable securities
U.S. government securities— 12,877 — 12,877 
Commercial paper— 21,367 — 21,367 
Certificates of deposit— 60,211 — 60,211 
Total current assets$222,326 $98,455 $— $320,781 
Equity securities380,756 — — 380,756 
Available for sale debt securities— — 131,280 131,280 
Warrants (1)— 30,815 — 30,815 
Forward purchase contract (1)— 11,500 — 11,500 
Total non-current assets$380,756 $42,315 $131,280 $554,351 
Liabilities:
Interest rate swaps— (9,215)— (9,215)
Total current liabilities$— $(9,215)$— $(9,215)
Interest rate swaps— (18,902)— (18,902)
Total non-current liabilities$— $(18,902)$— $(18,902)
(1)Related to Epizyme warrants and put option as described in Note 4–Derivative Instruments and both recorded in the non-current asset portion of Derivative financial instruments in the consolidated balance sheet as of December 31, 2019.

The tables presented below summarize the change in the carrying value of Level 3 financial instruments, which relate to our investment in the Series A Biohaven Preferred Shares and the Series B Forwards (in thousands).
For the years ended
December 31,
20202019
Available for sale debt securities
Balance at the beginning of the period$131,280 $— 
Purchases— 125,121 
Unrealized gains on available for sale debt securities52,725 — 
Transfer to Level 2(184,005)— 
Transfer from Level 2 (1)198,526 — 
Unrealized gains on available for sale debt securities15,874 6,159 
Balance at the end of the period$214,400 $131,280 
(1)     Includes $14.5 million of unrealized gains on available for sale debt securities included in other comprehensive income while the instrument was classified as a Level 2 asset.

For the year ended
December 31,
2020
Forwards
Balance at the beginning of the period$— 
Unrealized gains included in earnings (1)18,600 
Balance at the end of the period$18,600 
(1)     Recorded within Unrealized gain on forwards on the consolidated statements of comprehensive income.

108
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS




Valuation inputs

Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.

Investment in Series A Biohaven Preferred Shares

The fair value of the Series A Biohaven Preferred Shares at December 31, 2020 is based on the cash flows due to us from Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”) of two times (2x) the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6 million following U.S. Food and Drug Administration (“FDA”) approval and starting one-year after FDA approval through December 31, 2024. The FDA approved Nurtec ODT (rimegepant) in February 2020, at which point we became entitled to receive a fixed payment amount of $250.0 million payable in equal quarterly payments from March 31, 2021 through December 31, 2024. For additional discussion of our investment in the Series A Biohaven Preferred Shares, see Note 5––Available for Sale Debt Securities.

The fair value of the Series A Biohaven Preferred Shares at December 31, 2020 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate of 8.3% could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower. At December 31, 2020 we estimated the fair value for the Series A Biohaven Preferred Shares as $214.4 million, which we classified as available for sale debt securities.

For periods prior to March 31, 2020, we valued the Series A Biohaven Preferred Shares using a Black-Derman Toy (“BDT”) lattice model. The fair value of the Series A Biohaven Preferred Shares at December 31, 2019 was determined based on significant inputs that were not observable in the market, referred to as Level 3 inputs. Key inputs to the BDT model for the December 31, 2019 valuation included, most notably, the probability (1) of Biohaven’s pipeline product, Nurtec ODT (rimegepant), being approved by the FDA by specific dates, (2) of a change of control event by specific dates and (3) that Biohaven will elect to redeem the Series A Biohaven Preferred Shares for a lump sum payment as opposed to payback over time. Probabilities for the above considerations were developed by management, which has significant healthcare and finance expertise to make such assessments. The most critical assumption that impacted the valuation of our Series A Biohaven Preferred Shares at December 31, 2019 was the probability that Nurtec ODT (rimegepant) would be approved by the FDA.

Assumptions used in the valuation model as of December 31, 2019 included the following significant unobservable inputs:
•Change of Control probability on a quarterly basis (0%)
•Likelihood of FDA approval (0%-86%)
•Likelihood of FDA approval at the end of any given quarter by December 31, 2024 (Range: 0%-59%).

Our investment in the Series A Biohaven Preferred Shares was transferred from a Level 3 asset to a Level 2 asset in February 2020, when Nurtec ODT (rimegepant) received FDA approval, at which time we began using a discounted cash flow analysis that relied on observable inputs. During the three months ended December 31, 2020, we became aware of Biohaven’s issuance of debt and its effective interest rate and refined our valuation of the Series A Biohaven Preferred shares as of December 31, 2020 to incorporate this significant unobservable input. As a result, we reclassified the investment from a Level 2 to a Level 3 asset during the three months ended December 31, 2020.

109
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Investment in Series B Biohaven Preferred Shares

We have committed to acquiring 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share for a total of $200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024 (“Series B Forwards”). In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments equal to approximately 1.8 times the original issue price per share between March 31, 2025 and December 31, 2030. For additional discussion of our investment in the Series B Biohaven Preferred Shares, see Note 5–Available for Sale Debt Securities.

The fair value of the Series B Forwards as of December 31, 2020 is based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a 10-year time period and developing a risk-adjusted discounted rate requires significant judgement. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimate fair value could be significantly higher or lower than the fair value determined by management at any particular date. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower. We have elected the fair value option to account for our Series B Forwards as it most accurately reflects the nature of our Series B Forwards, which we record within Other assets in our consolidated balance sheet. The unrealized movement in fair value of the Series B forwards is recorded within Unrealized gain on forwards on the consolidated statements of comprehensive income.

Other financial instruments

We use a third party pricing service for Level 2 inputs used to value cash equivalents, marketable securities and borrowings, which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. Warrants are valued using a Black-Scholes option pricing model which considers observable and unobservable inputs. Level 2 interest rate swaps are typically valued using counterparty confirmations, LIBOR yield curves and credit valuation adjustments.

Financial assets not measured at fair value

Financial royalty assets are measured and carried on the consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. The fair value of financial royalty assets is calculated by management using the forecasted royalty payments we expect to receive based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts’ consensus forecasts. These projected future royalty payments by asset are then discounted to a present value using appropriate individual discount rates. The fair value of our financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of our financial royalty assets as of December 31, 2020 and 2019 are presented below (in thousands).

December 31, 2020December 31, 2019
Fair valueCarrying value, netFair valueCarrying value, net
Financial royalty assets, net$18,718,179 $12,368,084 $16,501,819 $10,842,052 

4. Derivative Instruments

We have historically managed the impact of foreign currency exchange rate and interest rate risk through various financial instruments, including derivative instruments such as interest rate swap contracts and foreign currency forward contracts. Our policy is to use derivatives strategically to hedge existing interest rate exposure and to minimize volatility in cash flow arising from our exposure to interest rate risk and foreign currency risk. We may also acquire other financial instruments that are classified as derivatives. We do not enter into derivative instruments for trading or speculative purposes.

110
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Interest rate swaps

As of December 31, 2020, we do not hold any interest rate swap contracts. In connection with the Exchange Offer Transactions described in Note 1–Organization and Purpose, RPIFT terminated all outstanding interest rate swaps in February 2020. We paid $35.4 million to terminate our swaps and reclaimed $45.3 million of collateral that was held by the respective counterparties.

As of December 31, 2019, RPIFT held interest rate swap contracts to effectively convert a portion of its floating-rate debt to a fixed basis. The notional values and fixed rates payable on the swap contracts are shown in the table below.
Notional Value
(in millions)		Fixed RateMaturity Date
$6002.019 %November 9, 2020
$2502.094 %March 27, 2023
$5002.029 %March 27, 2023
$2502.113 %March 27, 2023
$5002.129 %March 27, 2023

We do not apply hedge accounting and recognize all movement in fair value through earnings. All outstanding interest rate swaps were terminated in February 2020. During the years ended December 31, 2020 and 2019, we recorded unrealized losses of $10.9 million and $72.6 million, respectively, on interest rate swaps in the consolidated statements of comprehensive income. During the year ended December 31, 2018, we recorded unrealized gains of $11.9 million on interest rate swaps in the consolidated statements of comprehensive income.

As of December 31, 2019, the fair value of the swaps was a net liability of $28.1 million (a current liability of $9.2 million and a non-current liability of $18.9 million) and included within Derivative financial instruments on the consolidated balance sheets.

RPIFT had master International Swaps and Derivatives Association (“ISDA”) agreements in place with its derivative instrument counterparties which provide for final close out netting with counterparties for all positions in the case of default or termination of the ISDA agreement. Under these agreements, RPIFT has set-off rights with the same counterparty but elected not to offset such derivative instrument fair values in the consolidated balance sheets.

RPIFT generally had executed a Credit Support Annex (“CSA”) under the ISDA it maintains with each of its over-the-counter (“OTC”) derivative counterparties that requires both posting and accepting collateral either in the form of cash or high-quality securities. These CSAs are bilateral agreements that require collateral postings by the party “out-of-the-money” or in a net derivative liability position. Various thresholds for the amount and timing of collateralization of net liability positions are applicable. RPIFT elected not to offset fair value amounts of any outstanding derivatives against the fair value amounts recognized for the related cash collateral receivable or payable that arise from those derivative instruments on the consolidated balance sheets.

Only the swaps maturing in 2023 had collateral requirements. At December 31, 2019, RPIFT had a receivable of $45.6 million in cash collateral previously posted to trade counterparties, which was recorded in Other assets on the consolidated balance sheets. At December 31, 2019, RPIFT did not have the obligation to return any cash collateral to counterparties, as it did not hold any cash collateral at that date.

Epizyme put option and warrant

In November 2019, RPIFT made an equity investment in Epizyme Inc. (“Epizyme”) of $100.0 million. Under the terms of its agreement with Epizyme, RPIFT made an upfront payment of $100.0 million for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5 million shares of Epizyme common stock at $20 per share over a three-year term and (3) Epizyme’s royalty on sales of Tazemetostat in Japan payable by Eisai Co., Ltd (“Eisai”). In addition, Epizyme had an 18 month put option to sell an additional $50.0 million of its common stock to RPIFT at then prevailing prices, not to exceed $20 per share.

111
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



On December 31, 2019, Epizyme notified RPIFT of its intention to exercise the put option. As a result, we recorded a forward purchase contract equal to the difference between the market value and exercise price of $11.5 million in the non-current asset portion of Derivative financial instruments on the consolidated balance sheet at December 31, 2019. The exercise of the put option was settled in February 2020.

The warrant was recognized at fair value of $5.4 million and $30.8 million within the non-current asset portion of Derivative financial instruments on the consolidated balance sheets at December 31, 2020 and 2019, respectively. We recorded an unrealized loss on derivative contracts of $25.4 million and an unrealized gain on derivative contracts of $22.0 million related to the change in fair value of the warrants on the consolidated statements of comprehensive income for the years ended December 31, 2020 and 2019, respectively.

Biohaven written put option

We determined there was a derivative associated with the Second Tranche (as defined below) of the Series A Biohaven Preferred Shares Agreement that was entered into in April 2019. The derivative related to Biohaven’s option, exercisable within 12 months from when the NDA for Nurtec ODT (rimegepant) was accepted by the FDA for Priority Review, to require Royalty Pharma to purchase up to an additional $75.0 million of Series A Biohaven Preferred Shares (the “Second Tranche”) at the same price and on the same terms as the First Tranche, in one or more transactions of no less than $25.0 million. As of December 31, 2019, management determined that the value of the Second Tranche written put option was immaterial, and therefore no derivative liability was recognized on the consolidated balance sheets. The exercise period for the Biohaven written put option expired in the year ended December 31, 2020, and therefore there was no value or movement in fair value associated with the Biohaven written put option as of or for the year ended December 31, 2020. See Note 5–Available for Sale Debt Securities for a description of our investment in the Series A Biohaven Preferred Shares.

Summary of derivatives and reclassifications

The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2020, 2019 and 2018 and the line items within the consolidated statements of comprehensive income where the gains/(losses) on these derivatives are recorded (in thousands).
For the years ended
December 31,		Consolidated Statement of Comprehensive Income location
202020192018
Derivatives in hedging relationships (1)
Interest Rate Swaps:
Amount of loss reclassified from AOCI into income$4,066 $6,189 $8,003 Unrealized loss/(gain) on derivative financial instruments
Change in fair value of interest rate swaps(73)16,954 (3,357)Unrealized loss/(gain) on derivative financial instruments
Interest expense/(income)114 (9,565)(9,758)Interest expense
Derivatives not designated as hedging instruments
Interest Rate Swaps:
Change in fair value of interest rate swaps6,908 49,472 (16,569)Unrealized loss/(gain) on derivative financial instruments
Interest expense/(income)408 (2,681)(440)Interest expense
Warrant:
Change in fair value of warrant25,375 (21,977)— Unrealized loss/(gain) on derivative financial instruments
Forward purchase contract:
Change in fair value of forward purchase contract5,800 (11,500)— Unrealized loss/(gain) on derivative financial instruments
(1)     Certain older interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in AOCI have been released into earnings.

112
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



5. Available for Sale Debt Securities

A summary of our available for sale debt securities recorded at fair value is shown below as of December 31, 2020 and December 31, 2019 (in thousands):
CostUnrealized gainsFair Value (1)
As of December 31, 2020
Series A Biohaven Preferred Shares$125,121 $89,279 $214,400 
Total available for sale debt securities$125,121 $89,279 $214,400 
As of December 31, 2019
Series A Biohaven Preferred Shares$125,121 $6,159 $131,280 
Total available for sale debt securities$125,121 $6,159 $131,280 
(1)As of December 31, 2020, $70.0 million and $144.4 million are recorded as the current and non-current asset portion of Available for sale debt securities, respectively, in the consolidated balance sheet. As of December 31, 2019, the entire balance of the Series A Biohaven Preferred Shares was recorded as a non-current asset.

Series A Biohaven Preferred Shares

On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven at a price of $50,100.00 per preferred share, for a total of $125.0 million. The approval of Nurtec ODT (rimegepant) by the FDA in February 2020 results in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning on March 31, 2021 through December 31, 2024. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price. In the event that Biohaven defaults on any obligation to redeem Series A Biohaven Preferred Shares when required, the redemption amount shall accrue interest at the rate of 18% annually until the redemption price for such unredeemed Series A Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert all unredeemed Series A Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date.

Series B Biohaven Preferred Shares

On August 7, 2020 we entered into a Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven to purchase up to 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”), for a total of $200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards, as discussed in Note 3––Fair Value Measurements and Financial Instruments. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Preferred Shares and to redeem any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the Series B original issue price per share. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the Series B original issue price. In the event that Biohaven defaults on any obligation to redeem Series B Biohaven Preferred Shares, the redemption amount shall accrue interest on the applicable original issue price at the rate of 18% annually until the redemption price for such unredeemed Series B Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert any or all unredeemed Series B Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date.

113
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Upon the acquisition of the Series B Biohaven Preferred Shares, beginning on March 31, 2021, we will classify the Series B Biohaven Preferred Shares as available for sale debt securities. We have elected the fair value option to account for our Series B Forwards and will elect the fair value option for the Series B Biohaven Preferred Shares, when acquired. We believe the fair value option most accurately reflects the nature of the Series B Forwards and the associated Series B Biohaven Preferred Shares.

Tecfidera

In 2012 and 2013, RPIFT acquired interests in the earn-out payable to the former shareholders of Fumapharm AG. The Fumapharm earn-out primarily represents an indirect interest in Biogen’s sales of Tecfidera, an oral therapeutic for the treatment of relapsing-remitting multiple sclerosis. Our investment in the Tecfidera earn-out was classified as available for sale debt securities.

This investment was structured in the form of multiple potential milestone payments, of which all were earned as of December 31, 2018. The allocated cost of each milestone was derived using a third-party analysis based on projected sales over time, the future competitive landscape, the strength of the patents underlying the product and the prevailing interest rate environment. The $600.0 million milestone payments that RPIFT was entitled to receive based on sales during the year ended December 31, 2018 were recorded as a $419.5 million realized gain in the consolidated statements of comprehensive income and a $180.5 million reduction of the investment in Tecfidera recorded as available for sale securities at the balance sheet date. As of December 31, 2020 and 2019, we had no available for sale debt securities related to our investment in Tecfidera.

6. Financial Royalty Assets, Net

Financial royalty assets consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of those products by unrelated companies.

The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2020 and December 31, 2019 are as follows (in thousands):
December 31, 2020Estimated royalty duration (a)Gross carrying valueCumulative allowance for changes in expected cash flows (Note 7)Net carrying value (d)
Cystic fibrosis franchise2037 (b)$5,274,896 $— $5,274,896 
Tysabri(c)2,003,797 (112,720)1,891,077 
Imbruvica2027-20291,406,291 (46,872)1,359,419 
Xtandi2027-20281,150,335 (145,565)1,004,770 
Promacta2025-2027686,129 — 686,129 
Evrysdi2030-2035 (e)675,440 — 675,440 
Other2020-20393,022,213 (634,950)2,387,263 
Total$14,219,101 $(940,107)$13,278,994 
Less: Cumulative allowance for credit losses (Note 7)(323,717)
Total financial royalty assets, net$12,955,277 
a)Dates shown represent management’s estimates of when a royalty will substantially end, which may depend on patent expiration dates (which may include patent term extensions) or other factors and may vary by geography. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. There can be no assurances that our royalties will expire when expected.
b)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on generic entry.
c)Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
d)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7—Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.
e)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
114
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



December 31, 2019Estimated royalty duration (a)Gross carrying valueCumulative allowance for changes in expected cash flows (Note 7)Net carrying value
Cystic fibrosis franchise (d)2037 (b)$4,639,045 $— $4,639,045 
Tysabri(c)2,131,272 (71,789)2,059,483 
Imbruvica2027-20291,332,077 — 1,332,077 
Xtandi2027-20281,193,918 (332,624)861,294 
Promacta2025-2027776,555 — 776,555 
Crysvita2033-2038 (e)321,234 — 321,234 
Other2019-20391,768,929 (464,005)1,304,924 
Total$12,163,030 $(868,418)$11,294,612 
a)Dates shown represent management’s estimates of when a royalty will substantially end, which may depend on patent expiration dates (which may include patent term extensions) or other factors and may vary by geography. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. There can be no assurances that our royalties will expire when expected.
b)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on generic entry.
c)Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
d)The Vertex triple combination therapy, Trikafta, was approved by the FDA in October 2019. Sell-side equity research analysts’ consensus forecasts increased due to expected sales of the newly approved cystic fibrosis franchise product and resulted in a reversal of the entire cumulative allowance for changes in expected cash flows in the fourth quarter of 2019 related to this financial royalty asset.
e)As of December 31, 2019, the timing of when we expected to reach the royalty cap of 2.5 times our purchase price was 2032.

Cystic fibrosis franchise payment reduction

In November 2019, Vertex announced that it reached an agreement with French authorities for a national reimbursement deal for Orkambi. As a result, management expected a reduction to royalty receipts in 2020 from the cystic fibrosis franchise of approximately $35.0 million to $45.0 million, to reflect an adjustment related to prior periods where we collected royalties on French sales of Orkambi at a higher selling price. We recognized a reduction to the current portion of Financial royalty assets of $41.0 million as of December 31, 2019. Upon receipt of the royalty payment in the first quarter of 2020, we did not recognize any material adjustments related to our estimate.

7. Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets

The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of Financial royalty assets, net on the consolidated balance sheets and includes the following activities:

•the movement in the cumulative allowance related to changes in forecasted royalty payments we expect to receive based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts’ consensus forecasts, and
•the movement in the cumulative allowance for current expected credit losses.

The periodic movement in the cumulative allowance is presented on the consolidated statements of comprehensive income as the Provision for changes in expected future cash flows from financial royalty assets.

Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to Retained earnings of $192.7 million to recognize an allowance for current expected credit losses on our portfolio of financial royalty assets. The current period provision for changes in expected cash flows from financial royalty assets reflects the activity for the period that relates to the change in estimates applied to calculate the allowance for credit losses, namely any new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts used in the effective interest model to measure income from our financial royalty assets. Refer to Note 2–Summary of Significant Accounting Policies for further information.
The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):
115
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Activity for the year
Balance at December 31, 2017$(2,045,868)
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(284,214)
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets341,548 
Reversal of cumulative allowance (a)5,637 
Balance at December 31, 2018(1,982,897)
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(322,717)
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets1,342,038 
Reversal of cumulative allowance (a)95,158 
Balance at December 31, 2019(868,418)
Cumulative adjustment for adoption of ASU 2016-13(192,705)
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(645,612)
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets570,959 
Reversal of cumulative allowance (a)2,964 
Write off of credit loss allowance (b)25,174 
Current period provision for credit losses (c)(156,186)
Balance at December 31, 2020$(1,263,824)
(a)     Relates to amounts reversed out of the allowance at the end of a financial royalty asset’s life to bring the account balance to zero. Reversals solely impact the asset account and allowance account, there is no impact on the consolidated statements of comprehensive income.
(b)     Relates to amounts reversed out of the credit loss allowance associated with omecamtiv as a result of the write-off of the related financial royalty asset balance of $90.2 million.
(c)     Primarily related to the allowance for credit losses resulting from increases to our portfolio of financial royalty assets in 2020, predominantly the final tranche of Tazverik, zavegepant, and the residual interest in the cystic fibrosis franchise.

8. Intangible Royalty Assets, Net

The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2020 and 2019 (in thousands).
As of December 31, 2020CostAccumulated amortizationNet carrying value
DPP-IV patents$606,216 $577,550 $28,666 
Total intangible royalty assets$606,216 $577,550 $28,666 
As of December 31, 2019CostAccumulated amortizationNet carrying value
DPP-IV patents$606,216 $554,492 $51,724 
Total intangible royalty assets$606,216 $554,492 $51,724 

The DPP-IV patents associated with the intangible royalty assets terminate at various dates up to 2022. The weighted average remaining life of the intangible royalty assets is 1.25 years. The projected amortization expense is $23.0 million and $5.7 million in 2021 and 2022, respectively.

Our revenue is tied to underlying patent protected sales of other DPP-IV products of various licensees. Such revenue from royalty assets is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate our royalty revenue from licensees based on the geography of the underlying sales, as this level of information is not always included in royalty reports provided to us. The marketers paying us royalties on these products do not always provide, and are not necessarily required to provide, the breakdown of product sales by geography. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 97% , 91% and 73% of our revenues from intangible royalty assets in the years ended December 31, 2020, 2019 and 2018, respectively.

116
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



9. Non-Consolidated Affiliates

The Legacy SLP Interest

In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) from the Continuing Investors Partnerships for $303.7 million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participated in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also own a non-controlling interest in Old RPI.

The income allocation from the Legacy SLP Interest is based on an estimate, as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this annual report. Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the year ended December 31, 2020, we received cash distributions of $22.7 million from the Legacy Investors Partnerships and recorded an income allocation of $62.0 million within Equity in (earnings)/loss of non-consolidated affiliates.

The Avillion Entities

We account for our partnership interests in Avillion Financing I, LP (“Avillion I”) and BAv Financing II, LP (“Avillion II”, or, together, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the entities. We recorded a loss allocation of $17.6 million, $32.5 million and $7.0 million within Equity in (earnings)/loss of non-consolidated affiliates during the years ended December 31, 2020, 2019 and 2018, respectively.

On December 19, 2017, the Avillion Entities announced that the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif (bosutinib). Avillion I is eligible to receive fixed payments from Pfizer based on this approval. Subsequent to the asset sale, the only operations of Avillion I are the collection of cash and unwinding of discount on the series of fixed annual payments due from Pfizer. We received distributions of $13.4 million and $14.1 million from Avillion I during the years ended December 31, 2020 and 2019, respectively, in connection with Avillion I’s receipt of the fixed annual payments due under its co-development agreement with Pfizer.

In March 2017, RPIFT entered into an agreement with Avillion II, amended in 2019, to invest approximately $19.0 million to fund approximately 50% of the costs of a phase II clinical trial for the use of Merck KGaA’s anti-IL 17 nanobody M1095 (the “Merck KGgA Asset”) for the treatment of psoriasis in exchange for certain milestone and royalty payments. We received a distribution of $21.3 million from Avillion II in respect of the Merck KGgA Asset, for which development ceased during the year ended December 31, 2020.

In May 2018 RPIFT entered into an additional agreement to invest up to $105.0 million in Avillion II over multiple years to fund approximately 44% of the costs of Phase II and III clinical trials to advance Pearl Therapeutics, Inc.’s product PT-027 (the “AZ Asset”) through a global clinical development program for the treatment of asthma in exchange for a series of deferred payments and success-based milestones.

RPIFT had $28.6 million and $70.8 million of unfunded commitments related to the Avillion Entities as of December 31, 2020 and 2019, respectively. Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments.

117
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



10. R&D Funding Expense

During the year ended December 31, 2020, we did not enter into any new R&D funding arrangements. R&D funding expense incurred in 2020 related to ongoing development stage funding payments, primarily under our co-funding agreement with Sanofi, and upfront funding related to a royalty on an unapproved product that we acquired from BioCryst in the quarter ended December 31, 2020. R&D funding expense in 2019 primarily related to funding agreements with both Sanofi and Pfizer. We completed our funding commitments in the fourth quarter of 2019 under our agreement with Pfizer. R&D funding expense incurred in 2018 related to funding agreements with Sanofi, Pfizer, Immunomedics and Biohaven.

We recognized $26.3 million of R&D funding expense for the year ended December 31, 2020, of which $18.5 million related to our co-funding agreement with Sanofi. We recognized $83.0 million of R&D funding expense during the year ended December 31, 2019, of which $18.2 million and $62.8 million related to our funding agreements with Sanofi and Pfizer, respectively.

We recognized $392.6 million of R&D funding expense during the year ended December 31, 2018, of which $6.9 million and $99.3 million related to our funding agreements with Sanofi and Pfizer, respectively. We recognized the $175.0 million and $100.0 million in upfront payments and premiums paid over market value for stock purchases related to our Immunomedics and Biohaven funding agreements, respectively, as R&D funding expense during the year ended December 31, 2018.

As of December 31, 2020, we have a remaining commitment of $16.6 million related to a R&D funding agreement with Sanofi.

11. Borrowings

Our borrowings at December 31, 2020 and 2019 consisted of the following (in thousands):

Type of BorrowingMaturityInterest rateDecember 31, 2020December 31, 2019
Senior Unsecured Notes:
Senior unsecured notes (issued at 99.322% of par)
9/20230.75 %$1,000,000 $— 
Senior unsecured notes (issued at 98.875% of par)
9/20251.20 %1,000,000 — 
Senior unsecured notes (issued at 98.284% of par)
9/20271.75 %1,000,000 — 
Senior unsecured notes (issued at 97.760% of par)
9/20302.20 %1,000,000 — 
Senior unsecured notes (issued at 95.556% of par)
9/20403.30 %1,000,000 — 
Senior unsecured notes (issued at 95.306% of par)
9/20503.55 %1,000,000 — 
Senior Unsecured Revolving Credit Facility— — 
RPIFT Senior Secured Credit Facilities (1):
Term Loan B Facility(2)
LIBOR + 200 bps
— 4,123,000
Term Loan A Facility(2)
LIBOR + 150 bps
— 2,150,000
Unamortized debt discount and issuance costs(183,416)(34,878)
Total debt carrying value5,816,584 6,238,122
Less: Current portion of long-term debt—(281,984)
Total long-term debt$5,816,584 $5,956,138 
(1)     The carrying value of our senior secured term loans, including the current portion, approximates its fair value and represented a Level 2 liability within the fair value hierarchy.
(2)     In February 2020, the outstanding principal amounts of our Prior Credit Facility (as defined below) were repaid in full with net proceeds from our senior secured credit facilities which we subsequently repaid in full in September 2020 with net proceeds from the Notes (as defined below) and available cash on hand.

118
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Senior Unsecured Notes

On September 2, 2020, we issued $6 billion of senior unsecured notes (the “Notes”). Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. Interest on each series of the Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, commencing on March 2, 2021. The Notes were issued at a total discount of $149.0 million. In connection with the transaction, we capitalized approximately $40.4 million in debt issuance costs primarily comprised of underwriting fees. The discount and the capitalized debt issuance costs are recorded as a direct deduction from the carrying amount of the Notes on our consolidated balance sheets and are being amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50% as of December 31, 2020, respectively.

Our Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the Treasury Rate, plus a make-whole premium as defined in the indenture. Our Notes maturing after 2023 also have a call feature, exercisable at our option, to redeem the Notes at par in whole or in part one to six months immediately preceding maturity. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.

Upon the occurrence of a change of control and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

We are required to comply with certain covenants under our Notes and, as of December 31, 2020, we were in compliance with all applicable covenants.

We used the net proceeds from the Notes offering, together with available cash on hand, to repay in full the senior secured credit facilities.

Senior Unsecured Revolving Credit Facility

On September 18, 2020, our subsidiary RP Holdings, as borrower, entered into a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) which provides for borrowing capacity of up to $1.5 billion for general corporate purposes. In connection with the transaction, we capitalized approximately $6.1 million in debt issuance costs related to the revolving credit facility which is recorded within Other current assets for the current portion and Other assets for the non-current portion. As of December 31, 2020, there were no outstanding borrowings under the Revolving Credit Facility.

The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% per annum (“ABR”) or (b) adjusted LIBOR, plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our consolidated leverage ratio. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the ABR, LIBOR and future changes in our consolidated leverage ratio.

The revolving credit agreement (the “Credit Agreement”) that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated charges, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. As of December 31, 2020, RP Holdings was in compliance with these covenants.

119
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Senior Secured Credit Facilities

On February 11, 2020, in connection with the Exchange Offer Transactions (as discussed in Note 1–Organization and Purpose) and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement (the “Senior Secured Credit Agreement”) with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. The senior secured credit facilities contained in the Senior Secured Credit Agreement consisted of a term loan A (“Tranche A-1”) and term loan B (“Tranche B-1”) in the amounts of $3.20 billion and $2.84 billion, respectively. Tranche A-1 had an interest rate of 1.50% above LIBOR and matures in February 2025. Tranche B-1 had an interest rate of 1.75% above LIBOR and matures in February 2027. In September 2020, the Company repaid in whole the outstanding principal amounts of term loans under the senior secured credit facilities governed by the Senior Secured Credit Agreement with net proceeds from the Notes and available cash on hand. Upon refinancing of our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $25.1 million as part of Other non-operating expense/(income), net, which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.

RPIFT Senior Secured Credit Facilities

The RPIFT Senior Secured Credit Facilities (the “Prior Credit Facility”) was repaid in full in February 2020 in connection with the Exchange Offer Transactions. We recorded a loss on debt extinguishment of $5.4 million as part of Other non-operating expense/(income), net,. As of December 31, 2019, the Prior Credit Facility included two term loans, Term Loan A and Term Loan B. Tranche A-4 required annual amortization of 5.9% per year and tranche B-6 required annual amortization of 3.2% per year. The Prior Credit Facility was secured by a grant by RPIFT of a security interest in substantially all of its personal property and a grant by RPCT of a security interest in RPIFT’s share (80%) of all amounts on deposit in RPCT’s bank account.

The Prior Credit Facility contained the following covenants measured quarterly: (i) maximum total leverage ratio of 4:00 to 1:00; (ii) debt coverage ratio of greater than 3.50 to 1.00. RPIFT was in compliance with these covenants at December 31, 2019.

Principal payments on the Notes

The future principal payments for our borrowings as of December 31, 2020 over the next five years and thereafter are as follows (in thousands):

YearPrincipal Payments
2021$— 
2022— 
20231,000,000 
2024— 
20251,000,000 
Thereafter4,000,000 
Total (1)$6,000,000 
(1)     Excludes unamortized discount and loan issuance costs on long-term debt of $183.4 million as of December 31, 2020, which are amortized through interest expense over the remaining life of the underlying debt obligations.

As of December 31, 2020, the fair value of our outstanding Notes was approximately $6.2 billion and represented a Level 2 measurement within the fair value hierarchy.

120
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



12. Shareholders’ Equity

Capital structure

Following the completion of our IPO as discussed in Note 1–Organization and Purpose, there have been no material changes in our capital structure, except for the secondary offering that was completed in October 2020, whereby 17,343 thousand of our Class A ordinary shares were offered for sale by certain of the Continuing Investors (the “Selling Shareholders”) at a price of $42.00 per share. We did not receive any proceeds from or pay any underwriting costs associated with the sale of Class A ordinary shares offered by the Selling Shareholders. The shares sold in the offering consisted of (i) 4,137 thousand existing Class A ordinary shares held by the Continuing Investor Partnerships and (ii) 13,206 thousand newly-issued Class A ordinary shares issued in connection with the redemption of 13,206 thousand RP Holdings Class B Interests by the Continuing Investors Partnerships that participated in the secondary offering. As of December 31, 2020, we have outstanding 388,135 thousand Class A ordinary shares and 218,976 thousand Class B ordinary shares.

In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The purpose of the Class R redeemable shares was to ensure Royalty Pharma Limited had sufficient sterling denominated share capital at the time it was re-registered as a public limited company to Royalty Pharma plc, as required by the U.K. Companies Act. The Class R redeemable shares may be redeemed at the Company’s option in the future. Any such redemption would be at the nominal value of £1 each.

The RP Holdings Class B Interests are exchangeable on a one-for-one basis for our Class A ordinary shares pursuant to an Exchange Agreement entered into by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings that governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of December 31, 2020, we have outstanding deferred shares of 316,407 thousand.

Non-controlling interests

Prior to the Exchange Offer Transactions in February 2020, the only non-controlling interest related to RPSFT, for which the related movements are presented in the historical statements of shareholders’ equity. The net change in the balance of our four non-controlling interests for the year ended December 31, 2020 is as follows (in thousands):

RPSFTLegacy Investors PartnershipsContinuing Investors Partnerships (1)EPA HoldingsTotal
December 31, 2019$35,883 $— $— $— $35,883 
Contributions— 1,165,258 9,418 — 1,174,676 
Transfer of interests— 1,037,161 — — 1,037,161 
Distributions(112,339)(594,592)(85,426)— (792,357)
Net income prior to IPO42,151 102,892 — — 145,043 
Effect of exchange by Continuing Investors of Class B shares for Class A ordinary shares and reallocation of historical equity— (750)2,433,848 — 2,433,098 
Issuance of Class A ordinary shares sold in IPO, net of offering costs— — 758,354 — 758,354 
Other exchanges— — (309,566)(309,566)
Net income subsequent to IPO46,741 218,137 316,993 — 581,871 
Other comprehensive income:
Unrealized gain on available for sale debt securities— 15,015 7,488 — 22,503 
Reclassification of unrealized gain on available for sale debt securities— (3,612)(6,018)— (9,630)
December 31, 2020$12,436 $1,939,509 $3,125,091 $— $5,077,036 

121
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



(1)     Related to the Continuing Investors Partnerships’ ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A and Class B Interests as of December 31, 2020.

RP Holdings Class C Special Interest held by EPA Holdings

EPA Holdings is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period will be grouped together as separate portfolios (each, a “Portfolio”). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests for which we will issue the same number of Class B ordinary shares, which will be subsequently exchanged for our Class A ordinary shares. We do not currently expect any material Equity Performance Awards to be payable until the mid to late 2020s.

Dividends

The holders of Class A ordinary shares are entitled to receive ratably such dividends, if any, as may be approved from time to time by the Board of Directors. Subsequent to our IPO, we declared and paid two quarterly cash dividends for an aggregate amount of $112.5 million, or $0.15 per share during the year ended December 31, 2020 to holders of our Class A ordinary shares. Future dividends are subject to declaration by the Board of Directors.

2020 Independent Director Equity Incentive Plan

Our 2020 Independent Director Equity Incentive Plan was approved and became effective on June 15, 2020 whereby 800 thousand Class A ordinary shares were reserved for future issuance to our independent directors. As of December 31, 2020, approximately 675 thousand shares remain reserved for future issuance under the Equity Incentive Plan.

RSU activity and share-based compensation

We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year. The estimated fair value of RSUs is based on the closing price of our Class A ordinary shares on the grant date. During the year ended December 31, 2020, we granted approximately 125 thousand RSUs, of which approximately 71 thousand RSUs were vested. No RSUs were cancelled or forfeited during the year.

We recognized share-based compensation of approximately $5.7 million for the year ended December 31, 2020, which is recorded as part of General and administrative expenses in the consolidated statement of comprehensive income. As of December 31, 2020, the total unrecognized share-based compensation expense related to total outstanding RSUs was less than $1.0 million, which we expect to recognize in the next six months.

In periods prior to the IPO, we did not have share-based awards or related share-based compensation.

122
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



13. Earnings per Share

Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares potentially issuable to EPA Holdings, and unvested RSUs issued under our Equity Incentive Plan. We use the “if-converted” method to determine the potentially dilutive effect of our Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.

Prior to the IPO, our capital structure included predominantly unitholder interests. We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements. Therefore, earnings per share information has not been presented for the years ended December 31, 2019 and 2018.

Our Class B ordinary shares, Class R redeemable shares, and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares, and deferred shares under the two-class method has not been presented. Our Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because shares of Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. Class B ordinary shares potentially issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact for the year ended December 31, 2020. Class B ordinary shares currently in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive.

The basic and diluted earnings per share for the year ended December 31, 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares. We have 607,111 thousand fully diluted Class A ordinary shares outstanding as of December 31, 2020. The following table sets forth reconciliations used to compute basic and diluted earnings per Class A ordinary share (in thousands, except per share amounts).
123
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Year Ended December 31, 2020
Basic earnings per share:
Numerator
Consolidated net income $1,701,954 
Less: net income attributable to Continuing Investors Partnerships prior to the IPO (1)479,842 
Less: net income attributable to Continuing Investors Partnerships subsequent to the IPO316,993 
Less: net income attributable to non-controlling interest - Legacy Investors Partnerships and RPSFT409,921 
Net income attributable to Royalty Pharma plc$495,198 
Denominator
Weighted average Class A ordinary shares outstanding - basic375,444 
Earnings per Class A ordinary share - basic$1.32 
Diluted earnings per share:
Numerator
Net income attributable to Royalty Pharma plc$495,198 
Denominator
Weighted average Class A ordinary shares outstanding - basic375,444 
Dilutive effect of unvested RSUs11 
Weighted average Class A ordinary shares outstanding - diluted375,455 
Earnings per Class A ordinary share - diluted$1.32 

(1)     Reflected as Net income attributable to controlling interest on the consolidated statements of comprehensive income.


124
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



14. Indirect Cash Flow

Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).
For the Years Ended December 31,
202020192018
Cash flow from operating activities:
Consolidated net income$1,701,954 $2,461,419 $1,517,855 
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Provision for changes in expected cash flows from financial royalty assets230,839 (1,019,321)(57,334)
Amortization of intangible assets23,058 23,924 33,267 
Amortization of debt discount and issuance costs11,715 12,790 13,127 
Realized gain on available for sale debt securities— — (419,481)
Unrealized loss/(gain) on derivative contracts42,076 39,138 (11,923)
(Gain)/loss on equity securities(247,073)(155,749)13,939 
Equity in (earnings)/loss of non-consolidated affiliates(44,459)32,517 7,023 
Distributions from non-consolidated affiliates42,334 14,059 39,402 
Loss on extinguishment of debt30,272 — — 
Share-based compensation5,428 — — 
Interest income accretion(20,551)— — 
Unrealized gain on forwards(18,600)— — 
Impairment charge65,053 — — 
Loss on derivative financial instruments(34,952)— — 
Other9,621 (2,122)(7,771)
(Increase)/decrease in operating assets:
Financial royalty assets(1,959,975)(1,648,837)(1,524,816)
Cash collected on financial royalty assets2,121,923 1,934,092 2,052,592 
Available for sale debt securities— (150,000)(150,000)
Accrued royalty receivable370 2,471 (27,372)
Other receivables— 150,000 150,000 
Other royalty income receivable(770)7,390 (11,099)
Other current assets(10,278)4,607 (442)
Other assets45,264 (45,635)— 
Increase/(decrease) in operating liabilities:
Accounts payable and accrued expenses(766)6,496 1,350 
Interest payable42,146 — — 
Net cash provided by operating activities$2,034,629 $1,667,239 $1,618,317 

Non-cash investing and financing activities are summarized below (in thousands).
For the Years Ended December 31,
202020192018
Supplemental schedule of non-cash investing / financing activities:
Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)$303,679 $— $— 
Settlement of Epizyme forward purchase contract (Note 4)5,700 — — 
Accrued purchase obligation - Tazverik (Note 17)110,000 — — 
Repayments of long-term debt by contributions from non-controlling interest (1)1,103,774 — — 
Milestone payable - Erleada (2)18,600 — — 
(1) Related to the pro rata portion of RPIFT’s outstanding debt repaid by the Legacy Investors Partnerships
(2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020.

125
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



15. Accumulated Other Comprehensive Income (Loss)

Comprehensive income is comprised of net income and other comprehensive income/(loss). We include unrealized gains and losses on available for sale debt securities and unrealized gains/(losses) on the interest rate swaps that were designated as cash flow hedges in other comprehensive income/(loss). Prior to January 1, 2018, unrealized gains and losses on available for sale equity securities were included in accumulated other comprehensive income/(loss). Beginning on January 1, 2018, following the adoption of ASU 2016-01, unrealized gains and losses on equity securities are recognized through earnings.

Changes in accumulated other comprehensive income/(loss) by component are as follows (in thousands):
Unrealized gain/(loss) on equity securitiesUnrealized gain/(loss) on available for sale debt securitiesUnrealized gain/(loss) on interest rate swapsTotal Accumulated Other Comprehensive Income/(Loss)
Balance at December 31, 2017$(2,863)$402,502 $(18,258)$381,381 
Activity for the year— (402,502)— (402,502)
Cumulative adjustment for adoption of ASU 2016-012,863 — — 2,863 
Reclassifications to net income— — 8,003 8,003 
Balance at December 31, 2018— — (10,255)(10,255)
Activity for the year— 6,159 — 6,159 
Reclassifications to net income— — 6,189 6,189 
Balance at December 31, 2019— 6,159 (4,066)2,093 
Reclassifications to net income— (10,921)4,066 (6,855)
Activity for the year— 60,617 — 60,617 
Reclassifications to non-controlling interest— (24,022)— (24,022)
Reclassifications from non-controlling interest— 2,562 — 2,562 
Balance at December 31, 2020$— $34,395 $— $34,395 

The total reclassification of unrealized gains on available for sale debt securities of $20.6 million in 2020 is presented within interest income on the statement of comprehensive income, including the reclassification of $10.9 million attributable to controlling interest noted in the table above.

16. Related Party Transactions

The Manager

The Manager is the investment manager of Royalty Pharma and its subsidiaries. The Manager is an affiliate of RP Ireland, the administrator of RPIFT and RPI Intermediate FT. The sole member of the Manager, Pablo Legorreta holds an interest in us and serves as our Chief Executive Officer and Chairman of the Board, and as a director on the board of RP Holdings.

In connection with the Exchange Offer Transactions (discussed in Note 1–Organization and Purpose), the Manager has entered into new management agreements with RPI and its subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the new management agreements, RPI pays quarterly Operating and Personnel Payments in respect of operating and personnel expenses to the Manager or its affiliates equal to 6.5% of the Adjusted Cash Receipts (both, as defined in the New Management Agreement) for such quarter and 0.25% of the GAAP value of our security investments as of the end of such quarter. The Operating and Personnel Payment for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in our income statement, is calculated as the greater of $1 million per quarter and 0.3125% of Royalty Investments (as defined in the New Management Agreement) during the previous twelve calendar months. Operating and Personnel Payments incurred during the year ended December 31, 2020 were $112.5 million.

126
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Historically, the Manager received operating and personnel payments in equal quarterly installments that increased by 5% annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships. RP Ireland receives an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the Limited Partnership Agreements of the Legacy Investors Partnerships. Operating and personnel payments incurred during years ended December 31, 2019 and 2018 were $60.0 million and $57.2 million, respectively, and were recognized within General and administrative expenses on the consolidated statements of comprehensive income.

Distribution payable to non-controlling interest

The Distribution payable to non-controlling interest represents the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPSFT’s non-controlling interest in RPCT. The Distribution payable to non-controlling interest of $126.4 million at December 31, 2020 includes the following: (1) $100.0 million due to the Legacy Investors Partnerships from Old RPI in connection with the Legacy Investors Partnerships’ non-controlling interest in Old RPI that arose in the Reorganization Transactions and (2) $26.3 million due to RPSFT from RPCT in connection with RPSFT’s non-controlling interest in RPCT. The Distribution payable to non-controlling interest of $31.0 million and $44.3 million at December 31, 2019 and 2018, respectively, represents the contractual distribution of cash flows due from RPCT to RPSFT in connection with its non-controlling interest in RPCT.

Acquisition from Epizyme

In November 2019, in connection with an equity investment in Epizyme Inc. of $100.0 million made by RPIFT, Pablo Legorreta, our Chief Executive Officer, was appointed as a director of Epizyme, for which he received compensation in cash and shares, all of which will be contributed to the Manager and used to reduce costs and expenses which would otherwise be billed to us or our affiliates.

Acquisition from Bristol-Myers Squibb

In November 2017, RPI Acquisitions entered into a purchase agreement with Bristol-Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga, and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”). We agreed to make payments to BMS based on sales of the products over eight quarters beginning with the first quarter of 2018 in exchange for a high single-digit royalty on worldwide sales of the products from 2020 through 2025.

On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly owned subsidiary of BioPharma Credit PLC (“BPCR”), an affiliate of us. BPCR is a related entity due to the sole member of the investment manager having significant influence over both entities. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement.

We began making installment payments to BMS during the second quarter of 2018 and completed our funding in the first quarter of 2020. Installment payments made to BMS during the year ended December 31, 2020 and 2019 totaled $24.3 million and $171.0 million, respectively, of which RPI Acquisitions funded $12.1 million and $85.5 million, respectively. Upon transfer of funds from BPCR to RPI Acquisitions to meet the quarterly funding obligation to BMS, RPI Acquisitions derecognized 50% of the financial royalty asset. Cash received from BPCR in respect of each funding obligation equaled the carrying amount of the assigned transfer of interest, therefore no gain or loss was recognized upon the transfer. The financial royalty asset of $150.6 million and $150.3 million included in Financial royalty assets, net on the consolidated balance sheets as of December 31, 2020 and 2019, respectively, represents only our right to the future payment streams acquired from BMS.

We funded a cumulative amount of $162.4 million, net of the assigned funding obligations. We began to measure this financial royalty asset using the effective interest method once our installment funding obligation was completed and we received our first royalty payment on the asset in the second quarter of 2020.

Other transactions

In the year ended December 31, 2020, we reimbursed Pablo Legorreta, our Chief Executive Officer, approximately $1.0 million for the cost of purchasing and donating ventilators to hospitals on our behalf.
127
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS




In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 9–Non-Consolidated Affiliates for additional discussion.

RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnerships, whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3 million is recorded as treasury interests, of which $1.9 million is held by non-controlling interests in the consolidated balance sheet as of December 31, 2020. The total investment of $4.3 million was recorded as treasury interests held by controlling equity in the consolidated balance sheet as of December 31, 2019.

Based on its ownership percentage of RP Holdings relative to us, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and the ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.

17. Commitments and Contingencies

In the ordinary course of its business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.

On August 7, 2020, we entered into a funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, for up to $450.0 million to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones. Biohaven received $150.0 million at closing and will receive $100.0 million upon the start of the oral zavegepant Phase III program. Pursuant to the Series B Biohaven Preferred Share Agreement, we will also provide further support for the ongoing launch of Nurtec ODT with the purchase of committed, non-contingent Commercial Launch Preferred Equity for a total of $200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030.

In November 2019, RPIFT agreed to pay $330.0 million to purchase Eisai’s royalties on future worldwide sales of Tazverik (tazemetostat), a novel targeted therapy in late-stage clinical development that was approved by the FDA in January 2020 for epithelioid sarcoma, and with the potential to be approved in several cancer indications. Under the terms of its agreement with Eisai, RPIFT acquired Eisai’s future worldwide royalties on net sales by Epizyme of Tazverik outside of Japan, for an upfront payment of $110.0 million plus up to an additional $220.0 million for the remainder of the royalty upon FDA approval of Tazverik for certain indications. The FDA approval of Tazverik in January 2020 triggered our obligation to fund the second $110.0 million tranche in November 2020. In June 2020, the FDA approval of additional indications of Tazverik triggered our obligation to fund the final $110.0 million tranche in November 2021, which is recorded within current liabilities on the consolidated balance sheet at December 31, 2020.

We have commitments to advance funds to counterparties through our investment in the Avillion Entities and R&D arrangements. Please refer to Notes 9–Non-Consolidated Affiliates and 10–R&D Funding Expense, respectively, for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the management agreement as described in Note 16–Related Party Transactions, which are variable and based on projected cash receipts.

128
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Legal proceedings

We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings in our consolidated balance sheets as of December 31, 2020 and 2019. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.

18. Subsequent Events

In January 2021, we acquired a royalty interest in seltorexant from Minerva Neurosciences, Inc. for an upfront payment of $60 million and up to $95 million in additional milestone payments, contingent on the achievement of certain clinical, regulatory and commercialization milestones. Seltorexant is currently in Phase III development for the treatment of major depressive disorder (MDD) with insomnia symptoms by Janssen Pharmaceutica, N.V., a subsidiary of Johnson & Johnson.


129


Item 9.         CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES

None.

Item 9A.     CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this Annual Report on Form 10-K. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were, in design and operation, effective to the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal controls over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the three months ended December 31, 2020 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Management’s Report on Internal Control over Financial Reporting

The Annual Report on Form 10-K does not include a report of management’s assessment regarding internal control over financial reporting or an attestation report of our independent registered public accounting firm due to a transition period established by the rules of the SEC for newly public companies.

Inherent Limitation on the Effectiveness Over Financial Reporting

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.

Item 9B.     OTHER INFORMATION

Not applicable.

PART III

Item 10.     DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this Item will be presented in our Proxy Statement to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.


Item 11.     EXECUTIVE COMPENSATION

The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.

130

Item 12.     SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.

Item 13.     CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTORS INDEPENDENCE

The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.

Item 14.     PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.

131

PART IV

Item 15.     EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

The following exhibits are filed as a part of this Annual Report on Form 10-K:

Incorporated by Reference
Exhibit Number
Exhibit Description
FormExhibitFiling Date/
Period End Date		Filed or Furnished Herewith
3.18-K3.16/19/2020
3.28-K3.26/19/2020
4.1S-1/A4.16/11/2020
4.2x
10.18-K10.26/19/2020
10.28-K10.16/19/2020
10.38-K10.46/19/2020
10.4†S-1/A10.56/2/2020
10.5†S-1/A10.66/11/2020
10.6#S-1/A10.76/2/2020
10.7#S-1/A10.86/2/2020
10.8#S-110.95/22/2020
10.9#S-110.105/22/2020
10.10S-110.115/22/2020
10.11#S-110.125/22/2020
10.12#S-110.135/22/2020
132

10.138-K10.36/19/2020
10.14†S-1/A10.156/11/2020
10.158-K4.19/2/2020
10.168-K4.29/2/2020
10.178-K4.99/2/2020
10.18#8-K10.111/5/2020
21.1S-121.15/22/2020
23.1x
24.1Power of Attorney (reference is made to the signature page hereto)x
31.1x
31.2x
32*x
101.INS
XBRL Taxonomy Extension Instance Document
x
101.SCH
XBRL Taxonomy Extension Schema Document
x
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
x
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
x
101.LAB
XBRL Taxonomy Extension Label Linkbase Document
x
101.PRE
XBRL Taxonomy Extension Presentation Linkbase
x
104Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101)x

†     Management contract or compensatory plan or arrangement.
#     Certain information has been excluded from the exhibit because it both (i) is not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
*     The certifications furnished in Exhibit 32 hereto are deemed to accompany this Annual Report on Form 10-K and are not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of the Exchange Act.

Item 16.     FORM 10-K SUMMARY

None.
133

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

ROYALTY PHARMA PLC
(Registrant)

Date: February 24, 2021/s/ Pablo Legorreta
Pablo Legorreta
Chief Executive Officer
Date: February 24, 2021/s/ Terrance Coyne
Terrance Coyne
Chief Financial Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Terrance Coyne and George Lloyd, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.


134

SignatureTitleDate
/s/ Pablo Legorreta
 Chairman of the Board, Director & Chief Executive Officer
(Principal Executive Officer and Royalty Pharma plc’s authorized representative in the United States)
February 24, 2021
Pablo Legorreta
/s/ Terrance Coyne
Executive Vice President & Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
February 24, 2021
Terrance Coyne
/s/ Errol De SouzaDirectorFebruary 24, 2021
Errol De Souza
/s/ William FordDirectorFebruary 24, 2021
William Ford
/s/ Gregory NordenDirectorFebruary 24, 2021
Gregory Norden
/s/ M. Germano GiulianiDirectorFebruary 24, 2021
M. Germano Giuliani
/s/ Rory RiggsDirectorFebruary 24, 2021
Rory Riggs
/s/ Bonnie BasslerDirectorFebruary 24, 2021
Bonnie Bassler
/s/ Catherine EngelbertDirectorFebruary 24, 2021
Catherine Engelbert
/s/ Ted LoveDirectorFebruary 24, 2021
Ted Love
/s/ Henry FernandezDirectorFebruary 24, 2021
Henry Fernandez
135
 EX-4.2 2 rprx-20201231ex42.htm EX-4.2 Document
Exhibit 4.2

DESCRIPTION OF SECURITIES
REGISTERED UNDER SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934
As of December 31, 2020, Royalty Pharma plc (“Royalty Pharma” or the “Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934: our Class A ordinary shares, par value $0.0001 per share, which are listed on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “RPRX.”
The following description is a summary of our share capital as specified in our Articles of Association. This summary does not purport to be complete and the statements in this summary are qualified in their entirety by reference to, and are subject to, the detailed provisions of our Articles of Association and the U.K. Companies Act.
Capital Structure
Issued Share Capital
We have two classes of voting shares: Class A and Class B, each of which has one vote per share. The Class A ordinary shares and Class B shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. We also have in issue 50,000 Class R redeemable shares, which do not entitle the holder to voting or dividend rights, and deferred shares, which do not entitle the holder to voting or dividend rights. The purpose of the Class R redeemable shares was to ensure we had sufficient sterling denominated share capital at the time we re-registered as a public limited company, as required by the U.K. Companies Act. The Class R redeemable shares may be redeemed at some future point in order to leave the Company with only U.S. dollar denominated share capital. Any such redemption would be at nominal value.
The board of directors has been granted authority from our shareholders to allot and issue new Class A ordinary shares and other shares, and to grant rights to subscribe for or to convert any security into new Class A ordinary shares or other shares, up to a maximum aggregate nominal amount (i.e., par value) of $300,000, for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) on May 31, 2025. Renewal of such authorization is expected to be sought at least once every five years, and possibly more frequently. This authority is in addition to authorities to allot and issue new Class A ordinary shares in exchange for Royalty Pharma Holdings Ltd Class B ordinary shares or the depositary receipts that represent them. The rights and restrictions to which the Class A ordinary shares are subject are prescribed by our Articles of Association.
Class A Ordinary Shares
Voting rights. The holders of Class A ordinary shares are entitled to one vote per share on all matters to be voted upon by the shareholders other than with respect to matters that require a separate class vote in accordance with applicable law.
Dividend rights. Subject to preferences that may be applicable, the holders of Class A ordinary shares are entitled to receive ratably such dividends, if any, as may be approved from time to time by the board of directors out of funds legally available therefor.
Rights upon liquidation. In the event of liquidation, dissolution or winding up of Royalty Pharma the holders of Class A ordinary shares are entitled to share ratably in all assets remaining after payment of liabilities.
Class B Shares
Voting rights. The holders of Class B shares are entitled to one vote per share on all matters to be voted upon by the shareholders other than with respect to matters that require a separate class vote in accordance with applicable law.
 
Dividend rights. The holders of Class B shares do not have any rights to receive dividends.


Rights upon liquidation. The holders of Class B shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of Royalty Pharma, following the prior payment of the nominal capital paid up or credited as paid up on each Class A ordinary share as well as an amount of $10,000,000 on each Class A ordinary share upon such liquidation, dissolution or winding up.
Dividends
Under English law, the Company may only pay dividends out of profits available for that purpose. The Company’s profits available for distribution are its accumulated, realized profits, to the extent that they have not been previously utilized by distribution or capitalization, less its accumulated, realized losses, to the extent that they have not been previously written off in a reduction or reorganization of capital duly made. The amount of the Company’s distributable reserves is a cumulative calculation. The Company may be profitable in a single financial year but unable to pay a dividend if our accumulated, realized profits of that year do not offset all previous years’ accumulated, realized losses.
Additionally, the Company may only make a distribution if the amount of its net assets is not less than the aggregate of its called-up share capital and undistributable reserves, and if, and to the extent that, the distribution does not reduce the amount of those assets to less than that aggregate.
Our Articles of Association authorize our board of directors to approve interim dividends without shareholder approval to the extent that the approval of such dividends appears justified by profits. Our board of directors may also recommend a final dividend to be approved and declared by the shareholders at an annual general meeting and may direct that the payment be made by distribution of assets, shares or cash. No dividend may exceed the amount recommended by the board of directors.
Our Articles of Association also permit a scrip dividend scheme under which the board of directors may offer any holders of Class A ordinary shares the right to elect to receive Class A ordinary shares, credited as fully paid, instead of cash in respect of the whole (or some part determined by the board of directors) of all or any dividend subject to certain terms and conditions set out in our Articles of Association.
The entitlement to a dividend lapses if unclaimed for 12 years.
Voting Rights
Under the Articles of Association, each holder of Class A ordinary shares or Class B shares is entitled to one vote for each share that he or she holds as of the record date for the meeting. Neither English law nor any of our constituent documents places limitations on the right of nonresident or foreign owners to vote or hold ordinary shares. The voting at a general meeting must be taken by poll. Subject to any relevant special rights or restrictions attached to any shares, on a poll taken at a general meeting, each qualifying shareholder present in person or by proxy (or, in the case of a corporation, a corporate representative) and entitled to vote on the resolution has one vote for every Class A ordinary share or Class B share held by such shareholder.
An ordinary resolution must be approved by a simple majority, and a special resolution approved by at least 75%, of shareholders attending and voting, whether in person or by proxy.
Amendment to our Articles of Association
Under English law, shareholders may amend the articles of association of a company by special resolution. However, certain provisions of our Articles of Association require a higher threshold of shareholder approval or satisfaction of other procedures before such provision or provisions can be varied.
The article in our Articles of Association which requires voting at a general meeting to be taken on a poll may only be removed, amended or varied by resolution of the shareholders passed unanimously.


Winding Up
In the event of a voluntary winding up of the Company, the liquidator may, with the sanction of a special resolution of the Company and any other sanction required by law, subject to the U.K. Insolvency Act of 1986, after effectively applying the Company’s property to satisfy the Company’s liabilities, divide among the holders of Class A ordinary shares of the Company the whole or any part of the assets of the Company, whether they consist of property of the same kind or not, and vest the whole or any part of the assets in trustees upon such trusts for the benefit of the holders of Class A ordinary shares of the Company as the liquidator, with such sanction, may determine. No shareholder of the Company shall be compelled to accept any assets upon which there is a liability.
On a return of capital on a liquidation, reduction of capital or otherwise, the surplus assets of the Company available for distribution among the holders of Class A ordinary shares shall be applied pro rata (rounded to the nearest whole number).
Rights of Pre-Emption on New Issues of Shares
Under the U.K. Companies Act, the allotment of “equity securities” (except pursuant to an employees’ share scheme and as bonus shares) that are to be paid for wholly in cash must be offered first to the existing holders of ordinary shares in proportion to the respective nominal amounts (i.e., par values) of their holdings on the same or more favorable terms, unless a special resolution to the contrary has been passed or the articles of association otherwise provide disapplication from this requirement (which disapplication can be for a maximum of five years after which shareholders’ approval would be required to renew the disapplication). “Equity securities” means ordinary shares or rights to subscribe for, or convert securities into, ordinary shares where ordinary shares means shares other than shares that, with respect to dividends and capital, carry a right to participate only up to a specified amount in a distribution. In relation to the Company, “equity securities” will therefore include the Class A ordinary shares, and all rights to subscribe for or convert securities into such shares.
The board of directors has been granted authority from our shareholders to allot and issue new Class A ordinary shares and other shares and to grant rights to subscribe for or to convert any security into new Class A ordinary shares or other shares, up to a maximum aggregate nominal amount (i.e., par value) of $300,000 for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) on May 31, 2025. Renewal of such authorization is expected to be sought at least once every five years, and possibly more frequently.
Disclosure of Ownership Interests in Shares
Section 793 of the U.K. Companies Act gives us the power to require persons whom we know have, or whom we have reasonable cause to believe have, or within the previous three years have had, an interest in any shares of the Company to disclose specified information regarding those shares. Failure to provide the information requested within the prescribed period (or knowingly or recklessly providing false information after the date the notice is sent) can result in criminal or civil sanctions being imposed against the person in default.
Under our Articles of Association, if any of our shareholders, or any other person appearing to be interested in the shares of the Company held by such shareholder, has been duly served with a notice under section 793 and fails to give us the information required by such notice or has made a statement which is false or inadequate in a material particular, then our board of directors may, in its absolute discretion at any time by notice, withdraw voting rights and place restrictions on the rights to receive dividends and refuse to register a transfer of such shares.
 
Alteration of Share Capital/Share Repurchases
Subject to the provisions of the U.K. Companies Act, and without prejudice to any relevant special rights attached to any class of shares, we may, from time to time, among other things:
•    increase our share capital by allotting and issuing new shares in accordance with our Articles of Association and any relevant shareholder resolution;


•    consolidate all or any of our share capital into shares of a larger nominal amount (i.e., par value) than the existing shares;
•    subdivide any of our shares into shares of a smaller nominal amount (i.e., par value) than the existing shares; or
•    redenominate our share capital or any class of share capital
The Company may not consolidate, divide, subdivide or redenominate any class of voting shares without consolidating, dividing, subdividing or redenominating (as the case may be) the other classes of voting shares.
English law prohibits us from purchasing our own shares unless such purchase has been approved by our shareholders. Shareholders may approve two different types of such share purchases: “on-market” share purchases or “off-market” share purchases. “On-market” purchases may only be made on a “recognised investment exchange,” which does not include Nasdaq, which is the only exchange on which the Company’s shares are traded. In order to purchase our own shares, as a Company listed on Nasdaq, we must therefore obtain the approval of our shareholders for an “off-market purchase” (on the basis of a specific purchase agreement with a financial intermediary) to acquire shares that are traded on Nasdaq. This requires our shareholders to pass an ordinary resolution approving an “off-market purchase,” where such approval may be for a maximum period of five years. In relation to an “off-market purchase,” we may not acquire our own shares until the terms of the contract pursuant to which the purchase(s) are to be made have been authorized by our shareholders.
Transfer and Registration of Shares
Our Articles of Association allow shareholders to transfer all or any of their shares by instrument of transfer in writing in any usual form or in any other form which our board of directors may approve.
The instrument of transfer must be executed by or on behalf of the transferor and (in the case of a transfer of a share that is not fully paid) by or on behalf of the transferee. Our Articles of Association also permit transfer of shares in uncertificated form by means of a relevant electronic system.
We may not charge a fee for registering the transfer of a share.
Our board of directors may, in its absolute discretion, refuse to register a transfer of shares in certificated form if it is not fully paid (provided that the refusal does not prevent dealings in the shares from taking place on an open and proper basis) or is with respect to a share on which we have a lien and sums in respect of which the lien exists are payable and are not paid within 14 clear days after due notice has been sent. If our board of directors refuses to register a transfer of a share, it shall notify the transferor of the refusal and the reasons for it as soon as practicable and in any event within two months after the date on which the instrument of transfer was lodged with us (in the case of a transfer of a share in certificated form) or the instructions to the relevant system received. Any instrument of transfer which our board of directors refuses to register shall (except in the case of fraud) be returned to the person lodging it when notice of the refusal is sent.
Computershare Trust Company, N.A. acts as our transfer agent and registrar. The share register reflects only registered owners of our Class A ordinary shares, Class B shares, Class R redeemable shares and deferred shares. Registration in the Company’s share register is determinative of ownership of shares of the Company. A shareholder who holds shares beneficially is not the holder of record of such shares. Instead, the clearance service or depositary (for example, Cede & Co, as nominee for the Depository Trust Company, or DTC, or GTU Ops, Inc., as nominee for Computershare Trust Company, N.A.) or other nominee is the holder of record of those shares. Accordingly, a transfer of shares from a person who holds such shares beneficially to a person who holds such shares beneficially through a clearance service or depositary or other nominee will not be registered in the Company’s official share register, as the depositary or other nominee will remain the record holder of any such shares.
In the event that the Company notifies one or both of the parties to a share transfer that it believes stamp duty or stamp duty reserve tax is required to be paid in connection with a transfer of shares of the Company, if the parties


to the transfer have an instrument of transfer duly stamped to the extent required and then provide such instrument of transfer to the Company’s share registrar, the buyer will be registered as the legal owner of the relevant shares on the official share register, subject to our rights with respect to the disclosure of interests in our shares.

Takeover Provisions
Regulation of Takeover Bids
Given that our central management and control is currently not situated within, and our current intention is not to have it in the future situated within the United Kingdom (or the Channel Islands or the Isle of Man), we do not currently envisage that the City Code on Takeovers and Mergers (the “Takeover Code”) will apply to an offer for the Company. It is possible that in the future circumstances could change that may cause the Takeover Code to apply to us. The Takeover Code provides a framework within which takeovers of companies subject to it are conducted. In particular, the Takeover Code contains certain rules in respect of mandatory offers. Under Rule 9 of the Takeover Code, if a person:
•    acquires an interest in shares that, when taken together with shares in which such person is already interested and in which persons acting in concert with such person are interested, carries 30% or more of the voting rights of shares; or
•    who, together with persons acting in concert with such person, is interested in shares that in the aggregate carry not less than 30% of the voting rights but is not interested in shares carrying more than 50% of such voting rights and such person, or any person acting in concert with such person, acquires an additional interest in shares that increases the percentage of shares carrying voting rights in which that person is interested,
the acquirer, and, depending on the circumstances, its concert parties, would be required (except with the consent of the Takeover Panel) to make a cash offer for the outstanding shares at a price not less than the highest price paid for any interests in the shares by the acquirer or its concert parties during the previous 12 months.
Under English law, an offeror for the Company that has acquired (i) not less than 90% in value of; and (ii) not less than 90% of the voting rights carried by the shares to which the offer relates may exercise statutory squeeze-out rights to compulsorily acquire the shares of the non-assenting minority. However, if an offer for the Company is conducted by way of a scheme of arrangement the threshold for the offeror obtaining 100% of Company shares comprises two components (i) approval by a majority in number of each class of Company shareholders present and voting at the shareholder meeting; and (ii) approval of Company shareholders representing 75% or more in value of each class of Company shareholders present and voting at that meeting.
Share Issues in the Context of an Acquisition
Our Articles of Association provide the board of directors with the power to establish a rights plan and to grant rights to subscribe for our shares pursuant to a rights plan where, in the opinion of the board of directors, acting in good faith, in the context of an acquisition or potential acquisition of 15% or more of our issued voting shares, to do so would improve the likelihood that:
•    an acquisition process is conducted in an orderly manner;
•    all our shareholders are treated equally and fairly and in a similar manner;
•    an optimum price is achieved for our Class A ordinary shares;
•    the board of directors would have time to gather relevant information and pursue appropriate strategies;
•    the success of Royalty Pharma would be promoted for the benefit of our shareholders as a whole;


•    the long term interests of Royalty Pharma, our shareholders and business would be safeguarded; and/or
•    Royalty Pharma would not suffer serious economic harm.
Our Articles of Association further provide that the board of directors may, in accordance with the terms of a rights plan, determine to (i) allot shares pursuant to the exercise of rights or (ii) exchange rights for our shares, where in the opinion of the board of directors acting in good faith, in the context of an acquisition or potential acquisition of 15% or more of our issued voting shares, to do so is necessary in order to prevent:
•    the use of abusive tactics by any person in connection with such acquisition;
•    unequal treatment of shareholders;
•    an acquisition which would undervalue Royalty Pharma;
•    harm to the prospects of the success of Royalty Pharma for the benefit of its shareholder as a whole; and/or
•    serious economic harm to the prospects of Royalty Pharma,
or where to do so is otherwise necessary to safeguard the long term interests of Royalty Pharma, our shareholders and our business.
Under the Takeover Code, the board of a public company incorporated under the laws of England and Wales is constrained from implementing such defensive measures. However, as discussed above, these measures are included in our Articles of Association as the Takeover Code is not expected to apply to us and these measures are included commonly in the constitution of U.S. companies.
These provisions will apply for so long as we are not subject to the Takeover Code.
 


 EX-23.1 3 rprx-20201231ex231.htm EX-23.1 Document



Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-239193) pertaining to the Royalty Pharma plc 2020 Independent Director Equity Incentive Plan of Royalty Pharma plc of our report dated February 24, 2021, with respect to the consolidated financial statements of Royalty Pharma plc, included in this Annual Report (Form 10-K) for the year ended December 31, 2020.

/s/ Ernst & Young

Dublin, Ireland

February 24, 2021



 EX-31.1 4 rprx-20201231ex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Pablo Legorreta, certify that:
1.    I have reviewed this Annual Report on Form 10-K of Royalty Pharma plc;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    [Reserved];

(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 24, 2021
/s/ Pablo Legorreta
Pablo Legorreta
Chief Executive Officer

2
    
 EX-31.2 5 rprx-20201231ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Terrance Coyne, certify that:
1.    I have reviewed this Annual Report on Form 10-K of Royalty Pharma plc;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    [Reserved];

(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 24, 2021

/s/ Terrance Coyne
Terrance Coyne
Chief Financial Officer

2
    
 EX-32 6 rprx-20201231ex32.htm EX-32 Document

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report on Form 10-K of Royalty Pharma plc (the “Company”) for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company certifies pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and;
2.    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 24, 2021
/s/ Pablo Legorreta
Name: Pablo Legorreta
Chief Executive Officer
/s/ Terrance Coyne
Name: Terrance Coyne
Chief Financial Officer

 EX-101.SCH 7 rprx-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Purpose link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Organization and Purpose (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2106103 - Disclosure - Fair Value Measurements and Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Fair Value Measurements and Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2112104 - Disclosure - Derivative Instruments link:presentationLink link:calculationLink link:definitionLink 2313302 - Disclosure - Derivative Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Derivative Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - Derivative Instruments - Schedule of Notional Values and Fixed Rates (Details) link:presentationLink link:calculationLink link:definitionLink 2416409 - Disclosure - Derivative Instruments - Summary of Derivatives and Reclassifications (Details) link:presentationLink link:calculationLink link:definitionLink 2117105 - Disclosure - Available for Sale Debt Securities link:presentationLink link:calculationLink link:definitionLink 2318303 - Disclosure - Available for Sale Debt Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2419410 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2420411 - Disclosure - Available for Sale Debt Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2121106 - Disclosure - Financial Royalty Assets, Net link:presentationLink link:calculationLink link:definitionLink 2322304 - Disclosure - Financial Royalty Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - Financial Royalty Assets, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2125107 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets link:presentationLink link:calculationLink link:definitionLink 2326305 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2427414 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2428415 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 2129108 - Disclosure - Intangible Royalty Assets, Net link:presentationLink link:calculationLink link:definitionLink 2330306 - Disclosure - Intangible Royalty Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2431416 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) link:presentationLink link:calculationLink link:definitionLink 2432417 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2133109 - Disclosure - Non-Consolidated Affiliates link:presentationLink link:calculationLink link:definitionLink 2434418 - Disclosure - Non-Consolidated Affiliates (Details) link:presentationLink link:calculationLink link:definitionLink 2135110 - Disclosure - R&D Funding Expense link:presentationLink link:calculationLink link:definitionLink 2436419 - Disclosure - R&D Funding Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2137111 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 2338307 - Disclosure - Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 2439420 - Disclosure - Borrowings - Schedule of Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 2439420 - Disclosure - Borrowings - Schedule of Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 2440421 - Disclosure - Borrowings - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2441422 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details) link:presentationLink link:calculationLink link:definitionLink 2142112 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2343308 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2444423 - Disclosure - Shareholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2445424 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 2146113 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2347309 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2448425 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2149114 - Disclosure - Indirect Cash Flow link:presentationLink link:calculationLink link:definitionLink 2350310 - Disclosure - Indirect Cash Flow (Tables) link:presentationLink link:calculationLink link:definitionLink 2451426 - Disclosure - Indirect Cash Flow (Details) link:presentationLink link:calculationLink link:definitionLink 2152115 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2353311 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2454427 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2155116 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2456428 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2157117 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2458429 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2159118 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2460430 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 rprx-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 rprx-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 rprx-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Restricted stock granted during period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Revision of Prior Period [Axis] Revision of Prior Period [Axis] Document Type Document Type Milestone payments Payments For Milestones Payments For Milestones Other non-operating expense/(income), net Other Nonoperating Income (Expense) Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Related Party [Axis] Related Party [Axis] Series A Preferred Stock Series A Preferred Stock [Member] Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Treasury Interests Treasury Stock Treasury Stock [Member] Available for Sale Debt Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] RPSFT Royal Pharmacy Select Finance Trust [Member] Royal Pharmacy Select Finance Trust RP Holdings RP Holdings [Member] RP Holdings Contributions Noncontrolling Interest, Increase from Contributions Noncontrolling Interest, Increase from Contributions Funding Agreement With Biohaven Funding Agreement With Biohaven [Member] Funding Agreement With Biohaven Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] RPCT Royalty Pharma Collection Trust [Member] Royalty Pharma Collection Trust Reclassification of loss on interest rate swaps Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax Level 3 Fair Value, Inputs, Level 3 [Member] Proceeds from sales and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Long-term Purchase Commitment, Category of Item Purchased [Domain] Long-term Purchase Commitment, Category of Item Purchased [Domain] Debt issuance costs Debt Issuance Costs, Gross Derivatives Derivative Asset Contributions from non-controlling interest- other Proceeds From Noncontrolling Interests, Other Proceeds From Noncontrolling Interests, Other Exchange Offer Transaction Exchange Offer Transaction [Member] Exchange Offer Transaction Statistical Measurement [Domain] Statistical Measurement [Domain] Old RPI Royalty Pharma Investments (Old RPI) [Member] Royalty Pharma Investments (Old RPI) Liabilities and equity Liabilities and Equity [Abstract] Effect of exchange by Continuing Investors of Class B shares for Class A shares and reallocation of historical equity (in shares) Stockholders' Equity, Shares, Effect Of Exchange And Reallocation Stockholders' Equity, Shares, Effect Of Exchange And Reallocation Increase in quarterly installment payments (as a percent) Related Party Transaction, Annual Increase, Percentage Related Party Transaction, Annual Increase, Percentage Additional issuance, purchase price, minimum Debt Securities, Available-For-Sale, Additional Issuance, Purchase Price, Minimum Debt Securities, Available-For-Sale, Additional Issuance, Purchase Price, Minimum Distributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Derivative Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Preferred Shares Preferred Stock [Member] Security Exchange Name Security Exchange Name The Notes The Notes [Member] The Notes Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Operating income Operating Income (Loss) Debt issuance costs and other Payments of Debt Issuance Costs Issuance of Class B shares to Continuing Investors Partnerships Stock Issued During Period, Value, Issued To Partnerships Stock Issued During Period, Value, Issued To Partnerships Total current liabilities Liabilities, Current Other royalty income receivable Increase (Decrease) In Other Royalty Income Receivable Increase (Decrease) In Other Royalty Income Receivable Variable Rate [Domain] Variable Rate [Domain] Variable Rate [Axis] Variable Rate [Axis] Commitments and contingencies Commitments and Contingencies Available for sale debt securities Available for sale debt securities, noncurrent Debt Securities, Available-for-sale, Noncurrent Purchase of treasury interests Payments for Repurchase of Common Stock Assets Assets [Abstract] Investment, Name [Axis] Investment, Name [Axis] Accounting Policies [Abstract] Share-based compensation and related issuance of Class A ordinary shares Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Legacy Investors Partnerships and RPSFT Legacy Investors Partnerships and RPSFT [Member] Legacy Investors Partnerships and RPSFT Entity Address, State or Province Entity Address, State or Province Restricted stock vested during period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Distribution payable to non-controlling interest Due to Related Parties, Current Equity Investment In Epizyme Inc. Epizyme Inc. [Member] Epizyme Inc. Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] 2023 Long-Term Debt, Maturity, Year Three Transfer of interests Noncontrolling Interest, Transfers Of Interests Noncontrolling Interest, Transfers Of Interests Retained earnings Retained Earnings (Accumulated Deficit) Measurement input, percentage (as a percent) Debt Securities, Available-for-sale, Measurement Input Cystic fibrosis franchise Cystic Fibrosis Franchise [Member] Cystic Fibrosis Franchise Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Unamortized debt discount and issuance costs Original issue discount Debt Instrument, Unamortized Discount Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent) Related Party Transaction, Rate, Adjusted Cash Receipts Related Party Transaction, Rate, Adjusted Cash Receipts Common Class B Common Class B [Member] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of Fair Value Hierarchy Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Unrecognized share based compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount RPI Intermediate FT RPI 2019 Intermediate Finance [Member] RPI 2019 Intermediate Finance New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Maximum consolidated leverage ratio following qualifying material acquisition Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition Upfront payment and premium paid Research and Development Expense, Upfront Payment and Premium Paid Research and Development Expense, Upfront Payment and Premium Paid Customer [Axis] Customer [Axis] Beginning balance (in shares) Ending balance (in shares) Shares, outstanding (in shares) Shares, Outstanding Derivatives not designated as hedging instruments Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Redemption default, interest rate Debt Securities, Available-For-Sale, Redemption Default, Interest Rate Debt Securities, Available-For-Sale, Redemption Default, Interest Rate Income taxes Income Tax, Policy [Policy Text Block] Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense Hedging Designation [Domain] Hedging Designation [Domain] Redemption, Period One Debt Securities, Available-For-Sale, Redemption, Period One [Member] Debt Securities, Available-For-Sale, Redemption, Period One Investments in non-consolidated affiliates Payments to Acquire Equity Method Investments Other comprehensive income/(loss) Other Comprehensive Income (Loss), Net of Tax [Abstract] Common stock, par value (in dollars/pounds per share) Common Stock, Par or Stated Value Per Share Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block] Cumulative funding amount Related Party Transaction, Cumulative Funding Amount Related Party Transaction, Cumulative Funding Amount Document Information [Table] Document Information [Table] Avillion II Avillion II [Member] Avillion II Amount paid to CEO Related Party Transaction, Amounts of Transaction Thereafter Long-Term Debt, Maturity, after Year Five Denominator Weighted Average Number of Shares Outstanding, Basic [Abstract] Measurement Frequency [Domain] Measurement Frequency [Domain] Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Concentration risk (as a percent) Individual licensees exceeding 10% or more of revenue (as a percent) Concentration Risk, Percentage Royalty Distribution Payable to Legacy Investors Partnerships Royalty Distribution Payable to Legacy Investors Partnerships [Member] Royalty Distribution Payable to Legacy Investors Partnerships Preferred shares, weighted average cost of capital Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital Upfront payment for equity investment Payments to Acquire Equity Investments, Upfront Payment Payments to Acquire Equity Investments, Upfront Payment Payment for purchase of royalties Long-term Purchase Commitment, Amount 2020 Equity Incentive Plan 2020 Equity Incentive Plan [Member] 2020 Equity Incentive Plan Statement [Line Items] Statement [Line Items] Debt Securities, Available-For-Sale, Redemption, Period [Domain] Debt Securities, Available-For-Sale, Redemption, Period [Domain] Debt Securities, Available-For-Sale, Redemption, Period Forecast Forecast [Member] Class of Stock [Domain] Class of Stock [Domain] Earnings per Class A ordinary share Earnings Per Share, Basic and Diluted [Abstract] Debt instrument, term Debt Instrument, Term Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Interest payable Interest Payable, Current Entity Voluntary Filers Entity Voluntary Filers Measurement Input Type [Domain] Measurement Input Type [Domain] Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Credit Facility [Axis] Credit Facility [Axis] Other commitments, percentage of costs (as a percent) Other Commitments, Percentage Other Commitments, Percentage Derivative financial instruments Interest rate swaps Derivative liability, noncurrent Derivative Liability, Noncurrent Exercise price of warrant (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Interest received Proceeds from Interest Received Payments for rebates Payments For Rebates Payments For Rebates Amount of loss reclassified from AOCI into income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Aggregate royalty amount when patents cease Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents Tecfidera Tecfidera [Member] Tecfidera Entity Small Business Entity Small Business Basis of consolidation Consolidation, Policy [Policy Text Block] Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Unitholders’ Contributions Unitholders Contributions [Member] Unitholders Contributions Number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Borrowings Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense Prior to the applicable par call date Debt Instrument, Redemption, Period One [Member] Amendment Flag Amendment Flag Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Denominator Weighted Average Number of Shares Outstanding, Diluted [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Debt issuance costs related to revolving credit facility Debt Issuance Costs, Line of Credit Arrangements, Gross Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Research and development funding expense Research and Development Expense, Policy [Policy Text Block] Fair value measurements Fair Value Measurement, Policy [Policy Text Block] Total non-current liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure, Noncurrent Financial and Nonfinancial Liabilities, Fair Value Disclosure, Noncurrent Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Class R Redeemable Stock Class R Redeemable Stock [Member] Class R Redeemable Stock Entity Central Index Key Entity Central Index Key Related Party [Domain] Related Party [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Current portion of Financial royalty assets Financing Receivable [Member] Shareholders’ Contributions Shareholders' Contributions [Member] Shareholders' Contributions Related Party Transaction [Line Items] Related Party Transaction [Line Items] Available for sale debt securities Available for sale debt securities, current Debt Securities, Available-for-sale, Current Accrued purchase obligation - Tazverik Accrued Purchase Obligation, Equity Investment Accrued Purchase Obligation, Equity Investment Price per share (in USD per share) Debt Securities, Available-For-Sale, Price Per Share Debt Securities, Available-For-Sale, Price Per Share Series B Preferred Shares Series B Preferred Stock [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Allowance for current expected credit losses Credit Loss, Financial Instrument [Policy Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Interest rate swaps Derivative, Gain (Loss) on Derivative, Net Installment payments made during period Related Party Transaction, Payments Made Related Party Transaction, Payments Made Upon occurrence of a change of control triggering event Debt Instrument, Redemption, Period Three [Member] Schedule of Intangible Royalty Interests Schedule of Finite-Lived Intangible Assets [Table Text Block] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Indirect Cash Flow Cash Flow, Supplemental Disclosures [Text Block] Overnight Bank Funding Rate Overnight Bank Funding Rate [Member] Overnight Bank Funding Rate Derivatives Derivatives, Policy [Policy Text Block] The Manager Management [Member] Subsequent Events Subsequent Events [Text Block] Number of instruments held Debt Instrument, Number Of Instruments Held Debt Instrument, Number Of Instruments Held Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Cost Debt Securities, Available-for-sale, Amortized Cost Unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Accrued royalty receivable Accrued Royalty Receivable Accrued Royalty Receivable 2024 Long-Term Debt, Maturity, Year Four Income Statement Location [Axis] Income Statement Location [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] Additional issuance, purchase price, maximum Debt Securities, Available-For-Sale, Additional Issuance, Purchase Price, Maximum Debt Securities, Available-For-Sale, Additional Issuance, Purchase Price, Maximum Unrealized gain/(loss) on interest rate swaps Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Notional Value (in millions) Derivative, Notional Amount Amortization of intangible assets Amortization of Intangible Assets Interest Rate Swap, Due November 2020 Interest Rate Swap, Due November 2020 [Member] Interest Rate Swap, Due November 2020 Continuing Investors Partnerships Continuing Investors Partnership [Member] Continuing Investors Partnership Merck Asset - Phase II Clinical Trial Merck Asset - Phase II Clinical Trial [Member] Merck Asset - Phase II Clinical Trial Number of shares converted (in shares) Sale Of Stock, Number Of Shares Not Converted Sale Of Stock, Number Of Shares Not Converted Other assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] Non-Consolidated Affiliates Equity Method Investments and Joint Ventures Disclosure [Text Block] Writeoff related to financial royalty asset Financing Receivable, Allowance for Credit Loss, Financial Royalty Asset, Writeoff Financing Receivable, Financial Royalty Asset, Writeoff Interest income accretion Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss) Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss) Issuance of Class A ordinary shares sold in IPO, net of offering costs Stock Issued During Period, Value, New Issues Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Total assets Assets Related Party Transactions Related Party Transactions Disclosure [Text Block] Epizyme Common Stock Warrant Epizyme Common Stock Warrant [Member] Epizyme Common Stock Warrant Scenario [Axis] Scenario [Axis] Assignment Agreement - Benefit of Payment Stream Assignment Agreement - Benefit of Payment Stream [Member] Assignment Agreement - Benefit of Payment Stream Derivative financial instruments Interest rate swaps Derivative liability, current Derivative Liability, Current Title of 12(b) Security Title of 12(b) Security Financial Royalty Assets Financial Royalty Assets [Member] Financial Royalty Assets (Gain)/loss on equity securities Equity Securities, FV-NI, Gain (Loss) Intangible royalty assets, net Net carrying value Finite-Lived Intangible Assets, Net Put Option Put Option [Member] Evrysdi Evrysdi [Member] Evrysdi Deferred Shares Deferred Shares Deferred Shares [Member] Deferred Shares Subsequent Event Type [Axis] Subsequent Event Type [Axis] Credit Loss [Abstract] Unrealized gain/(loss) on available for sale debt securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Initial share issuance upon registration of Royalty Pharma plc Stock Issued During Period, Value, Issued For Registration Stock Issued During Period, Value, Issued For Registration Investments, Debt and Equity Securities [Abstract] Former Operating and Personnel Payments Former Operating and Personnel Payments [Member] Former Operating and Personnel Payments Intangible royalty assets, net Intangible Assets, Finite-Lived, Policy [Policy Text Block] Pablo Legorreta Chief Executive Officer [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Concentrations of credit risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Provision for changes in expected cash flows from financial royalty assets Provision for Loan and Lease Losses Interest expense Interest Expense Number of shares authorized under plan (in shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased Number of noncontrolling interests created Number Of Noncontrolling Interests Created Number Of Noncontrolling Interests Created Sale of stock, consideration received Sale of Stock, Consideration Received on Transaction Other exchanges Stockholders' Equity, Other Noncontrolling interest (percentage) Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners (Gain)/loss on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Receipt of contribution of investment in Legacy Investors Partnerships Transfer from Investments Effect of exchange by Continuing Investors of Class B shares for Class A ordinary shares and reallocation of historical equity Stockholders' Equity, Value, Effect Of Exchange And Reallocation Stockholders' Equity, Value, Effect Of Exchange And Reallocation Product and Service [Axis] Product and Service [Axis] Total liabilities Liabilities Amount calculated for operating and personal payment Related Party Transaction, Operating and Personal Payment Calculation, Amount Related Party Transaction, Operating and Personal Payment Calculation, Amount Reclassifications from non-controlling interest Other Comprehensive Income (Loss) Reclassification Adjustment, Attributable From Noncontrolling Interest Other Comprehensive Income (Loss) Reclassification Adjustment, Attributable From Noncontrolling Interest Unrecognized share based compensation expense, period of recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Supplemental Cash Flow Elements [Abstract] Individual Licensees Concentration List Individual Licensees Concentration Risk [Member] Individual Licensees Concentration Risk Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Equity securities Equity Securities, FV-NI, Noncurrent Equity Securities, FV-NI, Noncurrent 2022 Long-Term Debt, Maturity, Year Two Shareholders’ contributions Shareholders Contributions Shareholders Contributions Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Commitments and Contingencies Disclosure [Abstract] Net income attributable to Royalty Pharma plc Net Income (Loss) Available to Common Stockholders, Basic Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Weighted average coupon rate (as a percent) Debt, Weighted Average Interest Rate Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] R&D Funding Expense Research, Development, and Computer Software Disclosure [Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Swap collateral received Proceeds From Collateral Received On Derivative Instruments Proceeds From Collateral Received On Derivative Instruments Cumulative allowance for changes in expected cash flows Beginning balance Ending balance Financing Receivable, Allowance for Credit Loss Unrealized Gain (Loss) on Derivatives Unrealized Gain (Loss) on Derivatives Unrealized loss/(gain) on derivative financial instruments Gain (Loss) on Derivative Instruments [Member] Dividends paid (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Realized gain on available for sale debt securities Realized gain on available for sale debt securities Debt Securities, Available-for-sale, Realized Gain Debt Instrument [Axis] Debt Instrument [Axis] Additional Paid-In Capital Additional Paid-in Capital [Member] Purchases of equity securities Payments To Acquire Equity Securities, FN-NI Payments To Acquire Equity Securities, FN-NI Class of Stock [Line Items] Class of Stock [Line Items] Asset Class [Axis] Asset Class [Axis] Purchase of treasury interests Treasury interests Treasury Stock, Value, Acquired, Cost Method Adjustments to reconcile consolidated net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Derivative liability Derivative Liability Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Amortization rate (percentage) Debt Instrument, Amortization Rate Debt Instrument, Amortization Rate Point Seven Five Percent Senior Notes Due 2023 Point Seven Five Percent Senior Notes Due 2023 [Member] Point Seven Five Percent Senior Notes Due 2023 Number of shares purchased (in shares) Debt Securities, Available-For-Sale, Number Of Shares Purchased Debt Securities, Available-For-Sale, Number Of Shares Purchased Common stock, outstanding (in shares) Common shares outstanding Common Stock, Shares, Outstanding Investments in non-consolidated affiliates Equity Method Investments Revolving Credit Facility Revolving Credit Facility [Member] DPP-IV patents DPP-IV Patents [Member] DPP-IV Patents Consolidated net income before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Research and development funding expense Research and Development Expense IPO IPO [Member] Subsequent Event Subsequent Event [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Dilutive effect of unvested restricted units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] US Government Debt Securities US Government Debt Securities [Member] Revenue from intangible royalty assets and Accrued royalty receivable Revenue [Policy Text Block] Avillion Entities Avillion Entities [Member] Avillion Entities Senior Unsecured Revolving Credit Facility Senior Unsecured Revolving Credit Facility [Member] Senior Unsecured Revolving Credit Facility Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Income Statement [Abstract] Related party, rate (as a percent) Related Party Transaction, Rate Total Accumulated Other Comprehensive Income/(Loss) AOCI Attributable to Parent [Member] Debt issued as a percent of par value (as a percent) Debt Instrument, Issuance As A Percent Of Par Debt Instrument, Issuance As A Percent Of Par Three Point Five Five Percent Senior Notes Due 2050 Three Point Five Five Percent Senior Notes Due 2050 [Member] Three Point Five Five Percent Senior Notes Due 2050 Upfront development-stage funding payments Payments For Upfront Development Stage Funding Payments For Upfront Development Stage Funding Reclassifications to non-controlling interest Other Comprehensive Income (Loss), Reclassification Adjustment, Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Reclassification Adjustment, Attributable to Noncontrolling Interest Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Credit Loss, Financial Instrument [Text Block] Unamortized discount and loan issuance costs on long-term debt Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Minimum consolidated coverage ratio Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio Use of estimates Use of Estimates, Policy [Policy Text Block] Percent for calculating operating and personal payment Related Party Transaction, Operating and Personal Payment Calculation, Percent Related Party Transaction, Operating and Personal Payment Calculation, Percent Current Assets Assets, Current [Abstract] Accumulated Other Comprehensive Income/(Loss) AOCI Including Portion Attributable to Noncontrolling Interest [Member] RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 [Member] RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 Financing Receivable, Allowance for Credit Loss [Line Items] Financing Receivable, Allowance for Credit Loss [Line Items] Comprehensive income attributable to controlling interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent AZ Asset - Phase II and Phase III Clinical Trial AZ Asset - Phase II and Phase III Clinical Trial [Member] AZ Asset - Phase II and Phase III Clinical Trial Purchase of warrants Payments To Acquire Warrants Payments To Acquire Warrants Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] 2021 Long-Term Debt, Maturity, Year One Numerator Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Scenario [Domain] Scenario [Domain] Maximum consolidated leverage ratio Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio Counterparty Name [Domain] Counterparty Name [Domain] Legal Entity [Axis] Legal Entity [Axis] City Area Code City Area Code Royalty Distribution Payable to RP Select Finance Trust Royalty Distribution Payable to RP Select Finance Trust [Member] Royalty Distribution Payable to RP Select Finance Trust Document Period End Date Document Period End Date Valuation Technique, Black-Derman-Troy Valuation Technique, Black-Derman-Troy [Member] Valuation Technique, Black-Derman-Troy Shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Exchange offering, ownership percentage Sale of Stock, Percentage of Ownership before Transaction Equity in (earnings)/loss of non-consolidated affiliates Equity in income (loss) of non-consolidated affiliates Income (Loss) from Equity Method Investments Unrealized loss/(gain) on derivative financial instruments Unrealized loss/(gain) on derivative contracts Gain (Loss) on Derivative Instruments, Net, Pretax Consolidated net income Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Financial royalty assets Increase (Decrease) in Finance Receivables Reclassifications to net income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Distributions to shareholders/unitholders Payments For Distributions To Shareholders and Unitholders Payments For Distributions To Shareholders and Unitholders Deferred stock, par value (in dollars per share) Deferred Shares, Par or Stated Value Per Share Deferred Shares, Par or Stated Value Per Share Hedging Designation [Axis] Hedging Designation [Axis] Old Credit Facility Old Credit Facility [Member] Old Credit Facility Expected reduction in royalty receipts Financing Receivable, Expected Decrease In Royalty Receipts Financing Receivable, Expected Decrease In Royalty Receipts Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Redeemable stock, redemption price (in euros per share) Redeemable Stock, Redemption Price Per Share Redeemable Stock, Redemption Price Per Share Share-based compensation Share-based Payment Arrangement, Noncash Expense Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Equity securities Equity Securities, FV-NI Likelihood of FDA Approval Likelihood of FDA Approval [Member] Likelihood of FDA Approval Interest payable Increase (Decrease) in Interest Payable, Net Entity [Domain] Entity [Domain] Equity method investment, unfunded commitments Equity Method Investments, Unfunded Commitments Equity Method Investments, Unfunded Commitments Dividends to shareholders Payment Of Dividends To Shareholders Payment Of Dividends To Shareholders Designated as Hedging Instrument Designated as Hedging Instrument [Member] Cover [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Summary of Available for Sale Debt Securities Debt Securities, Available-for-sale [Table Text Block] Marketable securities Debt Securities, Trading Activity for the year Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Distributions from non-consolidated affiliates Proceeds from Equity Method Investment, Distribution Intangible Royalty Assets, Net Intangible Assets Disclosure [Text Block] Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Affiliated Entity Affiliated Entity [Member] Total debt carrying value Long-term Debt Financial royalty assets, net Financing Receivables, Fair Value Disclosure Financing Receivables, Fair Value Disclosure Fair Value Disclosures [Abstract] Contributions from non-controlling interest- R&D Proceeds From Noncontrolling Interests, Research And Development Proceeds From Noncontrolling Interests, Research And Development Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Other current assets Increase (Decrease) in Other Current Assets Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Available for sale debt securities Fair Value Debt Securities, Available-for-sale Reclassification of unrealized gain on available for sale debt securities Reclassification of unrealized gain on available for sale debt securities Reclassification of unrealized gain on available for sale debt securities Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Total operating expenses, net Costs and Expenses Equity Components [Axis] Equity Components [Axis] Bristol-Myers Squibb Bristol-Myers Squibb [Member] Bristol-Myers Squibb Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Receivables [Abstract] Minimum Minimum [Member] Intangible Royalty Assets Intangible Royalty Assets [Member] Intangible Royalty Assets Secondary Offering Secondary Offering [Member] Secondary Offering Swap termination payments Swap termination payments Payments To Terminate Derivative Instruments Payments To Terminate Derivative Instruments Schedule of Cash Flow, Supplemental Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Less: Net income attributable to non-controlling interest Less: net income attributable to non-controlling interest Net Income (Loss) Attributable to Noncontrolling Interest Equity Method Investments and Joint Ventures [Abstract] Summary of Derivatives and Reclassifications Derivative Instruments, Gain (Loss) [Table Text Block] Put option, term (in months) Option Indexed to Issuer's Equity, Term Option Indexed to Issuer's Equity, Term Public Stock Offering - Continuing Investors Partnerships Interests IPO - Continuing Investors Partnerships [Member] IPO - Continuing Investors Partnerships Entity Interactive Data Current Entity Interactive Data Current Fair Value Measurements and Financial Instruments Fair Value Disclosures [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Other exchanges (in shares) Stockholders' Equity, Other Shares Interest Rate Swap Interest Rate Swap [Member] Class B Holders Class B Holders [Member] Class B Holders Customer [Domain] Customer [Domain] Payments To Related Party Funded By Acquisitions Payments To Related Party Funded By Acquisitions [Member] Payments To Related Party Funded By Acquisitions Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Purchase commitment, additional payments Purchase Commitment, Additional Payment Purchase Commitment, Additional Payment Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Statement of Stockholders' Equity [Abstract] Assets: Assets, Fair Value Disclosure [Abstract] Likelihood of FDA Approval At End Of Any Given Quarter By 2024 Likelihood of FDA Approval At End Of Any Given Quarter By 2024 [Member] Likelihood of FDA Approval At End Of Any Given Quarter By 2024 Accrued purchase obligation Accrued Purchase Obligation, Current Accrued Purchase Obligation, Current Impairment charge Asset Impairment Charges Other operating expenses Other Cost and Expense, Operating Debt Securities, Available-For-Sale, Redemption, Period [Axis] Debt Securities, Available-For-Sale, Redemption, Period [Axis] Debt Securities, Available-For-Sale, Redemption, Period Put option to sell additional common stock Option Indexed To Issuers Equity, Value Option Indexed To Issuers Equity, Value Reversal of cumulative allowance Financing Receivable, Change in Present Value, Expense (Reversal) Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Weighted average effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Forward Contracts Forward Contracts [Member] Number of noncontrolling interests Number of Noncontrolling Interests Number of Noncontrolling Interests Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Preferred shares, fixed payment amount Debt Securities, Available-for-Sale, Fixed Payment Debt Securities, Available-for-Sale, Fixed Payment Ownership percentage (as a percent) Noncontrolling Interest, Ownership Percentage by Parent Cash collected on financial royalty assets Increase (Decrease) In Cash Collections On Financing Receivables Increase (Decrease) In Cash Collections On Financing Receivables Avillion I Avillion I [Member] Avillion I Research and Development [Abstract] Other Other Financial Royalty Asset [Member] Other Financial Royalty Asset EPA Holdings EPA Holdings [Member] EPA Holdings Cash collections from intangible royalty assets Proceeds From Cash Collections From Royalties Received On Intangible Assets Proceeds From Cash Collections From Royalties Received On Intangible Assets Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] RPIFT Senior Secured Credit Facilities - Tranche B-6 RPIFT Senior Secured Credit Facilities - Tranche B-6 [Member] RPIFT Senior Secured Credit Facilities - Tranche B-6 Scheduled repayments of long-term debt Repayments Of Long-term Debt, Scheduled Payments Repayments Of Long-term Debt, Scheduled Payments Payments to acquire royalty interests, additional milestone payments Payments To Acquire Royalty Interest, Additional Milestone Payments Payments To Acquire Royalty Interest, Additional Milestone Payments Sale of Stock [Axis] Sale of Stock [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Royalty Income, Other Royalty Income, Other [Member] Royalty Income, Other Available for sale debt securities Increase (Decrease) In Debt Securities, Available For Sale Increase (Decrease) In Debt Securities, Available For Sale Document Transition Report Document Transition Report Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Funding Agreement With Biohaven Pharmaceuticals Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals [Member] Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals Warrant Warrant [Member] Debt issued, amount Debt Instrument, Face Amount Level 2 Fair Value, Inputs, Level 2 [Member] Royalty assets Royalty Assets, Policy [Policy Text Block] Royalty Assets, Policy Other current assets Other Assets, Current Liabilities: Liabilities, Fair Value Disclosure [Abstract] Potential milestone payments Potential Milestone Payments Potential Milestone Payments Asset Class [Domain] Asset Class [Domain] Operating and personnel payments incurred Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party Equity [Abstract] Crysvita Crysvita [Member] Crysvita Promacta Promacta [Member] Promacta Change Of Control Probability Change Of Control Probability [Member] Change Of Control Probability Funding Agreement With Immunomedics Funding Agreement With Immunomedics [Member] Funding Agreement With Immunomedics Supplemental schedule of non-cash investing / financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Financial royalty assets Financing Receivable, after Allowance for Credit Loss, Current Put option, selling price, maximum (in dollars per share) Option Indexed to Issuer's Equity, Strike Price Fixed Rate (as a percent) Derivative, Fixed Interest Rate Subsequent Event [Line Items] Subsequent Event [Line Items] Accounting standards update [Extensible List] Accounting Standards Update [Extensible List] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Customer Concentration Risk Customer Concentration Risk [Member] Credit Facility [Domain] Credit Facility [Domain] Settlement of Epizyme forward purchase contract Settlements With Equity Method Investments Settlements With Equity Method Investments Derivative Contract [Domain] Derivative Contract [Domain] Diluted (in shares) Weighted average Class A ordinary shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Basic (in dollars per share) Earnings per Class A ordinary share - basic (in dollars per share) Earnings Per Share, Basic Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Other (income)/expense Other Income and Expenses [Abstract] Number of operating segments Number of Operating Segments Entity File Number Entity File Number Restricted stock units forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Disclosure [Abstract] Financial royalty assets, net Financing Receivable, after Allowance for Credit Loss, Noncurrent Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment [Line Items] IPO - Shares From Company IPO - Shares From Company [Member] IPO - Shares From Company Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Purchasing And Donating Ventilators Purchasing And Donating Ventilators [Member] Purchasing And Donating Ventilators Unsecured Debt Unsecured Debt [Member] Xtandi Xtandi [Member] Xtandi Net cash provided by/(used in) financing activities Net Cash Provided by (Used in) Financing Activities Repayments of long-term debt Repayments of outstanding debt Repayments of Long-term Debt Share based compensation Share-based Payment Arrangement, Expense Net carrying value, before cumulative allowance for credit losses Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows Unrealized gain/(loss) on available for sale debt securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Counterparty Name [Axis] Counterparty Name [Axis] Common stock Common Stock, Value, Issued Goodwill and Intangible Assets Disclosure [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Preferred shares, quarterly payments Debt Securities, Available-for-Sale, Quarterly Payments Debt Securities, Available-for-Sale, Quarterly Payments Document Fiscal Year Focus Document Fiscal Year Focus Less: net income attributable to Continuing Investors Partnerships prior to the IPO Net Income (Loss) Attributable to Parent, Prior To Offering Net Income (Loss) Attributable to Parent, Prior To Offering Document Annual Report Document Annual Report Projected amortization expense, 2022 Finite-Lived Intangible Asset, Expected Amortization, Year Two Repayments of long-term debt by contributions from non-controlling interest Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash Commercial Paper Commercial Paper [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash collections from financial royalty assets Proceeds From Cash Collections From Royalties Received On Financing Receivables Proceeds From Cash Collections From Royalties Received On Financing Receivables Current portion of long-term debt Less: Current portion of long-term debt Long-term Debt, Current Maturities Category of Item Purchased [Axis] Category of Item Purchased [Axis] Summary of Financial Royalty Assets, Net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share Available-for-sale Securities Available-for-sale Securities [Member] Acquisitions of financial royalty assets Payments to Acquire Finance Receivables Deferred shares, $0.000001 par value, 316,407 and 0 issued and outstanding, respectively Deferred Shares, Value, Issued Deferred Shares, Value, Issued Related Party Transaction [Axis] Related Party Transaction [Axis] Subsequent Event [Table] Subsequent Event [Table] Purchases of available for sale debt securities Purchase of warrants Purchase of available for sale debt securities Payments to Acquire Debt Securities, Available-for-sale Earnings per share Earnings Per Share, Policy [Policy Text Block] Share based compensation and related issuance of Class A ordinary shares (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Non-controlling interest Stockholders' Equity Attributable to Noncontrolling Interest Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee [Domain] Vertex Vertex [Member] Vertex Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Reduction in financial royalty assets Financing Receivable, Increase (Decrease) Due Increase (Reduction) In Royalty Receipts Financing Receivable, Increase (Decrease) Due To Increase (Reduction) In Royalty Receipts Initial share issuance upon registration of Royalty Pharma plc (in shares) Stock Issued During Period, Shares, Issued For Registration Stock Issued During Period, Shares, Issued For Registration Redemption, Period Two Debt Securities, Available-For-Sale, Redemption, Period Two [Member] Debt Securities, Available-For-Sale, Redemption, Period Two Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Unrealized gain/(loss) on equity securities AOCI, Accumulated Gain (Loss), Equity Securities, Parent [Member] AOCI, Accumulated Gain (Loss), Equity Securities, Parent Long-term debt Total long-term debt Long-term Debt, Excluding Current Maturities RPIFT Senior Secured Credit Facilities RPIFT Senior Secured Credit Facilities [Member] RPIFT Senior Secured Credit Facilities Interest expense Interest Expense [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Unrealized gain (loss) on equity securities still held Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) Beginning balance Ending balance Stockholders' Equity Attributable to Parent Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total liabilities and shareholders’/unitholders’ equity Liabilities and Equity Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Deferred stock, outstanding (in shares) Deferred Shares, Shares, Outstanding Deferred Shares, Shares, Outstanding Entity Address, City or Town Entity Address, City or Town Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Issuance of Class B shares to Continuing Investor Partnerships (in shares) Stock Issued During Period, Shares, Issued To Partnerships Stock Issued During Period, Shares, Issued To Partnerships Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1 RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1 [Member] RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1 Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Purchase Of Eisai Royalties Long Term Purchase Commitment, Purchase Of Eisai Royalties [Member] Long Term Purchase Commitment, Purchase Of Eisai Royalties Net carrying value Financial royalty asset, net Financing Receivable, after Allowance for Credit Loss General and administrative expenses General and Administrative Expense Financial Instrument [Axis] Financial Instrument [Axis] Other Other Noncash Income (Expense) Finite lived intangible assets, useful life Finite-Lived Intangible Asset, Useful Life Equity Component [Domain] Equity Component [Domain] RPSFT Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member] Legacy Investors Partnerships and Royalty Pharma Select Finance Trust Derivative financial instruments Derivative Asset, Noncurrent Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Axis] Immunomedics Immunomedics [Member] Immunomedics Other assets Increase (Decrease) in Other Noncurrent Assets Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Increase (Decrease) in Operating Liabilities [Abstract] Increase (Decrease) in Operating Liabilities [Abstract] Entity Tax Identification Number Entity Tax Identification Number Maximum total leverage ratio Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio Term of warrant (in years) Warrants and Rights Outstanding, Term Net income attributable to controlling interest Net Income (Loss) Attributable to Parent Other receivables Increase (Decrease) in Other Receivables Tysabri Tysabri [Member] Tysabri Ongoing development-stage funding payments Payments For Ongoing Development Stage Funding Payments For Ongoing Development Stage Funding Collateral as a percentage of the collection trust account Debt Instrument, Terms, Collateral, Percentage Of Collection Trust Account Debt Instrument, Terms, Collateral, Percentage Of Collection Trust Account (Increase)/decrease in operating assets: Increase (Decrease) in Operating Assets [Abstract] Distributions to non-controlling interest Payments to Noncontrolling Interests London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Current period provision for credit losses (c) Financing Receivable, Credit Loss, Expense (Reversal) Investment, Name [Domain] Investment, Name [Domain] Number of shares available to convert (in shares) Sale of Stock, Number of Shares Available To Convert Sale of Stock, Number of Shares Available To Convert Other comprehensive income/(loss) Other Comprehensive Income (Loss), Net of Tax Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Total current liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure, Current Financial and Nonfinancial Liabilities, Fair Value Disclosure, Current Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Operating expenses Operating Expenses [Abstract] Less: Other comprehensive income attributable to non-controlling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Earnings Per Share [Abstract] Cumulative allowance for changes in expected cash flows Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows Shareholders’/Unitholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Warrants to purchase additional shares (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Document Fiscal Period Focus Document Fiscal Period Focus Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Redemption price, percentage Debt Securities, Available-For-Sale, Redemption Price, Percentage Debt Securities, Available-For-Sale, Redemption Price, Percentage Derivative instrument, exercise period (in months) Derivative Instrument, Option, Exercise Period Derivative Instrument, Option, Exercise Period Certificates of Deposit Certificates of Deposit [Member] Net income attributable to Royalty Pharma plc Net Income (Loss) Available to Common Stockholders, Diluted Financial royalty assets, net Financing Receivable [Policy Text Block] Change in fair value of derivative contracts Unrealized Gain (Loss) on Derivatives and Commodity Contracts Equity Method Investment, Nonconsolidated Investee or Group of Investees Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] One Point Seven Five Percent Senior Notes Due 2027 One Point Seven Five Percent Senior Notes Due 2027 [Member] One Point Seven Five Percent Senior Notes Due 2027 Funding Agreements With Pfizer Funding Agreements With Pfizer [Member] Funding Agreements With Pfizer Redemption price (as a percent) Debt Instrument, Redemption Price, Percentage Schedule of Balance Of Non-controlling Interests Schedule of Stockholders Equity [Table Text Block] Entity Filer Category Entity Filer Category Common Stock Common Stock [Member] Deferred stock, issued (in shares) Deferred Shares, Shares, Issued Deferred Shares, Shares, Issued Product and Service [Domain] Product and Service [Domain] RPIFT Senior Secured Credit Facilities - Tranche A-4 RPIFT Senior Secured Credit Facilities - Tranche A-4 [Member] RPIFT Senior Secured Credit Facilities - Tranche A-4 Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Distributions from non-consolidated affiliates Proceeds from Equity Method Investment, Distribution, Return of Capital Number of limited partnership interest acquired (in shares) Related Party Transaction, Number of Partnership Interests Acquired Related Party Transaction, Number of Partnership Interests Acquired Financing Receivable, Allowance for Credit Loss [Table] Financing Receivable, Allowance for Credit Loss [Table] Dividends Dividends, Cash Other royalty cash collections Proceeds From Cash Collections From Other Royalties Received On Financing Receivables Proceeds From Cash Collections From Other Royalties Received On Financing Receivables Loss on derivative financial instruments Gain (Loss) On Derivative Financial Instruments Gain (Loss) On Derivative Financial Instruments Other Commitments [Axis] Other Commitments [Axis] Milestone payable - Erleada Milestone Payment Accrued But Not Paid Milestone Payment Accrued But Not Paid Other Commitments [Domain] Other Commitments [Domain] Senior Secured Debt Secured Debt [Member] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Issuance of Class A ordinary shares sold in initial public offering, net of offering costs (in shares) Stock Issued During Period, Shares, New Issues One Point Two Zero Percent Senior Notes Due 2025 One Point Two Zero Percent Senior Notes Due 2025 [Member] One Point Two Zero Percent Senior Notes Due 2025 Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Cost Finite-Lived Intangible Assets, Gross Revenue Benchmark Revenue Benchmark [Member] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Debt instrument, stated rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Interest Rate Swap, Due March 2023 - 4 Interest Rate Swap, Due March 2023 - 4 [Member] Interest Rate Swap, Due March 2023 - 4 Money Market Funds Money Market Funds [Member] Gross carrying value Financing Receivable, before Allowance for Credit Loss Common Class A Common Class A [Member] Total non-current assets Assets, Fair Value Disclosure, Noncurrent Assets, Fair Value Disclosure, Noncurrent Diluted earnings per share: Earnings Per Share, Diluted [Abstract] Related Party Transactions [Abstract] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Remaining commitment for R&D funding agreement Research And Development, Remaining Funding Commitment Research And Development, Remaining Funding Commitment Total other (income)/expense, net Nonoperating Income (Expense) Unrealized gains on available for sale debt securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Unrealized gains on available for sale debt securities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) Basis of preparation Basis of Accounting, Policy [Policy Text Block] Basic (in shares) Weighted average Class A ordinary shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Basis spread on variable rate (percentage) Debt Instrument, Basis Spread on Variable Rate Subsequent Events [Abstract] Ownership [Axis] Ownership [Axis] Document Information [Line Items] Document Information [Line Items] Investments in non-consolidated affiliates Consolidation, Variable Interest Entity, Policy [Policy Text Block] Two Point Two Zero Percent Senior Notes Due 2030 Two Point Two Zero Percent Senior Notes Due 2030 [Member] Two Point Two Zero Percent Senior Notes Due 2030 Interest Rate Swap, Due March 2023 - 3 Interest Rate Swap, Due March 2023 - 3 [Member] Interest Rate Swap, Due March 2023 - 3 Sale of Stock [Domain] Sale of Stock [Domain] Distributions to non-controlling interest- other Payments To Noncontrolling Interests, Other Payments To Noncontrolling Interests, Other 2025 Long-Term Debt, Maturity, Year Five Ownership [Domain] Ownership [Domain] Reported Value Measurement Reported Value Measurement [Member] Plan Name [Domain] Plan Name [Domain] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Imbruvica Imbruvica [Member] Imbruvica Interest Income Interest Income [Member] Total shareholders’/unitholders’ equity Beginning balance Ending balance Cumulative adjustment Cumulative adjustment to retained earnings Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Organization and Purpose Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Revision of Prior Period, Reclassification, Adjustment Revision of Prior Period, Reclassification, Adjustment [Member] Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs Proceeds from Issuance Initial Public Offering Additional paid-in capital Additional Paid in Capital Shareholders' Equity Shareholders' Equity and Share-based Payments [Text Block] Fair value of outstanding Notes Long-term Debt, Fair Value Projected amortization expense, 2021 Finite-Lived Intangible Asset, Expected Amortization, Year One Cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Revenues Revenues Transfer to Level 2 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Class of Stock [Axis] Class of Stock [Axis] Schedule of Notional Values and Fixed Rates Schedule of Derivative Instruments [Table Text Block] Income tax expense Income Tax Expense (Benefit) Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Schedule of Repayments of Debt by Year Schedule of Maturities of Long-term Debt [Table Text Block] Purchases of marketable securities Purchases of marketable securities Payments to Acquire Marketable Securities Accounting Standards Update and Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Ownership percentage following IPO Sale of Stock, Percentage of Ownership after Transaction Diluted (in dollars per share) Earnings per Class A ordinary share - diluted (in dollars per share) Earnings Per Share, Diluted Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Proceeds from equity securities Proceeds From Issuance Of Equity Securities, FN-NI Proceeds From Issuance Of Equity Securities, FN-NI Proceeds from available for sale debt securities Proceeds from Sale of Debt Securities, Available-for-sale Local Phone Number Local Phone Number Minimum debt coverage ratio Debt Instrument, Covenant Terms, Minimum Debt Coverage Ratio Debt Instrument, Covenant Terms, Minimum Debt Coverage Ratio Derivative Instruments and Hedging Activities Disclosure [Abstract] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Swap collateral posted Payments For Collateral Posted On Derivative Instruments Payments For Collateral Posted On Derivative Instruments Numerator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Interest income Investment Income, Net Long-term debt, gross Long-term Debt, Gross Schedule of Borrowings Schedule of Long-term Debt Instruments [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Related Party Transaction [Domain] Related Party Transaction [Domain] IPO - Shares From Selling Shareholders IPO - Shares From Selling Shareholders [Member] IPO - Shares From Selling Shareholders Entity Emerging Growth Company Entity Emerging Growth Company Quarterly payments to affiliates, percent of security investment (as a percent) Related Party Transaction, Rate, Value Of Security Investments Related Party Transaction, Rate, Value Of Security Investments Acquisition Of Limited Partnership Interests In Affiliate Acquisition Of Limited Partnership Interests In Affiliate [Member] Acquisition Of Limited Partnership Interests In Affiliate Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Federal Funds Rate Federal Funds Purchased [Member] Operating and Personnel Payments Operating and Personnel Payments [Member] Operating and Personnel Payments Royalty Pharma Investment Financial Trust Royalty Pharma Investment Financial Trust [Member] Royalty Pharma Investment Financial Trust Line of credit, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Award Type [Axis] Award Type [Axis] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Other royalty income receivable Other Royalty Income Receivable, Current Other Royalty Income Receivable, Current Maximum Maximum [Member] Purchase commitment, upfront payment Purchase Commitment, Upfront Payment Purchase Commitment, Upfront Payment Non-Controlling Interest Noncontrolling Interest [Member] Dividends declared and paid Dividends, Common Stock, Cash Payments to acquire royalty interests, upfront payment Payments To Acquire Royalty Interests, Upfront Payment Payments To Acquire Royalty Interests, Upfront Payment Purchase commitment, purchase of committed, non-contingent Commercial Launch Preferred Equity payable Purchase Commitment, Committed Non-Contingent Commercial Launch Preferred Equity, Amount Purchase Commitment, Committed Non-Contingent Commercial Launch Preferred Equity, Amount Retained Earnings Retained Earnings [Member] Assignment Agreement - Funding Obligations Assignment Agreement - Funding Obligations [Member] Assignment Agreement - Funding Obligations Measurement Basis [Axis] Measurement Basis [Axis] Equity securities and Available for sale debt securities Debt Securities, Available For Sale, Policy [Policy Text Block] Debt Securities, Available For Sale, Policy Write off of credit loss allowance Financing Receivable, Allowance for Credit Loss, Writeoff Interest Rate Swap, Due March 2023 - 2 Interest Rate Swap, Due March 2023 - 2 [Member] Interest Rate Swap, Due March 2023 - 2 Unrealized gains on available for sale debt securities Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash (used in)/provided by investing activities Net cash flow from investing Net Cash Provided by (Used in) Investing Activities Award Type [Domain] Award Type [Domain] Cumulative allowance for credit losses Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal) Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal) Total current assets Assets, Fair Value Disclosure, Current Assets, Fair Value Disclosure, Current Schedule of Cumulative Allowance for Changes in Expected Cash Flows Financing Receivable, Allowance for Credit Loss [Table Text Block] Corporate Debt Securities Corporate Debt Securities [Member] Trading Symbol Trading Symbol Weighted average Class A ordinary shares outstanding Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Legacy Investors Partnerships Legacy Investors Partnerships [Member] Legacy Investors Partnerships Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accrued royalty receivable Increase (Decrease) In Accrued Royalty Receivable Increase (Decrease) In Accrued Royalty Receivable Other commitment Other Commitment Redemption default, threshold period Debt Securities, Available-For-Sale, Redemption Default, Threshold Period Debt Securities, Available-For-Sale, Redemption Default, Threshold Period Payments for operating and professional costs Payments For Operating Costs and Professional Services Payments For Operating Costs and Professional Services Treasury interests Treasury Stock, Value Earnings Per Share Earnings Per Share [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Milestone payable Milestone Payable, Current Milestone Payable, Current Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Axis] Three Point Three Zero Percent Senior Notes Due 2040 Three Point Three Zero Percent Senior Notes Due 2040 [Member] Three Point Three Zero Percent Senior Notes Due 2040 Funding Agreements With Sanofi Funding Agreements With Sanofi [Member] Funding Agreements With Sanofi Current liabilities Liabilities, Current [Abstract] Entity Shell Company Entity Shell Company Financial Royalty Assets, Net Financing Receivables [Text Block] Fair Value, Recurring Fair Value, Recurring [Member] Segment Information Segment Reporting, Policy [Policy Text Block] Transfer from level 2 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Interest Rate Swap, Due March 2023 - 1 Interest Rate Swap, Due March 2023 - 1 [Member] Interest Rate Swap, Due March 2023 - 1 Recently adopted and issued accounting standards New Accounting Pronouncements, Policy [Policy Text Block] Entity Public Float Entity Public Float Statement of Financial Position [Abstract] Basic earnings per share: Earnings Per Share, Basic [Abstract] EX-101.PRE 11 rprx-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 rprx-20201231_g1.jpg begin 644 rprx-20201231_g1.jpg M_]C_X 02D9)1@ ! 0$!( $@ #_X1#R17AI9@ 34T *@ @ ! $[ ( M - (2H=I 0 ! (6)R= $ : 0T.H< < @, /@ M &UL;G,Z9&,](FAT=' Z M+R]P=7)L+F]R9R]D8R]E;&5M96YT#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@ M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8 M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4 M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ_\ $0@#NPK< P$B (1 0,1 ?_$ !\ $% 0$! 0$! M ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $ M$042(3%!!A-180'EZ@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! M @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$' M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F MY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBN?\<>+[+P+X0O=>U%3(MNH$4*G#32'A4'U/?L,GM0!T%%?%_C# MX@_%W4LZQJ3Z]H>G.VZ'[)#-:0(#P ' &[\6-=)\'_CWKUMXHLM#\8W[:EIM M]*($N9^9;=V.%);JRDX!STSG/&" ?5E%-EE2&%Y9G5(T4LS,'_#D:R227%D0ES-&G&_?C*DD@ #H#SDT ?1M%?-_B_QA MXH^!7Q L;0ZYJ'B;P]>P"8PZM+YLZ_,0X$N,[A@$=OFP1QFOH32-5L]=T:TU M73)?.M+R%9H7QC*L,CCL?:@"Y17S)\1?BYXZ\5ZQ?6'PPLM3&B6,C127^FVC MRO.R]6\Q0=B^F,'')/.!YKH'QF\?^%]5$K:_?7PC?$UIJ*K3QKX/T_7]/!2*\CW-&3DQ.#AT/T8$9[]:\M^.OQJNO!,R>'? M"Q0:Q+&))[IE#"U0_= 4\%SUYX QP<\ 'MU%>">,_#'C/P%\._\ A,;/Q]X@ MNM9LUAEOK6ZN!+:MN958)$1@ %N^> >E=Q\'?BC%\2_#4DMS%';ZO8E4O(8\ M[3G.V1<_PG!X[$'V) /0Z**IZIID&KV+6ES)=11L0=UI=RVT@(]'C96_#.#0 M!._AQ9Z]J?Q"\;6]Y%(W(ZONY&X<@\@@\=![5\'/BG'\3/#LSW4"6VK6!5+ MR*/.QMP.V1<] <-QS@CZ4 >BT444 %%%% !1110 4444 %%%5M1L8]3T^:SF MEN(DF7:9+:=X9%]U="&!^AH LT5\+^*_&7C+0O&>M:1;>-/$3PV&H3VT;-JD MV2J2,H)^;K@5]T4 %%=J.M2N%C5\&*)49C(?;*[0.,\ M\\&NDH **** "BBB@ HKG_%/A./Q+:2!-4U?3+OR2D,^GZG/;A#S@E$8(W)Z ME2:^(/\ A8_C?_H>V5 7(_&O#H?C%\2/AOXRN=(\0:D=7%C<&*YM;LAQ(!W63&X9!R#[C( M/2@#[#HK)\+^(K+Q;X7L-=TLL;6^B$B!OO*T\'RO'JTD:B+RWV.R[@756[$KN ^O;K0!UM%?- M?[.'A3QSH?B^^N-7L-0TS1FMV6:*^1HQ-+E=I5&Y)'/S =,C/-?2E !1110 M445S?CKQM8>!/#O]IZ@/-DDE6"VM@^UIY&. >< #))QP : .DHHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHKQ/XQ?%;Q%IVM-X/^&]C<7FL)&)+ MVXM;8W#VX895%4 _,1@DD< C'/( /;**^%)?B1\2_#^N,U_XBUZUO4.YK>^E M? ^L4GRX_"OJ;X,?$W_A97A26:]CCAU;3W6*\2/A6R"5D [!L-QZJ>U 'HM% MP MM,$^;*>Y YV@!GRWQPP(!P>N1CG/ !]& MT55U/4;72-*NM1U"40VMI$TTTA_A51DG\A7SYX5\9^)OCK\0KZRMM:U#PSX; ML8#,(],D$5PPW!5#28)W'DGL,8QW(!]&T5\W:A\1_$/P7^*A\.:]K%WXB\.R MI%*LM^=]S%&_!8/U8@@\'(('&":^C;>XBN[:*XMI%DAF0/&ZG(92,@C\* )* M**\W^+_AV7_A"-<\0:1KFN:7J5I;&Y5K35KB.)M@&5\H/L ('\(')R>] 'I% M%?#O@CQ7XO\ $OCK1M%OO&OB6.VO[R."5X=5F#A6."022,_4&OH77_@]XCAT MV6;PC\2_%HU"-"T46I:FTL&]=CM?&$[ MZOIHD\NX29 )X.<%E8 $D?W6SGIQUKZYMKB*\M8KFVD$D,R"2-UZ,I&0?R- M$E%%% !1110 4444 %%%% !117BO[1Z:CHGA*W\1Z#K^LZ7>"[CMY([349HX MI$*M_ &"@Y Y Y[T >U45\\?LP>)==U_4?$:Z]K6HZFL,5N8A>W;S!"2^<;B M<9P.GI7T+++'#"\LSK'&BEG=S@*!U)/84 .HKGO!7C&S\<:'-JVF1LMHMW+; MPNQSYJHV ^,< ]<5T- !1110 444V1!+$T;%@&4J2K%3SZ$<@^XH =17S5^T M);ZQX"DT:\\+^*_$EK!?&6.:W;6KF0*R;2"I9R>0QSD]A[UE_ ZUUWXF7FLQ M:]X\\7VZV,<31&RUAU)+E@<[MW]T=,4 ?5-%?.7Q3\,>//AGHH\1>&OB!K^H M:='(J7$6H71EDAW':K9/RLI) Q@8)'7MI? _XZWWBS6$\,>,/+DU"56:TO8T M"><5&2CJ. V 2", XQC/4 ][HHHH **** "BBB@ HHHH ***^9?VBO"7CO6_ M'-MT[X<:- M:>+I6EU>* BX9WWL/F)56;NP3:">>0>3744 %%%% !117-:!XVT_Q)XN\0Z' MI@$@T'R$GN5?*O+)YFY /]GRP"<]21QCD Z6BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HKS#XQ?$Z^\%6UIHWA6S;4/$FIJ6@B2(RF&,<&3 M8.6).0!TX)/3!^:-:\>?%32-76;7M;\2:9=/\ZPW+2VZL/:(X7'/I0!]S45X MO\!?C#>>/$N=#\2M&VL6D0FCN$4+]IBR 20. P)'3J#TX->C>//&=CX"\'W> MO:BID6$!8H%.&FD;A4!_4GL 3VH Z*BOGSX;#Q9\:[;5=?U[QAK&B6<%S]GM M+70Y_LRJX4,=W!+ !EZ\G)YJ/X<_&+6M%^)%SX \?7@U!8[U[&VU-U"R"0.5 M4/CJK<8)Y!(R2.@!]#T5D>*O$MCX0\+WVNZJQ%M9Q[V5?O.2!U(.>,XYKZ\)P,G@4 %%?.FH_%37/B M?\6K;P7X+U271=%,KI+?VN/.G5%9G=6_A!VX7'J">N WQ]K_ (J^!/BK2);' MQ'J?B/1=11S):ZW/Y[Y0KO DP".'7!'0]0: /HVBLOPUX@L?%7AJQUS2G+VE M[$)$SU4]"I]P00?<&M2@ HKG_%/A./Q+:2!-4U?3+OR2D,^GZG/;A#S@E$8( MW)ZE2:^(/^%C^-_^AR\0?^#2?_XJ@#[_ **\MO\ X,Z@UJW]D?$[QM!= 91[ MK53-'GME0%R/QKPZ'XQ?$CX;^,KG2/$&I'5Q8W!BN;6[(<2 =UDQN&0<@^XR M#TH ^PZ*R?"_B*R\6^%[#7=++&UOHA(@;[RG.&4^X8$'W%:U !1110 4444 M%%%% !1110 45POQ@T^:;XZ7:2W$$NGWLL&2 "0X1@'!VXYS MC)QC)KP/X!^,_%&L_%_3[/5_$FKW]J\,Y:"ZOI948B-B,JS$<&@#ZVHHKFM M\;:?XD\7>(=#TP"0:#Y"3W*OE7ED\S<@'^SY8!.>I(XQR =+1110 4444 %% M%>+_ !ZT:[T#P/=>)O#GB+Q!IMY%=(TL<6L7/E2"1\$!"Y"X+# 7 &,4 >T M45\:?";5O%'COXB6>@ZOXX\4PVL\E>N>./ACXN\/^ M';S6/!GQ%\4W,]E$TSVFHZ@TWFHHRVTC #8!(&#GI0![?17RS\*_VB=.+A=0T^ZD6%;UD"RV[$X!)4 ,N>N>1USQ@_4U !1110 4444 %%%% !11 M10 45X7^TKX=\8Z]INE?\(U;7E_ID1?[7:62L[ER5VLR+RPZXX..?6NF^ >C M^*=$^&XMO&(GBD-PS6=O5^;<0IZ9_"@#TZBBB@ HHHH **YNY M\:Z?!\1+'P?$/.O[BUDNIBK\6Z+C;D>K<\>@SW%=)0 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !6;JN@:=K5UI\^IP"X.G3_:;='.463:5#%>A(#'&>A.:TJ* (;RSM]0LIK. M^@CN+:=#'+%(NY74C!!'<5\(Z%X6_M7XPP>'-)W21?VL84<Q#^M>S?M(P/+\%;]T&1#/?LJ? M\E3U+_L"R_\ H^"@#;_:U4#5O## #<8+@$XY(W)_B:[3]F[4#KWP8GTJZDD" MV=U/9@JQ#"-U#\'MS(V/3%<9^UM_R%/"_P#UQN?_ $*.NG_92B=?AUJTK+A' MU5@I]<11Y_G0![/I.DV.A:3;:9I-LEM9VL8CBB08"@?S/J>I/-?*O[4FD6&G M_$2PO+)$BN+^R\RZ5%QN97*AS[D#'_ :^LYIHK:WDGN)%BBB4N[N<*J@9))[ M "OG31?"[_'3XO7?C+58&'A'3W6WLEE4C[:L9.% /\);+-_O;?7 !Z5\"-"N M- ^#NCPWBE)KH/=LA&-HD8E?_'=I_&ODGQWJ4OB?XJ:U=RRI21HQYVH'V M(/P4*/PK[Z "J HP!P .U?GK0017SA^S/K+Z=\7HK$.1'J=I-"R]B57S ?P"'\S7TA\8O\ DCGB M;_KQ;^8KY=_9YADE^.>ANBY6);EW/]T?9Y!G\R!^- 'VO1110!\7_M'?\ELU M/_KA;_\ HI:]_P#V<_\ DB.E?]=KC_T ?M'?\ELU/_KA;_P#HI:V]$\%^ M(Y_V=8O$WA/Q-K\4\$DSW&EPW[I;F%9&#&-%QAAC<'-0MH=:\07,+Q65TL=O;,PQY MQ4DL1[#@9]21V->+?#G5] LOB!:77CJPCU339W*7#7!9O*9CQ*1GYL'J#G@G MC.*^[[2.VBLX8[%(DME0")80 @7'&T#C&/2@"OK>MZ=X=T6YU;6KI+2QM4WR MS/T4=!P.222 .23@5Y;I?QQU;Q9+>2> ?A]?ZW869Q+ MSRD_WB"$S_XYC\* -GX??&;P[\0+I].@6?3-8C!W:?> !FQ][81][&.1P1@\ M8YJS\0/BKIOPWE@_MW1=:GM;@82\LX(WAW<_(2TBD-@9P1R.F<''R=X[U&X\ M.?'37-2TEOL]Q9ZS+/$5XPPD+?D3U'O7V#XGT*R^)'PUGL)5 CU2S6:W=N?* M72/#N@Z_<7.WS'+16ZK%'N"EV)FZ L.F3Z M UU7C?QQ#X$TIM3U'1=5OK", S7-@D3K#D@#<&D5NI'(!'J:^.OASXEN?AI\ M5;6ZU!6@6VN&LM1B/\*%ML@..NTC=CU45]7?$S;XB@T7P9;L)!XANE>Y93G; M9PD2RL".F<(@/^W0!T/A/Q5%XM\.QZU#IFH:9:3#?#_:*1QM*F,B0!7;"GL3 MC/7I@UR0^,*:[J5Y8?#GPY>>+)++B>XBGCMK92!ONJI*X ..@/3CL:\0^#7@CQ+\)]OM+XB>-9_!'AQ[VQT/4-9NV1S'':6SR1Q[1DO*Z@A%&< M\\GG'0D?%OQ'_P"2I^*_^PU>?^CWK[E\9_\ (AZ__P!@VY_]%-0!\=^#?'>I MZC\<].\6:Y;W^L7AG=VMM.@\V5AY;*$CCR. #TST!-?3C?%V*+0+_6+KP/XR MM;;3RAF%SIB1/M8,2ZAI!N5=GS$=-R]N1\O? K_DMWAS_KM)_P"B7K[ADC26 M-HY55T<%65AD,#U!% 'C=C^T[X0U+4+:QL=%\1375U*L,,2V\&7=B JC]]W) M KU.\U>YM=!745T/4;F8J&;3X3"9TSU!S($)'?#'VS7Q/\2_"UQ\-?BG=6E@ M7@BAF6]TZ0'D1EMR$'_9(*Y]5KZNA^)=O=_!9?&MHJO/): );KSF[)\L18Z_ MZT@?3F@"?P%\4+#XB27)T71-:MK:V)26[O88HXA(,?N^)"2V#G ''?&1GMJY M[P'X87P?X'TS1/D2>7&D9*^H)0D'OFNY^//A# MQ/X+^RR1>*?$.L>'KQ3$?[1U!YC'+W1NBD,!D<=B.W-C]F6_\)OXAFTS6-*M M#KQ)FTZ^F!9F 'S(H)(5@ 2" "1N]* //?B/H'PZTI+O7IV,LV1;VD(#2SD=<#(P!W)P!]2!75 MU\1_$GQ,?$GQXN[G4HYKNRL]36S2VA7I;#'!ZEJ />[[XYZOH- MC9:OXI^'FHZ9H-\RB&^6\CE?!&1NBP"I(R<,1FO4M$UO3O$>BVVK:+=)=V5T MF^*5.A'0C'4$'((/(((KQ7XI^-;OQS\-]1\/Z7\._&\5Y<&$POH M [[Q]\7M"\"7]OI30W&JZW=%1#IUF 7RQPNXG[N3T')/I7)ZI^T)<^$_$,6E M^/O UYHAE194>&^CN24)(W8 [= Q/6O%_A#J,_BK]HW2=3UJ3S;B[NKBYD8 MGC>(9'4#/8$ >@%?17Q7^#ME\4?L,SZI)I=[9*R),L(E5T8@D%=R]"."#W/ M6@#O=)U6RUS2;;4]*N%N;.ZC$D,J=&4_R^G:O/M=^--C#XN_X17P;H]QXJUM M2RR0VTRQ0QE>H:5L@8[G&!TSGBH?%4"_![]G6\L=#N97DL;;R(+A^',DTN&< M>F#(S =L#K7AW[/7B>#PMX@UB]D\.Z[KEQ);)&@T>R%RT2ELL6Y& 2%_*@#W M3PW\;+.^\8GPGXOT6X\+ZX7"1P7$RRQ2,?NJ) ,G(QQ@] .<8Y SGBOG'XRP>(_B!XZM-=\.>!O M%MFD-E'"QN=)D23S%D=MPV[NS+SG/%>O?%N\O-0_9^GLK"2YAE0 MHT(FT;1;+58+E8&G+7<4:IM4@$961CGYA MVIWCGXT:1\/-4CLO$>A:XHFW&WN(8H'BG"XR5/F@\9'! //2O!?V7O\ DKDW M_8+F_P#0XZ[C]K7_ )!'AG_KO'9-1T73-8O+PSM;V^E M1VRO&;CQ3 MJ-KN^T,EVEM$FTX;#L"" 2!DX&>F:]1E1I(71'V,RD!P/NGUKX0T+Q#XF^$/ MQ N7A40ZA:.UO>6\ZDI,N02I[D' (8>Q% 'U#I7QI:[\2 MLLB7,B&*- C-O1Q_K,E<< #KSQBO4:\@\+>+_"7QIU#0]1B;^S/$>@7'VK[) M* SE"I#JK<;D.0$_M5:382^!-,U>1$74( M+];>.7;\SQLCLR9],J#[8/K5']D_09[?1=>UV966&\EBMH,C&[RPQ8^XRX'X M&G?%""\^,GQ0LO _AZ3_ (E6AL9=5OE&4BD;@KGH6 !4#^\6[*2/Y)R2>Y)- 'RA^T[K$E_\5ET\N?*TVRCC5,\!GRY M/U(91^ KZ%^"D/D?!?PTA.[-J7SC^\[-_6OF3]HBWDA^..M22#"SQV\B>X\A M%_FIKZ@^#O\ R1SPS_UXK_,T ?''A;5F\.?%/3=1MSY2VFJ*2%''E^9AEP.Q M4D?C7W5V43Q6S.,M(L-=\%ZMI^KQH]I+:R;RZYV$*2''N" 0?45\=_ MG0I]=^,6B^2I\NQD-[,X'W%C&1GZMM'XU](_'/Q;+I'@T^'=&1[G7O$6;*TM MH1N?8W$C8'L=H]S[&K?P=^%\'PV\+E+C9-K-Z ][.O(7'2-3_=7)^I)/I@ Q MOVEM9DTOX/RVT+%3J5Y%:L5.#M^:0_A^[Q^->>?LEQ9U[Q)-G[MM"N/7+,?_ M &6NN_:K@D?X;Z7.HRD6JJ&P.F8I,'Z*/\ KC;?^A24 87[ M52JOQ4T\J "VC1$D#J?.F']*]Q^ NL2:S\%]$>=MTMJKVA/M&Y5!_P!\;17A M_P"U7_R5/3?^P+%_Z/GKU_\ 9MB>/X+V3.N!)=3LI]1OQ_,&@#U>N2^*O_)( M_%'_ &"Y_P#T UUM=837]X\V]!U5LG&] M3P< =0<#.* .*U 3^*_&]XVC6LL\VJ7\CV]NBY=M[D@8_&OO7PMIZ+-;6VE6EKXGL@?/GP6DN(2>'5F) M(]&"X&<''.*]TU2^33-(O+^492U@>9A[*I8_RH X7XB?&?P_\/KR/3)8I]4U MB0 K86@&Y,_=WL>!GL!D\CC%8NH_'#5/"DMG)\0? &H:#8WIQ%)+6ZMW*2PRVD*LC#L09:XW]E#Q)/]NU MOPS+(6@,2W\"$\(0P1\?7-=#35[/2M1L+.8!H'OEB4SKS\RA'8@<=\>V:YMOC!;1^-(_" MDOA#Q,FLR*)!;^3;$;/[^\3E=O!YSCMUKCOV7_&HU7PG=>%KN0&ZTEO-MP3R MT#G)_P"^7)_!E%=OX#A37_%WB/QLRJT=S+_9>FOCK;0,0S ^CR[S]%% &YXT M\=Z#X!T<:AXCN_)20E888UW23,.RKW^IP!GDUPOB'XR>)]!T(:_+\,M0712% M;[5<:C''(JMC!:)5=EZCKCJ*P?V@OA5XM\<^(-,U3PQ$E_!!:_9WM#.L9C;> MS&0;R <@@'G/RBK'BS6XO#?P!G\&>(-774_$\>E%)X;7,[1 '(,A ^557:NY ML9QWS0!W/PW^+.@?$NWF72Q+:W]LH:>RN,;E7.-RD<,N>,]N,@9%!_"VG:7J.CZ5,#YMS>VSV\E\ >0 M@8 B/.,]ST.!P9OV2?\ D*>*/^N-M_Z%)5?]K+_D9O#W_7G+_P"AB@#6^!_Q M%_X1KX9P:=_PAWBS5MMS*_VG2M+\^$Y/0-N'([UW/BKX_:#X,UM]+\0>'_$= MM.!NC8VT.V9,D!T)EY!Q]>Q .14'[-7_ "1FV_Z_)_\ T*G?M#^"!XJ^'$NI M6L.[4=$S /BIIWQ':9]!T;6(K2!BDMW=QPI&KX!V M\2EB<$= ??%,\:?%:R\":G;V>L>'-?F6\D$5I<6<,,L=P_'RK^]#9R<8(!/8 M&O!?V9/&HT3QK/XR\)V MWVN8XZWR>5 QM[C;YD?LVUF&?H35B MBB@#YX_:U_Y!'AG_ *[W'_H*5F?LD_\ (4\4?]<;;_T*2M/]K7_D$>&?^N]Q M_P"@I7 ? CP??>+8_$\>D^(]6T*^M[:(V[Z?=F%)7._:)=HRR@CL1C)H ]S_ M &B-?L-)^$.HV-U,@N]3,<%K"3\SD2*S''H%!.?7 [U\^_L_>'-0UOXM:9>6 MD+_9-+8W%U/CY4&TA1GU8\ ?4]C7%:K/JEIXK9/%R7%_>6-QY=S;WT[L7V-\ MT9;.[!Y&0>^17W#\.+CPQ?>!K&]\$V5O9:;<)O\ (A0*4?HROCJP(P2!7EES\;H=4\33:!\.O#USXNO;=2TTD-REO;J <$B5L@CWQ@\8)J3 M]H7Q)<>'/A%>?8Y#%-J4R6 <=0KAF?'U1&'XUX_^SQXP@\):?KC#PMXCUNXN M98@TNC:>+A8D4-A6.X;222??% 'L_@CXS:9XI\1S^&M8TZX\/>(86*FQNG#! MV'54< 9('."!D@7U_:Z9I\]]J-Q';6MNADEFE;:J*.I)KY#^(=KXN\0_ M%J3QCX7\$^*;/#V\T/VG295D$D2J,D+D=5'>N\_:D\5W,?AS0M!@WP1ZENN[ MI""#A-NQ"#_M,20>ZB@#J%^.UUK<&IWG@/P1?Z_INE@FYO)+I+5< $Y52&9N M!G &['4"M3X;?''P_P#$6_.F1P3:9JNPNEK.P82@#)V..I Y((!QSS@XI?LX M6=N/@E:X0'[5)+?6[FYAM6=K6S: *4+ M*5^:3)W8#'H!VH ]-\2^)])\(Z'-J_B"[2TM(N-S#7E_[4?B2XO_B!:Z") M"+/3+57\L=#+)R6/K\NP#TY]:]"T/XBP1_">QT"S^'WC:YB;1UM4FBT;?#-N MAV[PP?YE8G.0.0G>"_'6B^/?#HU?P]*TBJ=LMNX"RPOC.QAG&??.#ZUP MVO\ [1?ASPOK4VDZ]X>\1V5]!C?$\%N<9&001,01@]0:\Y_9QT;Q=X8^(=Q# MJWA_5[#3;^S9)9+JQEBC#H0R$L5 S]X#/]XUS7[3'_)8YO\ KQ@_D: /J71_ M&,'B#P+;^*-%TO4+R&YC,D5F@B6X8!RIX9PF1@G[W0<9/%>=)^U!X-:^6S?2 M/$$.:ZCX&_\D3\-_P#7!_\ T:]?'WBF)9_BAK,,F=DF ML3JV/0S,* /J#QG^T!;^'&>;1/"^H:YID4OE2ZLI:&T+@X*I+L8.0>.P]":Z MGX,_F!D5LZ_P"';"[\ :AX?CMH MX;%]/>VCB1<+&NPA<>F."/I7QE\&M;GT+XO^'IK=F NKQ+.50>'28^7@^P+ M_4"@#Z ^.WQ8UGPEILND^'=*U"W><^3+K4UJZ01EE)V0N1AGP#R.!@XR1QYK M^SMXT/A1O$C-X=\0ZZUV;8DZ-8_:?*V^;_K/F&,[N/7#>E>D?M5_\DLTW_L- M1?\ HB>N:_9&_P"9N_[_:MT;4+SPOHFJVJL]EI]Q*ET%&=ID"!'/L"I&?5AZUQWPD_:%D\,V5KX> M\91-%[J*YTG4KR2_MO(QLC60+\B MD'D J<=,=,<5U- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9MOH&G6WB" M\UM( =1O(TBDG)?'C5+[Q5=:=\,?"B?:=3U&1+B_QG;;PJ$_#^HZK +B%TM]32)N$9S'E=R]P"^<'N!Z5 MT$L4<\+PSQK)%(I5T=ZW>,IDC39:PD\S3$?(@_'D^@!/:@#XOUOPJMU\8M0\+>'ERCZQ) M9VP52?+7S2H_!1U/H,U]B?$_4V\-?"'7[NU=D>&P:&)P>59\1J?J"P-<'\"/ MA5-C^@- 'SO^S9#YOQHLGSCRK6=\8Z_)M_]FKT/]K55.E^&'*C<)K@!L<@% M8\_R'Y5P/[,__)8X?^O&?^0KT#]K7_D$>&?^N]Q_Z"E &I^RMK$EYX U/2Y7 M+?V??;HP?X4D4''_ 'TK'\:]SKYZ_9+B<:#XDF*_NWN855O4A6)'_CP_.OH6 M@ K\W*_2.OS)_!?V62+Q3XAUCP]>*8C_:.H/,8Y>Z-T4A@,CCL1 MVYL?LRW_ (3?Q#-IFL:5:'7B3-IU],"S, /F1020K D$ $C=Z4 >X?!;P[? M>%_A)HVG:M&T-WM>>2)A@Q^8[.%([$ C(['(J]X_^).@?#G2X[K7IG::?(MK M2 !I9B.N < 9&2<#\<"NMKX5^,GB2X\3_%C6YYY"T5IM/#L7B?4?AO?P>&Y=K+?KJ$;OL8@*QBV@@'(P2<'(YYKT/P; MXWT/QYH8U3P[=>=$#MEB<;9(&_NNO8_F#V)K/\<6,=M\$]?LVB"I;Z!.@3J% M*0-C\B!^5?,/[.GB.?1/BY9V2NPM=6C>VG3/!(4LAQZAEQ]&- 'NWB7]H7P[ MX1UV?2->T#Q':W<)Z-;0[77LZGS>5..#73> /B38_$:VFN]%T?5K:QB)0WEZ MD*1LXQ\@"R,Q.&SG&..N< \/^TOX(&O>!X_$5G%NOM%.9"HY>W8_,/\ @)PW ML-WK7#?LM>-18ZY?>$+R0+%?@W5IN/\ RV48=1[L@S_P"@#V7Q3\6K/PCXBM M-&U3PQXADN+^4QV+6T,$B79! ^0^=G^(<$ C(R!73:OXHTWP]X8.N^(I#I5J MD:O(EQ@O&Q'^KPA8,^>,*3ST)ZUS$$*>*OC5+?,JO9^$;4VL+$=;RX :0@_[ M,00?5ZQOC_\ #_Q!X^\+Z=#X9V3RV5RTLEF\HC\[*X!!8AC>(OCAI?A33K"^U[PMX MHL[>_0F)I;*)-K G*,#*"K<9P>HY%)X,^.FA^/==72O#F@Z]-, 'EDDB@1(4 MW %V)FZ#/0 GT!KI_B)X0@\<^!-2T.8+YLT9>V=O^6OC[X4> M+)OAU\5+2XU &W@,C6.HH_&Q&8!B?]U@&_X#0!]>>.O'UOX TTZEJFBZM>:< M@7S;NQ2%TB+-M 8-(K#)(YQCD,X/'3&">9^),:>);S0?!*A98M7NA=WXQD"SMV61L^FY_+4'W-=^ M%4!1@#@ =J "O+OVC/\ DB.J_P#7:W_]'+7J->7?M&?\D1U7_KM;_P#HY: / M /V2X MNI0N5&?+7/S.?0 (H YOQ5\9M,T;Q5 M'X6\.:;<>)?$,CE#9VCJB1L.JO(<@$ $G@X .<54TGXW01^,E\+>//#]QX4U M27;Y/G7"SPON^[^\4 <] >1D$9%>!_ 7Q+'X?^(%]JEUHNMZ_=-8N$CTJU^T MRJ6D3=(P)!QVW9_B]ZW_ (WG7/B5KNF7^@^ O%MN+6V:&4WFCR*S?-D8V[N. M3^= 'U@3@9/ KRV[^-UOJ'BB?P]\/O#]SXLU"W5FE:&X2W@ 4X.)&SG!P,XP M<\$UA?$'QCK6B_LPV%QJ$=S9ZSJ4$.FS>?&T'O$>DW'AW4C.;8"682Q"4- MMV,V%*G/'3&>]>LZAJ%II6GSW^I7$=K:6Z&26:5MJHH[DUY%XB_9STC7_B,_ MB?\ MFXMH+BY%SZN M0.-X3 0?3+,<>H'I0!U5M\;]0\1F_N/A_P"!-1\0Z;IYQ->-=);;N,_(A!+G M'.T?-R,@9KI?AS\5=!^)-G*=+\RUO[<9N+&XQO09QN!'#+GN.G<#(KS#X*_$ M.#PS\+;#3X/!/B[4W\V:2:[TS2A-!*QD;[K[AG"A0>.H(KB_A]I'B_2/CU;: M[!X3U^QTV\U*19#<:;,BI!,Q'S_+@ !@>N 5SGC- 'MWC/XXZ-X!UK^S?$?A M_7X7;C>=T[X.",C(%=!X%^(FF?$+PQ=ZWH%E?B*VG>W,%PD M:22.J*^%PY7D. "6'/7 YKQ']K;_ )"GA?\ ZXW/_H4==;^RI_R2S4O^PU+_ M .B(* +FK_M*>%M!U>YTO5]!\1VM[:OLFA>W@RI_";!^HJUXC^/%CIVBPZAX M:\.ZIX@!M8[JY,*%8K%717"S2J'57VL,@9QZU\^?M!_\EV\0_P#;M_Z315]5 M_"S2[*P^$?AJWM+>..*?2X)Y5"\.\D8=R?7)8T 8/PU^.>@?$2]_LP02Z5JQ M4LEK.X=90!D['&-Q YP0#CGG!Q>^*_Q$O? 7AV2;2-"OM3O6C+B9;5VM;96^BZO*L&"?^64Q 'TPN/I7V-\7)5G^ M"OB*5 0LFGE@#UP<&@#YE^$7C6^MOC#+XCU:QU?Q!>7,,QFCTVW\^=V;'.S( M^4>W & *^J-+\?V5[X6U'7]5TK6/#MGIVXS+K5G]GD*A0=RKD[AS@>IXKYB_ M9G_Y+'#_ ->,_P#(5] _'G1=0USX.ZM;Z2C2S1&.X>%!DR(CAF '? &[_@- M&/I'QKUWQ1!:>NDB!9/MN%D:1_,#*4&=NTQ]@QS\S?";XUZE\-V.GW4']H: M'+)O>W!Q)"QQEHS_ .RG@^W)KZ:\!IX8UW7-4\<^$+Y)H]:AABNX53:4FCW9 M+#JK$,H(QVSDYH [JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ JEK.L6&@:-=:KJ]PEM96D9DEE<\*/Z MDG@#J20*NUR/Q ^'6G_$?3[>PUG5-4M+.!S(8+&6-%E;L7W(V<CV\E\(DLD[OM\MLR-@$MGCH.@-;^H_M:7LVGS1 MZ9X3BM+IE(CGEOS,J''!V>6N<>F:Z[_AE3P1_P!!7Q!_X$0?_&:D@_99\#P7 M$& M_&>I0ZI?1W-CJT CU+3IC!.N.GS<@D=B0<4 >&_M6S"X\9^'[&!C+<)9LWD MKDD;Y,+QZG:?RKV_X1>$9?!7PQTO2KR/R[TJ;BZ7NLCG<5/NHPO_ &H?#?P M@\->'=>_MV9]0US6/X=0UFY^TRICH0< 9'0'&1ZUV.I63:CI=S9K=W%F;B-H M_M%LRB6/(QE2P(!]\&@#Y[^.WQCL3JR^#M/22^TZ&4?VS]FN?)-QC_EV63:V MT9QO(&?X>.:J6/[55KIFGP6.G> 8[:UMT$<4,6J;511T 'DUUK?LK>"78LVK M>(68G))N8>?_ "#2?\,J>"/^@KX@_P# B#_XS0!M?!3QGK'Q$77_ !/JH-O: MM<1V=I91N3' (T+,1GJS>:,MCG '0 5X%\?O!USX3^*5WJ,$;)8ZO(;VWF4< M"0G,BY]0^3]&%?5W@?P3IG@#PRFAZ(]Q);K*\IDN65I'9CR254#T'3H!5WQ) MX8T?Q=HTFE>(;&.]M)#G8^05;LRL.5//44 <9\:]4MI/@+K5Y%.!%>6T/DL# M]_?(F ,>H/Y5YA^ROX.N/MVI>+KN%DMQ$;.S9A_K&)!D8?3:!GW([5Z,GP \ M+LMO;:AJOB+4M+M6#0:5>:D6M8R/[J!01Z=>]>E65E:Z;8PV>GV\5M;0($BA MB0*J*.@ '04 3T453U2RGU"Q:WMM2NM,D8@_:+18C(!Z#S$=>?IF@#XY_:,9 M6^-VJ!6!*PVX8 ]#Y2G^1%?0'[.@S\$=+!Y'G7'_ *-:L_5?V:?"VN:K<:EJ MVO\ B2[O+E]\LTMU 6<_]^?PQV%=-X.^%<'@6%+;0/%/B%+%9A*UE/);21/R M"1S#E0<<[2IZ\@\T ?.'QZ^&/_""^*O[2TJ';H>J.6A"CY;>7JT7L.Z^V1_# M7I_[-WQ/&JZ4/!FM3_Z;9)G3W<\S0CK']5[?[/\ NU[%XM\*:9XU\,W6AZY& M[6MP!\T9 >-@RU3PH_A_Q%)-KEM*A262^">9(,Y!)C50".,$ ' M@'KS7G.E_ [5_";W<7@'XA:AHEC>',MM-8QW//3(8E=IQQN STYXH ^)/CAKMAH\9N+B\UF:"%5&=S>85_+(Z^G-?<>F62:9I-I81'*6L"0J?95 ' M\JX7X>_!?P[X O'U.-Y]5UB0'=?W>"4S][8H^[GN3D\GG!Q7;ZIK.F:):BYU MK4;33X&8();N=8E+'MEB!F@#Y7_:;\%?V)XU@\26<6VTUE<3%1PMP@ /TW+@ M^Y#5Z5^SO#JFNZ$OBGQ _FO;VBZ/IK$Y+%5S_P!,JZ3XX6%AKWPH MGM)!]HN+NXMTTL1,"9+EW"Q[3T((9L_[.:['PKX?M_"OA/3=#L\&*QMUBW 8 MWL!\S?4MD_C0!1^(/BZ/P-X$U+Q!)$)VM8P(HB%[[0=7 M5C:7D>URAPRD$%6!]00"/I7DOA/]F>R\->(EU.3Q9J^W;0!XC\>KF"[^.'B*6UE65 \,99#D;E@C5A]0P(^HKZR^%7_)(_"__8+@ M_P#0!7$_$']G31?&>K1:CI.HG09EB6*2..U$L;A1@';N4AL<$Y.<>O-=GX2^ M'Z^$/!3:!9>(-7D=E %Z\P=X1Z1(X9(U]@IZ^N" #XP^(_\ R5/Q7_V&KS_T M>]?9X#UT1_,6TVXV[><_NFKS"Y_9=\&W=U+I->J:#H1T311ID^J7VKQ+\JR:B8V<)@#82B*&''\0)Y/., 'QA\#&" M_&WPX6( \^09)[F)P*^X$GBDFDA25&EBQYB!@63/3([9KPS4_P!EW3'\3#4_ M#?B:\T6$2^:D"0>8\+9S^[D#J5QVR"1ZFO6/#?AS3/ _A^2%+J5QDW%[J-_/ MNEG? S))(?8 >@ H \R_::\%?VYX'B\16<6Z\T5LRE1RUNQ ;_ODX;V&ZO./ MV=(=4\2:VFB3OO\ #^D7:ZQ(C#/^D!2D:_3<0^/6.OIU]2T+7?#-Y<+?V=_H M\D,B7$T,RR1&/:=X+*2.F&/AY]MBCD5]:F:\4R@;Q!TA!Q_L?- M]7- 'J-%%% ",RHI9R%51DDG K\W:_03Q/X7F\36SVI\1:QI5K)$8I8=.:% M/,!SDEVB9P<''# 5YC_PRIX(_P"@KX@_\"(/_C- 'J_B?PWI_B[PU>:)K$?F M6MW'M;'5#U#+Z$'!'TKX5\1:'K/PV\>2V,LKV^H:9.)+>YC&-X!RDJ^QX/Y@ M]#7W'X<\-W'AV%8'\1ZQJT"1"..+46@?9C&#O2)7)P,?,QK#^(?PD\.?$J2S MFUUKNWN;,%$N+)T1V0\[6W*P(SR..,GU- $_PN^(%I\1?!D&IQ%8[Z("*^MP M?]5*!R0/[K=1[''4&OD/XI:3>>%/C!KB-NBD&H/>6SXZH[>8A![XSCZ@U].^ M%?@-HW@K4S?^&O$WB2RF8!9 MQ R2J#G#*82#^/2MKXC?"GP_P#$JTB_M99+ M:^MUVP7UO@2(N<[3GAESV/3)P1DT ;G@_P 4V'C/PI8ZWI],FU#3O%*:_X>LY6D>WA^RW4JKF-'E1@4#=V48+#MN7UKRCP[^S M9<>'[R3[/\0M8M[.8XF@TU#:M(OHS"0@\?[->QZ!X?TWPQHL.E:+;"WM(230!\*>'-0O/AY\3+*[OX7BN-'OP+F''S85MLB_BNX?C7WII MVH6FK:;;ZAITZ7%KZMU#"4 M#@;T/WB!QD$'MDX%87A3]GJP&T:1VPB2;@R$GMR"N?\ :K[%L;&UTS3X+'3K>.VM;=!'%#$NU44= !7C M?C+]F3P[XBU6;4-"U&709)VWR0I )H0Q/)5,J5SZ9QZ 4 >Q:IJ=EHNEW.I: MI<);6=K&9)99#@*H_P ].]>M)X2^"-OHDEH_B;Q-JWB=;%@]I:7?#ZU^(. MGKI^K:SJUII_!>TL9(D25@'_"6LQZKX=\1>([&]C4J)4GMVR#U!#0 MD$>Q%X_P#04H O_LH2(? FM1AU+KJ6XKGD Q)@X]\'\C7" M?M57<#2U+^Q:20X_( _C6W^SKX2.M>"=3U'2]5N]$UBWU!HHKZ MT"MN0QH=DD;@K(N>0#T/0C)SV5A^SM9W?BY_$/CSQ'<^)[IY!(T;VRV\*4ENP]WM/99&)3\UVG\:^2/$Q$7 MQ6U";?5Y8A8:J@:$W-NP>6TE4X:)S@;U!Y (&0IRQ+#)?W\I=Q&O2- 2=B9YQG\>!CD-(^!%UX7N)KWP?X[U72 M;^X=FG8V\_3- 'SE<>'-?^&GQ@LM+60-J=I>PM;2P9VS! MB-I'?# X(^HK[LKS+PQ\%[73?&A\7>*]FT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !7DOQS^+2> ]#_ +)T:93K M]^AV;3DVD9X,I'KU"CUY[8/K5>0ZY^S?X7\1:Y=ZMJ^N>(KB\NY#)+(US#U] M!^YX ' '8 "@#R_PC^T7I7@K0(]*T7P(50'?--)JV9+B0_>D=O)Y8_\ UAP* M[SX:?%O6/BO\3H84LO['TG2[.6YEMXK@R>?(=L:AVPN0-Y(7&,C/4#$O_#*G M@C_H*^(/_ B#_P",UV?P[^$GA_X9SW\VA7%_#)Y)=.\8643/%'']CO2HSL^8F-C[$LRD_[H[UZ5\#M5MY/@5H MMU+.!':0S).SG_5[)'SG_@(!^F*]"N[2WO[.:TO8([BWG0QRQ2*&5U(P00>H MKS63X ^&%%S!INJ^(=+TV[8M<:79:D4MI<]F0@DC\: /GGX#>#[GQ;\4[&ZD MB:2QTJ07MU*W0,IS&/,?%NF>"/#%SK>M2[((1A(P?FF<_=11 MW)_09/0&I?#/A71?!^CIIGAVPBLK53N(3EG;^\S'EC[FN:^(/PDTCXDW=K+K MVK:Q#%:H5BM;2:-(@3U?#1L2QX&<]!]: /GW0?C]#IWBW4/%.L^%?[6UN[)C MAN'U#RUL[?\ AAB3RCM'JF],S1 M%V"Y4!%PW/!SQUKL/^&5/!'_ $%?$'_@1!_\9K1\/?LW>#O#GB.PUFUOM9GG ML)UN(H[B>)HRZG*D@1@\'!ZCI0!U/Q1\'-XQ^%^I:';%GNA"LEJ7;+-+&0R@ MD_WL;2?]JO#?V5;C[%XX\0:7=;X;E[-6,,@VD&.3# @\Y&_I]:^I:X;Q-\(O M#?B771KBO?Z-K/\ %J.D7)MYFXQR<$$XXSC/O0!\^_M(1RZU\;K?3=,5KJ[^ MQ6]LL$?+>8S,P7\0X/XU].>!?#:^$/ >CZ$-I>RME24KT:0_,Y'U8L:RO"7P MI\->#]4EU6UCNM1U>;._4]3F\^X.>#AB 3W( )KM* "N1^*[!?A'XH+$ ?V M9,,D]RI KKJX_P 9_#Q/'%O<6>J^)M=M]-G*[K"S>WCBX XR82[ D9PS$9]L M"@#XZ^%'_)7?"_\ V$H?_0A7V+\3_ %I\1/!=QI4VV.\CS-97!'^JE XS_LG MH?8YZ@5P]K^R_P"#[&\AN[/6_$<%Q XDBECNH0R,#D$'R>"#7J^C:7VU'3+@QSV[G&X X M>-O8C(_4=J^WM*U?3/B)X!^V:9+NL]5M'B.3\T992K*V.A!)!^E/&J2FQEC02XZ,P9&^;&!GC@"K7@?X0Z?\/KDMX>\1:^+9WW MS64\T+PRG&,E?*!!QCE2#P.: /EGX=VEQX6^/&B6&KQ^3<6FK+:RJQP Q;9G M/IDY'K7T3^TU/'%\'9$=L--?P(@]3\S?R4UL?$+X+^'_ !_?)JCRSZ5K$8&V M^L\ OC[N]>Y'8@@\#GBL34_@=JWBR2SC\?\ Q!O]O/- '#?LH>';C^TM;\22Q,MNL*V,,A'#L6#N!]-J9_WA7O\ XQ\-6WC# MP?J6@WH41WL!17(SY;]4?ZJP!_"K>B:)IOAS1K?2M$M([.RMEVQQ1]![D]23 MU)/)-$&NZ3=:K-IEMJEE-J%N,S6D=PC2Q_[R Y'XB@#X:\'R>)_"WQ'&F:&# M;ZW)+)I31L#@,^8SG']UL-GL5!K[C\/Z+;>'/#FGZ-8#%O8VZ0(<8+;1C)]S MU/N:\TTWP;I>I?M,:MXDLX\KI5E$+@D94WLBDN4 ?.W[1'Q;UC M0]7'A'PUJ2Z3J*QB&200"9)5&<97< MO(SC.>G:KGACX)Z#H/A.?0M1O;_68IXI(LW4Q\N#>"&,,>=L;')^89;GK0!\ M[_LX_P#);-,_ZX7'_HIJ]M_:@_Y)%'_V$H?_ $%ZSO#?[,=GX>\51:JGB[4O M)@_"O3_ (BK!#KNMZU%90,'CLK66)8@ MX!&\[HV8M@GDD]3C&: /'/V2B/[5\3C//DV_'_ I*@_:S!_X27PZV#@VDH!_ MX&*]4\'_ +T7P)K']I>&_$/B"WE8!94::!DF0$':RF'IQVP1V(K<^)'PRT; MXEZ/#::LTEMPY% ')?LX75O;_!..:XGCBBANYS* M[N%5!D'DGIP<\UZ\Z+)&R2*'1@0RL,@CT->/>!?V?+7PG]@Y&!C/H,YKU.[UW2+#4;?3[[5+*VO;K_46TUPB22_[JDY M;\* /B+XB^&KKX9_%:ZM=/9[=;:X6\TV4=HR=R$9Z[2"OU4U]=?"[3+RU\'K MJNM*HU?7IFU.] 7&QI,%$YY 5 BX[8-">6>Z &1 M]BCPSA_J^Q1_OM7K8&!@<"@ HHILBEXF57:,LI =<97W&01GZB@#YX_:U91I M?AA"PW&:X(7/) 6//\Q^=9W[)/\ R%/%'_7&V_\ 0I*]*\4_ G2?&M[%=^*/ M%'B6_EA4K%NFMD5 3DX58 HS].P]*;X7^ NC^"]0>]\,>)_$MA/(FQRD]NRN M,YP5: J?Q% ''?M*?# 7]B?&^BP?Z5;*%U*-%YDB' E^J]#_ +./[M>>_L__ M !.'@OQ0=&U>?9HFJ. S,?EMYNBR>P/"M^![5]?1VH_L];2[D:]'E"*62=5S M-Q@E@H"Y/< <\ #BO';C]EGP-/=2RI?ZY LCEA%'<1;4!.=HS$3@=.23[T M:/[1^ASZW\'YYK1#(VFW4=\RKSE &1C^ D)^@->2_LP>,+30_%^H:%J,ZP)K M$@QCG/E7B7]EG0M3U22[\.ZW<:(DCES;M;B=$]D^92!]2: /9=?U MZP\-:)/JFJR%((1]U1EY&/"HB_Q,QP .Y->"_M6Z!<7&GZ#XA@C=H(#):W!V MGY-^&0GTZ,/KCUKT;P?\(;;P_>6NH>(?$&J^*+^RYM&U&=FAMC_>CC+'!]R3 MCMBNYU?2+#7M(N=+U>V2ZLKI-DL,@X8?T(/(/4$ T >"?LL>,K9])U#PC=S! M;J.8WEHK'_6(P =5_P!TC=C_ &B>QKWN^U:QTR6TBOKE8I;V806\9R6E 23T !)P*\-O?V5K!-86\\.^++W2XTDWHC6XEDCYXVR!T(QV.":]-\'_# M>Q\+7(U&]U+4O$&L[#&-2U6X::2-3U6,'[@/MR?6@#YU_:@T.XL/B=#JK(?L MVIV:%).V^/Y&7Z@;#_P*O;?@%XPM/$WPMTZS6=3?Z1$+.YAW?,JKQ&V/0H!S MTR".U=?XR\%:+X[\/OI'B"W\V$G?'(AQ)"_9D;L?T/0UY!8?LOR:/K(O=$\? M:CIRC(!MK?RYMOIYBR#_ -!H ]LDU^P3Q-#H(D:34);=[DQQKN\J-2!N<_PY M)P,]<'TKY*_:8_Y+'-_UXP?R-?4OA/P3IG@ZPGATV2YGN[HAKK4+N7S;BX8# M 9W/7'88P/3K7"Z_^SIX<\4:U-JVO>(?$=[?3XWRO/;C.!@ 0@ 8'0"@#=^ M!O\ R1/PW_UP?_T:]?'_ (E94^*FK.[!576IB6)P //-?:W@;P);^ M+_LS3 M=9U6]L$!\FVOWB=826+$J5C5N23P21[5\4^)55_BIJR.H96UJ8%2,@CSS0!] MWZY>0V7AK4;V9P((+269FSQM"$DY^@KXD^#6ASZ]\7_#T-NK$6MXE[*P'"I" M?,R?8E0/J17TUXF^$&J:MH\NA:'XYU#2?#\W#:9):I<*BY_U:2$JZI_LDD=N MG%;7PX^%.@_#6SE&E>9=7UP )[VXQO<#G: .%7/./S)P* .*_:J4GX5Z>0"0 MNLQ$X'3]S-7,?LCLH;QXA>VST61U?S /P6,X]_> MOH*L+P=X.TCP+X]FV3:C<9CL;0GF5_P"\>^Q> MI/T'4BOGOP5^T!:^$(;NXD\)/J>M:C(9M0U2;4PLER_H!Y)V(.RC@5[;XU^! M/A_Q[XCDUG7M9UTSLH1(H9XECA0?PH#$2!U/4\DUS_\ PRIX(_Z"OB#_ ,"( M/_C- &'H7QXUCXF^._#_ (;TK2CH=O->I-=RQW9EDECBS*R!@J[5(3!ZY''0 MFNE_:4\&3^)/ ,&K:?"TUWHDC2LBC),#@"3'T*JWT!K9\#? GPOX \2KKFD7 M>J7-TD3Q(MY+&R+NX) 6-3G''7N:]+(R,'D4 >'?LJ7J2_#C5+/S-TMOJC.4 MS]U'BCQ^95J\9U;P[/\ $/\ :+U;2M,+3QW.KR^=,O2.%7P[Y] <>O '45] M(7OP.\,R:M<:AH=]K7AJ6Z_X^%T.^-NDOL5P0!ST&!71>#/A]X<\!6+V_ARP M$+S?ZZYD;?--Z;F/;V&![4 ;=S=66BZ3)K'5?B6-=U'PZ^L:;IAVZ-9R7?DI$V>9W78VYS@8Z!>.I&:^C_'G@2R^(.AI MI.JZEJ5G9B0221V$J)YQ'0/N1L@'G''//85YU_PRIX(_Z"OB#_P(@_\ C- ' M*W7[6UP]K(MEX.CAG*D))+J)D53ZE1&N?ID5['X;TFY\2_!>UT_Q)#OVBK31M;5K:Y0W%HZG@,WEL5Z]0V 0>^178_M; M7*-<>%+1),R*MU(\8/0$Q!3_ ..M^1KV;QG\,O#?CF:"ZU>WEAU"VQY&H61D'':L[1/@UX:TKQ FN:C/JGB+5(L>5=ZY=_:7BQTQP!QVR#C MM0!!\"O!T_@WX6V=O?PF&_OG:]N8VZH7P%4^X15R.QS7HU%% ",RHI9R%51D MDG K\W:_03Q/X7F\36SVI\1:QI5K)$8I8=.:%/,!SDEVB9P<''# 5YC_P , MJ>"/^@KX@_\ B#_ .,T >K^)_#>G^+O#5YHFL1^9:W<>UL=4/4,OH0<$?2O MA7Q%H>L_#;QY+8RRO;ZAIDXDM[F,8W@'*2K['@_F#T-?'85@?Q'K M&K0)$(XXM1:!]F,8.](EYLP42XLG1'9#S MM;N"2OU4U]->%?@-HW@K4S?\ AKQ- MXDLIF 60+<0,DJ@YPRF$@_CTKH_B!\-/#_Q'TR.VUV)TG@R;>\@(66'/4 D$ M%3W!X_'F@ ^(%_#-\&O$5[N BN-#N&0@Y'SPD+S]6%?+O[.WAVYUKXNV-Y'& MQM=*1[F>3'"G:509]2Q!QZ*?2O;)O@=X@O/#D?AF_P#B5?3>'(]JK8C3HU?8 MI!53+N)(&!@$8&!QQ7H7@OP-H7@'0QIGAVU,4;'=--(=TL[8QN=NY]A@#L!0 M!NW=K!?61+-;W$;12QN,AU88(/L0:^$?$.F:E\*OBO+!:.ZW&DWBS6DA MS^\CSN0^X*D CZBON2;7=)M]7BTJ?5+*+49EW1V;W""9QZA"=Q'![5YEX^\& MZ5XN^.GA &/?=6%O)>ZA@97[/&X,(;ZREA]-WI0!VOP\T*YT'P9;)J>#JEZ[ MW^HMC&;B8[W'X9"_117"_M ?%+4/ 6C66F^'V$6IZH'/VD@'[/$N 2 ?XB6X M/;![XKV&N"^*7PGTWXH:?:I=7DNGWUD6^SW4:!P V,JRDC<. >H/'7K0!Y[\ M ])TZ/X>:YX[UNZ%SJUTTZ3WUT^YH8T7D%B2E?5OP\^!FE^!HI!>:O>ZSYCB1K>0F*T+#HQ@#$,P]6)Q@8Q7+3?LL:8 MOB@:CI?B>]T^S6;SH[>* >="0)_ -OXH\+0^'KG7-:M-/6/RYA;W*-)=# MC'F22H[GIV(SDYSQCB]%_9N\,>'M8M]5T77_ !':7ULQ:*9+B#*D@@]8<'() M&#ZT 4OVJE)^%>GD D+K,1.!T_>!CJ,8.*\G\/?LRP:%K$LW_ F> MJ&PF&R6UM$-LTT>?N/(KGW%Q,D,8 &%1=Q Z#I7#?';2K+Q%\-8]/8"6_O+^WBTK8?O7#M@'/IL+D^ MV30!E?L_0ZIK?AW_ (2[Q$_FW$MM'I=B[#D6T!.3GN6D+9]=@KV&L[P_HMMX M<\.:?HU@,6]C;I AQ@MM&,GW/4^YK1H *\M_:-8+\$M3!(!:>W !/4^:I_I7 MJ5<#XS^$]KX]4P^(?%'B&2S$QFCLX9+>.*,\X ARV < L6/N: /FW]G'_DM MFF?]<+C_ -%-7T'\AQZFLS1_P!F MWPQX?U:#4]&\0>)+.]MVW1317, *G&#_ ,L>002".X->JZ993V%BL%UJ5UJ< M@)/VB[6(.1Z?NT1>/IF@#X9^&7CR\^''CB#4U$C6K'R;^V''F1$\\'^)3R/< M8[FOK[QY:)XZ^#NKQZ#(MVNH:>9K1HSD2D .@'U*@?C7-^)_V=/!GBGQ)>:U M<3ZI93WC^9+%931K&7[L T;$$GD\]2:Z3P+\-K7X?PBUT?Q!K=SIXW$6-[+# M)$I)R2,1!EYYX(&2<@T ?*GP,\76W@SXJ65UJRN)6.!&'P5)]MZI MDGH,GM7VO=7MM96,M[=W$<-K#&9))I& 15 R6)Z8Q7D?CO\ 9P\.^+M8GU72 M[Z70[RX8O,L4(EA=CU;9E<$]\''M5CPK\!;?2(X(?$WBK5O$=E;,&ATV:1HK M,$'(S%O;.,#C./4&@"'XZ69\<_ <:OI$,[);O%JD</KC2=1F6&VUJ)8D=C@>>A)C!^H9P/,HRJR$8*D<$ M>F*\.\5?LN>']9U26\\/:M-H:RL6:V\@3Q*3UV#V3CM@<4 >T:IJMCHF MF3ZCJMS':VD"[I)9#P/\23P .2>!7SW^U?HD\UKX>U^%&:VC\RUF)4C86PR9 M';.'_(5Z/X2^#EKH*9[-@]JFHSL;>W8=&2(L0".Q)..V*[G7- M#T[Q)HMSI.M6J75E=)LEB?OZ$'L0>01R"* /$_V7/&%I=>%+OPK<3JM]9SM< M6\3-@R0O@G:.^&SG_>%>T:IX@L-(OM.LKN0FZU*?R+6",;G/M:_M+Q'X@U^9UW+##'- D<"$YV(OD].V3DG MR36EX!^%.G_#F21= US6I+29B\ME=20O$[XQNXB# \#H1G SF@#Y?_:#_P"2 M[>(?^W;_ -)HJ^M/AK(DGPJ\*M&RN!H]HI*G/(A4$?@017R7^T'_ ,EV\0_] MNW_I-%7O/AKX=:G=_"W0CX/\87WAE=1TBUDN[>.!+B%G:%2[HK8:-F)))5AD MG.,Y- 'S3K]G+XL^,6JVFE#S)-5UR=8,IP# M_0U]3^+?&%EX2\-W.MW&RXMK*YAANQ'(,PB21$)( /*B0-MXR/3->3)^R[:V M'B9-3T#QCJ6EPQN6C2&+_2(\@@A9@XQP<9V]/6O1M8^&6E:C\,+CP3:3S6EI M<%&DN6/FS.PE65G8G[S,5Y)]>F!B@#@_B?\ #2/&-O+X@\%/#9:G,GG^5'C M[/>9&NM1M_BE=V,/F"UEL)#=Q$' *,NUB.Q!./^!& MO8+7X.^(=!TQ])\(?$O5M-TI@5%OE&6YO+K'VF]GQODQT X5>>GYDT =K1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7CO[0'PPU[X@Z? MI5SX:9)[C33*&LI)0GFA]O*D_+D;<,HTT-_B$MI;6 M?AR%DTO3H&#L92"OG2L"5)520N#WS@8Y]BHHH **** "BBB@ HHHH *Y+XH> M$[OQO\.=3T'3KE;:ZN%1HF#''L8[0X !) ./R/TE%$D,*10HJ1HH5548"@< M"G44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X/\??"/C;XA M7FFV/ASPM-)9Z:\K-=RWML@G9PH&U3)D ;3]X G/08Y]XHH \0^ WASQG\/[ M*]T;Q)X4N4M[VZ69+N"\M76(E0K;U\W=C !^4$^U>WT44 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %?+MG\'/B;X-^+)U[PM;6.HA9YGAOK MJY7R]LBLI,B%@Y.'[ \^M?45% '/>"/##>%?#@M;NY^VZE;,M?^)#^*/"D2:C'<"$B% MKA(VMVC4+QO(!4[0W!SDGBOHZB@#B? ?AO7K>^OO$WCJ6TE\0ZBB0^59@^39 MVZ9*Q(3DG+$L3D\XY.,UVU%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 5-3N[BQTV:XLM/GU*= -EK \:/(2<<&1E48SDY/0'&3@'Y U/X)_ M%+4?$UYK"^%1%);Q=X2MX=526ZBNXQ)<)&T#IMPKAV M7*@KQM/3TKV3P%X9U;2EU#6O%UQ;W7B+5W5[IK8$101H,1PIGG:H)/N2>O4] MA10 4444 %%%% !1110 4444 >+?M _"SQ!X_32K_P ,^7M/LNDZ=;L'*,5VF:5@2"^P; M1@XY/ [^MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R:1H MK>21(GF9%++%&0&<@?=&X@9/3D@>]/HH ^3/B1\*/B3XX^(>J^(K;P@]M#>. MGEQ2:A:E@J1J@SB7&2$S^-?0/PR;7;/P7I>B^)/#]SI5SIEE%;&5[B"6*;8H M0;3'(S9P 3D#ZFNRHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH X75?C/X'T*=8-;U*]TV5QE8[S2+R) MF'J T0JA_P -!_#'_H9O_)"Y_P#C=V6?QU^&U]*(X/%-NK$XS/!-"/S= *[JTO+;4+ M..[L+B*YMIEW1S0N'1QZAAP17S_^T[X'T6V\+VOBC3[*&TU!;Q;>=H4">>C* MQRP'5@5'/7!/M7,?LN^*]0M?&ESX9:5Y-.O;=YUB))$4J8.X>F1D'U^7TH ^ MK:*** "BBB@!&8*I8YP!DX&3^0KA=4^-/@71+@6^M:I>:=,PR([O2+R)B/7# M1 UW=?/_ .UE&A\,>'I2H,BWDBJV.0"@R/T'Y4 =O_PT'\,?^AF_\D+G_P"- MUL:+\6_ ?B"X2#3/$]B\TAPDUCM$U:*7SH85"IYD97+@#H2)!GZ9[F@#ZTHKPO\ M9A\;:AKWAO4= U6:2X.D&-K::1MS")]P\O/HI3CV;'0"O=* "BBB@ HHHH * M*** .?\ %'CC0?!L0E\1W%U:0%0WGK83RQ+DX +QHRJ<]B0:R_#GQ=\#^+=; MBTCP]K?VN^E5F2+[)/'D*,GET Z#UI/C'S\&_$V?^?%OYBOF3]G'_DMFF?\ M7"X_]%-0!]H4444 %%%% !1110 445XU\1OBRMO\2O#/@GPY='SY-9LQJD\+ MXV(9E_<9'G'<@ 'LM%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% &+XA\6Z3X6B$NM->10["[3 M0Z?<3QH!UW/&C!?Q(KD/^&@_AC_T,W_DA<__ !NO22 RD,,@\$'O7YR:@BQ: MG=1QC:B3.J@=@": /M-?V@?ABS!1XF&2<*/4H<,![XHU#POHOBKPS%8:_IT%[!+;JI\Q 67Y>JMU4CL17PI< M27O@SQO<_P!D7LD-UI-])'#[5FA'V>67>%Q MG[BG'4=:Z:O-O'7P^@\<_%#PQ)K%JT^D:;:7,\X*GRY9-T02-C[\MCN%(H / M^&@_AC_T,W_DA<__ !NC_AH/X8_]#-_Y(7/_ ,;KH/'UK;V7PC\406<$=O"F MBW86.) JJ/(?@ <"OBGXE 'UM_PT'\,?\ H9O_ "0N M?_C==+;_ ! \-W?@[_A*K2]FN-&RP-S#93N1M)#$H$W@ @Y)&*O>(_#&C^+- M'FTS7[&*[MY5*_.HW(3_ !*W56'8BN:^$/AJY\*_#I-!U*)M]I>7<69$V^:G MG/M< ]F7!'L: (M-^.7PZU?5;33=/\0^==WDR001_8KA=[NP51DQ@#)(Y)Q7 MH%? 'PX_Y*GX4_[#5G_Z/2OO^@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **\:^/OQ97P?H;^']!NBNO7R?-)"^&LXCU;(Y#GH MO<=?3/LM 'F_B_XZ^#O!7B;^PM4>]GNT($[6D(=+?(!&XE@>A!PH)KT&QOK; M4]/M[ZPF6>UN8UEAE0\.C#((^H->0^//V<]+\:^,Y=?BUN?33=,&NX%@$HD( M &5)8;20.X;FO6-&TFUT'0[+2=.5EM;*!((0QR=JC R>YXH NT444 %%%% ! M117&?%CQC_P@WPVU/5HGVWC)]GL_7SGX4C_=&6^BF@#4\,>,](\73:M%HTK. MVDWK65QO &67^)<$Y4\@'C.TUOU\:?L[^,CX:^)\5E=2[;/6U^RREFP!+G,3 M?7=E?^!FOLN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,W6M>LO#] MJMQJ*WAB8D9M;&:YV^[")&*CW.!7$G]H'X9*Q#>)<$<$'3[GC_R'7I%?!'Q3 MB2'XM>*$B4(O]ISG ]W)/ZF@#ZN_X:#^&/\ T,W_ )(7/_QNNB\/?$CP?XJN MA;:#XALKNY896#?LD;Z(V"?P%9OP]TC3M:^"_AJTU>QM[VW?2H5:*XB#J04' M8U\@_$70XO!?Q2UC2]&EDBBL;H-;,KD-$" Z@-URNX#/7B@#[WHKCOA-XFN_ M%_PLT36=2):[FB:.9R,>8T;M&6_';GCN:[&@ HHHH *R]<\0V'AVW6?4UO/* M;/S6MA//J&@_LL>,/LFMZCX2NG_=WR_:[4'M*@PX_%<'_@!H ^H:Y_Q;X[ M\-^!K:VG\5:FMA'=.4A_=22%R!D\(I/&1STY%=!7S!\=2?%J^)->)+:=XQ(;Y7N&8/M6_Q[^&]W<1V]KX@DGFD8*D<>FW3,Q] !%DFNZTS M4H-6LA=6L=U'&6*[;JTEMGX_V)55L>^*^./V=(TD^-NE%U#%(;AER.A\IN?U MK[2H **** "BBB@ K)\2>)]*\):6=2UZ::"S#8:6.UEF"<9RWEJVT>YP*UJP M_&\:3?#[Q#'*H9&TNY#*>X\IJ ,+0OC-X"\2ZY;:1HFO?:;ZZ8K#%]CG3<0" M3RR #@'J:[FOASX%?\EN\.?]=I/_ $2]?<= !1110 4444 %%>9?&OXIV_P^ M\,/:V,RMKU_&5M(U()A!X,S>@';U/L#CMO"4TMSX+T2>XD>6:73X'DDD8LSL M8U)))ZDGO0!KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X3^U M=_R3_1_^PH/_ $4]>5?L_P#BO_A$?%.JWG]A:SK/F6!3RM)M//=/G4[F&1A> M,9]Z]5_:N_Y)_H__ &%!_P"BGKB?V4/^1\UK_L&_^U4H Q_B[\5;WXDZI:>' MIK3_ (1O3+:<2,-1#[_,VD!Y JDJ &( /7.?3V'X#?#3P_X7L)=>T_7;3Q! MJ%U'Y+7-HP,5NO!*+WR2!DM@\#@ZNT"#4M(43PS@ ,4W M.A/<8)./4"OF[X.>+-0\*?$[2&L97%O?W45I=P _++&[!>1W*[MP]Q[F@#V; MXX^)OB7\.M4@U'1?%#R:'J$C+&CV%L3:RB_$?PA'XY\ :GH;! M?/FBWVSGC9,O*'/89&#[$U\B?"#Q=+\/?BG:2ZANM[69S8Z@DF5V*QP21VVL M ?P- 'T?\2Y/&]IXP\.V'@SQ;-:-KER\;VLUE;2I;QH@9Y%)CW8 Y(8G)(Y' M2O3+"WFM=/A@NKR6^FC0![F545I3ZD( H_ "N,\,@>)?B9KOB5OGM-*']BZ< M>Q92'N7'U?:F?2,^]=W0 5X#^UC_ ,BEH'_7\_\ Z+KWZO ?VL?^12T#_K^? M_P!%T 7*1>9@OG;N(SC(Z>M97Q\\>6 M?Q&\9:9IOA02:A;:7?$?XK_$K MP/\ $/5?#UOXN>XALW3RY)-/M=Q5XU<9Q%C(# ?A7UG7Q+^T'_R7;Q#_ -NW M_I-%0!VWB?XD_%#Q9\/K34_"UKJ%KHUG:11ZEJMLJI-:ZA<,J!]PR@P M.*[+X7 M6D-E\)?"T5N@1&TJWE(']YXP['\68FLKXZW,]K\$?$T,<9P/X7F16_\ M=8T >0V_Q.\5_&/XJP>'/#NKW/AW09'D(>S^6TB_#A[;6Y?M+;D(W*7P" 0PP5P>#UKC?V88A)\7F8 MYS'ITS#'KE!_6N[_ &M?^01X9_Z[W'_H*4 >S^!O&%CX[\'V6O:<"B7"XEA8 MY,,@X9#]#T/<8/>OGWXB?&?Q+XL^(*>$/ %\VG6C7BV*7,!Q)<2%]A;>.53) MXQV&2><#1_9SU*]M?A/XV,);;:;[BW]I# 6?C%X9\[&W[>F M,_WN=OZXH ][^)/@_P 2^#_A3JSV'BK4_$5E):F/4;?691*P4D?O87^\NTX^ M0E@03SD"O(_V$O"2>(_"OB*73_)EC@EM#:P2QR!BWS@NA8-D@=<8 M'0'D\S^SS\2?%GCG7=9M_%.J_;HK:V1XE^S11[6+$$Y11GCUKH/VE?\ DC-S M_P!?D'_H5>;_ +)O_(S>(?\ KSB_]#- #OC!\2/B'\//'\FCZ9XNEGM)($N8 M?.L+4N@8D;21$,X*GG'3%>X_"G7-1\2_"[1-7UJX^TWUU$S32[%3<1(P'"@ M< =!7S?^U#_R5R'_ +![?"&>6U_9[TBXMQF6*PG=!C.6#R$UWQ#\3+;X?_ ]O5TX-=BSN=2"AG9\X?;GHJ\Y(Y)'&!UPOBY)XR^#^ MO:3=:#XW\07]K?1L6_M.Y^T*)$(W#!&W!##C&>M>;_!F_2U^-7ARXNY"?,O/ M++L>6>160<^I9A7V[J>D:;K5I]EUG3[74+?.[R;N!94SZ[6!% '!:#JWB'XK M_!RPO]+U9?#%_?!X[FYCM?..%9D;RLNNW<1G/)'('/-?(/@R.\O?B#H$5E>F MSO9]4MUAO#&)3#(95VR;3PV"0<'KBOT#M[:"SMH[>TAC@@B4+'%$@54 Z < M 5\"?#C_ )*GX4_[#5G_ .CTH ^U/"?A_P 7:1?S2^*/&W_"16[Q;8X/[)BM M/+;(.[>'_ PBZ;X)UZSNC"J1W.LVAMX4.W ; )W^ MPR,UY)\+?AYH_P 0O$$<_B/Q=8PO-,7ETX.RW=RQ.2 6 7GKE2Q]A7V)!:V] M]H,5K>P1W%O-;JDD4JAE=2HR"#P17PM\3O#D>(&\'F#P!JO]C7]E%_HT:VT4D"?^$7^([ZG:1;;#6P;E M"!PLV?WJ_F0W_ Z /K+5K"\D\._9[;Q#=Z=<01@MJ0A@=VVKRSJT93GJ=JK[ M8%<7\%I_&FM^%(?$?C;7I+P7Z$VMC]D@B5(\C;(2B!BQP<#.,-T)ZOB3XOB3XO@ZYN M;+QUH-U86AO;J#4K>2"V#;3,XE4JF>V2 ,^]>Z?&:U^)WAC0[3Q1?^.)D\^Y M6&33])+VT5J64L "&S(/E(RPSR*\6^''_)4_"G_8:L__ $>E?3G[4'_)(H_^ MPE#_ .@O0 _]GKXDZIX[\.ZC9>(9A<:AI3QC[1M"M+&X;;NQU8%&!/H1WY,O MQP^,3_#NS@TO0TCEUR]C,BM(-RVT><;ROF#P'[)/_(4\4?]<;;_ M -"DKSWX_74US\;M>$Q.(3#%&/[JB%/ZDG\: /8-1\'^.+3X3OXTE^(.OCQ# M#9?VC+:BYQ:!-N\Q^4!C(7//3(Z8KJ?@;\59OB-H%S;ZPL:ZSII43M&NU9T; M.V0#L<@@@<=#QG I6W@7Q]XI\%PQS?%82:;JVGJKPCP];X:&6/E=P8'[K8R, M&I?A5\#I/ACXHN-77Q)_:27%HULUO]A\GJZL&SYC)[R]OK2&>,6=Q>NSN6(?S5# MMR0,)QVR:YZW^,E[\2OBM%X9LM>F\,^'YI'AM[BSC7[1=L.$!D8'R]W; ]!R M37T?7SMXET7X3_"SQ_%JEI#J&J>(A.)+30;24/'%*3\AQMRO)& 6)Z84T <] M\6+WQC\'_&5@=#\=:[J%M>0F9(]3NC/M*M@JRGY2#QT ]/>O>/AKXQE^(?PW MM-9D4V-Y,KPSF #]W*I*EDW CT8 @^AS7SE^T/)XDN=4T"\\6QVEI6?$CXK_ M !)\#_$/5?#MMXN>YALW3RY9-/M=Q5XU<9Q%C(#8/TKT2/3OB?\ $_X>:?JM MIXG;PWNL8VA@@0I+J$@0;I9)4*^4'8$JJ@C:1D"#]%^./&%CX%\(7NO:D"Z6Z@1PJ<--(>%0?4]^PR>U?#_ M ,05%O\ %#Q.L'R"/6;L)M/W<3-BO>?VIKVX?P3X7A8DQSW#32''5UC '_H; M4 2?#M_%_P ;O[5UW6O%FJZ#I=O/]GM+30Y_L^)-H8Y;!+ !EZY)SU&*C^'7 MQ4U_PY\5+GX=^.=0.JQ_;&M+74)1B19,_)D]65^.N2"PYQ67\ ='\8:YX%O/ M^$9\>CP_;VU^Z-9_V/#=9)1#YF]R",YQC_9]ZZ&?]FW4K[Q@OB74O'GVK4?M M274DG]CB/>ZD$<+* .@Z"@#7^/\ XC\6^!]$LM?\+^));.&>Z6SELFM()$!* M.P=6:,L/N'()/48Q53]G;X@>*/'J^)!XJU4WILQ;"W86\49CW^;N^XHS]U>N M>E+^U7_R2S3?^PU%_P"B)ZYK]D;_ )F[_MR_]KT 8OQ0^*/Q(\!?$*_T"S\7 MR7-M (WBDET^UWE70-AL1 9!)''_ -:O>O#ESK_BKX0:3=6^L1V.LZAI\4CZ M@]HLNUV4%F$8*KGKCL/0]*^8?VCO^2V:G_UPM_\ T4M?4?PJ_P"21^%_^P7! M_P"@"@#XA\7VESI_C;6[*^OI-0N;74)X);N4$-.R2%2Y!)QG&<9/UK[2T3PG MX[L]1,FN?$F34[1HG0P1:);6[AF4A75_FY4D, 00<<@BOCGXC_\ )4_%?_8: MO/\ T>]??] 'R/\ $#XN?$KP9X^U;0(/%S7,5E,%CE?3K4,RE0PSB/KAL5]- M>#]5FU#X=Z%J^K3JT]SI5O=7,[ ("S1*SL0, (_^NT? M_HE*^B->NI[/]DB*6U)$A\,VD9Q_=>*-6_\ '6- '&VWQ+\1?&/XK+X:\*ZM M<>'_ [$'DDN+7"W,T2=7W$$J22 ,8!YSBN:\<^+?&_P:^)SZ=8>*-4U?3M MD=Q#'K$QN/-C88*L6]U897'2JG[+EW%;?%JXBD(#76E311C/5@\;_P D-?5N MIZ!H^MM"VLZ38Z@8&W1&[MDE\L^J[@<'Z4 +H.J?VWX$]2UV]QY-C TNTG&]NBK]2Q _&O)/A_>_$KPOX?ES\,# MJ-WJ=U)J-W>MKUO"9Y)3G.P@E<+M&">U 'S9XMT"[\$^.=1T=W=)M.NB(I0< M,5SNC<$=,J5/XU]O?#GQ:GC?P!I>N*5\Z>$+!(HPZCW*@'_@!H ^E-6L[J_TV6WL-2GTNX;&RZ@CC=D.?[LBL MI'8\?3'6OD%?CQ\1].\3BTU7Q/YEO;7GE7.VPM_F17PV,1YZ U]E5^?MW:QW MOQ,GM9P3%/J[1N ?X6FP?YT >H?$_P ??%748;?Q!#!JOAOPS='-A]ED\MF7 M^%I60[@6!! ; /;/6O;]&\;7/AKX$V'BGQUYIO(;)7F1EVR3.3B,8_O,"N?J M37H2(L:*B*%51@*!@ >E>$_M77,J>!-&MD)$4NH[GQW*QMC_ -"- %'X>WGB M_P".-[JVKZOXHU/P]HUI((;:TT.?R&WD;L%\$D 8SGJ6XP!BHO!/Q0\0>#?B MY/\ #[QOJ;:Q9F[^R6]_,/WJ,V/+)/4ALJ"#G!/7 K'_ &?-(\6ZUX1U./PM MXZ'AZ""^W2VG]DPW6]FC7]YN<@C(7&.GR^]=+J?[->JZUXG?Q!JOC_[1J>$M4\- M?"#3'M_#UC%,]]KVK LTSE.0D8QN=@!RQ^HZ^#?A'*T7Q@\,,AP3J,:].Q.#^A MK[RH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH *^"OBO_ ,E=\4?]A*;_ -"-?>M?!7Q7_P"2N^*/^PE- M_P"A&@#W+1?C=)X/^$NBPP^"?$$\EKIT4:W=S:^3:2$*!O63G*]\X&?:O(_# M&A6_Q7\;7.H>*_%^F:/<7UR9)HYMRR2$G[L88!,?PC+9''!KZQ^%BJ_PA\,* MX#*VEP @C((V"OE;X^^$;'P?\4IX-)A6WL[^W2^C@086(LS*P [#\(:@^AM:P+%:720I,8R.YR>0:^5-=^-'Q; M\.:_>Z/JGB+R[NRF:&5?L%M@D'J/W?(/4'N"*]B_9D\5ZAK_ ($O=-U.9[@Z M1.L<$KG)\IERJ9[[2&Q[$#M7&_M3>"3!J%AXQLHCY=P!:7Q4=' _=L?JH*Y_ MV5]: /H#1XIK_P &VWD^(KR\>[@$L6J^5 LI#CN)6P?0%:]V\'>'8_"G@_3M&C;S&MH0)I?^ M>LI^:1S_ +SEC^- &W1110!XGX:\*1>-? GQ1T&7:'NO%NH^0[#[DJ^6R-_W MT!GVS7R_H>JW_@[QA::E"C17NEW89HVXY5L,A^O(/UK[#^#?_,^_]CGJ/_M. MO!?VD?!O_".?$;^U[6/;9:XIG&!P)UP)!^.5;_@9H ^E_$?CFTTSX73^+M// MGQR6:S62@9,LD@ B7'J6901]:\M^*GAEO"7[+]OI4[&2\6X@FO)"$_LX_\ELTS_KADZO")[*[B,+]2\/&W026NF:&RP$QDX+F4AF;!*@] M.H(QGCB-2^)'C?X3?%#4-';Q)>>(+*QN KQ:E*TOG1E0P&6)*MANH.,CH1Q7 M:>&IO!7P^\;S:+\)+.\\6>*+T&W,]S<+]FM$R"V9%4948!. >F-V>*\;^+\> MH0_%G7$UFXAN;X21F>6WB,<98Q(<*I)( Z(/#4-QIMY<:?]NM MTFAN(D1I(@P# X=67.#CD&ODCQ%\;?B?H/BC5='/BKS3I]Y-:F3^S[8;O+T9CCJ3"IKXA^(__ "5/Q7_V&KS_ -'O0!ZO M\4/B%\3=H;MT7H.3R?5O"&HZYJO[ M-L]YXI:9]0DTJ\S).N))$ D",WN5 Y[C![YKTRRM(=/L+>SM4"06\2Q1J/X5 M48 _(5E^,_\ D0]?_P"P;<_^BFH ^-O@5_R6[PY_UVD_]$O7U%\8]>O?#?@W M^T='\0W.DZEO\FRMK>VAG^W3,1MCV.C'L>5(QDYW<"ODWX476I6?Q2T6?0[! M=0U!97$%N\OEJS&-AEF[ 9R?85TEM\4/$FB_'"+7/'\7VJXL)WMKBTDC&VT0 MG#>2O12.H(Y;N3DF@#Z0^'&D>/Q86VI_$+Q1-//P_X:\LZS/%YLMPZAA:H?NX!X+G!// &#@YKV*R MO+?4;&"]L9DGMKB-98I4.5=2,@C\*^&_B]?7$GQI\1W+L1-%?E4)'0)A5Z^R MB@#V_P 6^$/''A'X;-XNB^(.ORZ_9QI<7MK+<;K4@D;E2(C VYZG(.T\#/'7 M_"GXD7GQ0\!7C12P:=X@L\03R>3YL:LP^241[AD'!^7/53VJGJ?PV\>^)_#\ MUAJ/Q7%WIU_#MD0>'8%\Q#SU5@1^!JQ\)O@R_P +M4U"Z'B'^U([Z%8VB^Q> M3M*MD-GS&SU(QCOUH ^6OBCIVH:1\3-9L=8U>36;V&5?-OI8]AE+(K?=R=H& M< X&.,=*^J/A_X8\<0:7X>OKSXA?:M*%I!(=+_L2!,QF,8C\T'=QD?-U.*^ M:OCK_P EN\1_]=H__1*5]D^#/^1#T#_L&VW_ **6@#R;XU_&C4?#NMQ^#_!. MS^V)=@N+M@&\@OC:B@\;B""2> ".YXI_$'PUXS^''@:/Q=IOQ!UV^U&S>+[? M#=S^;;/O8+E(R,* Q P MH7 X/I7TQXA^%'COQ5H-QHVO?%/[7I]SM\V'_A'H$W;6#CYE<$?,H/![4 ;W MPN\??\+/^'[7VXZ?J49:UNS;@$PR[>)$#@C!!# ," <@YQSX)X_^+GQ+\&^/ M=6T"'Q:UQ%93;8Y7T^U#,I4,N<1]<,,U[?\ "/X2R?"S^U5_M[^U8]1\H[3: M>3Y13?R/G;.=_MT%?,OQU_Y+=XC_ .NT?_HE* .^\9_$CXG>*?!5OK'A>UU& MP\.VT*1W6IVP5)KJ8 "23Y<,J!@1\H ]3V'JW[/NK^(M;^%R77BJ:XN9OMK8(4$] M>@K[.HH ^:/B_P#&BV\=>'I?"?P^L[W4DNV3[5=+;/RH;<$1<;LDJ,D@<#'. M>(/@C\"]:A\2V7BCQA:-I]O8N)[6SF'[V60@:M:ZG-!.\\S6DHE1%VX W+QD\\ ]J M^G:* /DG]FCQCH?A?Q%K-OX@U"#3EOX(O)FN7"1ED9LJ6/ X;/)'2OK*VN8+ MRUBNK.:.>WF0212Q.&212,AE(X((.014E% #)IHK:WDGN)$BAB4O))(P544# M)))Z #O7PQ\:-:L/$/Q@UW4M(N8[JSE>)(YHSE7V0HA(/<94\U]U44 <-\'_ M !+I&O\ PRT.#2;^&XGT[3;:VNX%8>9 ZQA,,O4 E&P>A XKIO$>A6WB;PSJ M&B7V1!?6[PLP'*Y'##W!P1]*TZ* /COX=QW'P:^.D-MXV5K"W9);9KIL^4R, M/DD![H6"\]N^"#70_M&>*-/\BZ?II?[QL[5(=W MUV@9H Y#X0?#O_A!OANNDZHJO>W[-/?IG(#.H7R\]P% ''?)[U\K^(_#NK?! M_P"*5NTT$A6PO4N[&8\+?IPP['(K[JJIJ6DZ=K%J;;5["UO[-/A=JVG^"X+K4;B:SWWS/ \<>GQ<%B[$ %OX0%)!/? MBO&/@;K$.@?%;3]2N[>[FMHXY4D-K;O,R;HV .U 21G'05]G6WAS1+/2Y-,M M-&T^"PE_UEI%:HL3_5 ,'\JNVUI;V4 AL[>*WB'2.) JC\!0!Y[\=-#O/$_P M;U*+28)9[B/RKI(0A#LJL"PVD9R%R<=>,=>*^?OV?/'NB>!?%>I-XEG>UMKV MU$:2K"\F)%8$+M4$\Y/;M7V165'X5\/0ZL=5BT+3$U$MN-XMG&)B?7?C.?QH M ^0?V@=3NM9^)45]=:?)81S:?$;:&?B4Q;GPSK_"Q.3MZ@8S@Y ^@?V?=>TO M5OA%I>FVUU#)>:?&\=W:[@7CS(^TE?1AR#7J5% 'PW\3O .J_#'QS(T$@)!YQ[UZY=V=M?VS6]];0W,#_>BFC#JWU!XJAI?A;P_HWH@4"QCM75]^ -I9@%Z]P3^->!#P;X[^+WC>]UB'0YX3J$Y MEDN)T,5O"IX WL/F"J .,DXZ5]NT4 <[X"\'VW@3P78:!9R&86RDRS%<&61C MEFQVY/ [ 5SWQO\$_\ ":_#.]AMH]^H:>/MEI@9+,@.Y!_O+D8]<>E;WQ \ M:VOP_P#!MUK][;R72PE4C@C.TR.QP!D]!W)]!T/2N.T/XXV7B#X8:CXEATYK M/4+>?[%;Z>\PD-Q+;M,K#_ *%9 MY_O$!I6'X;!GW:OI:N>\">&5\(>"--T8E6GABWW,BC_63.2TC?\ ?1./;%=# M0 4444 >=_%_QQX=T3P!XBTN]U>S&IW.G2VT=BLP,Q:6,JI*#D#YLY(QBOCC MPAJ<&B^.-"U2\)%O8ZC;W,I )PJ2*QZ>PK]"Z* ,O0_$NB>);=I_#^K6>I1Q MX\PVLZR&//0, #P<5)KNO:9X:T>;5-P')K0HH M_/?P7J%OI/CWP_J-Z_EVUGJ=M/,^/NHDJLQ_(&OHO]I;Q?H5_P##?3].T[5+ M6\N;R[BNHDMY0^80K_O./X?0U[[10!\J?LL:_IFE^*-9T_4;R*VN=1B MA6U65@OG,K-E03U;YA@=35S]IKX=7RZ\/&NEVSSV=Q$L=^8UR870;5=O]DJ M,]BO/45]/TC*&4JP!!&"".M 'S?\&?C]HFC>$;?P[XVGDLSIZ^7:WBPO*KQ= ME8("05Z#C!&.F.?8_"7B;4?&.I3:M:6LMEX96'R[3[5"4FOI"03, >5C &%_ MO;B>PK23P3X5COOML?AG1UNL[O/6PB$F?7=MS6Y0!\7?M#>(=*\2?%-KG0[Z M"^MH+** SV[AT9@68X8<'[PY%>^_L^^)M(U3X5Z5I-G?0OJ.GQ.MS:%@)(QY MC$-MZE2&'(XYQUXKU2B@"KJCW46CWCZ<@>\6!S A_BD"G:/SQ7PMX"\1PZ%\ M6M,U[Q3YTRPWK2WCR(7D#G(+D=20QW>O'K7WG66?#&@-K']K'0]-.I9S]L-I M'YV?]_&[]: /F+]I>]N];U30=8BT^X@T=[=XK2YN(FC:=LAF)1@&08(P& )P M3C&*[S]EO7]/E\#W6@I)*=0@NY+B1! Y18V"!29,;020>"<\'BO:]1TRPU>S M:TU:RM[ZV&=*^&.BV_B*_CT6[T_2;8-;7K!'FC$2[)(A M_P M%8 $;CZ_\)?"46M:78ZE$ MFCVA5+NW295/DIT# XH ^5O!/A.^^+7Q;GNDM9/[-GU![[4)F'RQQM(7*D_W MFSM ]\] :^E?CEX"N?'OP]>WTM/,U.PE%U:IG'FX!#1Y]P>/<"N_L-.LM*M% MM=,L[>RMU^[#;Q+&@^B@ 59H ^+?@U\37^%GBF\M-=MIQIMZ1'>1;")+>1"< M/M/ID@CK^6#]&6?Q0@\Z_P#"9VTZ"2>33KR.]>.,9)0*Z,<=\!\_09[5XW^SK\0]"\#Z MAKEMXAFE@&I)!]G:*!Y2[H7&P! 3D^9QQVKZ[K*M?"OAZQU-M1LM"TRVOF)+ M74-G&DI)ZDN!G]: /C/XY7M[J/Q8U"[U&P;3Y)HH62VD;,B1^6-N_' 8C!(& M<9QVKZC^"FOZ;K7PIT2'3KN*:>PLX[>ZA5P7A=1C##J,X)'J*[ZB@#X0^+VB MWNA_%KQ%'J$+Q_:K^:\A9EP)(Y7+JP/<%OBKHGC'S+C14F_LRT MM3<7^I7*F""T8 'RRS@;B!N)(^4!6R3!3 MZ@,#BK%G96NG6B6NGVT-K;QC"0P1A$4>P' H ^%OB[K%AKWQ9U[4M(N%N;.: M=1',GW7VHJDCU&5//>OJKP'-H7C[X&V.@V]_#*O#OARUOTN]!AU*&YUBZA M^>)U5QB,'^)1RS8SVQR*]YT3Q#H_B2S:[T#4[348%;8TEM,KA6ZX..AP0<'U MK1HH X/XP7GAB3X>:OI'B?5K*Q>ZM'>VCGE42,Z?,C(F=S88#I]*^*O#NNW? MAGQ)8:UIS8N;&=9DST;!Y4^Q&0?8U^B-% ')Z)\3?">N>$F\10ZU:0642J;G MSY0C6S-T1P>ASP/7MFOB+^U;?_A//[6.[[-_:7VDX'.SS=W3UQ7Z$T4 4=&U MO3/$.EQZCH=]!?617&_&GP)-X^^'-Q8:>H;4;25;NS4G M&]U!!3/NK,!VSBO0** /BGX0_$:?X3^,KN'6[.X%A=@0W\&PK+"RD[7VG'*Y M8$>A-?1T'Q5MO&]S!I?PR,M]<2.OVO4IK1TM["+.6+;P-SD<*HX).2<"NSU3 MPMX?UR42ZUH6F:C(.CW=G'*1^+ U>LK&TTVU6VT^UAM(%^[%!&$4?0#B@#YQ M_:RN=4%QX?M?WBZ2R22<9VM."!S[A3Q_O-5OX)>+K:?X-WOA30=/N+OQ"HN! MY*PL(V\S.V1Y<;5 ! Y.X[< 'BOH#4=,L-7LVM-6LK>^MG.6AN8ED1OJK BC M3M+T_1[1;72;&VL;=>1#;0K&@_X"H H ^"O >HV_AWXE:'?ZP7M[>QU"-[@F M-BT85OFRH&'WUC M^UGT+36U+.[[8;.,S9]=^-WZUJT %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 9NM>(M&\.6JW&OZK9Z;$ MY(1KJ=8]Y'.%R>3["O@[Q[J]KK_Q#U[5=/8O:7=_++"Y!&Y"QP<'D9'.*_0. MB@#PKP+\>O GA_X7Z-9:C?W(U"PLD@ELX[1V=F5<<-C9@XXRP_"O'_$]OXR^ M-OQ"FU;2?#EYY,P6*V#1E8X8EZ;I#A<\DGGJ3BOM6B@#AOA)\.D^&W@M=-EF M2XO[F3[1>3(/E+D ;5SSM4#'OR>,XK<\:^%[?QGX+U/0;O:HO(2LXD$8RQ"J3@>YQ7G'P_\ CWI'C2TUNXU& MP;1(](A^T2/+<"17BY&&RS3QL. MEP&*HI^A#-]4%?7E<5\,-+GA\/W6OZE;^1J7B.Z?4IXR,&)'XBC_ . QA<^Y M:NUH *RM?\4:'X6M%N?$6K6FG1/G8;B4*9,=0J]6(R. #6K10!X5\%?B;X3, MWBN"^U>WTZ;4O$5UJ-LEZXB#Q2[=N&;C=\IR,YZ5V/QQ\&_\)E\+[Z*WC+WV MGC[;:X&260':YWXU1ZB/BYK-QJ]@UA+= MM'/'"S!OW910IR."<#G&0&!&3BOM33?#6A:-<23Z/HNG6$TO^LDM;1(F?ZE0 M":=JWAW1=>\O^W-'L-2\HYC^V6J3;/IN!Q0!R/PP\7Z'.M?&OC34+?5O'NOZE9/OMKS4[F>)A_$CR MLP/Y$5^@T$$5M D-M$D,48VI'&H55'H .E/H R_#OB72/%FCQZIX?OX;VU?@ MM$P)C; .QAU5@",J>>16/\3O$&F>'OASK4VK7D5M]HLIX(%=L--*T;!44=R? M_K]*ZRB@#X.^$6L6.@?%G0=2U:X6VLX9V$DS_=3+K"V>72]1"FY= M!G[/, %.[T# @^I(],_6--DC26-HY45T8896&01]* /GSX4_M#>'[/P;:Z/ MXWN);*[TZ(01W(A>5;B-1A<[02& !SP<9SS@>N>$->U;Q1KRVN!GC(J];>"_"UG?"]M/#6CP70.1/%81+)GUW!5=P+*F?7# BG:=I>GZ/:+:Z38VUC;KR(;:%8T'_ 5 % 'R-^T)\.K[ MPWXYO/$-K;.^CZM*9_.1&Y/"=M:>-+F:R MU6TB$32+;O*MUM& PV X8]P<#/?GCW2:&*XA>&XC26)QAD=0RL/0@]:R;+P= MX8TV]^V:=XRM[P". M6*! Q>>8G[N[KM/W54>IKXW^+FL6.O\ Q8U_4M*G2YM)K@"*9#E7"HJY![C* MGFOO&B@#D/A?XFTCQ)\/](;1KZ&Y>UL8(;F)6&^!P@!5UZ@Y4_7'&:Z^BB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** //?'?P4\)_$'5DU/5UO+6^ M"A'GLI50RJ.@8,K X]<9]^*Z7PCX-T3P/H2Z3X! M^ P*W:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,SQ%X>TSQ5H-SHVN6PN; M*Y4!T)(.0<@@CD$$ @UP_@_X">"_!FO)K%DE[?7D+;H&OIE<0'U4*JC/H3G' MUKTNB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDT;2 MV\D:2O"SJ566, LA(^\-P(R.O((]J?10!X]J_P"S7X7U[5KC5-8U[Q'=WMR^ M^:9[B#+'IVAQT &*[[P=X.7P7I<>FVFN:KJ%C#&(X(+]H6$(']UDC5O;!) [ M"NCHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&\M+?4+&>SO M84GMKB-HI8G&5=6&""/0@UY;IO[-W@'3=>74Q!?72(X=+*YN T"DS M,0>^:]8HH ,# X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 55@N96DE^T((T3HQXXJRSJB[G( ]35'6-.&L:-<62S-#YZ M%1(O:FC.IS6O'==.Y=CE29 \3JZGHRG(K$\4^)1X:LX)S:27/G2;,)_#Q1X9 M\.R>'-#>Q6\,\C,6$A7 4GVS6O%%_HZ1W3+/(H^9BO4^N*>B?.4*5WJ&P>HS4E8NF>*M,U;5KC3;-W,]O]X,N <=<5M4FFMS:G M4A4C>#N%%%%(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBL'7_ !GHWAR,_;;G?-_#!#\SL?I3C%R=D:4ZI&= M47+L%'J3BO+KCQQXM\1,8O#&C-;PMQY\BDD>^>,?D:A7X=>+-9;S->US9NZJ MKEC^F*W]C;XY)'H++U#6O44?+=_0P;59VEQ\K8XS4G@*34[2^U#P?K,KQS6#+-;S*?] M9&3T&>U5[&,HN4)7MN% M/#YVSWH\ZXDS@1Q#N:MT(RE&,.JN_P!3AIQ6 MZF.'*3*2?PS6VK*PRI##U!KS%O@O;>0NW5IA+CYFV\9_.JK?#[QAHC>9H.M^ M:!_"SE3^N:S=.G+:?WGKQP6"M:C52]58]9HKRVW\?>*= ?R?%.BO+&O'G1*5 M)'KWS^E=MH/B_1_$<(;3[H>9_%#)\KK[$5G*C.*OT,JV"K45S-7CW6J-RBBB MLCB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YW5(]= MUF[:TL)/[,L5RLER>99/]P=A[G%,TCP%H6DS?:!:BZNCRT]S\[$^O/2NAGN( MK:(RW$BQH.K,< 4]65T#(0RL,@CO6G/)*RT1O]:FH^S@[+RZ^H!0JX4 =A2 MT5C7WB:SL/$%KI$R2F>Y VLJY49..:A)O8Y*E2%-7F[=#9JG)IEM+JT.I,F+ MF%#&''=3V/YUES^))(O&L.AB!2DD7F&7/(]L5T%/6(H5(5;J/1V?J5!IMN-6 M;4=I^T&+RLY_ASFF0Z/:0ZU/JJQYNYXUC:0]0@_A'H.,U>HHYY=S2R"BL7Q+ MXD@\.6<R MOK^7J]D;C*KJ5=0P/4$5S&J_#[0]2N!=10&QNU.5GM3L(/K@5TZ.LB*Z$,K# M(([BEHC*47HSMI5JE)WIRL<]I(UW2KM;+5&&HVC<17BC#K[./ZBNAHHHD[NX MJD^=WM;T"BBBI,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH MX'XH7=^NCM;)9;K)BA:YW?=;<,#%;'AC4M:N(XH=0T@6ELD *3>8&W<<<57^ M)G_(ES?]=(__ $(5T6F?\@6V_P"N*_RK6ZY%H>1&G+^T)OG?PK33N]-CE%^( M$LLX%9GPXM MHA=:Y<[1YINRF[T&3Q3O$?\ R4[0?]S^IJK1YK)'/&MB'AHUIRO>25K+^:WW ML2\_Y+#:_P#7M6M<>*9)O$RZ-HULMTZYKE_%7]HGXDQIHP'VN2 MUVH2.M:OPYN+6.UNM.EB\K589&^U%CEI#G[V:?Z&OK.MZM:7WV72=%DO6"!FE+A4Y[#FH="\7/J&K2:3JEB]A?HNX(Q! M5A[&H+WQ+JFH:U/I7A>VBD>U.+BXGSM4^@K $.JV_P 4-,_MFXAFG>(D-"NT M!>>*E15M36KBIQJJ5.3<>9)Z+EWMH][HC\8W^JMXTTM6TW/D3_Z,I<8G_P * M7QIJ_B"[\-2Q:GH0L[&O^N]7?B5_R)<__72/_P!" M%6FKQT.6M1FXXI\[T]-?=7D3>%]3UJXMXHM1TC[+;) "DHD!WX''%59?%7B' M:UQ#X9E^RJ,EGD ;'TS6]#>PZ=X8BO+IML4-LKL?8+7/6VI>*_$<'VK38K73 M[&0'RS."[L/4C-9JS;=COFY4X0IJI)RM?1)O\K61T/A_7;?Q#I2WMJK)R5>- M^J,.QK2.=IQUQQ7"_##S%M=4CE8%ENV#8Z9[XKNZF:2DTCLP5:5?#QJ3W>YF M1?VL+F/S3$T.3O.,-U_PK3HHJ3IC'EZA1112+"BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHKSCXS^/?^$/\)FTT^=5U?4O6N MK:;(4N+:0.!D@.,\J<=B.#7VCX<\067BCP[::SI;,UM=)N7>NUE()#*1Z@@C MTXX)'-=&(H>R::V-:E/EV-.BBBN0Q"BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH R?$NBCQ!H,]@7\MGP58CH0R(Q9WGZFNEHJN9VL\EUZUUOP\\4-ZC 3"0D+(OO@?A76 M44^=BE@J4HRB^KYO1^1Q/_"-^(-)UNZO_#\UILO2&FAN"<*WL0*(?">LGQ99 M:U?W<-Q(H/G 94(,T9G_ &?1ON[)WM?1.]]CF?$'A^\U/Q-H]_;& M(0V4N^4.Q!(]N*T/$VB_V_H-Q8;_ "VD *L>Q!R*UJ*7,]/(W^K4VII_;W^Z MQQ]AH/B"ZTFXTCQ%<6KV;0>5&T&=^>Q.14.G:+XPLK%=+%]8K9H-BSX)D">F M/6NVHI\[,?J%-6?-*ZTO?6W8YCP;X(Y-, M&DW1A2W\X7O'E,W]P=\TTF]AI7-:BL&^U\Z=:V^I:HT.F:=G;.;IL,K$X4#' MK6ZCK)&KQL&5@"I'0BFXM:A9H6BBBI$%%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>=?$SXAWGAW4](\+ M>%HH;CQ+KD@2#SN4MHR<>:P[]#@?[+'M@^BUX%XA!@_;1\.R7HVQ26)\DOR# MF"=1C_@?ZT >E0_#R22S4ZIXM\2W.H%?WEW#J3VZ[NY6%,1@>@*G\:P/#GCC M5O#WQ/?X>>-KI;Z2XB$^D:KY8C:Y3!^20#C=\K#<,9*GU%>I5X'\88GN/VA_ MAQ'9#-RL\3N%ZB,7 ))]L!_UH ]1;QS9R_%&#P;8O%/<)8RW=Z0@V^M<'XU@-K^TMX$\NYNVCN5GD>&2Y=XPP1P"J$D+P?X0*SD\*^'KG] MJV]T^XT+3);)M$^T-;26<;1F4LN7VD8W')YZ\U>^(MH)/VA?AY:6TC6B_9[A M%: &-=C<+Q@<<#TH ]JHKPSQ1H5A\._C=X#N_"XN;9M=N)K745>ZDE^T@>6 MH9R[$L?WA.3W /7FMO4]9)5F ME0/A2%4?,!\Q(S@T >L45X[X6\->)M&^+$S:-X;O]$\$:G:LMW9S7MN%MIMK M?/$D4S%,D*/EQ]X],#'.>!?!MKXN\=_%+0=8O]2DTV.[AAV?;)#(?FGV$R,2 MS!>>&W D@D'% 'T+16=X?T2W\-^';'1K.6>:WL85ACDN'#2,!T+$ #/T K1H M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HJM)J-E#?PV,MY;I=S@F*W:51)( ,DJN]O9%BM M[>,R2.Q 4#)ZU\:>.O%USXU\67.K7.5C8[((LDB.,?=']3[DUZS^T)X[ "^ M#M/)W?)/?.",8ZK'ZYZ,>G&.N37@=>KA*7+'G?4ZZ,++F85Z]\!O'@T+7&\/ M:G<+'IVH-NA+\".?@#G_ &@ /KBO(:?'(\,J21.R2(P964X*D="#774@JD7% MFTHJ2LS[SHKB?A5XW7QOX-BN)V4:C:$0W: Y.X='Y_O#GZY':NVKP91<9.+/ M/::=F%%%%2(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ I'=8T9W8*JC)8G ]:6O/_ (ZW]QIW MP2\1SVC[)&ACA)']V29(V'XJQ% #-)\?:QX\OKP?#ZSLUTBSD,+ZUJ>]HYY! MU$4*$,P&1\Q9>M-USQSXC^'Y@N_'5C8WNARR"*75-(21#:,3@&2%V8[3ZJQ^ MF2!5GX)6<-E\%_#B6Z[1);&5O=G=F)_,UH_%*TBO?A+XIBN%#(NE7$H!&?F2 M,NI_ J#0!T$FJV,>BMJS747]GK ;DW(8%/+"[MV?3'-& M)8+=TT_[>@O;7& MA(Y ^8L?E'/7(!U_PVUF^\0?#;0]6U:;S[V[M1)-($"[F)/8 ?A73UXAXU\ M>:C!&]S) $\A&V))<>88L9/W5W@D]<#/7% 'I-%>*>,?B%<^'_"_]O:)\3-# MU?4[4H]QHT;VKP7 + ,L07]\,9)Y=N!4GC[XF^(K7PAX0\2>%Y[>"SUZX@C> MU:V#3J6&YE$C-L[%?NCUS0![/17(^']/\=6_C&^NO$FLZ;=Z%/;@VUG;6_ER M6TV0<9QEE W#<6R3@[5Z5UU !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% &5JJM##= M-)$R2!U:)]H8CL:VV"LN' (/8UR\\4T6MOY;)Y)DX3&"OTKYG'/$8"NL13G> M,GK%G;1Y*L>5K5=2I?II5C=:UK6L/>W-NQ2(V-T T.Y>AC4\9)[UR&J?$;6M M6D%II$?V*-CM1(!ND;VSV_"NE^+C2CPQ;>2 6YR8+"'&?,<#!8XZ+D=1SR,]_7@?PA=KO]HSXC7-[\UW M'+-#&7^\(A/M 'MA(_R% 'J8\-^)E@WCQS>M=X^ZVGVOV?./[@CWXSV\S/O5 M;X?ZKXHOI?$%EXV6T%]8:@(HC9QE(FA,2%64$DD$[CR26 MB037<,6I//&KM(JNLD"DPH@W$ [0"0!DYYV?C'XAUVW^"=AXFT?6KS2KFXBM MFEBM"BJWFJ"?FV[P1GC:P^E 'LE0W<4T]I)%;7#6LK#"S*@8I[@'@_C7GKZ9 MJWAJX?Q]K?C#4;BPM-*>6[T4#-NS!,CR^1C'&"06)Y+WATV^DMX;*/<0BJB$"0X ),@;))'2@"E\!];UG6]+\3/X@U M6XU.XMM:D@66<]%5%&%4<*.^ .:[/PGX;U+P]-JSZGXDO=;6^NVN($NA@6B M'_EFO)X^F!QP!SGS;]G:VN&\+^+;:2]D6Y_MR9&NXD0-NV*"X# KG/.""*T/ M@WXCU*Y7QS-XEUBZU"/2M5DC6:Y<'9%&#G"@!5X&2% % 'KE-E5GA=$D:-F4 M@.H!*GU&>/SKS#P!)=?%+PS-XGUS4]3M8KRYE2QL]/OI;1;6)&VKDQ,"[D@D MEB1Z 4SX<^+=9MOB-X@^'7B>[?4;C2T%S8ZA* ))K<["%?& S 2)S_O9Z4 1 M?"/6-:O_ (C?$33]:UF\U2/3+R""V-PP 1=TXX50%4G S@#.!7K->-_!]@OQ M;^*[,0 -2A))[?-<5I> ]1F^+-KJ^OZAJ.H6VEK?O::;9Z?>RVNV- /WCM&5 M9G;=G!.!@<4 >I45Y1X-\3ZSH/Q=U+X=>(;Z;5;;R/MFDWUR09C'@$QN1C=C MYOFZY4]B,)X4U"[^)/C;QC%K&I:A9V.AWOV"TL+"\EM"N"X,KM&RLQ8KP"<# M!XH ]8HKQ;X=R^*==\:>+?#6M^+]3GT_0+C[.JHD2O<12"0+NG51(KC:#D,# MGZ4OPS&H^&?C%XA\)^*=>UC5+D0+WHH Y2W\1> M*HK18M0\$W,M\%PTEE?VQM6;U#/(L@'?&PD9[UF^&? =X?'%SXY\92V\^NRQ M>1:6UL2T.GP\_(K$ NQ!.6P/O-@8-=[10!Y5KGACQ5IGQXA\8^'M'@U:RNM, M^PS+)>K!]G;.=QR"2O"_=!/7CIFCXNT?QC??&+PMXAM?"MQ?66A1/'<30W5M M']H9U(9HD>;(49X#$'^=>QT4 >/_ !*TCQ7X@^(G@W5=&\)7MQ9^';IKB=VO M+5#,',1(0&7.1L(YQD^W-2>,O!OC.P\=I\0/ALD!U"\M4AU/2+YU'G8 Y#; M<@!1PPP5X)!->N44 <'X>_X3C5;A=:\:Z7;Z3?$+QGJNI_$C2?AIX3O'T^YO1YNIZC%CS+>':6*QG^ M%RJDY[97'4UTX^$W@LVPCET5)IPN#>RRNUT3_>\[._/XUYK&C:5^VK/)>CRT MU6Q!M6/1\6RK_.%Q^%>^4 >0>$/%FJ^$_BW<_#7Q+?S:G;31^?HU_'KCXL2:"NNZ?;Z39:;*]Q>3W$<<4MUYL05%=B 2 MJ[^AYR?[MYGM]*U:QOI[?B:*VN4D:+_ '@I)'XUY'XML+?5/VLO#UI>J9+>3P\XDCW$ M"1=UQ\IQU![CN.#Q1X@TO3O"_P"TQX(;P_86^G+?VEQ%PZEJVG:/:FYU>_M;"W!P9;J98D_-B!2Z=JFGZQ9B[TF^MKZV8X$ MUK,LB$_[RDBO+-$U;6]:^,WC&:RTW3-2ET9H+*U6_P!1>W-I&5)8QJL,F2[ MEFX/RJ.@J;PU\/M;TOXIZOK.I0Z#9:#KUN8[C1;>Z>=9)0H^8*T**BN2<*?8UHQ2QS0I+"ZR1NH9'0 MY# ]"#W%?/\ \'_ _AWQ&_CS3];TR*[L(=;EAAM6^5( ">4VX*M@ ;@<@# Q MDY]ZT^PMM*TRUT^PB$-K:0I!!&"3L10%49// ZT 6**** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** &R2QQ*#*ZH"< L<4D&0X89Z]QQTX-,#V!Y$C7=(ZHOJQQ M33<0B,2&6,(3@-N&#^-HB,,84#)).2.U5?B/IEKIG MPIEL[2%$BM3$(OE^Z=X!/U.3D^YH [@WMJ.MS#_W\%/CECESY4BOCKM;.*\[ M^%6B:7-X&2ZO+&WGEEFD+/-&'.!QQGITKKO#6C:5I5C)-HB*MM?,MPF!CY2H MV@9YQWY]32 \[O\ X$>%-1OY[V_\1:M-<3N7DDDNHB68^I*5!'^SSX,F;;#K M>IR-TPMQ"?\ V2LCP1IENGQ=ETZXC2Y@AEN(]LRA@=H8#(/':K/Q L$TCXEV M(\+ PWO!G_0"W>XD$3J"APVT M#'3O^E92DYN\F2Y-N[/<$NK>1@J3Q,3T <'-#75NC%7GC5AU!<#%8@\-:!)X MB@N[:U@AO; !RL*!1A@P4D#CL3^%A%,6>)I#&LJ%QU4,,_E7E7@;XBD^%O[),,EUK, M\JRA"Y^T9^Z,]@O4DXX&)] M?%7A? M4-#U#(M[Z!HF91RA/1A[@X(^E:M% 'DGPUU:;X:Z(?!GQ 8:<-/E?[!JLH(M M+J%F+#]Z?E5@2?E8@X(JYX_\2GQKX7NO"WP[*ZS>:JAMYKZW.ZTM(2<.SS#Y M22,@*"3SG'KZ?10!Y%X_\#?\(]^S'?\ A;0HWNGL[:%B40EI66=))7P,]<,< M=NG:J>J>.] O_P!FVZ2&\,:G0ULDDG0Q++<^3M,*;L;V!4YVY '>O::* /%_ M"GB_P[!^S&J3:W81R0Z1+9R1O<*'6=HY-L>W.=QP2!U(!(KFO"VEGQS^R;#H M/AJ\AGUS2Y&N&M$D7S$<74DBJP[%ER5SP2/K7T;10!X_X>_:!L=2@CTR_P## MFM)XH51&^EQ6N3))TX)(VKGJ6QM]\9K ^/6O06NA^#[+7-2M&UFVU2"\OK>! MP3"NTECM'.T$X!(R0/K7O]% %73=3L=9TZ*_TF\@O;.8$QSV\@='P2#@CC@@ M@^A!%6J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HJKJ.I6>DV;W>HSK!"G5F[^P Y)XZ#FL;P5XYT;Q M_I5UJ7AUIY+2VNVM#)-'L\QE56W*#SMPXZ@'KQ0!T=%% M6;5(;0W4S(H,40R/D8YSOPP.,8P>M '2T5SNM>-++2-AW6.$ ^5&H^:5\D83)5>Y)8 \XTJ "BBB@ HH MHH *AFO+:V8+<7$41;H'<+G\ZEH=>*) M07+S18Z>(FZJI58V;5UK>^NOZ/YFVTB(RJ[JI;A03C/TIC75ND/G//&L7]\N M OYUQ-Z6\0^/)]C'[)HMNV<'@RD'_/X52\#>&H=;T,3:RSW%M'*ZP6Q:3_IG-]?J3J^SI0O>]G?3W;7>VUVU\CT2"Y@NH]]M-',G]Z-@P M_2HWU"SCF\E[N!9/[AD ;\J\ZU_19O"_B"S7PS<26D6IDPO'NR$/J,^U=')\ M.M"DL&B,,C7!'_'TTA,A;US2=."2;>C'#%XFHY0C37-'?73RMI^=K'55!-?6 MENX2XNH8F/17D /ZUYYIWBF^TOP1>Q-(9KRUNOLD$C M)RC<'\JZ6XLX)'6XE;84P2V< _6O.O%>A2Z#=:;#9SR/IDETI6&1MWDOGL?0 MUJ7TB^*O%T^FWEWY&E:>!YD8DV><_IGTJ:V%I5Z<8SUCO_7F<]+&U*5>H^6T MVXI*_D^O:VNWR-_6M-TSQ99I9O?*R1R"0B"123CM6'XBM(M(U+PQ9:<&@@CN ML!58\_7UI^L^%-#CT][G0Y8M/OK=2\4D,V,DZ4EZ;'IE-21) 3&ZN <':H6\MUD_N&50?RS4[2(B;W= M57^\3@5S2?#WPZMJ8I+-I7(YF>0[R?7-96F)/I/B.X\):A<275A>0%[223ED M&#E>?Q_(4DTJT$E+16=]>B>BW[G="6-L;74Y.!@]>,_RIU9D6 M@VL.HK>H7$JON S\OW-G3Z5IUD[=#N@YM/G5@HHHI&@4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7DGBOP/K_AOXH+ M\1/ 5JNH//%Y.K:3YHC:X3C+(QXS\JG'JH/.2*];HH Y&P^(45]$ /#'BB"Z M(_X]I](D3GT\PXC_ !WXJ'Q7#XPU'X=:\VE_Z'K%S;D6-I!(-\ !Y'F=Y&7/ M(.%. #QN/:44 ?/^I6^K:[^SE=>&-$\!ZOIM[%;0?:Q=6_E&:6.1'=HQR\KL M5)SM&Z=]NL6M66^LY()(9-@Y*. 2 <>/<2H:5B%7KP2>F,@'K[-10!XW\$K7 M6_#&F^)V\1>'=1L8+C4YKU)3%O++C!58U_>L?EXPF"#Q5;X,VLYO?&VFZ[H6 MLV$6N:A-<0F]TV:))(7W @NR[0<'H3WXS7MM% 'C_P ,XM8^%=M>^$?$NEZE M=Z=%<8)VO"OAJZ7XB^)/B)K-I-9_;; M=+6QLV0O,ENBKN=D7)W.4!"CY@.",G%>C44 >*?">2YMOBEX\FU/0M;M+7Q! M>I)8S7>DSQQR*IF)W,4PF0X^]CTZ\58^'NFZI\']2U?PYJ>F:C?>'KFZ-YIN MHZ?:27>S< #'(D89U.%7G&,@^M>QT4 >=:#X8O-7^+U]X]U*TEL;:.Q6PTR" M<;99%SEY73JG)("GG!)('%';P2I:^?H=K%+%=1! M<<= .<4 7?A7XP\ W%W/HOA=[V'5;QGO;C^U M(F6XO'/WG9SPQZ\#IS@=:C^.&C7EO8Z1XW\.[5USP]=Q^4I_Y>(Y7"&+WR6' M'H6 Y-=+9Z=XAUS4+/6_$>G6&F7&FK(^GZ?%<&X*S/&4+2S;5&-K$;5'?))P M ,7P[8^/_%EY92?$K3M+TFSTRZ^U);6,F\WDJY\LM\[!44G=C.2P7@8H Z[P M;H+>&_"5EIUQ()KL*9;R;'^NN')>5_Q=F_#%;E%% !1110 445ROBC4;O4=0 MC\*:!.T%[=1^9?7D?6PM22"P/:1\%4]PS?PX(!+X?\?:+XF\5:WH.D/+-/HI M1;F;:/*9FR"JG.205(/ Y'&:KZS\1=,TG4M1L8+'4=5ETF%9]3-A$C+9(PR" MY9ER2H)VIN; )Q7$?"O3;/1OC;\0M.TR!;>TM8[&.*).BJ(S_G/>H;#4+?P+ MXJ^)47BDK;OJTGVS3?,S_P 3!&1@(XO[[ D+M'//I0![!I>IV>LZ5:ZEIDZW M%I=1++#*O1E(R#[?2JXUVV?Q*=#@26:YCM_M$[Q@%+=2<('.%).! MC/ > 7U'P#\$/#NF7EH9=?N \=GI[DJSRR2/(JMW4*K9<_PA374Z*=%\()%I MFK:[8G7-2D-QS' +*A.<# 55&<*JCM0!U%%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% %'5X]5EL"-!NK.VN\Y#WML\\9& M#QM5T(YQSDX]#7E7PW\=?$7XBZ3J5Y!+X7L#8W36NQ["XDWL%!SGSQ@<^E>Q MU\U_!WQK)X)^'WBS4Y/#VIZG:6^JR22SVAAV1_*@PP9P_N2$( _' !Z5X-^* M-]J/Q O_ +XQTN'3M>M%WQ26DA>"Y3:&RN[D?*0PSVSG!&*]*KQSX9>%[GQ M3XWE^+>LWEFS:C!MT^RLG+K;IM"$.Q ^< %2,=2?I78^+-1\4/XPT'0?#\$] MII]\)I-0UF* 2_951"50;@45F. "P/7@'F@#LJ*\L\/>--4M/C==>![S6T\0 M6#6!NH;IHXEFMY >8W,053P#_"#ROXU)_%?CF7XYWG@RVU/3Q;G2VN(95L<+ M 25P[*7+.5Y& P!)!(P* /7J*\JNO%WB/P1I6B:%XV\0:.VO:Q>S*NJR!8K> MVMD&XNP(0%^0JC@$L.3CG&\0?%0^#?%>B26'C>Q\7:-J,_V>]M@]LT]GDC$B MM %XY/# ],9R<@ ]NHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@#DO'/@"R\:1V=RMS)INLZ9()M/U.!07@<'."#]Y20,J?TIZ2 M?$!+9;=[3PW)-C!OOM_F$EPK9!+$0$ M(<'H-V#W->IT4 >5^,/A?XAD\;'QG\.=>AT36KB)8[Z"X!:WN< $_*>P ^[ MV!&#UWO#OA_Q=:+-K7BK4K'6=?6 PV=M$3;V=NI(+ ,$+$L5&7*DX YSVU M% 'EWPM\$^,?!>N:W)K2Z'/8ZU>O>RM:7(^.H9O!GQ1M=>M5;R9G6?C'S=I$Z8&1 MG_OJO;JP?%7@_3?%]K!#JC3Q^0Y:.2!PK#(Y'((P<#MVIH"AHT\?B3QC<:W; M2"73[&$6MK(IX=V 9V'T!4+-'L=;\/RVFKWLEG9;@\TD;HN0#D E@<#.#VZ4=0. M/^&_AK1=:^'<7]I:9:SR222*TK1#S.&X^, ;1GT)QG%<+9:!X5TVV%OI_CW4;6$$D1PZK&J@GV"ULZ"_A3P[:7<5EXDC MEFNW,DMU<7L;R%L=?3C.>GUS3Y6.S/,] LTUOXO7T,=Y<6ZS3W3)/:RE''WB M""/\FMKP9J[>$/'EYHOB9(S<74A U*8@R9(!&YSSM; [\'%;.A^'/!'A[6XM M4L/%!-Q&3Q)>0%6!&""-OOVQ5WQ5IO@CQ=<07&HZ[!#- I0/;W<:EAUP<@]. MPRH&,[J"[D9F>:'4(48ECD]$'6CE?8+,[.TTC2O"LU[>V40MXKUH@8( M5XWY(^4>^[H.F*L>(/$%KX?LEEGS+/,WEVULGWYG/0 ?B,GM7+Z?I?A:/7+. M^G\7W.J7%NW^CQWFI)( QXX .:UYO ]I<^*H?$%WJ-_<7<# Q1RM&8T Z*% MV<#Z24R3_9$VI;2$]!ZJ'=42_TO4=3CF3@[GC8,O=2/+Z&@#M****0!1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 5 U]:+?K8M=0B[=#(MN9!YC*."P7K@9'/O4S*&4JVNG6 *PO^%C^"/^AR\/_P#@T@_^*JWXH\,6?B[2TTO5V=M.:99+FW1BOVA5 MY",000N[:QQUV@5YW\2/A[X$\,_#_4[^P\):>;]HQ;V2K'DM/*0D>!GLS _A M0!ZA;:SI=[I(U6SU*TN-.*LPO(IU:$A203O!Q@$$'GC!HTO6=+URU-SHNI6F MHP!MIEM)UE4'TRI(S7D7CW0T\,^%_AGX4ZZ0-;LK:^&T%)R#G#]L,VYC^?:M M>R+6G[4E_;Z;E+:Z\.QSWZ(N%,RR[49O]K;@ ^A- 'J$TT5M;R3W$B10Q*7D MDD8*J*!DDD] !WHBECGA2:"19(I%#(Z-E6!Y!!'45R.I'_A-?$+Z)'DZ%IDJ MG4Y!]V[G&&6V'JJ\-)Z_*O=@.Q P,#@4 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XY^S1_R(>O? M]C#_[&&X_]%0T >A>*M]>9^']"M?#G[3T6GV1>0+X9+RSRG,EQ*T^7D<]V8DDG^ ME=#K?@'QU<>-M3U[PYX[ATI+U8XUADTJ*=HHT'"!GS@;BS8&.6KSG_A'/'__ M T)]@_X3J+^W/[#\S^U/[*BQY/F8\KRL;>O.[K0!W4]Q#X._:!U;7/$TT=C MI.K:1'':7\[;8A)&5W0[N@8X+ 'KVYXIGPJG?PC\-=9US6;6>WBU36KB]L;, MH1-(LI1(HU0\[F9>![@UZPA,5NIGD!*)\[G@' Y/M7):*K>,-=3Q)3>%XH]5^-WQ(7Q)&LGDVMI;6Z3+E5M&1RX M&1]T\$^Y-7OV>[R_O/@OI+ZB\DGEO+% \G),2R$*,^@Y ]ACM0!Z91110 44 M44 1W$Z6MK+<2Y$<2%VP,G &3Q7//_PB?BZW$SFTN21CXF)ZY8$@?E3? MAQ_R)\?_ %V?^==3L7R]FT;<8QCC%0V-A:Z;:BVL85AA!)"*.,FL95.9._5G MI4\)[*=-QVC%K[[?Y'*>-O\ D8/#G_7T?Y5V=5KK3K2]F@ENH$EDMVWQ,P^X M?459J923BEV-:5%PJU)O[37X)(\EBTR;4?#FOFU0R36VI>"YR*[[0?% M.F:OI<4RW44FVFGF8V5ND)F??)M'WF]:S+[P;H&HW1N M+K38C*3EF7*[C[XZUM*I">DC@H8.OA4I4FF[6:=[;MIIV\^QR7C;Q!!J>H:= M9Z4W9X4'N:2YTS2=,\>72^)+6-[34!YEM/)G:K=P37Z-X(T^T:YNK>Q6-1GA\D_0 \U@>)[6UN+?PW'X>7[#%<3 MDPG85*$_Q8ZUUUKX(\/6EP)HM-C+JN?SKT:J=MI-A9QSI;6D4:7#%Y M5"\.3ZBDJW\VK_0TJ9=9VH/ECH[=I+9K\F,BUS2Y[07,>H6YA*[MWF@<5RVF MR_\ "4?$(:M:*3IVFQ&*.;&!(YX./7K6N_@3PW)<>:=+C!SDJ"0I_#.*W+>V M@M+=8+6)(8D&%1%P!4\T(I\N[-71Q%>4?;V2B[Z7=VMMTK+KU):***Q/2"BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBLOQ%KT'AW1WO9HWN)698K:UB_P!9 : &WGBC1K#Q-I_AZZOD35M21WM;4*S,ZHI9B2!A1A6Y8C."!FG:WX MDTKP\+<:K=&.6ZO+'DFNFUSS+;]IOPW<7Y*6,^AS063.V$-SO8N M!_M%"OUXH ]"T77=-\1:8FH:+=I=VK,5WJ""K X*LIP5(/4$ T_4=6LM)6W- M_-Y9NIUMX%",[22-T4*H)/ )/H 2< $UYI\*+F*'7/B-JXE6+0WUIY(IV;$1 M* ^CVDHP;>!NLK#M))@'_94*O!+9 M .MHHHH **** "BBB@ HHHH **** "O*3\._B+::UJM[HGQ%@LH]2O'N71M& MAE89X52[9)"J%4=@!P!7JU% 'SKX!T'QL?C?XMB3QE&MU9RV;:I/_9L6-03; MD*%QB/Y^OYTM[6WC,DLKG"HH&235#3_ OH^E>(-3UR MPL_*U'5=GVR;S7;S=@PORDD# ] *M:GI-EK-O'!J<'VB&.9)Q&S$*70[E+ ' M# $ X.1D#CB@#"\,6-UJNH2>*];@:&YN(S%I]I(.;*V)SR.TCX#/Z85?X>?* MM'B34OAG\8;SQ BOJ9O[]9?-'S((H08 "1G"M]WZ#%>_5SFJ> /#.M:A->ZC MI:R2W&W[2JS2)'<[?N^;&K!)<=MX.* (OAG=WU]\+O#EUJS.]W+I\3.\GWG^ M7ACZDC!SWS744B(L:*B*%51@*!@ >E+0 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110!1UC6]+\/Z>U]KFH6VGVJG;YUS*(U)P3@$]3P>!R M:\(_9N\1:!)I/B#0K^_M%N;_ %)Y(K2X=5-S&Z 856^]]TY KZ%HH ^?[6_D M_9[^(DNF7_FOX$UV0S6LN"WV&7N.Y.. 1U*[3U!!TO'?C_3KKQ_X;74-3>;X M?7=NQEN;!F>&XN]S 12M'\Q5<(=G,_#:?M87%\VMV/V*32!9K=>>OE M&;*G9O\ NYX/?KQUKWVB@#RCXQV.N:5KOA?QYX=L)-3;P]+,MW9Q EWAE4*S M #G@;@>N-P., U9T/XQV?CSR].\$Z;J9U&5@L\ES;!8K!<_,[MD@D#.U1G<< M#CFO3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "N<\;>,K?P1X>N-6NM/O[Y($WLEI#NVC(&68X51D^N<+?S% &_X6UP>)O">EZVMO\ 9AJ%LEP(2^_9N&<9P,_E6;X[\8S^$=+M MWTS1KC7M4NY?+MM-MF*O( ,NV0K851U..I [U%\*O^21^%_^P7!_Z *YWX@_ M#CQ;X@\51^)/"?C1](O+6U^SV]H82(]I.Y@SACG._%7BG M6I;37/A_>>'+2.$R?:[JZ+!FR $"F-A'5-,\-.8 M]3NOM8B;VBVOB;2D\QGC4!+J M+(&\ <9^93QP0PP!@U@P:9K7@[1/B%X<_L34-0N=>N[FXTF:UM&EAF%PFP!Y M -L>P]?,*CKC- 'L.DZI::YHUIJFFR^;:7D*S0OC&589''8\].U4M/U_^U/$ M5_86-MYEIIX$<]Z7POVCJ8E&/FVJ06.>"0.3G'*:9;ZGX6\"^'? NES)_P ) M#)9*DDZC;.?7:6VJ/XF*]LXU+'Q/X.\*1Q^';?4!$MBZVTLACD>..5 MCTFG"E%D9CD[V!).>] '84444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_ M\6/"GB?QIH\&D>'Y["VLR_F73W$SJTA'W5PJD;>_/<#TY] HJH2<):0_#/Q+%\3'\;MXNT]K^2V%J\ T1A#Y7' 'VC<#QG.3^ M7% 'IE*-? MUVXN_M5SK$D6!Y6P00Q)M2,,ENE &CK&BZ=X@TN73M9LX[RTEQNBD M'&0<@@]00>01R*Y.^TVR\,3G1O!EN8_$&O9,E[/+)X\PG4R6: M*WC,D\B1(O5G8 #\37SMJ_QC\5:DS"UGATZ(]$MXP3_WTV3^6*XR^U2_U.7S M-1O;B[?.=T\I<_K75'!R?Q.QDZRZ'TQJ/Q&\):9D7&MVSL/X;_'/P[!D6=G?W3#H=BHI_$G/Z5X#16\<'36YFZTCV&Y^/LQ)%GH"*.QEN2WZ M!163-\=/$K\0V6FQ#U\IR?U>O-**U6'I+H3[2?<[^3XT>+G/RS6D?LMN/ZYJ MI=_&3QI'8SRIJ$*LB@C_ $6/^\!Z>]<74-]_R"[K_<7_ -#6J]C3_E0*?'*GYKRU?_>M4_I5R']H;QE%]^#2IO\ KI;N/_07%>5T4O8T_P"4TYF> MU6G[2>K(1]NT"RF'?R9GCS^>ZM_3_P!I+1IVOG:BH> M&I/H/GD?66F_&WP+J)"MJS6;G^&Z@=?U *_K78Z;K6EZS%YFD:C:7R8R3;3+ M)C\C7PY3XI9()5DA=HY%.59#@C\:QE@X]&4JC/NZBOC_ $;XL>-=#V+;:[<3 MQ+QY5WB<$>F6R1^!%>D:#^TCRL?B;1,#O/8/_P"R.?\ V:N>6%J1VU+4T>\4 M5S/AWXB>%O%.Q-(U>!KA@,6TI\N7/IM;&?PS735S.+B[,O<****0%/5=*MM9 ML&L[UKE87(+?9KJ6W<^V^-E;'MG!K#\+_#GPQX+G>7PS97%CYF2\8U"X>-R1 MC)C:0J3[D9%=110 5D_\(OH__"7?\)/]C_XG'V7[)]I\U_\ 59W;=N=O7OC/ MO6M10!5U33+36=+N-.U&,RVERFR:,.R;U/525(.#T([C(/!JQ'&D4:QQ*J(@ M"JJC 4#H *=10!A:WX+T#Q#>"[U2Q+W/E&%IH9Y('DB)R8W,;*73_9;(]JUK M*RM=-L8;+3[>.VMH$$<4,2A511T Z"IZ* "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBJ>JS:E!8-)HUG;7MT"-L-SKWQ/^(FK_#C3!JR^'+?5-+\Q8FE7 M4C%*CMGJGE$8XQD,?H* ._HK&\+ZIJ^L:+#?ZWI5MI;7$:2Q007IN2%9<_,? M+0 \]!N'O6S0 4444 %%%% !115:YU"UL[JSM[F98YKZ4PVZ$',CA&D('_ 4 M8\^GTH LT444 %%>>_$CQ_K/@O6?#MK8Z9936FL:A%9M/X-8\*0^'KJRL[;R[6 M/57ES#(W^LD"H0-Q&%R,-.TZ]N&AC:[MS");?SMHW;0^?E M#9QGG%4]2\%:=JGCO1O%EQ-=+?Z/'+';QHZB)A(K*VX%22<,<8(K.W\,Z+(!>I @2.YG M4AEME XV)PSXX)VK_>%<]>)'XN_:%O/#_B*%+O1]*T19[?3YUW12RNZYF*GA MB 2HR#CJ,&O2M'TBTT+2+?3=.C*6]NFU=S;F8]2S$\EB010!RGP0U:]OO#^NZ;>327 M$.BZW<6%I+*Q9O)7!52QY.,]?3 [5Z963X9\,Z9X2T1-+T:)HX%=I&:1R[RN MQRSLQY+$]_Z5K4 %%%% !1110 4444 %%%([K&NZ1@J^K'% "T5GS:]I5O\ MZV_@^BON/Z51E\9Z-']V:27_ '(S_7%.S%=&]17+OX]T\?ZNVN6^H4?UJ%O' M\'\-A(?K(!_2GRR"Z.NHKS;Q/\8(O#>EI>MHSW >81;!"+@@337UK[S6I./^^"U#H5%T#F1Z917)6/Q4\#Z@0+?Q)9)D9_TAC#_ M .A@5TMGJ%EJ,7F:?>074?\ >@E5Q^8-9N,ENAW18HHHJ1A1110 4444 %%% M% !1110 4444 %%%% &)J'C7PKI%_)8ZKXET>QNXL>9;W-_%'(F0",JS C(( M/T-0P_$#P;<2B*W\6Z%+(W1$U*%B?P#5YA^U9%&?AEIDQC4RKK$:J^WY@##, M2,^AP/R%>NW7AK0[W3VL+O1[":T88,#VR%,?3&* -&.1)HUDB=71AE64Y!'U MK)O_ !;H>E^)-/T"_P!1CAU34E+6ML58F0#/<# Z'&2,XXKQ6%KCX)?&_3-! MT^YG?PAXD8".TE^U)UMXY?)DNTM)I+>-\X*M,J&-3GC!8#S^8JAJOQ!\,Z*9S?W\GEVS^7 M<3P6DT\,#?W9)(T9$//1B* .EHJ"RO;74K&&\T^XBN;:= \4T3AE=3T((ZBI MZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH ***Q]0\,VFH,S&[U*VD9]Q>VOY4_#&[ 'L!07!0;M-V M^5S8HKR[7?A]XK@4S>'?%6HW.WGR+B[=6/7HV<'MUQ]:X^3X@^.?#VH/;:I< M/YL:[3#=0K^>0!GIUS6;G;='M4"0H2>YPOE&-H:RIM MKRU_(["218HFDD8*B@EB>PIEK<+=VD=P@*K(NX ]:YCQ7K=O/H\46GW,4ZW. M'+Q.&!3J.GJ?Y5H>$;T7>A)&6S) 2C9].H_#''X59Y;33LST73M3:$$1&]M$F* ]<; M@<9P.GI0!A_">1)/A'X7,;JX&FPJ2IS@A0"/SJY;_$'PIHZ>V MRXMYV,14]\;P V.Y7.*TM(\/:+H"2IH.D6&F+,09%LK9(0Y'3.T#.,FHKWPI MX=U+4!?ZCH&EW=X.ES/9QO(/^!$9H Y;2-/@\1?%Z?QEI_S:=::4-,ANE'RW MDAE+LR'^)%&!N'!+'!^6NMU_7+;P]H\M_=J\FTA(8(QF2>5CA(T'=F) 'YGC M-:*J%4*H & .E13V=M(:?(EC^S/XWT_7&5=7CU M.XBO8Y/OO:(U#Y]]V:V*** "BBB@ HHHH **" M0 23@#J:RKWQ-I%AD37L;-_=C.\_IT_&JC&4G:*"]C5HKC;KXB6J9%G92R^A MD8)_+-8]QX^U:7/DB" =MJ9(_/\ PKICA*LNEB.='I5%>0S^)-9N,^9J,XS_ M '&V?RQ5&6YGF_UTTDG^^Y-;+ 2ZR)]HCV9[NVB_UEQ$G^\X%0G5]-7[VH6H M^LZ_XUXU16GU!=9"]H>M7/BWPY9R".[U_2X'(W!9;V-21ZX)HC\7>&YO]3X@ MTN3_ ';V,_UKY8^)G_(>M?\ KV'_ *$U<94/!1[A[1GW3;ZA9W7_ !ZW<$W_ M %SD#?RJQ7P=6A9^(-9T]@;#5[ZU(Z&&Y=,?D:EX/M(?M#[AHKY L/BUXYTY M@8?$-S*!C*W(6;/_ 'V":ZO2_P!HOQ-:X74]/T^_4'EE5HG/X@D?I64L)46P M_:(^E**\AT?]HKPW>;5UC3[W37/5EQ-&/Q&&_P#':] T/QSX8\2,JZ+K=I M/>O%?%7QBUK6]]MI(_LNS.1^[;,KCW;M]!^9K>G0G4VV(E4C'<]B\2>/- \+ M*PU*\#7 '%M!\\A_#M^)%>2>(OC9K>HEX=#B33(#P'^_*1]3P/P&?>O-7=I' M+NQ9F.2Q.2325Z%/"PAOJ&M=\NWUHG1+QL#]^VZ%C[2?P_P# @![UZ='(DT2R1.KQ MNH974Y# ]"#W%?"%=/X2^(?B/P7,O]CW[&UW9>RG^>%_7Y?X2?5<'WKBJ81/ M6!HJG<^RJ*\W\$?&K0/%1CM-19=(U)L 13O^[E/^R_ S['!],UZ17!*$H.TD M:II[!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH ***IWFK65@<7-PJM_<')_(5$ZD*:YINR\QI-[%RBLRU\1Z5>3"& M*\C$IZ(YVD_G6G2IU85%>#3]!!12*ZNN48,/4'-+6@!1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !112,RHI9R%51DDG H ^?/@?XGM=!G\8Q7-CJUT9=9D8&PTR>Z4- M%^88'WA@Y(] :H:5XS^!NJZ+%=Q>']#6]D TS^Q8VN#(>D:J(_G))P",B@# MH/&OQ0U+0[?PKJ&@Z=9WFD^(;JWBCNI)7,@63!QY0 .TG!WGGJ*@\=_$/QC MX GLM:UC2=';PS/=K;S1PS2/>0ALD,3PA. 3M //&?XJQ?C \=AH7PXM[JWM M-+DCURT=K.#"QVZJ/F50.-JY STJS^U!+&/A+"I=0SZE#M&>6^5^GK0!J^/_ M !SXY\&:8WB9=%TAO#UO*BSVLLTAO0C,%#9'[M221Q\V,CD\XW?&?CJ70--T M Z/8_;+OQ!>PVEH9LB.+S,'?)CG !S@>_/%8O[0-Q"WP'UQEEC*S?9O*(88D M_P!(C/'KP">.PK.\9^/I_#^@> K&QU%--T[7A''=ZTH#?9HE2/[I(*JS;C\S M9P%)QW !L7'C?Q!X9^)6A>&/$XTR_MM>206]Y86\ENT4B#)#(TDF020,AAUZ M<<\GXQ/B5OVGO"-G%K=J%:UN9K&.6Q9HK8&*4-N02@R,0N-VY>W'&#D^,[GP MMI7QF^']_INI0RVL<\_VS5)KLS*S +PT[$@D9^[GY=PX&16WXSU.SM/VE? & MLWTZ6>GRZ;/B>Z/E*"TZ5KFB>%+)+74/$FIQM M*\A1HK>")!\\S+N9L$@A5W')XW#K61XA\?:Y\.]:TW_A-TTV\T'4IA;C5-/A M>W-I*1D"2-W?*X!.0PX!XXP>7\4W\?AWX^^&_'=Q*7\,ZK9?V>;\@B.!COVD MDCA22I!Z$%B.!6U\>;8>)O!VF^&-*,=SJNKZA";6)3N(09+3''1 .K=.: *G MQ[.=2^'Y'(_X2&'^:UW/C+QF/#5SI.EV-LM[K.M7'V>QMG?8@QR\CG!(10WGOQU\FPN/AU;R3J/)UN'EVP2JE 6.>WJ:D^,$=QX>^)G@KQY*DDNC: M=*;:^=!N6V5SCS"!V(<\^J@=Q0!T'BWQKXH^'45KJ_B:'3=5T"298;N73K>2 M":S+=&VO(XD7M_"% ZXH V/%WC_Q MAX U;1[?5=/T?78-:G%K;RVK26/DS$@!7W&7(.>&&.AR!5/Q]X^^('@Z_P!" MN)K/P_9:/JUQ%:SRSQRSG3I&P&WNLB"1<;F!"KP"#TR9]0LQ\1-?T'_A(]<\ M-0V6CW2W@L]*U/[5)=S+@+DLJ;%SGY0&)SC-=QXW\*VWC7P7J6@WF%%W$1'( M1_JI!RC_ (, ?<9'>@"G\0-;UOP[X02[T%]/DU9[F"VBANX'9+F21PFQ0LBE M3EMV.XZ/3UO5T^ :K)!+>!!YSVT;)&6[[59F('U)KQSX5:GK/C:_P!+ MLO$EM+$W@A)(+LR?\M[W+11GW*1!R3_>?/I7M= !1110 4444 %%%% !1110 M 4444 %%%9VLZ_I7A^T^TZS?0VD?\/F-RWLHZD_2FDY.R#8T:"0JDL< 6:]XV\1>)6;^U]4GEB8_ZA#LB M'_ !@?B>:].CEE:IK/W482K16Q]&:Y\3?">@;DN=5CN)E_Y8VG[UL^G' /U( MKS_6?V@6W,GA_1@!VEO7SG_@"_\ Q5>*T5ZM++*$/BU,95I/8^@SXRU75+2* MX2Z:&*>-9%6,!2 1D1O5V)/ZUSO@N[^U>&(5)8M S1,6 M/7!R/PPP'X5O5XE6G[.HX]C9.ZN%%%%9C"BBB@#C?BA_R*D'_7ZG_H$E>3UZ MQ\4/^14@_P"OU/\ T"2O)Z[Z'P$2W"BBBMQ!3X9I;>59;>1XI%Z.C%2/Q%,H MH ZW2OBEXUT+45E*C3ENAJ31]7Z#\;O!>M[4EOGTN8\>7?IL'_ 'V"5Q]2*[Z" MXANH$GM98YHG&5DC8,K#V(ZU\)5IZ+XDUGPY<>?H>IW-B^HKYX\,?M%ZC;,D/BO3TO8NAN+0".7ZE2=K?AMKV7PSX\\. M>+HQ_8>IQ33;)?M5_\DLTW_L-1?\ HB>O;:\X^*/PQU?XFVL>G3>)K;3=*@N%N(H$TLR2 M[PA7+2&8 _>?&%7KSG&:W'T;QQ-:_9Y/%^F19&#<6VA,LWX%[AD!_P" &@#R MOXOI_P )7\?O WAS3,RW-A(MS=E2?W49D5SG'0A(R?\ @2^M;GCX#_AI;X=G M'/DW S_P%Z[?P;\.=&\&7%W?6K7-_JU\=UWJ=])YD\W.<9P !GL!Z9S@5B^) MOAMKFO\ Q&TSQ9;^*+.SDT@,ME;-I)D4*V=V]O/!8G)Y&WV'>@"KXPT;Q?I? MQ E\8?#]['5I?L<=GJ.BW,@5RJDNI1L_*<-T./7#9Q65+\1K77/ACX[OM(TR MYT#Q-9VQ.IVDH(EBD,>P2 \9PJXS@$;1D=*[2[\(:^GC.Z\0Z'XGCLS=P10S MV-SIYG@?8.&P)48-R>01P<'-3Z%X$M--O-=U#5IEU74?$ 5=1D:$1Q.BIL6- M8\G:NWCDL3GDF@#EO#&@ZYXC^#NFZ;8Z]X?71[_2$MPBZ'*S(C1[6&[[4 7! MSD[?O G%95_X8\,>%O@S9^&O%NO7FL6UCJHCM38Q>7-/NQRV%/^UM)X&2>M=+XN^%>F^) M/!6GZ!87MQI+:7.MS8W6GB[P![? FMWD+@JRPJ0H).#N8LT'Q7):S)I\=E-#>VGVF.ZVR22%Y M'3G,IQMV[>0.#@ '.:9\28=:T#QK/%HEQH'C/2]*D>[LY@2S&.-S&RGC< 6Z MX!P5ZC%'PST_7]9^#NDQ:9KF@#3[JR:.2.31I97W-D2AV%TH9MQ;)VC)SQ79 M:%X+33_$.I>(=8NUU+5]2A2WFD2W$,*0KT1(\L0#WW,Q-<3%\"KK0]8GF\#^ M.M6\.Z;!/"ESX=77?[:%I>O^ M\^S^3Y&Y$?R\;FS][=G/\>.U=O6=H&AVOAS18=-L3*Z1Y9Y9W+R3.3EG=C]Y MF)))K1H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH *R]>\-Z7XDL3:ZM;+*O57'#H?4-U'\JU M**"X5)TY*4'9H^;O&?@/4/"%P'D/VBQD8B*X4?D&'8XKE:^H_%=WI-EX8O)/ M$*+)8E-KQD9,A/15_P!K/0]NO&,U\OS&,SN8%98RQV!CD@=LFN:<5%Z'Z1DN M85<;1;JK5:7Z/_@]R+SY89,PRNA&.58BM[1O'OB/16D%EJ3#S<;O,17_ /0@ M:Y](Y+FX$<*/(['"J!DFNQT+P>L+)OTK6*=K(\['8C#4Y M.I62?DU>YZU\.[OQ1JNGOJ?B:XS!,H^RP^4B$CNYP,\\8Y]>.E=I5/2;LWVD MV]PWWG0;L>HX-7*M*R/C,165:JZBBHI]%L@HHHIF 444C,$4LQ 4#))[4 +1 M2*RN@9"&5AD$'@BEH ***YKQA/>Z;IWVZQOIHB9 ACPI7!';C/;U[T =+15& M".6\T:USZC!>'4)VF:*0*I( QU]* .FHHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK M&U?Q3IND;DDE\Z@KB-5\9ZGJ)*0O\ 9(3_ 1'YC]6Z_EBNFEA MJE379$N21W^HZ_INE9%Y=*'_ .>:_,WY#I^-M?\ KV'_ *$U<96+W ** M**0!1110 4444 =9X?\ B?XO\-;4T_69Y(%X%O='SH\>@#9V_P# 2*]6\-_M M&VDY2'Q7I36K8YN;(ETS[H>0/H6KY]HK&=&G/=%*31]MZ%XHT3Q-:^?H.IV] MZF,E8V^=?]Y#\R_B!6M7PK9WMUIUTESI]S-:W"'*2P2%'7Z$?& DZC_ -!?\<'U-<53"26L-315%U/I*BL'PQXVT#QA:^;H M6H1SNJYD@;Y98_\ >0\_CT]ZWJXVFG9F@4444@"BBB@ HHHH S]5U_1]!B23 M7-5L=-CD.$>\N4A#'V+$9JU:7EM?VJ7-C<17,$@RDL+AU8>Q'!KD7^&.@:QJ ME_JOB_3[?6=0O)&56N,NEO "1''&IX7"X)(&2Q8YKBOA1HS^#OC/XT\*Z//+ M)X?MX8;F.%F+"WDD"L%R>AP6'J0HSTH ]IJM::E8Z@]PEA>V]TUK*8;A895< MPR#JC8/RL/0\UA>*]7O3/!X<\.R!-9U%"WGXW"QMP;1+#3_&-G$\CI;^(IXE>5MS,%"@$GN>.30!ZA<^(=&L]5BTR[U>P@OYL>5: M2W*++)GIA"HP=H M [9./?UNQ\37&D_"[0M3U:*6[U>ZL+5%M1Q+=7;QK\GL2V23T4 D\ T =2+R MV:^>R6XB-TD8E: .-ZH20&*]0"01GV-35A^%]!DT>SFGU&9;K5]0D\^_N0.& M?& BYZ(@PJCT&3R23N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%9/B+Q-I?A;3&O=7N!&O2.->7E/HH[_P O6FDV[(+V M-.::.WA>6>18XT&YGE1PJ6LSEG5OI$GO+VZU&[DNK^XD MN)Y#EY)6+,WXFH***[C **** "BBB@ HHHH **** "BBB@ J&^_Y!=U_N+_Z M&M35#??\@NZ_W%_]#6DQQW.=HHHH-@HHHH **** "BBB@ HHHH **** "O2O M 7QHUKPEY=EJ>_5M*7Y1%(_[R$?[#GL/[IX],5YK14RA&:M(:;6Q]L^&O%>C M^+M+%_H-XMQ%P)$Z/$W]UE/(/Z'MFMBOB#0O$&J>&=434-$O)+2X3^)#PP]& M!X8>QKZ7^''Q@TWQHL>GZD(]/UK'^IS^[N/>,GO_ +)Y],\UYE;#.&L=4;1G M?<](HHHKD+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBHYWDCA9H8_-<#A-V,_C0)NRN5-8O6L[$F+B1SM4^GO7#MX:Q)XR>U9MK<:U%XCLTM+M(].;/G( MY ]^>]?/3?/G"IU]DKQOM>W_#_<8U*L947RW:O9V_K[SEO%7PE;1K!]2TB\ MEN1#\TB.,.!Z@CK3O"OQ#U:/[+X?O[1]12=O*\X.?-5#Q^./6N]UF^@T/PQ< MVMQJ+7]Q.'5/,8%OF[<=A7.?#+0FAU2;42N$6/8I/#*#A MC84\-I=>\M['2Q>&]0\/Z=96'A&YC2!;DR7)O29&9"$+"\BN['PKHEM&[UG MP[I.H7)4*9KNQCE<@=!N92<5LT4 9^DZ!H^@0R1:%I-CIDK MYX7T6X%O$(81+I\3>5&"2$7*\+D MDX'')K=HH PI? WA*>TM[6?POHLEO;;O(A?3XBD6XY;:I7"Y/)QUJ9?"7AQ= M';25\/Z6NFM)YC60LH_)+_WMF-N??%:]% &>_A_1I8K.*32;%X[%MUHC6R$6 MY]4&/E/TQ3]2T72M96$:QIEG?B!_,B%U;K+Y;?WEW X/N*NT4 17-I;WEJ]M M=P13P2#:\4J!E8>A!X-4])\.Z+H*N-#T>PTT2??%G:I#N^NT#-:-% &-J?@_ MPSK5X;O6?#NDZAF>&-!T2X>?1M$TW3YI/OR6EI'$S?4J!FO//BUJUI;>)=%M M/&7AV>_\&K&\]Q>16QG"7/*HKXY10N3QRQ8#D!A7J]% '@=OIGP.\4+-!X3\ M.3ZU>OG;#86UW%AO4R-M2,#CDD#Z]*Z^;XB6GPX70?!NOVFLZMK/]F1[9[.U M\U;F15VE5)8,6)7TXR"2*]-HH YWP1HMSH^@O+JJ(NJZG'K WNLW MD=I #@,YY8^@ Y)]A7*^)?B3:V.ZVT/9=SC@S'F-?I_>_E]:\4\;27NM2_VK M>7#SS(-KECT7/&!VP3T'K[5Z&&P3JR7/HC"=9+1'8^+/CM3ZAJ5[JUX]WJ=U-=3O]Z25RQ_7^55:*^EHX>E05H(Y93E+ M<****Z"0HHHH [7X=W>+B]LSN.Y%E7G@8.#^>Y?RKNJ\I\*7?V/Q/9L<[9'\ MH@'KN&!G\2#^%>K5\[F,.6MS=SIIN\0HHHKSC0**** .-^*'_(J0?]?J?^@2 M5Y/7K'Q0_P"14@_Z_4_] DKR>N^A\!$MPHHHK<04444 %%%% !1110 4^*:2 M"9)8)&CD0[E=&(*GU!'2F44 >I^#?COXAT%H[;7\ZU8C@M*V+A![/_%Z_-DG MU%>^>%/'GA_QG;F30[Y7E49DMI!LEC^J^GN,CWKXPJ:TN[BQNX[JRGDM[B)M MT^ MJ\^QZU[OI^HV>JV,5[IMS%=6THRDL+AE;\17G5*4J;M(V4D]BS11160PHHHH M **** "BH;R[@L+&>\NY!'!;QM+*YZ*JC)/Y"O+-8\9?%B/3I-?TCP=I::1& MIE%C=S.U^\0YW$*P53CG;R1TY- 'K-%L :_IT/A+5_$M MKIRZ/XJECABCM5D$UBTJ[H=[EB) 1UPJ8]Z /4:*J:KJEIHNDW&HZC*(K:V0 MO(V,\>@'6_P!0 MD%I;H@R=S Y/_?(//TI-V1M1I2K5(TX]3R+XF^,F\2:ZUI9R-_9UFQ2, \2O MW?'Z#V^M5M"^'6KZKI[:E=(;&P1=WF2#YY/]U?ZGBO1_!/PIM-'V7WB!8[V^ MSE8C\T47X'[Q]^@_6ND\:78@T58 0&F< #.#@9Z5HUIIJB*QBP[<&1N6;ZG^E=O/X'G%HDEM.&EV@M$XQ@]\&CP? MH9EF74;I/W:']T#_ !-Z_A_.NWK;8^3E*4Y'1((2L3E)+BY)";AG*@#DX/&>E:]8<.NS:GJ$MOHD$@'/\ GI5:Q\4W^F7\>G^*(/*+$!;D# /N3T(]2.E:/CC_ M )%2X_WD_P#0A0!;T4ZE]EM_M8M!!Y*[?*+;N@QG(Q39M9>;6CI6FJC31KOF MFD&4C'I@$$GIW'6KVG?\@NU_ZXI_(5Q?ABR74M8UCS;VZAE$H(\F8HS#+9SZ M]OSI ;NKZS?Z ]O/>K;W-G*_ENT4;1NC=>A8YX!JOX\<2>%0Z\AI4(_(U:N/ M"-G=QA+J]U"= VX++$UC3[J2(H^@!I@=#I_P#R#+7_ *XI M_P"@BN8\ ?ZK4O\ KX_QKI]/_P"09:_]<4_D*YCP!_JM2_Z^/\:0C> MM,9U6M:M'HNFM=2(9#D*B XW,>@SVJO=2:[#ICW*&R:94WFW\ES]0&W\G\*F MU[1TUO2WM'%)8F#QR*&5@>"#T-/I %%%% !1110 4444 %%%% !1110 44 M44 %%%% !117)>(/&T-D7MM*VSSCAI3RB'^I_2M*=.51VBA-I;G0:GJ]EI$' MFWTP3/W4'+-]!7 :UXUOM1+161-I;]/E/SL/<]OH*P+J[N+VX:>[E:61NK,: MAKUZ.$A3UEJS&4VPZ]:***[" HHHH **** "BBB@ HHHH **** /,OB9_P A MZU_Z]A_Z$U<979_$S_D/6O\ U[#_ -":N,K%[@%%%%( HHHH **** "BBB@ MHHHH FM+NXL;N.ZLIY+>XB;='+$Y5D/J".17M/@;]H&XMFBL?&T9N(?NC4(5 M_>+_ +Z#AOJ,'V->(45G.G&HK20TVMC[FTS5+#6=/CO=*NX;RVD&5EA<,#[> MQ]NHJW7Q9X4\::YX,U$76AWC1J3^]MW^:*4>C+_7J.QKZ9^'_P 5M%\SE;[_ *F,_P 0]NH],(=>7 M1;6-8(OM>I7;&*QLE8!KB3&>O90.6;H /H#2\)>&&\+Z5>3W$@OM9U&9KS4+ MD<>=,1]U<]$4851V ]S7'W_PP\;W?BJ[UZW^)IM+FX7RE6/1$80Q Y$:;I#@ M>N.I&3FMCPQX$\2Z;XCAU/Q7XZN/$D5M&XMK5K%;9(Y&&/,.UB&(4L!D<;CS M0!R&@>)/B1H\E]=W?PIN+[4]0F,MS=G684R!PD:KM.U$7@#)[D\L365\"/$' MB(:]K]F/"4AL;[7KB6^OOMR8L)"N3&4VY?! &01UKZ KDO ?@;_A"?[=_P") MC]N_M?5)=0_U'E^5OQ\GWCNQCKQ]* )=6\"^$;BZNM6U73HP&87-WNGD2WE9 M!D22Q!A&Y'75C9L\)NP6&#NP!P,YURJE"I4%2,$$<8H M\ _X2;Q"?@6WQ5_MF\&L?;/.6U^T/]D$'VKR/(,&=F,<[L;_ /:KWFQNA?:= M;7:*46XB64*>H# ''ZUYV_P=C;07\++K;KX1>\^UG3!;#SOO^9Y0GW<1[N<; M-W^U7I2(L:*B*%51@*!@ >E "T444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !117$_$+XB6W@^S^S6NR?5IES'">1$/[S?T'>JC%S=HB; M25V6_''C[3_!EC^\VW.H2#]S:JW)_P!IO1?Y]J^=-?\ $.I>)=4>_P!6N&FE M;A5_AC7^ZH["JNH:A=:KJ$U[J$[W%S,VYY'.23_GM5:O7HT(TEYG'.HY!111 M709A1110 4444 %%%% !1110 4444 %%%% !4-]_R"[K_<7_ -#6IJAOO^07 M=?[B_P#H:TF..YSM%%%!L%%%% !1110 4444 %%%% !1110 4444 %.CD>*1 M9(F9'0AE93@J1T(--HH ]_\ A;\;1=-#H?C2=5EX2WU%S@/V"RGL?]KOW]3[ ME7P=7M/PD^,;Z8T'A[Q9<;K'B.UO9#S;]@CG^YZ'^'Z=//KX;[4#6,^C/HBB MD!#*"I!!&01WI:\\U"BBB@ HHHH **R=0\4:-I>OZ;HE]?)%J6J%_LEMM9FD MVC+'@$*,=S@'M3];\1:5X>AA?5KKRC<2>5!$D;2RSO\ W4C0%G/LH- &G16= MH>OZ9XCT\WNBW:W4"R-$Y"E6C=?O(RL RL.X(!J74M6LM(@BEU";REFF2WB M1G:21SA555!)/T' !)X!- %RBBB@ HHHH ***RM7\0VVDRQVYCENKR89BMH% MW.P]?8>YIQBY.R(J5(4X\TW9&K17._\ "6_994&M:5=Z;%(0JSR89,^A*]/Q MJWK?B&+11:9MIKM[M]D208))QGN:OV<[VL8_6J/*Y7VWW_+1H@0H]< YJ_/XCLHK6PN8BT\-]((X MFC[$^M/VB,88YXTU33;[3DE8(DMQ'\I)[$C.*KV4[7L9/&4% M+EM[?,T****DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR>]\1ZM\2_ MB!?>$O"U_-I>@:,0NL:I:MB:>3)'D1-_ .#EAS\I[8W>IW32)9S-""9%C8H M,\XXXKP?]GOP=H7B/X77EUKUJNIR7FH2B=)Y&9,@+@E,[=W.=V,\]: /5!X> MT;P+X+WN=(^ &A_$2TE+^*Q>Q MW4FI,Q,UT6F96A=NK)MXV?=^7CWZKX9?;?"_QD\5?#WSYKK0;>U%]8QSN9/L MZL8_W8)YQB7&#_JE^&?AG2+*-[V^O4\/Z5<-J,6ESSI]CM7&6+_ '=^ MT$L=IP !9F_A56/:F^&-! M;0].D-Y.+O4[R3[1?W>W'G2D <#LB@!57LJ@5S$NIO9:+JWQ(UVV<"ULI&TJ MPD&UH+?&06':24A2?[J[5[-GGF\<>)O#OAWP9XLUO4A?6GB2Z@@O-/%O&D=J MLZ%XVA*C?\H'(=FS_LT >Q4444 %%%% !1110 4444 %%%% !1110 445SOB MGQA9^&X-G$]ZX_=P ]/=O0?SJHQE-\L1-J*NS3U?6K'0[(W.HSK&O\*]6<^@ M'>O(_$WCC4/$#-!&3:V.>(4/+_[Q[_3I6-JNKWNM7S76HS&60\ =%0>@'852 MKV:&%C3UEJSBJ57+1;!2,H=&5P&5@00>XI:*[# X74[$Z??/#R4^\C'NIZ?X M?A52NRUW3_MUB6C&9H,&WE>/KU_BS_X] MC\*\K,H7IJ?8UI/6QT5%%%>"= 4444 <;\4/^14@_P"OU/\ T"2O)Z]8^*'_ M "*D'_7ZG_H$E>3UWT/@(EN%%%%;B"BBB@ HHHH **** "BBB@ HHHH *Z7P M9X]UOP/J'GZ1<9MW8&>TDYBF'N.Q_P!H<_RKFJ*32DK,-C[#\"_$C1/'EF?L M$GV:_C7,UC,P\Q/=?[R^X]L@9KKJ^%;&^NM-OH;S3YY+:YA;?'+&VUE/J#7T MA\+_ (SV_B8Q:/XF:.UU8_+%/]V.Z/IZ*_MT/;TKS*V&CL;1G?1GK5%%% M<9H%%%% #)H8[B%XIXTEC<;61U!5AZ$'K6?XCUVU\->';S5KW)CMHRRQJ,M* M_18U'=F8A0/4U8U75;'1-*N-2U:Y2UL[9#)--(>$'^>W>O%+;XZ^ ]9U\:KX MCU*2*"RE/]F6'V.5_+(X^T2$#!D(^Z.0@/7). #M/ACH(^&GPF0^(I4M90)- M0O\ ^[ SOP-#?W6@WD=G:2=;"V,+$) M[2/@,Y]<+T45I:=K7AKXU^&=6L([6XNO#WF1PO.Y:$SR*1(0HX8!<1\\9R1C MCGC_ !G\!/A_H_@/7]3L-*GCNK+3;BX@F^(-.MGCU'5;)#=R&5F#X)/"D MX'X5U/B:\N-:U)?"6CS20R31B74[N(X-I;$XVJ>TDF"J]P S=AD SKS4[/7+ MZ?Q#J\X@\)^'7>2)V^Y>7$>0TW'WDC(*J.=SY/\ "I.CI'Q"TW5-6L-.N+*_ MTN?5(&N--^WQH@O8U )*;78@@$':X5L'.*ROBWX6N-4^"NJZ%X9MMCQ01?9[ M2!<;DB=6\M0/]E>!W.!7*ZI?6_CKQM\-H_"K^?\ V0[7>HF(<6"!$'ER_P!Q MR05V'GVH ]JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H7LX);V&[DC5IX%9(W M(^Z&QNQ]=HJ:B@:;6P5SE]H\NOZP);HM%8V_RHN,&3U(]/3/L*Z.B@0V*-(8 MECB4(B#"J!P!3J** &RIYL+QDE0RE&9KJSN--GNHY)-R2P8 M(/'^%=I10!QE_::I)XLL-4FLI'C1!N2( ^6N3\N>Y[GZXK>O;^ZAN+*XAM+B M2V8.LZ*GS)TVG;^!_ FM6B@#E]>LIO$[V=O#:SP0QR;Y)IEV87N #SG\*O>+ M;&XU#P[-!:(7ERK!1WP:VJ* ,;0[Z\N;.UCDTZ6W6.(++),0N2!CY1U//KBL M6\T;4M"\1'5-#A^U0SD^; #@C/)'T]#_ )/9T4 9,.KWEWA8-)N(F)'S7!"* M!GD]<_ABL[QG'=ZCI_V"QL)YF\P,T@ "@8[$]>M=/10!EV5_)%I,7FV%V)8H MU1HQ'R2!VYZH>'?$ M]Y.+*>]M;K.'B(9ADY&?Y4GB2UU75IK"Z2QE$<4A(@&"RCC);W/8>WO7:44P M,J_OKO['! M?RKHZ*0$%C;"RT^WM0VX01+'N]<#&?TJ>BB@ HHHH **** "BBB@ HHHH ** M** "BBB@ J.XN(K6W>>YD6.)!EF8\"HM0U"WTRS>YO)-D:_F3Z =S7E^O^(K MG7+CY\QVRG]W"#T]SZFNFAAY57Y$RDD7_$?C";4R]M8%H;3H3T:3Z^@]JYBB MBO;A3C3CRQ,&V]PHHHJQ!1110 4444 %%%% !1110 4444 %%%% 'F7Q,_Y# MUK_U[#_T)JXRNS^)G_(>M?\ KV'_ *$U<96+W ****0!1110 4444 %%%% ! M1110 4444 %/BFDMYDF@D:*6-@R.C$,I'0@CH:910!] ?#'XXB[>'1?&TJI* M<)!J1X5_02]@?]KIZXZGW $,H*D$$9!'>O@^O6_A5\8Y_#30Z)XFD>?2"0L5 MPE<%?#?:A]QK&?1GTM13()XKFWCGMY$EAD4.DB-E64\@@CJ* M?7G&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !116!XR\6VG@_09+ZYP\S92W@SS*_^ ZD^GX4XQV_@W2]D.V;5+A3]GA[*/[[>P_4_CCYNO;VYU&^EO+Z9IKB9BTDCG)8U- MK&KWFNZM/J.I2F6XG;W3IT^A:^+-%\/FYVW-^I6#JL?0 MR?X#^?;UKZ)^&?CG[=&FA:M)_I"#%K*W_+11_ ?<#IZCZ<^7B81YKQ^9K"71 MGI5%%%<9J%9OB#7+;P[HTNH7:O)M(2*"(9DGE8X2-!W9B0!^O%:5>;^-](^( M5UXZL-5\)P^'[JQL+8BWBU9Y?W<[9#R!4(RVW"@GH"V,9.0#C=6T6\L/CW\/ MM2UV42ZSJ;7"KJ^W+8/8W4 M%K(YPBW)5LC/]YEP .]>?>+YOB@WQ=\$MJUMX8765^T_V:MN9_(;Y/G\W+;N MG3%>]P::^M>&;:U\9Z?IUY;;F3'.U7SD9Z9YH X'X8S*/B!\3=4 MCD":*VHQ".8M^Z\V-'\]@>G7;DUT_AZ&7Q1K"^+-1B9+2-6CT2VD&"L3<-C28[; M5_B;&!JX3Q3^T-%X7UV%+C1-/T$WL=A.NZ&XF:54WLAX; /&0<;21ZT >K45 MYE\%]3NYH_%FB7$TD]IH>O7%G8O*Q9EA#';'N/4+CCV..@%>FT %%%% !7+> M&E%WXG\07T_S31W(MD)_@11T%=37+WEIJ&@^(+C5M+M&OK2] ^U6T9 D5@,! MUSU^E:T]4X]6<6*NI4ZEKJ+U^YJ_R-[4[2*^TNYMKE0T M$KJ=9;AHKIEQ&-S.%R!CU.!71W^L:KK=J]AHVDW5LTR[)+J\3RUB4]<#J33; M[0I+.3PW;:?#)+!8W&9' ^Z,E[BM+^M&<&+O7?/23LDE>W7FB_G:S^ M\-4\9^1ILSKHNHYVD9EAVH,\9)]*Q=0CCT+PAX?>643I'="5FA^8'.3A?6O0 M;J(3VDT1&X.A7'KD5Q%OI.HGPWH5M)92^9:WN94*_=4$\_2BE*-M--?T88NE M6YG=\S<=--M8]N_Z"6=T^O>+8E\3P26L>P2Z?9R?=>L;CI^%9-S>Z[=^$)K:33IDU-B+=BJ_*0>#(#Z M8J)6J6MITL;TW+".:FG)O5/J_)^?;R,D)9^(;/6[^XNX$FG;9:[Y5!18SP<9 M[D5HW>J#6/A;<7607^S[).>C @&M2T\&Z%!9PQ2:9;2.B ,[1@ECW-8-WHM[ MI]OK^EV%E(]E=1"6V\M?E5^Z"M5*$WIT:..5&O1@W-+WHM.UWJ[M/[[KYDWA M ?V-JITP\07MNEU;CL&Q\X'\ZQ_%W_$YN-1O^MOISQ6T/H7+@L:Z#7=+U#_A M']-O-+A8ZG8*NU .2",,M5[W0+J#X=I8P0O->/(DLJJ.2Q<%J<91YU.^KT_K MY&=:C4=&6'Y?=BG)?-:+Y._W(;+>W5EX_F:STZ6_9K&,%(W52H]>:B\4:M?7 M]E%9ZGH\VF6$LR>==R,)/+ .>B]/J:MW,E_I7C*2^CTB\O89+1(@T"C@CKUI MVJW^L>(=,ETRTT&YM?M V//=LJJB]SC.2:2^*,K+IK6Z?S MMU]28[?^%F6?EGIA(OWW)?:?Y(****Q.X**** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "O/M*\%:UX(\0:M<^"CI]UI.KSFZETR_G>W%M.1\SQNB/E3Q\I48P M,'BO0:* .5\*>#FT;6-6\0:O<1WFNZPZFYFB4K'%&@PD48/.T #)/+'GCH+F MO:%=:_JEC!=R1#0H#Y]S;@DO=2J08T88QY8/S'DEB%&, YWJ* *&O:-;>(?# M]_H]^&^S7UN\$FTX(##&1[CK7G:?#/7M2TSPMX>\1WFGOHGAFYBN$FMFY]3[?Y/D-Q<37=P\]S(TLLAW.[G))ILDCS2M)*[.[DLS,X_K^/M7856U"S6_LG M@;@GE6_NL.A_SV)K2E/DD,X.BG.C12,D@*LI(8'L13:]$84444P"NQ^'EULO M[RU('[V,2 D]U.,?^/?I7'5J^&;K['XFL9, AI?+.3@ -\N?PSG\*Y\3#GHR MB5%VDCUJBBBOE#K"BBB@#C?BA_R*D'_7ZG_H$E>3UZQ\4/\ D5(/^OU/_0)* M\GKOH? 1+<****W$%%%% !1110 4444 %%%% !1110 4444 %'3I110![S\) M_C1GR- \97//$=KJ,A_ )*?Y,?Q]:]XKX.KW+X._%\VS6_AGQ5.3"2([*]D/ M^K["-S_=[ ]NAXZ>?B,/]N!K&?1GO]%%%>>:A1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M5M0U"WTNR>ZNWVQH.G=CZ#WI]W=PV-I)1,I6&:YKMSKEX99SLB4_NH@>$']3[UF445[D8J*LCGW"B MBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** /,OB9_R'K7_ *]A_P"A M-7&5V?Q,_P"0]:_]>P_]":N,K%[@%%%%( HHHH **** "BBB@ HHHH **** M"BBB@ HHHH ],^%'Q7G\&72Z7K#O-H?7/%B,/S>_'W M0O(Y[ ?U]J^7_&?BRZ\7^()+ZXW) OR6T!/$2>GU/4FNN^,'CGUSZ"O,:]7"T>5<[W9R59W=D%%%%=AB%%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 5#??\@NZ_P!Q?_0UJ:H;[_D%W7^XO_H: MTF..YSM%%%!L%%%% !1110 4444 %%%% !1110 4444 %%%.CC>:18XE+NQP MJJ,DF@!H&3@5T^C>'?**W.I1@MU6!AT_WA_3\_2K6CZ$FG[;BYP]UU '(B/M MZGW_ "]:UZY:E7I$=@)))).2>IITH/N#P?I7+4CRLVB[ENBBBLRCG=8\%:=K? MC#0_$EW-=)>:)YOV:.)U$;^8N#O!4D^V"*WYHVEMY(TE>%G4J)(\;D)'49!& M1[@BGT4 4-$T:T\/Z/!INGJ_DP@Y>1MSR,3EG=OXF8DDGN2:SM>\'66N:M:: MNEU>:9JUG&T4-_8L@D$;?>0AU9&4]<,IP>1@UT%% &/X9\+Z9X2TDZ?H\;K& M\SSS2RN7DGE<_7/\ 2G444 ( V\Y(VXX&.1^-+110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 445D^(]?@\/:1)=S?-(1MAB[NW^'K3C%R=D)M)79F^-/%L?AVQ\FV*OJ$R_ MNUZ^6/[Q_IZUXS--)<3/-.[222,69V.2Q/>IM0O[C4[Z6\O9#)-*V6)_D/:J MU>]0HJE&W4X*DW-A111709!1110 4444 %%%% '-^)=/VL+Z(<-A9!Z'L?Z? MEZUSU>A31)/"\4HRCC:PKA+RU>RNY().J'@^H[&NVA.ZY6,@HHHKI&%*#@Y' M6DHH ]HL;H7VGV]TN!YT:N0#G!(R1^'2IZYKP)>?:/#OD$KNMI60 ==I^8$_ MB6_*NEKY*M#V=24>QV1=U<****Q&<;\4/^14@_Z_4_\ 0)*\GKUCXH?\BI!_ MU^I_Z!)7D]=]#X");A1116X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** /H/X*_%8WZP^%O$D_^DJ-EC=2'_6@=(F/][T/?IUQGVZOA!':.17C9 MD=2"K*<$$=P:^IOA!\2E\::-_9^J2*-:LD'FDX'VA.@D ]>S>_/? \W$T+>_ M$VA+HSTFBBBN$T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **J:GJNGZ+I\E]J][!8VD?WYKB0(H_$_P JJ:#XGTOQ+'++HTEQ-#%M MS,]I+%&^[)&QW4!^G\)..,]10!K45S=G\0?"]_JD-A::JLDMQ*T-O)Y,@AGD M7[R1S%?+=AZ*Q-=)0 453T_5K+56NAI\WGBTG:WE8(P42+]Y0Q&&P>#C.""# MR"*N4 %%%% !2$A5)8@ #))[4M<7XV\0;%.E6;_,P_?LIZ#^[_C5TX.X/\ >_QJ-E*G##!KWZ2C M&/+$Y^:^HE%%%:@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YE M\3/^0]:_]>P_]":N,KL_B9_R'K7_ *]A_P"A-7&5B]P"BBBD 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% 'OGP-^)OFK#X1UZ?YP-NG3N>H_P"> M)/\ Z#^7H*]UKX0BEDAE26%VCD1@R.AP5(Z$'L:^L?A-\0D\<>&Q'>R*-8L5 M"72=/,'02@>_?T/H"*\W%4;/GB;0ET9WU%%%<)H%%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 44CNL<;.YVJH))/85YYJGQ/FBA\[3+"#R",QO=3$,X['8HXS[G M/L*TA3E4?NE1BY;'HE9OB/68_#OAG4=8F3S$LK=YBF[&_:,A<]LGBO+;']H& MU@U6*T\1:6+>&1PGVJUE+A,]RA ./H3]*WOCMJ7V'X1WZHW-[)%;J?7+!C^B MFMUA:D:L836[*Y&I),XH?M-DJ6'A-BJXW$7O _\ '*W6^/\ 9-X$;Q!#HDWG M)?K9-:/.!DE"^X.%Y&!TP*\4M)XK#X,:BHE3[3JNL11>7N&[RX8R^<=<;G%5 M=4_T/X9Z!;=&O;RZO6'J%V1+_P"@O7M/!8=NRC;6V[['1[.'8]9'[30&UI/" M<@1NA%[U^GR5Z*K^5[.TO(]T4+C,C-R-@ ZG(/MWKY;U>_77] M%\*>'M AGNKBQMI$>)(CN>XED+,%'?C;S75:[IEWJ_CO0? [R^5'IT%MIX . M0C%%:5_B#]HO13>;&T2^% MOG'F;TW8]=O_ ->O3O#WB/2_%&DIJ.BW*W$#'![,C=U8=0:YN3X/>"WT4Z>N MD*AV;1=!SYP/][=Z^W3VKROX37=SX0^+E[X'S=BQF,)F^U[-Y'7 MC8<"PFN))W;TWN^(FM/XA\1FYB;?96$$%A"V>/DCYQ]6WG\J^M_L M^CS05O7?R/*]E&Z/I7P)\1U\8>#]0\17>G?V9:V,CJ09O,W*B!F;.!ZUQ>@? MM$#7?$FG:4OAHP_;KE(!(;S.SO2N?O+__ (13]EBPM4;9=:]*P]]C M.68_]\*!_P "KB/".E_V;\4?!T##$DLEI$HM5)-=7;?H2 MJ<=6>\?$CXRV?@'5XM*ATQ]2O6B$L@\[RTC4DX!."23C.,5S.C?M'?;=>M-/ MU#PR]LMQ.D)=+KN7/ MP0@O/B0?%ESKDCDWZWAM/LPQ\K A-V[IP!G%0Z6%HTXJJM6K]=QSS0K%=P&SOBK6F_'O[;X;UG6+GPX]K%IJ1>6 MK7.?M$DC;54'8,< G// KS[]H>_;4/B=%8Q\_9+..(*/[SDM_)EK<^.=T\%A MX3\"V'+Q0QLZ+W; BC'_ *'6D<-0E&FN366N[V7^8U"+2TW.T^'?QH_X3WQ2 M='&AFQQ;O-YOVKS/ND#&-H]:]3KYJ^!EG'9_&K5K6#F.UMKB)3ZA947^E?2M M>?CJ=.G5Y::LK(QJ)*5D%%%%<)F%%%% !1110 4444 %%%% !7%?%#QC_P ( MKX:,=I)C4;W,<&#R@_B?\.WN17:,P12S'"J,DGL*^YXKHP\(SJ6D9U)-1T.')+$DG)/))[TE%%>R<04444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#??\ (+NO]Q?_ $-: MFJ&^_P"07=?[B_\ H:TF..YSM%%%!L%%%% !1110 4444 %%%% !1110 445 M:L-/GU&X\JW7IRSG[J#U-)NVX$5M:S7EPL%LA>1N@';W/H/>NSTK1X=,C#<2 M7!&&E]/9?0?J?TJ;3].@TVW\NW&6(^>0CYG/]![?SZU:KDJ5>;1;#L%%%%8C M"BBB@ KT+X5>*O[.U0Z+>/BVO&S"2>$E]/\ @73Z@>IKSVE5BC!D)5@<@@X( M-3)75AIV9]445SO@?Q&/$OAF&YD8?:HOW5R!_?'?\1@_F.U=%7(U9V-PHHHI M %%2RY'7;ZYH ]#HKP*'Q%KVN?!K5_B M9%K=];:K!>//9VRW+"VB@24*(&A!"/E+O%M MSXE\1-?*S101?);1Y^XGN/4]_P J[#XN>+C/,=F^GO[59KGJT+34< 1W1) M&>),9(^OK]>OUKOLXP0>A!R#12 **** "BBB@ HHHH *QO$6G_ &FT M^TQC]Y .?=._Y=?SK9HZ]:J,G%W0SSJBM#6-/_L^_94!\E_FC/MZ?A_A6?7I M)IJZ&%%%%4!UWP^O/*U6YM&*A9X@PSU+*> /P9C^%>@UY%X?O/L/B&RG+*JB M4*S-T"M\I/Y$UZ[7S^90Y:JEW1T4GI8****\PU.-^*'_ "*D'_7ZG_H$E>3U MZQ\4/^14@_Z_4_\ 0)*\GKOH? 1+<****W$%%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 5H:%K=[X=URUU;2Y3%=6L@=#V/JI]01D$>AK/HI-75 MF!]J^#O%5EXR\,VVL:>0!(-LT6MRODSX1^/6\%>*E2\DQ MI-^5BN@>D9S\LO\ P'//L3WQ7UD"&4%2"",@CO7CUZ7LY6Z'1&5T+1116!04 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4V65(87EE8)&BEF8] !U- M.K,\2VDVH>%-6L[0;I[BRFBB&<99D('ZF@#PWPWXOT3QYXKU'QQXWN9'T?29 MS#HVDK;RW"P@#)N9(HU8Y(Q\S#&<\_*,>MZGK5MXP^&.M7G@J_34'N-.N8[6 M2U;YA-Y1VKZJV2.#@\BN5_9RD@/P;LK>,;;BVNKB*Z0\,LGF$X([':5ZUG_" M;3&TCXQ_$>STP%=&2YB947_5K,P+%5[#&6! Z#;[4 _L[?#^PT<[] M4?4[6.TCB;]XDZ,WF' Y&#G/ID9KV7Q1JEY-=P>&O#\IBU2^4M-BM2ZU'X?\*";Q#%H=FVK3L(8FM[9%N;N5^%C#XR23U). 2> M:Y[Q&FI^"/A/XEU_S1-XDN;8W%U=1CA)" JA,]$B!^4>Q)Y)H [O2M+L]$TF MVTW381#:VR!(T!S@>I/T#C4M4N[2VU*X4DMJ M23Q@R&4\ESGE2<[<\5[S0 444C,%4LQP ,DGM0!E^(M971=*:88,S_)"OJWK M]!7E,DCS2M)*Q9W)9F/4DUJ^)=8.LZL\B$^1'\D(]O7\:QZ]6A3Y(Z[LY*DN M9A3L_+M;D?RIM%=!F(R;>1RO8TVI 2.G?J/6AD!R4],E?2MHSOHRTR.BBBM" M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH \R^)G_ "'K7_KV'_H35QE= MG\3/^0]:_P#7L/\ T)JXRL7N 4444@"BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH *V_"'BF]\'>)K;6-/.6B.V6(G FC/WD/U_0@'M6)12:35F! M]R:-J]GK^BVNJZ9+YMK=1B2-N_N#Z$'(([$&KM?.OP \']!6Z@94WS+$[E/,900?NIGYCD#CG R<'%?-.J:C+/KQM["ZE^S M._[R,Q!%C'^R,#'TZ5]0^(M!77K.)%F\B>!R\,A3>H)4J0R\9!!/<'WKPGQA M\-]>?4)OL\^GQR1L!YB3.IY /3;[^M=U&I&--I246^K/0P3I\_OJ_H/\&>$- M"75XM2U:U;5"C*R0SOA0V>,*.&/L>M;/[3.H^7HFAZ8K?ZZXDG8>R*%'_H9K MSW2UD\&>);#4O$%U/J,NGS"86@F*QOC[K*QZD'L1U'I7MVK>#?"OQET_3/$4 MMY?F#R"D*P2*FW+?,&!4_,",'Z5I1YZ,X5JT^>/BQ>7:Z79P64 M$8.<%B7//F6086]G"D,>XY.U1@9]^*XS4/@WX;U/QH M?$]Y-J#WS7*7)3SE\LLN,#&W./E'&:UHX_\ ?.=1NVMD<<:OO79\_:UHUK9? M&Z+1/#B-:QP:A;VT9C&>2.[A)^ZS M* KIGUX_)A7I]I\&_#EIXV'BD3ZA+J'VMKO$DRF,R,2>FW.,GCFNLU_P]I?B M?2WT_6[1+FW8Y /!0_WE(Y!]Q7%F%6.)C!1>L5^)WX+'1PU;FDKQ:L_1G&/\ M<_!JZ+]L2YG:YV9%EY+"3=_=SC;^.:\<\,2WNHZIXI\;7"E$L[.ZG9Q]T3S* MRH@/_ R?PKU ?L\^&A>>8=1U(P9SY.]/RW;:[.\\ :%<^")?"EO#)8Z9-MWB MU;#MA@V2Q!R20,DUY]*,I58RJ[)G9+%8'"T9PPEVYZ-OHOZ_X<^3;#3]OPUU MG4F'_,0M+53_ ,!E=OY+2Z]IYTKPEX?^!5]) MCX)^&%\'OX;6;4!9O>B]9_.7S#($V 9VXQCMBI-:^#/AG7=8L]0O)+Y6LH(; M>&&.91&$B^Z,;2?KS7T_]I4N:^MK_I9'D>VC<\4^+4D]WKOASP5IL;3/I.GP M6HA3JUQ(JY'UQL_6J7AZYU2X^.^CGQ% EK?6UW##-"B@+$(D"@8!/15'>O?H M/A%X>B\=_P#"6O-?SZC]I:YVRRJ8]YSCC;G SQSV%-'P?\.?\)P_BIIK][][ MAKAD:9?++,"",;Y/M(I6/GKP/J]L_Q6F\0ZE/%$D)N] M0!E<+N?8[*HSU)8C KM_@/X@\2^)/'T_]K:YJ%Y:6MD\C13W#,A8LJC@G'<_ ME787'[./@Z69GBN=5@0G(C2="%]AE"?UKL?!/P\T+P%;W":'',TER1YT]P^] MW Z#. !D\ 4L1C,/.G+EW:2VV"=2+6A\[ZG_P 57^TBT?WXY-:2+ZI$P!_1 M#46N:OK/B[XVWNK^&+3^T+FRN?,M(R 5\N @!B"0,9&>O>O.HQUCK:-E^OZ![2*V['D/[.TCW?Q-U2YF.9)+"1W/NTJ$U], M5Q/@GX4Z!X"U6?4-%FOI)IX/(87,JL-NX'C"CG(%=M7G8VM"M5YX;&522E*Z M"BBBN,S"BL'6?&WAW0;];#4M207S+N6S@C>>7/\ ="[NO'% &I169H?B/2O$EK+/HUUYZP2F M&9&C:.2&0=4=' 9#[$"I]4U6RT6P:]U.?R8%94SM+%F8A5554$L22 2&^U"6;/RDX3V4=*J4 >:KH MFH:+/Y>H6[1@G"R#E'^A_IUKW&HY[>&Z@:&YB26)QAD=<@_A772Q4X:2U1C* MDGL>!T5Z+KGPXCDW3:'+Y3=?L\IRO_ 6ZC\<_45P5[876G7!@OH'@D'\+C&? M<>H]Z]&G5A47NLYI0<=RO1116I(4444 %%%% !1110 4444 %%%% !1110 4 M444 %0WW_(+NO]Q?_0UJ:H;[_D%W7^XO_H:TF..YSM%%%!L%%%% !1110 44 M44 %%%% !116OH^A2:AB>?,=KGJ/O/Z@?X_SI.2BKL"#2M(FU.7Y?W<"G#RD M=/8>IKL[6UALK=8+9-B+^;'U)[FGQQI%$L<*+'&@PJ*.!3JXIU',H****S * M*** "BGQ0R3R!(49V/8"M>TT0+AKQLG_ )YH?YG_ _.M:=*=1VBB)3C'"]7&D:W'$V$M;C]TZ@8"G/!Q]3^IKUFO!J]A\*ZM_;&@0S. M(+ M71Y'C97,EJ6=\_W90WR?4(3W!%-P9MX^NTY]!T MK1\'>%9="N-7U?5'AEUG7+@7%X8 ?+C"KMCB0D D*O\ $<$DDX&< YV?X0* MVC7WANSUQ[7PKJ%Y]KGTY;4&9L5OK]) K6\('S*@S MNWO]T$#"C<9CXLZS%X(M?'] MW8VP1;>&\ EUP3Q^2UL)C("L>?,\S! VE=O'WJ]MBC6&%(D&%10J_ M04 .HHHH ***BDEEY6"+HRHG_/*T'E _5N6_(BHX?#6C6TAF^P0R2]3-<#S7^NY\G]:K3J/0K2 M>-= #%8+XWC#^&RA>XS_ -\*14#>,99/^/'PSKUSZ$VJP@_]_&4_I711-&T2 MF$J8\?*4Z4^B\>P71RQ\1^)G8?9_!-QM]9]0@3] 343Z[XWW?NO!MKC_ &M7 M3_XBNNIKR)$NZ1U1?5C@4^9=OS_S"Z70X[^W/'V_CP=8[?3^UES_ .@U&WB; MQW$V^LG[:MS#&"MLLVU< M]<$#OSS@\U)/N%NVJ-:737$2Y%M&^2^/05K56OK>"XA"W,AC4,,$/MYJ;G)* MC%*3CHWK\^YBA=7U&SM[O1X8]&F=SY\=W#EV&>/\\5/>^-/#>F:FVG:CK=E; MW: %XY)0NW/J3P#[5M(@CC5 20HP"3DU2O=#TG4L_P!H:99W6[J9H%6]RG]Z&57'Z&K-;%I(LI MLY$EG*\)'TVG'Z5$/!&MZ9SX>\::E$H'$.HJMVGTR<$#\:?+![,Z++N=K17' M+JWC71U_XG&AVNL0CK-I$VV3'J8I,9_!J6#QN=4UF"RTH0Q2$KYUIJ :WN%& M><(V,\>F12Y&'*SL****@D**** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "HKM;E[.5;&6*&Y*D1231&1%;L2H92P]@P^M2T4 >.:+X MZ^(NM?%+6_!D)M(C$CW;6%P1(IVXPGG\'YQW_.MCQ/XM\?\ @2P;5M7T M?2?$&D0_-=2:5YMO- G=S&[."!['ZX'-<]X%_P"3JO'O_7G'_*&O:98DGA>* M9 \%?%.E^,O#MMK>A3F6TN!QN&&1AU1AV8'_ZV1S53P?9 M>++*'4!XTU2RU&22[=[,VD.P1P?PJW Y_/\ WC7CO[-IO;:7QWH6F3)%#9WD M9MGGC,J1N3*A+*&4MD1KT(^[UKNO@YXQU[Q9I/B.?Q%/%=7%AJLEK"L$(B4* MJ+P!UY.>I)YZT >EUQ7Q8U[7?"_P\U'6_#EQ:0S6:!G^T6YD+ NJ_+\P (R3 MR&'M7*3Z]XU;X6:EXSUO7)O"VI0K/-;://9P+$%C)V1-YJ>8S.%P"&7J,#U; MXQ\2S>,/V4KS7KJ)(I[RQC:5$^Z'$RJV/;()% 'H_@K4+K5_ /A_4M0E\Z[O M-,MIYY-H7>[Q*S' R2> ,5MUXGIUI\5)/A7X>U/PEK&EV<-IH]JT&E?9A* M]TBPK]Z5APS 9"J !G&[O6GI_P :XKKX,6OBV>"VAU&>Z73A#+)L@%R3C<6/ M(C"_.?0 CWH ]9K/UO7++P_IZWFHN5C>>*W0+@L[R.$4 =^6'X GM7D/C;XD MS^$]'@UW0/B-I'B2:&5%N]&WVI69&."8O*_>+CW9^.3TYH_&=SKLGPYUVQU; M4(K35-1M7@M@8_+AWA664*4.7PW\18#TY.0#WRBN"\7^+&\!V.CZ7<:ZDM_K M%VT,>I:R88TMXU&Z21O+6-#M! P,EADUQ?BOXK?\(/K.D7^G^.K#Q;I%U<> M1J%B'M7FME//FQF X'/# ]AGG( /<:*\WUCQF\_Q7G\'W/B$^&8H;.*>VE6 M.'S+Z1RG[#.D2QEK?RX\;E M7^(/Y@/KUX&!0!N4444 %%%% !7/^-?$B>%_#4]YD&X?]U;H>\A'!^@ZGZ5T M%?/WQ,\3?\)!XH>&W?-G8YABP>&;/S-^)X^@%=.&H^UJ6>R,JL^2)R,TTEQ, M\TSEY)&+.S')8GJ:9117T!YP4444 6+6]DMOE^_'G)0G^7I6O%*DZ;XFW+G! M]1]1VK I\4TD#[XFVGI]:5AF]14%M>1W0P,))W3/7Z?X=?K4]( HHHH **** M "BBB@"CJ]A_:%@R*/WJ?-&??T_'_"N)((.#P:]$KE/$>G_9[K[5&/W5C,6BBBNP85[+IEY]OTJUNBRLTL2LVWH&QR/P.17C5>D> KT M7&@M:LP+VLA 4#HK<@_GN_*O+S*'-24NQK2>MCIZ***\ Z#C?BA_R*D'_7ZG M_H$E>3UZQ\4/^14@_P"OU/\ T"2O)Z[Z'P$2W"BBBMQ!1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !7TS\"/')U_PVV@:A+NO]*0"(GK); M]%_[Y.%/L5KYFK9\(^)+GPEXJLM9L\EK>3]Y'G'F(>&7\03^.#VK&M3]I"Q4 M79GVQ15;3K^VU73;:_L)1+;7,:RQ./XE(R*LUXIT!1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110!RC_#^R@UJ]U30=4U+09]1;?>II[Q>7'M-\,Z9]ATB QQL[2RN[EY)I&.6D=SRS$]2:TZ* ,V M;0K:Y\1VVLW,DTLUI"T5M"S#RH2WWI N/OD87))P,@8R MVN(VBEB<95U88((]"#4U% '':9\,M'TZ^TN:2\U&_@T7/]EV=Y,K0V61CY<* M&8@< N6([8KL:** "N7\;ZQ]BTT64+8FN@0V/X4[_GT_.NG=UC1GI-JVKSW1SL8XC![*.E=.'I\T[OH95)65C/HHHKU#E"BBB@ I0<=*2B@ M!Q DZ\-Z]C49!!P>#3J=D$!7Z#H>XK2,[:,I,BHIS(5QW!Z$=Z;6Q84444 % M%%% !1110 4444 %%%% !1110!YE\3/^0]:_]>P_]":N,KL_B9_R'K7_ *]A M_P"A-7&5B]P"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110!);W$MK^:^R/A_XLC\9^"[+5E*BX(\JZ1?X M)E^\/8'AA[,*^,Z]6^ GB_\ L/Q@VB72;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SGBOPW+J]N;C3G6 M.]1<;6.%E'H?0^A_R.CHJ914E9FE.I*E)2B?+GB^.>TG>SUFS:&0?\LYTZ^X M['ZBIOA%XRNO#_C6TTF$EM,U&80O;CHCMPKJ.QSC/J/PKZ3U#2[#5K8V^J6< M%W"?X)XPX_6LG2_ ?A?1=0%]I>B6EO=+]V54R5^F>GX5SQHSB[1EH?0_VOAZ MF'E3JTM6K?UU1T%%%%=1\T%%%% !1110 4444 %%%% !1110 4444 %%%% ! M7G?QH\?S^ _!(;2MO]L:G+]DLBV,1L1\TG/'RCIGC)7/&:]$KQ?X[V_E>,OA MKK%XG_$LLM:V74A.%0N\++GVQ&Y_"@#3\!ZIX$\"0VVD3ZVLFNZF1)=:I=PR MJ-0F/4K.Z[6&3P Q_,DE_P 1O,M_C%\-[V\++I275U$[LV(UG>+$8/;)/3Z' M%7?CSIMEJ/P8UQK\(#:HEQ!(W5) X Q[G)7_ (%6]X1T]]2^%^A6?BJUCO)9 M-,@%W#>1B0.WEC(=6')]<]Z .3\$-YWQZ^(=]8D_V:$LX9I5;]VUPD0W#TRO M(/H?K71:.I\9Z]'XBN%SHU@[#1HF'$[\JUV1Z$$K'_L[F_B&(-0LK35+S_A" M/#MK#8:/;J'U@V<8B1$;E;90N &D'+8Y">[@C#\6%=8^./ACP??Q(WA^/3); MY[%E'DW4@W(J,G1@@4,%.1STH ]4HKS#X47]Q#XN\=>&%9SI>BZC&;!&.1"D MH(;S[+I;*IP\QV#Z=_P!/YUJUQ_B:Z\_4_)!^6%3_ $_*@#&HHHH **** "JNH:;9ZI;&"_MTGC[!ARI]0>H/N*M44TVG=!N> M;:[\.KBWWSZ*_P!HCZ^0YPX^AZ']#]:XN6*2"5HIXVCD4X9'4@CZ@U[[69J_ MA_3M;BVWT ,F,+,G#K]#_0Y%=M+%M:3U,)44_A/$J*ZG7/ >HZ9F6R!OK?KE M%^=?JO?ZC]*Y:O1C.,U>+.9Q:W"BBBJ$%%%% !1110 4444 %%%% !1110 5 M#??\@NZ_W%_]#6IJAOO^07=?[B_^AK28X[G.T444&P4444 %%%% !1110 44 M 9.!75:/X>$&VXU% 9>JP,,A?=O?V[=_03*2BKL"KHWAXS!+G4%*Q'E(NA<> MI]!^I_(UU'I@ # & !Z4$DDDG)/4FBN*4W)ZE!1114 %%* 68!022< #O6 MG::+))AKHF)?[O\ $?\ #\?RJX4Y5':*N3*2BKLS41Y'"1JSL>BJ,DUJVNB% ML->-M']Q#S^?0?K6K;V\5K'M@0(#U/=OJ:DKU*.!2UJ:G+/$-Z1&111P1[($ M6-?1>_U]?QI]%%>BHJ*LCF;;U84444Q!77?#W4_LNLO92-B.Z7Y1_MKR/TS^ ME6-U>RK%#'$Q9V/^V?UK=MK];G31>B MWN(T*EQ&\?[PC_=&3SZ5YWHJ7-GHVB:KJZK=:/"I B0'_1FW'$K#^+G/TKN= MNV_IVM^>A%- MXHMK1D.H6=]90NP43SPX0$],D$X_'%4_'YSX1D(Z>?#_ .C%JGXP@U,>#;Z7 M4;^WQL7,$,&%SN'&YB2?TI_BTD_#V#/7-MG/^\M.*5TUW)Q%:HZ=:E/I"_2^ MM^S\CH;O5K:PU"SM+G>KWC%8GV_+N Z$]B>U.U75+?1]-EOKTL(H\9"C)))P M !^-4?%>EOJGA^5;?BZMR)[=AU#KR,?7D?C6*-13QA>Z);1\P(@OKQ1T#+\J MH?\ @6?P%2HIJYU5L34ISE3ZNW+\]']SU?DSI;W6;6P@@>X\SS+C B@1"TCG M&/2@T&W#D!C>P[ >YW?X9IQ24D<^*J5*F'K.]E&Z_#]>AN M:AJ-MI=H;B]DV)D* 2S,>B@#DD^@K/_ .$FMXKF&&_M+RP%PP2*6XC 1F/0 M9!.#['%9OBT2GQ)X=_?^1 9Y!YA4,%D*_+P>,]<5=U3PWC;\2=+6\.8A9/]G+]Y<\_C MMKJCG!QUJ6DD;4ZDZLY:V47:WR3U^_0RIO$$"WLMI9V]S?30_P"M%L@(C/H6 M) S[9S46=$\6VTMM>V:3F!L2V]W#B2%NQP>1[$?G5'P -OAV59,?:A=R_:?7 MS-W?\,4)@_%*3[-G"Z& M(/VD_&>JW&NV$&GWENL5O=RSJD4K+Y0(#'@_=//0XS7HOBKXI6@TJ:T^'ZMX MGURX4QVR:8OGQ1,>!))(N451UY/..W)'H=% 'FWPH\#P_"GP%<2^(KZ".]NG M^UZE=2R@1Q<8"ESQA>>>Y)]JXOX#^(;XU=]0NKVRM"XWS+L&Q M@IP2I; _'M7OM% 'SOX#8T+[3XF_9(GT71-/O;J[ALS&5$##S'%QN*)GER%YRN1SC.< M@?0%% 'EO@WXE>'].^&6CV$4\MUKFGZ7!;/HT<#_ &IITB5"GEXW?>&-V,=\ MXKD[GX5>(])^ 5E!8Q))XEL=77Q ]K$H;=* 1Y8Q]XA2.!U*X&>*]^HH \DT M3X^Z?K\:Z=8^'=8/B8@(=+,'"2>K29^5 >K, 0.U4?CM%=V&A^"-5U,M<1Z3 MJ]O+J-S#$2JX +/M X!*G\P*]IHH \=^)TVIZM#X7^(7@O3[G4E\.WDKFW:% MD:ZMY%0.Z*1NQ\N,XSR6 ( )T-'^-%GXX1=,\%Z9JG]L3?NW-S; 16'9I)&R M1A>2%ZL<#O7J5% 'E7B[5/ ?B3Q5JOA7XDV]E;K9>6UC?71,"E7B5F43Y&'# M'.,@$%>#@T[X*6>IZ:/$6GC4+O4O#%K=1IH5W=Y+21[27VD_>0?( 1\I(;%> MIT4 %%%% !1110!RWQ#\1?\ ".^$IY(7VW=S^X@QU!(Y;\!G\<5\[5V_Q6U[ M^U_%SVD3YM]/'DK@\%^KG\\#_@-<17O82E[.G=[L\^M+FD%%%%=9B%%%% !1 M110 =*TK74=YV71YQQ)Z_7_'\_6LVB@9T/\ ^L>]%9%K?/;X1_GB].Z_3_#_ M /76JDB2QAXV#*?T]C4@.HHHH **** "H;NU2\M9()?NN.OH>QJ:BA.VHSSZ M>%[:=X91M=#@BHZZ;Q+I^^,7L2_,ORRX'4=C_3\O2N9KTH2YXW&%=7X O/)U MJ6U9\+<1':N/O.O(_P#'=U3UZQ\4/^14@_P"OU/\ T"2O)Z[Z M'P$2W"BBBMQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110!]#_ +/'BTWFDW?AB[DS+99N+7/>)C\X_!B#_P #]J]JKXK\&>(Y?"?C M#3M9CW%;>4>#NA]%%%!3C)R2Q] !R3]*\8\4_%G5=5=[?1&;3;0C&Y3^];_@7\/;I MS[UV8;!U<0_=6GYX8>9.XC&>Q &21^1KQEW:1BTC%F/4DYH1&D=40%F8@ #J M37NTLIH07OZ_@?-ULZQ$W:FE'\7_ %\CT&[^,WB"?9]F@L[;&=VV,MN_,FJC M_%SQ4RD"XMU]Q M:=WX&TWP9X/;6/$:B^U&4*D%F7*QI(>QP06P.3]#5OP;X M3'C72I;_ %>TTR&TD>1(?LEOY,L38 R"N 0#V8-WYI7P48.:@N5.U_\ +N6H MX^=14W4?,U>U^GGV,)?B[XJ50#/;MCN8!5NT^,^OP(PN;>SN23PS(5Q^1KAM M5L'TK6+O3Y6#O:S/$67H2IQFJE=GU3#35^1'G?7L7"5N=W7F>UZ9\:]*N) F MJ:=<68) $D;"51ZD]"/P!KN=(\2:1KJ;M*OX;@[0Q0-A@/=3S7RW3XY9(7#P MNT;#HRG!%<=7*:,O@=OQ.^CG=>#_ 'B4E]S_ *^1]:45X?X3^+=_I@6U\0>9 MJ%MD 39_>H/K_%^//O7LVG:G9ZM8QW>FW$=Q!(,AT.?P/H?8\UX6(PE7#OWU MIW/I,+C:.*5X/7MU+5%%%X[@]Z1DX+)R/0]112@D'(X M-5&30T[$=%2%0^2,*WIV/^%1D$'!X-;*29844450PHHHH **** "BBB@ HHH MH \R^)G_ "'K7_KV'_H35QE=G\3/^0]:_P#7L/\ T)JXRL7N 4444@"BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I()Y+:XCGMW:.6)PZ M.IY5@<@C\:CHH ^U?!OB./Q9X/T[68L!KF(>:H_@D'RN/P8'\,5N5X-^SCXE M^;4_#=Q)V%Y;*3]%D'_H!Q_O&O>:\2M#DFXG1%W04445D4%%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M6?KN@Z;XFT6XTG7+1+NRN5VR1/WYR"".000"".16A10!R,7P\LWCM+?6-8U; M6K&R=9+>QU"6-HE9?NEMB*TF.WF%N@-=:PRI )4D=1VI:* ,W0=#M?#^EBRM M&EER[2S7$[!I;B5CEI'( !8GT '8 54\0>$K'Q!>6%^\US8ZGIK,UG?V;* M)8=PPP^965E(X(92*W:* ,7PSX4T[PI:7,6G>=+->7#75W=7#[Y;B5NKL< ? M@ .PK:HHH ;+(L,+R/]U%+'Z"O.YI6GG>5_O.Q8_C79>(KCR-'D .&E(0?S M/Z"N*H **** "BBB@ HHHH **** "L'7/"&F:V&D:/[/HJHRE%WBQ-)Z,\;UOPEJ>AEGFC\ZV!XGBY4#W'4?R]ZPZ^@",C!Y%WX?K7H4\6GI,YY4?Y3RJBM'5M!U'1)=M_;E%)P MLJ\HWT/].M9U=R::NCG::W"BBBF 4444 %%%% !1110 5#??\@NZ_P!Q?_0U MJ:H;[_D%W7^XO_H:TF..YSM%%%!L%%%% !1110 4Z*)YI%CA1G=C@*HR34EK M:S7MP(;9"[GMZ#U)[5VFEZ3!I<.$Q).P^>4C]!Z#^?Z#.=100$&CZ&FG 33X MDNO4'*Q^P]3[_EZG5HHKBE)R=V4%%%7;32I[K#-^ZC/\3#J/8=_Y4XQE-VBA M-I*[*5:-KH\\^&F_<)_M#YC^'^-:UI806>#&NZ3_ )Z-R?P]*LUZ5' ]:GW' M+/$=(D-M9P6@_<)AB,%V.6/X_P"%3445Z<81@K15CE;;=V%%%%4(**JW&HVE MKD2SKN'\*\G\ATK,N/$G:U@_X%(?Z#_&J49/8KE;-VJMQJ-I:Y$LZ[A_"O)_ M(=/QKF+C4KNZR)9FVGC:O _(=:JUJJ/-J\#\AUJK16JA%%V2/>/A!JWV_P7]C<_O+"9H^O)1OF!_,D?A7>5 MX?\ !G5#:^*Y[!GQ'>P'"^KIR/\ QW?7N%?&YE2]EB9>>OW_ /!/2HRO!!11 M4-W=V]A9S7=[,D%O!&TDLLC85% R23V %><:F?XB\4:-X3TY+[Q#?)96\DJP MHS*S%W;HH5023]!P 3TJUJVKZ?H6ES:CK%W%9V< S)-,VU5[#\2> .I->#?& M:WN]=\'V7BW5%E@275;>'2;*0%3!;MN)D=?^>DFU20?NJ%7KNSVGQT$R:/X7 MNWW?V9:>([2;4U(@Q&YS_ ',D4 =SH?BO1O$4]S;Z5=.US:[?/MI[ M>2":,,,J3'(JL 1T.,&M&^OK;3-/GOK^=+>UMXS)+*YPJ*!DDUYFS?;/VI89 M=+)DCM?#?EZA)$V54M*S1HV.Y^5@/3'I70R?\5QXD,&-WAW1YQYI_AO[M#D+ M[QQ$9/K( /X#D ZVVN([NUBN(=_ES('3>C(V",C*L 0?8@&I:** "BBB@ IL MD:RQ/&_W74J?H:=10&Y3L=+M=/TF/3H$W6R*4"2'=D'.0?7K59/#>FKH[Z6\ M;RV;-N6.20GR^_RGJ,5JT4^9F/L*323BM%;Y=O0PI_"5C>6AMK^XO;N+&%6> MX+!/<>I]SFK]_I%KJ6F"PN@Q@!0@*V#\I!'/X5>HHYF)8>DDTHK71^:,[5M: M@TI4C*27%W,#Y%M$N7D/]!ZD\"J7A7P__8EG-+<*@O;R0S3[/NIDDA![#-;V M.<]Z*=]+(3HJ5559:VV\K[_,HZGH]IJR1B[1@\+;HI8W*/&?4,.E49O"6GW> MTW\MU>.A!22>J<&@I!(A&H:BZ1D%8WNF*\=CW(^IK5HHNT5*C3E+F:U*FHZ79ZK M;B&^A$BJ=R,"59&]58<@_2HK721:SK)]OOI@O1)I]R_CZ_C6A11=VL-TH.7/ M;4R[CP_:37DEW!)<6<\N/->UE*>9C^\.A/OC-6-.TJTTM)!:(=\K;I978N\A M]68\FKE%%V)4:<99:1JB^)OVE==T_5=LD7A MW3X_[.MI!E49]ADFQTW?.%SZ&JWCNX_X0?XY>#=8TA5B7Q+,VF:G A 6X^=% M21E[LIDSNZ_*!WH ]3U37M(T-8CK6JV.G"9ML9N[E(MY]!N(R:O(ZR(KHP96 M&0P.01ZUY1X;BBU;X\?$-/$$23+;V5I;6Z3H-JVKQDN!G^$GD^N33_@=K0LO M@3;:AK5VRV%BUQY=Q/VMT- MN9F-Q*!_='"_F2?^^:VH4_:5%$BI+EBV>0R2/-*\DK%G=BS,>Y/4TVBBOHSS M HHHH **** "BBB@ HHHH *D@N)+>3?&?J#T8>AJ.B@#;MKJ.Z7Y/E<#E">? MJ/6IJY]6*,&4E6!R"#R#6G::@LF([@A7S@/T!^OI]>E389=HH(P<'@T4 %%% M% ".JR(R.-RL"&![@UPVHV36%\\+9*]4)_B7M_GUKNJR]=T_[;8EXQF:'++C MN.X_S_6MJ,^65F,XZBBBO0&>Q:+>?;]$L[DL7:2(;V(ZL.&_4&KM(A[.K*/F=<7=7.-^*'_(J0?]?J?^@25Y/7K' MQ0_Y%2#_ *_4_P#0)*\GKHH? *6X4445N(**** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "OJCX%^)/[=^'<5G-)ONM*.= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U74[;1M+GU"^D$ M<$"%F)[^@'N3P*MUY'\:M?D#6FA0/A"/M$^UN6/(52/3J?R]*Z<+0=>LH')C M,0L-0E4Z]/4YB\UH_$/Q0$UF^EL8681V5O! 9<%C@+C(Y/=C_+IMZW\)]-\/ MZ5)J&I^(Y(X(R 2MEDDDX WUA?"S2QJ?CVT=U#1V:M<,"#C(X7\=Q!_"NW^ M-NI&'1-/TY"P-S,TC8 VE4'0]^K _A7O59SAB88>B[+Y?Y'S=&G3J82IBJ\; MRZ/7_,P;;X2P:QH(U+P[X@2\\QZD[C@_A57X3^'_M7C::6_CVMI M:EC$XP1+G:./;G\<5Z5\,M-?3? %@L@8/.&G*L,8W'(_#&#^--\ 6L;0ZSJ\ M0;9JFIS2QL3]Z-6*@X[<[JY*F-J.:YKQ7\.D\*BP$^M1 MRO>S^6-T'EJBC[SEBQ'&1Q[UV8:6&]C##SU>]K/U.'%PQ?MYXFGHMKIK;;N< M9D:9\*].UII%TGQ?;7?E %_*M2=N>F?GK M.\6?#G_A&(K1(]4_M"]O)?+@M(K;:S>I^\>.G;O79'&4'+V:>O:S_P CSYX# M$J#J..G>Z?ZG$45Z(_PSL= TN._\:ZX+)9/E$%K'O?<>V>^W;[Q2P&(A%R:VU:N MKI>AP]='X-\7WGA/6$FBH6TFK1PQVCJB2>1N:3*AL[=WRCG YYP:RJ8O" MSC*$WZZ/_(UI8'&0E&I3CKTU7^9[19WD&H6,-W:/YD$Z"2-P.H(R*FKS[X9& M\T:ZU;PGJ3;Y=/D$L;*P_/%6JY;QW>>5I4-J.L[Y8?[*__7(JHI.2N)['GC,78LQ)9CDD]S3:G*(Q MZ%>>W('X?_7IAB/\)!XSZ5Z\:D7U.-Q:(Z*>_(/K25*&XP1E?2F,F!E>5_E6\9W M+3N-HHHJQA1110 4444 %%%% 'F7Q,_Y#UK_ ->P_P#0FKC*[/XF?\AZU_Z] MA_Z$U<96+W ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110!T7@+Q ?#'CO2M5+[(HIPLQS@>6WRO^A)_"OL_KTKX.K['^&>N? M\)%\.-'OG.91 (9<]2\9V$GZ[<_C7GXR.TC6F^AU5%%%>>:A1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 W@!Z N1^@_K7.5J>(Y?-UJ0=HU51^6? MZUET %%%% !1110 4444 %%%% !1110 4444 ,FABN(6BGC66-QAD=<@CZ5Q M.N_#J&??/HD@@D//V>0_(?H>H_7\*[FBM(5)4W>+)E%2W/"+[3[O3+DV]_ \ M$HYPPZCU!Z$?2JU>[WVGVFIVQ@O[=)XSV8=/<'J#[BN!USX*C+26C.:5)K8X:BGS0RV\S17$;Q2*<,CJ5(^H-,KL,0HH MHH **** "H;[_D%W7^XO_H:U-4-]_P @NZ_W%_\ 0UI,<=SG:***#8**** " MK>GZ;/J4_EP+A5^_(?NH/?\ PJ;2='FU.3=_J[=3AY"._H/4_P J[*VMH;2W M6"V0)&O;N3ZD]S6-2HHZ+<=B.QL(-.M_)MAUY=SU<^I_H.WYDV:*L6ME/>-^ MY7Y0<%SPH_&N3WI/NP;2W*]6K33KB[Y1=L?]]^!_]>M>TTB"WPTN)Y/]H?*/ MP[_C^57Z]"C@9/6IH<\ZZ6D2G:Z9;VOS8\V3^^XZ?0=OUJX3DY/6BBO4A3A3 M5HHY)2XU.[N!^0ZU5HK50BBK)!1115C"BBB@ HHHH V/".H? MV7XPTN[)VJER@<^BL=K?H37TY7R77U1H]Y_:.AV-[WN+>.4X_P!I0?ZU\WG= M/6$_5'9AGNBY7#?$[1O%FN66F6_A%-*FBBN?/O;;4V<13A<&-3LY*[OF(R,E M5SD9![FBOG3K/F[XRS_%%_!MH/&%KX8CL?[2@,9TXS>9YOS;<[V(V]<]Z]R\ M,IXCO/#\D7C^VTG[;)(RM%IX=H&BP,9#DDGKGMTIOC3P7IWCO18=,U>:ZA@A MNDNE:U=58LF< [E(QSZ5T- '%:G;VNFR1>$/ UE:Z3=7X\Z[EL;=(ELK?HTQ M"@#>V-J9[Y/(0BN<^(\:Z;J/P_\ !.GJUKH6HW_DW4:,0)8H@I$+'.2'W'/K MCG->C:1H5MH\U]<1237%SJ%P9[BXG8,['HJ\ *JX50!P!W)),/B7POIWBJQ M@M]2$J/:SKIU@>'_!]AX?U+4-36>ZO]4U(I]KO[QE,L@485 M<(JJJ@=E4"M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** .!\4_"_^UO&EOXO\-:W+X?U^)!%)<);K/%<)TQ)&2,\< M9ST ]!CSZ;3-1\<_M#:/92:Q+K5GX/Q=7UWY*Q0PW&X,(D51UW)'G+,?E;GY M<5ZYK^A:_K>0@(]>]6_#'A71_!^C)IG MA^S6VMP=SG.YY7/5W8\LQ]3].@Q0!#KG@K0/$=X+O5;%GN?),#307$D#O$>L M;M&RET/]ULCVK%L;*U\2:O#9:?;Q0>%?#THCBAB3;'=W4?0 #CRXC^<@_P!C MGJ-NT^%_BBY\9_#/1M>OU5;JZB99MHP&=':-F [9*9Q[U1U'X M'=!L?"_ARQT M32D*6EE$(H]QR3ZL?7P]YR.7$2T2&T445ZQQA1110 4444 %%%% !1110 4444 %%%% %RTU!H0( MYLO'V]5^GM[5J*RNH>-@RGHP[US]2V]S);,3&>#U4]#2L,W**C@N([E2T1P1 MRR'JO^/U_E4E( HHHH X[7=/^Q7V^)<0S?,H'0'N/\^M9==WJ-D+^Q> X#'E M">S#I_A^-<,Z-'(R2*5920P/8UWT9\T;,9TW@*[\CQ UNQ;;CUXWI=W]@U:UNB6"Q2JS;>I7/(_$9%>R]*\?,H6J*73UE0^ J6X4445N(**** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K>DZC+I&LV>HVQQ M+:3I,GU5@?Z54HHW ^ZK*\AU#3[>]M6WP7,2RQM_>5AD'\C4]<#\%=8_MCX6 M::&?=+9%[23VVGY1_P!\%*[ZO!G'EDT=*U04445(PHHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "O OB]_R/TO\ UPC_ )5[[7DWQKT-V2RUN%"RH/L\Y ^[W4G] M1GZ>M>GE1G%-SPK:Z-,D^".F%+'4M48$>;(L"'<,$*,GC\11XW? MP9JGBP7&O:Y,)-/40R6$5N_S[225W8QR3U!_&KO@?Q;X6\/>"K*SGU:!;D(9 M9E",#O8YP>.2.%S[5XUJ=\^I:M=WLA8M<3-)\YR>3D9_"O1I49UL54J2O'HO MRZH\NMB*>'P=.E&TGNUOY]&>G^(OBU;W&D?V7X2LIHWE00J\D87RU/&U4&>< M8 KT"%(_"?@$!5)73K L0 %+%4R?Q)_4UX/X$TP:OXXTRU<*4$WFN&)&50;C MT^E>L_!9>"39C;OOIECP0?NJ=Q(]\@?G6&*P].-6GAZ:W=W_7WG1@\54G M1JXJJ]E9?U]QS7P6T][O6-4UFY^=D41AW3)+N=S$'UP.?]ZL_P"+U_)J?C:W MTRV_>&VB6-45\YDGZ5O_#?Q/X:\.^#X[>_U2&"[FE>:9#N.">!VX^4 M+6/X4UK0)_'FJ>)_$&IQ0MYS_8XI$(.#P'.!CA<#ZY-;>^L54KN+M%66F_0P MM!X.GAU-7D[O5:==3T3PMH=GX%\'G[4421(S/>S@?>(&3]0!P/\ Z] >591B*UB)_P!6&)"\?0,3[FKOC'Q#X8\5Z0NG1^+HK"$N&F"V M[/YH'0'ICGFN-\#^*;#P5XLO;0W1N])N6$?VI4V\K]V3'7')&/?-<]*C4G2J M3:?M'Y/;J=-:O2A6I4TU[./FM[:?<==\28O#>L:Q;66M^(I=/FM8\K;1VK2Y M+_Q9 /. .*;XT\9>';OX?WFF6%ZTLS11QQHUM*@;#+W*@#@9_"J7D>&_^%AG MQ?=^)-/>Q9_,B@!8R>8%"C(Z@ C.?85D>.O'5IXNU.QTJTE-OI,D>";5/ M#OPYLFN@R".W:YFR0Q&ZA>RR3236[-._;.0%'L!C 'M7M= M>9?!?0WMM'NM8F7'VMO+A.>J*>3_ -]?>"-!^)EAKQN/''C&RU731"P6VM;2-"TAQ@EA&IP!G MH>N*H'Q)XE\6:_XSA\/ZHVD6WAG%O:JEM')]KN A9O-+J?D!7 ";3SG/:@#U M"BN:^'?BL^-_A]I/B%X1!)>1'S8UZ"1&*/CVW*<>V*-$U:^\1:]Z\_7O)!^6",+^)Y/ M\Q7HE>1ZK?XN?U_\ K5JJT60X,AHIYB<=!D8SQSQ3*U33V("BBBF M4444 %*"5.1244 *4#?<&#_=_P *CI]..'^]PW][U^M:1GT9:9%12LI5L,,& MDK8H**** "BBB@#S+XF?\AZU_P"O8?\ H35QE=G\3/\ D/6O_7L/_0FKC*Q> MX!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"OH;]F[5_.T'6-'<\VUPEP@)[.NTX]@4'_?5?/->H?L_ZI]A^)HM&)QJ%I+" M!GC@&: . U"3S=2N7]96Q],U6IQD$JHI5H"44HV]R1]!FE !_B ^HJ'AZJZ%*I! M]1M%."YZ$?GBD",3@#/TYK-PDMT7S)[,2BE((.",'WI*@84444 %%%% !111 M0 4444 9VK:%I^MP[+^ ,P'RR+PZ_0_TZ5YYKG@'4--W3:?F^MQSA1B11[KW M^H_(5ZI16].O.GML1*G&1\_D$'!X-%>RZWX3TS7 7FB\FX_Y[Q<,?KV/XUYQ MKG@_4]$W2NGVBV!_U\0R /\ :'4?R]Z]*GB(5--F-O/\ SS4X'XG_ M _.M1%5$"(H51T51@"M:6"G/6>B_$PG72TCJ9UKHT4/S7)$S]E'"C^I_2M( M < 8 JM<:A:VN1-,H8?PCD_D*R[CQ(!Q:P9_VI#_0?XUZ]'#Q@O<1S M2) .+6#/^U(?Z#_&LNXU.[NH4TBPNS8P%/H[!?YU+E%;L!E?1GPWNOM?P] MTMSU1&B//3:Y4?H!7SLT+*<,R#W#@_RKW7X/R!O!#QAU?R;MUR,]U5NX]Z\7 M-W"=!6>S.G#Z3.\HHHKY4[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** ..^*E^;'P#=*IPUU(D /U.3^BFOGZO7OC=>;;32;('[[R2L M/H !_P"A&O(:]S!1M1OW."N[S"BBBNTP"BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@!4=HW#(Q5AT(/2M6UOUG^6;"2=CT#?X']/Y5DT4#.A(P<'@T5F6 MFH%,1W&60# ;NOI]1_GMBM,$%0RD,K#((Z&I *YKQ+I^R07L2_*_RR8['L?Q M_P ]:Z6HYX8[F!X9EW(XP15TY\DKC//J]>\/W?VWP]93_,28@K%CR67Y2?S! MKR>[MGL[N2"3[R'&?4=C^5=Y\/KOS=)N;4[B8)0P)/ ##@#\5)_&C,8O.H? ;2W"BBB MMQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M >^_LUZH#:ZYI+$Y5X[E!ZY!5O\ T%:]TKY=_9_U$V?Q.6VR=M]:2PX[$C$G M\D-?45>1BHVJLWAL%%%%KZMU'3;35M/ELM1@6>WF7:Z-_,>A]Z\=\4_""_L6DN?#K&]MAEO(8X ME4>W9N_O[&OI\'F4*BY:NC_!GR&.RFI2;G15X]NJ_P RS\$-,9M0U+5&#!8X MEMT/&"6.YOQ&U?SJK\:M3,_B.ST]2=MK!O8!\C6563:RG. &SW&*\0\6ZI_;7B[4K_ "2LL[!,K@[%^5VK&DV[(AKK? O@6Z\6WXDE#0Z;"W[Z?'WO]A?4_P OR!Z3PE\( M+FZ,=WXF)MHC$?=S^?TKUZQL;73+&*SL($@MXEVI&@X _SWKQ<9 MF48)PHN[[]CW\!E,ZC52NK1[=626UO%:6L5O;H$BB0(B@< 8%2445\SN?6I M65D%%%% PHHHH *XKQI\)/"/CVZ-YX@L9FOO*$27<-RZ/&HZ #.W@DGE3U/K M7:UP]W\0M2TSQE=Z-J/@C76L4Q]EU2P@:ZBGR,G<% \OGCJ??% '(?#:/7_A MW\3KCX=:M?RZIHUQ9-?:1<2G+1*K8*>W?(Z @$ ;JZ&X\":_H^N^*+KPA/IQ MM_%"!IQ?2.C64VTJ9$VJWF AB=IV\XYQ6UI.C76J>,F\6ZS9FQ>*T^Q:?9R, MK21QLVYY)"I(#,0 %!. O7+$#8\0ZE>:7H[RZ782:A?2,L-M BG:9&. SL/N M(.K,>@'K@$ XNPT :3H&F?#'P]$1HNHZA/KUU=S M:5/:VS213+V: /9M+U*UUG2;34].E$UI>0K-#(!C[*%_-@*\OK:GL1(****T("BBB@ HHHH **** "G% MMWW\-]>OY]:;133:V 0QH?5?IS33"W\.&^AI]%:JM)$N"(2"IPP(([&DJQN/ M Z@QI:4$C/N,'WJHR:*3L1T4]D!Y3TR5]*96Z M:>Q04444QGF7Q,_Y#UK_ ->P_P#0FKC*[/XF?\AZU_Z]A_Z$U<96+W ****0 M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5TGP[U M#^R_B1H-UG"B^C1CG&%<[#^C&N;J6VG>UNX;B+[\+JZ_4'(I25TT"/NRBF0R MK/"DL9RDBAE/J",T^O .H**** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** MIZMJMIHFDW&HZA)Y=O;IOI)XHW*C%RDHQ5VRY6)J/C/PYI+E+_6K. M)QU02AF'X#)KC_[*\1^/F6YUZ\GT31YOF@TRU.)I4]9&[9]_R%7]"TGX>V7B M*;P[I]E:2ZK;1[Y4GC,K8XS\S C/(R!ZUJH1U6]M[=#T)4<+0TKS;EVC;3_M MYZ7]$S9L?B!X5U*X$%IKEJTC'"JY,>?IN KHZYS4/#OA?5)Y-+O-(LF;R?,9 MDB5&09Q]X8(-.\#07%MX2MX;F:2=(WD6WED^\\ <^63]5Q^&*SO"2;@]M#*K M##RI^THMJSLT[=;[-6[=CH:P'UUK_P 8R>'],?:;"".YU"<8)CWD^7$ >-S! M68GLH'=@1OUYW\.]W_"Q?B,)_P#7_P!J09R.?+\@;/PQTI'$/\6^(?B#I<%_ MK&A:-HSZ/IID:2WO99!=W,<>=[H5^1 <':#N)&#WQ6G=^,"/ UCXULU9M+:U MCN[NU=?G2!@&9UQSO0'..A (')!J]XE637+2X\.6$H1[J/R[V8?\N\#@AO\ M@;#(4=L[NV#%XGAL+?X6ZW:V8A%C;:3O^SBNKH **** "BB MB@ HHHH **** "H;QMMC.WI&Q_2IJK:D<:7='_IB_P#Z":J/Q(3V//Z***]\ M\X**** "BBB@ HHHH 4,5^Z2/H:7>%I/H4JTQ=O. P/Z?SH* MD''4^QS245F\'#HRO;R["E67[RD?44E )!R.#3B['J2?KS6;P3Z,I5UU0VBE M+$]0/P&*4L#_ @?3-9O!U%V+]M$;1UIQ*]@1^.:0A>Q/XBLWAZJZ%>U@^IR MNN^!-/U3?-9_Z%=-SE!\C'W7^H_6O.]8\/ZCHHZ[\-X;@-/HQ^S2=3#)DH?H>H_4?2O/-6T74K6.>RGLY5N'50B;<[SO M7H1P?PKMA5A46ACR.+U.04%F"J"23@ =ZZW0O#9C9);J(RW)Y2$#/E^Y]3_+ MZ]-30_"]KI($NJSK]J(Y2/YV3V &7"A"/NK(JC'TSS^-5%B!)#2HGUR?Y UZ%'#T*757.>3E+ M,#^M=*J48]1)6(J*E'D;?FCD)]1(!_2A612?W2L/]HG^A%#Q5,9%14I<%LK& MB?3)_F32M,S#!6/\(U']*EXN/1 0TY(I)/\ 5QL_^ZN:D%Q,JX6:0#T#&F$E MCEB2?4U#Q?9 #02JP#HR$_WQM_G2M;NHR3'^$BG^M-HJ'BY]$ Y85*Y,\:^Q M#?X4*D>XAY#CL47/\R*;14O$U ',L08;6=QWR O]32GR,?+'(#[R _TIE%0Z M]1]0'JZ!<&"-O[ >TK,0?E4C^ZH7^5*;B= MAAII"/0L:CHJ6V]P"BBBD 5[-\$Y,Z#J47]VY5OS4?X5XS7K_P $&_T+6%]) M(C^C?X5R8S^"S:C\:/4Z***\$] **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@#Q#XS77F^+K:W!^6"T7CW9F/\L5YY78_%)GE^(-^=K; M$6) V./]6O\ 4FN.KZ/#JU**\CS:CO-A1116QF%%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 5/;7;VS?+\R'[R'H?\ U!10!O0S)<1[XCG^\#U M7ZT^L".1X9 \;;67H:UK6]2YVHPV2GC'9OI[^U2,SO$>G_:+4740S)"/F]T_ M^MU_.HO =WY'B+R#NQMAJ-=6JQN>+7/P1U1))/LNIVDB# M.S>&5F^HP0/SK+_X5!XI_P">5M_W_%>^T5W1S7$K>S^1YTLFPC>EU\SP(?"# MQ23_ *JV'OYXK6MO@CJ33)]KU6UCB_B,:L[#Z X'ZU[/11+-<2]K+Y!')L)' M=-_/_(\[TOX,Z#:;6U&XN;]P"""1&A]#@<_^/5V^FZ-IVCPF/2[*&U4]?+0 MGZGO5VBN*KB*U7XY-GH4<+0H_P .*7]=PHHHK Z0HHHH **** "BBB@ HHHH M **** "BBB@ HHHH Y[QO)L\.E?[\JK_ #/]*\YKO_'K8T6!?6X!_P#'6K@* MWAL9RW"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "E!(S@XR,&DHH 4[ M6^\@^HX_^M3#$I^ZV/9A3J*T522ZDN*9&8W SMR ,DCG%,JP#@Y'!H)W'YP& MYSSW_'K6RK]T2Z?8@!QTH(#XZ*WZ&I3&A'!8''UR?Z4TPMGY?GYQ\O?\.M;1 MJQZ,BS1"00<$8/O25+P?E<'COW%,9"O7D'H1WKJC),I.YYA\3/\ D/6O_7L/ M_0FKC*[/XF?\AZU_Z]A_Z$U<94/<84444@"BBB@ HHIR(TC!8U+,>@49H ;1 M5]="U=URFEWK#U%NY_I5N#PAKUPN8].D _Z:,J?^A$4[-["ND8M%=)#X"UV1 ML2010>[S*?\ T'-6U^&^J;AON[(+GG:SDC_QVJ]G-]"?:1[G(45WB_#/*_/J MV#Z"VS_[-5N#X;Z>H_TF\N9#_P!,]J?S!JO8U'T)]K#N><45ZC#\/M$B?+_: M9A_=DE'_ +*!5M?!GA]6!735R#WED/Z%L5?U>9/MX'D=%>TIH.D(N!I=D1_M M6Z'^8JW!;PVPQ;0QPCTC4+_*J^K2ZLGVZ['B$%K<7+;;:"29O2-"Q_2KB^'M M9<@#2KT;NA,# ?F17M!))R3GZTE4L-W8OK#['DJ>"O$#KD:?@?[4T8_FU6H/ MA]K4JYD-M ?220G_ -!!KU"BJ^KQ[D^WD>=0_#:_+XN+ZV1?6,,_\P*MK\,T M!!?5F([@6V/UW?TKNJ*I4($^VF!-"A4"2W MDG/K)*P)_P"^<5T=%5[*"Z$^TGW/;-%(;0=/*\*;:/ SG^$5=K,\-/O\,::>%]:U.Z^./B33 M+F_GEL;>WW0V[.2D9S'R!VZG\Z]+KPS^U)M'^*'Q#U.SYFM=,D:,XSM;,8!_ M \_A77AH\ZFO+]48U96<7YGL5QXAT:TOULKK5K*&Z8X$$EPJN?P)S4IU?30+ M@G4+4"V.)SYZ_NCG'S<_+SQS7E7P[^&/AWQ!X'AU?Q!#)J%_J6^1YWF8-'\Q M'&#UXR2<\UQ=EIXTKPO\3-/$QN!:R00B5CDN%N&&3[\5JL+3DW&,G=-+;SL0 MZLDDVMSZ!D\3:%%<102ZSIZ2S &-#YBMI[J"*>;_5Q/ M( S_ $!Y->)3?#KP_'\"_P"VVM"VJ_8A=?:C(V=QP<8SC&.,8JK:WDU_XD^% MUQ=.9)6MPI9CR=LA4?H!1]5A*[C+:Z^Y7#VTENNQ[O/?VEK-%#X%<9\3O\ MDIW@/_K\_P#9TK.N+J+X4_%R[N)\QZ#KL#S84<)(N3@#UW9'T<5$,/>*<7JU M=+T9M#$2HU.==&>AW^K366JS?9+G3Y"T8=[>YG$N+OP[\"=>UZRS#=ZK>>4LB#&Q-P7(].K@5SO+(N4HJI+= M*R=E=[K36WS,?:[-K35GJVG_ -AK>/I=O1^$),$-89K?4_&7B34+[4PZS-:V5R]K9PL.0@CC*F11T.\MNQR.HH [*BO+8;J^ M\=_%?Q;H4^JZAIVG:!;6\5LFGW;6[&:52QF8H06QC 4DKZCFMCX.^*=0\6_# M.RU#7'62_ADDMIYEQB4QL1OXXR1C/ODT =U17*:)>77BK7VUN"YEBT&TW0V$ M<;E1?/G#SMC[T8QM0'@_,_.5(ZN@ JMJ7.E7?_7%_P"1JS4%ZN[3[A?6)A^E M5'XD)['GM%%%>^><%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M45#)>6\?WIESZ*<_RHN!-16?)JR#_4Q,?=CC]*JR:E8=C M98A%W.0J^K' JO)J-M'_ !ESW"#/_P!:L5F9V+.Q8GJ2X"@?\ H1J*$O:UXQZ&CBHQ9C+,Y5AD&O4J4^1^1RL=11160@HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]>^" _T/6# MZR1#]&KR&O9/@DF-%U23^]<*OY+_ /7KDQG\%FU'XT>G4445X)Z 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S9X^D\WQ]J[>EP5_( M ?TK"%S.!@3R >F\UK^,VW>.-9/_ $^RC_QXUB5]_1BO8Q3[+\CRI?$Q_FOO MW%MQ_P!H;OYTXW#D8(C_ B4?TJ*BM'3@]T22)*JC#1(_NQ/]#2-(K$8C5!_ MLD_U)IE%3[&F^@R;?!C_ %4F?^N@_P#B::IC+'<65>V &/\ 2HZ*CZO2[ 2M MY('R/(3[H!_6A41ER9XU/H0W]!45%3]5IA&6,9DC=1_M*145%2\)V8#J*<+J=1A9 MY /0.:;YK[]Q;0#:*5I%8C$2H/\ 9)_J33]\&/\ 529_ZZ#_ .)J7AZG8".BG*8RQW%E7M@; MC_2E;R0/D>0GW0#^M2Z%1= &44]41ER9D7V(;^@I"H# +(K9[C('ZXJ?9S71 M@7K74<8CN3D9XDQR/KZ_7K]:=K&GC4+ J@!E3YHF!Z^V?0_X51,#@9W1_P#? MU?\ &I[.>XB)6-&ECSRH&?R/:H2E%W0R#Q7=?;/A?I4F,%;F.,C.?NI(OZXS M^->>5Z%XKMW;PHT5K!(PDU%)@NT[LF-PW';H#]2:XD:1J1Z:?='_ +8-_A7) MI&3]3J3NBG15P:3J!<*;*X4_[497^=3IX=U1QE;8#_>E0?S-+FCW&9E%:K>& M]548_T!I<\>X&-16]_PB-Y_S]6GYO\ _$TJ M>$[@D^;UAW"QS-%=27#?[KJ/_933CX6TWLUT/K*O_P 32]M =CCZ M*[.+PWIT8^>)Y?=W/],5-_86E8_X\$_[^2?_ !5+VT0L<-17WCV"QY]17H)L;,_\ +E;#Z0*/Y"IT'E#$?R#_ M &>*7MUV"QYO4L5M//\ ZF&23_<0FO1C-*>LC_\ ?1IE+V_D%C@QI&I$9&GW M1_[8-_A0-(U MM-E.I_VHRO\Z[RBE[=]@L<4GAS5'&1;#\94'\S3CX;U5>MN MOX3(?Y&NSHI>WD%CD(_"U^_WGAC_ -YC_0&I?^$1O,?\?5I^;_\ Q-=512]M M(+'+Q>%+CTTJT:ZN(H%:<@-+($!.T\9->>?VQI?_03LO_ E/\:W?V@$)\(::_9; MX#\XV_PKY_KV\'@HUJ*FVQ_VSI?_ $$[+_P)3_&C^V=+_P"@G9?^ M!*?XUXY179_9D/YF9^U9[%_;6E?]!.R_\"$_QI#K>E#_ )B=G_X$)_C7CU%' M]F0_F8O:L]A.N:2/^8G9_P#?]?\ &D.NZ2/^8E:?]_E_QKQ^BC^S*?\ ,P]J MSU_^W])_Z"5K_P!_5I/^$ATC_H)6W_?P5Y#13_LRG_,P]JSUS_A(]'_Z"-O_ M -]TA\3:,.NHP_@:\DHH_LRGW8>U9ZR?%&BCKJ$7X9/]*0^*]$'_ #$(_P#O MEO\ "O)Z*?\ 9E+NP]JSU;_A+M#_ .?]?^_;?X4T^,=!!_X__P#R"_\ \37E M=%']FT>[_#_(/:R/5/\ A,=!_P"?_P#\@R?_ !-+_P )CH/_ $$!_P!^9/\ MXFO*J*?]FT>[_#_(/:R/5?\ A,- _P"@B/\ OS)_\31_PF&@?]!$?]^9/_B: M\JHH_LVCW?X?Y![61ZK_ ,)AH'_01'_?F3_XFC_A,- _Z"(_[\R?_$UY511_ M9M'N_P /\@]K(]5_X3#0/^@B/^_,G_Q-'_"8Z#_T$!_WYD_^)KRJK,%C/< % M4VH?XWX'_P!?\*3RZ@MV_P /\@]K(],_X3+0B,'4 1C S#(')?$NK13Z7=VXCC@"D3%E;[S'LIK,A^&DK+_I&I MI&?2.$O_ #(K6CGFMWB=6^=5!SUSGYN?SKH[2[CO(?,CX(X93U4TJ7LY5)4W MNOQ%4E.*YDS@ MNA//+N5H-.L;9B;:RMX2>IBA5<_D*M%B1@DG\:2BJLEL3=L****8@HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** /8O"O_(JZ?_UR'\ZUZRO"Z[?" MVGC_ *8@UJU\;6_BR]6>W#X$%%%%9%A1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .N=NPYRH)Y.<] M>.WI7>T5LJTU#D7_ 2/9IRYF>36'P^\?>&!-I?A7Q/:QZ/*Y9#<1YDA!ZX& MT\_0@9YXJ/3O@]JNG^'?%&F'5;:=]8$0AF<-D;)"Q+\=3GMGFO7:*U^MU?+[ MNQ'L8')S^$KJ7X5?\(LMQ"+K[ MKYQSLW #GUQQ7-:A\*;^?P=X>M[#4X;77 M=!R8;E0?+?+;L=,C!P0<>O%>HT5G'$5([/K/IP_T6"V7 W=B?E4#GGH2>*Z+XB>"D\;^'%LE=8KJ&99(9F'W><,/Q4G\ M0*ZRBAXB;FI[6V!4X\KCW.Y28/;FW5+4D)"-Y?<,_>?<02<=@/7/?T4E6FH\J?6_P Q MN$6[GDMCX!^(ECI__"/0>*[6/1,&,2B/,RQG^%M M_"GQSX'=4^('B30[C7=*DT M;1M$N1?"VN9HY)[JX'W!B)F547D_>);.,"@"]J7@.Z'BO4/$7A76ET:^U6V6 MWO\ S+3[0DFT8211O4K(HX!R5]5-95CX:L].TRT^&GA=YDTZTCWZU>;OG$;Y M;RMPZ22DG./NID\96NXURXU*VT:=]"LUO-0("01R.$0,2!O1OJ>@Z < 4 <4?&NL7E]XELO! M5GIL.G^$8Q"ZW43M]KE5"3#'L91$%"[K)!?1 M;PC')1@2K*3WPP(_"N%'A7Q%X4U;QJF@:3_:UKXH=KFVD6XCC%I<.K!_.#D$ MIEMP*;CQC'>NO^'GA4^"?A_I/AYYA-)9Q'S9%Z&1V+OCVW,<>U '2TUUWQLI MZ,"*=10!YL1@X-%3WL?E7\\?]V1A^M05] G=7/-"BBBF 4444 %%%% !1110 M 444C,J %V50>A8X% "T55DU&V3^,N?1!T_.JLFKN?\ 51*O^\<_X4N9#LS4 MIDDT4.?-D5".H)Y_+K6))>7$OWY6QC! X!_ 5!2YAV-B35($^X&D/Y _Y^E5 M9-5F;_5A8Q],G]:HT5-V.Q))/++_ *V1F'8$]*CHHH *4#)P.32JA??$.5CK%K"3\ MBV^\#T)8@_\ H(KT&O+_ !M*S^*KA20_\M;QR/H%4?T->&U]#?#&V^S?#W3L]9-\A M_%SC],5PXYVI6\SHPZ]\ZRBBBO$.X**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@#YF\9C'CC6?\ K]E/_CQK$KHO'\?E>/M77UN"WY@' M^M<[7Z!0=Z47Y+\CRI?$PHHHK8D**** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "I[.SEO9Q'"/=F/11ZFBSLY;V<10CW9CT4>M=;9V MD5E;B*$>[,>K'UK*<^71";L4Y].BMM&EBA3>P I(/)_+/%85=>4$BF-SA M7!5B/0\&N0((.#P:^=S"/[Q2[G1AY7BT%%%%><= 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !7U#IXVZ9:J>T*#]!7R^ 2 M0!U-?4L2>7"B#^%0/RK"KT-(#Z***P- HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH \S^/$)E^'T#C_EE?QL?^^'']:^=:^GOC%;?:/A?J1 R M86BD'_?Q0?T)KYAKZC*G?#V\SBK_ !!1117JF(4444 %%%% !1110 4444 % M%%% !1110 4444 %%30VD]QS%&2O]X\#\ZOPZ5&N#.Y<_P!U.!^??]*SE4C' M<1F(C2.%12S'@ #)-78=*E?!G<1#T^\WY?\ UZU$1(EVPHL:^BCK]3U/XTM< M\J[?PA#F./+?WGY/\ A4Q))R3DGN:*>BC:9)/N X _O'TK'WINW40J MJ$422#(/W5_O?_6_S](F8NQ9CDFAW+L6;_\ 53[;'VF,D9 8$CV')KTZ=-48 MW8MRU*-LK*#D*=H/L.!3[6YDM)Q)&?8CLP]*AHKY'F?-S=3MLK6.KM[A+F!9 M8SP>H]#Z5+7+V5X]G-N7E#PZ?WA_C72PRI/$LD1RK#BO;PV(556>YP5:?([K M8?111788A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 MUZ4 >U:%'Y7A[3T[BVCS_P!\BK]1VT7D6L47_/- OY#%25\5-WDV>[%65@HH MHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !114%[?6NFV _1&/]*YR/P->MCS;F%?H2?Z4]_ ER!^[O M(F/NI%?,SQ^*#_M*P_F*T(+F"Z3? M;31RKZHP-<#<^#]5@4LB),!_SS;G\CBLH&\TVZS^]MYE]L45SWAGQ$=44VUW@7*#(8# 75I2I3Y);A111729A1110 4444 %%%% !1110 4444 %%%% !1110!Q'B"+ MRM:F]'PP_$?XYK-KH/%D.VYMYA_$A4_@<_UKGZ]NA+FIIG!45I,****V("BH MY)XH?];(JD=03R/PZU5DU6%>(U:0Y^@/^?I2N@LR]1V)].M8\FJ3M]P+']!G M/YU5DEDEQYDC/CIN.<4N8=C;DO+>+[TJD^B\_P JJR:LHSY,1/H7./T'^-9= M%*['9%J34;F3H^P>B#&/QZU79F=BSDL3U).9.O9?\:<22>:YZE5+1&D87W#(QA1A?2DHHKE;;U9J%%%% M( KR+Q!*9O$>H,QSBX=0?8' _05Z]Q_$<#N?2O$I9&FF>5^6=BS?4U[&61]Z M4C&KLAE%%%>V8!6AI][Y>()C\G\+'^'_ .M6?14RBI*S$=(00<'@T5GZ??;@ ML$YYZ1L?Y'^GY?30K@G%Q=F(****@04444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !7U#X?LSI_AO3;0C#0VL:,/<*,_K7S?X>L/[4\2:=9$96>X1 M&_W<\_IFOJ&O+S"7PQ.O#K=A1117E'6%%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110!\]_%2#R?B)?MVE6)Q_W[4?S%945IL****[#,**** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH *LV-C+?S^7$,*.6<]%%%C8RW\_EQ<*. M6<]%%=9:VL5G;B*%<*.I[L?4UE.?+HMQ-V$M+2*R@$4(X[D]6/J:GHHKE,@K MF=3C\O4YP3DLV_C_ &N?ZUTU8FO1D3PR@ *R%<^I!_P(KS\?&]-/L=&'=I6, MJBBBO&.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@"WI4/VG6;*#_GK<1I^; 5]/5\Z>![?[5XYTF/&=MRLG_?/S?TKZ+KG MJ[HUAL%%%%8EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !115;4M1L](TVXU#4[B.VM+: M,R332'"HHZF@"S17 Z-XM\5>.(S?^%--LM)T-B1;ZAK$3D?ET_/-6**YY592%<"2<9[# ]A1116 M0@HHIR)N)).U1]X^E-)MV0 B9!9N$7J?Z4V20R-DC P%'0"EDDWD!1M1?NK MZ?\ UZ97IT:/LU=[@%3V@/F.X_A0Y_'Y?ZU!5BV \J1L_-E5QZCD_P!!2Q2'T445\B=@57T]Q[U3HJHR<7S(32:LSKD=9$#QL M&5AD$=Z=7/:;J!M9/+E)\ECS_LGUKH000"""",@@]:][#UU6CYGGU*;@PHHH MKI,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K>DV_VK6;.#_G MI.BGZ9&:J5T/@>V^T^*[WK^E:6O7ILM+)4X>5A$I],]?T M!KA->@AA@41D'Y>:ZL/2C)WD<]:I**]TAU?XK:DDW_$HT^V6)20WVG<['G@X M!&/UJYH'Q3:XD$6O6:19/^NML[1]5.3Z\Y_"O-=3)@OXW7[DN5/U'_UJV--T M]KM%:)<@]3V%<>81EAY<\-CBC4K.5TSW6WN(KNW2>W<212#*L.XJ2N5\$B2U MM9+&24R*HWH,<)Z@?B:ZJHI5%4@I(]2+;6H4445J,**** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH ***P=9U+4+FZ;2/#83[9@?:+R1*?&UKX>D2PL[>35-:G'[C3[;ES_M-_=7W-)J7Q'U)O+!W1:39-MCB'H6]?7'/O5W4M0T7X52:6K65SJ%[KMX+>:^=P M9I')'S.Q[<]!P*]"JG"2BI-:/8Z%B(TO=H[]^OR[?F9^CZ!I6@6HM]&L(+./ MN(TP3]3U/XUH445)S.3D[L****!!56^TZVU* Q7<0<=F[K]#5JH;V[AT^PN+ MRZ;9!;Q-+(V,X51DG ]A4SIQJQY)*Z?0:DXNZ.&MM-FT3QA:PY+*T@V/TW*> M/\:[^L+3[ZP\56.G>(=';[3;!9&A)4H9.JXP>G(/6N;LOC!I%SH.LZA;E^ > =6FMG*Z7;1?KI\CNJ2GBU&45=I)/YO0 M]!HKS+4?C59:7IVF7=UH=Z!J4330H'7=L#%03]<9'M74>"O'6E^.=/FN-,66 M*2W8+-!,!N3/0\=0<'GVKU#">&K0ASRCH=+11105L'J!P#^ J"BNLQ"BBB@ HHHH **** "BBB@ HHHH ***>D9?V7N3 M2;2U8"*I=L*,FI5 CY'+?WO3Z4O"KM08'?WI*Y*E5O1&T86W"BBBL"PHHHH M**** *FK2&'1;Z13ADMY&4^X4XKQNO5O%LAB\*7S*<$JJCWRX!_0FO*:][+( M_NY/S.>KN%%%%>J9!1110 5KV%Z)@(93^]_A8_Q^WU_G]>N12]*B<%-68CHZ M*JV-W]I78Y_>J,_[P]?\?S^EJN"47%V8@HHHJ1!1110 4444 %%%% !1110 M4444 %%%% !1110!WGPATTWGC7[45REE TF3_>;Y0/R)/X5[M7G7P:THVGAF MYU&1<->S80^J)P/_ !XM7HM>#C)\U9^6AZ%&-H!1117(;!1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 >6?&^SW6&DWH'^KEDA8X_O $ M?^@G]:\>KZ#^*FG_ &_P!=LHR]JZ3J/H<'_QUC7SY7V&4SYL,EV;_P SSZZM M,****]8P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *LV%A+?S[ M(_E4??*U@6*!=JK^9/J?>LIU.71 M;B;L):VL5I (H%PHZGN3ZFIJ**Y3(****!!6=K<6^Q60 EHW'/H#U_7%:-07 MJ>;I\Z$X&PGCOCD#\Q6&(CS4I(TINTTSEJ***^=/2"BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH [GX26AN/&OG8R+:W=\^A M.%_]F->X5Y?\%['%KJ=^P^\Z0J?H"Q_FM>H5RU'[QM'8****S*"BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "O$OCU<7NN^)_!W@6S :WU6[\^[C:4QK,J,,(6 ) QO/0\ M[3CBO;:\L^+6@ZC!XD\+^.]&M9KY_#]R1>VD"EI'MGQN9 .I4;N/]KVH /&' MC7Q5\,(;#4=7TW1[WPP94MI8]-CDBFL@1\OWF*NHP0.%[#C-:7B30=0N/'WA MOQ]X;A.J16MJ]M<644JQO-!("5>,N54D%LX8C(QR*Q_B9K.F_$GP*WA7P5=P M:QJ&K30C-NV];-%D5VDF(_U> N,-AB3@ UZ996UOH.@6]LTP2VT^U6,RR' " M(N-Q/;@9H \]T"SO_!4WBKQAX@M2-4\2WT2V>DQ2K)(=H98(MP^7>=Q+$$J M"CR#IGE4P."S5R^L;/"O[0T?B?Q!*EMHE M]H+6,5].=L5O,LJOL9SPF0#C)&2Q ]* /0/#7B;3?%>D?VAI$C-&LK0RQR+M MD@E4X:-U_A8>GT/0UK5YC\%=.O(X_%NM3PRP6>MZ_$L<2;3T#9X M^GIBO3J "OE_XNZ7_9?Q+U':FR.[VW*<==P^8_\ ?8:OJ"O%?V@M(XTC647^ M_:RM_P"/(/\ T.O3RRIR8BW?0QK*\#Q.BBBOJCB"BBB@ HHHH **?'&\KA(D M9V/91FKT.DL<&XD"#^ZO)_P_G42E&.X&=5J'3[B8!MHC4_Q.4G+<04445(@HHHH ***5%+L%7J: %1"[8' R2>@'K222!@$C&$'KU)]3 M2R. /+C.5'4_WC4=>E0H\GO2W ****ZQ!5J+BV4$8)8L#ZC@?T-5:N$%8XU) MSA 1^//]:\S,Y6H6[LUI+WA****^:.H**** "M/2]1\@B"<_NR?E8_P__6K, MHJZ=25.7-$F45)69V%%8VE:EC;;7!XZ1L>WM6S7OT:T:T>9'GS@X.S"BBBMS M,**** "BBB@ HHHH **** "BBB@ HHHH **** "NZ^&MIF:]O".%58E/UY/\ MA7"UZQX'LOL?A:!F&&N&,I_'@?H!7G9C/EH-=SIPT;U+]CH:***^9/5"BBB@ M HHHH P?&,$LN@^9#DFWE64@#)(P0?YY_"O--2U R1_.>U>T,JNA5U#*PP01 MD$5CZMX7TS5HU$MNJ.@.TQ_+^>*ZZ.(5.-FKG+6HRF[Q9X>ME<:MJ$:11,V# MA$'KZFNSL=,ETJ$03#G.2PZ$^U=9#H)TU/*M;0(OK&,[OJ:LP:1-<'$R;$]7 M']*\C&UZF+]R,6D.E1Y-61^%HF,TLN/E";?J2?\ ZU:5I5P M&5;CRH(A;HS'G XR37KUK:QV=NL,*X4?K7A.JS16_QH\ZXD6**/58V=W. H M#@DD]A7L910C&,HS5[*YSXZ4HQCRNUV:S^)OB=%&SR65TJJ"6)T\< ?\!KH/ M _Q+GUW5AI.M6\4-PPQ%+'E0S <@@GK]/RKJY/&?AN*)Y&URP*HI8A9U8D#T M .2?85Y5X95O$?Q<;5-+M6BM!-_%&OZ1XSL+'2G*V$=.4(JS:A< ^1"3P!_?;V'Z_GC MEG1E.-.,8J[[=?4Z858PE4E*3LOP]#J:*\7M[WXFZM;)K-IY[6^-ZJA10X7T MCSDYQZ_'8C]:FI@IPBY)IVWMT*IXR$Y* M+35]K]3OJ*\O\6>/M6F\5'PYX4V+*LGD/,0"6DZ$#/0#UZY!JGJUE\1_#>FR M:G-K*7<40Q(D4C2%5(QNPRC@>O;K3C@I-+FDDWLF*6,BF^6+:6[1ZYFBO+?A ME)<7?V[Q/JVL33+#&\,T4XX3[K;PV[I@>@J"/Q7XO\>:A/!X55-/LHVYF#DIN/,K+=[(%BXN"E9W>RZGK-%>0R>*_%W@/6(+;Q0RZ MA9R-G>K!BZ\9*-P5/XN\5^)].M[/PE"9IDMD:]O%"H!(>JJS M$ =1[]<<"H/!WC[6[/Q3%H/BEFD\V7R-TJ_O(I"<+R!R"<#\0I)[D^M3T4#N[6/(?CJ<:AX()Z?VRF?S6N;_X2'XE>,K/7 M_&'AK6HM/TG3))8[>QV@F5$&2<;2"VT@Y)Z],5N_\(=\0?%OQ"TVX\;?8HM% MT>]>[M_)929/F!5!CD]%&2!P#WK+N?AY\2?#ZZYX<\'S64GA[5I))%EFD"O" MKC!7GD$C"Y ([\5[])TH4XTW*+DN^JLWK\[')+F;;L[&38^,/B#XEN_"&DZ/ MXB-M=:MI\LD\TD28RLLP+'Y>NU ./2G6WQ)\80Z?9:7>ZL6OK+Q*NG7-RB+_ M *1$"?AEXCT+Q5X/O[^*W$&DZ?/;W128,0[O,1@=^'6LV^ M^#OB:YL/$,T!MH=0;7!JFF_O01(H+\$_PGY@>>XK1U,*Y\KY;?+>[_2PK3M? M4N?$+QQXCT?QEXKL]-U.2"WL=%BN+= BGRY#)$"PR/1CU]:P(-8^*G]M:'HK M^)X3-XJLEN8I6B'^BK@L<87@[1SCU_&M4_#3QSXBL?%.L^)Q9IK>JV<=G;6T M4@"A5D1B21D#A!CD]375IX&UI?''@75#'#]FT33/LUX?-&5?RBORCN,FLU4H M4X'3[G4(DUM-8DTUM3= 0L: % MG(QU!8#..G;-5K7QIXJUG3=>\*VOBZUU@G3WO(M26)D_=H#YL)W(#RI/4=NO M-;]Q\'/$4^AZE-$+2/5H=?DU.P61P\\,^$_&MU:Z] M<^);31M.:[TZ6TM+"RMXUP[*1N,BY(!SR,G/MBM)5,+&+E'EO?RWTVT_X&XK M3;U+/P!M=7@^&L$NIWD<]G.Q:PB4O./BE#HT?Q=DA2XDCM) MY(6U(1]$8D;\>IVX/U)KUKP#I7B7PMX#AT2YL+=KFRM',)6;*O*78A2WIR*Y MS2OA#>7'A#7_ /A(VBDU_4W,D4H?<$93N7YO]IB<^U>+BY*=> #@\8K6^"6G74SZYX MGG@CM;;5Y\V\,9& S%L#L 6P/H:J6/P^\57>J>%7U^WM7@TA&MYV\\-YD63 MCCOP*%%%% !1110 4444 %%%% !1110 4444 %>8>,K# M[%XBE=1B.X'FK]3U_7/YUZ?7,>.M.^UZ*MT@S):MDX_NG@_T/X5T8>?+/U,Z MBO$\XHHHKU3D"BBB@ HHHH **** "BBB@ HI0"3@#)/85,J"/KAF_,"HE)15 MV-)L:D7&Z3CT'K3R<^P'0#M03DY/)I*XYSNZ^(TA$6GQAN&:1F7Z;<']37"U])@( MVH+SNL. MGQ2O#(LD;;67H:SJ04T(Z&BH;:Z2ZCW+A7'WD]/I[5-7 TT[,04444A!1110 M 4444 %%%% !1110 4444 %/AB>>=(85+22,%51W). *97;?"K0_[6\8QW,J M;H-/7SFR.-_1!^?/_ :BI-0@Y/H5&/,['MVB:8FC:'9Z=%@K;0JA([D#D_B< MFKU%%?--MN[/4V"BF2RQP0M+/(L<:#+.[8"CU)-9F@^*-$\41W4GA_48=0CM M)O(FD@)*!\ X#=&X(Y&12 UJ*CN+B&TM9;FYD6*&%#))(QP%4#))]@*X*Q^. MOPYU/4;>QL?$)FNKJ5888UL+G+NQP!S'W)H ]!HK)UOQ/I'AYK>/5;HI/=$B MWMX87GFFP,MLBC#.P ZD#CO5C1M;TWQ#I46I:+=QWEI+G9+'Z@X((/((/!!Y M% %ZBJ=_JUEIDEJE[-YW0(S-(Y!. %!/ !)/0 $G JY0 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !7 _%KQ/XG\$^$KKQ+X?DTF M6ULEB$UI?6DKNQ>0)N6195&/G7Y2O8G/05WU>;?M!_\ )"?$/_;M_P"E,5 & M_P##[4O$>N^%;#6O$LVF?\3*UBN8;>QM9(_*#KN&YFE?=P1T"X]ZZJN TF[U M/3_V?='OM#N+:"[M/#D$ZM0R/C*B1'7YAC/!ZG&*Y'X :5>2:3K]RFOZC#%!XEN5DM4CMS'<$+' MEG)B+@G.#M91QP!0!Z?X+G\27'A2U?QM:6]IK(W+/';N&4X8A6X) )&#@$_T M&]7EB?$;3_$>J:U$WCK3_"EII]V]E;*9[87%PZ8W2L)PP$98X4!03M)SS@4? M 7QC-SIWBZ'Q1=VVH/X7WRC4K #9?P L R@$KN)4=#CYAZ$T >PU5U/4;71] M*NM1U"416MI"TTKG^%5&3_*N#MCXW\3> (_$NEZZ;#4[VT%Y8:7#! UMM8;H MXY'D0NS%2 6#(,GH *Y+XT)XBU#]GM-1\4/-I&J1-$+W3;.5&MY6,H4%B Q( MQA@H? )YS@4 >R2SW&I>'7GT>1;>YNK0O:R3IN$;LF4+*#R 2,C-5/"-KX@L M_"UG!XQO[;4-90-]HN+5-B/\QQ@87M@9VCZ5SZ0Z[H/PKFO]-\027=U#I@N8 MO[4M8I$C"0EMBB%8CSQRQ;&.AJCX$^(%Q+\!8/&WBV?[1-'#S>'?$GAT3+>K:Q121M+&C$?+*K?(2IX!! M!4\XZ@'K=%>>^"]4UWQ=\$-.U6?7)[36+BVDE:^@MX22RNX&49"F, X /N* MY_PU\2O$"?LU3^-=1(U76(%EP6B5%)\[RU)5 HPH.3C'"F@#V*BN!TJ;6-8L M-,U?PIXX&OVQ!P17UC7SK\2M*_LKQY? #$=T1LIU.71$MV$M[>.U@6*!=J+^9/J?>I:**Y3,****!!1110 M4H.&!(SST/>DHH Y*:(P7$D1()C8J2.^#BF5>UB+R]18A=JR*&'OQ@G\P:HU M\Q./+)Q['JQ=U<****D84444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 445:TVR?4M5M;*+.^XE6,8[9.,T >[?#C3O[.\"V(88>X!N&XZ[C MQ_X[MKJ:9!"EO;QP0C;'&H11Z # I]<3=W#_JW]QZ>]>>_&K4]7TR^T>32-4O+-)T=2MM MJU\5-2^WZM8Z':C?(C!F _OMPH_+^=+\5]*=],\*Q'YWCO4M MB?4LH_\ B:K+*W-C7%ZI?Y&N;X54\NIU%I*7Y75G]QZ3IP==+M1*S/((4#,Q MR2=HR2:LU6GO[6RDCBN)!#OX0L,*?;/2K(.1DH&-V5V^_'/Y5K3IRJRY8;F52I&E'FGL=K15&+ M41J6BI?Z&8;H31AX-[E4;ZD D?E5+PMK-[KNFO>7UG#:+YKQHL-KGP_KUOIOBVRBMHKLXM]0MG)A8^C \J?SK14*C=DM>W4S=>FE>^G?H=C1 M7(^.O&&H>#K6*^CTN*\L781M)YY5D8YZC:>..N:Z#3KNZO-%BNI(K=;B:+S% M2.4M'R,K\V ?3M4NE)04WLRE5BYN"W1>HK \+ZYJ6NQW$]Y8V]M;1RO#')%< M&3S2K;21E1\N0<&LO4_B##IWQ"LO#AMP89R$ENBW"2,,JH[?W<_6FJ%1R<4M M4)UZ:BI-Z,[.BBN%_P"$WUQ_&=QX:AT2S:\AB\[<;U@C+QCG9UY%33I2J7Y> MA52K&G;FZG=45R>B>-S>^)7\.ZUILFEZJJ>8B&02)*N,Y5ACMS^!J_>ZOJ__ M D$FFZ1IL$Z0VZ323W$[1J&9F 084Y.%S5.C-.S]1*M!JZ]#=HKAM \:ZYX MCNM2@L=&LE?39O)E\V]8;FR1QB,_W36_9ZOJ&H>%8]2M["..]927M9Y2H0JQ M##<%//'I1.A.#M+\T*%>$U>/Y,VJ*X_P+XSOO&<<]R=-@M+2"0Q,WV@LY< ' M@;0,<]_! ^H-8:J MSL%0%F)P !DFOMXR4XJ2V9YK5G8;15^'2IGP9B(E]#RWY?XXJ]#96\'W8][8 M^])\WZ=*B56,1&5!93W !1,)_?;@?GW_ J_#I<4>#,WFGT'"_XG]*NDECDG M)]317/*M)[:"N(H")LC4(OHHP#2T45B(**** "BBB@ HHHH *** ,G ZT *J MEF"J,D\ "G.X13&ASG[S#O[?2E9A$I1#\YX<^GL/Z_YS#7H8>C;WY %%%%=H M@HHHH *NR!1(P0Y4'"_3M5:V_P"/F,[=VUMQ'L.34]>%FTOACZG116["BBBO M$-PHHHH **** "MS2]2\T"WG/[P<(Q_B]OK_ #_GAT X.1UK6E5E2ES1(G%3 M5F=A16?IFH?:D\J4_OE''^V/7ZUH5]!3J1JQYHGGRBXNS"BBBM" HHHH *** M* "BBB@ HHHH **** "BBB@":SM7O;Z&VB^_-($'XG%>X0Q+;V\<,8PD:A5' ML!BO-?A]IOVK7'O''R6B9'^\W _3->FU\]FE7FJ*"Z?J>EA(VBY=PHHHKR3L M"BBB@ HHHH **** "BBB@ KY]\0V*:G\6I["5F1+K45A9EZ@,P&1^=?05?/7 MB>\DTSXHW=_%'YC6M^)E4]"5(.#^5>KEE^>=M['EYC;DC?:YWO\ PI71_P#H M)7OY+_A7,Z1JNI?#OQNV@-<"YL&G4.K#:I#@?./0C(_*K?\ PNC5?^@3:_F_ M^-9/AG1-:\;>,DU>_A<0&833W+1[48+CY5['H!@5V0C649?6G[MO+"; MY,J 6^^!O/\ X\QK2TWXQSVFBQVUYIC7%Y''L$WF8#$# )&,_7FIOAUX7U/4 M?$C^*M;C>$%VEB#J5,K,/O '^'!X_#%8T:,L*JDZNUK>IM6JQQ+A&EO>_H9_ MBFQ_L[XI+<>$R;[43(;F:T1"WE/U.3T(.2?;\JU]:\1^,/$NC_V1:>%+NSDN MDV3RR(RJ>F<%@ H/(Y/>N8EOM5T_XC:O?>#6?5"\LCLUM TB[7;)! '(!XST M.,BM67QO\1(8FEFTB>.-!N9VTYP%'J3BNB5.34'9-I+=V?W'/&I%.>K2;>RN MOO-*_P##$WA#X-:K#--F[N&B>;9T7,B#9GN,V>4 M[V=H]VX ==QS70^'O&$?Q!TZ[\,Z[''#=7$!\J5.%!&['3@^E<[X? MU_5/AC?7>G:OI;R12MN&#MW$<;E;&"M3'VO).G))SO>SV:*E[/GA.+:A:UUT M9?\ $.@?$3Q/:Q0:K96[I$^]=DD:\XQV--\9:??Z5\)-$L=6!6ZANV5E+AL# M]YM&1_LXHO\ QOXC\;:E:V7A6UGLEC8.[(Q)!S]YVQ@+]?UK7^+,$]OX%TJ" MYG:YG2Y59)2.7;RVR<4HNI&=.$TEK>RZ#DJEKOJ;OPLA6+X?V155# M2/(S$#&3O(Y]> !7$^+8TC^.&F[$5=UW:,V!C)W+S7=?#(8^'VGY_P"FG_H9 MKA_%X)^-^EX!_P"/FT_]"6L:+_VJKZ2-JW^[4_D>R4445XYZP4444 %%%% ! MGG%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4R:)+B!X95W1R*593W!X-/HH \;U*Q?3=2GM)>L3D ^ MH['\156NZ\?:3NCBU2%>4Q'-CT_A/Y\?B*X6O8I3YX)G%*/*[!1116I(4444 M %%%% !3D0N>.!W)Z"G)'D;GX7M[U(3P . .@%8SJJ.BW+C&X#"KA/Q)ZFDH MHKC;;=V;)6"BBBD 4444 %%%% !1110 4444 >>?$*0G6[:/=E5M@=OH2S9_ M0"N3K>\:2&3Q7=#=N5 BK[?("1^9-8-?5X:/+1BO(Y)_$PHHHKH)"BBB@ HH MHH **** )(9G@E#QGD=0>A'H:W(9DN(1)%TZ%3U4^G_UZY^IK:X:VF#KR.C+ MGJ*QJ4^=>8C>HIL#XI9EQ<7Y^T29'(4CY1^7/XFO(? OAT^)?%5O:NI-M$?.N M#CC8.WXG _&OH\ *H"@ 8 ':O+Q]714T=>'C]H6BBBO*.LBN;2WO8?)O+>* MXBR#LE0,N1WP:\@_9SC2'1_%L<2*D:>()E5%& H"K@ =A7LE>._L[_\ (,\7 M_P#8PS_R6@#I?B]!XKOO""6'@W1XM5>XG4WL4LRHK0*=S1G+*2'X4X/W=P[B MN6^'7CKP[JGBQ?#WB/P19^%/%,/S0(;-%$I SE&V@J< D=00.":]FKS+XN>' MH=7USP/<62*-;AUZ'R'7A_(7,DN?]E0@;VZ?Q<@$5Z9+7]J/3YM2)2UN?#LD M-@SMA#*)=SJO^UMY(ZX(J#X0WD%G#X^UJ280:"_B"ZN+>=VQ$4!^>13TV\#D M>F.U>FZIH^F:W:?9=:TZTU"WW!O)NX%E3/KA@1FN5%M!XJUM=+LH8X?#&A2J M)4B0+'=W2'(A ''EQ$ L!P7 7^%@0"WX9L[G6=2;Q;K4#0S31F+3+248:SMC M@Y8=I),!F] %7L<]77DYBA\9_M :[HOB6!+S2M%TN$VEC<#=$SR[6:;:>"PR M5!ZCMBK_ ,#-9O\ 5? ]];:C/+<_V3JUQI]O-,VYWA3:5R>^-Q7/M0!Z3111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>3?M%^(-(M/A-JVB MW&I6T>J7BV[061E'FR*+A"6"==N$;GIP1UKUFB@#R+1_''AB3]G)$&O6"RVO MAU+.:%KA1)'-]G*!"NT_\ 9ZM8K[6["WDL(KE;J.6X M56A+S2L@()SE@>/7M7M-% 'A_P"SQXKT#3/@ZT>I:S8V;V-U*]RMQ<+&8E=A MM)R>AZ#U/'6F?L\>+M!;3]?TQ]5M8KV\U^>YM8)90CSHZIM**<%ON'@5[G10 M!X!HGC.;X'^)=#Q9:@WB/3H9H+BP^RN/*^9R'>0C:BX(SD MYSD $XS3^%WBT>%OV<4N9]+NI_L5TJSPRV&:[56\LD!9#LD; !/(Y]_? M** /GK7=&\,0ZYI&O?!#4UB\03WL:SZ9ILI:.2(GYS-#_P LE7ON"CKQG!'T M+110 5Y?\:M'\[2['5XE^:WJD'!%,K[ MP\L****8!1110 4444 %%%% !1110 4444 %7-.TZ2_FP/EB7[[XZ>WUI=-T MU]0FYRD*GYW_ *#WKJXHHX(5BA4*BC K&I4MHB6["001VT*Q0KM1>E2445S M&84444""BBB@ HHHH **** ,?7H_]1*,DX*$]@.H_F:QZZ/5X]^F.\Y:"XF= W?:2%_(8_*NX\7:;_:*:/\N?L^JP3'Z D' M^=4-?\'W,FOQ^(/#LT<&H(Q'2L_ MP3=S7&C.DQ+"&3:C'TQG%)J-OJ^OH+23U8]R:YHPG5QWMHIJ*5M=+_+R.>4HT\-[)N\F[^A:KE?$=I!?^,="M+R M)98)H+M)$89# HM=57+ZU:ZY+XOTR^T_3H)[6Q612SW.QG\P ' P<8Q^->Y1 M^+?H_P CRJVL;6ZK\SCM%N[CX6^+CH.J2._A_4'+65RYXA8]CZ>A_ ^M=%I$ MLL/PMU.6U)\U?MK(5]=[XK>\4^&K/Q7H,NG7ZX+#=%*.L3]F'^>15;P1H5QH M7@RVTG4U1I8MZN%.Y6!8_P P:Z9UH3I\[^*ZOYVOK_F M:));EAT!V\*OXDU?-%8GVRE[M[^?I;\".63PWL7'WK6\O6_XDR:0_B;X2V^G MWV3-<:='AFZAPH*G\P*YOP;XLG7X57-KG_B:Z?)_9\2'KO5W$8P%V\_[->H^,+76-3LX]/TVQAN+:21& MN6DN-F]%;)C P>N ,UJWZ3W.@S1FQ2:6:'8UJTH"G(P1NQ[^E*C55)J;U;?? M\_4=:DZJ<%HDNS_#T(/"^LIX@\,6&IH1F>(%P.SCAA^8->>75W>67Q[U";3M M/.H3+IP_^&^@^(?"MI+I>JV]NUDTK2Q21W&YHLC[N,<]/Y MU3M]&\2Q_%*;Q,VC1_9IH1;^5]K7W2M(*%.I42::L[:FI()_R*]-Q7!7GA+5]&\?_P#" M0^%$@>WO%(O[.27RPY]1P>>_USZUV??"?\ Y#OC#_L(?^S25Z-<#%I+C^XW M\JX3P)X>\0^'=;U674;&V\C5+CSF>*YR8>6.,8Y^]7:ZFUTNG2_8+9;F6#GOG!IXIJ5>\7V_(6%3C0M)=_P SSWX&_P#(KZG_ -A!O_0%K2\:>#M7 MN=>@\3>$;Q;?5H(_+>)_NS*.W/'X'@TWX9^&]<\)VEU8:K:V_E7$YG$\5QNV MG &W;CVZUJL?$&D^*-2G@T\ZEIMX8WB5+A5>%P@5N&QP<"MJE1_693IM?H_( MQITU]6C":?ZKS,_P?X[N-5UEM!\2Z:=-UN)"P7'RR@X]Z[BN-L?#VI M:IX^B\4:S;Q6*VD!AM;99 [G((+.PXZ,>!FNRKEQ')S)P[:^IU8?GY7S]]/0 M****YSH"BBB@ HHHH **** "BBB@#R+XW^%HKM;'7PK9B'V6?9U(.2A/L#N' M_ A7E$:)"I6%%C4]0O?ZGJ:^IM;TJ'7-$N]-N>([F,INQG:>S?@<'\*^8KZS MFTZ_GL[I-DUO(T;KZ$'!KW,%6N:)Y\HN+LPHHHJR0HHHH **** "BBB@ HHHH ***U_#&DG M6->A@89A3]Y*?]D=OQ.!^-1.:A%RELBHIR=D>B>#=+_LSP[#O&);C]\^1TST M'Y8K>HZ=**^.J3=2;F^I[48J,4D%JS:]X,T75[M(TGU#3X+ MJ58@0JL\:L0,DG&3W)K$\>>)/$6F_9-*\":=:ZGK]T&F\J[;$4,"8#.QW+U9 ME4#/.3Z&KOPX_P"26>%/^P+9_P#HA*Y;Q[\%K3QGX@?Q#;>(M6TK6A$L<$T, M@,<2J. % # 9R>&ZDT :7@2_^)M[JMP/B!I6B:=8)#^Y^P%FDDDR._F, ,] MNX]ZQKGXF:]?Z/XG\1^&[337T7PW=R6SPW*R&:^\H!I65PP$8 ;Y)XO$NJ^ /'S?:=7TJ$7-O?#G[3;D@9)_BQN7GKR0>0:I?\ "%>*] \+ M^,/"&CZ:-0M?$%W/+9:D;J-([:.=0LBRJQWY4 XV*V[/:@#U;1-7MM?T"QU> MP+&VOK=+B+<,$*R@@'WYK/T#7;GQ!J5]6#\ MHXRQ#'.,9YU=-EATC2OAOHUU)LL[")-6OXSM:&W"[=BD?=DEVD#NJ[FZ[ M01WHH **** "BBB@ HHHH C,$+3K,T2&51A9"HW >F:+B'[1:RPEWC\Q"F^- ML,N1C(/8U)13NQ61X=I$GB?X::G=&XTJ2>Q?!F8*6C8 D!@X'!Z]?7D5TL7Q MC2\D\C3]!NI[EP?+C1]Q8_0#->F45W3Q5.J^:I3N_5HXH8:I37+3J67I<\P\ M!>$M2E\5S>*-;LQ8;B[P6X7:=S@@DKV !/!YR:]-DC26-HY45T88*L,@_A3J M*YZU:5:?,SHHT8TH\J&HB11A(U5$48"J, 4ZBBL#8**** "BBB@ HHHH *** M* "BBL#7_&6GZ!JECI+17-_JVH;C:Z?9JK2R*HRS99E55'JS <4 ;]%:=K_B*^\/M:7VEZU8QB6:POXU#^62!O5D9D9>1R&/45FM\7_"Z>*+W0'_M% M+VRMC<2+)8R(6^9 (T1@)'=O,! "D$ G.* .YHKC?"/Q/T;Q?KMYHL%GJFEZ MK9IYLEEJMKY$ICR!O"Y/'S#K@\CBM/5O&%EIFM1Z-:VUWJNKO%YWV&P16=(\ MXWNSLJ(,\#1A)(W!8X."5(PP(*D@YZU[G0 45S^H^,;. MTUN31M/L[S6-4AC66>TL%0F!&^Z7>1D12>H!;)'.*A\.>/=(\2WU]IMNEU9Z MOI__ !\Z7>QB*XC'8XR58'CYE8CD<\B@#IJY6Q^(FB:EX]E\(6BWIU*&W:XD M,MJT2*H*CJ^"<[@00"".]<'X9\>>(-5^-WB2WO/#.H,NGVD5M%8V\]L7MU+; MO,D+2JI+9!PA;& .V3!=:G;:1^UA?W=ZS"-/#HPL<;2.YW+A5102S'L "30! M[;17'>&?B9I'B;Q-=^'A8ZII.K6L?G?9=4M?)>6/(&].3DGV-[K&HP1K+/:V"INA5ONEVD=$4G!P"V3@X% &[17+>'?B'HGB6SU& M6S%Y#> * /2Z*YF7QS9O=06FD:=J.KWDMI'>O;6B1JT,,GW M&*N^'/$UKXFAOFM;6\M7L+LV<\5Y%Y;K($1SQDY&)%Y[]LC M!(!LT444 %%%% !7#^,?B#-I7B"T\*>%+%-6\3WR[TAD?;#:1]Y9F'('?:.3 M[9&>XKP#X,:;K'BW5_&GBZ/66TVZO]2:U\]+9)98PF&"HSY4* R @J?NKR,< M@'K^B:;KNFB2]\2^)'U)O).^VALXH;>,]2RX4R$@#'+D8GXA>++CX5 MS?$^VO@MK'>DQZ&;:/RGM!/Y)!DP9/,ZMN#;>/NUM^#/&6OP_$S5OAUXWEBU M&>*W^TV6I)"L)N83C(=%X!PW8#E6Z\&JA^$NNIX%F^'UO?V"^&)KWSOMI9_M M:0>;YOD^7MVEMP W[QQ_#0!ZB^KV46A?VQ?5=7W6T-XX:RT]HPK6\(^Z7.,^8_WB"<+D+U!)Q)A;>)-2-L66/PI MX<8&=B?DN[B(?C; /\ >'8_B*]CKEO&VB?;K 7]NN9[9?F ZLG_ -;K^==.'JD,OB' M4&W;A]ID /L&('Z5GTYW:21G<[F8DDGN:;7V,5RQ2.)A1115 %%%% !1110 M4444 %%%% %BTNVM9FV?:_S1,?F'I[ MC_//Y8PJT^;5;B-FB@$%05(92,@CO17$2%%%% !1110 4444 %%%=G\-/"G_ M D7B);BZCW6%D1)+GH[?PK^?)]A[U$YJ$7)E1BY.R/2_ACX8_L#PTMS6U[?S&679G.T'@*N><* ">3S6S10!!?6S7NGW%J MES/:--&R"XMR!)%D8W*2" 1VR#4>E:7::+I5MINFQ"&UMHQ'&@.< >I/))ZD MGDDYJW10!SFL^"[+5M=CUNVO;[2=66W-JU[I[HKR0DY\M@ZLI&>0<9!Z$5?\ M-^&],\)Z#!H^B0>3:09(#,69F)RS,QY))/6M2B@ HHHH **** "BBB@ HHI" MRK]X@?4T +149N8%^]-&/JXK)UK7FLH/+TJ 7]XX^1%+O#>AW@M=:\0Z5IUR5#B&[O8XG*GH=K,#C@\^U54^(?@J60)% MXOT%W8X"KJ<))_\ 'JXW]H^*.3X*ZB[QJSQSVY1BH)4F51D>G!(_&NK\(Z'I M-Q\.]$@GTNREAETVW,D;VZ%7S&N<@C!S0!TL%Q#=0K-;2QS1,,J\;!E/T(K* MUSQ;H7AN^TRSUO48[.XU6?R+-'5CYK\#' .!EE&3@G>(;S3)-6-U M&MC;RHLT\@^0NI7#++<$B"WAA>::8CD M[(XPSMCO@'%1:)XJT?Q#=7=MI-TTMQ9",W,$D$D4D._=M#*Z@@G:W!&?S% & MQ17/:OX[\/:(]RM_>RG[)_Q]-;6DUPMMQG]ZT:,(^"#\Q'!K1M]?TF[T$:W; M:E:R:68C-]L$H\L(.I+=!C!SGIB@#0HKE8OB9X3ENK.!M2D@^WL%M)KFRG@A MN2>GERN@1\YXPQS6SK&O:;H,$4NJ7/E><_EPQI&TDDS8)VI&@+.< G"@]* - M&BL;2/%NC:YJ$MAIUS(;R",2S6T]M+!+$I. 6215*Y]Q4.K^-] T26>.^NY6 M:U -S]EM)KG[.",@R&)&\L8Y^;% &_16=8^(-(U/05UJPU&VGTPQF3[6L@\L M*.I)[8P'?^$C M\(W$$2;[J#]_;XZEE'W1]1D?7%?.5?999B/;4$GO'3_(\^M#EEZA1117J& 4 M444 %%%% !1110 4444 %7=-TR2_ESRL*GYG_H/>G:9I;W\FYLI I^9O7V'O M74Q1)#$L<2A$48 ':L:E2VB)E*P11)!$L<2A448 %/HHKF,PHHHH$%%%% !1 M110 4444 %%%% #)8S-#)$H!:12HSZD8KDJ["N6O8O)OID";%#G:OH#R/TKR MLPCK&1UX=[H@HHHKRSK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** -?POHK>(/$EGIXSLD?,I'\*#EC^5?2"(L<:I&H55 "@= *\\^$?A[ M['I,NLW"8FO/DAR.D8/7\2/T%>BURU)7=C6*L@HHHK,L**** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\=^,?AOR+V'7[9/W=QB M&YQV<#Y6_$#'_ 1ZU[%5+6=*M]O)^9VP5HH****YB@HHHH **** "BBB@ HHHH D M@G>VF62(X8?D?:NEM+J.\A\R/@]&4]5-HKIP^(=&7D95* M:FO,ZJBH[>=+F%98CE3^A]#4E>]&2DKH\]IIV844450@HHHH **** "BBB@ MKU+P-HITW1_M4RXGN\/SU5/X1_7\:XCPIHAUO6D21$>@%>9?'W7-+L?A+K.G7FH6T-]>0H+: MU>4"6;$JY*KU(&.3T%>FT4 <=\*-9TW5OA?X>33+^WNWL],M;>Y2&0,T,BQ* M"C@;*1G+'LB@%F;LH/? .U10!B^'O#PT/17MFN6N+ZY9 MIKR^(P\\[#YG]@. !T"JH[5X/"&TK]GG5?AY=0L?%AO6MH]-529KDM<*PE13 MRT>WG?T^7K7TE10!0T*RFT[PYIMC=/YD]M:10R/G.YE0 G\Q5^BB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O.O$NI6 M$GQ>TK3-%TJWN/%T>GR2KJ%V[K#96K$@DJI_>,3D!>.I^89->BUQWBGX9:-X MJ\26/B"2\U/2]6LD\M+S3+GR7=.?D8X/'S'I@\XS0!P6B6]W:?M97::G?_;I M_P#A']SS>2L2CYDX51T ]R3[FK.B(K?M@^(BR@E/#Z%21]TYMQD?@2/QKK#\ M(O#)\6V_B$&_%U%;_9Y4^UL4NQG.9R?FE)[[F(. "#BF6?PJMK+QY-XPB\3Z M^VK7""*=W:V*2Q K^[*^1@+\BCC!XSG/- ',W!V_M?6NWC=X>.['?YF_P%0_ M!O4S.,XSCC. * .5N?^3O[3_L7C_Z$]>Q5PMM\(O#=OXNB\2O/JUQJ44(B$LV MH2$MURS,"&8D-@@G;@ ;0*[J@#QKX(7TLGC;XBVFK'&KC5_-E#=3'EU7&>JC M''H"/6E\6V,B_M3^#;G2@RW$FGS&^V=#"HD +>V3CGN%]!7=:Q\/=*U3Q-'X MCL[F]T;6T3RVOM-D56F3^[(KJR../XE/0>@QH:/X5L=(U*XU,R7%]JMT@CGU M"\8-*Z#D(-H"HN>=JJHSSC- 'F_@'_DY3XB?]<;;_P! 6DMP#^V!=$@$CP\" M/;YEKL+_ .%NA7_CB?Q2;C4K>[NXEBO;>VNC'!>* !*H&2,* 0" <<@\U63 MX4VL?CQO%Z>)]?&K.OELV^V\LQO?.>: .9UMBG[7WAT*?"JVO?'D/C"7Q/KZZM;H8H'1K8)%$2W[L+Y&"OSL.%O'>J1ZIJ*W=CJ<84?;M/F$4K =,Y!!QZXS[\"@"/PWX)T;PW\4-0U2+6 MM6U+7=3L2]X+EH?+"!XPK,L<:!6.W"^H#US7[.T:"Q\8R!%#MX@F4MCD@ 8& M?;)_,UWF@> =-\+>'[K3= NKZTGNR&GU,R++=2,. Q:164\< ;<#)P >:H>! M_A=9> ;VYFT?7M;GBO)#+>/6** /._#GAR\UGXKW_C[4[.;3X%LET[3;:X7;,Z Y:9U MZIDY 4\X)R!72>*9]4G6VT70DGAN-1+++J*QG990C&]]W3S#D!%]3NP0IKH* M* ,2\\,6C^!+OPQIP%I:S6$EE'C)\L,A7/J3SG/4FO'+_P .:]KWP=T/X;2: M)?V^JV]W'#>W#6["VA@1V/G+,1L?*[<*I+9SP*]^HH **** "CKUHHH \O\ M%>A'1]1\R%?]$G):/'\![K_A[5@U['JFFPZKI\EI<#Y7'RMCE&[$5Y5>:;+I MM[);WBX=#P >&'8_0UZ5&NG'WMT:I%>:%+8\JHHHKZXXP MHHHH **** "BBB@ HHHH **** "BBB@"]87H@;RYB?*/0_W#_A_GZZWZ]P0> MMOI/PSX?M_#.@P:=;8)4;I9,?ZQSU;_/8"N3 M^%_@K^Q; :OJ4>+^Z3]VC#F&,_U/?VX]:]"KQ<97YYSFG?R_X<]ZHKP4?$'Q41E=0TZ;<7=SH=E-\C32P(SO)P,E1G@5&)P53#).;6O8TP.8TL;)QIIJW=N?*7\QR?SHMO#FCVK[XM/ MA,F<^9(N]L_5LFN'4]F,:2^)M^G^;_R,Z3QSIC,5TV"^U-_2TM68?]]' JN_ MB#Q5=C_B6>%#"#T:_NU3_P =7)KJP HPH ["EHU-%6HQ^&G?U;?Y6..>W^( M5X?^/W1M.4]DB>5A^)XJ!_!_BRZYN_'%S'GJ+>V5!7<446+6.J1^",5_VZOU M3//W^%T]P \VVOW"^F^$'^1KURBCEB:QSK'QVJ?@O\CP M^Y^"OB*U&=,UJ&3;G W/$Q_*O3O!?A=_#&BK!=7LU[>28::660L ?[J@] *Q MOB9XAU/08]/.E7)@,S.'PH.<8QU^M2_#37M1U[3KZ35;@SO%*JH2H&!CVKL^ MIS5#ZQ?3\>QY5?B*IB:WU">^^B2OU_KS.VHHHKE)"BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \N_:, M_P"2(ZK_ -=K?_T<5-IGAKQII>AVNE0^+=*,5K"D$ZI>732;%Y\M&P@8CT^\<^B&MGXV1JGC MKX6!1]W7XU!)R<>;#W_"NT\*_#72O#>N7.OW-S=:SK]V,2ZG?L&<#&-J*H"H MO&, =.,XXK-\?_#?5_&WB31=3@\2VVFQZ')W\8Z=XH\ W=C/J^F6C03Z3>/A9X)&R"#D;260\\9V]>"#!X0^ M(EOK]_X@AN_#\^@^,K*P#7=G.-WFQQ;C&RGC>*=8OEU# M6[JU6S,D-OY$,4(;=L1-S'DX)+,QX'2@#A?@P/$>K?"FPN=+U[1 DTD[7*W. MD2SRF9I6+F1QAR>#FM&?X&3:;XCN=3\!>,M1\+07DGF7%C!$)8B3UVC$YKV\/VB07$NHROYD\MP"#YKD_>)P!CT Q@8 / M-?CO/K.HY'%4-?^$&I^+/ PT'Q/XVO-0N( MVC:"Z^QI'''M[F-6!=B#C+,?48.<[-]X"UF35=(U73/%]S!J.GP2Q337-JLR MWGF%"V] R +\@PJXQQ@YYH RO!WQ#37?%5YI?B+PU-H'C.UL6_<2'>EQ"&S\ MCC[PW<@<]3@GFL7X(3>)=:^&,%]INO:*LD]WHZNEH;*#[-;?9X(8BVXX0N[%B3U+'V MKD+_ .!\MKXHNM9\">,-0\*_;I#)=6L$7FQ.QZ[5W*!R21G=C/&!Q0!!H_PI MAT3P+XN\(2^+(I!J[I("EK]GCLI)3A5 ,C9#$*-N0<8'\0JHWCK7O!W]G:)\ M9O#L4NFK<0BW\06+;H?,C<-&\B_PD,H;MT/RD9KN;CX=0O\ #^]\-VVK7B7- M](DUSJTS>9<22AU;S"VRO\RQX M'"O_ !K^?/T/M7O]8?C#PW%XI\-SV#X68?O+=S_!(.GX'D'V-=^ Q/U>LI/9 MZ,RJPYXGS/13YX);6XDM[A&CEBEO?R;GRL"GYF]?84NEZ4]\^]\I IY;NWL*ZF.-(HUCB4*BC 4=JQJ5+: M(F4K!'&D4:QQ*%11@*.U.HHKF,@HHHH **** "BBB@ HHHH **** "BBB@ K M!UR,+?*XR3)&"?J./Y 5O5EZ['NM8I,\(Y7'KD?_ &-<>-CS46^QO0=IF'11 M17A'>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5J>&]$E\0^(+ M;3H<@2-F1Q_ @^\?R_7%9=>X?"_PN=%T,ZA=IMO+X!L'JD?51]3U/X>E1.7* MBHJ[.UMK>*TM8K>W01Q1($11T4 8 J2BBN0V"BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \W^+7A,ZCIHUVQCS< MV:8G51R\7K_P'G\"?2O%:^L64,I5@"",$$=:^?OB)X.;POK7G6B'^S;LEH2. M1&>Z'Z=O;Z&O6P5>Z]G+Y''7I_:1Q]%%%>F@KHHT74=WL .YD;)P/0#H!3:**]1) M)60@HHHI@%%%% !1110 445);?\ 'S&<;MK;B/4#DU,GRIMC+,@42,$.5!PO MT[4VBBOBFVW=G<%%%%( HHHH **** "BBB@ HHHH **** +-E>O9S;EY1N'7 MU'^-=)%*DT2R1GXKLPN)=)\LMC"K3YU=;G24 M4BNKH&0AE(R".]+7N)IJZ.$****8@HHHH *='&\LBQQJ6=B JCJ33:[OP%X= MR1J]XG XMU(_-_Z"L*]:-"FYLTIP=27*CI_#.B+H>CI <&>3YYF]6]/H.E:] M%%?)3G*Z(!;N(?NV/&X?W36U133L!XU)&\4C1RJ4= M3AE(P0:;7H/BKPU_:"&]L4'VI1\ZC_EJ/\:\_((.",$5T1E=&35A****8@HH MHH **** "BBB@ HHHH **** "BBB@ KE_B!)M\/Q*#RURO'J-K?UQ745Q'Q& M<8TY >?WA(_[YQ_6NS!1YL1$B?PLX>BBBOISE"BBB@ HHHH **** "BBB@ H MHHH **** "BBB@#4T^]W 03')'",?_0?\/RK0KFZU[&^\\"*8_O1]UC_ !__ M %_Y_7KRU:?VD)EVBBBN4D*]+^%_@4ZA<)KNK1?Z)$V;>)Q_K6'\1']T?J?I M65\/O [%[?JT>EPO\QZ&9A_"/;U->]111P0I%"BQQHH5$48"@= !7G8O M$\J]G#0_%^ M-(]J M_,U/ .GRZA\.;J*RF^S71N7,4P4$@A5P#GM6=X6\4S2 M@#R6'?Z5T7PF_P"1.D_Z^W_]!6L?XN:+;1QVVKQ#9/(_DR8'#C&0?J,5UJ4) MXJI0J+23T?5,X)0JTL#2Q5%V<4KKHT4;WQAKWB;Q@++PU=26]NS;(PHZJ.KF MCQ3XIULZVGAW1[R;= RPM*#AYY.Y)[#-=#\*M%MK;P^=4QNN;IBI8C[J@XP* MS?&/PYU&\UJ;5=#D20S-YC1%MK*WJ#5QJ8:.(]DTDHJROW\S.='&SPGMU)N4 MW=I/:/9%KPSIOCBQ\0P1:K=NUB06E9G$BD#^'V-=5XNUK^P?#%U>(VV;;LB_ MWSP*\UT3QQX@T'7(].UUI)HQ((Y8YQ\Z9[@U<^+FL^=?6NDQ-E85\V0#^\>@ M_+^=9SPM2IBH*:5M]-FD;4\=2HX&HZ3E=:6ENF_ZN9OACQ[K">)+-=5U"2>U MD?RY%?&!GC/YUZKXHNIK+PMJ%S:R&.:.$LCCJ#7C?B>UTF#1]&;2;V&:XCAV M7 C/(;[V3^)(KT,ZN-;^$=Q=$YD%J8Y?]Y< U6+HPE*G5A&RO9Z>9&7XBI&% M:A4G=J-T[WZ:Z^1P^E:WXVUFVNI].U&:5;10\HW*"!ST'?H:[3X;^+;[Q MU M::H1)-;J'64+@L#Q@UYYX5L/$>H6]_%X;D*(RJ+A1(%W YP.?QKHOACJL&D: MY-HUY9F*\N'*&8MR"O\ 171C*,'3J*,5=6M;==[G'EV(JQK4I3E*TKIWO9] MK%%_$7BO4?%=QIFEZE+O,[K&A8 GO]!5FQ\;^)?#WB-;#Q$[3IO"RQR ;@ M#_$I%<^-1N])\<7=]I\8DGAGE8*RY&.I'_D>/T_]M/1Z***\$^J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKSJ]^(VL6W MQHT+P7+H<=I9ZE#+.;J:,==T;Q]H_AKQC'ISG7+:22TN-/CD012Q MC+PL&9MPP>'&W/\ =%=5XAUV'P]H[WLL3W$I816UK%_K+F9N$C7W)_ #)/ - M &I1532_[0_LNW.L_9_MY0&<6RD1ANX7))P.F3UZ\=*MT %%%% !1110 444 M4 %%%% 'D?Q?\(;7'B2PC^4X2\51T/19/Y _A[UY/7UA<0175M);W$:RPRH4 M=&&0RD8(-?.?CCPG-X3UYH,,UE-E[64_Q+_=/N.A_ ]Z^IRG&<\?83W6WI_P M#BKT[/F1S=%%%>ZRCNQ]A2 Z/X<^$SXBUP M7-VF=/LV#2YZ2-_"G]3[?6O>*SM!T6V\/Z+!IUF/DB'S.1R['JQ^M:-0K^S9\/H+7?>C49W1 M=TMQ+>$%CU+' K%\#V2^!_V?_%7BGPW%);2:B;F[L?-R7B@4E(2<]2!E\G^ M]0![Q17@=[:P^$/#?PO\2Z$VS5]4O+*#4+D,Q?44N(MTAE)YDYZ;LEO> M*==FTN"WL-)1)]:U)C#8PMRJD#+2OCI&@Y/KPHY84 ;U%9GA[0X/#VCQV4,C MSR;C)<7,O^LN96.7D;W8\^W0< 5IT %9VO:):>(M'FTZ_7,C;LP]Q6 MC133:=T)J^C/E[7M#O/#NL3:=J"8DC.58?=D4]&'L?\ ZU9U?1?CCP=!XMTC M8-L=_ ";:8^O]T_[)_3K]?GJ\L[C3[V6TO8FAGA8K)&PY4U[^'KJM'S//J4W M!^1#111729!3D3>3V401WKCZU- M*U'R6$$[8C)^5B?N_P#UJ]#"8GD?)/8YZU+F]Y;FY1117LG"%%%:&BZ/M1QI M%&L<2A$0!54# ]*KZ;IUOI5A':6B[8T'7NQ[D^]6J^6Q>)>(G?HMCUZ-)4X M^84445QFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %X]_P"?UZ]5133:8FKGC)!5B&&" M."#VI*]#\1^%4U(-=6(6.[ZLO02_X'W_ #KS^6*2"9HID9)$.&5A@@UT1DF9 MM6&4444Q!1110 4444 %%%% !1110 4444 %>=?$%P=>@4'[MLN1Z'H_J/Q^G> M>!/ -SXINA=7@>#2XV^>3H92/X5_J>U5_AK\*;KQ!+#J^N+):Z6IWQIDK)&TMH[>VC6*&-0J(@P% ["OG\=BHTY.%)Z_D;TZ-]9#;2T@ ML;2*ULXEA@B4*D:# 45-117A;G8%%%% !1110 4444 %%%% !1110 5YK\3? M#FK:UJ]E+I=D]PDE45OAZ\J%3VD=SEQ>%ABZ3I3=D^QR?PX MTJ]T?PP]MJ5NUO,;AG",1T(7GCZ5#\2]'O\ 6M"MX-,MFN)$G#,JD<#!YYKL MJ*OZS)5_;VUOQX_I'@[Q#X@\2#5?$<,D,:N))3* K28Z*J_A2P>"M9\1>-)+K7K*:VLYI&> M1MXR%[*.?I7K]%;O,JMVTDM++R]#D62T+)2DWK=WZOS_ *ZGG^J?"G2!I=P= M,%Q]K"$Q;Y<@MZ8K)\-:%XBLO#.MZ5=Z;*BW,.Z#++R_0CKW'\J]6HK../K< MG)/WM;Z^1M+*L/[13A[NC6G6YXKHFC^.O#PG&E:?)#YX ARET_N/._B'I&K>)-.TF6PTV8 MRJ':6$D9C) X//L:=X!T76]#T2^CFM6MIY)U90^#E=O/ZUZ%16?UR?L?865O M^#]FBDN)698K:UB_UES, MQPD:^Y/?H!DG@&O%_%OC#PX/VH_"%]_;FGFSL;*>"ZN1<*8X)&2=0K/G .6 MY/&>:]9\6^"O#WQ"TFVM?$$!O+2.07$/E3L@)VD!LJ1D88T >9?&+0)M*^!> MNW^KR)<:WJ5Q;2WTZ?=!$J[8DSTC0' '?ECRQKN/B#X.N/'7PL;1M/N%MKTQ MPSVTCDA?,3# $CH#R,]LYKROXR_!KP5X/^&%_K.@Z;+!?0R0JDC74C@!I%4\ M$D=":]E\!>"M$\$^'_LOAVV>WANBMQ*KRM)ERH!.6)QP!Q0!S1=K%2C,!&H&=S%2 MHQAI/8JO\38Q?C=I%[>^%]&O;"WDN8-'UFVOKJVA0L7@3(8A0"3C<#CTSZ4 M=3HOC.RU?7)]$N+.\TG5X8%N38WX02/"QP)%*.RLN>#@Y!X(%=%7DUO-'XO_ M &A]-UWPW.M[I&E:,\5U?0-NA:1V?$08<%AN#$=L<\UZS0 4444 %%%% !11 M10 4444 %8_B?PW:>*-$DT^\&TGYHI0,F)^S#^H[BMBBJA.4)*479H32:LSY M8U?2;O0]5GT_48_+GA;!QT8=B#W!'-4J^B/'O@F'Q;IF^';%J5NI\B4C[X_N M-[']#^.?GRYMI[.ZDMKN)H9HF*O&XP5([&OM<%C(XJG?[2W1YU2FX/R(JT]) MTEKUA+,"L /_ 'W[#V]Z72=(:\837 *P \#H7^GM[_Y'3*H10J *H& , 5T M5*EM$82E8%4(H5 %51@ #@"EHHKG,@HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@#FM43R]3FP<[FWY]R,G]352M;7H\30R\892N!UX.<_^ M/?I637S=:/)4DCTX.\4PHHHK(L**** "BBB@ HHHH **** "BBB@ HHHH =' M&\TJQQ(SNY"JJC))/8"O>? /@U/#&E^?=*&U*Y4&5O\ GF/[@_KZGZ"L;X;> M!/[.CCUK6(O]+<9MX7'^I!_B/^T?T^O3T>N>I.^B-8QZA1116)84444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q/Q8U*>V\"RZ7 MIS%=1UZ>/2;3&GV_AR+0A;1OIT=J+3R'7*M$%V[2 M/3%9&J^&[S5OB)H>KW$D']EZ/;SO'#N)D>ZD 0,5QC:J;L'. M!?#?A&UL]7U;4=2NM-\.J9-.M+N59(K,G@; JAW;HJAV6+'D+AWC7PK;>-O!NH^'[V0Q1WD8 E49,;@AE; M'?# ''?I0!QC>)_$/A+Q1X.M-?U0ZM;>)PT-PKP1QFSN-JE?*V*,H2VW#%B, M9W5ZA7G47@77M:\2>&+_ ,7W&GB#PPC&!+%W=KR8JJB5]RKY8&T':"W/\5>B MT %%%% !7%?$#P%%XHM#>6"K%JL*_*W03J/X&]_0_ATZ=K15PG*G+FB3**DK M,^49X);:XD@N(VBEC8JZ.,%2.H(IB(SL%49)KWSQ[\/X/%%N;RP"0:K&O#=% MG _A;W]#^!XZ>%WUM-IMQ)97,3PW$9VRJZX(/I]/YU]'A)K%:1WZGGU*;@]2 M"1U"^7'R/XF_O'_#_/TCHHKW8Q4%9&044458!1110 4444 %%%% !1110 5; MCR+5 1U8L#ZC@?T-5*N$%4C4G(" C\>?ZUY>9RM0MW9K27O"4445\V=04444 M %%%% !1110 4444 %%%% !1110 4444 %%%% &QI6I?=MKAN.D;'^7^%;%< M?76>$[>]\178L(8R\B#+3$':J^K'_.?Y^EA<4HKDJ/3NB#U/M7KFB:+;:'IZVUM\S'F20CEV]?_K4FAZ':Z%8B"V&YVYDE M(Y<_X>U:5>?C,8Z[Y8_#^9TT**IJ[W"BBBO/.D**** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R=<\/6NM1 M9;]UT]5865OJ%LT%Y$ MLL9['L?4'L:X/6_!]S8;IK#=3A5&6/M7B1)8DD MY)Y)/>O8RN.LGZ&-7H)1117MF 4444 %%%% !1110 4444 %%%% !1110 44 M5T/A3P1K7C"\$6E6Q$"G$EU("L4?U/<^PR:BI_V>GKGI7:>"?AOH M_@R$20K]KU%AB2\E7D>R#^$?J>YKKZ^>Q>9.?N4=%W.NG1MK( J@*, < #M M1117C'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7&^-_ -GXF*7\*!-0A' M.#@3J.BM[^A_#TQV5%:TJLZ,U.#LR914E9GA$D+V\C0R1F)HSM*$8VX[8IM> MK>*?"D.N1&XMML5\HX;H)!Z-_C7EUS;36=R]O=1M%+&<,C#D5]/AL5#$1NM^ MQY-6E*F]2*BBBNLQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** ,_6HM^G[PN3&X)/H.G\R*Y^NJNX_-LIHSDY0X [DK_ Z^ M'IC,>M:]#A^&MK9QT]'8>OH/QJ7P#\-_LC1:MXAB!FX:"U8?ZOT9_?V[=^>G MIM83J=$:1CU84445@:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%17=U%96*[_Q M5K$MU=RR"WWGR+NX>E>EUSRBXNS/;H5HU MZ:J1ZA1114FX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 5RWC/P+8>+;0NP%OJ$:XBN0/_'6]5_4=NX/4T5I3J3I2 M4X.S$XJ2LSY;UO0M0\/:D]EJL!AE7E3U5Q_>4]Q6?7U#KWA[3?$FG-9ZK )$ MZHXX>,^JGL?Y]Z\+\8?#W4O"LC3J#=Z<3\MRB_<]G';Z]#^E?68+,H8CW)Z2 M_/T."I1<-5LZZ%H-AX=TU;+3 M8MB#EW/+2'U8]S5VUM(+&UCMK.%(88QM2-!@ 5+7-*;D:J-@HHHJ"@HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBN=T[QA;WOBR\\/SVTEI>6PW+YC B5?4?A@U+DE:_4TA3G M--Q6VK.BHK!\5>+;3PK:0/<127-Q<2".&VB^^YK7@N=\,)G @FD4-Y+,"0?3 MWHYDW8'2FH*;6CV)Z***HS"BBB@ HHKD/B??76G>!Y[BPN)+:82H!)$VU@"W MK4SERQ,LS'EB5%7::=UL>%;+5( M+H6^C6$]W)G!\M?E7ZMT'XFIN^&/@*Q$=QXKO=OLA:Z-8PVD7<1KRQ]6/5 MC[FO*KYI2AI3]Y_@;QHM[GE7@_X%QQ;+OQA,)7!#"RMW^7Z.W?Z+^9KV"UM; M>QM8[:SAC@@C&U(XU"JH] !4M%>#6Q%2N[S9U1@H[!1117.4%%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %8_B#PW::_;XE_=7*C]W.HY'L?45 ML45<)RIRYHNS%**DK,\4U72+S1KPV]]'M;JK#E7'J#5&O;]0TZUU2T:VOH5E MC;IGJI]0>QKS7Q#X-N]'W7%MNN;,<[P/F3_>']1^E?187'PJ^[/27YGF5<.X M:QV.:HHHKTCE"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 4':P( MZ@YKDKB(074L0.X1N5SZX.*ZRN>UJ,IJ)8@ 2*&&/R_F#7FYA&\5(ZL.]6BA M1117D'8%%%% !1110 4444 %%%;_ (9\':IXHN +.+R[93B2ZD&$7Z>I]A^E M)M+<#'LK&YU*\CM;&!YYY#A8T&2?\^M>T^"?AU;Z J7VJA+G4NJCJD'T]3[_ M )>M;OAGPEIOA:S\NQCWS./WMPX^=_\ >PKTC4;9+C3]5LKJ"1E1)8+A'5F/0 @X)/85SGPZ\$6WA? M0+>YOD^V>(+N,2ZCJ5Q\\\LK#+#>>=HS@#T'J347BWX=:;K'B#1/$>GV44.L MZ7J,$QFB C,T.\"17/\ %A26'?(P.IH [>BL35O%^BZ+J":?>W,KWSQ^:+2T MM9;J81YQO,<2LP7/Z1W$ZL60,P)55('SDA3PF>E:?ACQ?H/C/36 MO_#.I1W]NC['9%961O1E8!A^(H VJ*P-4\;Z!I%S<6]U=S22VHS&KF"VUO6K6UN;AE6 M*W+[I7+' (1&-#FU.^R M4CP%1?O.QX %>*7GQ8U;6]7CAOMEMHLSB*ZLX4#&2$G#@N> M"70,FCJRL,@BZF((_P"^Z7_A5/@O_H"C_P "9O\ XNN-^$GB+Q-+;C38]..H M:9"ZK]HDF$?V8$\@$@[AC^$?H*]/U^]U/3])DN-%TP:EE?/G[3_\ Q]>&O]RY_G'7$?8HZ;X%_$C4?&,.IZ=XDOOM6IV[">)C&B;H M3A2 $4#Y6QD_[8K"^-'Q;UWP]XLCT7PI?BT^S1!KIQ#'(6=N0/F!Q@>PZUQ- MW$_P@^+>F:I!$_\ 9TL27,:+R7@D3:Z_>Y(.X#)'(!]*SK;2[KQ7X<\:>.-7 M7?Y801%CG$KS)T.<_*G'3HWM0!Z%;_$KQ:_P!N?$;:L3JR:L+=;C[/%Q'A?E MV[=O<\XS6=X5U_XU^,])?4M!UB*6V28PEGBM4.X $\%/1A6/:_\ )K%[_P!A MP?\ H*4OPR\:^//#WA:6S\)>%O[6L6NGD:?[)-+ARJ@KE"!T X]Z .[\;^*/ MB!X+^$NEW>J:DL&OR:BT4\R10N&C(V\IX]H"R ':Q)Y M'-4X/BMJ_@GX3:-I,&B1AKVPD^QZD+OF<=#STH ]!^%/QKXA\BSO]-C\V>4';%)%G[_/W2. 1[@CK@<1K_P :/%WBWQ,=(^&-J\<* M-\DJVZR32XSECNRJIT[9X'/.*Y;3_"6K>&_@OKGB6[S!_;"06]N@8,7@9PS. M1CC.%QSGKQTKUC]G?2-/M/AS_:-ML>]OKA_M+\%DVG:J9Z@8^;!_OF@#!LKO MXU^'M;TV?Q!*+W3);R.*Y18X9 JNP4D[ &4#=D$'&1SQ5J3Q_P")A^T>/"XU M,_V-]I"?9?(C^[Y&[&[;NZ\]:]LKYHU5KI/VJKIM.19+Q96-NCG :3[)\H/M MG% ':_&3XK7OAR]M_#GA"Y5=9=U-PXB#F$$ J@# CAP/K7H7@BV\06WA M6V/C"_:\U:7]Y-E(U$6>B (H' Z]><\XKYY^#Z6EU\9)SXY9CJP+^4EZ"6:Z MW 8;/\0&[&>X&.U?4U !1110(**** "BBB@ HHHH **** "BBB@ HHHH *1T M61&210RL,,K#((]*6B@#S'Q=\(K>]9[SPP4M9SRUHYQ&W^Z?X3[=/I7D6HZ; M>Z3>O::E;26TZ=4D&/Q'J/<<5]5UGZSH.FZ_9FVU:TCN$YVEA\R'U4]0?I7M M87-:E+W:OO+\?^"<]2@I:QT/ENBO2_$OP=O[+?<>'9OMT(Y^SR$+*H]CT;]# M[&O.+BVGL[AH+N&2"9#AHY4*LOU!KZ2CB:5=7INYQRA*.Y'111700%%%% !1 M110!/: [W8'!1"?KGC^M24RW \F0G[VX ?3G/]*?7S.92YL1;LCJI+W0HHHK MS34**** "BBB@ HHHH **** "BBB@ HHJ[I>CZAK5U]GTNTEN9.^Q>%]R>@_ M&D!2K6T+PSJOB.Z$6F6K.NQMDM[*"."%!A8XU"@?@*RE42V+4.YROA3X=:9X<*7-QB^O MQR)77Y8S_LK_ %//TKL***P;;W-$K!1112&%%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F:C-J% MB#<6^RXA7EHR,,/H:-,UVVU([%S'-_<;O]*O7,P@@,A1G Z@#-<5>0Q6VOHU MI-'Y3NKJRL,+SR/:O$QM>I@ZD9P=XMZI^?5'HX>E#$0<9*S6S_S.ZK@OB5HT M\<=KXHT@;;[2V#2%>KQYY'OC^M=M!=QW$C)"=ZJ,^8O*GVS7!_$'4[C6=4M? M!FBN3<71#WK*?]7%UP?Y_E7I590E3;6O;U%@8SCB%;2V]^W6_P BEX02;Q]X MN?Q7J,?EV5CB.S@/.'QR?PZ_EZ55\;^*+.Q^*NCR2_:-FG B<*AYSD\#OUJS MX?#_ Z\T:7SYI[R,216T4>9-I[D=JK MI\4M -J))Q8(S;RQ$2#/0X]*RO!<4-S\3_$\^H*K:A"RK"K#E(_4#M_# M^?O2?&&WL_L&E7#J@NQ=JL;=&*]Q[BM'4J&P[=.FT[S5[WVWZ?(Z?Q+XQTKPK'%_:,CO/-_JH(EW.WOCTK@_'/C?3/ M$7@B[M(DN+2[5XV$%S&49EW=1ZUI:?%#=_'75/[4 >2WM4^PK)T PN2OORWY MFK/QBM[1_!1FG5/M$2Q'S9)Y _"E4E.4)N^FJ+PU.C2KT8--R=G>_?7;\ MRMXHB@DTWP@+C5+JQ+&-46!21(=J]<$8_P#KUZ.HPH&<%%%% !1110 45Y#\2 M-8\2:-\5_ =G#KTB:9J^HLLME;Q"(;4>/AFR6?(DP1D#CIS7J]Z]REC.UA$D MMR$/DI(VU6?' )[#/4T 3T5XU\0O"'BG0?"M]XNL?B+KC:OIT7VF2!I%2RD" M\E5@ PO&<9+9X!SUKJ-9\;:GIOP';Q?);+#JATF*X\IEPJ32*H!VGL&;.#VX MH [VBO&KC4-6\&W'P[U1=:U#4&\0W,%EJL-W=M+',\Z@B1$)*Q[6)P$ &, Y M[^E^)]>;0]/C6SA6ZU2]D^SZ?:%L>=*03R>R* 69NR@]\"@#:HK.T'3;C2M' MAMKZ_FU"ZY>>YF8DR2,@W'@739>8 M))X#Z!@P_7G]:S9_ %PN?LU]&_IYB%?Y9JN>(N5GDWQ!E"Z%!%G#/< XSU 5 ML_S%>=5[/XX^&?B?4X[0:9:Q7/DERX6=5SG;C[Q'H:X.?X8^,[8D2:!=''_/ M,J__ *"37T6!JTHT4G)7]3EJ1ES;'*45O2>!_%47WO#FJ_\ ;.1OY"H?^$1 M\2#KX?U7_P I/\ "O0]K!_:1GRLQZ*VT\&>)Y/N>'-6/_;E)_A5J+X=>+YO MN>'KX?[\6S^>*3K4UO)?>'*^QS5%=S:_!SQK<\MI:0#UEN8Q^@)-;EE\ O$$ MI!OM1T^V4]0A>1A^&T#]:REC,/'>:*5.;Z'E5%>\Z?\ L_:7%M.J:S=W![B" M-8A^NZNMTOX5>#M*(:/1X[F0?QW3&7/X$[?TKDGFF'C\-V6J,GN?,FGZ5J&K M7'D:797%Y+_<@C+D?E7=Z'\$?%&IE'U 0:5">IG??)CV5?Y$BOHNWMH+.!8; M2".")?NQQ(%4?@*EK@J9M4EI!6_$UC02W/.- ^"/AK2@DFI^=JTZ]?..R//L M@_J37H-K:6UC;);V5O%;PH,+'$@55^@%345Y=2M4JN\W2N/W;GZ=OJ/RKSW4=+O-)N3!?P-$_8GHP]0>]>W5# M=V=O?6[07D*31-U5QFO2P^85*7NSU7XG+4PT9ZK1GAE%=YK7P\.6FT27CK]G ME/\ )O\ '\ZXN\L;K3YC%>V\D#^CKC/T]:]VCB*59>XSSYTYP^)%>BBBN@S" MBBB@ HHHH **** "BBB@ HHHH **** "LC7H_EAE"]"59OU _G6O5/5HQ)ID MF:C(UI.TTR@DN)G/RQQJ6)_ 5WGAWX3:C?E9MGP6\-K;I!;1)#%&,(B* JCV J2BL)2'_M3Z1=7OP[T_4+="\6GWP,^!]U74J&^F[:/^!"O<*@OK&UU.PGL=0@C MN;6X0QRPR+E74C!!% $.C:K;:[H=EJM@ZR6UY DT;*<\,,U;EECAC,DTBQH, M99S@#/'6O/=(^&>K>$&>W\"^+IM/TIF+KIFHV8O8HB>3L;>CJ,]LGWS7367A MZZ:ZBN_$.K/JLT)#10K"L%O&X_C$8));T+,V.HP>: .3AETZ'XO>(9?!MK-J MOB*>W@CU5[BY$=G8@* @)"EBY"YVJ#T.2O-8/P3^TK\3OBC'>O&\PU*%I/)4 MK'O+3[BJDG'YUTK_ OOK/XA:EXF\->+;K1DU<+_ &A:+:1S>85& R,^0IZD M95L9/8XI- ^%4OAGQ?KVN:5XCNMNKE9?LD\6]1.H;:\K[@\BAF8[0R9S@GI@ M Y?X*:?9R?$CXEW@J/P%-+I7Q2^+O]EQJI MAV3Q0H %,@61AQ[D_K74^"?AKKW@S7M_VY$?AMK?ACQ[J_B6?Q/:7QUIPU];#2C$#C.WRV\X[<9[ALCW MYH J?L^7EOJ?P=M)3(MQ>275R=1=CN9YFE8Y?U)0IU[8K&^*>G:)X%^"FMZ3 MX,A6PMGOX4OXXFDDV>:4+@DG/S)L!4$?*P'&:NR? J32_$MUJ7@3QCJ/A>UO MFW7-C;1!T)_V/F 7J<9#8R<<<5W$/@/1%\$3^%KJ.:^L;I6%U)=2EYKAV.3* M[]2^0#GL0,8P* .?\2>"=?\ '/@F70[KQ)H(TN]BC*26>A2 JH*LA0FZ('0= MNE<%\6=.CM/AE\/-..I'5HX-6M[87P4QF=55EW#DD< <@G/7-=+HOP0U/16_ ML^#XBZY_PCF:R.B[5^8R@;0.@"C\: .ZMM%TNSOOMMIIMI!=F%;.@M4 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110!R_C_ ,(KXO\ #C6T6Q;V%O,MI&XPW=2? M0C^GI7S\?"VIV_B:TT74;:2SN+FX6%#*I"G+!<@]QSU%?5-4]7T]=5T:\L'8 MH+J!X2PZKN4C(_.MH57%6/+QF7PQ$O:+1_F+I>EVFC:9!8:=$(K>!=J+_4GN M35NODC4]/N](U*>POT:*X@[[.UO/_@'L/QR MT"!8K'7XL),TGV690/\ 6<%E;ZC:1^(]*POA[\--0U;5;?4=;M&M],B(DVS# M#3^@"]<>I[CI6U\#M"N!/?:[-E8&C^RQ*1]\Y5F;\, >^3Z5['4RFX+D1M1P M<,7-8J:M?I^OS"OGS]I__CZ\-?[ES_..OH.D(!Z@&N<]P\F^+_A'_A)/A%9W MMO'NO=(@CN(SGK&4 D7GV ;_ ( !WJMXF\,?\(A^S!>:5(H6X6"&2XQ_ST:9 M"W<].GX5['01GK0!\KVO_)K%[_V'!_Z"E.^&/QEM/ 'A672;C1YKUY+IY_,2 M<( "JC&"#_=KZEVC&,#'THVK_='Y4#/GSXN^+8O&_P %='UN"T>T2;52@B=P MQ&U9!U 'I74>'/!5IX[_ &=]&TJY813"!I+:XVY,4@D;!^AZ$>E>M[1C&!CZ M4O3I0(^:?AMJTD*:K\*/&XELHKO?%;AU.^&8G.W/3:?O ]"3U^:J>@^(_%7P M(UJXTK6M,-QI=W(9%4G"RD8!DC?IG&,@_P"SD"OJ' SG S4=U:V][;26U[!% M<02J5DBE0.K@]00>"*!GB=I^T6-9UC3=,TKP^T,UY>16[/-/O"J[;20 !D\B ML&7_ ).^'_7VO_I,*]^TWP]HNBO(^CZ186#2 !VM;9(BP'3.T#-:&!G.!F@# MPSX[^!);:5/'?AS=;WELRF]\G.XD$!91CH1T/M@]CGOOA7X]B\>>$4N)"%U& MTQ#>1Y&=V.' _NMV]P1VKMNM( !T % A:*** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH *S-9\.Z3X@@\K5[&*XP,*Y&'3Z,.16G151E*+O%V M8FD]SR+7O@LZ[I?#E\&'7[/=<'\'']1^->=ZOXO0S>O3TG[R_$PEAXO;0^3:*^A]7^&7AC5 MBS_8?L1EFT?5(9AU"7*%#],C(/Y"O8I9KAJGQ M/E?F<\J$T>745T>I?#_Q1I>XSZ1/(B_QV^)1CU^7)'XUSTL4D$ACFC:-QU5U M((_"O1A4A45X-,Q<6MRQ'D6J CJ2P/J.!_0TM.(VI&N<@("/QY_K3:^3Q4N> MO)^9V05HH****YR@HHHH **** "BBI[6RNKZ3R[*VFN'_NQ1ES^0H @HKJM/ M^&WB>_(_XE_V9#_'']%*M9:;$95.1+*/,<'U M!;I^&*W:S=7L4H=SSC0OA!86C+-KMRUZXY\F+*1_B>I_2N_LK"TTVU6VL+>. MWA7HD:A15BBLG)OWUZ^7FD4#:/08K>@M8K=F9 2[?>9CDFIJWIT[)N MW=[?1R!A._15'\(%>@T5#HTY.[1K#'8B$4HRV]+^E^QS]SX4BN?&&GZ^;EUD MLH3$L048;((SG\:7Q5X6C\41V2RW+P?9)Q,-B@[B.W-;]%7[.+35MS)8BJI1 MDGK'1?U\SE_%7@B#Q%=V^H6UW+I^IVPQ'IKT*BIE1A)W:-:>-KTXJ,9;;;:?,YK6/!L.KPZ*CWUA*27#SDL3N?J/:K-%6H13NC"5:O8Z\?^)>D>+-?^(WA#5-%\(WEQ9>&[R2 M::5KRU3[0&:/_5@RYZ1_Q;3ST%>EZE=ZP?"\UWHNFK_:Q@WP65]*J@/_ '79 M"R_DQ'OWH \_^+OAKQ]J^GR77A[5M/N-.M'6Y.BR66#$=6L_B[\(89]8LQ'#JEO);W<"' #*Q1BA[/=3T=H+CP? M'HNJ,NT7%QJ$,ULAZ;P(R7;'7:0,]-W>MOP;X6L_!7A&PT#369X;.,KYCC#2 M,269C]6)..W2@#E/^$"32UT;4?&'B1;W2?",1ELD:U$.S:N%DF?1G!)J+5?$!\+^&M3^)?B>R^(?$T$&HP"/0-/*7(4NI^W7 .5R >(X\ X.-S8[+S7^)_@QO'OP^U#0H)E MAN90LEO(_P!T2(P8 ^QQ@GWH S8/&NMZ)XRT#0O&45@?^$BAD:TFL8GC^SS( M S0N'9MW# !QMR?X17?UYG+X=\0^,?B%X5UO7]*.C6OAN.9W62XCD:ZN)%4? M)Y;'$8*@Y;:3TVBO3* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH ***\_^+7Q!U;X>^%WU33-#2]42+&;B><+'&6S@[ =S M'-%FU&[5Y-I"0P1C,EQ* MQPD2#NS,0!]?2@#3HKB/A3XXO/'G@%?$&K06]K(UQ,FR ,%5%/&SI_%0!Z[144=U M!)9K=K*OV=HQ*)"<#;C.>>@Q6/X8UF\\00W&IM#'!I4SXTW*D2S1#CSFYP%< M\J,9VX)^]@ &[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !4-U9VU]"8;R".:,_P +KFIJ*:;3N@W.+U/X=6LVY]*N&MV[ M12?,GTSU'ZUR&H^&-6TO)N;-VC'_ "UB^=A2S&M3TEJCFGAH M2VT/!J*]FO\ PYI.IY-U91ES_P M$&UOS'7\:YJ]^&T+9;3[YT/9)E##\QC^ M5>G3S*C+XM#EEA9K;4\^HKHKOP-KEJ3LMTN%'\4,@/Z'!_2L6YL+RS)%W:S0 MX.#YD97^==T*U.?PR3.>4)1W17HHHK4@**** "BBB@ HHHH *:\?FQO$#CS% M*9/;(Q3JDAMY[E]MO#)*WI&I8_I4RLTTQJ]]#BZ*Z]/ASXEU"^E:'3OL\+2$ MJT[A 3GIU[^E='IWP8D.&U;554=X[://_CS?X5\M*48NS9ZR39Y;6II/AO5 M]=D"Z7833C.#)MP@^K'C]:]OTOX>>&M**M'IZW$J_P#+2Z/F$_@?E_(5TJJJ M*%10J@8 P!63J]BU#N>4Z)\'';;+X@O@@[P6O)_%C_0?C7HND>'M*T&(II5 ME%;Y&&<#+-]6/)K2HK)R;W+22"BBBI&%%%% !1110 4444 %%%% !116'XKU M^YT+3HAI6FOJNJ7DODV=FCA [X+%F<\*B@$D_0=2* -RBO&=6^*/CWX?ZG93 M_$GP]I7]@WDPA^V:1)(QMR>?FW$[CC)Q@9P<'M7HWBGQ'=Z186R:#IIU?5;] M]EG:K($0\9:1W/W44M^$?$,=M_:FEI'/'<6B,D5U X&&",S%" M"0"-QZ\&M7Q+KMQISV>F:-'%<:UJ+E;:*4$I$BX\R>0 @[$!'0C+%5!&[( - MZBD7.T;B"<)/*][>*O/E3RKL)]]J@ M_K7H-%6IR2LF.#7G>A:U%X._:8\ M5VWBF5+./Q!##)87=PP6.0(H 0,>!W7ZICN,Q_$77-/U#X^?#D:!?0W5W!% ':P>(/MOBNXTBPMO.BL8@ M;V[\S"PRM@I"!CYF*G<>1M!7KNK9KB[/Q%X1\#6_]@RZJQFM2&OKAHI)-LLA MR9+B55*1L['/SE!/#%X?WNC6R]OW0,?_H)%9-Q\)O#,V?+2ZM_ M^N4^(/]L(W\@*K-\%K<_';''V?1K0$="\8<_FV36Q'&D482)%1!T51@"G44KMC"BBBD 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7DO[2O\ MR1FY_P"OR#_T*O6J\7_:9US2X_AI+H[ZC;#4Y;F&1+/S1YI0,?FV=0O!YZ4 M>O64B1:/;R2LJ(D"LS,X_\#IO_ (J@"I^S?&LWP3AB?[KW5PIQZ$UF#X?>+K?X4S?"^"Q5 MK:2\(373[S/,ZC:%V\_>JM^S3X*T0>$;;Q<+9_[9,L]N9O-; M;LR!C;G'XXKUCQ3K=S9+;:3HFQ];U,LEJ&&Y8$&-\[C^X@(X_B8JO?- &/J$ M">(KQ?"5K(1H6E1QC6)BW$V%!6US[C#2?[.%_CX?9_%'0;C[#*EO>PZ/?77V M*RU>2)%M9Y1D!5^;> 2I 9D"DC@UHS^%5M/AUJ'AW1I66:XL9X5N9&^>2:1& MS*[=V+-N)]:\3U'=K7P%\.^ -.C>+Q2M[%;3:<%(FM"DC%I9%ZHF,-O/!W=> MM 'TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1UZT44 4;C1=,NLFXT^VZ.5D^'>C/\ =DNH_P#=D']15=OAMIY^ MY>W(^NT_TKLJ*U6,Q"^TR/8T^QQ7_"M;//\ Q_SX_P!P4]?AM8#[][M7D_WY6_H170T M5#Q5=[S8U1IKH9T'A[2+;_4Z;; CH6C#'\S6@B+&H5%"J.@ P!2T5A*!+'YKS5[I)IV S]EM8FW23'TYVJ,]2V*]$CM8(S$ MRQ+OAC,4;D995.,@'K@[5SZX'I7C&@_&_P"'&D1W%]?:Y/?ZS> />72Z?*OF M$?=C0$?+&N<*N?4G)))ZSQ?\6]*\'^#K#5=5B^S:CJD0DL].E8EQNQ@R;0=H M4$%L ]P-QH I_%W31XU?1? EJ-\U[=I>7KC_ )=;2/.YSZ%B0J^ISZ&M+XA> M%=2U77/"_B70HQ0V9D$9N(9% D56/ ?Y1C) /.2*XW0_CA\-M#M;B MZN-:N=0U:[_>7MT-/E5IW X501A47HJYP!WR23[%IMW)>Z3:W=S;-:23PK*\ M#MDQ9&=I/J.AH \]TVRN]$\8>)_B/XLMWTV*XMHK.RT[>LL^Q<8!V%E+N^ J MJ3R<9J[!J<7A6YAU+Q+%->>*?$DGEV^G6@5Y$C0%EMX]Q50J DLY(!8DYY % M[2_^*T\01Z[)DZ'ILC#2HR.+J895KHCNHY6/_@3=UQS_ ([@?1_C/X.\6:C\ MNAVT%S:7%TW^KLY'1MKN?X0V=NX\#')]0#M_#?BK3_$\-W]B$T%S8SFWO+.Y M4++;R#^%@"1SU!!(/8UM5Y;\+[::_P#B1X\\4VP;^Q]4N;>*RF((6Y\I"&D7 MU7)X8<')Q7J5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110!SGC2Z\(VFC-/XY33);.'YUCOXDER?]A&!+,>P R:X3P!X M1O/$'Q D^(>O:5_8]K!!]ET#2FC"-!!@CS'4?=)#-A?]L^QKTW_A'=%_ME]7 M_L>P_M)\;KW[*GG-@ #+XW' Y["M&@"CK.L6>@Z/<:EJ4A2W@7)VC+,2<* MJCNS$@ =R0*RO"ND7B27&O:^H&LZB!NCSD6< )*6ZGVR2Q_B8D],8W;BSMKO MROM=O%/Y,@EB\U VQQT89Z$>HYJ:@#P'2)H]-^&7QAM/$,BQZG]OOVE$S8+" M6$" @$]&;.W\*]5^&5O?6GPM\-P:JKK=1Z=$'63[RC:-H/H0,#%;-YX?T;4= M0@O]0TBQNKRW_P!3<3VR/)%_NL1D?A6A0 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %>0_&+6/$NA^(/")T_7I+:PU#68K>:TMX MA&67H:3X;U+3 M_"[?\3E=-GO9)NUE;QHQ,A_VF*[$'=LGHIKH_&7BBU\%^#]1\07ZL\-E&&V+ MU=F8*B^V691GMG->,WGQ4^'Z_#3Q-:MXH74/$>N:?Z+W$A=I756(W,>3R!S7* M3ZQKGAKP3X%\;?VYJ%]>ZO>VR:I;W-T6@GCN%+$+%G9&5X"[ /?-;/P:\0^& M/&'PJM/"*7(O+BVTSR-2M##(NU7RI&XJ >O\)-:"?#!+33]&M?$7B/[7X;\, M2_;+2VDMA$P,8.PSR[B'5 3C"IQUS0!VGB/7HO#VE?:6B:YN9G6"TM(S\]S, MW"H/YD] 2> :/#FFWVFZ2%UB^>^U"=S-%#X MMM]/%GXJQ' +2-T>QF95:.-RS$29W;=P"8/:@#TBBBDS0 M%)FC- "T5C:MX MNT'1,C4]4MX6'5-VYOR&34^CZW#K4)GM;:ZC@_@EGBV"3W )S^8%3S1O:YN\ M/6C3]JXM1[VT-*BDS1FJ,!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H M6BDS1F@!:* 0275G+#!=S6<7>@Z=XG^*7BS1]:MEN;*ZT*Q21#_UUN,$'L0>0>Q% '=RXU?1 M]VFZE);I6[!3@AEWJRG(]0>M<5\./^$DOKW6I_$'BR[U*/3M6N+" M&W^R6T2.B8PSE(PQ;YL\,!QT-<7X%US4OA%XU3X=^,KAYM%O')T+4Y!A1D_Z MLGMR0,?PL1V8$=GX0U2'1-!\=ZK= F&QUS4+F0#J5158_H* /0J*\7L=9'BW MP*FJZEJOC"WUR^@-Q ^DZ=J*6]J2,HB+''Y_9VU M#6O%(UW0/$FBI*B31RSV#3XV$2-&I4."#C)!&0VW&30![I17F>HK&DOTO+:^EAE:9;3?N=E8%\GDALYZ]>:P-1UC7D_97L_$-IXAU" MVU.#3XY7N%=7>[JS=">5(/N>E 'M=%>5>%M"UZ[T/PCXTU7QQJ4=O: MZ1%<7NGY+P7$?D Y8Y!+_P 3,V\DYQBI/ $EU\4O#,WB?7-3U.UBO+F5+&ST M^^EM%M8D;:N3$P+N2"26)'H!0!Z>ZEHV56*,00& &1[\UY1\,M7UJZ^+WCW2 MM7UJ\U.WTYX$MA<,H" ESPJ *#T!( SBI?ASXMUFV^(WB#X=>)[M]1N-+07- MCJ$H DFMSL(5\8#,!(G/^]GI5'X8?\EZ^)O_ %VM_P#V:@#V*BO+?!&JR_%B M?7M7NM1OK?1K/4'L-/M=/O)+7(158S.\95V+;Q@9P!V/6H?#'B;6/"_QFN/A MYKM_-JMC>6WVS2+NZ;=.BX),;M_&/D?!//R^_ !ZQ17D_A34+OXD^-O&,6L: MEJ%G8Z'>_8+2PL+R6T*X+@RNT;*S%BO )P,'BL[X=R^*==\:>+?#6M^+]3GT M_0+C[.JHD2O<12"0+NG51(KC:#D,#GZ4 >TT5XO\,QJ/AGXQ>(?"?BG7M8U2 MY$"W.CR7^H2R)+;$G=\A;:7' SC/ROC SGJ=&L)-9^+>MZQ#J>JC3-+$=FMH M-0F^S2W>TM*_E[MN%5HUVXQN#'&1F@#OZ*** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "O(OB_HWBKQ/K?AU?#WA6[NX-$U-+V6 MX:[MHTF"[3A TN[U'S!>G?K7KM% %6TE;4=-CDOM/EM&D&7M;HQNR<]#L9E/ M3/!-8WC/0%U3P'K]AIEA#)>W6FW$-N@5%+2-$RJ,G ')')(KHZ* .4^&>@W/ MASX(]9MM,NH/+\/0JMQ=N77 M_39 ?D@V@Y" C<^<;OE49&ZNEHH YWQ[X57QIX#U7P\95@-Y"%CD(X1U8.A/ MMN49]JXJ3PGXE\5ZEX'@UW2O[+MO"\J7-WB@ /2HY#B-B.H!J0]*CE_P!2_P#NG^5(.IRN@:2EWH-OJ-_JFIL\B&20 MF^=5')[ X KS7Q9\0KFZDFT[P]K%6N&E+23]L[CR%]J['Q!>RV/P3#6 MY*M)&L1([!GP:\T\$^'?^$E\4VUDZ_Z-'^]N/]P=OQ/%<%63]V$>I^@Y3AZ- MJV.Q6L82=ET5M=N_1':?#/X?1W*Q^(=>B\P,=UK!(,Y_Z:-GK[#\:[GPQK3Z MSJFO8?,%I>BWA'8!4&P6H/3S7 )^@IFN:FNC:#>ZBXW"VA9P/4]OUKSOP7X0B\6P/XE\6,][+< MR$PPLQVJH/7']*Z#YD[VR\5:%J-PL%EJUK-,QPL8D&YC[#O5N_U2QTM$?4;N M*V61MJ&5L;CZ"L1?!OA33-4L[V.RMK.Y@?="0^S+8QTSSUKG?C(/^)7H^?\ MG]_I0!W][J%GIUH;J_N8[> 8_>2-A>>G-30S1W$"30.LD?AK)G^_%_.NE\+_ /(I:5_UZ1_^@B@"W?ZG9:5 LVI745K&S;0\K;03Z5G? M\)EX;_Z#=C_W^%GTJSF*VM<\)%$F? M95 _PKPB^74-2-_X]@W?Z-J*^4,?P+W^G0?G2$>]U@OXW\-)(R/K5J&1BK#= MT(."*U=.OHM3TVVOK8YCN(UD4_45RVEZ/X%\0S7AT[3;.XD@E*W!\G&').>O MN#0!TNGZSINJJ3IM];W6.2(I 2/PJ[7E7CGP?;>%;1/$?A9GL)[:5=\:,=I! M/I_2O1M$U'^UM!LK_ !N(5<@=B1S^M &@.E+2#I2TQA1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%4[/5K&_N;BWL M[F.66V;;*BMDK_GI^% %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHK+\3:[;^&/"^HZW> M#86[S,J]7P M.%'N3@?C0!J45A^%+>Z/AVVO=5?=JM_ D]W(!C:S#/EKZ*FX@#\3R23@?#B[ MU&?6/&=MJ>IW6HBSUMH8'N6&4C\J,A0% 4 9/0"@#NZ*XY=6/A[XF6OAUV/] MGZY:2W%BAZ0SPX\R-?\ 9*,&QV(;LW'8T %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 445D^)-=7PYH[:A);O<*KJI1#@\ MGKFIG.,(N4MD3*2BG*6R-:BO-+CQ?))XYLM0M;V;^R6MP7M\G&-IW97.-P/? MVIOA?7==\1?$!9Y9Y$L(T=FMT8B-5P0H([G)')KSHYG0E45..K;M_P 'T.;Z MU&]K/>W_ ?0]-HHHKTSK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1F"J M6.< 9.!D_D*\QT;Q*K_&+5[Y]$\116-[86EI;W#E@! MP>U>GT4 !!)S^?.:]3HH \*\(>)OB#\-K&+P?KO M@34=?ALR8K'4=,!9'CS\H8X*@<]200, CC-=SKN@^(O$GPDU^RU%8TUG5K>2 M2.R63%&6Z;F8]*[RB@#Q32]:\3:I\$+WPI_PA&LV5_8>'Y;": M:\@V1R[(#&HA'WY7; P N,GJ> :&HIK<'[,$?A:\\+ZVFL26BV\-O!9-<;]L MJL6)BW>6-N.)-I)S@'%>]44 <5\.V35_A3IFCZCIVH64EMI<6GWEO?V4ENV1 M$$;&]0&!P>1D5RGPSBUCX5VU[X1\2Z7J5WIT5R\VF:II]E)=1R1MR4=8E9D; M.3R,9)YQ@GV"B@#SKPGX8NS\2/$?Q"UBUELS?0):6-HZ[IDMT5=SNJY^9R@( M7J!P>3BN9^&MS=6_QJ\9W]YH>NVEEKDT7V&YN-(N(XWV;L[B4^3.5DZH/G90&PQSD@=_1J1PQ1 M@C;6(X;&<'UH ^?-7\6:;H/Q5\57VH6GBCP[>"5+7S]#M8I8KJ(+D22^8KH7 M;<"#M!"XYR6KL_A7XP\ W%W/HOA=[V'5;QGO;C^U(F6XO'/WG9SPQZ\#IS@= M:I>'_P#A:G@2SETJ3PM9>,(VN)9QJ<.JI:R2EW+$R"0')YQQT YQ776>G>( M=6]C MI'C?P[M77/#UW'Y2G_EXCE<(8O?)8<>A8#DUW/@W06\-^$K+3KB03784RWDV M/]=<.2\K_B[-^&*Y'P[8^/\ Q9>64GQ*T[2])L],NOM26UC)O-Y*N?++?.P5 M%)W8SDL%X&*]*H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ /2HW!:-@.I!%2'I3:0'):5IMMX MD^&ZZ9<9571X6/='5R,_@16'\.].M/!^CZKJ&LW4,>;LV_GGH0G _,YK=N3+ MX0UF>^6-Y=$OG\RY"#)M)>\F/[I[^G6L;XCP6D/PN86$JS6\ETDJR*P8-N_6N:22][K%'U%"4ZS^JJ3]G7FMNFNJ]5IZ[['._$?XAVVN67]CZ&S-;,P: MXG(QYF.0H'IGFN@^"T+KX7OI2,))>$*?7"C/\Z\HT+0;_P 2:HEAI<1=R1YD MA'RPK_>8_P!.]?1VA:-;>']$MM,LP?*@7&X]6/4L?J:RH_5TW^V?#]]IV[:;F%D!]#CC]:\Z\#>,K?PO:/X<\5![&> MUD(C=U.T@GI_]>O5:H:CH>EZN!_:=A;W6WH9$!(KN/@3S+X@Z_I6L^(O#:Z7 M?1W/DW0\SRSP,LF/Y5J_&0XTS1_^OW^E=A9^%-!T^<366DVD,HZ.L0R*MZCI M&GZO'&FIVD=RL3;T$BYVGU% ')?%7_DFTG_72+^=&@_$#PS9^'=/MKC4T26& MV1'7:>"%&:Z^^TVRU.S^R:A;1W%OD'RW&1QTK*_X0;PP>NAV?_?L4 :LV>I_#J.SMS*VG"58U+$Q\A@![>M=A<>'])N M]-AT^YL(9+2#'E0LORICI@51_P"$%\+_ /0#L_\ OV*8S+^)&OK8>!G-G(&D MU'$,)4]5;DD?A_.L*R^%-V^@QP-X@NH4EB#/:JHV!CSC\Z] NM!TN^2V2[L8 M9EM,>0'7/EX]/RK0I"//_A+JCOHUWH=V<76ESE-I/.PD_P F##\JQ/AMKVE: M+>>(1JE_#:F2\)02'&[#/FO3;;1M.L]2GO[6SBBN[C_6S(N&?G/-4)/!/AJ6 M1I)-%M&=V+,3&.23DFF,X;QIXLC\:11^&O"DE:18+ MI6C6EBIW"WB6//K@=:6PTK3]+C*:=9PVRGJ(D S5ND(4=*6D'2EIC"BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK&U^_N+ M6-8;=) 9>%:)=SL>NU1ZX!_"LJU54:;FTW;MJRHQYG8PO'GC./2;=M-T^16O M95(D93GR5_Q/Z?E7ENEZK=:1J,=[8RF.5#^##N#Z@UTVHZI'/))"UC%L^ZWF MK\^?KUS7.-H]W*Y:RMY)X\\;!DK]:TRS-<-6BZ=6/(_-K7Y]/0C'Y;BZ"5;= M>70]Q\/Z[;>(-+2[M3AL8DCSS&WI6I7D_A/1;^PF8/*RRW"E5MD;[P]6/M7J M-C;M:6,4$DK2LBX+,?\ /ZUC'$TJU:4:&L5]KHWV7>W?8<8S4$YJS[$]%%%; M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M5QOQ=TNXUCX1>([.R0O,;,R*@&2VPAR /4A3794$9&#R* ,[1K^WN?"]AJ"R M*MM+9QSB1FPH0H&SGTQ7 _"CQ#H^J^+/',.FZI:74DVL-2BG^YGD#^'D XP!HT >=>+; M.34_CIX!6V+?\2RWU&\N2IQLC9(XU_ L??7859)R MN,1KG;&H[*-S''/+$]ZT* "BBB@ HHHH **** "BBB@ KDO'::ZR:>= O5M1 MYC+*3.L6XG&W[W7^+C]#76UYG\868#1P"0"9B1G_ '*[,##GQ$8Z==U?IV/- MS2I[+!SF[Z6V=GNNIZ+'<(C16T]Q$;HH"4W ,V.I ZXIL>I6,MR;>*]MWG!( M,2RJ6X]LYKRGQC;7-]\2+:ULIC#/-'%&L@)&W(P3Q[$U7\8>"/\ A$[.UO[* M^DF!E"-N4*R/@D$$?0_2NJ. IRY%*=G)72L<-3-:L?:2A2O&#LW?_@'KUSJ5 MC9R!+N\MX'(R%EE52?S-8GCO4+BP\%W=UI\[12?(%EC." 6 .#]#UKBH?A]/ MJ_AEM=N=3DDU"XB-R%89#<9 )ZY([]JS["^FG^%&KVDK%DM;B'R\_P (9QP/ M;()_&KI8.GS*49-@P/XBO)O"G@*3Q+HT5[JE_-% M;KN2VCCP2 "!1I,=[X#^(4.F/<&2TNW53@8$BN<*V.Q!_D?6IJX.E M.I45.?O*[M;3T3*P^85J5*E*M3]QV7-?6]MVO,]7%W;,\JK<1%H?]: XS']? M3\:;_:%E]F6X^UP>0QVB7S5VD^F-@D). M?49QQZXK9\:>'H_#7@JPL8YVN";TR-(RXR2F.!V&!2>7P52--SUE;ITL-9M5 ME2G65+W8WUOUOML>L57%_9FV:X%W!Y"'#2^8-JGT)Z554X\+ CK]B_\ 9*\K M\,Z7+J_@+7[> GS(Y(YD4?Q%021^0_E7-1PJJ1E*4K)-+[W8[<3CI49PA"%W M)2>_97M\SV56#J&4AE(R"#P152]F,MK=VUA<1K?+ Q1=XRC$':2.PS7(_#GQ M!')X.GCNY,'2P=QS_P L\%@?T(_ 5S_A.&XUO4?$'B*YW*HMYE'/!9E/'T ' M\JT6#<93YG;E_&^QD\RC.%+V:NZE^NR2U^X[+P(NLC29VUR[%TQF/E,)EEP M.?F4GOVS5'QZVJS-':Z?J%C':21E9[::2)78YZ_/VZ="#FN8\-:W-H/PUU2Z MM>)WO?*B;'W247G\ #4OAWX8GKGT_6GC,OA5 M]I[:?+&]O=7Y(XJ.-G4HTZ%"+E)J[O+97ZNVM_0Z;0_ ]E_PCR+?'?=2HW[Z M-P?+SQQC@]/?J:XJYTO6](FFLK>Z,6YS_J[Q(]^#QT8'\#78^'/"%[X?TG6+ M34-51;2XC*Q/&Q'E#!R_. IY'Y=:XYVG@;0?$6FWDM[KFHR&U: M,A;=[@RY/][.2!CV-=K;W5O=Q^9:SQSIG&Z-PPSZ9%>0^$#J&I:+K7A^UE%P M@C$D2%RJMAQN4'L&'T_G73?#/PUJ6@+>MJ%LUJDNT*C."7/))P"0,9P/6N_^ MSH8.G*GSW:VON[FN!QDJJ@J<'RN]VW>SUT.]HHHKE/;"BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@#'UKQ=H'AZYM;;6=5M[6XO)5BMX&;,DC M,0!A!DXR1SC [UL5XK\=["SAU[P'=0VL$=Q)XAB#S+& [?,O4]3T'Y5[+=7, M5G:37-RXCAA1I)'/15 R3^0H KZMK&FZ%I[WVM7UO86B<--<2!%![#)[^U5M M%\3:7X@M9KG2Y9VMX<;IIK26!&!&/[J M1K&PG:+1M+6WDN4LHQUG=(U;#'^\P'*MCHN/3/&FJP^+?@OK]WX.O%U%;C3Y MEB>T;<7X^90!SNQD8ZT :VF>/_#&LZG#8:=JBRSW(W.KZ MDGA/196BFGC$NI7<;8-G;$D8![228*KZ ,W\(R ;VF:M9:Q;R7&FS>?#',\) MD",%+(<-M)'S $$9&1P>:N5!8V5MINGP6-A EO:V\:Q0Q1C"HH& /I4] !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !117%_$GQ5=>'=*MK?2@&U+4)?)MP> MQ]?UJHQ)]?U":[D&YTCE954GL #4TGP7TX(3::SJ<,O\+"=N#^=:\E):.7X&?-/L>E M5YUK?B;5+'XR:5I$$^+*YA)DB(ZGUK)\/:SKG@?QO!X8\27;7UE>#_1+ES\P M/H3^-8OQ4?4E^+FDC0SB^DA"1MCIG/-:TZ-IV>J:9$ZGNW7<]S:1$.&=5^IQ M2"6-NDBGZ,*\SM/A'<7M44F#Q!JR./NG M[2W!_.LN2G_-^!?-/^4]'K@T\0:B/C9+HGG9L#8+*(L=&^;FLO0];UOP;XQA M\->)KK[=:7@_T.Z/WOH:YGQQ_;DOQU^R^&I/*NKBQC0RX^XN6R:TITO>:?;< MB=31-=SW1I8U.&D4'W84"1&^ZZGZ-7FEO\'O-B$FJ^(]4FN6YK'%.!R..E>1: M=>:G/K%YX \7W#O+)'NL[V-BK,.W(I_@'Q1J7A[Q1/X+\62L\BG-G<2'[ZGH M,GK3=!V=G_PPE55SUJBBN7\?>+XO"'AY[A3?N[>(^.*Y[P4WB1K&Z/BOR_.\X^5LQ]VL+P)H.K6^A76N>)+ MJ:34KV%G$;.=L2D9 Z"J7PJ\03IX$U*^U6YDG2TF3@\T6RNI1AYK>.1AZ$J"?YU$Z:BE).Z*C)MV:+ M=%%%9%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4F*6B@!I0,I#8(/!!'6N2U?X\:ZUJEE)X/NO(MXX2LP^T"/+;N.._% 'I%%?)W]K>./^$L_P"$<_MJ MY_M#[5]EV^?\OF9QU],]Z]3^&L^L:#XJO;#QIXBLY9WAVQVIO5=U<'<-H8@D#/KA3^5:+:YI:Z+_;#7]N-.VA_ MM7F#R\$X!W?7B@#G_&/A3^T%.HZP M+1RYPSYP$')&9=%U M.WNY$7<\:/\ ,HSC)%=\8J*48JR1Y3;D[LV:*Y[4/'OA?2M1-CJ&MV<%PI(= M&D'R'_:]*\MT+Q)JMQ^T7-IK:E-)IYNK@+#ORFT1L1C\A5"/Z M-FQQSZ9KG/B]X[U#PCI\=M9Z2EU'>(5,\Q^0'G*X!SD _C7F_AGQ&VHZ;&^ M?WB#:Z'L:(M-V,L9'$4*"KQC[K=KG1W/C36;Z[!N[ZYMI4/^KMY&C4_@#S]: MZ_P[X]F%O,-?660@CRFAASD>_O7'1W4,K L@WCID5,UV0A/"*HR2>U=M2I"< M%%1L?.4\37A4Q]9*A6I0BZT;.2N(TB*<,Z@^A- M.SQGM7E/B)]$_P"%G:JOB+3[F_C%G;F%(?,.P_-GA3WXK2^'ET9_#&L+$\B6 ML<>E).[-ZF'Y(*2?;IW5^YZ'N7;NW#'KF@L%7)( ]37ES M2N/@+8^X"8[MQS_K6[U:T227XD7"RWLCVFCV!55L-VV69P!\TG<#GVHN3 M]7:BY-Z)M'HQEC'5U'U-"R(QPKJ3Z UROC#PKHM[I-YJ%U9;[J&U81R"5U*X M!QP#BHO 7AG1[/P_I.KP6FR^DLT9YS*Y)+*-QP3BG=W)]G3]ESW=_3];_H=C MD9QGGTH)"C).!ZFO(=1UZ>;Q--XN@OU2RT^Y6T6U\Y?FB!Q,VW/J!BNT\?W MF^&.JW$#D+):!U8'!P<'^5*^A?U=\\(7WT]&=0LB/]QE;Z'-+D9QD9]*\=OW M\*1Q6 \$--'XA9T^SK$9?GZ;MV_C&,UU_B"23P_XXTS6C(XM+U?L=V.JKC)0 M_BQQ1<)4$GH][[JVWS^[S.S+ =2!2@@C@Y^E<7,[>(/B;';JAQ;Y-K$!Y M'' /^Z5JGJ5Y)\.=:GOY%DFT"_;S$DT[F:HMM16[6QW^1G&>?2 MESGI7(>%M*OK^6Y\0ZXS17E\A2WA5CBVA/0 =,G -7_"OAAO#D=PKWDEQYSE ML,20/S[T$2BHNUSH****9 4444 %%%% !1110 4444 %%%% !7F?QB!QHYQP M#-D^G^KKTRHKBTM[L(+J"*8(P=1(@;:WJ,]#71AJWL*RJ6O;_(X\=A?K>'E1 MO:]M?1W/,]6&?C%IF/2'_P!!K9^+ SX3@Q_S^+_Z ]=FUK;M=+VQ MC:""/ %D".?[/7_T"O*])4GX<^(2 2/.M^0/]NO<@ J@ 8 X ':JZ:?9QVTE MO':0+!*29(EB 5R>N1C!S3HXSV7-[N[3^YW%B];EC*.W=6N>5^$O'W M_".:/'I^JV4\D/+VTD8&2I)SUQD9SR/I3=-FO/'GQ$@U$6_EVMFZ,>3B-%.X M G^\3_/VKU.?2=.NK9+>YL+::",82-X5*J/8$<5-;VL%G"(;2"."(=$B0*H_ M 5I+'4[RG"%I2OK?OY&,(&(Y!FP?^VHK M2^*UG/<>&89X4+);SAY<#[JD$9^FI&4 M,I5@"",$$=:QEC']8C62VM^!T1RY+"2PTI?%?7U=SRN+XEO)X733(=/EDU%H M/(5UY4_+C=CJ3CG%7_A!S8:F>QD3^1KNK71],L9FELM/M;>1NKQ0JI/X@5/; MVMO:1F.T@B@0L6*Q(%!)ZG [U=3%TW2E3IPMS6ZF='+ZT:].M6J\W(FMK;JQ MXGXJM+KPOXBU*QLLQVNH("H X,98' ^A!'T^M>EZ3HO]@_#V2S90)OLLDDW^ M^5)/Y=/PK?GLK6ZDCDN;:&9X3F-I(PQ0^H)Z5/UZTJV-E5IQ@UMOYVV*PV60 MH59U$_BT2[)ZO\3Q_P .Z--KGPSU2WM!NGCO?.C0?QD(./J03C\*M>&?B1'H MNC)INJV4[R6N41H\ XS]U@<8(Z5ZC;VL%I%Y5K!'!'DG9&@49/4X%5KO1-+O MYA-?:;:7$HZ/+ K'\R*TECH57)587BW=:ZHQAE=2@H2H5+22L]+IK?8\]O?$ MVJ^+_!VN&*P,-O"8S&T622H;YE)[D 9.,8K,\/:[X/L?#JQZGHPN;X9W,\2R M>8<\88]!T_\ KU[!%%'!$L4$:QQH,*B+@*/0 5431-*CN_M4>FV:W&<^:(%# M9]ZL[=+%2RZLZD:OM+RM9MQ3ZWT70\X^%AW>*M480>0#"Q M\H#'E_./E_#I7JM116EO!-++#!%'),(M2LGG.2#^#*?H M161\%M,;2/B)\1['3LKHD.I(L"+_ *M)WR@J#]%KMQ\/;*TU:^O] U7 M4]!.HR>;>P:>\7E3OW?;)&^QCW9-I-;FA:#IWAO2DT[2+?R8%8NQ+%GD=CEG M=CRS$\DDYH QM:31?""2:EH^@V!UW4I!;VR6]ND>>>3BO:* MY/2?AUIFFZQI^I7-[J&JSZ5"T&FB_E1ULD8 $)M523@ ;GW-@=:ZR@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ KRSXN9TWQ!X:UV8$VEK<;9CV0>OZUZG5' M6-'LM=TV2QU*$302#!4UI2FH2NR)QYHV1-9WMOJ%G%6%N3D0D[@M.;X:^(IEV7'C.[*'J%4C(_.KY*?21/-/ M^4Y#XT>([9?&VB1V<@>6Q??*R'.W)''Z5I^-;E-.^*GA?7;GBSFB">8>@/\ MDUT9^#NB?\(]2'+Y%;]WX+L-4\)V^AZQ_I*P(%6;&&!'<5O[ M6G%12Z77WF?LYMMLZ&.5)HUDC=61AD$'J*=D>H_.O,D^%VN6*^3I'B^Z@MA] MR-P3M'YTI^''BF0;)?&MP4;A@$/3\ZP]G#^;\S3FE_*4/'5Q'KWQ7\/:9IK" M::R?S9RASL''6I-8NHM!^/EG>Z@1';WMDL"2-TW#/'ZUUOA#P!IGA$R3P%[F M]F_UMS*235^M[FZ&5E! M5@0>A!H) &20!]:\T7X9>(K51%8>,KJ.!>$5E)('YT-\-?$TZ^7<^-+EHFX8 M*I!(_.L_9P_F_,KGE_*9]W>1>(OC[8C33YL>F1'SY%Z9XXKIOB3X+/B;25N] M-'EZM9?/;R+PQ([9K4\)^"=+\(6KKIZ%YY>99Y#EG/UKHJL(5TNU(H+<$R/))M []:]IFB$T# MQMP'4J?Q%<[X,\'1^$-/NK..?SXYYFD&X= >U13FHP:ZZ%2BW)?,\G^&O@B+ MQ+X762'Q)?6DT3%);:*0@(?IFNP_X5!-_P!#7JG_ ']/^-7=5^%-L^J2:EX= MU&?1[F0Y?R?NL?I47_"!^+O^ASE_[]G_ !KHE6YG=3M\C)4[*SB-M?@[8?;8 M9]5U:]U)86#+'/(2N1^->C1HL4:QH,*H"@#L!7G]OX(\6PW$,)'56!*F, MX(].M>@1AEB0.=S!0"?4US59-VO*YM!)=+#J***Q- HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@#Y?/_)QS?\ 8?\ _:E2^+]+FUOX[W&F6]PU MLUW<^4TJ]51AAL?\!SQ76'X6^)O^%Q'Q'Y-M_9YU;[5N\\;O+WYZ>N.U:-Q\ M.O$$GQK3Q*L4']FBY\PMYPW;=N/NT#.=^+'@;2?!'@6UBT;SO]*U",S&5]V2 ML<@!'I]XUT=Y_P FMC_KQC_]'"NH^*G@RY\;>$5L]/D5;NWG$\*N<*YP5*D] MN&_2O,U^&/Q)OO"KZ'?:A%%I]HH:UL_-3$C9^Z6'(&"3R2*!''-HS77P7MM8 MC^]9:Q-$^!R5>.,CGT!7_P >K;\<:^WC/2O!&D64322FT7<0V6,A;RB"/^V> M?QKT;P=\.=2LOA+J_AC75CBN+R>22,Q2!P,JFTY[CP-H_C@QO!J?BJ[M(A;M:Q6RM$#&HC .3D[ M0O8$5S4.JW'A_P")=SJFE:2=%DCADFBLG.[8#&2 1VR.<=LUWMO\._''A3X@ MW^M^%X]/O(IY)&C-RX'RNM_9-1MIIE>\?S= MORL/G4+Z#) ]<4 8?P?\!:3XW75=0\0^;<&%U14#ELSPWI=KX=^- M5WICWSP6MH+R(W9X:-?(<;_J!S73P?##X@^#M=NV\$:A']EG^596D0;EZ@,K M \CU JO8_!#Q._BJ=]7NHI;699@U\)U7Q3<2@HMU<6ZA(S@_,""2N>N2 >*O_ C3DU#4-;@DS%Y8B=00'VD,W!! MZ_\ ZJU?"G@KXD^&=.OM%L8],BM+XX>YD<,T0((++@@GCL<_A6U\(_ /B#P7 MK6IOK,4!M[F-526.8,258]O<&@#U.WMX[6W2&!0J(. *DHHH$8GB[PU:^*_# MESIETHRZYB?'*..A![5\GW46H^%M;N+*4F&YMW*2#LV#^HK[+KR#XX>!?[2T M\>(]-BS=6RA;A5'+IV/X4XN%.;H5E>$N^USR_3_&[(I^U6X>0 M#@J<9JGJ7B>_U%6CW>5$W&Q/3W-[<^GIY5E.!4L7[)::][>B>AZ1\$_!/DP'Q)J,0W2 BT5EZ#N_L M>HKV.H[>".UMXX(%"1QJ%50.@%25U1BHJR/B,9BIXNM*M/K^"['&7FG^)-.\ M;ZAJVBZ?9WMO>V\,6)KHQ%2F>VTYZU/H&@:I%)K.IZQY$=_JH53! ?SHL0JD ME;R.;\#>';KP]H)359$FU&XE::YE4YW,>V>X%3>--&NM>\/-96/E^:95;]XV M!@5O%03DYZ8X)%*!@8H%*;E/G>Y%:QM#9PQO]Y(U4X]0*EJ-H59B27R1CB1A M_6E2)48D%B3ZN3_,TR!]%!&1BD VJ ,\#')S0 M%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !3)8DGA>*90\6][(I^S3A#0!XSKWP#NGUP MSZ%>PBTFD+-'*-IA!/08ZUZAX(\&6G@K1/L5L_GS2-OGG*[2Y[<>W2HI=*\1 ML^4U%0*NV5AK$6/M5XK_ (5*BD[H[:V/Q-:DJ525XHW**C17"CXZ8(H ZJBO&-+@-G^UI>6R M7-W-#_81E5+BY>;869,[=Y.T<=!QZ5[/0 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110!Y[\1-,6Y\2^'[[Q#K%G!X5MFE%[I=P MS9OYF4B)0@!\W!.=G/0\'-'O%D7Q;T#QEX;TN'7K6RLWM)-/DNE@:$L6W2H7. 2 M& XY^7'?BC=^%?';_&_3_%\.F:;Y4VEFTE/VK*6));[W :8@$'Y54'IE<;B M9$FB&[_:COM(CU34X+230S))B]D>0!F3'_ SY]OI6L:,UU<6KW#R+YH:3Y_G))/[H* )O#%W!\4OB/XL.O(+S1O#UPMA9:;*-T#OEQ M)-(G1R2GR[@0 >F>:QM-T&P\._M9P6FDQ&"T?0VE2W#$I#DD%4'\*Y&=HX!) MQ6@?!WC/X>_$[5_$7@73;?7M&U^3S;W37NDMY8I,EBRL_P N S,1[,1C@&I8 M?#'CJZ^.UKXRN-'TVVLUTP6KHU^6V EN,A26<9!/RA>1^";FU^* M?C#Q;?>(X4U#3=+O1I^GZ=<+O@C1<[I#&?E9V(!R02.@KURO+-/\'Z_\/?B/ MK&M>&-/_ +:T'Q XFO+"*=(KBVFR3O3S&5&4EFXW \_[(R 94,D_PW^/>F^& M=*>0^%_$MNSII[.62SF4-GR@<[5.T<#CYC_=%9OAKPEX2&TDLHVBC8QP$LJ$8!)8DD#N?6N_M?"E[K_ ,3;7QGX@M!81Z9:-;Z; M8/(LDJL^=\LA4E <$J%4MZYSQ6%+X7\7:'\>M6\4:'I-MJ.GZY91V[3RWBQ" MT=%C7<*#G/44 9-WIXU7]K"^LY+BX@BD\/ 2FWD,;LNY OVG;;0?#0FM=+UK1FN;BT,S.GG!I/G^8DY_=#G_:/8XJY;Z3 MXNC_ &@IO%TOA"\.E26 T_>MW:!^J_O=GG?=XZ9SCWXI=7TGQ9<_M":7XOM_ M"%\^DV%@U@[?;+0229,O[Q5,WW?W@X)!P.@/% #K?6'\8>/_ !3%JOA:_P#$ MFG:/[-T.#@ 8QS3OA]X;\4:/XYUZPDT;4-*\#7T M.^RMY]0B\RTEPN53R969 29,;3T"]*BU_P '>._!_P 1-1\5_#&*TU.UUG:V MHZ1=2"/,@_C4DJ.Y.=V06/!%=9X>7QA-YWB+QCIT4=Y# 8K+1--F5BH8@LS2 M.P1G)4 <@* >3N- 'EOPU\#6?CJW\>Z1K^H:D]C'K3Q1A+M_,#*2%=G8G>0 M P(Y)()P1M^,Y;?P3XOTT>--$N]>\#VVDPV5M/+&+J.UF4X,DT9X9R /G(S M_=[BK_P>T7Q9X9U_Q&GB+PM<#FNI MO+WQ=IGCC46C\/S:UX=NH(O+$%W"LL4@&'PDKJ"IR,\CD=\T 2?#J+PR]AJ& MI>"M22]TW4+A9A$CDBV81JIC ;E1QG:0,9XXQ78UYY\./ T_AOQ/XGUUK&/1 MK76Y86M](B=6^SA%.6;9\@9F9CA20,]:]#H **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB 0B@ HHHH **** "BBB@#_V0$! end GRAPHIC 13 rprx-20201231_g2.jpg begin 644 rprx-20201231_g2.jpg M_]C_X 02D9)1@ ! 0$!( $@ #_X1#R17AI9@ 34T *@ @ ! $[ ( M - (2H=I 0 ! (6)R= $ : 0T.H< < @, /@ M &UL;G,Z9&,](FAT=' Z M+R]P=7)L+F]R9R]D8R]E;&5M96YT#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@ M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8 M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4 M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ_\ $0@%90H9 P$B (1 0,1 ?_$ !\ $% 0$! 0$! M ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $ M$042(3%!!A-180'EZ@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! M @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$' M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F MY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJAJNO:/H< M:R:WJMCIR-]UKNY2('\6(H OT50TO7M(UR-I-%U6RU%%ZM:7"2@?BI-6XKB& M=I5@FCD:%_+D","4; .TXZ'!!QZ$4 24444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !12,RHI9R%51DDG JAI>OZ/K9F M&BZM8ZB8&VR_9+E)?+/HVTG!^M &A1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 44V21(HVDE=411EF8X 'UK M$B\<>$Y[S[)!XGT:2YSCR4U"(OGTVALT ;M%1R7,$)B$TT<9F?9&&8#>V"<# MU. 3CV-/=UCC9Y&"(H)9F. !ZF@!:*H:5KVD:ZDCZ)JMCJ*Q-MD:TN4E"'T. MTG!J_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5M0TVQU>PDL=5L[ M>^M)<>9;W,2R1O@@C*L"#@@'ZBK-% 'Q3\?_ OI7A3XHR6FA6J6=I<6D5QY M$8PB,2RG:.P^7./>O0O@3\*/!GC3X;R:GXDTSVT[7-T\+AEB M.TJJ9'&3N8D=L#UJY^R[X%U33[J_\7:E!);6US:_9+-9!@S*75V<#^[\B@'O MD^E 'T=161XI\3Z9X.\.76MZY-Y5I;+D[1EG8\!5'=B> /Z5Y1X7^*GQ%^); MW]WX#T#0K/3+)]GF:Q+*S2MC(4&,@;L8)&,#(YH ]NHKR'P#\=X/$'BA_"GB M_3/[#UY)FMU DW12RJ<%,GE6R" "2#ZY(%='\3_'^K_#O2DU:U\,#6=,7 N) MUO\ R6@8G RGEME3QSGJ>E '=T5X=X'_ &A]0\>^*H-"TGP=;PW$RLYDN-8* MJJJ,D\0$DX[ 5Z7X\\2ZKX1\-W&M:9HUOJUO9Q/-=I)?&W=$7!R@\M@W&XG) M7H,9SP =-17+^!?%.J>*O"\>N:WH<>@P7$8FMT:]\YFB(SO;Y%" C!'7@]JX MRP^,&J>//$=]H_PMTNPN5L4W2ZEK%PT43QV^G%>^Z7J5IK.DVNI:=*)K2[B6:&0?Q*PR#^M 'P3\0M+M=$^(_B# M3=.C\JTMM0FCACSG8H8X7Z#I7WQIW_(+M?\ KBG_ *"*^$OBO_R5WQ1_V$IO M_0C7V'XQUOQ)H?@2.X\'Z'_:M]]FSO>>...V4)G>P9@6]E7KCG'< 9XI^(MK MH7CKPYX4M/*GU'5KD"="<_9X,'YCC^(D8'T)],]K7PEX)\0Z]J/QDTS7?L\F MO:U->>:()+A83BD: MX3#%]NQ#\RX7Y3UW''(P0#T*BOG;3_VK)=2U*VL;;P2HFNIDACWZOA=S$ 9/ MD\#)KW:>YUM-!$]OIME)JNT%K-KYEBSW F\HD\=/D&3Z=: -.BO/OAO\1=<\ M?S7LESX332-/LYGMWN7U'S2\R]511&,@=VSCTS7H- &)XC\&^'?%MN8O$>C6 M=^?+,:2S1 R1J>NQ_O+^!%?!6KZ)B2;%!/+0/DH?P.Y?8!:]GKX=^"/C'_A#?BCI\\TFRQOC]BNLG@(Y& M&/\ NL%.?0&OL/QQXD7PCX)U/6B-\EM"?(CQGS)6^6-<=\L5% 'S5^T5J%QX MEURYU*&7.DZ'>+H\ '22X*-).WU4A%_"L?\ 9T\,:1XH^)D\&OV,-];VNG27 M*03KN0N)(T&Y3P1ASP:[#XU^&G\)_ 3PMIMTWF7O]H^?>R$Y,EQ)'(\A)[_, M2,^@%8O[*G_)4]2_[ LO_H^"@#ZNL;"STNQCL],M(+.UB&(X+>,1H@SGA1@# MDU8JAKFMZ?X;T.[UC6+@6]E9QF260C.!T [DD@ =R0*\RT+XE>-OB-I]YJ/ MPYT31;;3[:8PI+K=TYDF8 ''EQ?=X(ZMCGK0!ZY17S[X3_:2O!XN/A[XAZ/; M:=,MRUI)"P;CTKW/6KG4[32Y9M$T^#4;M.5MI[HVX<=\ M.$;GT!&/<4 7Z*^>M*_:I&HZ]9:=/X0%HMS%U&HS@ ^HKYM_9Q_P"2V:9_UPN/_135]$^)/$'_ E? M[..IZZ;?[,;_ $*29H=V=A*'(![C/0U\[?LX_P#);-,_ZX7'_HIJ /M"BN-^ M)/C74O /AV37+;1;74[&W \_S-1^SR*68* JF-@W7U!]C3/ 'C#Q)XRT^'4] M2\)1Z'IMPA>&2;43)-(/X6$?E#"GU+#UP010!VM%><_%'XQ:5\.(XK-+=M3U MNY7=#8QMMVJ3@,YP<#/0 9/ZUS/B+XF?$WP%IMCKOC+PWHU:U0@QVNQB#&N"1@$'G)SUR: /OJBN+\.>)_'&IZW M%;>(?A[_ &'8LK%[W^VX+G80,@;$&3D\>U=I0!R?Q.\9'P'\/=2UV*-9;F)1 M';(W0RN=JD^PSD^PKR/X#>$-(\?Z?J?C+QN%\1:O)>M!MOOWJ1*%5L[#QSNX MR, 8YKTKXU^%[WQ=\*=4L-+0R7D6RYBB49,I1LE1[E"?'OB#X> M:T]]H%QY3.-EQ;3+NBF /1U]1ZC!'//)H ^MO%/P4\,:Q:M/X()X[AYY#(S,(H3DG.>^<^;>5O19/X3[-CTR:]7M-/M+*>\ MGM(A&]],+BX8$GS'V)'N]OEC0<>GKF@#Y!_:4T'3-!^*4*Z/9Q6:7NG1W4R0 MJ%4RF652V!P,A!GWR>]>_?L^?\D)\/?]O/\ Z4RUXE^U7_R5/3?^P+%_Z/GK MJ_ACX^\1V7P6TS2_ 'A6;7;_ $]9S>3S,([> M-(X09(,C[64[5/ ([\4 ?1 M=%> _"[]HZY\4^*K70?%>FVEK+?/Y=M=66Y4$A^ZK*S,>>@(/4CCG(]TU+4K M31]+N=1U*=;>TM8FEFE;HJ@9)H M45Y'HGQ2\5_$@ZA)\,]&TF&QL9!&;O7; MEP96(SQ%$"1QZG'ZXY72OVD-6T;QE-H'Q*T.TM&@N#;SW&GEAY!SC<59FW+W MR#TY /2@#Z&HJGJ%Q>II4D^BVUO?76T-#%->U '5T5XQIGQ@\3?$3Q'?:=\*M&TXV=@H:74M;>18WR2%PB?, M-V#CJ>.<=*M^!OC5/J7C:?P5XZTR+1]?BE,4;0.6@F<#.T9R5)'*\D'V. 0# MURH[FV@O+66UO(8Y[>9#'+%*@9)%(P58'@@@X(-244 ?"'Q>TBQT+XM:]IVD MVR6MG#.ICAC&%3=&K$ =ADGCM7V7\./^26>%/^P+9_\ HA*^0/CK_P EN\1_ M]=H__1*5[+IGQ(\>V_PLT63P%X':\L-,TJWBGU"_Z2M'$H?RH0ZNZ@J?F&_45XK\*?VA+;QMK$6A>([&+3=4GR+>6%B89VZ[<-RK>@R<^N< ]-\4OB M7J_PUMX=03PH-6TF0A'NTU#RC%(*AHNF>$K>V98C/-+/JYPD8958@"'YF^88'&?4=:[GXB^,-5\#>'9M=LM"M] M6L;50USNU V\B98*"J^6P8<^H/L: .OHK!\':UJ_B'PY!J>N:(NB27*B2*U^ MU>>XC(!!?Y%VG_9YQWYX&]0!\_ZC\(;?XC?M!^+-1UV2:/1[![2,I"=K7$AM M8CLW=@!@GOR,8ZC+^.WPH\&>"_AO'J?AO1S:7OVV*$S&ZFDRI5LC#.1V':OI M"*V@@DFD@ACC>X<23,B &1MH70?M0?\DBC_P"PE#_Z"] ' MA7P&\):)XT^(DFF>);+[;9K823"+S7C^<,@!RA![GO7J/Q:_9Z\/V/@^\USP M3!-8W.GQ&>6T,SRQS1J,O@N2P8#)ZX.,8YR.'_9>_P"2N3?]@N;_ -#CKZ]D MC2:)HY45XW4JR,,A@>H([B@"AX>_Y%G2_P#KSB_] %:-<7\1?&.H_#SPP=8T M[P];ZGIEHJK.JWIMWA!8*NU/*8%>1W&/2O/_ G^T[I>N7UXNN:(-%L[2S>Y M:X^W>>SD,H$:IY:Y8EN.: /=**^:M/\ VI-5U+QQ96D.@6<6CW-RD!1G=K@* MS!=V[(7/.<;?;/>O:/B)\1]&^&^A)J&L^9++.Q2UM(<;YF R>O0#(R>V1U) M(!UM%>-ZOXZ^*R^!3XQTK0?#,>E_9?MAM9;B6XN!!MW;R5*)PO) .?:K'PD^ M.UK\1-0;1M4L5TW5Q&9(A&^Z*X ^]MSR&'7'/ )SQ0!ZY17%?$WQSJ?P]\/' M7+;0(M7T^$JMRWV\P/"68*IV^6P(R0,Y!R1QWK@?"'[2]MXFU2>QN/"\UM,+ MA$RL4/0C(7J#7O?ACQ#9>+/#%AKNEEC:WT0D0./F7L5/N"" M#[B@#5HKQ5/C)XC\:>/[OPU\+=-TF:.Q5VEU'5I)#$ZJP4LHC((!8@#J3UP* MNVGQ0\9V'Q(T/P=XO\,V%A+J,SYU&WG9X9XPC']T#T;<%SN)//W>0: /7:*P MO&/C#2? OAN;6]>E9+>,A%2,9>5ST11W)P?P!)X%>?V/COXF>,?"A\2^"?#_ M (?AT]]YM[?4+J26XG"D@X";5!R.A84 >NT5X9\+?VBT\7Z_;Z#XGTZ'3[ZZ M.RWN;9CY,DG]PJQ)4GH.3D\5[A--%;6\D]Q(L442EW=SA54#))/8 4 /HKQF MT^,NO>//%EWHGPIT>PGALT+R:IK#R+"1G PB?,,GIDY// Q6/X:_:-OK?QL_ MAGXAZ/:V,T=TUI)=V+,$BD#;?F5BRTQ]L5SK7VB M/=\_&R- V]3V+D<=O6O(OV>=8\1Z/KNLOX6\+?\ "1RR6R"6+^T([3REW'#9 M<'=D\8% 'T[\1?#M]XM^'>L:'I5T+2[O(-D-? OX. M>,?!_CU];\111Z=:PP20^4MPDC7.[&.$) 48SS@Y X]/1?$OQ"\5^%O 0\3: MIX'AC\G/VVR.LJTEN#)L5@5B97!R"<$$9Z<9K"^&?Q^_X6+XR30?^$:_L[= M\WG_ &_S<;<<;?+7U]: /8Z*P/&GC+2? GAF;6M=E98(R$CC0 O,YZ(H[DX/ MT )/ KS'PO\ $OXG?$2QN]7\&>'O#]KI=O*8T34YI6DG8 $JC*0,X(Y( R>O M!H ]MHKR?X9_'6Q\;:PWA_7+ Z+KREE6%GW1S,OWE4D JPP?E/IU-=1\2?&> MI^ O#;Z[9:#%J]E;X^U WQ@DB!8*I"^6VX9;GD8]#S@ ["BO"O"7[3=IXBU: M2RO/#$UFWDEK=;>[^T2W,NY56)$\M "3Q6-XM_:#\>^#?%BV6O>#;# M3H'03+:RS-)*\9) (F1MG8C[IP0: /HZBL;PEXGL?&7A2PU[2MPMKR/<$?[R M,"0RGW# C\*V: .1^(?P\T?X@>';FTU"T@-^(&6SO63]Y;OU4AASMR!D=",U M\*R6[Z5K+6^IVNY[2X*7%L[;$-,LK"RU"".=3:6ZQ^8I7*EL#D M@'OSUJ;Q'X=\/^(=.9/%&F65];0JS!KJ(-Y0Q\Q5CRO Z@CI7DO[+_C#^UO! M=WX:NI-UQI$F^#)Y,$A)Q_P%]WX,HKL_BU?7%QH=EX0TN4IJ/BBY%BK+UBM^ ML\F/01Y'_ J //O@/\)=$DMY?&6IV/VA)[IVT:&Y!/DPJYV2D'JQQP2. 1U MKZ JOI]A;:7IEMI]C&(K:UB6&&,=%10 !^0KAOB7\7M)^'4EM8-;MJ.LW@!@ MLDD$8 )P&D<\*I(([]#]: /0:*\5\=^/OBSX%T5->U'1/"[Z9YBI+'!)/++# MN.!N8E1UP,@'FNH^%'Q:T_XG:;<;+9K#4[/!N+4ON&T]'1NXXQTR#^!(!YQ^ MU3X=TJ#1-,U^"RBBU.>]\B>Y10&F3RCC>?XB-B@$]!Q3OV2O^01XF_Z[V_\ MZ"]:/[5W_)/]'_["@_\ 13UG?LE?\@CQ-_UWM_\ T%Z /H>BO$_'WQ_U/X>> M*'T76/!<4KF,30S0ZN=LL1) ;F'(Y4@CL0>O6NZ\*^-M2\9?#"T\5:+H<)O+ MH2&/3IK[8IV2M&1YOEGDA,CY<3&6<+G;Y(SC/3BO?KBXAM+:6XNI4AAA0O))(VU44#)))Z #O0!)17C-C\ M8_$/Q \4W>C_ HTC3Y;>S3?+JFM-(L1&<#")\PS@X[GG(&*L>#OC5=3^/9O M _Q!TR#2-<240Q36SDP3.1D+@DE=P(*\G.<<'&0#UZBBB@#YA\>^+)?B9\>+ M3P%IKV[_A4O@#^S18_\(CI/E!= MN[[,OF8QC_6??S[YKY0^-?AC4?"7Q:U6>82)#J-T^H6=R,@,';><'U5B1Z\ M]Q7=> ?VGM1TR.&P\KKT?Z\'ZF@#HKWX>:IX!^,7@XZ7 MJVH7/A2?42MO9SW+NME+Y;?( 3C!7=@XS@$'U/J_Q/\ #&H>,?AQJNAZ/="U MO+I%\MF8A7VN&*$CH& (_'TJ[HVM^&_'VDVVI:1=PZE;0S+-&R,0T,J]-R\% M6&>A]:R/B9XYU7X?:"VN6WA^'5M-AVBX?^T#!)$6;:#M\M@5R5&G>@#S M#X"_"'Q?X,\97.M>)(TTZW^S/;BW6X21IR2I!.PD!1C/)SG'%?0M>0?"[X\_ M\+)\7/H?_".?V;MM7N/.^W>=G:5&-OEK_>ZY[5I_%3XK:G\,&MKB7PO%J6FW M3^7%=)J1C8/C)5D\HX[X()SCMTH ],HKQ?PE^T&_C*SNX=*\)32ZXK!;/3(+ MT/YPP2TCR,BB)%X!)SDL *Y.+]ICQ-H?C.72_''AJSMH()O*N(;;>L\'ODLR MO@<\ 9[&@#Z4HJ.WGBNK:*XMW$D,J!XW'1E(R#^5>5>+_C8;3QQ!X*\"Z9'K M>NRR^3(\LI6"!^X..6V@$MC &.I(( !ZS17S]K_QV\9_#KQDNB_$#0M'ND:- M)O,TAY4W1L2-R^83G!##!"\CKWKW'2M!_B1IEMI6K^:L4-S9N3;S.PRHPQ) 8$;3DYS@@&@#V&BBB@ M#A_'OC?7O#MG=CPOX0O]:N+:/?).0$MXQC.1SNDP.H0>V0:^7$^)OBOQY\1? M#_\ PD&INUL-5MBEG!^[@3]ZO\ ZGW;)]Z^T]1_Y!=U_UQ?_ -!-? '@G_DH M'A[_ +"EM_Z-6@#]!Z\!_:#^,.I>&;Q/"GA6Y-K>O$);V\C/SQ*WW40_PL1R M3U *XKWZOB+X^PSP_&_7SJ:E\&;!_@C%XHMI[ M[_A+H]-75)-0:\D9Y#L\QH\9QT) (YR!R>Z?L_\ QFU+6-63PCXMNVNYI4)T M^\E.9&*C)C=OXN 2">>",G(KUSPA')H&*.FJ6V"/^NJT ?6?QR^*$WPZ\+P1:04_MG4F9+=G 80HN-T MF.Y&0 #QD]\8KA/AE\,+#XH?#F?Q'XUO=0O]:OYIEM+V2[D)M IP"JYQ]X$X M(QC %8G[6,,R^+M!F8-Y#V+HA[;A(2WZ,OZ5Z9^S5>QW7P:MH8V!:TO)XI M#T);?S^#B@#R3X4??!7C)?"_B^^DN])-R;.0W$A=K*0-MW*QYV9X(/ '( MQC!^M:^!_BG$D/Q:\4)$NU?[4G;'N7)/ZFOK+Q5X[D\'_ BW\0LX;4)M.MTM MMW\4\D8P<'KCEB/130!B?%;XYQ>$=1_X1OPG;+JOB*0B,C!:.W9N N!R[\CY M1Z\^E.\-?"C7?$,,>J_%SQ%J6I74P#_V/!=-#;09YPPC(!;I]W _WNM>$_!& MYM(_B-+XAUNQU769K&)[B*&PLY+J62=CC>V/0%SEB.<5]!^'OVA?!&O:TNE3 M-?Z/=-)Y2C5(%C4OG&TLK,%.>/FQS0!Z'HVB:9X>TR/3M#L8+&SC)*PP(%7) MZGW/O5^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /D#]J'_ )*Y M#_V"X?\ T.2K7@+X/Z=X]^!-_J>GV^SQ+#>2"VG\UL2JBJ?**YVC.3@XSG'. M,U2_:>FCE^+P2-PS1:="C@?PG+MC\F!_&O7OV7G5OA)*%8$KJ(!X+\<66IW^FQ7D=I-MN;2Y@5B5Z, &'RN.QX((^M?>NCZK9:YHUIJ>E M3+-9W<2RPR+W4CT['V[5\U?M*?#$:???\)MHL&+:Z<+J4:#B.4])?HW0_P"U MC^]4'[-_Q171=2_X0[7+@)8WLFZPED;B&8]8_8/V_P!K_>H O_M8ZU.=1T#0 MU=EMUB>\=.SN3L4_@ W_ 'T:[C]F&V\CX0&3"CS]1FDX[\(O/O\ +_*N=_:H M\(W-]I.E^*+.,R)8;K:[VC)5&(*-] V1_P "%;O[+^H1W7PIFM%=?-L]0E5D M'4!@K GZY/Y4 ?/OQ?FDM/C=XAGMG:*6*_\ ,1T."K *00?7/-?9-A]F\;_# MNT;5(1);:WID;SQ]/EEB!./3[W'I7QYXZT^Y\:_'S6=.T!/M,][JCV\6TY!* MG:6S_=&TDGT&:^U]*T^/2=&LM-MSF*SMXX$./X44*/T% 'PH/[4^$_Q7YYO= M#OO3 F3_ =#^35]8^.-5M_&.@>'O#^C3EXO%TB.[KP5L542S-[97:GU?%>9 M?M3^"CG3_&5E%Q@6=\5'3J8W/_CRD_[HK8_9CT>_N?#\GB'5I7EB@1M-TI'Z M10[S)*1]7('_ #'I0![3K.C0ZOX8O\ 1-QMH+RSDM-T0YC5T*9 ]@:^?O!O MPVB^!_C#_A*?&_BW3;>SBBDCMK>V9S+=[AC!C*YXX.%W<@<\5[EX[\12>$O M>L:[!$)IK*V:2)""07Z+G';)&?;-?+?P5O%\;?':WU'QK>&_O/*DG@-TP(>9 M<;5 Z< LP4< J,=* ,KX\ZM+KGQ,;4)=-N]-6:RA,<%X%64I@X9E!.W/7!Y' M?%?3_P %9O/^"_AIP,8M-F,_W79?Z5\T?M$ZE:ZG\7[N2QD\V**WBA,@'RLR MY#;3W .1D=P1VKZ1^!C!O@GX,9(I)G_L32Y(]2F@_@>Y4,D/XC<[?\ 'H* /IWP7X<3PGX-TW M1E;S)+:$>?+_ ,]96^:1_P 7+'\:W:** "O-?@9$D_PBABF0/')=WBNK#(8& M=P17I$DB11M)*RHB LS,_!P?<&OH#P3XKD^+K^"M(G+2 M)H:(^7;J3T^9LR$>U1_M2^#?MN@6'BVTCS+I[?9KLCJ8G/R$_[ MKG'_ .NB_9O\'_\(Y\-$U2YCVWFN/\ :3D2!$^3C\1^ M=>??LK.J_%74 S %]'E"@G[Q\Z$X'X G\* /HOXG>"G^('@.\T&&\%G-*R21 M2LN5W*V0& YP>GMUYQBO+?AOI%K\"9=0M/$^N0ZGK>KM$EMHFCAYY'(W;3M( M4Y.[JP4 #J>W:?'CQSJ'@7X<_:=%/E7U]ZDRR1MN,DF6]2!EO\: /%_'.KN._^(GB*\@W M^51P1Q7WYIK!M*M&4@@P(01W^44 ?G[;Z<-7\<1::7V M"\U$6Y8?P[Y-N?UK[CU?X:^#]>T6QTG5=!M9K/3U"VJ+NC,0&. R$'!P,C// M>OB?PW-&?BAI,P=?*.L0OO)P-OG YK] * .,^)%G;:=\%?$5G8P);VUOI$L< M44:X5%$9 'H!7R9\&/$ECX3^)MIJ^J>0!T!(&""<_48&!@<"OCK]H#X: M?\(5XL76M(B\O1]5D+HJ<"WGZLGL#]Y?Q':O>%!8:G.#KNF($N MW!GCZ+*/7L&]#Z9% 'S9K?B"\UCX^R:N]L=1G&O)Y-HTHC\U8Y@L<6X\+E55 M<]NM>Z_$<_$[X@>";KP\?AC]@^T/&XN/[?MI=NQPWW?EZXQU[UX+\4M O?!/ MQ:U6,AHLWC7UG)CAHW:E::>]JEY,(C=SBW@R"=\A! M8+QTX4]:\S^(_P O#OCF:;4K!O[&UB0[GGA3,KIQR?[PP>YS3?VBM3N= M%^'5AJ=@_EW5GK-M/"WHRAR/U%=;\/OB%H_Q#\/17^E3HMRJC[79EOWEN_<$ M=QZ-T/YB@#XV\=_##Q-\/+H+KUF&M9&VQ7UN2\,A]-V,@^S 'K7MW[,'C[4- M4COO".JSR7*V4 N;)Y&):.(,$://]T%EP.V2.F,>M?%"71HOAAKW_"2-&+%K M.12'QEI"/D"Y_BW8Q[XKQ;]E7PA>Q7NJ>+;F)XK22W-C:EA@39=6=AZ@%%&? M4D=C0!SW[5?_ "5/3?\ L"Q?^CYZ]K_9ZC1/@7H+(JJ7-RS$#&X_:)!D^O M_"O$_P!JI@?BIIP!!(T:('';]]-7MO[/;J?@5H.&'R&Y#>W^DRG^1H ^3/#) M,7Q8T@Q?(4UN$KMXQB<8K[:\?^%/^$W\!ZGX=^U&T:]C4),%SM975UR/3*@' MV)KXB\-S1M\4-)F#KY9UF%P^>,><#FOL3XR^,;WP/\,[[5-*&+Z1TMH)"N1$ MSG[^/8 XSQG'TH \U^'?AFV^ NJWUWXR\1VMS?ZE$MO::1I6^:6X.X%6V%02 MV?E'&/F//->(?%6ZGO?BGKUS=64MC++<[FMIF4O%E1PQ4D9^A->F?LT"RUGX MAZUK7B*Y%UJ\-L)8);J3:?%:_M]4^*WB"]LF+V\UV6C M#M&F V^980/C/3,:FOA#Q?"UQ\2-(I8S\4-5FWJ(_[9F;>3@8 M\XG- 'VI$+'PUJ.BV]SIUB@$*D%&5@,%@RD,">Y!Y[UY]^T3<1>$ MO@M::%H,*V5I=7<=IY4(PJPJK.1^)5<^N3FO;05?M%^%[GQ)\*)I;& M-I9]*N%OMBC):-597_)6W?\ : /+OV>]?\ %.D>&M6C\*^!_P#A(E>[5I[C M^UHK3RSL&$VN#GN*KW2=;N%MK+6%0)/(<)',A.T,>P8,1GU KZ=\3> M+['PY90G_C]O[QECL-/@<>;=NW0+Z+W+= 2: -Y264$J5)&2IZC\J6BB@#X M<^.O_);O$?\ UVC_ /1*5]?_ X_Y)9X4_[ MG_Z(2OD#XZ_\EN\1_\ 7:/_ M -$I7UQ\.+VV/PA\,W(G3R(M&MA))N^5=D2A\GV*D'Z4 ?$NMR-X>^(FHR:7 M^Y;3M5E:VP/N&.4[?RP*^[?$&B6GC#P?>:1J,>+?4;8HP(R8R1E6^JG!'N*^ M,O"?AN;XG_&1XK.)FLKK4)+RZ\B7^./)20#URN2#]#7UEXYG@\7ZAX:\)6K2+J=\5Y5K M&$JX!]GD,:_G7CG[4G@HV.O67BZSBQ!?@6UX5' F4?(Q_P!Y!C_@%=Y^S;H] M^W@O_A(]:E>::XC6QL/,_P"65I"S8 ]B[/\ @JT >T4444 %>.?M0?\ )(H_ M^PE#_P"@O7L=>,?M1SQQ_">WC=P'EU.((O=L)(3^@H \G_9>_P"2N3?]@N;_ M -#CKZ_KX]_9AE2/XO,KL%:73IE0'^([D./R!/X5]A4 >5(,J[+@+D=\,P;\*^E?CK(L?P1\1LYV M@PQKD^IF0#]37S_^R^ZK\79 S %M,F"@GJ=R' _ &@#Z:O?AUX2U'Q5!XDO= M"M9=7MV5DN>1\R_=8J#M8C P2"1@8Z5Q7QN^#^H_$QM,N]%U&VMKNQ5XS%=[ MA&ZL0V*];KYO_ &G?B#J^G:A:>$-*GDM+6>T%S>21DJTX9F41 MY_N_(<^N<'I0!J1ZSIGA'X*ZO\/]+OY/%6K6VD7IO)-/&Z"R1DD+%I"^!C!?C;X<+$ >?(.?\ KD] 'TW^T'_R0GQ# M_P!NW_I3%7AO[+-M#/\ %B[DFB5WM])EDB9ARC>;$N1[[68?0FOI\Z$_R!H =^U7_P E3TW_ + L M7_H^>O9/V>@;CX$Z7#(S!=]R@(X*@S/T_,UXU^U40?BIIV#G&C1 ^W[Z:O9? MVDUQGV_>M0!\NWD'BGX/?$&1(99M/U*S? /V?Q';6\FHVCM%=) =DMI,#C?&2255L C)(/0YP:^;M<\#:AX'^-E MGX>#Y\NVF&E:1^\$! MVJ"&9L!!QDEMOTXY?^TGX_U;PEX>T[2="FDM)M7,OFW49(=(TVY53V)+CD<@ M#WK(_9J?0-%^'.M^(KN6,7ZW12ZD/S2+&%4HH'7YF)P!]XX') H ^?\ P!+Y M'Q*\,S$;O+U>U;'KB937U7^TAKMQHGP@GBM69&U.ZCLF9>H0AG8?B(R/H:^3 M_!G[OQ_H'F?+MU.VW;N,?O5K[ ^//A2Y\6_"B]@T^(S7EC(E[#$HR7V9# >^ MQGP.YX[T >=_LDK#]C\4L //\RU#'OMQ+C]/K3P1X^:/6)U@TS5(OL\TSG"Q.#E'8] MAG()[;L]J^M]=\5Z1X>TE=0OKI7CE(6VB@(>2Z=CA4C4??8GIC]!S0!Y]^TK M_P D9N?^OR#_ -"KS?\ 9-_Y&;Q#_P!><7_H9KTK]I%'E^"MVX1@$NK=G!Q\ MHWXY_$@5Y=^RE>6]OXLU^*>=(W>P5U#MC*J_S'\,B@#VKXY?\D3\2?\ 7!/_ M $:E?._[,_\ R6.'_KQG_D*]]^,.JV6K? '7[_3KE)[2:%!',OW7_?JN03U! M(X/0\$9S7@7[,Y ^,D.3C-E.![\"@#<_:KUNXN/&^E:+O86MI8BXV9X,DCL" M?^^47\S7KG[.L'D_ _1WPO[Z6X?CO^^=>?\ OFO.?VJO"%RUYI?BZUB+VZP_ M8;LJ/]60Q:-C]=S#/LH[UZ#^SAJ$5Y\%=-MXW5GLI[B&11U4F5I!G\'% 'R[ MXSU"XT;XS^(-0T]_*N+/7[F:%A_"RW#$?J*^L?C+=+>_ /7+I!M6>SBD /8- M(A_K7RS<:'??\:^J/CH * /G_ /9CMH;CXO[YHED:#3YI(BPSL;*+D>^&(_&M?]J_ M_D?-%_[!O_M5ZR_V8'5/BZX9@"^FS*H]3N0_R!K4_:N(_P"$^T89Y&F9(_[: MO0!ZI^S8[/\ !>S#'(2[G5?8;\_S)KUBO)?V:2#\&K;!SB\G!]OFKUJ@ KSS MXX>#O^$R^%U_#;Q[[ZP'VVUPN6+(#N4?[REACUQ7H=!&1@\B@#X2^$/C#_A" M/B9IFIS/LLY6^RWG/'E/@$G_ '3M;_@-?5'A/_BKOBAKOBU\O8:2#HNEYZ,5 M.ZXE ]VPH8=0IKY@^*'@"X\._%^Z\/:7;EDU"X233HUXW),WRJ/HV4_X#7V5 MX.\-6W@_P=IF@V>W990!&8#'F/U=_P#@3$G\: -JO!_C'\"=2\:^,6\2Z9K5 MA9P/"BW:W[,@A"#&Y2 01CG!QR#SSQ[Q7R%^T5\0-7U?QY>^&(YY+?2--*)] MG0E1/)M#%W]>3@#I@9[T =C\4?%^EWWP-N/#7AN:ZU^'28[2VO-:50+<.C( M-Y/SLV <+NP#DFN:_92FV_$?5H-O+Z2SYSTVS1#_ -FKK_B:= T/]EO3M)T2 M2,QW<-K)"(OF,IW*TDC8]^I/<@=P*XK]E5@/BIJ() )T:4#/?]]#0!Z#^U=_ MR3_1_P#L*#_T4]9W[)7_ ""/$W_7>W_]!>M#]JY@/ 6C*2-QU/(&>2/*?_$5 MF?LDR(=-\41AAO$ULQ7O@B3!_0T ?_2F6O&/VK;65/B-I-VP_=2Z4L:GU99I"?T=:]5^!GB'2]+_9]TRZOKR. M**P:X2?+/H:^5_#DZ_\ "SM*GDS&G]L0NV\8*CS@>?2O MK7X_^%[GQ1\);Q+")IKG3Y4ODC49+! 0V/?8S'\* /'OV>-=\3:/I6MIX4\% M?\)$9)XC<3?VK%:>5A6VKAP=W\1R*/'OPX^*?C3X@R^*K7P8=*G;RBD:ZK:R ME&C4 -NW+D_*#TK'_9U\?V'@SQI=6.M3K;6&L1I&9W.%CE0G86/9?F89[$CM MFOJ?Q-XOT_PWI27#,+R[N2(["Q@<&6]E;A40>YZMT R30!M6[2O:Q-<)Y>+8=3T]Y8FAD"7=JQ*B= ?FC;B.[_ &?M;N83F.9+ M21"1U!N(B*\2^,>@6_C7]H0:/X,C2>\N(XH[YH1E$F!(=V(X^5-FX^H/>O:O MCO;QV'[/>L6B-E88[2)"QY;;<1#\\"@#Q#]E[_DKDW_8+F_]#CKTG]J[_DG^ MC_\ 84'_ **>O-OV7B!\7)0/^V3T 9/[ M)5M#]C\377E+Y_F6\8DQR%PYQ],_R%>4?'7_ )+=XC_Z[1_^B4KUG]DF1#IO MBB,,-XFMF*]\$28/Z&O)OCH0?C;XCP<_OH__ $4E 'U-I^N3Z)^SQ9:VGSW- MKX9BN$)'606P(S^.*^<_V<76Y^-UM/>,9)VM[AU=R2Q%+J _>V M\I(H^JEL'IR#0!]@?$#X1>&?B1=6MUKHNX;JU3RUGLY51F3.=C;E8$9)/3/) MYKFOC6!)ZY52#_ +QKT>S\5Z%?^'%UZUU: MT;2VC\PW1E 11WW$]".X/(-<)\5[!OB3\"[NZT.VN"P"WUI'+'M>948\A>OS M)N*CJ%/!O\ PD"?'D ML.M3"WT[581!),WW8I ,-+\-Z*+^:9;F2;"V5K P M:2\D;A(XP.I)P,]!U/% &MIS7+Z7:O?Q^7=-"AG3CY7VC<."1UST)%6*;$SO M"C2)Y;LH+(3G:?3(ZTZ@"OJ/_(+NO^N+_P#H)KX \$_\E \/?]A2V_\ 1JU] M^:K(D.CWLDK*B);NS,QP% 4Y)KX!\&.L?CS0'D8(BZE;EF8X 'FKR30!^A-> M:_%KX-Z=\3(8;N*X_L[6;9/+BNMFY9$R3L<>F2<$Y/% 'A5AX?\ B9\*/A?J\%YX@\._V+8V\LL+&*6>9"._ SPO+XH^+6D@1EK;3I!?W#=E$9!7/U?:,>YKTCXF>-=6^ M-.I1^#/AG8W%[I<4H>\OBA2.5A]TEC]V,=>>6.,#@9]>^%/PQL?AGX;:UC=; MK4KHA[V["XWD=%7T5(?#KZ3/7H*] MWDD2*-I)75$499F. !]:\)^+/Q>&N6\W@?X9++K6J7ZF&YN;%?,2.,\,J,.I M(."WW5!ZYZ 'SV;74/B%\3WMX)1=7NL:BP\Y(MBMN8YDVYX &6QG@"O>_P!J M2)=/^'WAO3K7*6L5WM5/9(BJ_D"?SKH/@E\%?^$!C;6_$/ES:]<1[%1#N6S0 M]5!Z%CW;\!QDG?\ C9X&F\>?#>XL]/3?J-G(+NT3./,=004_%68#WQ0!Y?\ MLC?\S=_VY?\ M>N0_:_T76&%F=3@\E1/\A$Z-E4.>A(+C![X'>IOVDYAXD^+FF:-H2F_OH;-+ M=H;?YV\UI'.S [X(/XT >X? S6KO7?@WHESJ,C2W$:R6YD8Y+K'(RJ3[[0!^ M%>@UR_PV\*-X)^'>D:%*5,]O#NN"IR#*Y+O@]P"Q ]@*ZB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH *K:A80ZG826ER]PD4F-S6US);R#!!XDC96'3L1D M<=#5FB@#SNY^ WPXO;J2YO- DN)Y#N>674KIF<^I)ER:OZ)\(O!OAN[C#D=-P$N&'L"^N+GP_J>O\ AS[2"LT6D:B8DD![$,K'')XSBO4* M* .1\%?"_P *^ !(_A_3\74J[9+R=S),P]-QZ#IP <#-:GBCQ?H/@S2UU#Q M-J,=A;,XC1F5G9V] J@L?P%;5>=?&/X7/\3O#]I;V=\EG?6$K20-*"8W###* MV.1T'(!Z=.: '_$C6M%\0_!F]FL6BU:WUJ-;33EC/^ON)'VQ8SW5^3W&P^E= M5X1\.P>$_!^F:%:X,=C;K$6 ^^W5F_%B3^->QFLXA!%-I[+$1$.B8*E=HR<<<9J_X5^&'AGP;X?N=)T2VGC2\&+F MY^T.EQ-Z9E0JRX[!< 9/J:Z^B@#SA_V?_AG)(SR>&R[L269M0NB2?4_O*[+P M]X;TSPMI@T_18[B*T4Y2*:[EG"<8POF,Q4<=!@>U:M% 'E7B+]G7P+XCUV35 M72_T^29S)-#8S*D/T ["N@KG_'7A2'QOX(U+P[<3M;K>QJ!,HSL96#J<=QN49'<4 1Z+X^ M\*^)_#M[K&CZM#=Z=9JQNI&1D\I0I)W*X! P#U'-<[\$?"UOX>\"-?069LVU MRY?4! W)AA<_N8_PCVGZL:X'P1^S[XIT2:ZTW6_$UJOAN\FCDO;*P#%[T1DE M49F4%%.>0"+8!!KT=W/!M*- M!%J$\$;@_P!Y(W56_$&LG0/A-X/\+7:W/AZPO-.D5UD(@U6[57*G(WKYNUQ[ M,"#T(KLJ* *>KZ38Z[H]UI>K6ZW-E=QF*:)B1N4]>1@CZ@Y%3VUM#9VD-K:Q MK%! BQQHO15 P /H!4M% '#:M\&O!&O3)+KFG7VI21@A'O-8O)BH] 6E.*KV M7P*^'FFWD=WIVAS6ES$@T4 <]KO@?0_$?A$^'-8AGNK# M@J9KJ269&!)#"5R6)&3R2>..G%,?$DFMWWV^TNIV#7 LYU5)FXY8,K8)QSMQZ] M>:ZJU\!>';'P>OABRLI+72E^]%;7,L+2'N6=&#-GOD\UT=% 'FW_ SY\,?^ MA9_\G[G_ ..5WNDZ5:Z+IL5A8>?]GBR$$]S).P&>F^1F8CT&>.U7** ,3Q1X M/T7QGIZ6/B.VFNK16W>2EW-"K'_:$;+NQCC.<=JY>T^!'PYL+N.ZL=!EMKB) MMTSQJ#_>*HX! M;W.3[UC:5\$_ .AZE%J&CZ+-97<)RDT.I72L/_(G(]NAKO:* .;\9> /#OCW M3TM?$M@+CRLF&9&*2Q$]=K#UP..A]*X/3?V8_ -A?BXG.J:@BMD6]U/]3_ +2U M6*ZL[\@+)?;Q:I=!6Y[?O.,]#C&1P2ZTMXPFR>XDE<8.0?,9B^0<8)/&/2MRB@#RWPW^SOX#\.: MH+_[-=ZI*C;HDU&59(XS_NJJAO\ @6:M^-O@7X0\=Z[_ &QJ0O;.]<*)I+&5 M4$V!@;@RL,X &1CI7H]% '-:/\/_ [H'A%O#>DVDMII\G,I@N9(II6R"6:5 M&#Y. #@]..G%?\ L(7/_P G:2LZ6L M?^K2:ZEG*#&,!I&8@<< ' K1(R,'D444 >4^(OVIT4 8'A+P1X?\#Z:;+PUIT=HCD&6 M3):24CNSGD]^.@SQBE\5>-_#G@BT@N?%&J1V$=PY2+WM]*9&R&D=P5D!'0*H9C[ @]:[K1-(MM T&QTFP7;;64"01@ M]<*,9/OQFO.?AC\*];\,R6%WXSUV/59=)@:WTNTMU_<6:M]Y@2JEF(XR1P,C M)XQZI0 4444 %<3K?PA\%^)+D3Z_I]YJ4BDE3=:M=R!,G)"@RX4>PP*[:B@# MSRU^ WPYL;J.YLM EMYXFW1RQ:E=(R'U!$N0:[K3["'3+".TMGN'BCSM:YN9 M+B0Y)/,DC,QZ]R<#CH*LT4 <]XJ\"^'_ !K#'#XFM9[R"/[L*WL\49/J41U! M/N037/67P*^'>FWD=WIVA36ES$]IPZAI&BS6=W VZ.:'4KI67_ ,B=/;H:[VB@#@]7^"G@ M'7]5GU+6=%EO+RX;=)-+J-R23_W\X [ < <"MGPIX \.>"!*OABSFLHYA\\1 MO9Y8R?78[E0>.H&:Z.B@#S!/@#X/M9OM6D7&M:3J!9V:_L-1:.8[CG&>5 ^@ M'09S6MX1^$7AGPAK4FM0?;=4UB3.=1U2X\^89&"0< D<9QG'&:[FB@#F/'/ MP^T'XAZ1'I_B*&1A"Y>">!]DD+$8)4X(Y]"".G' K'\$_!7P;X#O!>Z99RW= M^OW+R_<221_[H "J?<#/O7?T4 >3ZI^SAX#U7Q%+JTB:A!YTAEELX+@+"S$Y M/&TL 2>@8>V*].TW3;+1M,M].TNVCM;.V01Q0QC"HHJU10!YAXJ_9]\#>*]4 MEU"2WNM,N9F+S-ITJQB1CU)5E903WP!FM7P5\'/!W@.Z%YH]@\]^!A;R\?S9 M%_W> J]>H -=U10!6U+3K/5]-N-/U.WCN;2YC,HKRJV_9F^']OK' MVUEU*>$-N%E+= PCVX4.1]6KUZB@#FO$7P^\->*["VL=[L+34-.EL+^WCNK6:,QRPS#>KJ1@@YZ_C7FA_9^\+V\MS_8>K>(M#M[H8GM M--U(I%*/[K!E8D>Q->IT4 :7V+'M[# ] MJL>*O ^@>-K>*W\36DUY!$25A6\FB0GU*QNH8\<$YQVKH** . T[X'?#[2-0 MAOM+T2:SNX6W1SP:G=(Z'V(EJ76_@QX$\1ZO/JFN:-+>WMPQ:2674;DGKG ' MF84#/"C '0 5W5% ',^%/AYX9\$22MX7L9[%9E(>+[=/)&V<<[',?,,,M2^W>)M-GU"<#"[]0N M%2,8 ^5%D"KG S@#)Y/-0^'_ (1>"O"NIIJ'A[2[C3[E2#OAU*YPV.S*9,,/ M8@BNUHH YSQIX#T'Q_HZZ?XCM#*L;%H9HVVR0L>I5OZ'(/&17-^"_@5X,\#Z MJFIV,%U?WT9S#/J$JR&$^JA550??&1V->CT4 >F44 248EN')>67_ 'G/./8<>U.\5> ?#OC98D\3V<][%%]R$7L\48//.Q'" MD\]2,UT=% 'G]A\#?A[I5['>:9HD]G=1G*3V^J7<;I]&$H(K3\4?"_PCXTU! M;WQ/ILU_,B[4WW]PJ1C_ &460*N<#. ,]ZZVB@#B_#_PC\%^%=0-[X=TNXT^ MX92C-#J5R P((P1YF#UXR.#R.:SI_@)\-KJXDN+GP\\TTK%Y))-1NF9V/))) MER2?6O1:* ,?PUX5TCPCIIT_0(9K>TSE89+N694]E\QFVCV&!6!XX^$7A+X@ M3"YURRDBOE78+VT?RY2.P/!#?B#BNWHH \M\-?L[^ _#=_'>&UNM5FB;='_: M4JR*I_W%55/X@UZD!@8' HHH \P\4_L^>!O%6J2ZA);W>F7,[%Y6TZ54#L>I M*LK*"?8"M3P3\&_!_@*Z%YI%E)<7X&%O+U_,D48_AX"K]0 >:[NB@ HHHH Y MSQ#X#T'Q491KJ7]S%, )+==5NHX6 &/]4D@3].:YG_AGSX8_]"S_ .3]S_\ M'*])HH R-"\,:=X;C:/2C?"-E"B.YU&XN50#H%65V"]?X<5G:I\-O">MZNVI M:WI"ZE,1HOT4 M<"K%%% '/^(? WA[Q7(;%[[RT"+#)Y+8]LUTE% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !17@7Q6^,LWA;XS:#IMC=2#3M+8-JT< M;G;+YHP58#KL0AA[GVKWN.1)8UDC8,C@,K \$'O0 ZBBOF3XS?$/XA?#CQTN ME:9XOEN+2XM%NXO.L+4O&&=UVDB(9P4//O0!]-T5P/PKUG6?&GP8TS4M5U65 M-5O5G#WT,,2NI6>15(39LX"@?=KYZ\6?&;XG^&?&&K:)_P )9YXL+N2!9?[/ MMAO"L0#CR^#B@#[#HJ&SD:6PMY)#EWB5F..I(J:@ HKQOXUZAXU\"^&?^$B\ M-^,KSROM0CEM+FRM'"*^<;&\H' .!@[CSUKS?X9_$CXG?$7QDF@_\)O_ &=N M@>;S_P"R;:7&W'&W:OKZT ?5E%>'>,+CXT?#[29=9B\0:=XIT^W!>X#ZW(O?##]H32O&M]#H^O6RZ1J\ORQ$/F"X;T4GE6/93G/8D\ M4 >QT444 %%%% !1110 452U>SNK_3);?3]3FTNX;&RZ@CCD9#G^[(K*0>G3 M\J^2;/XW?$N/QI;Z3>^)A,BZ@MM+ML+\TBZAMF,4*6UM+"[KDY821ELG@<, ,#CKD Z:BOBJU^/GQ.N M;R&#_A*-OFR*F[^S[8XR<9_U=>_:IX8^,FG6SW&C?$*RUJ5%R+6[T>&V$A] MR@\_4@?3K0!ZO17SGX6_:9O;#6GT?XEZ0MJ\4IAENK1"K0L#@[XR3GGJ5/T! MKZ&M+NWO[.&[LIX[BWG0212QL&5U(R"".HH FHHHH **** "BBD8%E(#%21@ M,.H_.@!:*^6/BM\2_B/\/O'USH=EXPDNK58HYH9)M/M=^UAT;$0&00>GM7O_ M ,-=8OO$'PUT+5=7G^T7MW:K)-+L5=[9/.% _ 4 =11110 4444 %%%% !1 M17.>._&^E_#_ ,+3:UK#%E4^7! A^>>0@X1?R))[ $T ='17SOX@\4?$SQ1\ M(=2\;#5K?PQI.P/:V5C$3U/QO\ $_X8:/IVK^(1 M9>+/#T\'WFH M2/-$3#'%Y<.=JC"* <[2V?\ :% '>T5XGXY^,^I3?$*V\!?#E+=]2EN1;7&H M7"[TA?/S!5[[1DDG/0C%4O&'CGX@?!K5M*F\3ZQ:^+]'U LKG["EI+$RXR%V M\T5F^']>T_Q1X?L]9T>;SK.\C$D;=QZJ1V(.01V(->N$#A93 _"@#Y4^(VB:]IGB./4?$ZG[7K ML"ZID@C'FDDIST*GC';BOJ/]GKQB/%/POM[2XD#7NC$6*_L]>,?\ A%OBA;VES+LL M=946@#VW]GS_DA/A[_MY_\ 2F6OE/XK_P#)7?%'_82F_P#0C7U9 M^SY_R0GP]_V\_P#I3+7RG\5_^2N^*/\ L)3?^A&@#[MT[_D%VO\ UQ3_ -!% M6*KZ=_R"[7_KBG_H(JQ0!Y+^TK_R1FY_Z_(/_0J\2_9G_P"2QP_]>,_\A7MO M[2O_ "1FY_Z_(/\ T*O$OV9_^2QP_P#7C/\ R% 'V+)&DT31RHKQNI5D89# M]01W%?G_ ..-$/A+XAZQI-JS1K8WKK;L&.Y4W90Y]=I6OT"KX;^.;!OC;XC* MD$>?&,@]Q$@- 'UE\)_%DGC3X8Z1J]TVZ[,9AN2>K2QDJS?\"QN_X%3O&/Q1 M\,^";N"QU2YFN-3N"/)TZQB,T[Y.!\HZ9/3)&>V:\Y^!NKMX5_9QU379XMRV MDMW=1(QP)-J+@?BRXKR/X0^,M&LOB[<>*OB'J91_(FF2YDADF+7#%5'" D?* MSXXP,8]* /I+P_\ &?PQKGB(:!=Q:EH.K,0J6>LVOV=W)Z 2">U>@$ MX&3P*^/_ -H/QMX6\::[HFH^$-0^US6\$D=Q*L$D3+A@4&752>K].E>U/J/B M'Q]^S$+K07:37+_31$Q5P&E9'"3 'IEE60?4T ;.H_&+PU;WUQ9:+!JOB6YM M?^/B/0K%KH1?5QA>Q[U2\*?'OP5XKUA-+CFN]+OI'\N.'4H1%O?.-H9690<\ M8)!/2N#_ &;M)\5^$_[>_P"$HT^;1M!\L2EM1C,!$P(&X;L';MSD].%KQ'XI MW]G?_%?7[_2)XYK6:\,D4T!^5\@'<".N3DYH ^]*^ _^:M?]QO\ ]KU]V:!< MF]\-:9=-(96GM(I"YZME <_CFOA/_FK7_<;_ /:] 'WCJNJV.AZ5<:GJUS': M65LF^::0X"C_ #QCJ37F\/[0/AFXAEO+?1O$LNDQ.5?5DTPFU7'JP;(_$9K, M_:ABU"3X4P-9;S;1ZC&UX$_N;7"D_P"SO*_CMKS[X*_';3_#.BV_A/Q=;B/3 MHV9;>^B3(C#,6*RJ.HRQ^8<^H/6@#Z$\&^/-#\>VM[=^&I9;BUL[C[.9Y(C& M)&V*V5#?-CYL<@<@_6NCKB_A[X/T_P +3:W=>'[BWET36;I+ZR2W?EC( M4M_WRR#\*[+]E?Q?/?:-JGA>\E:06!6YM-QSMCJS*I,2:0Z,W8,9HB!^2M^5 'TUXF\5Z)X.T M=M3\1W\=E; [5+9+.W]U5'+'V%<(O[07A6-[634M,\0:9I]X?]&U*]TXI;S# MU5@Q)'T%> _%[Q7\L1-M);NV'(D^[]P_* KR?M$^$['6AIFOZ7X@T*; M@EM2T_R\ ]"5#%\'_=KU"QOK74K&&]T^XCN;6= \4T3!E=3T((ZU\O?M4:MI M>H^(M#@TZ\M[FYM(IX[I87#&(DH0K8Z'KQ_C7H_[,-V]S\(6C>5I!;:C-$JD M_<&U'P/^^R?QH \9_:8_Y+'-_P!>,'\C7TE\'?\ DCGAG_KQ7^9KYM_:8_Y+ M'-_UXP?R->Z>%8M0F_9;@CT;=]O?0)1;[#AB^QL!??T]\4 6;SXZ>&4URXTK M1+#6_$<]KGSVT6Q\](\'!).X9'N,CWK2\*?%[PKXS\01Z+H4MW)?&"2>:.6V M:/[/L95*ONQ\V6_AR.#DBOEOX/?%>3X8:U=?:;$7FFZAL%TB8$J%N-Q M^4]?45]*>'=-\.>+O'EA\2/!E];NCVDMIJ*)E7D8A2F]>SC&#GJ-I["@#TBL M3QEX>?Q7X/U#1(;Y]/DNT 2ZC7O\[6AO^(]W<"0<#_@6WZ5 MZLS*BEG(55&22< "O#/BWXO^#=VDL.O6T.NZJH*J=)'[Y3TP9E(7@]B3C^[0 M![C!/%^'5T_Q.+74I)8?+O L&V*;(Y^0D\>V: /CG2_B_H]^M<#\//B? MK_PXU82Z9,9K"1P;K3Y6/ERCH2/[K8_B'MG(XH ^S%>W^'GPQB^V3_:(?#^E M(C2[=GG>3$%X&3@L5Z9/6OEOP7\6/".EVEPOC+P#9Z[?WEY+=W.I3)%-([2- MD@+(GR@<<;L=3QFOIG4].T?XO?#6&+[;>0:5JT<RG:58^P)/M7HWB*_@\)>!=3O[."."'2]/DD@AB0*BA$)50HX X MQTKXH\=_#7Q-\--3B&L0_N7?-M?VS$QN1SPW!5N,X.#Z>M>]Z9XROO'?[*.O M7=^YEU"RM9K.YEZ&4HJMN/J2C+GU.?I0!XS\##->_'C0))',DLDT\KNYY8^3 M(Q)]^M>R_M7QJ? FBR$?.NI;0?8Q/G^0KQW]GS_DNWA[_MY_])I:]D_:N_Y) M_H__ &%!_P"BGH @_92UU[KPKK6ARON%ABR@@@>V8R?JWO7A7BC6)O M%GQCO=09]S7>K!(BW&$$@2,?@H45ZS^R2K'4?%# ':(K8$XX!S)_@:\+\/I) M%XTTR.;B1=0B5\G/(D&: /LSX[1)+\$?$:R#($43#GN)D(_4"O#/V6==DL?B M'?Z.SX@U*R+;<]9(CE3_ -\M)7NOQR_Y(GXD_P"N"?\ HU*^;_V<%9OC7IQ5 M20MO<%B!T'ED?U% 'TWXB^+G@KPGJSZ;XBU::PNT&=DFGW)##U5A&0P]P2*K MR_&KP#'X7?Q FNK+8K.UN@$$BR2RJJL55&4,4?M<1J)/"4@4;V M%XI/J!Y./YFM/]E7P[I;>$]2\0R6B/J@U![1)W&3'&(XVPOIDNCFXO9I/GDN)9(=S2.QR6;<<@GIQCI0!;\!?%WPM\ M19I;;0YYX;V)/,:TO(PDA7IN&"0P'?!.,BNXKX9^"%S):_&KPX\)P6N&C/NK M1LI_0U]S4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1W%Q#:6LMS,>$/ 'A[XM)J?CKQIICWIU:]?\ LV-KB6+R;2/]V@PC M+R=I)_/O7:_$?P3KWCK2WTG3_%2Z)ID\86YB33_-DFY.09/,7"D8&T#L^!?$?@33+31W\5VNJ:1;%ML$FDF.50Q)PL@F./F.>5;C(], %,_L^?#$ MC_D6-]1T65W673[DK%*#AF7[R/D="5*G\:^_[Q M+I[.5=/FA@N2O[N2>$RHI]2@921[;A]:\2\9_L[:GXZ\33:YK?C6!;J953;; MZ-L1548 ,Y/YDT >D_#/Q?'XY^'VF:T&4W#Q^5=J/X9EX<8[9/(]B*^=/VJ M_P#DJ>F_]@6+_P!'SU[!\,_A!KGPSO)!8>,X[S3;B0/_[>?\ TIEKY3^*_P#R5WQ1_P!A*;_T(U]:^ /A_P"(? /AB30K;Q39 MWUJBN;0S:2RM!(S;LG$_S+RWR\')'S#&#YSJ_P"RW=ZYK5YJNH^.O,N[V=YY MG&D8!9B2<#SN!ST[4 >_:=_R"[7_ *XI_P"@BK%8WA;3-6T?0X;#7-6@U:6! M5CCN(K,VY*!0!N&]P6XZC'TK9H \E_:5_P"2,W/_ %^0?^A5XE^S/_R6.'_K MQG_D*][^(WPQ\1_$>Q73=0\7V=CIL^1[)Y&. I"]0M]/-RQDDL;I6$2L>I1E!*@G^'!QVXXH ^@B<#)X%&_A;\0YM,32/'GCUI]%5=CV6G\R M3ITV-<,BN%(X(YR.*[3Q]\/+'QI\/9/"\#)IT<8C-FT<8*P,GW1MX^7&5P.Q MH \3^&-WJOQU\?WE]XYO3<:1I"I/'I$9*V[.S'8"G\0&TDYR3P.F17EOQB\L M?&+Q(L.T(MX5 3H,*!C\,8KV[X9_ 3QAX+\0RWLWBZ#3[>1?+E32U\U[A,YP M3*FU#[@,1VQ57XA?LRWFL^*)-2\':C96MM<[3+;7SR91@ "P<*Q?<1N.[G)/ M)H ]P\&?\B'H'_8-MO\ T4M?#O\ S5K_ +C?_M>OLWPWX9\2Z#\/X-&;Q/'< MZK#&L<=[<6"O' @ 18U9"V ."S$D\GTKR-OV4KAK\WK>.V-R9?-,O\ 97._ M.<_Z[KGF@#W#Q1JFD6%G:6?B&%9K+5[I=.*R(K1[I%8J'!/W25V]^6';)'SE M\6OV=I=!MKOQ!X)8SZ;"K33Z?(V9+=0,LR,?OJ!V/S#_ &J]D\??#S7/'?P^ MMO#^H:[:&^2]CGDOX[-H5*+D<1[V^;#?W@#[5CS>$_C%%X=E\/V_BGP_?VDL M1@.I7D$J7BQD8XV@J3@XRNV4]CH?B"ST>VN+-N?\ L$__ &ZN^G^&7CZ_ ML18:G\6[Z2S*;'6WTF*"1EZ?ZQ7W?B&_M'^+[?Q-\2EL-.E6:VT>'[,7 M3D-,6S)@^WRK]5->S_L\?#RY\&>#9]2UB!H-3UAED:%UPT,*@[%([$[BQ'N M>16MX+^!/@SP7=QWT-K+J>HQG"O@Y\5O"/ MF:?IWCNPTS2I7)=;=&N2,]65)(P%8^H8?6@#W5-6L)+^\LDNHVN;&-)+F,'F M%7#%2WID*3CTY[BOE_7?BSKWQ<^(EEX2\/W\NB:!>W8MP\!*331YY=VZC*@X M0<=CGK7T=X=\(:?X=T&;38FFNVNRSWMW=/OFNY'&&=V[DCCV KP.+]E_P 2 M:5XPBO= \3V=K9V\XEM[IE?[3%@Y7Y -K$@#P[]IC_DL.(OM4P5=D. MC[415& J@SDX^I/6NW\+_#_6?#GP[O/"5SXAM]4M&LIK:T(N&^\WF-N M4;O0$>IH X;XB_ C1O']BOBKP!/!9WM[&+GRQQ;W@89##'W&.>O0GJ 237D' MP:U+7/!OQLL-)(EMWN+O[!J%FQX;DJ=P'!*GD'VZX)KW#PI\.OBA\/='33_# M/BG0]3M=N?L>K6\JQP.>6\MD);&2?0=\#)J[\/\ X-7.B>-KKQMXTU2'5?$% MP[NBV\96&!G&&89P2<$J. /4XP >LUB>,=1UC2O"%_>^&K :CJL2#[-;%2P MD8L!R 0< $GJ.E;=% '@2?"KXE?$=A-\3_%+:9I[G)TFP(/'7!"_(,>IWFO2 M?"'PD\&>"=DFCZ/')>)_R^W?[Z;/J&/"_P# 0*[2B@ KAOB3XV;P-<^&+R>< M0Z==:J+6_P JN/*:)\$DC("MM;(Q]WTXKN:YGQUX!T7XAZ&FE^(%N!%%+YL4 MEO+L>-\%:G(KQ']H?POH^GZ+X M5UZRCCM]1U"V$=RB<>>%C0B0CU&<$]\CTKK_ !G\(?%/A[X9:II_ASQGJ^JZ M8D2JFAR6(N'E7>N$1@U='X>^"-K>7>F:[X^UB_P#$=[;P1^1:W:"* M"WP 0GE#/0]L@'N#0!)X UJV^&/[..BZEXK$L4<$+2F.--TC>=,[QJ <']EPZ5K<6H^'/'-[IKPONB?[&&E3_@:R M+VXZ4 >A_&VSL+SX-^(!J>P)#;^;"S_PRJ1LQ[EL#\<5A?!3P))I_P "Y=*U MJ-HFU\3SS1,.42:,1@$>Z*IQ[UU%K\/C=-:R>,]?OO$[6CB2*&ZCCAM@XZ,8 MHU %/VB])TS4QY%U:7DUK(".I,3IQ['(P?<&O5OVL M9MOA'0(-X&^^=]F>3MCQG\-WZUZ!X]^$>C>.-2M=82XGTC7;-E:'4K0#?E3E M=P/WL'H>"/7%8S_!&7Q#KEGJ7Q+\677BH6((M[;[(EI" >NY4)SD@9Q@G SD M"@#/_9D\+3:)\.9]6NXFCFUFX\V,,,$PH-J'\27(]B#7@WQ0\/3>!?C5=^8# M';27PU"UD*\&-WW\>NTY7_@-?;L44<$*0P1K'%&H5$1<*H' Z"N7\??#G0 M?B+I"66O0LLD)+6]W"0LL)/7!(Y![@\' ] : ,+X_P!QY7P+U]DD"F06ZJ*9XF6"&'[%;N1P[L0SX_W0JC_ ('7?W?P1U?7 M-/L]&\6?$+4-5T&S93%8I91P.=HP TH)+X'J#7I^B:)IOAS1K?2M$M([.RME MVQQ1]![D]23U)/)- 'SY^US_ ,RC_P!OO_M"NE_94_Y)9J7_ &&I?_1$%:?Q M/^"^I_$[68+J^\6Q65I9AEM+6/2]WEAL;BS^<-Q.T=R#T->^ MVJSI:0K>2QS7"HHEDBC,:N^.2%))4$]LG'J>M $M%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R6M_\ M"QO[8G_X1O\ X1?^S?E\G[?]H\[[HW;MGR_>SC';%9__ !=W_J2O_)NN]HK1 M3LMD*QP7_%W?^I*_\FZ/^+N_]25_Y-UWM%'M/)!8X+_B[O\ U)7_ )-T?\7= M_P"I*_\ )NN]HH]IY(+'!?\ %W?^I*_\FZ/^+N_]25_Y-UWM%'M/)!8X+_B[ MO_4E?^3='_%W?^I*_P#)NN]HH]IY(+'!?\7=_P"I*_\ )NC_ (N[_P!25_Y- MUWM%'M/)!8X+_B[O_4E?^3='_%W?^I*_\FZ[VBCVGD@L<%_Q=W_J2O\ R;H_ MXN[_ -25_P"3==[11[3R06."_P"+N_\ 4E?^3='_ !=W_J2O_)NN]HH]IY(+ M'!?\7=_ZDK_R;H_XN[_U)7_DW7>T4>T\D%C@O^+N_P#4E?\ DW1_Q=W_ *DK M_P FZ[VBCVGD@L<%_P 7=_ZDK_R;H_XN[_U)7_DW7>T4>T\D%C@O^+N_]25_ MY-T?\7=_ZDK_ ,FZ[VBCVGD@L<%_Q=W_ *DK_P FZ/\ B[O_ %)7_DW7>T4> MT\D%C@O^+N_]25_Y-T?\7=_ZDK_R;KO:*/:>2"QP7_%W?^I*_P#)NC_B[O\ MU)7_ )-UWM%'M/)!8X+_ (N[_P!25_Y-T?\ %W?^I*_\FZ[VBCVGD@L<%_Q= MW_J2O_)NC_B[O_4E?^3==[11[3R06."_XN[_ -25_P"3='_%W?\ J2O_ ";K MO:*/:>2"QP7_ !=W_J2O_)NC_B[O_4E?^3==[11[3R06."_XN[_U)7_DW1_Q M=W_J2O\ R;KO:*/:>2"QP7_%W?\ J2O_ ";H_P"+N_\ 4E?^3==[11[3R06. M"_XN[_U)7_DW1_Q=W_J2O_)NN]HH]IY(+'!?\7=_ZDK_ ,FZ/^+N_P#4E?\ MDW7>T4>T\D%C@O\ B[O_ %)7_DW1_P 7=_ZDK_R;KO:*/:>2"QP7_%W?^I*_ M\FZ/^+N_]25_Y-UWM%'M/)!8X+_B[O\ U)7_ )-T?\7=_P"I*_\ )NN]HH]I MY(+'!?\ %W?^I*_\FZ/^+N_]25_Y-UWM%'M/)!8X+_B[O_4E?^3='_%W?^I* M_P#)NN]HH]IY(+'!?\7=_P"I*_\ )NC_ (N[_P!25_Y-UWM%'M/)!8X+_B[O M_4E?^3='_%W?^I*_\FZ[VBCVGD@L<%_Q=W_J2O\ R;H_XN[_ -25_P"3==[1 M1[3R06."_P"+N_\ 4E?^3='_ !=W_J2O_)NN]HH]IY(+'!?\7=_ZDK_R;H_X MN[_U)7_DW7>T4>T\D%C@O^+N_P#4E?\ DW1_Q=W_ *DK_P FZ[VBCVGD@L<% M_P 7=_ZDK_R;H_XN[_U)7_DW7>T4>T\D%C@O^+N_]25_Y-T?\7=_ZDK_ ,FZ M[VBCVGD@L<%_Q=W_ *DK_P FZ/\ B[O_ %)7_DW7>T4>T\D%C@O^+N_]25_Y M-T?\7=_ZDK_R;KO:*/:>2"QP7_%W?^I*_P#)NC_B[O\ U)7_ )-UWM%'M/)! M8X+_ (N[_P!25_Y-T?\ %W?^I*_\FZ[VBCVGD@L<%_Q=W_J2O_)NC_B[O_4E M?^3==[11[3R06."_XN[_ -25_P"3='_%W?\ J2O_ ";KO:*/:>2"QP7_ !=W M_J2O_)NC_B[O_4E?^3==[11[3R06."_XN[_U)7_DW1_Q=W_J2O\ R;KO:*/: M>2"QP7_%W?\ J2O_ ";H_P"+N_\ 4E?^3==[11[3R06."_XN[_U)7_DW1_Q= MW_J2O_)NN]HH]IY(+'!?\7=_ZDK_ ,FZ/^+N_P#4E?\ DW7>T4>T\D%C@O\ MB[O_ %)7_DW1_P 7=_ZDK_R;KO:*/:>2"QP7_%W?^I*_\FZ/^+N_]25_Y-UW MM%'M/)!8X+_B[O\ U)7_ )-T?\7=_P"I*_\ )NN]HH]IY(+'!?\ %W?^I*_\ MFZ/^+N_]25_Y-UWM%'M/)!8X+_B[O_4E?^3='_%W?^I*_P#)NN]HH]IY(+'! M?\7=_P"I*_\ )NC_ (N[_P!25_Y-UWM%'M/)!8X+_B[O_4E?^3='_%W?^I*_ M\FZ[VBCVGD@L<%_Q=W_J2O\ R;H_XN[_ -25_P"3==[11[3R06."_P"+N_\ M4E?^3='_ !=W_J2O_)NN]HH]IY(+'!?\7=_ZDK_R;H_XN[_U)7_DW7>T4>T\ MD%C@O^+N_P#4E?\ DW1_Q=W_ *DK_P FZ[VBCVGD@L<%_P 7=_ZDK_R;H_XN M[_U)7_DW7>T4>T\D%C@O^+N_]25_Y-T?\7=_ZDK_ ,FZ[VBCVGD@L<%_Q=W_ M *DK_P FZ/\ B[O_ %)7_DW7>T4>T\D%C@O^+N_]25_Y-T?\7=_ZDK_R;KO: M*/:>2"QP7_%W?^I*_P#)NC_B[O\ U)7_ )-UWM%'M/)!8X+_ (N[_P!25_Y- MT?\ %W?^I*_\FZ[VBCVGD@L<%_Q=W_J2O_)NC_B[O_4E?^3==[11[3R06."_ MXN[_ -25_P"3='_%W?\ J2O_ ";KO:*/:>2"QP7_ !=W_J2O_)NC_B[O_4E? M^3==[11[3R06."_XN[_U)7_DW1_Q=W_J2O\ R;KO:*/:>2"QP7_%W?\ J2O_ M ";H_P"+N_\ 4E?^3==[11[3R06."_XN[_U)7_DW1_Q=W_J2O_)NN]HH]IY( M+'!?\7=_ZDK_ ,FZ/^+N_P#4E?\ DW7>T4>T\D%C@O\ B[O_ %)7_DW1_P 7 M=_ZDK_R;KO:*/:>2"QP7_%W?^I*_\FZ/^+N_]25_Y-UWM%'M/)!8X[2?^%E_ MVM;_ -N?\(I_9^[]_P#8_M/F[?\ 9W<9^M=C114R=P"BBBI&%%%% !1110 4 M444 %%%% !1110 4444 %%%% '!?\7=_ZDK_ ,FZ/^+N_P#4E?\ DW7>T5I[ M3R0K'!?\7=_ZDK_R;H_XN[_U)7_DW7>T4>T\D%C@O^+N_P#4E?\ DW1_Q=W_ M *DK_P FZ[VBCVGD@L<%_P 7=_ZDK_R;H_XN[_U)7_DW7>T4>T\D%C@O^+N_ M]25_Y-T?\7=_ZDK_ ,FZ[VBCVGD@L<%_Q=W_ *DK_P FZ/\ B[O_ %)7_DW7 M>T4>T\D%C@O^+N_]25_Y-T?\7=_ZDK_R;KO:*/:>2"QP7_%W?^I*_P#)NC_B M[O\ U)7_ )-UWM%'M/)!8X+_ (N[_P!25_Y-T?\ %W?^I*_\FZ[VBCVGD@L< M%_Q=W_J2O_)NC_B[O_4E?^3==[11[3R06."_XN[_ -25_P"3='_%W?\ J2O_ M ";KO:*/:>2"QP7_ !=W_J2O_)NC_B[O_4E?^3==[11[3R06."_XN[_U)7_D MW1_Q=W_J2O\ R;KO:*/:>2"QP7_%W?\ J2O_ ";H_P"+N_\ 4E?^3==[11[3 MR06."_XN[_U)7_DW1_Q=W_J2O_)NN]HH]IY(+'!?\7=_ZDK_ ,FZ/^+N_P#4 ME?\ DW7>T4>T\D%C@O\ B[O_ %)7_DW1_P 7=_ZDK_R;KO:*/:>2"QP7_%W? M^I*_\FZ/^+N_]25_Y-UWM%'M/)!8X+_B[O\ U)7_ )-T?\7=_P"I*_\ )NN] MHH]IY(+'!?\ %W?^I*_\FZ/^+N_]25_Y-UWM%'M/)!8X+_B[O_4E?^3='_%W M?^I*_P#)NN]HH]IY(+'!?\7=_P"I*_\ )NC_ (N[_P!25_Y-UWM%'M/)!8X+ M_B[O_4E?^3='_%W?^I*_\FZ[VBCVGD@L<%_Q=W_J2O\ R;H_XN[_ -25_P"3 M==[11[3R06."_P"+N_\ 4E?^3='_ !=W_J2O_)NN]HH]IY(+'!?\7=_ZDK_R M;H_XN[_U)7_DW7>T4>T\D%C@O^+N_P#4E?\ DW1_Q=W_ *DK_P FZ[VBCVGD M@L<%_P 7=_ZDK_R;H_XN[_U)7_DW7>T4>T\D%C@O^+N_]25_Y-T?\7=_ZDK_ M ,FZ[VBCVGD@L<%_Q=W_ *DK_P FZ/\ B[O_ %)7_DW7>T4>T\D%C@O^+N_] M25_Y-T?\7=_ZDK_R;KO:*/:>2"QP7_%W?^I*_P#)NC_B[O\ U)7_ )-UWM%' MM/)!8X+_ (N[_P!25_Y-T?\ %W?^I*_\FZ[VBCVGD@L<%_Q=W_J2O_)NC_B[ MO_4E?^3==[11[3R06."_XN[_ -25_P"3='_%W?\ J2O_ ";KO:*/:>2"QP7_ M !=W_J2O_)NC_B[O_4E?^3==[11[3R06."_XN[_U)7_DW1_Q=W_J2O\ R;KO M:*/:>2"QP7_%W?\ J2O_ ";H_P"+N_\ 4E?^3==[11[3R06."_XN[_U)7_DW M1_Q=W_J2O_)NN]HH]IY(+'!?\7=_ZDK_ ,FZ/^+N_P#4E?\ DW7>T4>T\D%C M@O\ B[O_ %)7_DW1_P 7=_ZDK_R;KO:*/:>2"QP7_%W?^I*_\FZ/^+N_]25_ MY-UWM%'M/)!8X+_B[O\ U)7_ )-T?\7=_P"I*_\ )NN]HH]IY(+'!?\ %W?^ MI*_\FZ/^+N_]25_Y-UWM%'M/)!8X+_B[O_4E?^3='_%W?^I*_P#)NN]HH]IY M(+'!?\7=_P"I*_\ )NC_ (N[_P!25_Y-UWM%'M/)!8X+_B[O_4E?^3='_%W? M^I*_\FZ[VBCVGD@L<%_Q=W_J2O\ R;H_XN[_ -25_P"3==[11[3R06."_P"+ MN_\ 4E?^3='_ !=W_J2O_)NN]HH]IY(+'!?\7=_ZDK_R;H_XN[_U)7_DW7>T M4>T\D%C@O^+N_P#4E?\ DW1_Q=W_ *DK_P FZ[VBCVGD@L<%_P 7=_ZDK_R; MH_XN[_U)7_DW7>T4>T\D%C@O^+N_]25_Y-T?\7=_ZDK_ ,FZ[VBCVGD@L<%_ MQ=W_ *DK_P FZ/\ B[O_ %)7_DW7>T4>T\D%C@O^+N_]25_Y-T?\7=_ZDK_R M;KO:*/:>2"QP7_%W?^I*_P#)NC_B[O\ U)7_ )-UWM%'M/)!8X+_ (N[_P!2 M5_Y-T?\ %W?^I*_\FZ[VBCVGD@L<%_Q=W_J2O_)NC_B[O_4E?^3==[11[3R0 M6."_XN[_ -25_P"3='_%W?\ J2O_ ";KO:*/:>2"QP7_ !=W_J2O_)NC_B[O M_4E?^3==[11[3R06."_XN[_U)7_DW1_Q=W_J2O\ R;KO:*/:>2"QP7_%W?\ MJ2O_ ";H_P"+N_\ 4E?^3==[11[3R06."_XN[_U)7_DW1_Q=W_J2O_)NN]HH M]IY(+'!?\7=_ZDK_ ,FZ/^+N_P#4E?\ DW7>T4>T\D%C@O\ B[O_ %)7_DW1 M_P 7=_ZDK_R;KO:*/:>2"QP7_%W?^I*_\FZ/^+N_]25_Y-UWM%'M/)!8X+_B M[O\ U)7_ )-T?\7=_P"I*_\ )NN]HH]IY(+'!?\ %W?^I*_\FZ/^+N_]25_Y M-UWM%'M/)!8X+_B[O_4E?^3='_%W?^I*_P#)NN]HH]IY(+'!?\7=_P"I*_\ M)NC_ (N[_P!25_Y-UWM%'M/)!8X+_B[O_4E?^3='_%W?^I*_\FZ[VBCVGD@L M<%_Q=W_J2O\ R;H_XN[_ -25_P"3==[11[3R06."_P"+N_\ 4E?^3='_ !=W M_J2O_)NN]HH]IY(+'!?\7=_ZDK_R;H_XN[_U)7_DW7>T4>T\D%CG?#7_ F? MVB?_ (3'^P?)VCR?[*\[=NSSN\SC&/2NBHHJ&[NXPHHHI %%%% !1110 44P MS("06Y'M2>?'_>_2@"2BH_/C_O?I1Y\?][]* )**C\^/^]^E'GQ_WOTH DHJ M/SX_[WZ4>?'_ 'OTH DHJ/SX_P"]^E'GQ_WOTH DHJ/SX_[WZ4>?'_>_2@"2 MBH_/C_O?I1Y\?][]* )**C\^/^]^E'GQ_P![]* )**C\^/\ O?I1Y\?][]* M)**C\^/^]^E'GQ_WOTH DHJ/SX_[WZ4>?'_>_2@"2BH_/C_O?I1Y\?\ >_2@ M"2BH_/C_ +WZ4>?'_>_2@"2BH_/C_O?I1Y\?][]* )**C\^/^]^E'GQ_WOTH M DHJ/SX_[WZ4>?'_ 'OTH DHJ/SX_P"]^E'GQ_WOTH DHJ/SX_[WZ4>?'_>_ M2@"2BH_/C_O?I1Y\?][]* )**C\^/^]^E'GQ_P![]* )**C\^/\ O?I1Y\?] M[]* )**C\^/^]^E'GQ_WOTH DHJ/SX_[WZ4>?'_>_2@"2BH_/C_O?I1Y\?\ M>_2@"2BH_/C_ +WZ4>?'_>_2@"2BH_/C_O?I1Y\?][]* )**C\^/^]^E'GQ_ MWOTH DHJ/SX_[WZ4>?'_ 'OTH DHJ/SX_P"]^E'GQ_WOTH DHJ/SX_[WZ4>? M'_>_2@"2BH_/C_O?I1Y\?][]* )**C\^/^]^E'GQ_P![]* )**C\^/\ O?I1 MY\?][]* )**C\^/^]^E'GQ_WOTH DHJ/SX_[WZ4>?'_>_2@"2BH_/C_O?I1Y M\?\ >_2@"2BH_/C_ +WZ4>?'_>_2@"2BH_/C_O?I1Y\?][]* )**C\^/^]^E M'GQ_WOTH DHJ/SX_[WZ4>?'_ 'OTH DHJ/SX_P"]^E'GQ_WOTH DHJ/SX_[W MZ4>?'_>_2@"2BH_/C_O?I1Y\?][]* )**C\^/^]^E'GQ_P![]* )**C\^/\ MO?I1Y\?][]* )**C\^/^]^E'GQ_WOTH DHJ/SX_[WZ4>?'_>_2@"2BH_/C_O M?I1Y\?\ >_2@"2BH_/C_ +WZ4>?'_>_2@"2BH_/C_O?I1Y\?][]* )**C\^/ M^]^E'GQ_WOTH DHJ/SX_[WZ4>?'_ 'OTH DHJ/SX_P"]^E'GQ_WOTH DHJ/S MX_[WZ4>?'_>_2@"2BH_/C_O?I1Y\?][]* )**C\^/^]^E'GQ_P![]* )**C\ M^/\ O?I1Y\?][]* )**C\^/^]^E'GQ_WOTH DHJ/SX_[WZ4>?'_>_2@"2BH_ M/C_O?I1Y\?\ >_2@"2BH_/C_ +WZ4>?'_>_2@"2BH_/C_O?I1Y\?][]* )** MC\^/^]^E'GQ_WOTH DHJ/SX_[WZ4>?'_ 'OTH DHJ/SX_P"]^E'GQ_WOTH D MHJ/SX_[WZ4>?'_>_2@"2BH_/C_O?I1Y\?][]* )**C\^/^]^E'GQ_P![]* ) M**C\^/\ O?I1Y\?][]* )**C\^/^]^E'GQ_WOTH DHJ/SX_[WZ4>?'_>_2@" M2BH_/C_O?I1Y\?\ >_2@"2BH_/C_ +WZ4>?'_>_2@"2BH_/C_O?I1Y\?][]* M )**C\^/^]^E'GQ_WOTH DHJ/SX_[WZ4>?'_ 'OTH DHHHH **** "BBB@ H MJ*ZNH;*SFNKE]D,$;22-@G:JC).!ST%%K=0WMG#=6S[X9XUDC;!&Y6&0<'GH M: ):*** "BBB@ HHHH **89D!(+_2CSX_[WZ4 M 245'Y\?][]*//C_ +WZ4 245'Y\?][]*//C_O?I0!)14?GQ_P![]*//C_O? MI0!)14?GQ_WOTH\^/^]^E $E%1^?'_>_2CSX_P"]^E $E%1^?'_>_2CSX_[W MZ4 245'Y\?\ >_2CSX_[WZ4 245'Y\?][]*//C_O?I0!)14?GQ_WOTH\^/\ MO?I0!)14?GQ_WOTH\^/^]^E $E%1^?'_ 'OTH\^/^]^E $E%1^?'_>_2CSX_ M[WZ4 245'Y\?][]*//C_ +WZ4 245'Y\?][]*//C_O?I0!)14?GQ_P![]*// MC_O?I0!)14?GQ_WOTH\^/^]^E $E%1^?'_>_2CSX_P"]^E $E%1^?'_>_2CS MX_[WZ4 245'Y\?\ >_2CSX_[WZ4 245'Y\?][]*//C_O?I0!)14?GQ_WOTH\ M^/\ O?I0!)14?GQ_WOTH\^/^]^E $E%1^?'_ 'OTH\^/^]^E $E%1^?'_>_2 MCSX_[WZ4 245'Y\?][]*//C_ +WZ4 245'Y\?][]*//C_O?I0!)14?GQ_P![ M]*//C_O?I0!)14?GQ_WOTH\^/^]^E $E%1^?'_>_2CSX_P"]^E $E%1^?'_> M_2CSX_[WZ4 245'Y\?\ >_2CSX_[WZ4 245'Y\?][]*//C_O?I0!)14?GQ_W MOTH\^/\ O?I0!)14?GQ_WOTH\^/^]^E $E%1^?'_ 'OTH\^/^]^E $E%1^?' M_>_2CSX_[WZ4 245'Y\?][]*//C_ +WZ4 245'Y\?][]*//C_O?I0!)14?GQ M_P![]*//C_O?I0!)14?GQ_WOTH\^/^]^E $E%1^?'_>_2CSX_P"]^E $E%1^ M?'_>_2CSX_[WZ4 245'Y\?\ >_2CSX_[WZ4 245'Y\?][]*//C_O?I0!)14? MGQ_WOTH\^/\ O?I0!)14?GQ_WOTH\^/^]^E $E%1^?'_ 'OTH\^/^]^E $E% M1^?'_>_2CSX_[WZ4 245'Y\?][]*//C_ +WZ4 245'Y\?][]*//C_O?I0!)1 M4?GQ_P![]*//C_O?I0!)14?GQ_WOTH\^/^]^E $E%1^?'_>_2CSX_P"]^E $ ME%1^?'_>_2CSX_[WZ4 245'Y\?\ >_2CSX_[WZ4 245'Y\?][]*//C_O?I0! M)14?GQ_WOTH\^/\ O?I0!)14?GQ_WOTH\^/^]^E $E%1^?'_ 'OTH\^/^]^E M $E%1^?'_>_2CSX_[WZ4 245'Y\?][]*//C_ +WZ4 245'Y\?][]*//C_O?I M0!)14?GQ_P![]*//C_O?I0!)14?GQ_WOTH\^/^]^E $E%1^?'_>_2CSX_P"] M^E $E%1^?'_>_2CSX_[WZ4 245'Y\?\ >_2CSX_[WZ4 245'Y\?][]*//C_O M?I0!)14?GQ_WOTH\^/\ O?I0!)14?GQ_WOTH\^/^]^E $E%1^?'_ 'OTH\^/ M^]^E $E%%% !1110 4444 4I/]8WU--ITG^L;ZFFT %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 7Z*** "BBB@ HHHH R_$R-)X2U=$4LS6,P"@9) M/EGBCPRC1^$M(1U*LMC""I&"#Y8XK1GGBMK>2>X<1Q1(7=V/"J!DD_A1!/%< MV\<]NXDBE0.CJ>&4C((_"GT%U'T444AA1110 4444 4I/]8WU--ITG^L;ZFF MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 7Z*** "BBB@ HHHH I M2?ZQOJ:;3I/]8WU--H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH O MT444 %%%% !1110!E>*?^1/UG_KPG_\ 1;4>%O\ D3]&_P"O"#_T6M:*?^1/UG_KPG_\ 1;4>%O\ MD3]&_P"O"#_T6M:?R=7U[3+"7_GG=7D<3?DQ% &M15'3-H(O5K2X24#\5)J]0 445FZMXDT/06B77-9T_36F!,8O+I(2X'7&X MC.,C\Z -*BJ6EZSI>N6K7.BZE::C KF-I;2=95# E25)&<$''N*NT %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7 MZ*** "BBB@ HHHH RO%/_(GZS_UX3_\ HMJ/"W_(GZ-_UX0?^BUK2G@BN;>2 M"X0212H4=&'#*1@@_A1!!%;6\<%N@CBB0(B*.%4# _"G?2PNH^BBBD,**** M "BBB@"E)_K&^IIM.D_UC?4TV@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **H:GKVC MZ(H;6=5L=/5AD&[N4B!_[Z(J+3?%'A_6I3'H^N:;?R#JEK=QRG\E)H U**** M "BJFIZOINBVGVK6=0M=/M]P3SKN=8DW'H-S$#/!XJOI7B70M=DDCT/6M.U) MX@&D6SNTF* ]R%)Q0!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% %^BBB@ HHHH **** *4G^L;ZFFTZ3_6-]33: "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH \,_: ^*U[X:\OPMX;G-O?7$7F7=TAP\,9X"*>S'!)/4#&.N1?\ M@_\ "'0;?P9::WXGTRWU;5=5C%TYOHQ,L2/RH"L,9P022,Y)]*\1^.XF'QJU M[[1G):$IG^[Y*8Q7V!X<"#PMI0BV[/L4.W;TQL&,4 >"?''P%;^!/L'C3P(' MT65;@0W"6;%%4D$JZ@<*/EVD#@Y''7/IOP@^(W_"P?!C7=_Y<6I6#>3>A*;>\MXKG3Y M;>!)X9D#HY)? (/!&-W!H ZCQ#\<+"^^*FAZ#HFIQ6^C6UYNU'4FF"1384_( M&)QY8/4YP3CL.;_Q]U'3-;^"LU[I5Y::A +V()<6TJRJ#NP0&4D9KQC1-*TZ M7]IJ32Y;"U?3QK]S"+1H5,.P2. NS&-H '&,<5[3\?-*T_1O@E<6FD6%M86P MO86$-K"L2 EN3M4 4 9W[->H6>E_"35+O4[N"SMH]8EWS7$HC1?W,/5B0!7M M%AJ-EJMFEWI=Y;WML_W)K>59$;Z,I(-?,WPD^'VE>,/@]KUWK6>0(B_4G@5#I>M:7K=NT^BZE9ZA"IPTE MI.LJ@^F5)KYVUKQ@/%7[3EGI^M"XN-#T2\EBBLX+>2XS)%&Y+^4BLS'S%[ X M4>@)K4\23ZU;?M!:5XG\%Z%KCZ?YA63+E9 X>,9PFPYQ@$#TH ] MHU#QEX8TF^DLM4\1Z19746/,@N;Z*.1,@$95F!&00?H:L7'B30[/3[>_N]9T M^"SNL?9[B6Z18YL\C:Q.&S[5\_?M6*HU;PTX4;C!< G') 9,?S/YULZ3\&K; MXB?"?PY>:MJEQ::HMI&()D!DCBMP,+&(R0.1ABU?/WQ[EU/P=>^!H+$&XTG1X4-N+E=Z2S1%1^\'0G:J_FV*[#P1XG\'?%/Q M=HWB*UC32?%.D^:9[5E&ZYC>)T(#<;P"P8'J,$8&[- 'L-%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 7Z*** "BBB@ HHHH R_$SM'X2U= MT8JRV,Q# X(/EGFCPR[2>$M(=V+,UC"2Q.23Y8YJ_=6T-[9S6MRF^&>-HY%R M1N5A@C(YZ&BUMH;*SAM;9-D,$:QQKDG:JC &3ST%.^EA=26BBBD,**** "BB MB@"E)_K&^IIM.D_UC?4TV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSGXT?$A_A[X43^SM MAU?4&:*TW $1@#YI".^,C'N1VS7HU?,7[5 F_P"$LT(MGR#9.$]-V_YOTVT M:?P-^'=KXS@N_&WCI6UF:>=H[>.\/F*VW[TC _>Y^4 \#!XZ8Z+XR_"?0AX+ MN_$/A?38-(U325^TAK%!"KQKRV57 ! RP(&O MVB3K^&*ZOQMY?_"O_$/G[?*_LNYW[NF/*;.: /,/@!\4[SQ9;3^'/$4QGU*R MB\VWN7/S3Q @$,>[*2.>X//())\;_C)!X>T^?PWX7N]^LSKMGN8'_P"/)>X# M#_EH>G'*]>#BO)/V>5N#\:-,,'^K6&X,_P#N>4V/_'MM)^T!I>GZ1\5);72; M&VL;?[)$_E6T*QIN(.3A0!DT ?27C#7]"\1?"_Q<-&U;3]4$&D7)E%IZ\W[':I#YF(7QNV@9QDXSZFOGO]G_PC8^,=;UBQUJ2X;34MT>: MSBE:-;D[B%#LI#;1R< C)QZ4 ?56EZ[I.MI(^BZI9:@L1VR-:7"2A#Z':3BK MKNL<;/(P5%&69C@ >M?)/PO#^%OVEGT;3)76T6_O+!E)/[R)/,"@^N"BGZBN ML_:(\6W-SXPTGP8DTT>F,(IKY8=-\2:'K-Q)! MI&LZ??S1_?CM;I)63ZA22*35?$NA:%)''KFM:=IKR@M&MY=I"7 [@,1FO$OC M$EQJ)\-:C\.-#UQ-3T>1D1K?0KN Q18&T9:)00",8YZGL36I^T!&5"KPLT3%E(/((R010!ZS#XET*XTB35;?6M.ETZ(E9+Q+M&A M0CJ"X.!U'>K4&HV5SIRW]M>6\UDR%Q MVNN74\-M%?2"P$+D"*7:A:5ESASR% /0!L8)S5GXN>$KWX?_ &TKP]I=Y/> M627^Z_N-FW>6W,N5!.U-V.,GD+SF@#W:R\4^']1CDDT_7=-NTB8+(T%Y&X0D M@ $@\$D@?4BM6OG[PGXY\)?%BUT;1_$=O;Z+XDTR>"6RN$C4)*T;*=L9XQN MP8SZC&2./H&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH OT444 %%%% M !1110!2D_UC?4TVG2?ZQOJ:;0 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A_[0'PJO?$Z1>)_#=N MUQJ%K%Y5U:H,M-&,D,H[LN3QU(QCI@W_ (1_%O0)?!=GHGB?4X-(U;2HA:RI MJ$@A#JG"L&; S@ $$YR#[5[#67J7A?0-9D\S6-#TV_?^]=6D.QKU_XZ:NNK_ @7SP/:"\ MNXGAAGX=DWDJ2#R"5 ;;U&<=J]6O= T?4KV&\U'2;&[NK?\ U,\]LCO'W^5B M,C\*;JWAO0]>:)MXKWO0/BUHGC2X MMK+P:+B\O9"KW*RVSHEE'GYFD8X!.,@!2 MZIX;TB]NI<>9/,-:\*ZAXA3P+XSAM_(U*S%Q!)<2;5=]Y78#QM<8R"#SR/KX6WP MUN?!O[1.@:3X6OI+M#-#?;P/GMH-YWB3'&-JGGC(8#O7U'<:;8W;R/=65O,T MD8B=I(E8N@)(4Y'(R2<>]0Z7H.CZ&LBZ+I5CIRR'+BTMDB#GWV@9H OT444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!?HHHH **** "BBB@# M-\1S26_A759H':.6.RF='4X*D(2"#ZT>')I+CPKI4T[M)+)90N[LSM]WE6\2Q)N.3M48&?P% M/H+J3T444AA1110 4444 4I/]8WU--ITG^L;ZFFT %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %>=_&;X<-\0O"*II^T:MI[&:TW$ 29'S1D]MV!@^H';->B44 ?//P/\?VO@ MJSN_!7CQVT2YM[AI;9KY3&H#?>0D\+R"P)X.X\],[WQE^*VB2>#;GP[X4U"# M6=5U8"V"V+^U>M:EHFE:U&(]8TRSOT7HMU;I*!^# U M%IGAK0M% MMX<@D-Z,Q )'8 =\BO+/VE;2>'XK+<2Q,L-Q8Q&)R.'QD'!]C_3UKZWJEJ>C M:7K<"P:SIMIJ$2-N6.[@655/J P/- '%ZWXOL/%WP=\6ZII:R#3/[+NHK>ZG M4Q_:#Y+ E58 X#';GNP..G/DO[*S*/$^O*2 QLX\#/)^G)I^I M:797=E&04MI[=)(UP,#"D8&!6?;^!?"-I-YMKX6T6"0*5#QZ=$IP001D+T() M!]C0!\R>$[F$_M7R3B5/*?7;TK)N&UMQEQ@^^1CZUO?M,>&-0L_%ECXKM8W- MG-"D$DJ GR9D)*Y/;((Q[J:]Y_X5YX*_Z%#0?_!9#_\ $UOSP17,#PW,231. M,/'(H96'H0>M 'E?A;X]:%XBT:SMX8+J;Q-.@C&EQ0,?,EQ@D28VJF>22>!U M'%4OVDI&3X16L=W)%]I:_AW!/E#L$?=M!.'-#T21Y-&T;3]/>3[[ M6EJD1;ZE0,TFJ^&M"UV2.37-%T[4GB!6-KRT28H#V!8'% 'F/[,LT3_"R>)) M%:2/49=Z \KE4QD>]=OXW\4Z'H']FZ?XIBA;3-:E>TEDN,&)/ER-X(QM/3/; MK6KI?A7P]H=TUSHN@Z9IT[(8VEM+..)BI()4E0#C(!Q["M":TMKB2.2XMXI7 MC#!&= Q3<,-@GID<'UH ^4/BS\*+7PMXCT:7P+>IY&.I[?5]HDL=G"ER_F3+&HD<#[S8Y/YU2L/#>AZ5>27>EZ+I]E<#N3@X'Y4 =-16-X0\0?\ "5>$--US[-]D M^W0"7R/,W[,]MV!G\A7,^+_C3X,\'[X;C41J%\N?]$L,2L#Z,V=J_B<^U '? MT5A^"_$J^,/!UAKR6IM%O49Q"7WE '*]<#/3/2LKXB?$K2OAWI]O)?Q2WE[> M,4M;. @-(1C))/0#(YYZ]* .QHKSZT^*D=KX^A\'^+M+71M3NHT>U>*[^T0R ME^B;]B$,2".F"1UY&?0: "BN9\.^,/\ A)O$>L6FFV.[2M+D%N=3\[Y9[@?? MC1-O(7NV>N,#O734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !113@K-T!/X4 -HIYB*KERJ#U8XJ"2\L8?]9>P_13N_E0!)15& M37M,C^ZTLO\ NIC^>*@;Q-:C[EI(W^\^* -6BL1O%)_Y9V48_P!Y\_TJ(^*+ MS^&&W4?[I_QH Z"BN=/B>_["$?1/_KTL7B/4'GC4O& S '"#UH Z&BO#_B5\ M6_%?ACXC:GI&E7-NMG;^5Y:26ZL1NB1CSUZL:YI?C]XV7[SV#_6U_P #75'" MU))-$+8_\ 766D3#_:@<']'K1@_:/U08^U>'K&3U\N5D_G MFAX6J'/$]ZHKQFT_:/L7P+_PQ-%ZF"[#_H56MVT^/G@NYP+B/4[,]_,@5@/^ M^6)J'AZJZ#YHGI-%-EF<1 M ^\IX_[YW5ZC;R^?;138V^8@;& M2+GR?+1%Y=;U]C'%$%7RHOF9Y#T1>F3^7 ).*X=_C, CF6/8NT$,&^4MQ[\4 >JT4B.DL:R1LKHP#*RG((/0@U MS4OC'S/B%#X5TJQ^VR1VYN-2N?.VK8J?N C:=SL>BY''- '34444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 444X(S= 3^% #:*>T>Q=TC*@ M]6;%5WOK"+_67L7_ $[OY4 2T51?7M,C^ZTLO\ NIC^>*KMXFMA_J[-V_WG MQ0!K45B-XI/_ "SLHQ_O/G^E1-XHO#]V&W4?[I_QH Z"BN=/B:_["$?1/_KT M^W\17\MU$C.FUG4'"#H30!OT5X;\1_B[XL\,_$/5-)TNYMUM+9HQ&CVZL1F- M6//7J37.+\?_ !JO5]/;ZVO^!KJ6%J-)HCG1]*T5\Z0?M$>+8_\ 76.D3#ON M@<']'K1@_:/U,8^U>';&3U\N9D_GFAX6J'/$]ZHKQJT_:/L'Q]O\,SQ>I@NP M_P"A5:W+3X^>"KG'GIJ=F>_FP*P'_?+&LW0JKH/FB>DT5RUA\3_ ^IX%MXDM M8R>UT&@Q^+@"NEM+FUU"/S-/O+>[3^]!*KC\Q6;C*.Z'=,DHIQC=>JFFU(PH MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** +]%%% !1110 4444 4I/]8WU--ITG^L;ZFFT %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 5M1U"TTG3;C4-1G2WM;:,R2RNGZ M>_'V:V"9#./^>CG#'T&T=C7;?'3X@#PSXLT+3=0TS^U-)6/[=-9BX\D7$H;>%8_E"IA> .!V]*Z_] MGGQQ_P )+X0DT/\ L_[-_P (_!!%Y_G[_/W^9SMVC;C9ZGK7._M6?\@GPW_U MWG_]!2@#T7X)_P#)&/#O_7!__1KUY5^TOI-[#XP\/^('5SIBPK;NX4E8I%D+ MG..A*MQZ[37JOP3_ .2,>'?^N#_^C7KM[FV@O+=[>[ACGAD&'CE0,K#T(/!H M ^<_BI83^+?VDO#MEH \^6&UM6FDB.5C59GD+DCH K*<_3U%>K_$37KYFM?! MWA>4+K^M KYHY^PVPXDG;'3CA?4GCD5J:G+X9^&WAB^U>'3+/3;6%-SQV5LD M1F;HJ *!EB2 /K6)X/TJZT+1M7\<>+8RVNZC"UW'=!L?#'A^ST;2H_+M;2,(N>K'NQ]23DD^IK2KYN\*>)_$?Q \*>//% M&HZ]J%G0@HI ?(0+\X/>O1O@;X^U#QWX*EDUO#ZAI\ M_D23JH'G+M!5B!P#U!QZ9[T >ET444 %%%% !1110 4444 %%%% !1110 44 M44 %%*!GI2N%A3?/(D2>KG% #:4 MT!/TK.N/$%C;Y$"M1(E]7;%4)]?&S_ )+#K?\ VP_])XZX.OKV=]QG9%*"X^J]1^-?%E.1VC]&,E%;$B_5#AA^(K3(*G!&*YFFG9EB4444@"BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@"_1110 4444 %%%% %#7;N6P\.ZC=VY FM M[666,D9 94)''U%&A7\L3) MY8NH'AWXSMW*1G'?K1I=E_9NCV=B)/,%K D._&-VU0,X[=*>EA=2U1112&%% M%% !1110!2D_UC?4TVG2?ZQOJ:;0 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1W-M! M>6[07<$<\+_>CE0,K'_L&0_^AR5]6Z?_ ,@VU_ZXI_(4 M ?*7B_XMV[?%;6[Z3P[HOB&Q#+9VPU.W\WRXXB03&2<#QVD@'H5] M, 'I/[2^BW^I_#NUN["-YHM/O!-TEC%[KBV=OIUG:(< MFZNO+5 ![9&2?0?2M+P%X3?PKH#+?S_:]8OY#=:G=DY,T[=@]ZY_P M9;R^.O%+>/\ 4XV6PA5[?P];2K@I%T>Y([,_0>B_@:XW1_&.J_$?X]:CX?GU M*^L-!TQ+A8[:QN7MVE:-A'N9XR&.6.[&<< 8ZY />:*\2^!GQ#UK6?$FL^$? M$5V^HR:D8Q^O6@#J) D*[KB6.)?5V JA-KFFP9"N\[>B+@?F:Y1W:1BSL68]23D MTV@#>F\42]+6VCC'JYW'^E49M1Y&W2.SGU8YIM% M% !1110 4444 %3V7_'_ &__ %U7^=05/9?\?]O_ -=5_G0!X3\9O^2O:Y_O MQ?\ HE*X:NY^,W_)7M<_WXO_ $2E<-7N4_@CZ',]PHHHK004444 %/BFD@D$ MD$CQNO1D8@C\13** .ITKXE^,M%(^P^(;TJO1)Y/.4>V'R!7:Z5^T5X@M\+K M&EV.H*.K)NA<_CR/_':\AHK*5*G+=#4FCZ6T;X^>$M1*IJD-YI,AZLZ>;&/Q M7G_QVN^TG7=&U^/?H>K6=^,9*PS L/JO4?C7Q73HY'BD62)V1U.593@@_6N> M6#@_A=BU4?4^XF1E^\"*;7RIX?\ B]XR\/;4BU5KZW7_ )87X\Y3[;C\P_ B MO3M _:&T>[VQ>)-*FL)#P9[5O-C^I4X('TW5S3PM2.VI:FF>NT5GZ)X@T7Q+ M;F?P_JEO?*!EEC?#K_O*>1^(%:)!4X(Q7,TT[,L2BBBD 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 7Z*** "BBB@ HHHH I2?ZQOJ:;3I/] M8WU--H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH *\F^/W@GQ!XV\/Z3;>&-/^W36]TTDJ^=' M'M4IC.789Y]*]9HH YGX6_ M&OPWXV^)"Z3!HG@V\MX;$R.[W=[:*SLVT +,PP-I[]Z]XHH \_^$EOX@T'P M9IOASQ%X:N["6RC=3=_:;>6%AO+#[DA<'YO[N..M>@444 <-?^'=4\5?$>"X MUZT$'AS0BLUA TBM]NNB/]!Z)\,_%_@70_&7AO2M.&LVFOV_D6=['<11"(%70F578$?*_\ M"&Y7WKT'X1_#L_#GP@;&ZN%N+^ZE\^Z>/[BM@ (N>H '7N2?I7=T4 %%%% ! M1110 4444 %%%% !1110 44JJ6.%&:KW>H6>GY$\F^7_ )Y1\G\?2@"RJLQ^ M49J"ZO;.Q_X^IQO_ .>:K'-,HH **** "BBB@ HHHH **** "BBB@ HH MHH *DM_^/J+_ 'Q_.HZDM_\ CZB_WQ_.@#P_XV?\EAUO_MA_Z3QUP==Y\;/^ M2PZW_P!L/_2>.N#KW*7\./HCFENPHHHK004444 %%%% !1110 4444 %%%% M$D%Q-:SI/;2O#*ARDD;%64^H(Z5Z-X:^.GBO1 L.I/'K5J.-MWQ(![2#G\6W M5YK142A&:M)#3:V/JSPM\7?"?BG9";O^RKUN/L]Z0H8_[+_=/Z'VKN&0KR>A MZ$=*^&ZZ[PG\3O$_@]DCT^_:>S7K9W69(L>@[K_P$BN.I@^L&:*IW/K2BO/? M"/QI\->)O+M]2;^Q-0; V3MF%S_LOT'T./QKT0J0H88*D9# Y!KAE"4':2-$ MT]AM%%%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"_1110 4444 %%%% M%+6KR33M!U"]@"M+;6TDR!QE254D9QVXHT6\DU'0=/O9PJRW-M',X084%E!. M,]N:75[)M2T2^L4<(UU;R0AB.%+*1G]:-(LFTW1+&Q=P[6MO'"6 X8JH&?TI MZ6%U+E%%%(84444 %%%% %*3_6-]33:=)_K&^IIM !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 5#>3R6UG+-#:S7DB+E8(2@>0^@+LJY^I%344 ?,_Q:^'GQ ^(/CAM M8T[PC-;6J6Z6\:SW]KO8*2,GI7OWAC4-2O-,2/5]!N]'G@B166>: M"59#C!V&.1C@8_B"]1C/.-JB@#Q'3]-^,_A#QS_C3"$\;! M(P\LCT&5[>]=SXB\,7/C^XT:+6['^S])T^[6_EMYY%>:XE5654^0E53YB2=Q M)Z8'6NUHH *XKQWHFL^+;[3_ Y# UOX=F;SM7O1,JM*BG(ME4'=\Q^\< 8[ M]17:T4 ,@@BM;>.WMHUBAB0)'&@P%4# '8 5X[;?#?6O WQFN_%_AW3VUG2 M]128S6D4T<<\+R'<0/,95*[P.%MRP(SAV!8<$E@.G QUYX]9HHH **** "BBB@ HHHH **)IWRME&L"_WC\S5CRS2SR%YI&D8]V.:910 4444 M %%%% !1110 4444 %%%% !1110 5/9?\?\ ;_\ 75?YU!4]E_Q_V_\ UU7^ M= 'A/QF_Y*]KG^_%_P"B4KAJ[GXS?\E>US_?B_\ 1*5PU>Y3^"/H^D_L74&P/*N6'E.?]F3I^!P? MK7H#(5P3T/0CH:X90E!VDC1-/8;1114C"BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH OT444 %%%% !1110!2D_UC?4TVG2?ZQOJ:;0 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113L!8S)(P2-1 MDLQP!0 @&>E1W5S;V$>^\DVD](UY9OPK)O\ Q&$W1::OL9F')^@K DD>:0O* MS.['T4_,?J:R>O6BB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "I+?\ X^HO]\?SJ.I+?_CZB_WQ_.@#P_XV?\EA MUO\ [8?^D\=<'7>?&S_DL.M_]L/_ $GCK@Z]RE_#CZ(YI;L****T$%%%% !1 M110 4444 %%%% !1110 4444 %%%% !79>#?BCXC\&2)%:7/VS3Q]ZQN26CQ M_LGJI^G'J#7&T5,HJ2LPO8^L_!OQ/\.>-0L-M/\ 8-2(YL;E@"Q_V&Z/^'/L M*[!E*G##!KX=5BK!E)# Y!!Z5ZOX$^.6IZ'Y6G^*1)JNG#"B8G,\(]B?OCV/ M/OVK@JX1K6!K&IW/HJBJ6BZUIGB/3$U#0;V.\MFZE#\R'T9>JGV-7:X6FG9F MH4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** +]%%% !1110 4444 5-6O3INBWU\B" M1K6WDF"$X#%5)Q^E&DWIU+1;&^=!&UU;QS% 6NGIF[D^;'$:\L:RK_Q&%!BTT8[&9AR?H*P'=I'+R,69CDDG)- &I?^(+FZ M!C@_T>'T0\GZFLFBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "I[+_C_ +?_ *ZK_.H*GLO^/^W_ .NJ_P Z /"?C-_R5[7/]^+_ -$I7#5W M/QF_Y*]KG^_%_P"B4KAJ]RG\$?0YGN%%%%:""BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ KMO!GQ6\1^#&2"&?[=IPX-E=,64#_8/5/PX]C7$T5,HJ2L MP3:/K?P=\2O#GC:-8[&X^QZB1\UCM^!/CKJ&CB+3_ !:)-4L!A5N:MUPM-:,U"BBBD 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110!?HHHH **** "BBB@"E)_K&^IIM.D_UC?4TV@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *4#)P.32J MAC3=0OT]: +U[?VVFIFX.^7^&)3S^/I7+ZAJEQJ+YF; M;&/NQKT'^-57=I'+R,69CDDG)--H **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "I+?\ X^HO]\?SJ.I+?_CZB_WQ_.@#P_XV?\EA MUO\ [8?^D\=<'7>?&S_DL.M_]L/_ $GCK@Z]RE_#CZ(YI;L****T$%%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 :OA[Q+J_A;4UO\ 0[V2 MUF&-P4_+(/[K+T8>QKZ-\ ?%[2?&?EV&I>7IFM-P(B?W4Y_V">_^R>?3-?+M M*"000<$="*QJT8U%KN5&31]Q,I4X88-)7@'PY^-]QIK0Z3XSD>ZL,!(K[!:6 M#_>[NOOU'OTKWRWG@O+.*[L9X[FVF4/%-$P97![@BO*J4I4W9FRDF/HHHK(H M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@"_1110 4444 %%%% %74[T:;I%Y?,AD%K \Q0'&[:I M.,_A1IEZ-2TBSOE0QBZ@28(3G;N4'&?QJ+7K66^\.:E:6RAIKBTEBC!.,LR$ M#GZFC0;66Q\.:;:7*A9K>TBBD .<,J 'GZBGI874OT444AA1110 4444 4I/ M]8WU--ITG^L;ZFFT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !2@$G Y-*J%CQT[D]JQ]3U]8-T&G$,W1IO3Z?XT 7[[4+; M34_?'S)B/EB4\_CZ5R]_J5QJ$NZ=_E!^5!]U:JN[2.6=BS$Y))R324 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4]E_P ?]O\ M]=5_G4%3V7_'_;_]=5_G0!X3\9O^2O:Y_OQ?^B4KAJ[GXS?\E>US_?B_]$I7 M#5[E/X(^AS/<****T$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 :_AOQ3K'A/4Q?:%>O;2\!U'*2@?PLO0C_(KZ0\ _%G1_&RQV=YLTS6 M3Q]G9ODG/K&3_P"@GGZ]:^6*569&#(2K*<@@X(-85:,:BUW*C)H^XF4J<,,& MDKP7X<_'":S,.D>-9&N+3[L6HG+21>F_^\OOU'OV]XBEBN+>.XM9DGMY5#1R MQL&5P>A!%>74I2INS-U),=11160PHHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +]%%% !1110 44 M44 4I/\ 6-]33:=)_K&^IIM !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !2_*D;2RL$C499CVI)9(K: SW3[(U_-O85RNJ:M+J,F/ M]7 I^2,?S/O0!8U777NP8+3,5OT)_B?Z^WM6/110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !4EO_ ,?47^^/YU'4EO\ M\?47^^/YT >'_&S_ )+#K?\ VP_])XZX.N\^-G_)8=;_ .V'_I/'7!U[E+^' M'T1S2W84445H(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "NU\ ?$W5_ MV(XV-YI4C9FL9&XYZLA_A;]#WKBJ*F45)68)V/M#P] MXCTKQ9HZ:GH-R)X&X=#P\+?W6'8_Y&:TJ^.O"/C#5?!>M)J.C3;3P)H7YCF7 M^ZP_KU':OJ/P5XYTGQYI1NM+;R;N(#[39.?GB/J/5?0C]#Q7E5J#IZK8WC*Y MT5%%%IIVF75],K-';0O,ZKU M(4$D#WXHT^]34=,M;Z%66.YA29%;J P! /OS5;Q#;RW?AG5+>W0R33656H.F[K8WC*YO4445S%A M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110!?HHHH **** "BBB@"E)_K&^IIM.D_UC?4TV@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "FW%Q#96YN+HX4?=7NY]!1<7 M$-E;&XN3A?X5[N?05R-_?S:C.N#KW*7\./HCFENPHHHK004444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !6CH.O:CX:UF#5-'N&M[J$Y##H MP[JP[@]Q6=12:35F!]<^ /'^G>/])\VWVV^IP*/M5D3R/]M?53^G0^_4U\5Z M/K%_H&K0:EI-R]M=0-N1U/Y@CN#T([U]5_#_ ,?V'C_1?.BVV^J6Z@7=IGH? M[Z^JG].A]3Y=>AR>]'8WC*^C.IHHHKD+"BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** +]%%% !1110 4444 0WM MW%86%Q>7!(BMXFE<@9.U1D_H*+*[BO["WO+-HY8[*%71UPRD( 00>AI]!=3 M2HHHI#"BBB@ HHHH I2?ZQOJ:;3I/]8WU--H **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ IES@H 6_U";4+@RSG@<*@Z**JT44 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %3V7_ !_V_P#U MU7^=05/9?\?]O_UU7^= 'A/QF_Y*]KG^_%_Z)2N&KN?C-_R5[7/]^+_T2E<- M7N4_@CZ',]PHHHK004444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !6GX>\0ZEX7UJ'5-&N#!> M!/'FF^/M'^T6>+?4(0/M=D6R4/\ >7U4^OYUTU?%NAZYJ'AS6(-3T>X:WNH& MRK#H1W4CN#W%?5?@+QYI_C[1/M-MM@U" 7=GGE#_>7U4]C^%>77H>S]Z.QO M&5]&=/1117(6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 7Z*** "BBB@ HHHH I2?ZQOJ:;3I/]8WU--H *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "B22*V@:XN6VQI^I]!2_(J M-)*P2-!EF/:N4U;5&U&X^7*P)Q&G]3[T 1:CJ$NHW1DDX0<(F>%%5*** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ J2W_X^HO]\?SJ.I+?_CZB_P!\?SH \/\ C9_R6'6_^V'_ *3QUP== MY\;/^2PZW_VP_P#2>.N#KW*7\./HCFENPHHHK004444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5HZ%KNH>&]9@U31[A MH+J!LJPZ,.ZD=P>XK.HI-)JS ^OO GCBP\>Z!]NM (;R'"WEIG)B;U'JI['^ MH-=)7QSX1\6:CX-\00ZKI3_.GRRQ,?EF0]4;V_D<&OK+PUXDT[Q=X?@UC2'S M%)Q)$WWH7[HWN/UX/>O)KT?9NZV-XRN:E%%%)U M+^$=85 68V,X R2?+-'AA2GA'1U<%6%C "",$'RQ3MI<74U****0PHHHH * M*** *4G^L;ZFFTZ3_6-]33: "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ I)IHK2V:YN#A%Z#NQ]!3B4CC:69MD2#+,:Y+5=3?4;C/W84XC3T'K] M: (K^_FU"Y,LQXZ*HZ*/2JU%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 5/9?\?\ ;_\ 75?YU!4]E_Q_ MV_\ UU7^= 'A/QF_Y*]KG^_%_P"B4KAJ[GXS?\E>US_?B_\ 1*5PU>Y3^"/H MQKZST#7M/\4:#;ZQH\F^WG'*G[T3=T8=B/\\&O)KT73=UL;QE< MT****YBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** +]%%% !1110 4444 4I/\ 6-]33:=)_K&^IIM !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !3D4NP I ,G K+UW4_LL)L[=OWSC]XP_A'I0 M!1U[5!.N#KO/C9_P EAUO_ +8?^D\=<'7N M4OX/KKP)XB68EI=,N2$O; _O+ MGC\1WKCJ*F45)68)V/MZVNK:_LH;VPF6XM;A!)%*AR&4]*DKYZ^"?Q'_ +$O MT\,:U+_Q+;R3_1I7/_'O*>W^ZQ_(\]S7T.RE6(->-5ING*S.B+NAM%%%9%!1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!?HHH MH **** "BBB@!DTT=M;R3SNL<42EW=C@*H&231#-'0#G [2*/[P_49'I7$T5,HJ2LP3L?;\$ M\%W:PW=E,L]M.@DBE0Y5U(R"#3Z\!^"/Q(.G7O?V4JQ!ZUXU6FZ?&S_DL.M_]L/_ $GCK@Z]RE_#CZ(YI;L****T$%%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 5].?!SX@?\);H/\ 9&J3 ZQIZ L>;B$S#NI]01D'ZUC6I*I&Q4969]HT5G>'M?L_%7AVTUK33^YN4R MR$Y,3C[R'W!_QK1KQFFG9G0%%%%( HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@"_1110 4444 %%%% #9&1(G:8JL84ERQX [Y]J(V M1XD:$JT94%"IX([8]JS/%/\ R)^L_P#7A/\ ^BVH\+?\B?HW_7A!_P"BUIVT MN+J:M%%%(84444 %%%% %*3_ %C?4TVG2?ZQOJ:;0 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !114=S=6UA93WM_*L-K;1F661CPJ@9- ',_$;QO#X$\*O>*5 M;4KH&*QB(SEN[D>BYS^0[UP7@OXOZ=XDCBTOQPT=CJ(4+%JH 6.4_P#30=%/ MO]WK]WOY3X]\8W7C?Q5/J<^Y+<'R[6 G_51#H/J>I]S7-5ZD,+'DM+.> ?BYJ'A:-=+UI&U;0SA?("'YX3C.UEZ@^QY_G7#5HRIO78TC),KT4 M45B4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !4]E_Q_V_\ UU7^=05/9?\ '_;_ /75?YT >$_&;_DKVN?[ M\7_HE*X:NY^,W_)7M<_WXO\ T2E<-7N4_@CZ',]PHHHK004444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M"@D$$'!'0BOJ'X0^/_\ A,_#WV#4I=VM:<@$A/6>/H)/<]C[X/>OEVM3PWX@ MO?"_B&TU?3'VSVSAMN>)%_B0^Q'%8UJ2J1MU*C*S/LZBJ.AZW9>)=!M-9TQ] MUO=(&QGE&_B4^X.1^%7J\9IIV9T!1112 **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH OT444 %%%% !1110!2D_P!8WU--ITG^L;ZF MFT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 O6L?Q'?^5&MA"W)^:4C]!_6M6X MN4L;.2ZDYV\(O]YNPKBI97GF>64[G'_ !L_Y+#K?_;#_P!)XZX.N\^-G_)8 M=;_[8?\ I/'7!U[E+^''T1S2W84445H(**** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]/\ @GX[ M'AKQ&='U*7;I>J.%)8\0S=%?V!Z'\#VKZ592C$'M7PW7U5\)/&@\8^#$CNY- MVJ:8!#>:A1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% %^BBB@ HHHH **** &R1I-$\4R+ M)&ZE71AD,#U!'<41QI#$D4*+'&BA411@*!T '85F>*?^1/UG_KPG_P#1;4>% MO^1/T;_KP@_]%K3Z7%U-6BBBD,**** "BBB@"E)_K&^IIM.D_P!8WU--H ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@!0,G KP[X]^.LNO@_2Y3M3;)J#J?O-U6 M/\.&/_ ?0UZIXT\4P>"_"-WK,^UI5'EVL3'_ %LI^Z/IU)]@:^/[R\N-0OI[ MR]E::XN)&DED<\NQ.23^-=N%IF8A6SX8\5ZQX0U5;_0KM MH)./,C/,E:]@[K*1ODG(&2 M8SW]<=1SP1S6G/!+;3&*="CKU!KY5CD>&5)87:.1&#(ZG!4CH0>QKV?P/\9X MKN&'1OB 3(H^6'5E'SQ^@D ZC_:'X@\FO.K85KWH&L9]SOZ*MW5@888[JWE2 MZLIE#PW,+!D=3T.152N$U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "I[+_C_ +?_ *ZK_.H*GLO^/^W_ .NJ_P Z M /"?C-_R5[7/]^+_ -$I7#5W/QF_Y*]KG^_%_P"B4KAJ]RG\$?0YGN%%%%:" M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** /5O@?X\_L'7CX?U.7&FZFX$98\0S] ?HW /OM]Z^ MC64JQ![5\.@E2"#@CD$=J^L/A9XS_P"$T\%Q2W,F_4[#$%YD\OQ\LG_ @/S# M5YV+I6]]&M.70[&BBBN U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** +]%%% !1110 4444 4I/]8WU--ITG^L;ZFFT %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !2J"S #O25#?W8T_3I)_^6C?)&/?UH P_$5\)[P6T1_=0 M<'W;O_A^=8]!))))R3U)HH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I+?_CZB_P!\ M?SJ.I+?_ (^HO]\?SH \/^-G_)8=;_[8?^D\=<'7>?&S_DL.M_\ ;#_TGCK@ MZ]RE_#CZ(YI;L****T$%%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %=3\._&$O@GQC;:EEC:.? M)NXQ_'$QYX[D?>'N*Y:BE**DK,-C[B#1R(DL#AXI%#HZG(93R"**\Q^!7B[^ MW?"#Z'=R;KW2 !'D\O ?N_\ ?)^7Z;:].KPYP<).+.E.ZN%%%%0,**** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"_1110 4444 %%%% $=Q!% M=6TMO<()(I4*.AZ,I&"/RHMX(K6VBM[=!'%$@1$'15 P!^54/$SM'X3U=XV9 M'6QF*LIP01&>0:/#+M)X3TAY&9W:QA+,QR23&.2:?074TZ***0PHHHH **** M *4G^L;ZFFTZ3_6-]33: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I54LP [TEM5&+D[(3=CQ3XW>,O\ A(_& M)TRREW:?I.84VGB27^-O?D;1]#ZUYI2DEB23DGDD]Z2O;A%0BHHYV[NX4445 M8@HHHH **** .T\"?$W6/!$OD+_I^DR$^;I\S?+SU*'G:?T/<'C'N^CZAHWC M+3#J7A.Y\W: 9[%R!- 3V*_GZ@X.":^5*O:/K6I>']3CU#1KR6SNH_NR1GMZ M$="/8\&N:MAXU-5HRXS:/IL@@D$8(Z@TE87@[XGZ-XY$=CKODZ1KIPJ29Q#= M'H ,]&)_A/M@GH.DN[.>QF,5RA1NQ['W!KRYPE!VD;)I[$%%%%0,**** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I[+_C_ +?_ *ZK M_.H*GLO^/^W_ .NJ_P Z /"?C-_R5[7/]^+_ -$I7#5W/QF_Y*]KG^_%_P"B M4KAJ]RG\$?0YGN%%%%:""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NO^&7C)_!?C2WO9&/V& M?]Q>)V,9/WL>JGG\QWKD**F45)68+0^XSM.&C8,C#+O\ MA(_!7]EW$_.N#KW*7\./HCFENPHHHK004444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 ='X"\4R>#_ !I8ZLI/DH_EW*C^.)N&'Y.10Z,IR&!Y!%?#E?3_P2\4_\)#X"73[B3=>:.1 V3RT)_U9_ K_P !KAQ= M.Z4T:4WT/0Z***\TV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH OT444 %%%% !1110!%=VL5]93VERN^&>-HY%R1E6&",CV-%I:Q6-E!:6 MR[(8(UCC7).%48 R?852\1S26WA;59X':.6*RF='4X*L$)!%'AR:2Y\+:5/. M[22RV4+N[')9B@))I]!=32HHHI#"BBB@ HHHH I2?ZQOJ:;3I/\ 6-]33: " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@!57

MEY"QW1.9[8?7JZC\QVSP*\IHJ)PC-6D--K8^LC;076GQZGHMU'J&FS#*7$)R M!['T(Z'T/7%5:^?/!GCS6O!&H>?I,^ZV<_O[.7F*8>X['_:'/X<5[[X:\2:% MX_LC/H,BVFIHFZ?2Y6&Y?4H?XESW'J,XZ5Y=;#RIZK5&T9)DU%.DC>*1DD4J MZG!4C!%-KF+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MI[+_ (_[?_KJO\Z@J>R_X_[?_KJO\Z /"?C-_P E>US_ 'XO_1*5PU=S\9O^ M2O:Y_OQ?^B4KAJ]RG\$?0YGN%%%%:""BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#J?AQ MXK;P=XXL=29RMJS>3=@?Q1,<'\N&^JBOKMMN6CQ^[;\N/JIK@Q=/131K3?0[RBBBO.-0HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** +]%%% !1110 4444 4I/]8W MU--ITG^L;ZFFT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%.5EC#2R<)&I9C]* ,'Q/=9E MBLT/$8W/_O'_ .M_.L&I;F=KFZDFD^](Q8^U14 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 5);_\ 'U%_OC^=1U);_P#'U%_OC^= 'A_QL_Y+#K?_ &P_])XZ MX.N\^-G_ "6'6_\ MA_Z3QUP=>Y2_AQ]$/G(VG\&V\^F:X2E5BK!E)!! MR".U3**E%Q8)V9]QLNUB/2FUA>!_$0\5^!M,U(1W/M*ORM^9&?H16[7 MA-.+LSJ"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7Z*** M"BBB@ HHHH @OK./4-/N;*?<(KF)HGVG!VL"#C\Z+&SCT_3[:R@W&*VB6)-Q MR=J@ 9_*JVOW,MGX:U.ZMGV30VDLD;X!VL$)!Y]Q1H%S+>>&M,NKE]\TUI%) M(^ -S% 2>/MY,P:;'YDP!ZS.,\_1SO;G3KR*[L+B M2VN(6W1RQ,59#Z@BH** />?!?Q@T_P 11Q:7XZ:.RO@H6+55 6.0^D@Z*??[ MO7[O?N;[3I["0"491ON2+RK#V-?)M>A^ ?BWJ/A2-=,U=&U70S@&W=OG@'K& M3_Z">/3;R:X*V%OK#[C2,^Y[+15BT;3M?TH:MX6O%O[(_?5?]9">NUEZ@_7G M\.:KUY[33LS8****0!1110 4444 %%%% !1110 4444 %%%% !1110 5/9?\ M?]O_ -=5_G4%3V7_ !_V_P#UU7^= 'A/QF_Y*]KG^_%_Z)2N&KN?C-_R5[7/ M]^+_ -$I7#5[E/X(^AS/<****T$%%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7H?P3\2 M_P#"/_$2WMYWVVFJ+]DER> Q^X?^^L#Z,:\\ITKX&2 .]'_&S_DL.M_] ML/\ TGCK@Z[SXV?\EAUO_MA_Z3QUP=>Y2_AQ]$VZD]QA7_P#9/R->WU\@_#[Q M!_PB_CW2M49]D,5BH#T&4445R% MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!?HHHH **** "BBB@"M MJ-DNI:7=6,C,B7,+PLR]0&4C(_.C3K)=-TNUL8V9TMH4A5FZD*H&3^51:Y=R MV'A[4;RW($MO:RRH2,CHHHI#"BBB@ HHHH I2?ZQOJ:;3I/]8WU--H **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\S M^/7B#^RO ,6E1/MGU:<*PSSY289OUV#Z$UZ:!E@!WKYD^.NO?VO\2)K.-\V^ MEQ+;(!TW?><_7)Q_P&NC#0YJB\B)NR/-Z***]@P"BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH V/#7BK6/".JK?Z%=M;R9&].J2K_==>A'ZCM@\U M] >$O'6A?$.-8E\O2=?P=UF[?)<$F75@8H([JVECN[*90T-S"P9'4]#D5Y52E*F[2-U)/ M8J4445F,**** "BBB@ HHHH **** "BBB@ HHHH *GLO^/\ M_\ KJO\Z@J> MR_X_[?\ ZZK_ #H \)^,W_)7M<_WXO\ T2E<-7<_&;_DKVN?[\7_ *)2N&KW M*?P1]#F>X4445H(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#WG]G37_,L]7\.S M/S&1>VZD]CA7_P#9/S->TU\D?#/Q!_PC7Q$TJ^=]L#3>1/Z>6_RDGZ9#?A7U MS(NV0BO)Q4.6I?N;P=T-HHHKE+"BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@"_1110 4444 %%%% %*3_ %C?4TVG2?ZQOJ:;0 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 ]&5-TC\+&I8GV%<-/*T]Q)*_WI&+'\:ZO6)OL^B3$<-*1&/Z_IFN0H M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *DM_P#CZB_WQ_.HZDM_^/J+ M_?'\Z /#_C9_R6'6_P#MA_Z3QUP==Y\;/^2PZW_VP_\ 2>.N#KW*7\./HCFE MNPHHHK004444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !7V'X"UK_A(?AYHNI,VZ5K M813'OO3Y&)^I4G\:^/*^@_V=M9^T^'=6T61LM:3KKDQ< M;T[]BZ;U/7Z***\HW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"_ M1110 4444 %%%% %75;+^T]'O+#S/*^U0/#OVYV[E(SCOC-&E67]F:/9V'F> M;]E@2'?MQNVJ!G';.*9K-Z^G:#?WT*JTEM;23(K="54D ^W%&C7KZCH-A?3* MJR7-M',ZKT!902![J75_= M'=-=3/-(?5F))_4U]._&K6/[)^%EY&C;9=1E2U3UP3N;_P =4C\:^6:]+!QM M%R,:CUL%%%%=QF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %=EX%^)FL^")O)B/V[2I#^]T^=OD/J5/.P_H>X/%<;14RBI*S!.Q]5:-J6 MC>,]-.H^$[GS"H!GL9.)H">Q'IUYY!QP32$%201@C@@]J^8](UG4= U*/4-' MO);.ZB/RR1G'X$="/4'@U[YX-^*&C^.!'8>(/)TC7"0L,'V MP3G \RMAG#6.J-HSON;]%3W=E/8S>5

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੯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rprx-20201231_g3.jpg begin 644 rprx-20201231_g3.jpg M_]C_X 02D9)1@ ! 0$!( $@ #_X1#R17AI9@ 34T *@ @ ! $[ ( M - (2H=I 0 ! (6)R= $ : 0T.H< < @, /@ M &UL;G,Z9&,](FAT=' Z M+R]P=7)L+F]R9R]D8R]E;&5M96YT#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@ M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8 M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4 M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ_\ $0@#K0A3 P$B (1 0,1 ?_$ !\ $% 0$! 0$! M ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $ M$042(3%!!A-180'EZ@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! M @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$' M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F MY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHK+\3:];>%_"^HZY?KZEI=C>)->Z6\:7D*@YA+KN3.1@Y'<9Z$=016C7QS\&OB!>:/ M\<);GQ XC&OS26]^9LKY@"ALD^PK0DU MS28M632Y=4LTU"092S:X03,.N0F!6?I7BKP_KLSQ:'KNF:E(@RR6=Y',5'N%)QT- &K16;J_B/0_#_D_V]K. MGZ9Y^[ROMMTD/F;<9V[B,XR,X]15;3_&OA75[^.QTKQ+H]]=RY\NWMK^*21\ M DX56). "?H* -NBL6;QEX8M]5.F7'B/2(K\2"(VCWT2R[ST786SDY'&*U;J M[M[&U>YO9XK>",9>65PBJ/,/#.JWWV+3/$6DWEV,_N+>^CDDX.#\H8GK5CQ#_R+.J?]>;-\':YX*\7>%8K;PQ_9\VGF%0^FB- 81@?*\7;' Z8]" M: -^UUK3;ZZ2WLKZ"YDD@^T((7#AH]VW=D<8SD?@?0U>KS;P9\-K7P)\4]:O M-"MVAT?5+"-TC&2L$HD.] ?0@A@,]R.@%P:9 9K:WNXY M)(PJ(K;E4DC!(!ST)K?U37M'T.,2:WJMCIR-T:[N4B!_%B* +]%4=*US2==@ M:;1-4LM1B0X:2SN$E4'W*D^AKC?BM\5M+^'&@O\ .ESK5PI6TLE89!Q_K']% M'Z]!W( /0**\D^!/C;3=1^']C!K'B&PDU^]O+F62VENHQ<2.\S-GR\YYSD # MITKN8OB%X+GF2*'Q?H,DDC!41-3A)8G@ #=R: .BHK%U+QGX7T:^:SU?Q)I% MA=( 6@NKZ*)U!&1E68'D5I6-_9ZI8QWFF7<%Y:RC,<]O()$<9QPPR#R* +%% M9-UXK\.V.I+IU]KVEVU\W2UFO(TE/_ 2<]C^5:-O=V]V)#:SQ3"*1HI#&X;8 MZG!4XZ$=QVH EHHJKJ.IV&D6;7>K7UM8VRG!FN9EC0?\"8@4 6J*SM)\0Z+K MR.^AZO8:DL9P[6=RDP4^AVDXZBL_QQXDM/#/A'4;NXU*SL;HVDWV/[5<+%YL MPC)55R>3G' R: (-;^)/A+P]J$]CJ6KK]KMHC-<06T$ER]N@&2T@B5B@ (.6 MQU'J*UM!\0Z3XGTI-2T"_AO[-V*B6%LX8=01U!]CSS7R;\!;G3-0\0>*;'Q1 MK,5D-5P#M+GYG.2>Y)KZ(^%/POM_A?HEW91:I+J4UY,)99 M6B\I1@8 5,G''4Y.: -CQ=\0?#'@3['_ ,)7J?V#[;O^S_Z/++OV;=WW%;&- MZ]<=:YK_ (:#^&/_ $,W_DA<_P#QNM3Q?X"MO&'CSPMJ&K6Z7&FZ+'=S/$^" MLDSF$1*R]Q\KMZ90 \&O//VJHTA^'>B1Q(J1IJ05448"@1/@ =A0!U__ T' M\,?^AF_\D+G_ .-UTOA'X@^&/'?VS_A%-3^W_8MGVC_1Y8MF_=M^^JYSL;IG MI7EG[*:J_P /=:5P&5M3(((R"/*2O0/!_@2'PA\0/%=]I=HEMI>LQVS6[TF^MKZV8X$UM,LB'_@2DB@"U17G_P 5OBMI?PXT%_G2YUJX4K:6 M2L,@X_UC^BC]>@[D8GP)\;:;J/P_L8-8\0V$FOWMYE>*O#^NS/%H>N MZ9J4B#+)9WDX4G'0T -\2>*=)\(Z8=1U^:>WLPT56F'V>6+8&SC[ZC/0]*H?&+_DCGB;_KQ;^8 MKQK]DG_D*>*/^N-M_P"A24 ?35%%>*?M"?%:Y\':;!X>\.W+V^LWRB62XC(W M6\.<<>C,00#V /M0!Z)XD^)'@_PC(T?B'7[2TF4 F $R2@$X!V("W4'M531/ MB[X"\0W @TOQ/9-*PRJ7!:W9N<8 D"Y/L.:\[_9_^%NFQ^&H/&?B.VBU#5M2 M9IK9KC]YY";N&Y)!=B-V[J 0..:]BUOPUHOB33?L&NZ7:WUKMVK'-&#L_P!T M]5/ Y&.E %BTU:QOK^]LK.Y2:XL'5+E%Y\IF7< 3TS@@X]ZN5YM\)? ;_#V_ M\4Z5$)FT^2]CFLII1]^,Q],X )4Y4X]/>NZU37M'T.,2:WJMCIR-T:[N4B!_ M%B* +]%4=*US2==@:;1-4LM1B0X:2SN$E4'W*D^AJ:]O[/3+-[K4KJ"TMHQE MYIY!&BCU+'@4 6*Y?Q9\1O"_@>X@B\4ZA+8&X7=$YLIY$?G! =$*Y'=@#V#PUXHT?QAHJZMX=O/MED[LBR^4\>67@C#@']*UJ\;_9[U2PT? MX%P7NKWUM86J7LP:>ZF6)%)< 99B ,GBO6[#4;+5;-+O2[RWO;:3[D]M*LB- M]&4D&@"S7,^)_B'X;\&.!XENKJR0XQ,=.N'B)/0"1(RA/MG-=-7GWQVB27X( M^(UD&0(HF'/<3(1^H% %?_AH/X8_]#-_Y(7/_P ;KH/#_P 3?!GBBZBMM#\1 MV5S"_LGJK^)/$2N RM91@@C((WFM?]I?X>6%G MI-KXRT&SCM+F*X$5^;=0@<-]R4@?Q!AC(Y.\9Z4 ?1E%>,_LY_$:[\7^%[G1 MM;GDN-2TC9MN)#DS0-D+D]2RE2"3U!7DG->N:CJ=AI%FUWJU];6-LIP9KF98 MT'_ F(% %JBJ6EZUI>N6QN-$U*SU&!6VF6TG650?3*DC-9ESX^\'V=U+:WGB MS0X+B%S'+%+J4*O&P."K MD$$8(- '045BW/C+PQ9&V%YXCTBW-U&LMN);Z) M?.1N59EMHMEOXC(3C.-N[.<5KW-S!9VLMU>31P6\*&2665PJ1J!D MLQ/ R2: )**YO_ (6/X(_Z'+P__P"#2#_XJK^H^*O#VD6]K/JVNZ98PWBE M[:2YO(XUG4 '*%B-PPR\CU'K0!JT55TW5+#6+%+W2+ZVO[5R0L]K,LJ,0<'# M*2#@\52E\6^&[?51ID_B#2XK\ML%H][&)2WIL)SGVQ0!KTV1Q%$TC!B%4L0J MECQZ I^)] T6YCM]8US3=/GE_P!7%=7<<3/TZ!B">H_.@#E+CXX_ M#ZSU)M.O-;FMKU7$;6\^F74;JQ[$-$"#SWKOZ^+OC:RO^T5JC(0RM-9$$'(( M^SPU]HT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %(S*BEG(55&22< "EKS#X_>+9/#/ MPQNK6Q#-J&L;K2()]Y(]I:63 YP$!&>Q8$\4 =_H6NZ;XET2VU?0[I;NPNE+ M0S*I 8 D'@@$$$$$$9R*T*^=/V5O&(DLM3\(73\S \2+U[$*PP/ MXFKZ+H **YO_ (6/X(_Z'+P__P"#2#_XJKMSXM\-V6I_V;>>(-+M[[./LLM[ M&LN?]PG/Z4 :]%07E[:Z=9RW>H7,-K;0KNDFGD"(@]2QX K)LO'/A+4KV*ST M[Q1HMW=3-MC@@U")W<^@4-DF@#=HK(LO%OAO4M0^PZ=X@TN[O,9^SP7L;R8X MYV@Y[C\ZN:GJVG:+9&\UB_M=/M0P4SW4RQ(">@W,0,T 6Z*RM)\5>'M>N'@T M+7=,U*:-=[QV=Y',RKG&2%)P,GK4]AKFDZK--#I>J6=[+;G$R6UPDC1GT8*3 MC\: +U%4=5US2="@6;6]4LM.BHIVF:QIFM6OVG1M1M-0M\ MX\VTG65,].JDCM0!TNXY1"#G!8J3M'RGKZ'TH U**Q]+\7>& M]QRN%'4[58G'(Y]ZNZCJNG:/;&XU:_M;& =9;F98U M'XL0* +=<]XJ\=>'_!,$4_B:ZGLX)3A9Q93RQY]"Z(R@\'@D$U>TGQ+H6O,Z MZ'K6G:D8QEQ9W:3;?KM)QU%>OX+"T0X,L[X!/8#N3P>!S7,:3\9_A[K>I"PL/$]J;AFVJ)TD M@5CZ!I%523VP>:\5^+7BR&W_ &E--A\7K--XZ/#H&:0+_&-Q&>, MD(1VKZ!^S^$O'WA@0(NFZUI$B!56(JZ*.P&/N$8[8(QVQ0!KV>I6>HR726-P MD[6DPAGV'(1RBOC/?Y74\>M6J\^^%'@[_A7>C^)-)D9EL8]:EN+6>;@-;M!" M023P=O*D],HU>:>,/C=8^(/BQX^M4N;*>*X@D&4EB<.K#V(X M->"?'WXSV^GZ=<^#_"MT);^X4QW]U$P*P1D-_ M"DNB">+Q/HSPV<$9N9%U"(K #A1O.[YYQ5S3/&'AG6KP6FC>(M)U"Y* MEA#:7T"_.\K_A+M!\S=MV?VG#G/3&-W6NA9E12S MD*JC)). !0 M%8]OXP\-7EQ/!:>(=*GFMPS31Q7L;-$%R6+ -QC!SGI@UK1R M)-$LD3J\;J&5U.0P/0@]Q0 ZBBL[5O$.BZ"B/KFKV&FK(<(UYA MH T:1F5%+.0JJ,DDX %5M.U.PU>S6[TF^MKZV8X$UM,LB'_@2DBO(OVD_%<. MG_#B;1]/U>VBU&ZN(DN+1+H+/]G(8D[ =VTD*#G@@F@#L9_C#X#MF_>>((S# MYWV?[7';RO;>9C.SSU0QYQSC=TYKLX9HKFWCGMY$EAE4/')&P974C(((Z@CO M7R_\,O">C_$OX&KX/F\16^FZI'K+W\,*LDDN%C"Y,6X,5P[<@CG'I@_1GA3P M[;^$O"FGZ%9S2SPV,(B668Y9NY)_$].W2@# \0_&+P)X5UZXT;7M=^R:A;;? M-A^QSOMW*''S*A!^5@>#WK,_X:#^&/\ T,W_ )(7/_QNM+1OA]9P_%#Q+XQU M.TBFN[V:WCL&D ;RHH[>(%U_NL7##U 08ZG/SO\ M0_\E6=QI,*20RKD$%!^1]QR.U7?ACX9N/!WP_L] M N@0UE/=*A+!B\9N96C;(X^9"IQVS@@'B@#K**QK_P 8>&=*OOL6I^(M)L[L MX_<7%]'')R<#Y2P/6M>.1)HEDB=7C=0RNIR&!Z$'N* '45XC\=OC/;^&--N/ M#/AJZ$FN7";)YHF!%DAZ@G_GH1D =1G/'&?0/A[XFT'5?"NC:?I>MZ=>WL&F M0&:VM[N.22,*B*VY5)(P2 <]": .NHJAJFO:/H<8DUO5;'3D;HUW%O!-U'!XHOY[!I1F-VL M+AXW]0KJA4D=P#D9YK6\.>)=)\6Z'%J_A^[^UV,S,J2^6\>2I(/# 'J#VKQ7 M]K'_ )%+0/\ K^?_ -%UUO[.?_)$=*_Z[7'_ *.:@#U&BBOF#]HGXMWLNN2^ M#O#=Y+;6MH-NHS0MM,\AP?+R.=JCKSR201QR >U:W\8? /AVZ-OJGB:T68'# M);J]P5/OY:MC\:T/#OQ%\(^+&5/#_B"RNYF&1!YFR4CU\ML-^E8/PJ^$^C^ M/#MH\]C;S:_)$&O+UEWLKGDHA.=JC./EQNV@GVW/&GP\\.^/-*EM-=T^)IF4 MB*]1 )X#V*OC/8<'@XY!H V]*U>PUS3Q?:3[B?H89!'()%=;9ZUI>HM"-/U*SNC/$9H1!.K^9&"H+K@ M\J"R\CCYAZBODW]J'_DKD/\ V"X?_0Y* /KNWN([JUBN+=M\4R!T;!&5(R#@ M^U25SEEXCT30_#VBQ:UK.GZ=)<6<7DI=W21&3"+G:&(SU'3UKHE974,A#*PR M"#D$4 +7#ZS\9/ _AV^-GKVJ76GW SB.YTJ[0L <9&8N1[CBNXKYU_:VB0Z; MX7E(^=9;E0<] 1'G^0H ]#7]H'X8NX4>)QEC@9L;D#\S'Q77Z!XN\/>*DE;P M[K-GJ/DX\Q;>8,T>>A9>H!P<9'.*\X_9SM+>]^"4$%Y!%<0M=W :.5 RD$X. M0?8UXS\9_#4WPI^*MOJG@]Y-+MKQ!=VAMVP(9 V)(P/[N<':>,/CH,4 ?8M% MKV&G!QE3 M>7*1;AG'&XCU% &C151-6TZ72#JL5_:OIPB,QO%F4P^6!DOOSC: "/O!]Y=16MGXLT.>XF<1Q11:E"SR,3@*H#9)). !0!T%5=2U=.EOKP3F& M$ N+>WDG?!('"1JS'KS@<#)/ -4HO%OANXU4Z9!X@TN6_#;#:)>QF4-Z; 'M;^UWTJLR1?9)X\A1D\N@'0>M=I7Q?^SC_P E MLTS_ *X7'_HIJ^S9IHK>%I;B1(HT&6=V"A1[DT /HK(TOQ=X;UNZ^S:+X@TK M4)\9\JTO8Y6Q]%)/:K.JZWI6@VJW6N:G9Z;;NXC66\N%A1F()"@L0,X!./8T M 7J*P;3QWX0O[R*TL?%6B7-S,P2*&'487=V/0!0V2?84_4/&OA72+^2QU7Q+ MH]C=Q8\RWN;^*.1,@$95F!&00?H: -NBF--$D!G>1%B5=YD+ *%QG.?3'>LW M3?%/A_6;Q[71]=TR_N8P2\-K>1RNH]U4DB@#5JEJ^KVNAZ;)?7XN/L\?WS;V MLMPRCUVQJS8]3C [U=K*B\4^'Y]7.E0:[ILFH@X-FEY&9AQG[@.>GM0!@>'/ MB[X'\6ZW%I'A[6_M=]*K,D7V2>/(49/+H!T'K7:5\7_LX_\ );-,_P"N%Q_Z M*:OM"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X7Q$XUCEM;=_[8U7Y?B@#R/]HSPB_ACXGOJUH@AM-:'VJ(QY&V9<"7\2Q#_\#KZ;^&?B MX>./AWI6MN\;7,L7EW:QD?+,OROQ_#DC+^\6W9-.LK=X(YF7B29\#:OKA=V2.F0.]< MW^T=_P ELU/_ *X6_P#Z*6@#U?XX_"_PQH_P*-UPWDA0$8]QDEB!Z$'O0!X1K<-RG[3-Q;Z-*EE M(Q%!(%&V-WF #8QZG->VW'[/,5G\4M!\1^'-2-O86O-%]G7Q,-\ID 15\X L6Z #DGZ5]HT ?*OQ M?\4W?C+X\:;X.=G_ +'L]1MK,VRN0L[NR;V8=,_-M'H!GN:[/]I^PAT[P/X? MU735%E=Z?J*VUM);_NVAC:)SM4KC 'E+TZ8XQ7%_%SPU<^#/V@=)\73J1HU[ MJ5K=_:F4E(I$=?,1B._R%_<'C.#79?M1:@E_X1\/Z+IQ%W>7VH"YAA@'F/(B MQNH*@HX];1'U*6W>#[05&5N8CA90>,;BJE@,#YF7I M7CO[.NO?\(E\6Y]!U:W2*34E>Q9WQNAG0DA=WH2I7 ZDKZ5]"_![PC=^"?AA MIFE:GQ?-NN+B,'(C=SNV?4# /7D'!QBO#?CCX U/3_C5I6J>&4*2>(+F(V[A M<+#>!E4Y.,#/ROD]RW84 >Z:9I=CXA^)^H^)7MD8:/&-*M)"H^:7.^=^F>,I M&#V*R>HK@_C-X,\=Z_\ $'1-6T5[270--$=PR75RJ6]M)&Y9I9HV8;@0<97^ M$$''4^P^']&B\/>'K+2K>1I5M8@K2O\ >E?JSGW9B6/N:^8_VC?&6IW'Q)C\ M,:B;F'P]9""5X(@4^UA@&9\_Q8Y4=@5/?- %']HWQ)HVO>,M(U+PO<^>T$#1 M/?P(RH[I(<;), /M)/S*2.1S7T=I-__ VO MZ=JW[/MI/9S-Y5EHHLYGEC:-1+' %< L & /&X9&]?$CQCJG@SXP>'[O3],O=5LI-,G&HVEC 99/)#@^ M8!VVG!R<#&1D9S76VOQ;\!7>G&\'BK3857[T5Q.(IE/<&-L/G\* /-_@1\;; MSQ9J"^%?%KB74C&6LKP+@W 5.=!L)K/PO;37$EC* MT?E).\@:/"*?X?FSZ9 )KFWM(XY) R(S;F4 G) )SU(KRSP M3I/BCX>_$K7O%7Q2O["#3[N-XDOI[D2O3NKY_^'7Q#MM2^-Q\ M1?$V2>ZG,;K91I;O*+>Y+*(T2( DDZ;;Z/I&IV^GVL5_=7C+/=I"JRS M1X 9P,L ,GL*\QLM;MM$_:9GUC68Y[*WC\07$LR/$6DB#2OU5P?M46EQ>> =&O[:WE>V@O5R>.1U('4B@#3_9X\-:%-\+- M(UB;1=.DU19YRM\]HAG!$K 8DQNX''6O$OB7&D7[3%ZL2*BG5;9B%&.2(R3] M223^->N_LY^.--E\$Z9X2LX[BXU6&:=[E5B(2WA+,XE9^F"2% '.X] .:\J^ M-EM/X>_:$N=2OX)1:RW%M>1.%_UL:JF[;SSAE9?J* .W_:X50WA%@!N(O 3C MDC]Q_B:]#^%[W\?[-=@^C+OU%=+N3:*03F7=)L''/WL5XC^T+\1-'\?W6@GP MV)Y["Q6<&]>)XTDD?RRT:A@#E JD_P"^/J?;?A5JAT[]FVQU&R,4LMCIUS*J ML=R[T:1L-@^HY'% '@_PF^*UAX3DU30_'&F+J.DZS.7OKB2(23*YX)D#6^ M,O!?@?XM^!+WQYX8NH-+U:&V-S=@2*%WA2S1SKG"L>F_C/4YK9_9,L4W'\NPKZNKY2M/#TOPT_:NL)M5(@TR]OIY;.[E!$;I,CJ M%W>JM(%.>^#T(H W?VG9KCPWXL\)^)-#N'L=4:.>,W$)PQ$31LH/8C]XW!'/ M0Y%>H:G/I?C_ .")U[5=*L[AYM&DNXTG@67[/-Y)R4+ X(;.".>*\L_:;2Y\ M3>,O"WAG0H&OM2CBFV* /G_]F'1],UCQUJBZMIUI?""Q$L(N8%D\MQ*F M&7<#@^XYKZXKY0_93GBC^(.K1R2HLDNFD1HS %\2(3@=^.:^KZ "O"?VKO\ MDG^C_P#84'_HIZ]VKP3]J^Z@'@O1K3S4^T'4/-\K/S;/+<;L>F3B@"7]E'_D MG^L?]A0_^BDKVC7-5CT+P]J.KW"EXK"UEN74=2J(6(_(5XE^RA=P-X,UNT$R M&Y34!*T6[Y@C1J V/0E2/PKVW7-*CUWP]J.D7#%(K^UEMG8#D*Z%2?R- 'S= M^S]>W7CKXR:UXH\28O;R&S9XFD^9;=GD C!R5 7)9_AA^TQ M)JVD2-!:W0@FU"VC)"3HPQ(".A)P6!QPQS];?[/%G=>"OBYKWAGQ$JV=^UIL M2.3(\UE<$%#T(*DD>HZ5G?$3PY=?%3]I*YTK0U,UI;""&[NXON0QA 78MR 0 M2RCU88H Z7]JO2=-M]'TC4[?3[6*_NKQEGNTA599@(\ ,X&6 &3V%=+^SQ MX:T*;X6:1K$VBZ=)JBSSE;Y[1#.")6 Q)C=P..M9W[5EC=3^!=(NX('DM[6^ M/GR*,B/IW-@OA73I4D2ZOKM5M[.$H(W78[ K(> M3N QN*G/&!Y%\8?%5M)\9O\ A)O!EQ+ ?*@G@O%A:+S'"X\Q0X&Y3@#.,-@] M16M\1/'+:M\?TM?'8G'AK1=4\K[ 8SL\M&QYA3^+=]XGDE3@<8%8OQ]U2#6O MB6-0L;>XALY["!K9IX3$98\$!U4\A3VR >.G2@#ZB^,7_)'/$W_7BW\Q7C7[ M)/\ R%/%'_7&V_\ 0I*]3^).OZ=K_P"S_K6KZ;,QL[VP9H'FC:(ODX'RN >< M<<@R/S% 'TY7Q;^T8+@?&[53< M,3&8;

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end GRAPHIC 15 rprx-20201231_g4.jpg begin 644 rprx-20201231_g4.jpg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end XML 16 rprx-20201231_htm.xml IDEA: XBRL DOCUMENT 0001802768 2020-01-01 2020-12-31 0001802768 2020-06-30 0001802768 us-gaap:CommonClassAMember 2021-02-19 0001802768 us-gaap:CommonClassBMember 2021-02-19 0001802768 rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember 2020-11-01 2020-11-30 0001802768 2020-12-31 0001802768 2019-12-31 0001802768 us-gaap:CommonClassAMember 2020-12-31 0001802768 us-gaap:CommonClassAMember 2019-12-31 0001802768 us-gaap:CommonClassBMember 2019-12-31 0001802768 us-gaap:CommonClassBMember 2020-12-31 0001802768 rprx:ClassRRedeemableStockMember 2020-12-31 0001802768 rprx:ClassRRedeemableStockMember 2019-12-31 0001802768 rprx:FinancialRoyaltyAssetsMember 2020-01-01 2020-12-31 0001802768 rprx:FinancialRoyaltyAssetsMember 2019-01-01 2019-12-31 0001802768 rprx:FinancialRoyaltyAssetsMember 2018-01-01 2018-12-31 0001802768 rprx:IntangibleRoyaltyAssetsMember 2020-01-01 2020-12-31 0001802768 rprx:IntangibleRoyaltyAssetsMember 2019-01-01 2019-12-31 0001802768 rprx:IntangibleRoyaltyAssetsMember 2018-01-01 2018-12-31 0001802768 rprx:RoyaltyIncomeOtherMember 2020-01-01 2020-12-31 0001802768 rprx:RoyaltyIncomeOtherMember 2019-01-01 2019-12-31 0001802768 rprx:RoyaltyIncomeOtherMember 2018-01-01 2018-12-31 0001802768 2019-01-01 2019-12-31 0001802768 2018-01-01 2018-12-31 0001802768 rprx:UnitholdersContributionsMember 2017-12-31 0001802768 us-gaap:RetainedEarningsMember 2017-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2017-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2017-12-31 0001802768 us-gaap:TreasuryStockMember 2017-12-31 0001802768 2017-12-31 0001802768 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0001802768 2017-01-01 2017-12-31 0001802768 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2017-12-31 0001802768 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2017-12-31 0001802768 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2017-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0001802768 rprx:UnitholdersContributionsMember 2018-12-31 0001802768 us-gaap:RetainedEarningsMember 2018-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2018-12-31 0001802768 us-gaap:TreasuryStockMember 2018-12-31 0001802768 2018-12-31 0001802768 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-12-31 0001802768 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0001802768 rprx:UnitholdersContributionsMember 2019-12-31 0001802768 us-gaap:RetainedEarningsMember 2019-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2019-12-31 0001802768 us-gaap:TreasuryStockMember 2019-12-31 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2019-12-31 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2019-12-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2019-12-31 0001802768 rprx:DeferredSharesMember 2019-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001802768 rprx:ShareholdersContributionsMember 2020-01-01 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001802768 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0001802768 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001802768 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001802768 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-17 0001802768 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-06-17 0001802768 2020-01-01 2020-06-17 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001802768 rprx:DeferredSharesMember 2020-01-01 2020-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-12-31 0001802768 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0001802768 us-gaap:RetainedEarningsMember 2020-06-18 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2020-06-18 2020-12-31 0001802768 2020-06-18 2020-12-31 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-12-31 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2020-12-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2020-12-31 0001802768 rprx:DeferredSharesMember 2020-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001802768 rprx:ShareholdersContributionsMember 2020-12-31 0001802768 us-gaap:RetainedEarningsMember 2020-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2020-12-31 0001802768 us-gaap:TreasuryStockMember 2020-12-31 0001802768 rprx:ExchangeOfferTransactionMember rprx:LegacyInvestorsPartnershipsMember 2020-02-11 2020-02-11 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember rprx:ExchangeOfferTransactionMember 2020-02-11 0001802768 rprx:RoyaltyPharmaCollectionTrustMember 2020-02-11 0001802768 rprx:RoyaltyPharmaCollectionTrustMember rprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember 2020-02-11 0001802768 rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member us-gaap:SecuredDebtMember rprx:LegacyInvestorsPartnershipsMember 2020-02-11 0001802768 rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member us-gaap:SecuredDebtMember rprx:RPI2019IntermediateFinanceMember 2020-02-11 0001802768 rprx:OldCreditFacilityMember us-gaap:SecuredDebtMember 2020-02-11 2020-02-11 0001802768 rprx:RPIFTSeniorSecuredCreditFacilitiesMember us-gaap:SecuredDebtMember rprx:RPI2019IntermediateFinanceMember 2020-02-11 2020-02-11 0001802768 us-gaap:CommonClassAMember us-gaap:IPOMember 2020-06-18 2020-06-18 0001802768 us-gaap:CommonClassAMember us-gaap:IPOMember 2020-06-18 0001802768 us-gaap:CommonClassAMember rprx:IPOSharesFromCompanyMember 2020-06-18 2020-06-18 0001802768 us-gaap:CommonClassAMember rprx:IPOSharesFromSellingShareholdersMember 2020-06-18 2020-06-18 0001802768 us-gaap:IPOMember 2020-06-18 2020-06-18 0001802768 us-gaap:CommonClassAMember 2020-06-01 2020-06-30 0001802768 us-gaap:CommonClassBMember rprx:IPOContinuingInvestorsPartnershipsMember 2020-06-01 2020-06-30 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember rprx:LegacyInvestorsPartnershipsMember 2020-02-29 0001802768 rprx:RPHoldingsMember rprx:ContinuingInvestorsPartnershipMember 2020-12-31 0001802768 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2019-12-31 0001802768 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2019-01-01 2019-12-31 0001802768 rprx:VertexMember us-gaap:FinanceReceivablesMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001802768 rprx:VertexMember us-gaap:FinanceReceivablesMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2020-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2020-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2020-12-31 0001802768 rprx:ImmunomedicsMember 2020-01-01 2020-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2019-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2019-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateSwapMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateSwapMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateSwapMember 2019-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateSwapMember 2019-12-31 0001802768 us-gaap:AvailableforsaleSecuritiesMember 2019-12-31 0001802768 us-gaap:AvailableforsaleSecuritiesMember 2018-12-31 0001802768 us-gaap:AvailableforsaleSecuritiesMember 2020-01-01 2020-12-31 0001802768 us-gaap:AvailableforsaleSecuritiesMember 2019-01-01 2019-12-31 0001802768 us-gaap:AvailableforsaleSecuritiesMember 2020-12-31 0001802768 us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-01-01 2020-12-31 0001802768 us-gaap:ForwardContractsMember 2019-12-31 0001802768 us-gaap:ForwardContractsMember 2020-01-01 2020-12-31 0001802768 us-gaap:ForwardContractsMember 2020-12-31 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-12-31 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member rprx:ChangeOfControlProbabilityMember rprx:ValuationTechniqueBlackDermanTroyMember 2019-12-31 0001802768 srt:MinimumMember us-gaap:FairValueInputsLevel3Member rprx:LikelihoodOfFDAApprovalMember rprx:ValuationTechniqueBlackDermanTroyMember 2019-12-31 0001802768 srt:MaximumMember us-gaap:FairValueInputsLevel3Member rprx:LikelihoodOfFDAApprovalMember rprx:ValuationTechniqueBlackDermanTroyMember 2019-12-31 0001802768 srt:MinimumMember us-gaap:FairValueInputsLevel3Member rprx:LikelihoodOfFDAApprovalAtEndOfAnyGivenQuarterBy2024Member rprx:ValuationTechniqueBlackDermanTroyMember 2019-12-31 0001802768 srt:MaximumMember us-gaap:FairValueInputsLevel3Member rprx:LikelihoodOfFDAApprovalAtEndOfAnyGivenQuarterBy2024Member rprx:ValuationTechniqueBlackDermanTroyMember 2019-12-31 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-12-31 0001802768 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001802768 srt:MaximumMember us-gaap:PreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember 2019-04-05 2019-04-05 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember 2020-01-01 2020-12-31 0001802768 rprx:InterestRateSwapDueNovember2020Member 2019-12-31 0001802768 rprx:InterestRateSwapDueMarch20231Member 2019-12-31 0001802768 rprx:InterestRateSwapDueMarch20232Member 2019-12-31 0001802768 rprx:InterestRateSwapDueMarch20233Member 2019-12-31 0001802768 rprx:InterestRateSwapDueMarch20234Member 2019-12-31 0001802768 us-gaap:InterestRateSwapMember 2020-01-01 2020-12-31 0001802768 us-gaap:InterestRateSwapMember 2019-01-01 2019-12-31 0001802768 us-gaap:InterestRateSwapMember 2018-01-01 2018-12-31 0001802768 us-gaap:InterestRateSwapMember 2019-12-31 0001802768 rprx:EpizymeIncMember 2019-11-30 0001802768 rprx:EpizymeIncMember 2019-11-01 2019-11-30 0001802768 rprx:EpizymeCommonStockWarrantMember 2019-11-30 0001802768 rprx:EpizymeIncMember rprx:EpizymeCommonStockWarrantMember 2019-11-30 0001802768 rprx:EpizymeIncMember us-gaap:PutOptionMember 2019-11-01 2019-11-30 0001802768 rprx:EpizymeIncMember us-gaap:PutOptionMember 2019-11-30 0001802768 us-gaap:ForwardContractsMember 2019-12-31 0001802768 us-gaap:WarrantMember 2020-12-31 0001802768 us-gaap:WarrantMember 2019-12-31 0001802768 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001802768 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2019-04-05 2019-04-05 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2019-04-05 0001802768 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:GainLossOnDerivativeInstrumentsMember 2020-01-01 2020-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:GainLossOnDerivativeInstrumentsMember 2019-01-01 2019-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:GainLossOnDerivativeInstrumentsMember 2018-01-01 2018-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2020-01-01 2020-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2019-01-01 2019-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2018-01-01 2018-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2018-01-01 2018-12-31 0001802768 us-gaap:WarrantMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2020-01-01 2020-12-31 0001802768 us-gaap:WarrantMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2019-01-01 2019-12-31 0001802768 us-gaap:WarrantMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2018-01-01 2018-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2020-01-01 2020-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2019-01-01 2019-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2018-01-01 2018-12-31 0001802768 us-gaap:PreferredStockMember 2020-12-31 0001802768 us-gaap:PreferredStockMember 2019-12-31 0001802768 us-gaap:SeriesAPreferredStockMember 2019-04-05 2019-04-05 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-08-07 2020-08-07 0001802768 us-gaap:SeriesBPreferredStockMember 2020-08-07 2020-08-07 0001802768 rprx:RoyaltyPharmaInvestmentFinancialTrustMember 2018-01-01 2018-12-31 0001802768 rprx:TecfideraMember rprx:RoyaltyPharmaInvestmentFinancialTrustMember 2018-12-31 0001802768 srt:MaximumMember us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember 2019-04-05 2019-04-05 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember 2019-04-05 2019-04-05 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember 2020-08-07 2020-08-07 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember 2020-08-07 2020-08-07 0001802768 rprx:CysticFibrosisFranchiseMember 2020-12-31 0001802768 rprx:TysabriMember 2020-12-31 0001802768 rprx:ImbruvicaMember 2020-12-31 0001802768 rprx:XtandiMember 2020-12-31 0001802768 rprx:PromactaMember 2020-12-31 0001802768 rprx:EvrysdiMember 2020-12-31 0001802768 rprx:OtherFinancialRoyaltyAssetMember 2020-12-31 0001802768 rprx:CysticFibrosisFranchiseMember 2019-12-31 0001802768 rprx:TysabriMember 2019-12-31 0001802768 rprx:ImbruvicaMember 2019-12-31 0001802768 rprx:XtandiMember 2019-12-31 0001802768 rprx:PromactaMember 2019-12-31 0001802768 rprx:CrysvitaMember 2019-12-31 0001802768 rprx:OtherFinancialRoyaltyAssetMember 2019-12-31 0001802768 rprx:CysticFibrosisFranchiseMember srt:MinimumMember 2019-11-01 2019-11-30 0001802768 rprx:CysticFibrosisFranchiseMember srt:MaximumMember 2019-11-01 2019-11-30 0001802768 rprx:CysticFibrosisFranchiseMember 2019-01-01 2019-12-31 0001802768 rprx:DPPIVPatentsMember 2020-12-31 0001802768 rprx:DPPIVPatentsMember 2019-12-31 0001802768 rprx:DPPIVPatentsMember 2020-01-01 2020-12-31 0001802768 us-gaap:SalesRevenueNetMember rprx:IndividualLicenseesConcentrationRiskMember 2020-01-01 2020-12-31 0001802768 us-gaap:SalesRevenueNetMember rprx:IndividualLicenseesConcentrationRiskMember 2019-01-01 2019-12-31 0001802768 us-gaap:SalesRevenueNetMember rprx:IndividualLicenseesConcentrationRiskMember 2018-01-01 2018-12-31 0001802768 rprx:LegacyInvestorsPartnershipsMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-02-11 0001802768 rprx:LegacyInvestorsPartnershipsMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-01-01 2020-12-31 0001802768 rprx:AvillionEntitiesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-01-01 2020-12-31 0001802768 rprx:AvillionEntitiesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2019-01-01 2019-12-31 0001802768 rprx:AvillionEntitiesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2018-01-01 2018-12-31 0001802768 rprx:AvillionIMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-01-01 2020-12-31 0001802768 rprx:AvillionIMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2019-01-01 2019-12-31 0001802768 rprx:AvillionIIMember rprx:MerckAssetPhaseIIClinicalTrialMember 2019-12-31 0001802768 rprx:AvillionIIMember rprx:MerckAssetPhaseIIClinicalTrialMember 2017-03-31 0001802768 rprx:AvillionIIMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-01-01 2020-12-31 0001802768 rprx:AvillionIIMember rprx:AZAssetPhaseIIAndPhaseIIIClinicalTrialMember 2018-05-31 0001802768 rprx:AvillionEntitiesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-12-31 0001802768 rprx:AvillionEntitiesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2019-12-31 0001802768 rprx:FundingAgreementsWithSanofiMember 2020-01-01 2020-12-31 0001802768 rprx:FundingAgreementsWithSanofiMember 2019-01-01 2019-12-31 0001802768 rprx:FundingAgreementsWithPfizerMember 2019-01-01 2019-12-31 0001802768 rprx:FundingAgreementsWithSanofiMember 2018-01-01 2018-12-31 0001802768 rprx:FundingAgreementsWithPfizerMember 2018-01-01 2018-12-31 0001802768 rprx:FundingAgreementWithImmunomedicsMember 2018-01-01 2018-12-31 0001802768 rprx:FundingAgreementWithBiohavenMember 2018-01-01 2018-12-31 0001802768 rprx:FundingAgreementsWithSanofiMember 2020-12-31 0001802768 rprx:PointSevenFivePercentSeniorNotesDue2023Member us-gaap:UnsecuredDebtMember 2020-01-01 2020-12-31 0001802768 rprx:PointSevenFivePercentSeniorNotesDue2023Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2020-01-01 2020-12-31 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2020-01-01 2020-12-31 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2020-01-01 2020-12-31 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2020-01-01 2020-12-31 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2020-01-01 2020-12-31 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:RPIFTSeniorSecuredCreditFacilitiesMember us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:RPIFTSeniorSecuredCreditFacilitiesMember us-gaap:UnsecuredDebtMember 2019-12-31 0001802768 rprx:RPIFTSeniorSecuredCreditFacilitiesTrancheB6Member us-gaap:SecuredDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-12-31 0001802768 rprx:RPIFTSeniorSecuredCreditFacilitiesTrancheB6Member us-gaap:SecuredDebtMember 2019-12-31 0001802768 rprx:RPIFTSeniorSecuredCreditFacilitiesTrancheA4Member us-gaap:SecuredDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-12-31 0001802768 rprx:RPIFTSeniorSecuredCreditFacilitiesTrancheA4Member us-gaap:SecuredDebtMember 2019-12-31 0001802768 us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 us-gaap:SecuredDebtMember 2019-12-31 0001802768 rprx:TheNotesMember us-gaap:UnsecuredDebtMember 2020-09-02 0001802768 rprx:TheNotesMember us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:TheNotesMember us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:UnsecuredDebtMember 2020-09-02 2020-09-02 0001802768 rprx:TheNotesMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:UnsecuredDebtMember 2020-09-02 2020-09-02 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2020-09-18 2020-09-18 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2020-09-18 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember rprx:OvernightBankFundingRateMember 2020-09-18 2020-09-18 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember us-gaap:FederalFundsPurchasedMember 2020-09-18 2020-09-18 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-09-18 2020-09-18 0001802768 rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member us-gaap:SecuredDebtMember 2020-02-11 0001802768 rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member us-gaap:SecuredDebtMember 2020-02-11 0001802768 rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member us-gaap:SecuredDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-02-11 2020-02-11 0001802768 rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member us-gaap:SecuredDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-02-11 2020-02-11 0001802768 rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member us-gaap:SecuredDebtMember 2020-09-01 2020-09-30 0001802768 rprx:RPIFTSeniorSecuredCreditFacilitiesMember us-gaap:SecuredDebtMember 2020-02-01 2020-02-29 0001802768 rprx:RPIFTSeniorSecuredCreditFacilitiesMember us-gaap:SecuredDebtMember 2019-12-31 0001802768 rprx:TheNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 us-gaap:CommonClassAMember rprx:SecondaryOfferingMember 2020-10-01 2020-10-31 0001802768 us-gaap:CommonClassAMember rprx:SecondaryOfferingMember 2020-10-31 0001802768 us-gaap:CommonClassAMember rprx:SecondaryOfferingMember rprx:IPOContinuingInvestorsPartnershipsMember 2020-10-01 2020-10-31 0001802768 us-gaap:CommonClassAMember rprx:SecondaryOfferingMember rprx:ContinuingInvestorsPartnershipMember 2020-10-01 2020-10-31 0001802768 us-gaap:CommonClassBMember rprx:SecondaryOfferingMember rprx:ContinuingInvestorsPartnershipMember 2020-10-01 2020-10-31 0001802768 rprx:ClassRRedeemableStockMember 2020-01-01 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2019-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2019-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2019-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2019-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2020-01-01 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2020-01-01 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2020-01-01 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2020-01-01 2020-06-17 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2020-01-01 2020-06-17 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2020-06-18 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2020-06-18 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2020-06-18 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2020-12-31 0001802768 rprx:RPHoldingsMember 2020-12-31 0001802768 rprx:A2020EquityIncentivePlanMember us-gaap:CommonClassAMember 2020-06-15 0001802768 rprx:A2020EquityIncentivePlanMember us-gaap:CommonClassAMember 2020-12-31 0001802768 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001802768 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001802768 us-gaap:CommonClassAMember 2020-01-01 2020-12-31 0001802768 rprx:ClassBHoldersMember 2020-01-01 2020-12-31 0001802768 rprx:LegacyInvestorsPartnershipsAndRPSFTMember 2020-01-01 2020-12-31 0001802768 rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember 2017-12-31 0001802768 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001802768 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2017-12-31 0001802768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001802768 rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember 2018-01-01 2018-12-31 0001802768 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0001802768 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-01-01 2018-12-31 0001802768 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember 2017-12-31 0001802768 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001802768 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2017-12-31 0001802768 rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember 2018-12-31 0001802768 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001802768 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-12-31 0001802768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001802768 rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember 2019-01-01 2019-12-31 0001802768 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0001802768 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-12-31 0001802768 rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember 2019-12-31 0001802768 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0001802768 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-12-31 0001802768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001802768 rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember 2020-01-01 2020-12-31 0001802768 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-12-31 0001802768 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-12-31 0001802768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001802768 rprx:AOCIAccumulatedGainLossEquitySecuritiesParentMember 2020-12-31 0001802768 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0001802768 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-12-31 0001802768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001802768 us-gaap:InterestIncomeMember 2020-01-01 2020-12-31 0001802768 rprx:OperatingAndPersonnelPaymentsMember srt:ManagementMember 2020-12-31 0001802768 rprx:OperatingAndPersonnelPaymentsMember srt:ManagementMember 2020-01-01 2020-12-31 0001802768 rprx:FormerOperatingAndPersonnelPaymentsMember srt:ManagementMember 2020-01-01 2020-12-31 0001802768 rprx:FormerOperatingAndPersonnelPaymentsMember srt:ManagementMember 2019-01-01 2019-12-31 0001802768 rprx:FormerOperatingAndPersonnelPaymentsMember srt:ManagementMember 2018-01-01 2018-12-31 0001802768 rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember srt:AffiliatedEntityMember 2020-12-31 0001802768 rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember srt:AffiliatedEntityMember 2020-12-31 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementBenefitOfPaymentStreamMember srt:AffiliatedEntityMember 2017-12-08 2017-12-08 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementFundingObligationsMember srt:AffiliatedEntityMember 2017-12-08 2017-12-08 0001802768 rprx:BristolMyersSquibbMember 2020-01-01 2020-12-31 0001802768 rprx:BristolMyersSquibbMember 2019-01-01 2019-12-31 0001802768 rprx:BristolMyersSquibbMember rprx:PaymentsToRelatedPartyFundedByAcquisitionsMember 2020-01-01 2020-12-31 0001802768 rprx:BristolMyersSquibbMember rprx:PaymentsToRelatedPartyFundedByAcquisitionsMember 2019-01-01 2019-12-31 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementFundingObligationsMember srt:AffiliatedEntityMember 2020-12-31 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementFundingObligationsMember srt:AffiliatedEntityMember 2019-12-31 0001802768 rprx:PurchasingAndDonatingVentilatorsMember srt:ChiefExecutiveOfficerMember 2020-01-01 2020-12-31 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember srt:AffiliatedEntityMember 2020-01-01 2020-12-31 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember srt:AffiliatedEntityMember us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember srt:AffiliatedEntityMember us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember srt:AffiliatedEntityMember us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0001802768 rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember 2020-08-07 2020-08-07 0001802768 rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember 2019-11-01 2019-11-30 0001802768 rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember 2020-01-01 2020-01-31 0001802768 srt:ScenarioForecastMember rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember 2021-11-01 2021-11-30 0001802768 us-gaap:SubsequentEventMember 2021-01-01 2021-01-31 iso4217:USD shares iso4217:USD shares iso4217:GBP shares pure rprx:partnership rprx:segment rprx:noncontrolling_interest 0001802768 2020 FY false us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccountingStandardsUpdate201613Member 2 1.80 2 2 2 1.80 1.80 1.80 10-K true 2020-12-31 --12-31 false 001-39329 Royalty Pharma plc X0 98-1535773 110 East 59th Street New York NY 10022 212 883-0200 Class A ordinary shares, par value $0.0001 RPRX NASDAQ No No Yes Yes Non-accelerated Filer false false false 4200000000 388134040 218976830 Portions of the registrant’s definitive proxy statement relating to the Annual Meeting of Shareholders, or Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2020. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof. 110000000.0 1008680000 246199000 983279000 94455000 587193000 452560000 33155000 33525000 69984000 0 6011000 5241000 8596000 92000 2696898000 832072000 12368084000 10842052000 28666000 51724000 298689000 380756000 144416000 131280000 5439000 42315000 454936000 124061000 23158000 45635000 16020286000 12449895000 126366000 31041000 10775000 11177000 42146000 0 110000000 0 18600000 0 0 281984000 0 9215000 307887000 333417000 5816584000 5956138000 0 18902000 6124471000 6308457000 0 3282516000 0.0001 0.0001 388135000 388135000 0 0 39000 0 0.000001 0.000001 218976000 218976000 0 0 0 0 1 1 50000 50000 0 0 63000 0 0.000001 0.000001 316407000 316407000 0 0 0 0 2865964000 0 1920635000 2825212000 5077036000 35883000 34395000 2093000 2317000 4266000 9895815000 6141438000 16020286000 12449895000 1959975000 1648837000 1524816000 143382000 145775000 134118000 18996000 19642000 135960000 2122353000 1814254000 1794894000 26289000 83036000 392609000 230839000 -1019321000 -57334000 23058000 23924000 33267000 181715000 103439000 61906000 65053000 0 0 526954000 -808922000 430448000 1595399000 2623176000 1364446000 44459000 -32517000 -7023000 157059000 268573000 279956000 0 0 419481000 -42076000 -39138000 11923000 247073000 155749000 -13939000 18600000 0 0 28379000 22329000 24441000 -32821000 393000 -1518000 106555000 -161757000 153409000 1701954000 2461419000 1517855000 0 0 0 1701954000 2461419000 1517855000 726914000 112884000 140126000 975040000 2348535000 1377729000 4066000 6189000 8003000 83120000 6159000 -402502000 20551000 0 0 66635000 12348000 -394499000 1041675000 2360883000 983230000 12873000 0 0 1028802000 2360883000 983230000 1.32 1.32 375444000 375455000 3282516000 655446000 381381000 141203000 0 4460546000 814359000 217464000 1031823000 -2863000 2863000 0 1377729000 140126000 1517855000 -402502000 -402502000 8003000 8003000 3282516000 1215953000 -10255000 63865000 0 4552079000 739276000 140866000 880142000 2348535000 112884000 2461419000 6159000 6159000 6189000 6189000 4266000 4266000 3282516000 2825212000 2093000 35883000 -4266000 6141438000 0 0 0 0 0 0 0 0 0 3282516000 2825212000 2093000 35883000 -4266000 6141438000 307646000 1174676000 1482322000 -1037161000 1037161000 0 -192705000 -192705000 313408000 792357000 1105765000 50000 63000 63000 479842000 145043000 624885000 535383000 1000 1000 294176000 30000 -294176000 -1000 294176000 1402762000 -2553001000 -1261014000 -24022000 2433098000 2147000 -1000 71652000 7000 1150383000 758354000 1908744000 76000 5428000 5428000 22231000 -2000 -22231000 22231000 -307391000 -2562000 309566000 198000 -191000 112490000 112490000 495198000 581871000 1077069000 4066000 0 4066000 60617000 22503000 83120000 10921000 9630000 20551000 388135000 39000 218976000 0 50000 63000 316407000 0 2865964000 0 1920635000 34395000 5077036000 -2317000 9895815000 2121923000 1934092000 2052592000 143753000 143298000 106689000 18305000 27448000 125162000 42334000 14059000 39402000 7704000 20136000 24441000 45252000 360000 3467000 0 45630000 510000 35448000 0 0 20479000 83036000 108163000 5810000 0 284446000 179709000 88524000 72535000 0 0 125000 103196000 254964000 267657000 2034629000 1667239000 1618317000 15084000 0 0 0 125121000 0 0 8840000 0 50000000 78999000 152810000 3000000 150000000 750000000 1705283000 817402000 0 815440000 725070000 0 384840000 0 0 40155000 27042000 24173000 2182246000 1721291000 269593000 0 250000000 0 -2759320000 -2153625000 303424000 285353000 739276000 814359000 543952000 154084000 268693000 181135000 0 0 112490000 0 0 8482000 0 0 58957000 0 0 94200000 294000000 294000000 11116196000 0 0 11891030000 0 0 46715000 0 2049000 0 4266000 0 1908744000 0 0 1487172000 -1191626000 -1379101000 762481000 -1678012000 542640000 246199000 1924211000 1381571000 1008680000 246199000 1924211000 Organization and Purpose <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (the “IPO”) of our Class A ordinary shares that was completed in June 2020. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following our IPO, we control Royalty Pharma Holdings Ltd. (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K. tax resident through our ownership of RP Holdings’ Class A ordinary shares (the “RP Holdings Class A Interests”) and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our consolidated financial statements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV, which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish Unit Trust (“Old RPI”), for accounting and financial reporting purposes. RP Holdings is owned directly by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, (together, the “Continuing Investors Partnerships”), and Royalty Pharma plc. Old RPI is a unit trust established in August 2011 under the laws of Ireland and authorized by the Central Bank of Ireland pursuant to the Unit Trusts Act, 1990. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Management, LLC (the “Manager”), a Delaware limited liability company, is an external adviser which is responsible for our management. RP Management (Ireland) Ltd. (“RP Ireland”), is the manager of Old RPI and equivalent to the board of directors of a company or general partner of a partnership and is responsible for the day to day operations of Old RPI. Its functions can be delegated to third parties. RP Ireland delegated responsibility for investment management of Old RPI to its parent company, the Manager, in accordance with the investment objectives and policies of Old RPI. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Royalty Pharma,” “Royalty Pharma Investments,” “RPI,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Reorganization Transactions (defined below) and before the consummation of the IPO, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma Investments 2019 ICAV. Prior to the Reorganization Transactions, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Old RPI.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reorganization Transactions </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our IPO, we consummated an exchange offer on February 11, 2020 (the “Exchange Date”). Through the exchange offer, investors representing 82% of the aggregate limited partnership in the Legacy Investors Partnerships, exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under a new credit facility and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Exchange Offer Transactions, we own, through our wholly-owned subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”), an 82% economic interest in Old RPI. Through our 82% indirect ownership of Old RPI, we are legally entitled to 82% of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish Unit trust. From the Exchange Date until the expiration of the Legacy Investors Partnerships’ investment period on June 30, 2020 (the “Legacy Date”), the Legacy Investors Partnerships were offered to participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI has ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Following the Legacy Date, we have made and will continue to make new investments through our subsidiaries, including RPI Intermediate FT. </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Exchange Offer Transactions, the Legacy Investors Partnerships and RPI Intermediate FT entered into new credit facilities in the amount of $1.3 billion and $6.0 billion, respectively, the proceeds of which were primarily used to repay the $6.3 billion outstanding debt of RPIFT as of the Exchange Date and, in the case of RPI Intermediate FT, was also available to be used to fund investments. As part of the new credit facilities, RPI Intermediate FT repaid $5.2 billion, its pro rata portion of RPIFT’s outstanding debt and accrued interest. RPIFT also terminated all outstanding interest rate swaps in connection with the debt refinancing. </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to, and as a condition precedent to the closing of the IPO, various reorganization transactions became effective, including the following:</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Exchange Offer Transactions (as described above); and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the execution of a new management agreement with the Manager (the “New Management Agreement”).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to these transactions collectively as the “Reorganization Transactions.”</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Old RPI is our predecessor for financial reporting purposes, we have recorded Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date. The references in the following notes for the periods prior to the Exchange Date refer to the financial results of Old RPI for the same periods. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IPO</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we completed our IPO, in which we issued 89,334 thousand shares of Class A ordinary shares at a price to the public of $28.00 per share, of which 71,652 thousand and 17,682 thousand shares were offered by the Company and selling shareholders, respectively. The Company received net proceeds of approximately $1.9 billion from the IPO after deducting underwriting discounts and commissions. The Class A ordinary shares began trading on the Nasdaq Global Select Market under the ticker symbol “RPRX” on June 16, 2020. We used the net proceeds from the IPO to acquire the RP Holdings Class A Interests shortly after completion of the IPO. As a result, we own 100% of RP Holdings Class A Interests.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, pursuant to the Exchange Offer Transactions, certain of the Continuing Investor Partnerships agreed to exchange, upon consummation of the IPO, interests in the Continuing Investors Partnerships represented by their ownership of 294,176 thousand RP Holdings Class B Interests into an aggregate of 294,176 thousand Class A ordinary shares of the Company. Upon completion of the exchange, Royalty Pharma plc indirectly owned 294,176 thousand RP Holdings Class B Interests. The remaining investors in the Continuing Investors Partnerships who did not elect to exchange into Class A ordinary shares held 241,207 thousand newly issued Class B ordinary shares of Royalty Pharma plc. As a result, the Continuing Investors Partnerships held a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests indirectly held by them at such time which are exchangeable on a one-for-one basis for Class A ordinary shares of Royalty Pharma plc. Our Class B ordinary shares will not be publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. However, the RP Holdings Class B Interests will be entitled to dividends and distributions from RP Holdings. Our Class A ordinary and Class B ordinary shares will vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law, with each share entitled to one vote.</span></div> 0.82 0.82 0.82 0.82 0.66 0.34 1300000000 6000000000.0 6300000000 5200000000 89334000 28.00 71652000 17682000 1900000000 1 294176000 294176000 294176000 241207000 Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of preparation and use of estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, the pandemic has not materially impacted our financial performance and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of consolidation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements include the accounts of Royalty Pharma plc and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our consolidated statements of comprehensive income equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following management’s determination that a high degree of common ownership existed in RPI both before and after the Exchange Date, RPI recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Exchange Offer Transactions, our only historical non-controlling interest was attributable to a de minimis interest in RPCT held by RPSFT. As a result of the Exchange Offer Transactions in February 2020, a new non-controlling interest was created related to the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the consummation of our IPO in June 2020, two new non-controlling interests were created: (1) a non-controlling interest related to the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, which amounted to approximately 36% as of December 31, 2020, and (2) a non-controlling interest attributable to the RP Holdings Class C Special Interest held by EPA Holdings, an affiliate of the Manager. Income will not be allocated to the latter non-controlling interest until certain conditions are met, which we do not expect to occur for several years.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intercompany transactions and balances have been eliminated in consolidation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjustment to prior period presentation </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the preparation of our condensed consolidated interim financial statements for the three months ended September 30, 2020, we identified an adjustment to the classification of our short-term investments on our consolidated balance sheets, as of December 31, 2019, based on the original maturity dates of the investments. The adjustment resulted in an increase of $37.5 million to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and a corresponding decrease to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated balance sheet as of December 31, 2019. In addition, the adjustment resulted in an increase of $388.0 million and $350.5 million in cash activity related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Purchases of marketable securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Proceeds from sales and maturities of marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash used in investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the year ended December 31, 2019, with a net impact on net cash flow from investing of $37.5 million. The adjustment had no effect on our reported total income and revenues, consolidated net income, total assets, or shareholders’ equity for any period. In addition, the adjustment does not impact net cash provided by operating activities in any period. We evaluated the adjustment and determined that, based on quantitative and qualitative analysis, it was not material to the consolidated financial statements as of and for the year ended December 31, 2019.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2020 and 2019 were held with State Street, Deutsche Bank and Bank of America. Our primary operating accounts significantly exceed the FDIC limits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Abbott, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Gilead, Johnson &amp; Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche/ Genentech and Vertex. For the years ended December 31, 2020 and 2019, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise products, accounted for 27% and 17% of our current portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial royalty assets, net</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (“ASC”), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty assets is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the carrying value of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is presented net of the cumulative allowance for changes in expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of the prospective approach to measure financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties. </span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product and royalty duration, each discussed in further detail below.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analyst coverage.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to derive annual sales projections for each financial royalty asset by applying the median growth rates calculated from consensus forecasts among sell-side equity research analysts currently reporting on a product to the corresponding periods for which we are entitled to royalties. Growth rates inherent in these forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst estimates are not available for the full term of the royalty, particularly for the later years in a product’s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management’s own expertise. Further, based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms and rates are then applied to the adjusted sales projections to calculate the expected royalty payments over the term of the financial royalty asset’s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial performance.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The approval of a product for use in new indications can extend the date through which we are entitled to royalties on that product. Likewise, for certain royalties, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in sales projections. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts’ forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product’s performance in the market can materially affect our forecast of expected future cash flows over the royalty term.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty duration. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration of a royalty can be based on a number of factors, such as patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product’s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation outcomes. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) product growth rates and sales trends in outer years, (2) the geographical allocation of annual sales data from sell-side equity research analysts’ models, (3) the product and pricing mix for franchised products, (4) the strength of patent protection, including anticipated entry of generics and (5) estimates of the duration of the royalty. The most sensitive of these assumptions relates to management’s estimate of the royalty duration in the final years of an asset’s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears. </span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate financial royalty assets for impairment on an individual basis at each reporting date by comparing the effective interest rate to that of the prior period. If the current period effective interest rate is lower than the prior period, and if the gross cash flows have declined (expected and collected), management records a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset’s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period’s effective interest rate. The amount recognized as provision expense increases the financial royalty asset’s cumulative allowance, which reduces the net carrying value of the financial royalty asset.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. Management also recalculates the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset’s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of comprehensive income.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When royalties continue to be collected for financial royalty assets that have been fully amortized, such income is recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for current expected credit losses</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 1, 2020, we adopted ASU 2016-13, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheets. Any subsequent routine movement in the allowance for credit losses is recorded as part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated statements of comprehensive income.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to Note 7</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for further information.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible royalty assets, net</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currently, our only intangible royalty assets are the Januvia and Janumet (“DPP-IV”) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, which terminate at various dates until 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10,</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Property, Plant, and Equipment - Overall</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product’s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty’s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from intangible royalty assets and Accrued royalty receivable</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue on DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts’ projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone payments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain acquisition agreements provide for future contingent payments based on the financial performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts’ consensus forecasts. Milestones based on regulatory approval are not reflected in the expected future cash flows until such approval is achieved.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">–</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair Value Measurements and Financial Instruments.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents and Marketable securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value. </span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity securities and Available for sale debt securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities, including our investment in the Biohaven Series A Preferred Shares, are measured at fair value and unrealized gains and losses are included in accumulated other comprehensive income/(loss) (“AOCI”). Unrealized gains and losses are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management’s assessment.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of comprehensive income as part of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gain/(loss) on derivative financial instruments</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in non-consolidated affiliates</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at cost. Subsequently, we recognize through earnings our proportionate share of the investee’s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of these entities one quarter in arrears within </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in (earnings)/loss of non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of comprehensive income. The investment is reflected as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheet.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the “Avillion entities”). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development funding expense</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We enter into transactions where we agree to fund a portion of the research and development (“R&amp;D”) for products undergoing late-stage clinical trials in exchange for future royalties if the products are successfully developed and commercialized. In accordance with ASC 730 Research and Development, we account for the funded amounts as R&amp;D expense when we have the ability to obtain the results of the R&amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty payments owed to the Company on successfully commercialized products generated from R&amp;D agreements are recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria (i.e., typically the achievement of agreed upon sales thresholds) for products arising out of our R&amp;D arrangements are also recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the period that the commercial sales threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed and we have no further performance obligations.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (“the Code”) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI. </span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the U.K.’s “controlled foreign companies” rules (the “U.K. CFC Rules”). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the “Controlled Foreign Company”) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings)</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per share</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares and restricted share units (“RSUs”) issued under our 2020 Independent Director Equity Incentive Plan (“Equity Incentive Plan”). We use the “if-converted” method to determine the potentially dilutive effect of Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information has been presented for any period prior to that date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting standards</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, the Financial Accounting Standard Board (“FASB”) issued a new revenue standard under ASC Topic 606 (ASU 2014-09). ASU 2014-09 applies to all contracts with customers. Based on management’s assessment, income from financial royalty assets which are accounted for in accordance with ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is not subject to the application of ASU 2014-09. As a result, management believes that financial royalty assets represent contractual rights and obligations that continue to be within the scope of Topic 310 and therefore specifically exempted from the new revenue standard. The provisions of ASU 2014-09 became effective for us on January 1, 2018, including interim reporting periods. Our revenues are primarily derived from intangible royalty assets, which fall under the sales-based royalties exception in the new standard. Therefore, we did not recognize any adjustment upon adoption of the new revenue standard.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the FASB issued revised guidance for the accounting and reporting of financial instruments (ASU 2016-01) and in 2018 issued related technical corrections (ASU 2018-03). The new guidance requires that equity investments with readily determinable fair values currently classified as available for sale be measured at fair value with changes in fair value recognized in net income. The new guidance also changed certain disclosure requirements. We adopted ASU 2016-01 as of January 1, 2018 using a modified retrospective approach. We recorded a cumulative-effect adjustment upon adoption that decreased retained earnings by $2.9 million as a result of accumulated other comprehensive income previously recognized on its available for sale equity securities. ASU 2018-03 was also adopted as of January 1, 2018 on a prospective basis and did not result in any additional impact upon adoption.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the FASB issued revised guidance which makes eight targeted changes to how royalty receipts and cash payments are presented and classified in the Statement of Cash Flows (ASU 2016-15). Among the updates, the standard allows companies to elect the “cumulative earnings” approach or the “nature-of-the-distribution” approach in distinguishing whether distributions received from equity method investees are returns of investment, which should be classified as cash flows from investing activities, and returns on investment, which should be classified as cash flows from operating activities. We made a policy election to use the “cumulative earnings” approach and adopted ASU 2016-15 for the year ended December 31, 2018.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $192.7 million to recognize an allowance for current expected credit losses on our financial royalty assets. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.</span></div> The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, the pandemic has not materially impacted our financial performance and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements include the accounts of Royalty Pharma plc and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our consolidated statements of comprehensive income equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following management’s determination that a high degree of common ownership existed in RPI both before and after the Exchange Date, RPI recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date. </span></div>All intercompany transactions and balances have been eliminated in consolidation. 0.18 2 0.36 37500000 388000000.0 350500000 37500000 Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2020 and 2019 were held with State Street, Deutsche Bank and Bank of America. Our primary operating accounts significantly exceed the FDIC limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Abbott, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Gilead, Johnson &amp; Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche/ Genentech and Vertex. 0.27 0.17 Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties. 1 <div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.</span></div> <span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (“ASC”), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty assets is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the carrying value of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is presented net of the cumulative allowance for changes in expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of the prospective approach to measure financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties. </span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product and royalty duration, each discussed in further detail below.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analyst coverage.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to derive annual sales projections for each financial royalty asset by applying the median growth rates calculated from consensus forecasts among sell-side equity research analysts currently reporting on a product to the corresponding periods for which we are entitled to royalties. Growth rates inherent in these forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst estimates are not available for the full term of the royalty, particularly for the later years in a product’s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management’s own expertise. Further, based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms and rates are then applied to the adjusted sales projections to calculate the expected royalty payments over the term of the financial royalty asset’s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial performance.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The approval of a product for use in new indications can extend the date through which we are entitled to royalties on that product. Likewise, for certain royalties, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in sales projections. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts’ forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product’s performance in the market can materially affect our forecast of expected future cash flows over the royalty term.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty duration. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration of a royalty can be based on a number of factors, such as patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product’s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation outcomes. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) product growth rates and sales trends in outer years, (2) the geographical allocation of annual sales data from sell-side equity research analysts’ models, (3) the product and pricing mix for franchised products, (4) the strength of patent protection, including anticipated entry of generics and (5) estimates of the duration of the royalty. The most sensitive of these assumptions relates to management’s estimate of the royalty duration in the final years of an asset’s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears. </span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate financial royalty assets for impairment on an individual basis at each reporting date by comparing the effective interest rate to that of the prior period. If the current period effective interest rate is lower than the prior period, and if the gross cash flows have declined (expected and collected), management records a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset’s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period’s effective interest rate. The amount recognized as provision expense increases the financial royalty asset’s cumulative allowance, which reduces the net carrying value of the financial royalty asset.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. Management also recalculates the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset’s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of comprehensive income.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When royalties continue to be collected for financial royalty assets that have been fully amortized, such income is recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income.</span></div> <span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 1, 2020, we adopted ASU 2016-13, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheets. Any subsequent routine movement in the allowance for credit losses is recorded as part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated statements of comprehensive income.</span> Currently, our only intangible royalty assets are the Januvia and Janumet (“DPP-IV”) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, which terminate at various dates until 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.<span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10,</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Property, Plant, and Equipment - Overall</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product’s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty’s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.</span> <div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue on DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts’ projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone payments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain acquisition agreements provide for future contingent payments based on the financial performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts’ consensus forecasts. Milestones based on regulatory approval are not reflected in the expected future cash flows until such approval is achieved.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.</span></div> <span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">–</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair Value Measurements and Financial Instruments.</span> Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value. <div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities, including our investment in the Biohaven Series A Preferred Shares, are measured at fair value and unrealized gains and losses are included in accumulated other comprehensive income/(loss) (“AOCI”). Unrealized gains and losses are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management’s assessment.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.</span></div> All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements. <span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of comprehensive income as part of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gain/(loss) on derivative financial instruments</span>. <div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at cost. Subsequently, we recognize through earnings our proportionate share of the investee’s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of these entities one quarter in arrears within </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in (earnings)/loss of non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of comprehensive income. The investment is reflected as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheet.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the “Avillion entities”). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.</span></div>When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets. <div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We enter into transactions where we agree to fund a portion of the research and development (“R&amp;D”) for products undergoing late-stage clinical trials in exchange for future royalties if the products are successfully developed and commercialized. In accordance with ASC 730 Research and Development, we account for the funded amounts as R&amp;D expense when we have the ability to obtain the results of the R&amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty payments owed to the Company on successfully commercialized products generated from R&amp;D agreements are recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria (i.e., typically the achievement of agreed upon sales thresholds) for products arising out of our R&amp;D arrangements are also recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the period that the commercial sales threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed and we have no further performance obligations.</span></div> <div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (“the Code”) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI. </span></div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the U.K.’s “controlled foreign companies” rules (the “U.K. CFC Rules”). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the “Controlled Foreign Company”) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings)</span>, will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes. Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares and restricted share units (“RSUs”) issued under our 2020 Independent Director Equity Incentive Plan (“Equity Incentive Plan”). We use the “if-converted” method to determine the potentially dilutive effect of Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs. <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, the Financial Accounting Standard Board (“FASB”) issued a new revenue standard under ASC Topic 606 (ASU 2014-09). ASU 2014-09 applies to all contracts with customers. Based on management’s assessment, income from financial royalty assets which are accounted for in accordance with ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is not subject to the application of ASU 2014-09. As a result, management believes that financial royalty assets represent contractual rights and obligations that continue to be within the scope of Topic 310 and therefore specifically exempted from the new revenue standard. The provisions of ASU 2014-09 became effective for us on January 1, 2018, including interim reporting periods. Our revenues are primarily derived from intangible royalty assets, which fall under the sales-based royalties exception in the new standard. Therefore, we did not recognize any adjustment upon adoption of the new revenue standard.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the FASB issued revised guidance for the accounting and reporting of financial instruments (ASU 2016-01) and in 2018 issued related technical corrections (ASU 2018-03). The new guidance requires that equity investments with readily determinable fair values currently classified as available for sale be measured at fair value with changes in fair value recognized in net income. The new guidance also changed certain disclosure requirements. We adopted ASU 2016-01 as of January 1, 2018 using a modified retrospective approach. We recorded a cumulative-effect adjustment upon adoption that decreased retained earnings by $2.9 million as a result of accumulated other comprehensive income previously recognized on its available for sale equity securities. ASU 2018-03 was also adopted as of January 1, 2018 on a prospective basis and did not result in any additional impact upon adoption.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the FASB issued revised guidance which makes eight targeted changes to how royalty receipts and cash payments are presented and classified in the Statement of Cash Flows (ASU 2016-15). Among the updates, the standard allows companies to elect the “cumulative earnings” approach or the “nature-of-the-distribution” approach in distinguishing whether distributions received from equity method investees are returns of investment, which should be classified as cash flows from investing activities, and returns on investment, which should be classified as cash flows from operating activities. We made a policy election to use the “cumulative earnings” approach and adopted ASU 2016-15 for the year ended December 31, 2018.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $192.7 million to recognize an allowance for current expected credit losses on our financial royalty assets. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.</span></div> 2900000 -192700000 Fair Value Measurements and Financial Instruments <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary below presents information about our assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020 and 2019, and the valuation techniques we utilized to determine such fair value.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Our Level 1 assets consist of equity securities with readily determinable fair values and money market funds.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. Our Level 2 assets generally include marketable securities, warrants, derivatives and our interest rate swap contracts, which may be in an asset or liability position.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Level 3: Prices or valuation that requires inputs that are both significant to the fair value measurement and unobservable. Our Level 3 assets consist of our investments in the Series A Biohaven Preferred Shares and the Series B Forwards and, historically, our investment in Tecfidera. See Note 5––Available for Sale Debt Securities for a description of our investments in the Biohaven Preferred Shares.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value hierarchy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the inputs used to value our financial assets and liabilities measured at fair value as of December 31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,134,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">69,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,229,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">298,689</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,439</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">467,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Upon Gilead’s acquisition of Immunomedics, our investment in Immunomedics common stock was redeemed in full in the fourth quarter of 2020, resulting in a gain of $292.3 million recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Gain)/loss on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the year ended December 31, 2020. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Series B Forwards, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet as of December 31, 2020, relate to our obligation to fund the acquisition of the Series B Biohaven Preferred Shares. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to Epizyme transaction as described in Note 4–Derivative Instruments and recorded in the non-current asset portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet as of December 31, 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gain or loss recognized on equity securities still held as of December 31, 2020 was a loss of $45.2 million, a gain of $125.6 million and a loss of $7.8 million for the years ended December 31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">222,326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">98,455</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">320,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,815 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,815 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward purchase contract (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">380,756</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">42,315</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131,280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">554,351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9,215)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9,215)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,902)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,902)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(18,902)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(18,902)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to Epizyme warrants and put option as described in Note 4–Derivative Instruments and both recorded in the non-current asset portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet as of December 31, 2019.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables presented below summarize the change in the carrying value of Level 3 financial instruments, which relate to our investment in the Series A Biohaven Preferred Shares and the Series B Forwards (in thousands). </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the years ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer to Level 2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184,005)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer from Level 2 (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,874 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131,280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Includes $14.5 million of unrealized gains on available for sale debt securities included in other comprehensive income while the instrument was classified as a Level 2 asset.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"><tr><td style="width:1.0%"/><td style="width:70.948%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Forwards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains included in earnings (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gain on forwards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the consolidated statements of comprehensive income. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation inputs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Series A Biohaven Preferred Shares at December 31, 2020 is based on the cash flows due to us from Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”) of two times (2x) the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6 million following U.S. Food and Drug Administration (“FDA”) approval and starting one-year after FDA approval through December 31, 2024. The FDA approved Nurtec ODT (rimegepant) in February 2020, at which point we became entitled to receive a fixed payment amount of $250.0 million payable in equal quarterly payments from March 31, 2021 through December 31, 2024. For additional discussion of our investment in the Series A Biohaven Preferred Shares, see Note 5––Available for Sale Debt Securities.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Series A Biohaven Preferred Shares at December 31, 2020 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate of 8.3% could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower. At December 31, 2020 we estimated the fair value for the Series A Biohaven Preferred Shares as $214.4 million, which we classified as available for sale debt securities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods prior to March 31, 2020, we valued the Series A Biohaven Preferred Shares using a Black-Derman Toy (“BDT”) lattice model. The fair value of the Series A Biohaven Preferred Shares at December 31, 2019 was determined based on significant inputs that were not observable in the market, referred to as Level 3 inputs. Key inputs to the BDT model for the December 31, 2019 valuation included, most notably, the probability (1) of Biohaven’s pipeline product, Nurtec ODT (rimegepant), being approved by the FDA by specific dates, (2) of a change of control event by specific dates and (3) that Biohaven will elect to redeem the Series A Biohaven Preferred Shares for a lump sum payment as opposed to payback over time. Probabilities for the above considerations were developed by management, which has significant healthcare and finance expertise to make such assessments. The most critical assumption that impacted the valuation of our Series A Biohaven Preferred Shares at December 31, 2019 was the probability that Nurtec ODT (rimegepant) would be approved by the FDA. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assumptions used in the valuation model as of December 31, 2019 included the following significant unobservable inputs:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Change of Control probability on a quarterly basis (0%)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Likelihood of FDA approval (0%-86%)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Likelihood of FDA approval at the end of any given quarter by December 31, 2024 (Range: 0%-59%).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our investment in the Series A Biohaven Preferred Shares was transferred from a Level 3 asset to a Level 2 asset in February 2020, when Nurtec ODT (rimegepant) received FDA approval, at which time we began using a discounted cash flow analysis that relied on observable inputs. During the three months ended December 31, 2020, we became aware of Biohaven’s issuance of debt and its effective interest rate and refined our valuation of the Series A Biohaven Preferred shares as of December 31, 2020 to incorporate this significant unobservable input. As a result, we reclassified the investment from a Level 2 to a Level 3 asset during the three months ended December 31, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Series B Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have committed to acquiring 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share for a total of $200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024 (“Series B Forwards”). In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments equal to approximately 1.8 times the original issue price per share between March 31, 2025 and December 31, 2030. For additional discussion of our investment in the Series B Biohaven Preferred Shares, see Note 5–Available for Sale Debt Securities. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Series B Forwards as of December 31, 2020 is based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a 10-year time period and developing a risk-adjusted discounted rate requires significant judgement. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimate fair value could be significantly higher or lower than the fair value determined by management at any particular date. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower. We have elected the fair value option to account for our Series B Forwards as it most accurately reflects the nature of our Series B Forwards, which we record within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheet. The unrealized movement in fair value of the Series B forwards is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gain on forwards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of comprehensive income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other financial instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a third party pricing service for Level 2 inputs used to value cash equivalents, marketable securities and borrowings, which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. Warrants are valued using a Black-Scholes option pricing model which considers observable and unobservable inputs. Level 2 interest rate swaps are typically valued using counterparty confirmations, LIBOR yield curves and credit valuation adjustments. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial assets not measured at fair value</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial royalty assets are measured and carried on the consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. The fair value of financial royalty assets is calculated by management using the forecasted royalty payments we expect to receive based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts’ consensus forecasts. These projected future royalty payments by asset are then discounted to a present value using appropriate individual discount rates. The fair value of our financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of our financial royalty assets as of December 31, 2020 and 2019 are presented below (in thousands).</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying value, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,718,179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,368,084 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,501,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,842,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary below presents information about our assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020 and 2019, and the valuation techniques we utilized to determine such fair value.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Our Level 1 assets consist of equity securities with readily determinable fair values and money market funds.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. Our Level 2 assets generally include marketable securities, warrants, derivatives and our interest rate swap contracts, which may be in an asset or liability position.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Level 3: Prices or valuation that requires inputs that are both significant to the fair value measurement and unobservable. Our Level 3 assets consist of our investments in the Series A Biohaven Preferred Shares and the Series B Forwards and, historically, our investment in Tecfidera. See Note 5––Available for Sale Debt Securities for a description of our investments in the Biohaven Preferred Shares.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the inputs used to value our financial assets and liabilities measured at fair value as of December 31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,134,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">69,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,229,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">298,689</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,439</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">467,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Upon Gilead’s acquisition of Immunomedics, our investment in Immunomedics common stock was redeemed in full in the fourth quarter of 2020, resulting in a gain of $292.3 million recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Gain)/loss on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the year ended December 31, 2020. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Series B Forwards, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet as of December 31, 2020, relate to our obligation to fund the acquisition of the Series B Biohaven Preferred Shares. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to Epizyme transaction as described in Note 4–Derivative Instruments and recorded in the non-current asset portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet as of December 31, 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gain or loss recognized on equity securities still held as of December 31, 2020 was a loss of $45.2 million, a gain of $125.6 million and a loss of $7.8 million for the years ended December 31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">222,326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">98,455</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">320,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,815 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,815 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward purchase contract (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">380,756</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">42,315</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131,280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">554,351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9,215)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9,215)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,902)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,902)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(18,902)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(18,902)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to Epizyme warrants and put option as described in Note 4–Derivative Instruments and both recorded in the non-current asset portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet as of December 31, 2019.</span></div> 24302000 0 0 24302000 0 77176000 0 77176000 0 74502000 0 74502000 0 32754000 0 32754000 0 444554000 0 444554000 0 505971000 0 505971000 0 0 69984000 69984000 24302000 1134957000 69984000 1229243000 298689000 0 0 298689000 0 0 144416000 144416000 0 0 18600000 18600000 0 5439000 0 5439000 298689000 5439000 163016000 467144000 292300000 -45200000 125600000 -7800000 222326000 0 0 222326000 0 4000000 0 4000000 0 12877000 0 12877000 0 21367000 0 21367000 0 60211000 0 60211000 222326000 98455000 0 320781000 380756000 0 0 380756000 0 0 131280000 131280000 0 30815000 0 30815000 0 11500000 0 11500000 380756000 42315000 131280000 554351000 0 9215000 0 9215000 0 9215000 0 9215000 0 18902000 0 18902000 0 18902000 0 18902000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables presented below summarize the change in the carrying value of Level 3 financial instruments, which relate to our investment in the Series A Biohaven Preferred Shares and the Series B Forwards (in thousands). </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the years ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer to Level 2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184,005)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer from Level 2 (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,874 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131,280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Includes $14.5 million of unrealized gains on available for sale debt securities included in other comprehensive income while the instrument was classified as a Level 2 asset.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"><tr><td style="width:1.0%"/><td style="width:70.948%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Forwards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains included in earnings (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gain on forwards</span> on the consolidated statements of comprehensive income. 131280000 0 0 125121000 52725000 0 184005000 0 198526000 0 15874000 6159000 214400000 131280000 14500000 0 18600000 18600000 15600000 250000000.0 0.083 214400000 0 0 0.86 0 0.59 3992 50100 200000000.0 Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of our financial royalty assets as of December 31, 2020 and 2019 are presented below (in thousands).<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying value, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,718,179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,368,084 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,501,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,842,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 18718179000 12368084000 16501819000 10842052000 Derivative InstrumentsWe have historically managed the impact of foreign currency exchange rate and interest rate risk through various financial instruments, including derivative instruments such as interest rate swap contracts and foreign currency forward contracts. Our policy is to use derivatives strategically to hedge existing interest rate exposure and to minimize volatility in cash flow arising from our exposure to interest rate risk and foreign currency risk. We may also acquire other financial instruments that are classified as derivatives. We do not enter into derivative instruments for trading or speculative purposes. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2020, we do not hold any interest rate swap contracts. In connection with the Exchange Offer Transactions described in Note 1–Organization and Purpose, RPIFT terminated all outstanding interest rate swaps in February 2020. We paid $35.4 million to terminate our swaps and reclaimed $45.3 million of collateral that was held by the respective counterparties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, RPIFT held interest rate swap contracts to effectively convert a portion of its floating-rate debt to a fixed basis. The notional values and fixed rates payable on the swap contracts are shown in the table below.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.771%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Notional Value<br/>(in millions)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.019 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 9, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$250</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.094 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 27, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$500</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 27, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$250</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 27, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$500</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 27, 2023</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not apply hedge accounting and recognize all movement in fair value through earnings. All outstanding interest rate swaps were terminated in February 2020. During the years ended December 31, 2020 and 2019, we recorded unrealized losses of $10.9 million and $72.6 million, respectively, on interest rate swaps in the consolidated statements of comprehensive income. During the year ended December 31, 2018, we recorded unrealized gains of $11.9 million on interest rate swaps in the consolidated statements of comprehensive income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, the fair value of the swaps was a net liability of $28.1 million (a current liability of $9.2 million and a non-current liability of $18.9 million) and included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RPIFT had master International Swaps and Derivatives Association (“ISDA”) agreements in place with its derivative instrument counterparties which provide for final close out netting with counterparties for all positions in the case of default or termination of the ISDA agreement. Under these agreements, RPIFT has set-off rights with the same counterparty but elected not to offset such derivative instrument fair values in the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RPIFT generally had executed a Credit Support Annex (“CSA”) under the ISDA it maintains with each of its over-the-counter (“OTC”) derivative counterparties that requires both posting and accepting collateral either in the form of cash or high-quality securities. These CSAs are bilateral agreements that require collateral postings by the party “out-of-the-money” or in a net derivative liability position. Various thresholds for the amount and timing of collateralization of net liability positions are applicable. RPIFT elected not to offset fair value amounts of any outstanding derivatives against the fair value amounts recognized for the related cash collateral receivable or payable that arise from those derivative instruments on the consolidated balance sheets.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only the swaps maturing in 2023 had collateral requirements. At December 31, 2019, RPIFT had a receivable of $45.6 million in cash collateral previously posted to trade counterparties, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets. At December 31, 2019, RPIFT did not have the obligation to return any cash collateral to counterparties, as it did not hold any cash collateral at that date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Epizyme put option and warrant</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, RPIFT made an equity investment in Epizyme Inc. (“Epizyme”) of $100.0 million. Under the terms of its agreement with Epizyme, RPIFT made an upfront payment of $100.0 million for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5 million shares of Epizyme common stock at $20 per share over a three-year term and (3) Epizyme’s royalty on sales of Tazemetostat in Japan payable by Eisai Co., Ltd (“Eisai”). In addition, Epizyme had an 18 month put option to sell an additional $50.0 million of its common stock to RPIFT at then prevailing prices, not to exceed $20 per share.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2019, Epizyme notified RPIFT of its intention to exercise the put option. As a result, we recorded a forward purchase contract equal to the difference between the market value and exercise price of $11.5 million in the non-current asset portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheet at December 31, 2019. The exercise of the put option was settled in February 2020.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant was recognized at fair value of $5.4 million and $30.8 million within the non-current asset portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets at December 31, 2020 and 2019, respectively. We recorded an unrealized loss on derivative contracts of $25.4 million and an unrealized gain on derivative contracts of $22.0 million related to the change in fair value of the warrants on the consolidated statements of comprehensive income for the years ended December 31, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biohaven written put option </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We determined there was a derivative associated with the Second Tranche (as defined below) of the Series A Biohaven Preferred Shares Agreement that was entered into in April 2019. The derivative related to Biohaven’s option, exercisable within 12 months from when the NDA for Nurtec ODT (rimegepant) was accepted by the FDA for Priority Review, to require Royalty Pharma to purchase up to an additional $75.0 million of Series A Biohaven Preferred Shares (the “Second Tranche”) at the same price and on the same terms as the First Tranche, in one or more transactions of no less than $25.0 million. As of December 31, 2019, management determined that the value of the Second Tranche written p</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ut option was immaterial, and therefore no derivative liability was recognized on the consolidated balance sheets. The exercise period for the Biohaven written put option expired in the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> year ended December 31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and therefore there was no value or movement in fair value associated with the Biohaven written put option as of or for the year ended December 31, 2020. See Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">–</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Available for Sale Debt Securities for a description of our investment in the Series A Biohaven Preferred Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of derivatives and reclassifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2020, 2019 and 2018 and the line items within the consolidated statements of comprehensive income where the gains/(losses) on these derivatives are recorded (in thousands). </span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.143%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the years ended<br/>December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Statement of Comprehensive Income location</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives in hedging relationships (1)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount of loss reclassified from AOCI into income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss/(gain) on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss/(gain) on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,758)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss/(gain) on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss/(gain) on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward purchase contract:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of forward purchase contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss/(gain) on derivative financial instruments</span></td></tr></table></div>(1)     Certain older interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in AOCI have been released into earnings. 35400000 45300000 The notional values and fixed rates payable on the swap contracts are shown in the table below.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.771%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Notional Value<br/>(in millions)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.019 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 9, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$250</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.094 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 27, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$500</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 27, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$250</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 27, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$500</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 27, 2023</span></td></tr></table> 600000000 0.02019 250000000 0.02094 500000000 0.02029 250000000 0.02113 500000000 0.02129 10900000 72600000 -11900000 28100000 9200000 18900000 45600000 100000000.0 100000000.0 2500000 20 P3Y P18M 50000000.0 20 11500000 5400000 30800000 25400000 -22000000.0 P12M 75000000.0 25000000.0 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2020, 2019 and 2018 and the line items within the consolidated statements of comprehensive income where the gains/(losses) on these derivatives are recorded (in thousands). </span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.143%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the years ended<br/>December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Statement of Comprehensive Income location</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives in hedging relationships (1)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount of loss reclassified from AOCI into income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss/(gain) on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss/(gain) on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,758)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss/(gain) on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss/(gain) on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward purchase contract:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of forward purchase contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss/(gain) on derivative financial instruments</span></td></tr></table></div>(1)     Certain older interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in AOCI have been released into earnings. 4066000 6189000 8003000 -73000 16954000 -3357000 114000 -9565000 -9758000 6908000 49472000 -16569000 408000 -2681000 -440000 25375000 -21977000 0 5800000 -11500000 0 Available for Sale Debt Securities <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our available for sale debt securities recorded at fair value is shown below as of December 31, 2020 and December 31, 2019 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value (1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">125,121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">89,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">125,121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131,280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of December 31, 2020, $70.0 million and $144.4 million are recorded as the current and non-current asset portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, respectively, in the consolidated balance sheet. As of December 31, 2019, the entire balance of the Series A Biohaven Preferred Shares was recorded as a non-current asset.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven at a price of $50,100.00 per preferred share, for a total of $125.0 million. The approval of Nurtec ODT (rimegepant) by the FDA in February 2020 results in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning on March 31, 2021 through December 31, 2024. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price. In the event that Biohaven defaults on any obligation to redeem Series A Biohaven Preferred Shares when required, the redemption amount shall accrue interest at the rate of 18% annually until the redemption price for such unredeemed Series A Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert all unredeemed Series A Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Biohaven Preferred Shares </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 7, 2020 we entered into a Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven to purchase up to 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”), for a total of $200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards, as discussed in Note 3––Fair Value Measurements and Financial Instruments. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Preferred Shares and to redeem any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the Series B original issue price per share. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the Series B original issue price. In the event that Biohaven defaults on any obligation to redeem Series B Biohaven Preferred Shares, the redemption amount shall accrue interest on the applicable original issue price at the rate of 18% annually until the redemption price for such unredeemed Series B Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert any or all unredeemed Series B Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the acquisition of the Series B Biohaven Preferred Shares, beginning on March 31, 2021, we will classify the Series B Biohaven Preferred Shares as available for sale debt securities. We have elected the fair value option to account for our Series B Forwards and will elect the fair value option for the Series B Biohaven Preferred Shares, when acquired. We believe the fair value option most accurately reflects the nature of the Series B Forwards and the associated Series B Biohaven Preferred Shares.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Tecfidera</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2012 and 2013, RPIFT acquired interests in the earn-out payable to the former shareholders of Fumapharm AG. The Fumapharm earn-out primarily represents an indirect interest in Biogen’s sales of Tecfidera, an oral therapeutic for the treatment of relapsing-remitting multiple sclerosis. Our investment in the Tecfidera earn-out was classified as available for sale debt securities.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This investment was structured in the form of multiple potential milestone payments, of which all were earned as of December 31, 2018. The allocated cost of each milestone was derived using a third-party analysis based on projected sales over time, the future competitive landscape, the strength of the patents underlying the product and the prevailing interest rate environment. The $600.0 million milestone payments that RPIFT was entitled to receive based on sales during the year ended December 31, 2018 were recorded as a $419.5 million realized gain in the consolidated statements of comprehensive income and a $180.5 million reduction of the investment in Tecfidera recorded as available for sale securities at the balance sheet date. As of December 31, 2020 and 2019, we had no available for sale debt securities related to our investment in Tecfidera.</span></div> <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our available for sale debt securities recorded at fair value is shown below as of December 31, 2020 and December 31, 2019 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value (1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">125,121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">89,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">125,121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131,280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of December 31, 2020, $70.0 million and $144.4 million are recorded as the current and non-current asset portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, respectively, in the consolidated balance sheet. As of December 31, 2019, the entire balance of the Series A Biohaven Preferred Shares was recorded as a non-current asset.</span></div> 125121000 89279000 214400000 125121000 89279000 214400000 125121000 6159000 131280000 125121000 6159000 131280000 70000000.0 144400000 2495 50100.00 125000000.0 0.18 3992 50100 200000000.0 0.18 P1Y 600000000.0 419500000 180500000 Financial Royalty Assets, Net<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of those products by unrelated companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2020 and December 31, 2019 are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated royalty duration (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative allowance for changes in expected cash flows (Note 7)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value (d)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,003,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,891,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,359,419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,150,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(145,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,004,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 (e)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,022,213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(634,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,387,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,219,101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(940,107)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,278,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(323,717)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,955,277</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.79pt">Dates shown represent management’s estimates of when a royalty will substantially end, which may depend on patent expiration dates (which may include patent term extensions) or other factors and may vary by geography. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.79pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:11.34pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7—Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:11.79pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion. </span></div><div style="margin-bottom:5pt;margin-top:6.7pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated royalty duration (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative allowance for changes in expected cash flows (Note 7)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise (d)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,639,045 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,639,045 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,131,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,059,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,332,077 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,332,077 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,193,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(332,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">861,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776,555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776,555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crysvita</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2033-2038 (e)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321,234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321,234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,768,929 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(464,005)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,304,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,163,030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(868,418)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,294,612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.79pt">Dates shown represent management’s estimates of when a royalty will substantially end, which may depend on patent expiration dates (which may include patent term extensions) or other factors and may vary by geography. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.79pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">The Vertex triple combination therapy, Trikafta, was approved by the FDA in October 2019. Sell-side equity research analysts’ consensus forecasts increased due to expected sales of the newly approved cystic fibrosis franchise product and resulted in a reversal of the entire cumulative allowance for changes in expected cash flows in the fourth quarter of 2019 related to this financial royalty asset.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:11.79pt">As of December 31, 2019, the timing of when we expected to reach the royalty cap of 2.5 times our purchase price was 2032. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cystic fibrosis franchise payment reduction</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Vertex announced that it reached an agreement with French authorities for a national reimbursement deal for Orkambi. As a result, management expected a reduction to royalty receipts in 2020 from the cystic fibrosis franchise of approximately $35.0 million to $45.0 million, to reflect an adjustment related to prior periods where we collected royalties on French sales of Orkambi at a higher selling price. We recognized a reduction to the current portion of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $41.0 million as of December 31, 2019. Upon receipt of the royalty payment in the first quarter of 2020, we did not recognize any material adjustments related to our estimate.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2020 and December 31, 2019 are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated royalty duration (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative allowance for changes in expected cash flows (Note 7)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value (d)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,003,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,891,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,359,419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,150,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(145,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,004,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 (e)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,022,213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(634,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,387,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,219,101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(940,107)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,278,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(323,717)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,955,277</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.79pt">Dates shown represent management’s estimates of when a royalty will substantially end, which may depend on patent expiration dates (which may include patent term extensions) or other factors and may vary by geography. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.79pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:11.34pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7—Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:11.79pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion. </span></div><div style="margin-bottom:5pt;margin-top:6.7pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated royalty duration (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative allowance for changes in expected cash flows (Note 7)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise (d)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,639,045 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,639,045 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,131,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,059,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,332,077 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,332,077 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,193,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(332,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">861,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776,555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776,555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crysvita</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2033-2038 (e)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321,234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321,234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,768,929 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(464,005)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,304,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,163,030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(868,418)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,294,612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.79pt">Dates shown represent management’s estimates of when a royalty will substantially end, which may depend on patent expiration dates (which may include patent term extensions) or other factors and may vary by geography. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.79pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">The Vertex triple combination therapy, Trikafta, was approved by the FDA in October 2019. Sell-side equity research analysts’ consensus forecasts increased due to expected sales of the newly approved cystic fibrosis franchise product and resulted in a reversal of the entire cumulative allowance for changes in expected cash flows in the fourth quarter of 2019 related to this financial royalty asset.</span></div>e)As of December 31, 2019, the timing of when we expected to reach the royalty cap of 2.5 times our purchase price was 2032. 5274896000 0 5274896000 2003797000 112720000 1891077000 1406291000 46872000 1359419000 1150335000 145565000 1004770000 686129000 0 686129000 675440000 0 675440000 3022213000 634950000 2387263000 14219101000 940107000 13278994000 323717000 12955277000 1300000000 4639045000 0 4639045000 2131272000 71789000 2059483000 1332077000 0 1332077000 1193918000 332624000 861294000 776555000 0 776555000 321234000 0 321234000 1768929000 464005000 1304924000 12163030000 868418000 11294612000 35000000.0 45000000.0 -41000000.0 Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets<div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets and includes the following activities:</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the movement in the cumulative allowance related to changes in forecasted royalty payments we expect to receive based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts’ </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">consensus forecasts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the movement in the cumulative allowance for current expected credit losses.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The periodic movement in the cumulative allowance is presented on the consolidated statements of comprehensive income as the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of $192.7 million to recognize an allowance for current expected credit losses on our portfolio of financial royalty assets. The current period provision for changes in expected cash flows from financial royalty assets reflects the activity for the period that relates to the change in estimates applied to calculate the allowance for credit losses, namely any new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts used in the effective interest model to measure income from our financial royalty assets. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">–</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Summary of Significant Accounting Policies for further information.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2017</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,045,868)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284,214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reversal of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,982,897)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(322,717)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,342,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reversal of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(868,418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative adjustment for adoption of ASU 2016-13</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reversal of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write off of credit loss allowance (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision for credit losses (c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,263,824)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)     Relates to amounts reversed out of the allowance at the end of a financial royalty asset’s life to bring the account balance to zero. Reversals solely impact the asset account and allowance account, there is no impact on the consolidated statements of comprehensive income.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)     Relates to amounts reversed out of the credit loss allowance associated with omecamtiv as a result of the write-off of the related financial royalty asset balance of $90.2 million.</span></div>(c)     Primarily related to the allowance for credit losses resulting from increases to our portfolio of financial royalty assets in 2020, predominantly the final tranche -192700000 The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):<div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2017</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,045,868)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284,214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reversal of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,982,897)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(322,717)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,342,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reversal of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(868,418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative adjustment for adoption of ASU 2016-13</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reversal of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write off of credit loss allowance (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision for credit losses (c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,263,824)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)     Relates to amounts reversed out of the allowance at the end of a financial royalty asset’s life to bring the account balance to zero. Reversals solely impact the asset account and allowance account, there is no impact on the consolidated statements of comprehensive income.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)     Relates to amounts reversed out of the credit loss allowance associated with omecamtiv as a result of the write-off of the related financial royalty asset balance of $90.2 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)     Primarily related to the allowance for credit losses resulting from increases to our portfolio of financial royalty assets in 2020, predominantly the final tranche of Tazverik, zavegepant, and the residual interest in the cystic fibrosis franchise.</span></div> 2045868000 284214000 341548000 -5637000 1982897000 322717000 1342038000 -95158000 868418000 192705000 645612000 570959000 -2964000 25174000 156186000 1263824000 90200000 Intangible Royalty Assets, Net<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2020 and 2019 (in thousands).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,666 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,550 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,666 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,492 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,724 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,492 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,724 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DPP-IV patents associated with the intangible royalty assets terminate at various dates up to 2022. The weighted average remaining life of the intangible royalty assets is 1.25 years. The projected amortization expense is $23.0 million and $5.7 million in 2021 and 2022, respectively.</span></div>Our revenue is tied to underlying patent protected sales of other DPP-IV products of various licensees. Such revenue from royalty assets is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate our royalty revenue from licensees based on the geography of the underlying sales, as this level of information is not always included in royalty reports provided to us. The marketers paying us royalties on these products do not always provide, and are not necessarily required to provide, the breakdown of product sales by geography. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 97% , 91% and 73% of our revenues from intangible royalty assets in the years ended December 31, 2020, 2019 and 2018, respectively. <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2020 and 2019 (in thousands).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,666 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,550 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,666 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,492 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,724 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,492 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,724 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 606216000 577550000 28666000 606216000 577550000 28666000 606216000 554492000 51724000 606216000 554492000 51724000 P1Y3M 23000000.0 5700000 0.97 0.91 0.73 Non-Consolidated Affiliates<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Legacy SLP Interest</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) from the Continuing Investors Partnerships for $303.7 million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participated in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also own a non-controlling interest in Old RPI. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income allocation from the Legacy SLP Interest is based on an estimate, as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this annual report. Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the year ended December 31, 2020, we received cash distributions of $22.7 million from the Legacy Investors Partnerships and recorded an income allocation of $62.0 million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in (earnings)/loss of non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Avillion Entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our partnership interests in Avillion Financing I, LP (“Avillion I”) and BAv Financing II, LP (“Avillion II”, or, together, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the entities. We recorded a loss allocation of $17.6 million, $32.5 million and $7.0 million within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity in (earnings)/loss of non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the years ended December 31, 2020, 2019 and 2018, respectively. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 19, 2017, the Avillion Entities announced that the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif (bosutinib). Avillion I is eligible to receive fixed payments from Pfizer based on this approval. Subsequent to the asset sale, the only operations of Avillion I are the collection of cash and unwinding of discount on the series of fixed annual payments due from Pfizer. We received distributions of $13.4 million and $14.1 million from Avillion I during the years ended December 31, 2020 and 2019, respectively, in connection with Avillion I’s receipt of the fixed annual payments due under its co-development agreement with Pfizer. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, RPIFT entered into an agreement with Avillion II, amended in 2019, to invest approximately $19.0 million to fund approximately 50% of the costs of a phase II clinical trial for the use of Merck KGaA’s anti-IL 17 nanobody M1095 (the “Merck KGgA Asset”) for the treatment of psoriasis in exchange for certain milestone and royalty payments. We received a distribution of $21.3 million from Avillion II in respect of the Merck </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">KGgA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset, for which development ceased during the year ended December 31, 2020. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018 RPIFT entered into an additional agreement to invest up to $105.0 million in Avillion II over multiple years to fund approximately 44% of the costs of Phase II and III clinical trials to advance Pearl Therapeutics, Inc.’s product PT-027 (the “AZ Asset”) through a global clinical development program for the treatment of asthma in exchange for a series of deferred payments and success-based milestones.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RPIFT had $28.6 million and $70.8 million of unfunded commitments related to the Avillion Entities as of December 31, 2020 and 2019, respectively. Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments.</span></div> 303700000 22700000 62000000.0 -17600000 -32500000 -7000000.0 13400000 14100000 19000000.0 0.50 21300000 105000000.0 0.44 28600000 70800000 R&amp;D Funding Expense <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we did not enter into any new R&amp;D funding arrangements. R&amp;D funding expense incurred in 2020 related to ongoing development stage funding payments, primarily under our co-funding agreement with Sanofi, and upfront funding related to a royalty on an unapproved product that we acquired from BioCryst in the quarter ended December 31, 2020. R&amp;D funding expense in 2019 primarily related to funding agreements with both Sanofi and Pfizer. We completed our funding commitments in the fourth quarter of 2019 under our agreement with Pfizer. R&amp;D funding expense incurred in 2018 related to funding agreements with Sanofi, Pfizer, Immunomedics and Biohaven. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $26.3 million of R&amp;D funding expense for the year ended December 31, 2020, of which $18.5 million related to our co-funding agreement with Sanofi. We recognized $83.0 million of R&amp;D funding expense during the year ended December 31, 2019, of which $18.2 million and $62.8 million related to our funding agreements with Sanofi and Pfizer, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $392.6 million of R&amp;D funding expense during the year ended December 31, 2018, of which $6.9 million and $99.3 million related to our funding agreements with Sanofi and Pfizer, respectively. We recognized the $175.0 million and $100.0 million in upfront payments and premiums paid over market value for stock purchases related to our Immunomedics and Biohaven funding agreements, respectively, as R&amp;D funding expense during the year ended December 31, 2018. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we have a remaining commitment of $16.6 million related to a R&amp;D funding agreement with Sanofi.</span></div> 26300000 18500000 83000000.0 18200000 62800000 392600000 6900000 99300000 175000000.0 100000000.0 16600000 Borrowings<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings at December 31, 2020 and 2019 consisted of the following (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:234.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:81.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RPIFT Senior Secured Credit Facilities (1):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIBOR + 200 bps</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,123,000</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loan A Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIBOR + 150 bps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,150,000</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183,416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,878)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,816,584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,238,122</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(281,984)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,816,584 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,956,138 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     The carrying value of our senior secured term loans, including the current portion, approximates its fair value and represented a Level 2 liability within the fair value hierarchy.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)     In February 2020, the outstanding principal amounts of our Prior Credit Facility (as defined below) were repaid in full with net proceeds from our senior secured credit facilities which we subsequently repaid in full in September 2020 with net proceeds from the Notes (as defined below) and available cash on hand.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Senior Unsecured Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 2, 2020, we issued $6 billion of senior unsecured notes (the “Notes”). Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. Interest on each series of the Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, commencing on March 2, 2021. The Notes were issued at a total discount of $149.0 million. In connection with the transaction, we capitalized approximately $40.4 million in debt issuance costs primarily comprised of underwriting fees. The discount and the capitalized debt issuance costs are recorded as a direct deduction from the carrying amount of the Notes on our consolidated balance sheets and are being amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50% as of December 31, 2020, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the Treasury Rate, plus a make-whole premium as defined in the indenture. Our Notes maturing after 2023 also have a call feature, exercisable at our option, to redeem the Notes at par in whole or in part one to six months immediately preceding maturity. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the occurrence of a change of control and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are required to comply with certain covenants under our Notes and, </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as of December 31, 2020, we were in compliance with all applicable covenants.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We used the net proceeds from the Notes offering, together with available cash on hand, to repay in full the senior secured credit facilities. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Senior Unsecured Revolving Credit Facility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 18, 2020, our subsidiary RP Holdings, as borrower, entered into a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) which provides for borrowing capacity of up to $1.5 billion for general corporate purposes. In connection with the transaction, we capitalized approximately $6.1 million in debt issuance costs related to the revolving credit facility which is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the current portion and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the non-current portion. As of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, there were no outstanding borrowings under the Revolving Credit Facility. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% per annum (“ABR”) or (b) adjusted LIBOR, plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our consolidated leverage ratio. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the ABR, LIBOR and future changes in our consolidated leverage ratio.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The revolving credit agreement (the “Credit Agreement”) that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated charges, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. As of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, RP Holdings was in compliance with these covenants. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 11, 2020, in connection with the Exchange Offer Transactions (as discussed in Note 1–Organization and Purpose) and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement (the “Senior Secured Credit Agreement”) with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. The senior secured credit facilities contained in the Senior Secured Credit Agreement consisted of a term loan A (“Tranche A-1”) and term loan B (“Tranche B-1”) in the amounts of $3.20 billion and $2.84 billion, respectively. Tranche A-1 had an interest rate of 1.50% above LIBOR and matures in February 2025. Tranche B-1 had an interest rate of 1.75% above LIBOR and matures in February 2027. In September 2020, the Company repaid in whole the outstanding principal amounts of term loans under the senior secured credit facilities governed by the Senior Secured Credit Agreement with net proceeds from the Notes and available cash on hand. Upon refinancing of our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $25.1 million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other non-operating expense/(income), net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RPIFT Senior Secured Credit Facilities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The RPIFT Senior Secured Credit Facilities (the “Prior Credit Facility”) was repaid in full in February 2020 in connection with the Exchange Offer Transactions. We recorded a loss on debt extinguishment of $5.4 million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other non-operating expense/(income), net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. As of December 31, 2019, the Prior Credit Facility included two term loans, Term Loan A and Term Loan B. Tranche A-4 required annual amortization of 5.9% per year and tranche B-6 required annual amortization of 3.2% per year. The Prior Credit Facility was secured by a grant by RPIFT of a security interest in substantially all of its personal property and a grant by RPCT of a security interest in RPIFT’s share (80%) of all amounts on deposit in RPCT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s bank account.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Prior Credit Facility contained the following covenants measured quarterly: (i) maximum total leverage ratio of 4:00 to 1:00; (ii) debt coverage ratio of greater than 3.50 to 1.00. RPIFT was in compliance with these covenants at December 31, 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Principal payments on the Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The future principal payments for our borrowings as of December 31, 2020 over the next five years and thereafter are as follows (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.929%"><tr><td style="width:1.0%"/><td style="width:77.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,000,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Excludes unamortized discount and loan issuance costs on long-term debt of $183.4 million as of December 31, 2020, which are amortized through interest expense over the remaining life of the underlying debt obligations. </span></div>As of December 31, 2020, the fair value of our outstanding Notes was approximately $6.2 billion and represented a Level 2 measurement within the fair value hierarchy. <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings at December 31, 2020 and 2019 consisted of the following (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:234.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:81.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RPIFT Senior Secured Credit Facilities (1):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIBOR + 200 bps</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,123,000</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loan A Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIBOR + 150 bps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,150,000</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183,416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,878)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,816,584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,238,122</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(281,984)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,816,584 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,956,138 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     The carrying value of our senior secured term loans, including the current portion, approximates its fair value and represented a Level 2 liability within the fair value hierarchy.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)     In February 2020, the outstanding principal amounts of our Prior Credit Facility (as defined below) were repaid in full with net proceeds from our senior secured credit facilities which we subsequently repaid in full in September 2020 with net proceeds from the Notes (as defined below) and available cash on hand.</span></div> 0.99322 0.0075 1000000000 0.98875 0.0120 1000000000 0.98284 0.0175 1000000000 0.97760 0.0220 1000000000 0.95556 0.0330 1000000000 0.95306 0.0355 1000000000 0 0 0.0200 4123000000 0.0150 2150000000 183416000 34878000 5816584000 6238122000 0 281984000 5816584000 5956138000 6000000000 149000000.0 40400000 0.02125 0.0250 1 1.01 P5Y 1500000000 6100000 0.005 0.005 0.01 4.00 4.50 2.50 3200000000 2840000000 0.0150 0.0175 -25100000 -5400000 2 0.059 0.032 0.80 4 3.50 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The future principal payments for our borrowings as of December 31, 2020 over the next five years and thereafter are as follows (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.929%"><tr><td style="width:1.0%"/><td style="width:77.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,000,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)     Excludes unamortized discount and loan issuance costs on long-term debt of $183.4 million as of December 31, 2020, which are amortized through interest expense over the remaining life of the underlying debt obligations. 0 0 1000000000 0 1000000000 4000000000 6000000000 183400000 6200000000 Shareholders’ Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital structure</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the completion of our IPO as discussed in Note 1–Organization and Purpose, there have been no material changes in our capital structure, except for the secondary offering that was completed in October 2020, whereby 17,343 thousand of our Class A ordinary shares were offered for sale by certain of the Continuing Investors (the “Selling Shareholders”) at a price of $42.00 per share. We did not receive any proceeds from or pay any underwriting costs associated with the sale of Class A ordinary shares offered by the Selling Shareholders. The shares sold in the offering consisted of (i) 4,137 thousand existing Class A ordinary shares held by the Continuing Investor Partnerships and (ii) 13,206 thousand newly-issued Class A ordinary shares issued in connection with the redemption of 13,206 thousand RP Holdings Class B Interests by the Continuing Investors Partnerships that participated in the secondary offering. As of December 31, 2020, we have outstanding 388,135 thousand Class A ordinary shares and 218,976 thousand Class B ordinary shares. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The purpose of the Class R redeemable shares was to ensure Royalty Pharma Limited had sufficient sterling denominated share capital at the time it was re-registered as a public limited company to Royalty Pharma plc, as required by the U.K. Companies Act. The Class R redeemable shares may be redeemed at the Company’s option in the future. Any such redemption would be at the nominal value of £1 each.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The RP Holdings Class B Interests are exchangeable on a one-for-one basis for our Class A ordinary shares pursuant to an Exchange Agreement entered into by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings that governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of December 31, 2020, we have outstanding deferred shares of 316,407 thousand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling interests</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Exchange Offer Transactions in February 2020, the only non-controlling interest related to RPSFT, for which the related movements are presented in the historical statements of shareholders’ equity. The net change in the balance of our four non-controlling interests for the year ended December 31, 2020 is as follows (in thousands): </span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.334%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(594,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(792,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income prior to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange by Continuing Investors of Class B shares for Class A ordinary shares and reallocation of historical equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Class A ordinary shares sold in IPO, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income subsequent to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gain on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Related to the Continuing Investors Partnerships’ ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A and Class B Interests as of December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">RP Holdings Class C Special Interest held by EPA Holdings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPA Holdings is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period will be grouped together as separate portfolios (each, a “Portfolio”). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests for which we will issue the same number of Class B ordinary shares, which will be subsequently exchanged for our Class A ordinary shares. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently expect any material Equity Performance Awards to be payable until the mid to late 2020s.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class A ordinary shares are entitled to receive ratably such dividends, if any, as may be approved from time to time by the Board of Directors. Subsequent to our IPO, we declared and paid two quarterly cash dividends for an aggregate amount of $112.5 million, or $0.15 per share during the year ended December 31, 2020 t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o holders of our Class A ordinary shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Future dividends are subject to declaration by the Board of Directors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Independent Director Equity Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 Independent Director Equity Incentive Plan was approved and became effective on June 15, 2020 whereby 800 thousand Class A ordinary shares were reserved for future issuance to our independent directors. As of December 31, 2020, approximately 675 thousand shares remain reserved for future issuance under the Equity Incentive Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU activity and share-based compensation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year. The estimated fair value of RSUs is based on the closing price of our Class A ordinary shares on the grant date. During the year ended December 31, 2020, we granted approximately 125 thousand RSUs, of which approximately 71 thousand RSUs were vested. No RSUs were cancelled or forfeited during the year. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized share-based compensation of approximately $5.7 million for the year ended December 31, 2020, which is recorded as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statement of comprehensive income. As of December 31, 2020, the total unrecognized share-based compensation expense related to total outstanding RSUs was less than $1.0 million, which we expect to recognize in the next six months. </span></div>In periods prior to the IPO, we did not have share-based awards or related share-based compensation. 17343000 42.00 4137000 13206000 13206000 388135000 218976000 50000 1 316407000 The net change in the balance of our four non-controlling interests for the year ended December 31, 2020 is as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.334%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(594,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(792,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income prior to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange by Continuing Investors of Class B shares for Class A ordinary shares and reallocation of historical equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Class A ordinary shares sold in IPO, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income subsequent to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gain on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table>(1)     Related to the Continuing Investors Partnerships’ ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A and Class B Interests as of December 31, 2020. 4 35883000 0 0 0 35883000 1165258000 9418000 1174676000 1037161000 1037161000 112339000 594592000 85426000 792357000 42151000 102892000 145043000 -750000 2433848000 2433098000 758354000 758354000 309566000 309566000 46741000 218137000 316993000 581871000 15015000 7488000 22503000 3612000 6018000 9630000 12436000 1939509000 3125091000 0 5077036000 0.36 0.64 112500000 0.15 800000 675000 125000 71000 0 5700000 1000000.0 P6M Earnings per Share<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares potentially issuable to EPA Holdings, and unvested RSUs issued under our Equity Incentive Plan. We use the “if-converted” method to determine the potentially dilutive effect of our Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the IPO, our capital structure included predominantly unitholder interests. We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements. Therefore, earnings per share information has not been presented for the years ended December 31, 2019 and 2018. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Class B ordinary shares, Class R redeemable shares, and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares, and deferred shares under the two-class method has not been presented. Our Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because shares of Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. Class B ordinary shares potentially issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact for the year ended December 31, 2020. Class B ordinary shares currently in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The basic and diluted earnings per share for the year ended December 31, 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares. We have 607,111 thousand fully diluted Class A ordinary shares outstanding as of December 31, 2020. The following table sets forth reconciliations used to compute basic and diluted earnings per Class A ordinary share (in thousands, except per share amounts).</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Basic earnings per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,701,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net income attributable to Continuing Investors Partnerships prior to the IPO (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net income attributable to Continuing Investors Partnerships subsequent to the IPO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net income attributable to non-controlling interest - Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Diluted earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dilutive effect of unvested RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to controlling interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the consolidated statements of comprehensive income.</span></div> 607111000 The following table sets forth reconciliations used to compute basic and diluted earnings per Class A ordinary share (in thousands, except per share amounts).<div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Basic earnings per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,701,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net income attributable to Continuing Investors Partnerships prior to the IPO (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net income attributable to Continuing Investors Partnerships subsequent to the IPO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net income attributable to non-controlling interest - Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Diluted earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dilutive effect of unvested RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to controlling interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the consolidated statements of comprehensive income.</span></div> 1701954000 479842000 316993000 409921000 495198000 375444000 1.32 495198000 375444000 11000 375455000 1.32 Indirect Cash Flow<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,701,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,461,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,517,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,019,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gain on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(419,481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss/(gain) on derivative contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/loss on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(155,749)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,939 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in (earnings)/loss of non-consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,517 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions from non-consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,334 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on forwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,771)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Increase)/decrease in operating assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,959,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,648,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,524,816)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,121,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,934,092 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,052,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,390 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,099)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Increase/(decrease) in operating liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,034,629</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,667,239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,618,317</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash investing and financing activities are summarized below (in thousands).</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental schedule of non-cash investing / financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303,679 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of Epizyme forward purchase contract (Note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchase obligation - Tazverik (Note 17)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of long-term debt by contributions from non-controlling interest (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,103,774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milestone payable - Erleada (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="12" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Related to the pro rata portion of RPIFT’s outstanding debt repaid by the Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,701,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,461,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,517,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,019,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gain on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(419,481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss/(gain) on derivative contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/loss on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(155,749)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,939 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in (earnings)/loss of non-consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,517 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions from non-consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,334 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on forwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,771)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Increase)/decrease in operating assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,959,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,648,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,524,816)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,121,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,934,092 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,052,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,390 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,099)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Increase/(decrease) in operating liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,034,629</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,667,239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,618,317</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash investing and financing activities are summarized below (in thousands).</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental schedule of non-cash investing / financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303,679 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of Epizyme forward purchase contract (Note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchase obligation - Tazverik (Note 17)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of long-term debt by contributions from non-controlling interest (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,103,774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milestone payable - Erleada (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="12" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Related to the pro rata portion of RPIFT’s outstanding debt repaid by the Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1701954000 2461419000 1517855000 230839000 -1019321000 -57334000 23058000 23924000 33267000 11715000 12790000 13127000 0 0 419481000 -42076000 -39138000 11923000 247073000 155749000 -13939000 44459000 -32517000 -7023000 42334000 14059000 39402000 -30272000 0 0 5428000 0 0 20551000 0 0 18600000 0 0 65053000 0 0 34952000 0 0 -9621000 2122000 7771000 1959975000 1648837000 1524816000 2121923000 1934092000 2052592000 0 150000000 150000000 -370000 -2471000 27372000 0 -150000000 -150000000 770000 -7390000 11099000 10278000 -4607000 442000 -45264000 45635000 0 -766000 6496000 1350000 42146000 0 0 2034629000 1667239000 1618317000 303679000 0 0 5700000 0 0 110000000 0 0 1103774000 0 0 18600000 0 0 Accumulated Other Comprehensive Income (Loss)<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income is comprised of net income and other comprehensive income/(loss). We include unrealized gains and losses on available for sale debt securities and unrealized gains/(losses) on the interest rate swaps that were designated as cash flow hedges in other comprehensive income/(loss). Prior to January 1, 2018, unrealized gains and losses on available for sale equity securities were included in accumulated other comprehensive income/(loss). Beginning on January 1, 2018, following the adoption of ASU 2016-01, unrealized gains and losses on equity securities are recognized through earnings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in accumulated other comprehensive income/(loss) by component are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized gain/(loss) on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized gain/(loss) on available for sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized gain/(loss) on interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2017</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,863)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(402,502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(402,502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative adjustment for adoption of ASU 2016-01</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10,255)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10,255)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4,066)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,093</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,921)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,855)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassifications to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassifications from non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reclassification of unrealized gains on available for sale debt securities of $20.6 million in 2020 is presented within interest income on the statement of comprehensive income, including the reclassification of $10.9 million attributable to controlling interest noted in the table above.</span></div> <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in accumulated other comprehensive income/(loss) by component are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized gain/(loss) on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized gain/(loss) on available for sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized gain/(loss) on interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2017</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,863)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(402,502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(402,502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative adjustment for adoption of ASU 2016-01</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10,255)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10,255)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4,066)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,093</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,921)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,855)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassifications to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassifications from non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -2863000 402502000 -18258000 381381000 0 -402502000 0 -402502000 2863000 0 0 2863000 0 0 8003000 8003000 0 0 -10255000 -10255000 0 6159000 0 6159000 0 0 6189000 6189000 0 6159000 -4066000 2093000 0 -10921000 4066000 -6855000 0 60617000 0 60617000 0 24022000 0 24022000 0 2562000 0 2562000 0 34395000 0 34395000 20600000 -10900000 Related Party Transactions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Manager</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Manager is the investment manager of Royalty Pharma and its subsidiaries. The Manager is an affiliate of RP Ireland, the administrator of RPIFT and RPI Intermediate FT. The sole member of the Manager, Pablo Legorreta holds an interest in us and serves as our Chief Executive Officer and Chairman of the Board, and as a director on the board of RP Holdings.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer Transactions (discussed in Note 1–Organization and Purpose), the Manager has entered into new management agreements with RPI and its subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the new management agreements, RPI pays quarterly Operating and Personnel Payments in respect of operating and personnel expenses to the Manager or its affiliates equal to 6.5% of the Adjusted Cash Receipts (both, as defined in the New Management Agreement) for such quarter and 0.25% of the GAAP value of our security investments as of the end of such quarter. The Operating and Personnel Payment for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in our income statement, is calculated as the greater of $1 million per quarter and 0.3125% of Royalty Investments (as defined in the New Management Agreement) during the previous twelve calendar months. Operating and Personnel Payments incurred during the year ended December 31, 2020 were $112.5 million.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the Manager received operating and personnel payments in equal quarterly installments that increased by 5% annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships. RP Ireland receives an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the Limited Partnership Agreements of the Legacy Investors Partnerships. Operating and personnel payments incurred during years ended December 31, 2019 and 2018 were $60.0 million and $57.2 million, respectively, and were recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of comprehensive income.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution payable to non-controlling interest</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution payable to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPSFT’s non-controlling interest in RPCT. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution payable to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $126.4 million at December 31, 2020 includes the following: (1) $100.0 million due to the Legacy Investors Partnerships from Old RPI in connection with the Legacy Investors Partnerships’ non-controlling interest in Old RPI that arose in the Reorganization Transactions and (2) $26.3 million due to RPSFT from RPCT in connection with RPSFT’s non-controlling interest in RPCT. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution payable to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $31.0 million and $44.3 million at December 31, 2019 and 2018, respectively, represents the contractual distribution of cash flows due from RPCT to RPSFT in connection with its non-controlling interest in RPCT. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Epizyme </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, in connection with an equity investment in Epizyme Inc. of $100.0 million made by RPIFT, Pablo Legorreta, our Chief Executive Officer, was appointed as a director of Epizyme, for which he received compensation in cash and shares, all of which will be contributed to the Manager and used to reduce costs and expenses which would otherwise be billed to us or our affiliates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Bristol-Myers Squibb</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2017, RPI Acquisitions entered into a purchase agreement with Bristol-Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga, and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”). We agreed to make payments to BMS based on sales of the products over eight quarters beginning with the first quarter of 2018 in exchange for a high single-digit royalty on worldwide sales of the products from 2020 through 2025. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly owned subsidiary of BioPharma Credit PLC (“BPCR”), an affiliate of us. BPCR is a related entity due to the sole member of the investment manager having significant influence over both entities. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began making installment payments to BMS during the second quarter of 2018 and completed our funding in the first quarter of 2020. Installment payments made to BMS during the year ended December 31, 2020 and 2019 totaled $24.3 million and $171.0 million, respectively, of which RPI Acquisitions funded $12.1 million and $85.5 million, respectively. Upon transfer of funds from BPCR to RPI Acquisitions to meet the quarterly funding obligation to BMS, RPI Acquisitions derecognized 50% of the financial royalty asset. Cash received from BPCR in respect of each funding obligation equaled the carrying amount of the assigned transfer of interest, therefore no gain or loss was recognized upon the transfer. The financial royalty asset of $150.6 million and $150.3 million included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets as of December 31, 2020 and 2019, respectively, represents only our right to the future payment streams acquired from BMS. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded a cumulative amount of $162.4 million, net of the assigned funding obligations. We began to measure this financial royalty asset using the effective interest method once our installment funding obligation was completed and we received our first royalty payment on the asset in the second quarter of 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other transactions</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the year ended December 31, 2020, we reimbursed Pablo Legorreta, our Chief Executive Officer, approximately $1.0 million for the cost of purchasing and donating ventilators to hospitals on our behalf. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 9–Non-Consolidated Affiliates for additional discussion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnerships, whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3 million is recorded as treasury interests, of which $1.9 million is held by non-controlling interests in the consolidated balance sheet as of December 31, 2020. The total investment of $4.3 million was recorded as treasury interests held by controlling equity in the consolidated balance sheet as of December 31, 2019. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its ownership percentage of RP Holdings relative to us, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and the ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.</span></div> 0.065 0.0025 1000000 0.003125 112500000 0.05 60000000.0 57200000 126400000 100000000.0 26300000 31000000.0 44300000 100000000.0 0.50 0.50 24300000 171000000.0 12100000 85500000 0.50 150600000 150300000 162400000 1000000.0 27210 4300000 1900000 4300000 Commitments and Contingencies<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of its business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 7, 2020, we entered into a funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, for up to $450.0 million to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones. Biohaven received $150.0 million at closing and will receive $100.0 million upon the start of the oral zavegepant Phase III program. Pursuant to the Series B Biohaven Preferred Share Agreement, we will also provide further support for the ongoing launch of Nurtec ODT with the purchase of committed, non-contingent Commercial Launch Preferred Equity for a total of $200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, RPIFT agreed to pay $330.0 million to purchase Eisai’s royalties on future worldwide sales of Tazverik (tazemetostat), a novel targeted therapy in late-stage clinical development that was approved by the FDA in January 2020 for epithelioid sarcoma, and with the potential to be approved in several cancer indications. Under the terms of its agreement with Eisai, RPIFT acquired Eisai’s future worldwide royalties on net sales by Epizyme of Tazverik outside of Japan, for an upfront payment of $110.0 million plus up to an additional $220.0 million for the remainder of the royalty upon FDA approval of Tazverik for certain indications. The FDA approval of Tazverik in January 2020 triggered our obligation to fund the second $110.0 million tranche in November 2020. In June 2020, the FDA approval of additional indications of Tazverik triggered our obligation to fund the final $110.0 million tranche in November 2021, which is recorded within current liabilities on the consolidated balance sheet at December 31, 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have commitments to advance funds to counterparties through our investment in the Avillion Entities and R&amp;D arrangements. Please refer to Notes 9–Non-Consolidated Affiliates and 10–R&amp;D Funding Expense, respectively, for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the management agreement as described in Note 16–Related Party Transactions, which are variable and based on projected cash receipts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal proceedings</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings in our consolidated balance sheets as of December 31, 2020 and 2019. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.</span></div> 450000000.0 150000000.0 100000000.0 200000000.0 330000000.0 110000000.0 220000000.0 110000000.0 110000000.0 Subsequent EventsIn January 2021, we acquired a royalty interest in seltorexant from Minerva Neurosciences, Inc. for an upfront payment of $60 million and up to $95 million in additional milestone payments, contingent on the achievement of certain clinical, regulatory and commercialization milestones. Seltorexant is currently in Phase III development for the treatment of major depressive disorder (MDD) with insomnia symptoms by Janssen Pharmaceutica, N.V., a subsidiary of Johnson &amp; Johnson. 60000000 95000000 Related to the pro rata portion of RPIFT's outstanding debt repaid by the Legacy Investors Partnerships Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020, the period following our initial public offering (see Note 13). Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020. XML 17 R1.htm IDEA: XBRL DOCUMENT v3.20.4
    Cover - USD ($)
    $ in Billions
    		 12 Months Ended
    Dec. 31, 2020
    Feb. 19, 2021
    Jun. 30, 2020
    Document Information [Line Items]      
    Document Type 10-K    
    Document Annual Report true    
    Document Period End Date Dec. 31, 2020    
    Current Fiscal Year End Date --12-31    
    Document Transition Report false    
    Entity File Number 001-39329    
    Entity Registrant Name Royalty Pharma plc    
    Entity Incorporation, State or Country Code X0    
    Entity Tax Identification Number 98-1535773    
    Entity Address, Address Line One 110 East 59th Street    
    Entity Address, City or Town New York    
    Entity Address, State or Province NY    
    Entity Address, Postal Zip Code 10022    
    City Area Code 212    
    Local Phone Number 883-0200    
    Title of 12(b) Security Class A ordinary shares, par value $0.0001    
    Trading Symbol RPRX    
    Security Exchange Name NASDAQ    
    Entity Well-known Seasoned Issuer No    
    Entity Voluntary Filers No    
    Entity Current Reporting Status Yes    
    Entity Interactive Data Current Yes    
    Entity Filer Category Non-accelerated Filer    
    Entity Small Business false    
    Entity Emerging Growth Company false    
    Entity Shell Company false    
    Entity Public Float     $ 4.2
    Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement relating to the Annual Meeting of Shareholders, or Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2020. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof.    
    Entity Central Index Key 0001802768    
    Document Fiscal Year Focus 2020    
    Document Fiscal Period Focus FY    
    Amendment Flag false    
    Common Class A      
    Document Information [Line Items]      
    Entity Common Stock, Shares Outstanding   388,134,040  
    Common Class B      
    Document Information [Line Items]      
    Entity Common Stock, Shares Outstanding   218,976,830  
    XML 18 R2.htm IDEA: XBRL DOCUMENT v3.20.4
    Consolidated Balance Sheets - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Current Assets    
    Cash and cash equivalents $ 1,008,680 $ 246,199
    Marketable securities 983,279 94,455
    Financial royalty assets 587,193 452,560
    Accrued royalty receivable 33,155 33,525
    Available for sale debt securities 69,984 0
    Other royalty income receivable 6,011 5,241
    Other current assets 8,596 92
    Total current assets 2,696,898 832,072
    Financial royalty assets, net 12,368,084 10,842,052
    Intangible royalty assets, net 28,666 51,724
    Equity securities 298,689 380,756
    Available for sale debt securities 144,416 131,280
    Derivative financial instruments 5,439 42,315
    Investments in non-consolidated affiliates 454,936 124,061
    Other assets 23,158 45,635
    Total assets 16,020,286 12,449,895
    Current liabilities    
    Distribution payable to non-controlling interest 126,366 31,041
    Accounts payable and accrued expenses 10,775 11,177
    Interest payable 42,146 0
    Accrued purchase obligation 110,000 0
    Milestone payable 18,600 0
    Current portion of long-term debt 0 281,984
    Derivative financial instruments 0 9,215
    Total current liabilities 307,887 333,417
    Long-term debt 5,816,584 5,956,138
    Derivative financial instruments 0 18,902
    Total liabilities 6,124,471 6,308,457
    Commitments and contingencies
    Shareholders’/Unitholders’ equity    
    Shareholders’ contributions 0 3,282,516
    Deferred shares, $0.000001 par value, 316,407 and 0 issued and outstanding, respectively 0 0
    Additional paid-in capital 2,865,964 0
    Retained earnings 1,920,635 2,825,212
    Non-controlling interest 5,077,036 35,883
    Accumulated other comprehensive income 34,395 2,093
    Treasury interests (2,317) (4,266)
    Total shareholders’/unitholders’ equity 9,895,815 6,141,438
    Total liabilities and shareholders’/unitholders’ equity 16,020,286 12,449,895
    Common Class A    
    Shareholders’/Unitholders’ equity    
    Common stock 39 0
    Common Class B    
    Shareholders’/Unitholders’ equity    
    Common stock 0 0
    Class R Redeemable Stock    
    Shareholders’/Unitholders’ equity    
    Common stock $ 63 $ 0
    XML 19 R3.htm IDEA: XBRL DOCUMENT v3.20.4
    Condensed Consolidated Balance Sheets (Parenthetical)
    shares in Thousands
    Dec. 31, 2020
    $ / shares
    shares
    Dec. 31, 2020
    £ / shares
    shares
    Dec. 31, 2019
    $ / shares
    shares
    Dec. 31, 2019
    £ / shares
    shares
    Deferred stock, par value (in dollars per share) | $ / shares $ 0.000001   $ 0.000001  
    Deferred stock, issued (in shares) 316,407 316,407 0 0
    Deferred stock, outstanding (in shares) 316,407 316,407 0 0
    Common Class A        
    Common stock, par value (in dollars/pounds per share) | $ / shares $ 0.0001   $ 0.0001  
    Common stock, issued (in shares) 388,135 388,135 0 0
    Common stock, outstanding (in shares) 388,135 388,135 0 0
    Common Class B        
    Common stock, par value (in dollars/pounds per share) | $ / shares $ 0.000001   $ 0.000001  
    Common stock, issued (in shares) 218,976 218,976 0 0
    Common stock, outstanding (in shares) 218,976 218,976 0 0
    Class R Redeemable Stock        
    Common stock, par value (in dollars/pounds per share) | £ / shares   £ 1   £ 1
    Common stock, issued (in shares) 50 50 0 0
    Common stock, outstanding (in shares) 50 50 0 0
    XML 20 R4.htm IDEA: XBRL DOCUMENT v3.20.4
    Consolidated Statements of Comprehensive Income - USD ($)
    shares in Thousands, $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Revenues $ 2,122,353 $ 1,814,254 $ 1,794,894
    Operating expenses      
    Research and development funding expense 26,289 83,036 392,609
    Provision for changes in expected cash flows from financial royalty assets 230,839 (1,019,321) (57,334)
    Amortization of intangible assets 23,058 23,924 33,267
    General and administrative expenses 181,715 103,439 61,906
    Other operating expenses 65,053 0 0
    Total operating expenses, net 526,954 (808,922) 430,448
    Operating income 1,595,399 2,623,176 1,364,446
    Other (income)/expense      
    Equity in (earnings)/loss of non-consolidated affiliates (44,459) 32,517 7,023
    Interest expense 157,059 268,573 279,956
    Realized gain on available for sale debt securities 0 0 (419,481)
    Unrealized loss/(gain) on derivative financial instruments 42,076 39,138 (11,923)
    (Gain)/loss on equity securities (247,073) (155,749) 13,939
    Unrealized Gain (Loss) on Derivatives (18,600) 0 0
    Interest income (28,379) (22,329) (24,441)
    Other non-operating expense/(income), net 32,821 (393) 1,518
    Total other (income)/expense, net (106,555) 161,757 (153,409)
    Consolidated net income before tax 1,701,954 2,461,419 1,517,855
    Income tax expense 0 0 0
    Consolidated net income 1,701,954 2,461,419 1,517,855
    Less: Net income attributable to non-controlling interest (726,914) (112,884) (140,126)
    Net income attributable to controlling interest 975,040 2,348,535 1,377,729
    Other comprehensive income/(loss)      
    Reclassification of loss on interest rate swaps 4,066 6,189 8,003
    Unrealized gain/(loss) on available for sale debt securities 83,120 6,159 (402,502)
    Reclassification of unrealized gain on available for sale debt securities (20,551) 0 0
    Other comprehensive income/(loss) 66,635 12,348 (394,499)
    Comprehensive income 1,041,675 2,360,883 983,230
    Less: Other comprehensive income attributable to non-controlling interest (12,873) 0 0
    Comprehensive income attributable to controlling interest $ 1,028,802 2,360,883 983,230
    Earnings per Class A ordinary share      
    Basic (in dollars per share) [1] $ 1.32    
    Diluted (in dollars per share) [1] $ 1.32    
    Weighted average Class A ordinary shares outstanding      
    Basic (in shares) [1] 375,444    
    Diluted (in shares) [1] 375,455    
    Financial Royalty Assets      
    Revenues $ 1,959,975 1,648,837 1,524,816
    Intangible Royalty Assets      
    Revenues 143,382 145,775 134,118
    Royalty Income, Other      
    Revenues $ 18,996 $ 19,642 $ 135,960
    [1] Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020, the period following our initial public offering (see Note 13).
    XML 21 R5.htm IDEA: XBRL DOCUMENT v3.20.4
    Consolidated Statements of Shareholders' Equity - USD ($)
    $ in Thousands
    Total
    Cumulative Effect, Period of Adoption, Adjustment
    Class R Redeemable Stock
    Unitholders’ Contributions
    Common Stock
    Common Class A
    Common Stock
    Common Class B
    Common Stock
    Class R Redeemable Stock
    Deferred Shares
    Additional Paid-In Capital
    Shareholders’ Contributions
    Retained Earnings
    Retained Earnings
    Cumulative Effect, Period of Adoption, Adjustment
    Accumulated Other Comprehensive Income/(Loss)
    Accumulated Other Comprehensive Income/(Loss)
    Cumulative Effect, Period of Adoption, Adjustment
    Non-Controlling Interest
    Treasury Interests
    Beginning balance at Dec. 31, 2017 $ 4,460,546 $ 0   $ 3,282,516             $ 655,446 $ (2,863) $ 381,381 $ 2,863 $ 141,203 $ 0
    Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
    Distributions (1,031,823)                   (814,359)       (217,464)  
    Net income (loss) 1,517,855                   1,377,729       140,126  
    Unrealized gain/(loss) on available for sale debt securities (402,502)                       (402,502)      
    Reclassification of loss on interest rate swaps 8,003                       8,003      
    Reclassification of unrealized gain on available for sale debt securities 0                              
    Ending balance at Dec. 31, 2018 4,552,079     3,282,516             1,215,953   (10,255)   63,865 0
    Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
    Distributions $ (880,142)                   (739,276)       (140,866)  
    Accounting standards update [Extensible List] us-gaap:AccountingStandardsUpdate201613Member                              
    Net income (loss) $ 2,461,419                   2,348,535       112,884  
    Unrealized gain/(loss) on available for sale debt securities 6,159                       6,159      
    Reclassification of loss on interest rate swaps 6,189                       6,189      
    Purchase of treasury interests (4,266)                             (4,266)
    Reclassification of unrealized gain on available for sale debt securities 0                              
    Ending balance (in shares) at Dec. 31, 2019         0 0 0 0                
    Ending balance at Dec. 31, 2019 6,141,438 $ (192,705)   $ 3,282,516 $ 0 $ 0 $ 0 $ 0 $ 0   2,825,212 $ (192,705) 2,093   35,883 (4,266)
    Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
    Distributions (1,105,765)                   (313,408)       (792,357)  
    Net income (loss) 1,701,954                              
    Unrealized gain/(loss) on available for sale debt securities 83,120                       60,617   22,503  
    Reclassification of loss on interest rate swaps 4,066                       4,066   0  
    Contributions 1,482,322                 $ 307,646         1,174,676  
    Transfer of interests 0                 (1,037,161)         1,037,161  
    Initial share issuance upon registration of Royalty Pharma plc (in shares)             50,000                  
    Initial share issuance upon registration of Royalty Pharma plc 63           $ 63                  
    Issuance of Class B shares to Continuing Investor Partnerships (in shares)           535,383,000                    
    Issuance of Class B shares to Continuing Investors Partnerships 1         $ 1                    
    Effect of exchange by Continuing Investors of Class B shares for Class A shares and reallocation of historical equity (in shares)         294,176,000 (294,176,000)   294,176,000                
    Effect of exchange by Continuing Investors of Class B shares for Class A ordinary shares and reallocation of historical equity (1)       $ 30 $ (1)     1,402,762 (2,553,001) (1,261,014)   (24,022)   2,433,098 2,147
    Issuance of Class A ordinary shares sold in initial public offering, net of offering costs (in shares)         71,652,000                      
    Issuance of Class A ordinary shares sold in IPO, net of offering costs 1,908,744       $ 7       1,150,383           758,354  
    Share based compensation and related issuance of Class A ordinary shares (in shares)         76,000                      
    Share-based compensation and related issuance of Class A ordinary shares 5,428               5,428              
    Other exchanges (in shares)         22,231,000 (22,231,000)   22,231,000                
    Other exchanges 191       $ 2       307,391       2,562   (309,566) (198)
    Dividends (112,490)                   (112,490)          
    Reclassification of unrealized gain on available for sale debt securities (20,551)                       (10,921)   (9,630)  
    Ending balance (in shares) at Dec. 31, 2020     50,000   388,135,000 218,976,000 50,000 316,407,000                
    Ending balance at Dec. 31, 2020 $ 9,895,815       $ 39 $ 0 $ 63 $ 0 $ 2,865,964 $ 0 $ 1,920,635   $ 34,395   $ 5,077,036 $ (2,317)
    XML 22 R6.htm IDEA: XBRL DOCUMENT v3.20.4
    Consolidated Statements of Cash Flows - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Cash flows from operating activities:      
    Cash collections from financial royalty assets $ 2,121,923 $ 1,934,092 $ 2,052,592
    Cash collections from intangible royalty assets 143,753 143,298 106,689
    Other royalty cash collections 18,305 27,448 125,162
    Distributions from non-consolidated affiliates 42,334 14,059 39,402
    Interest received 7,704 20,136 24,441
    Swap collateral received 45,252 360 3,467
    Swap collateral posted 0 (45,630) (510)
    Swap termination payments (35,448) 0 0
    Ongoing development-stage funding payments (20,479) (83,036) (108,163)
    Upfront development-stage funding payments (5,810) 0 (284,446)
    Payments for operating and professional costs (179,709) (88,524) (72,535)
    Payments for rebates 0 0 (125)
    Interest paid (103,196) (254,964) (267,657)
    Net cash provided by operating activities 2,034,629 1,667,239 1,618,317
    Cash flows from investing activities:      
    Distributions from non-consolidated affiliates 15,084 0 0
    Purchases of available for sale debt securities 0 (125,121) 0
    Purchase of warrants 0 (8,840) 0
    Purchases of equity securities (50,000) (78,999) (152,810)
    Proceeds from available for sale debt securities 3,000 150,000 750,000
    Purchases of marketable securities (1,705,283) (817,402) 0
    Proceeds from sales and maturities of marketable securities 815,440 725,070 0
    Proceeds from equity securities 384,840 0 0
    Investments in non-consolidated affiliates (40,155) (27,042) (24,173)
    Acquisitions of financial royalty assets (2,182,246) (1,721,291) (269,593)
    Milestone payments 0 (250,000) 0
    Net cash (used in)/provided by investing activities (2,759,320) (2,153,625) 303,424
    Cash flows from financing activities:      
    Distributions to shareholders/unitholders (285,353) (739,276) (814,359)
    Distributions to non-controlling interest (543,952) (154,084) (268,693)
    Distributions to non-controlling interest- other (181,135) 0 0
    Dividends to shareholders (112,490) 0 0
    Contributions from non-controlling interest- R&D 8,482 0 0
    Contributions from non-controlling interest- other 58,957 0 0
    Scheduled repayments of long-term debt (94,200) (294,000) (294,000)
    Repayments of long-term debt (11,116,196) 0 0
    Proceeds from issuance of long-term debt 11,891,030 0 0
    Debt issuance costs and other (46,715) 0 (2,049)
    Purchase of treasury interests 0 (4,266) 0
    Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs 1,908,744 0 0
    Net cash provided by/(used in) financing activities 1,487,172 (1,191,626) (1,379,101)
    Net change in cash and cash equivalents 762,481 (1,678,012) 542,640
    Cash and cash equivalents, beginning of year 246,199 1,924,211 1,381,571
    Cash and cash equivalents, end of year $ 1,008,680 $ 246,199 $ 1,924,211
    XML 23 R7.htm IDEA: XBRL DOCUMENT v3.20.4
    Organization and Purpose
    		 12 Months Ended
    Dec. 31, 2020
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Organization and Purpose Organization and Purpose
    Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (the “IPO”) of our Class A ordinary shares that was completed in June 2020.

    Following our IPO, we control Royalty Pharma Holdings Ltd. (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K. tax resident through our ownership of RP Holdings’ Class A ordinary shares (the “RP Holdings Class A Interests”) and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our consolidated financial statements.

    RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV, which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish Unit Trust (“Old RPI”), for accounting and financial reporting purposes. RP Holdings is owned directly by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, (together, the “Continuing Investors Partnerships”), and Royalty Pharma plc. Old RPI is a unit trust established in August 2011 under the laws of Ireland and authorized by the Central Bank of Ireland pursuant to the Unit Trusts Act, 1990. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”).

    RP Management, LLC (the “Manager”), a Delaware limited liability company, is an external adviser which is responsible for our management. RP Management (Ireland) Ltd. (“RP Ireland”), is the manager of Old RPI and equivalent to the board of directors of a company or general partner of a partnership and is responsible for the day to day operations of Old RPI. Its functions can be delegated to third parties. RP Ireland delegated responsibility for investment management of Old RPI to its parent company, the Manager, in accordance with the investment objectives and policies of Old RPI.

    “Royalty Pharma,” “Royalty Pharma Investments,” “RPI,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Reorganization Transactions (defined below) and before the consummation of the IPO, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma Investments 2019 ICAV. Prior to the Reorganization Transactions, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Old RPI.
    We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

    Reorganization Transactions

    In connection with our IPO, we consummated an exchange offer on February 11, 2020 (the “Exchange Date”). Through the exchange offer, investors representing 82% of the aggregate limited partnership in the Legacy Investors Partnerships, exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under a new credit facility and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”
    As a result of the Exchange Offer Transactions, we own, through our wholly-owned subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”), an 82% economic interest in Old RPI. Through our 82% indirect ownership of Old RPI, we are legally entitled to 82% of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish Unit trust. From the Exchange Date until the expiration of the Legacy Investors Partnerships’ investment period on June 30, 2020 (the “Legacy Date”), the Legacy Investors Partnerships were offered to participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI has ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Following the Legacy Date, we have made and will continue to make new investments through our subsidiaries, including RPI Intermediate FT.
    As part of the Exchange Offer Transactions, the Legacy Investors Partnerships and RPI Intermediate FT entered into new credit facilities in the amount of $1.3 billion and $6.0 billion, respectively, the proceeds of which were primarily used to repay the $6.3 billion outstanding debt of RPIFT as of the Exchange Date and, in the case of RPI Intermediate FT, was also available to be used to fund investments. As part of the new credit facilities, RPI Intermediate FT repaid $5.2 billion, its pro rata portion of RPIFT’s outstanding debt and accrued interest. RPIFT also terminated all outstanding interest rate swaps in connection with the debt refinancing.
    Prior to, and as a condition precedent to the closing of the IPO, various reorganization transactions became effective, including the following:
    •the Exchange Offer Transactions (as described above); and
    •the execution of a new management agreement with the Manager (the “New Management Agreement”).

    We refer to these transactions collectively as the “Reorganization Transactions.”

    As Old RPI is our predecessor for financial reporting purposes, we have recorded Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date. The references in the following notes for the periods prior to the Exchange Date refer to the financial results of Old RPI for the same periods.
    IPO

    In June 2020, we completed our IPO, in which we issued 89,334 thousand shares of Class A ordinary shares at a price to the public of $28.00 per share, of which 71,652 thousand and 17,682 thousand shares were offered by the Company and selling shareholders, respectively. The Company received net proceeds of approximately $1.9 billion from the IPO after deducting underwriting discounts and commissions. The Class A ordinary shares began trading on the Nasdaq Global Select Market under the ticker symbol “RPRX” on June 16, 2020. We used the net proceeds from the IPO to acquire the RP Holdings Class A Interests shortly after completion of the IPO. As a result, we own 100% of RP Holdings Class A Interests.

    In connection with the IPO, pursuant to the Exchange Offer Transactions, certain of the Continuing Investor Partnerships agreed to exchange, upon consummation of the IPO, interests in the Continuing Investors Partnerships represented by their ownership of 294,176 thousand RP Holdings Class B Interests into an aggregate of 294,176 thousand Class A ordinary shares of the Company. Upon completion of the exchange, Royalty Pharma plc indirectly owned 294,176 thousand RP Holdings Class B Interests. The remaining investors in the Continuing Investors Partnerships who did not elect to exchange into Class A ordinary shares held 241,207 thousand newly issued Class B ordinary shares of Royalty Pharma plc. As a result, the Continuing Investors Partnerships held a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests indirectly held by them at such time which are exchangeable on a one-for-one basis for Class A ordinary shares of Royalty Pharma plc. Our Class B ordinary shares will not be publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. However, the RP Holdings Class B Interests will be entitled to dividends and distributions from RP Holdings. Our Class A ordinary and Class B ordinary shares will vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law, with each share entitled to one vote.
    XML 24 R8.htm IDEA: XBRL DOCUMENT v3.20.4
    Summary of Significant Accounting Policies
    		 12 Months Ended
    Dec. 31, 2020
    Accounting Policies [Abstract]  
    Summary of Significant Accounting Policies Summary of Significant Accounting Policies
    Basis of preparation and use of estimates

    The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.

    The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, the pandemic has not materially impacted our financial performance and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.

    Basis of consolidation

    The consolidated financial statements include the accounts of Royalty Pharma plc and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record Net income attributable to non-controlling interest in our consolidated statements of comprehensive income equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

    Following management’s determination that a high degree of common ownership existed in RPI both before and after the Exchange Date, RPI recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date.

    Prior to the Exchange Offer Transactions, our only historical non-controlling interest was attributable to a de minimis interest in RPCT held by RPSFT. As a result of the Exchange Offer Transactions in February 2020, a new non-controlling interest was created related to the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI.

    Following the consummation of our IPO in June 2020, two new non-controlling interests were created: (1) a non-controlling interest related to the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, which amounted to approximately 36% as of December 31, 2020, and (2) a non-controlling interest attributable to the RP Holdings Class C Special Interest held by EPA Holdings, an affiliate of the Manager. Income will not be allocated to the latter non-controlling interest until certain conditions are met, which we do not expect to occur for several years.

    All intercompany transactions and balances have been eliminated in consolidation.

    Adjustment to prior period presentation

    In connection with the preparation of our condensed consolidated interim financial statements for the three months ended September 30, 2020, we identified an adjustment to the classification of our short-term investments on our consolidated balance sheets, as of December 31, 2019, based on the original maturity dates of the investments. The adjustment resulted in an increase of $37.5 million to Marketable securities and a corresponding decrease to Cash and cash equivalents on the consolidated balance sheet as of December 31, 2019. In addition, the adjustment resulted in an increase of $388.0 million and $350.5 million in cash activity related to Purchases of marketable securities and Proceeds from sales and maturities of marketable securities, respectively, within Net cash used in investing activities for the year ended December 31, 2019, with a net impact on net cash flow from investing of $37.5 million. The adjustment had no effect on our reported total income and revenues, consolidated net income, total assets, or shareholders’ equity for any period. In addition, the adjustment does not impact net cash provided by operating activities in any period. We evaluated the adjustment and determined that, based on quantitative and qualitative analysis, it was not material to the consolidated financial statements as of and for the year ended December 31, 2019.
    Concentrations of credit risk
    Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2020 and 2019 were held with State Street, Deutsche Bank and Bank of America. Our primary operating accounts significantly exceed the FDIC limits.

    The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Abbott, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Gilead, Johnson & Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche/ Genentech and Vertex. For the years ended December 31, 2020 and 2019, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise products, accounted for 27% and 17% of our current portion of Financial royalty assets, respectively.

    We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.

    Segment information

    Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.

    Royalty assets

    An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.

    In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.

    Financial royalty assets, net

    Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (“ASC”), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 Imputation of Interest.
    The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty assets is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as Provision for changes in expected future cash flows from financial royalty assets and the carrying value of Financial royalty assets, net is presented net of the cumulative allowance for changes in expected future cash flows.

    The application of the prospective approach to measure financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties.
    The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product and royalty duration, each discussed in further detail below.

    •Analyst coverage. Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to derive annual sales projections for each financial royalty asset by applying the median growth rates calculated from consensus forecasts among sell-side equity research analysts currently reporting on a product to the corresponding periods for which we are entitled to royalties. Growth rates inherent in these forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst estimates are not available for the full term of the royalty, particularly for the later years in a product’s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management’s own expertise. Further, based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms and rates are then applied to the adjusted sales projections to calculate the expected royalty payments over the term of the financial royalty asset’s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.

    •Commercial performance. The approval of a product for use in new indications can extend the date through which we are entitled to royalties on that product. Likewise, for certain royalties, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in sales projections. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts’ forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product’s performance in the market can materially affect our forecast of expected future cash flows over the royalty term.
    •Royalty duration. The duration of a royalty can be based on a number of factors, such as patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product’s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation outcomes. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.

    As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) product growth rates and sales trends in outer years, (2) the geographical allocation of annual sales data from sell-side equity research analysts’ models, (3) the product and pricing mix for franchised products, (4) the strength of patent protection, including anticipated entry of generics and (5) estimates of the duration of the royalty. The most sensitive of these assumptions relates to management’s estimate of the royalty duration in the final years of an asset’s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows.

    A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.

    The current portion of Financial royalty assets, net represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears.

    Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets

    We evaluate financial royalty assets for impairment on an individual basis at each reporting date by comparing the effective interest rate to that of the prior period. If the current period effective interest rate is lower than the prior period, and if the gross cash flows have declined (expected and collected), management records a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset’s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period’s effective interest rate. The amount recognized as provision expense increases the financial royalty asset’s cumulative allowance, which reduces the net carrying value of the financial royalty asset.
    In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. Management also recalculates the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.

    Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the Financial royalty assets, net line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset’s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either Provision for changes in expected cash flows from financial royalty assets or as Income from financial royalty assets on the consolidated statements of comprehensive income.

    Income from financial royalty assets

    We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.

    When royalties continue to be collected for financial royalty assets that have been fully amortized, such income is recognized as Other royalty income.

    Allowance for current expected credit losses

    On January 1, 2020, we adopted ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of Financial royalty assets, net on the consolidated balance sheets. Any subsequent routine movement in the allowance for credit losses is recorded as part of the Provision for changes in expected future cash flows from financial royalty assets on the consolidated statements of comprehensive income.

    Refer to Note 7—Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for further information.

    Intangible royalty assets, net

    Currently, our only intangible royalty assets are the Januvia and Janumet (“DPP-IV”) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, which terminate at various dates until 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.
    Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10, Property, Plant, and Equipment - Overall. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product’s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty’s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.

    Revenue from intangible royalty assets and Accrued royalty receivable

    We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue on DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts’ projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.

    Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.

    Milestone payments

    Certain acquisition agreements provide for future contingent payments based on the financial performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts’ consensus forecasts. Milestones based on regulatory approval are not reflected in the expected future cash flows until such approval is achieved.

    Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.

    Financial instruments

    Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than Financial royalty assets, net are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 3–Fair Value Measurements and Financial Instruments.

    Cash and cash equivalents and Marketable securities

    Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value.
    Equity securities and Available for sale debt securities

    Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities, including our investment in the Biohaven Series A Preferred Shares, are measured at fair value and unrealized gains and losses are included in accumulated other comprehensive income/(loss) (“AOCI”). Unrealized gains and losses are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows.

    A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management’s assessment.

    We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.

    Derivatives

    All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements.

    Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of comprehensive income as part of Unrealized gain/(loss) on derivative financial instruments.

    Investment in non-consolidated affiliates

    Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at cost. Subsequently, we recognize through earnings our proportionate share of the investee’s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of these entities one quarter in arrears within Equity in (earnings)/loss of non-consolidated affiliates in the consolidated statements of comprehensive income. The investment is reflected as Investments in non-consolidated affiliates on the consolidated balance sheet.

    We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the “Avillion entities”). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.
    When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets.

    Research and development funding expense

    We enter into transactions where we agree to fund a portion of the research and development (“R&D”) for products undergoing late-stage clinical trials in exchange for future royalties if the products are successfully developed and commercialized. In accordance with ASC 730 Research and Development, we account for the funded amounts as R&D expense when we have the ability to obtain the results of the R&D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval.

    Royalty payments owed to the Company on successfully commercialized products generated from R&D agreements are recognized as Other royalty income in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria (i.e., typically the achievement of agreed upon sales thresholds) for products arising out of our R&D arrangements are also recognized as Other royalty income in the period that the commercial sales threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed and we have no further performance obligations.

    Income taxes

    We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (“the Code”) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.

    While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments.

    Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes.

    We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI.
    We are also subject to the U.K.’s “controlled foreign companies” rules (the “U.K. CFC Rules”). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the “Controlled Foreign Company”) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings), will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes.

    Earnings per share

    Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares and restricted share units (“RSUs”) issued under our 2020 Independent Director Equity Incentive Plan (“Equity Incentive Plan”). We use the “if-converted” method to determine the potentially dilutive effect of Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.

    There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information has been presented for any period prior to that date.

    Recently adopted accounting standards

    In May 2014, the Financial Accounting Standard Board (“FASB”) issued a new revenue standard under ASC Topic 606 (ASU 2014-09). ASU 2014-09 applies to all contracts with customers. Based on management’s assessment, income from financial royalty assets which are accounted for in accordance with ASC 310, Receivables, is not subject to the application of ASU 2014-09. As a result, management believes that financial royalty assets represent contractual rights and obligations that continue to be within the scope of Topic 310 and therefore specifically exempted from the new revenue standard. The provisions of ASU 2014-09 became effective for us on January 1, 2018, including interim reporting periods. Our revenues are primarily derived from intangible royalty assets, which fall under the sales-based royalties exception in the new standard. Therefore, we did not recognize any adjustment upon adoption of the new revenue standard.

    In January 2016, the FASB issued revised guidance for the accounting and reporting of financial instruments (ASU 2016-01) and in 2018 issued related technical corrections (ASU 2018-03). The new guidance requires that equity investments with readily determinable fair values currently classified as available for sale be measured at fair value with changes in fair value recognized in net income. The new guidance also changed certain disclosure requirements. We adopted ASU 2016-01 as of January 1, 2018 using a modified retrospective approach. We recorded a cumulative-effect adjustment upon adoption that decreased retained earnings by $2.9 million as a result of accumulated other comprehensive income previously recognized on its available for sale equity securities. ASU 2018-03 was also adopted as of January 1, 2018 on a prospective basis and did not result in any additional impact upon adoption.

    In August 2016, the FASB issued revised guidance which makes eight targeted changes to how royalty receipts and cash payments are presented and classified in the Statement of Cash Flows (ASU 2016-15). Among the updates, the standard allows companies to elect the “cumulative earnings” approach or the “nature-of-the-distribution” approach in distinguishing whether distributions received from equity method investees are returns of investment, which should be classified as cash flows from investing activities, and returns on investment, which should be classified as cash flows from operating activities. We made a policy election to use the “cumulative earnings” approach and adopted ASU 2016-15 for the year ended December 31, 2018.
    In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to Retained earnings of $192.7 million to recognize an allowance for current expected credit losses on our financial royalty assets.

    In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.
    XML 25 R9.htm IDEA: XBRL DOCUMENT v3.20.4
    Fair Value Measurements and Financial Instruments
    		 12 Months Ended
    Dec. 31, 2020
    Fair Value Disclosures [Abstract]  
    Fair Value Measurements and Financial Instruments Fair Value Measurements and Financial Instruments
    Fair value measurements

    The summary below presents information about our assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020 and 2019, and the valuation techniques we utilized to determine such fair value.

    •Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Our Level 1 assets consist of equity securities with readily determinable fair values and money market funds.
    •Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. Our Level 2 assets generally include marketable securities, warrants, derivatives and our interest rate swap contracts, which may be in an asset or liability position.
    •Level 3: Prices or valuation that requires inputs that are both significant to the fair value measurement and unobservable. Our Level 3 assets consist of our investments in the Series A Biohaven Preferred Shares and the Series B Forwards and, historically, our investment in Tecfidera. See Note 5––Available for Sale Debt Securities for a description of our investments in the Biohaven Preferred Shares.

    For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety.
    Fair value hierarchy

    The following is a summary of the inputs used to value our financial assets and liabilities measured at fair value as of December 31, 2020 and 2019 (in thousands):
    As of December 31, 2020
    Level 1Level 2Level 3Total
    Assets:
    Cash equivalents
    Money market funds$24,302 $— $— $24,302 
    Commercial paper— 77,176 — 77,176 
    Certificates of deposit— 74,502 — 74,502 
    Marketable securities
    Corporate debt securities— 32,754 — 32,754 
    Commercial paper— 444,554 — 444,554 
    Certificates of deposit— 505,971 — 505,971 
    Available for sale debt securities— — 69,984 69,984 
    Total current assets$24,302 $1,134,957 $69,984 $1,229,243 
    Equity securities (1)298,689 — — 298,689 
    Available for sale debt securities— — 144,416 144,416 
    Forwards (2)— — 18,600 18,600 
    Warrants (3)— 5,439 — 5,439 
    Total non-current assets$298,689 $5,439 $163,016 $467,144 
    (1)Upon Gilead’s acquisition of Immunomedics, our investment in Immunomedics common stock was redeemed in full in the fourth quarter of 2020, resulting in a gain of $292.3 million recognized within (Gain)/loss on equity securities in the year ended December 31, 2020.
    (2)The Series B Forwards, recorded within Other assets in the consolidated balance sheet as of December 31, 2020, relate to our obligation to fund the acquisition of the Series B Biohaven Preferred Shares.
    (3)Related to Epizyme transaction as described in Note 4–Derivative Instruments and recorded in the non-current asset portion of Derivative financial instruments in the consolidated balance sheet as of December 31, 2020.

    The net unrealized gain or loss recognized on equity securities still held as of December 31, 2020 was a loss of $45.2 million, a gain of $125.6 million and a loss of $7.8 million for the years ended December 31, 2020, 2019 and 2018, respectively.
    As of December 31, 2019
    Level 1Level 2Level 3Total
    Assets:
    Cash equivalents
    Money market funds$222,326 $— $— $222,326 
    Certificates of deposit— 4,000 — 4,000 
    Marketable securities
    U.S. government securities— 12,877 — 12,877 
    Commercial paper— 21,367 — 21,367 
    Certificates of deposit— 60,211 — 60,211 
    Total current assets$222,326 $98,455 $— $320,781 
    Equity securities380,756 — — 380,756 
    Available for sale debt securities— — 131,280 131,280 
    Warrants (1)— 30,815 — 30,815 
    Forward purchase contract (1)— 11,500 — 11,500 
    Total non-current assets$380,756 $42,315 $131,280 $554,351 
    Liabilities:
    Interest rate swaps— (9,215)— (9,215)
    Total current liabilities$— $(9,215)$— $(9,215)
    Interest rate swaps— (18,902)— (18,902)
    Total non-current liabilities$— $(18,902)$— $(18,902)
    (1)Related to Epizyme warrants and put option as described in Note 4–Derivative Instruments and both recorded in the non-current asset portion of Derivative financial instruments in the consolidated balance sheet as of December 31, 2019.

    The tables presented below summarize the change in the carrying value of Level 3 financial instruments, which relate to our investment in the Series A Biohaven Preferred Shares and the Series B Forwards (in thousands).
    For the years ended
    December 31,
    20202019
    Available for sale debt securities
    Balance at the beginning of the period$131,280 $— 
    Purchases— 125,121 
    Unrealized gains on available for sale debt securities52,725 — 
    Transfer to Level 2(184,005)— 
    Transfer from Level 2 (1)198,526 — 
    Unrealized gains on available for sale debt securities15,874 6,159 
    Balance at the end of the period$214,400 $131,280 
    (1)     Includes $14.5 million of unrealized gains on available for sale debt securities included in other comprehensive income while the instrument was classified as a Level 2 asset.

    For the year ended
    December 31,
    2020
    Forwards
    Balance at the beginning of the period$— 
    Unrealized gains included in earnings (1)18,600 
    Balance at the end of the period$18,600 
    (1)     Recorded within Unrealized gain on forwards on the consolidated statements of comprehensive income.
    Valuation inputs

    Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.

    Investment in Series A Biohaven Preferred Shares

    The fair value of the Series A Biohaven Preferred Shares at December 31, 2020 is based on the cash flows due to us from Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”) of two times (2x) the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6 million following U.S. Food and Drug Administration (“FDA”) approval and starting one-year after FDA approval through December 31, 2024. The FDA approved Nurtec ODT (rimegepant) in February 2020, at which point we became entitled to receive a fixed payment amount of $250.0 million payable in equal quarterly payments from March 31, 2021 through December 31, 2024. For additional discussion of our investment in the Series A Biohaven Preferred Shares, see Note 5––Available for Sale Debt Securities.

    The fair value of the Series A Biohaven Preferred Shares at December 31, 2020 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate of 8.3% could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower. At December 31, 2020 we estimated the fair value for the Series A Biohaven Preferred Shares as $214.4 million, which we classified as available for sale debt securities.

    For periods prior to March 31, 2020, we valued the Series A Biohaven Preferred Shares using a Black-Derman Toy (“BDT”) lattice model. The fair value of the Series A Biohaven Preferred Shares at December 31, 2019 was determined based on significant inputs that were not observable in the market, referred to as Level 3 inputs. Key inputs to the BDT model for the December 31, 2019 valuation included, most notably, the probability (1) of Biohaven’s pipeline product, Nurtec ODT (rimegepant), being approved by the FDA by specific dates, (2) of a change of control event by specific dates and (3) that Biohaven will elect to redeem the Series A Biohaven Preferred Shares for a lump sum payment as opposed to payback over time. Probabilities for the above considerations were developed by management, which has significant healthcare and finance expertise to make such assessments. The most critical assumption that impacted the valuation of our Series A Biohaven Preferred Shares at December 31, 2019 was the probability that Nurtec ODT (rimegepant) would be approved by the FDA.

    Assumptions used in the valuation model as of December 31, 2019 included the following significant unobservable inputs:
    •Change of Control probability on a quarterly basis (0%)
    •Likelihood of FDA approval (0%-86%)
    •Likelihood of FDA approval at the end of any given quarter by December 31, 2024 (Range: 0%-59%).

    Our investment in the Series A Biohaven Preferred Shares was transferred from a Level 3 asset to a Level 2 asset in February 2020, when Nurtec ODT (rimegepant) received FDA approval, at which time we began using a discounted cash flow analysis that relied on observable inputs. During the three months ended December 31, 2020, we became aware of Biohaven’s issuance of debt and its effective interest rate and refined our valuation of the Series A Biohaven Preferred shares as of December 31, 2020 to incorporate this significant unobservable input. As a result, we reclassified the investment from a Level 2 to a Level 3 asset during the three months ended December 31, 2020.
    Investment in Series B Biohaven Preferred Shares

    We have committed to acquiring 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share for a total of $200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024 (“Series B Forwards”). In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments equal to approximately 1.8 times the original issue price per share between March 31, 2025 and December 31, 2030. For additional discussion of our investment in the Series B Biohaven Preferred Shares, see Note 5–Available for Sale Debt Securities.

    The fair value of the Series B Forwards as of December 31, 2020 is based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a 10-year time period and developing a risk-adjusted discounted rate requires significant judgement. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimate fair value could be significantly higher or lower than the fair value determined by management at any particular date. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower. We have elected the fair value option to account for our Series B Forwards as it most accurately reflects the nature of our Series B Forwards, which we record within Other assets in our consolidated balance sheet. The unrealized movement in fair value of the Series B forwards is recorded within Unrealized gain on forwards on the consolidated statements of comprehensive income.

    Other financial instruments

    We use a third party pricing service for Level 2 inputs used to value cash equivalents, marketable securities and borrowings, which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. Warrants are valued using a Black-Scholes option pricing model which considers observable and unobservable inputs. Level 2 interest rate swaps are typically valued using counterparty confirmations, LIBOR yield curves and credit valuation adjustments.

    Financial assets not measured at fair value

    Financial royalty assets are measured and carried on the consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. The fair value of financial royalty assets is calculated by management using the forecasted royalty payments we expect to receive based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts’ consensus forecasts. These projected future royalty payments by asset are then discounted to a present value using appropriate individual discount rates. The fair value of our financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of our financial royalty assets as of December 31, 2020 and 2019 are presented below (in thousands).

    December 31, 2020December 31, 2019
    Fair valueCarrying value, netFair valueCarrying value, net
    Financial royalty assets, net$18,718,179 $12,368,084 $16,501,819 $10,842,052 
    XML 26 R10.htm IDEA: XBRL DOCUMENT v3.20.4
    Derivative Instruments
    		 12 Months Ended
    Dec. 31, 2020
    Derivative Instruments and Hedging Activities Disclosure [Abstract]  
    Derivative Instruments Derivative InstrumentsWe have historically managed the impact of foreign currency exchange rate and interest rate risk through various financial instruments, including derivative instruments such as interest rate swap contracts and foreign currency forward contracts. Our policy is to use derivatives strategically to hedge existing interest rate exposure and to minimize volatility in cash flow arising from our exposure to interest rate risk and foreign currency risk. We may also acquire other financial instruments that are classified as derivatives. We do not enter into derivative instruments for trading or speculative purposes.
    Interest rate swaps

    As of December 31, 2020, we do not hold any interest rate swap contracts. In connection with the Exchange Offer Transactions described in Note 1–Organization and Purpose, RPIFT terminated all outstanding interest rate swaps in February 2020. We paid $35.4 million to terminate our swaps and reclaimed $45.3 million of collateral that was held by the respective counterparties.

    As of December 31, 2019, RPIFT held interest rate swap contracts to effectively convert a portion of its floating-rate debt to a fixed basis. The notional values and fixed rates payable on the swap contracts are shown in the table below.
    Notional Value
    (in millions)    		Fixed RateMaturity Date
    $6002.019 %November 9, 2020
    $2502.094 %March 27, 2023
    $5002.029 %March 27, 2023
    $2502.113 %March 27, 2023
    $5002.129 %March 27, 2023

    We do not apply hedge accounting and recognize all movement in fair value through earnings. All outstanding interest rate swaps were terminated in February 2020. During the years ended December 31, 2020 and 2019, we recorded unrealized losses of $10.9 million and $72.6 million, respectively, on interest rate swaps in the consolidated statements of comprehensive income. During the year ended December 31, 2018, we recorded unrealized gains of $11.9 million on interest rate swaps in the consolidated statements of comprehensive income.

    As of December 31, 2019, the fair value of the swaps was a net liability of $28.1 million (a current liability of $9.2 million and a non-current liability of $18.9 million) and included within Derivative financial instruments on the consolidated balance sheets.

    RPIFT had master International Swaps and Derivatives Association (“ISDA”) agreements in place with its derivative instrument counterparties which provide for final close out netting with counterparties for all positions in the case of default or termination of the ISDA agreement. Under these agreements, RPIFT has set-off rights with the same counterparty but elected not to offset such derivative instrument fair values in the consolidated balance sheets.

    RPIFT generally had executed a Credit Support Annex (“CSA”) under the ISDA it maintains with each of its over-the-counter (“OTC”) derivative counterparties that requires both posting and accepting collateral either in the form of cash or high-quality securities. These CSAs are bilateral agreements that require collateral postings by the party “out-of-the-money” or in a net derivative liability position. Various thresholds for the amount and timing of collateralization of net liability positions are applicable. RPIFT elected not to offset fair value amounts of any outstanding derivatives against the fair value amounts recognized for the related cash collateral receivable or payable that arise from those derivative instruments on the consolidated balance sheets.

    Only the swaps maturing in 2023 had collateral requirements. At December 31, 2019, RPIFT had a receivable of $45.6 million in cash collateral previously posted to trade counterparties, which was recorded in Other assets on the consolidated balance sheets. At December 31, 2019, RPIFT did not have the obligation to return any cash collateral to counterparties, as it did not hold any cash collateral at that date.

    Epizyme put option and warrant

    In November 2019, RPIFT made an equity investment in Epizyme Inc. (“Epizyme”) of $100.0 million. Under the terms of its agreement with Epizyme, RPIFT made an upfront payment of $100.0 million for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5 million shares of Epizyme common stock at $20 per share over a three-year term and (3) Epizyme’s royalty on sales of Tazemetostat in Japan payable by Eisai Co., Ltd (“Eisai”). In addition, Epizyme had an 18 month put option to sell an additional $50.0 million of its common stock to RPIFT at then prevailing prices, not to exceed $20 per share.
    On December 31, 2019, Epizyme notified RPIFT of its intention to exercise the put option. As a result, we recorded a forward purchase contract equal to the difference between the market value and exercise price of $11.5 million in the non-current asset portion of Derivative financial instruments on the consolidated balance sheet at December 31, 2019. The exercise of the put option was settled in February 2020.

    The warrant was recognized at fair value of $5.4 million and $30.8 million within the non-current asset portion of Derivative financial instruments on the consolidated balance sheets at December 31, 2020 and 2019, respectively. We recorded an unrealized loss on derivative contracts of $25.4 million and an unrealized gain on derivative contracts of $22.0 million related to the change in fair value of the warrants on the consolidated statements of comprehensive income for the years ended December 31, 2020 and 2019, respectively.

    Biohaven written put option

    We determined there was a derivative associated with the Second Tranche (as defined below) of the Series A Biohaven Preferred Shares Agreement that was entered into in April 2019. The derivative related to Biohaven’s option, exercisable within 12 months from when the NDA for Nurtec ODT (rimegepant) was accepted by the FDA for Priority Review, to require Royalty Pharma to purchase up to an additional $75.0 million of Series A Biohaven Preferred Shares (the “Second Tranche”) at the same price and on the same terms as the First Tranche, in one or more transactions of no less than $25.0 million. As of December 31, 2019, management determined that the value of the Second Tranche written put option was immaterial, and therefore no derivative liability was recognized on the consolidated balance sheets. The exercise period for the Biohaven written put option expired in the year ended December 31, 2020, and therefore there was no value or movement in fair value associated with the Biohaven written put option as of or for the year ended December 31, 2020. See Note 5–Available for Sale Debt Securities for a description of our investment in the Series A Biohaven Preferred Shares.

    Summary of derivatives and reclassifications

    The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2020, 2019 and 2018 and the line items within the consolidated statements of comprehensive income where the gains/(losses) on these derivatives are recorded (in thousands).
    For the years ended
    December 31,    		Consolidated Statement of Comprehensive Income location
    202020192018
    Derivatives in hedging relationships (1)
    Interest Rate Swaps:
    Amount of loss reclassified from AOCI into income$4,066 $6,189 $8,003 Unrealized loss/(gain) on derivative financial instruments
    Change in fair value of interest rate swaps(73)16,954 (3,357)Unrealized loss/(gain) on derivative financial instruments
    Interest expense/(income)114 (9,565)(9,758)Interest expense
    Derivatives not designated as hedging instruments
    Interest Rate Swaps:
    Change in fair value of interest rate swaps6,908 49,472 (16,569)Unrealized loss/(gain) on derivative financial instruments
    Interest expense/(income)408 (2,681)(440)Interest expense
    Warrant:
    Change in fair value of warrant25,375 (21,977)— Unrealized loss/(gain) on derivative financial instruments
    Forward purchase contract:
    Change in fair value of forward purchase contract5,800 (11,500)— Unrealized loss/(gain) on derivative financial instruments
    (1)     Certain older interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in AOCI have been released into earnings.
    XML 27 R11.htm IDEA: XBRL DOCUMENT v3.20.4
    Available for Sale Debt Securities
    		 12 Months Ended
    Dec. 31, 2020
    Investments, Debt and Equity Securities [Abstract]  
    Available for Sale Debt Securities Available for Sale Debt Securities
    A summary of our available for sale debt securities recorded at fair value is shown below as of December 31, 2020 and December 31, 2019 (in thousands):
    CostUnrealized gainsFair Value (1)
    As of December 31, 2020
    Series A Biohaven Preferred Shares$125,121 $89,279 $214,400 
    Total available for sale debt securities$125,121 $89,279 $214,400 
    As of December 31, 2019
    Series A Biohaven Preferred Shares$125,121 $6,159 $131,280 
    Total available for sale debt securities$125,121 $6,159 $131,280 
    (1)As of December 31, 2020, $70.0 million and $144.4 million are recorded as the current and non-current asset portion of Available for sale debt securities, respectively, in the consolidated balance sheet. As of December 31, 2019, the entire balance of the Series A Biohaven Preferred Shares was recorded as a non-current asset.

    Series A Biohaven Preferred Shares

    On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven at a price of $50,100.00 per preferred share, for a total of $125.0 million. The approval of Nurtec ODT (rimegepant) by the FDA in February 2020 results in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning on March 31, 2021 through December 31, 2024. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price. In the event that Biohaven defaults on any obligation to redeem Series A Biohaven Preferred Shares when required, the redemption amount shall accrue interest at the rate of 18% annually until the redemption price for such unredeemed Series A Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert all unredeemed Series A Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date.

    Series B Biohaven Preferred Shares

    On August 7, 2020 we entered into a Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven to purchase up to 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”), for a total of $200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards, as discussed in Note 3––Fair Value Measurements and Financial Instruments. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Preferred Shares and to redeem any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the Series B original issue price per share. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the Series B original issue price. In the event that Biohaven defaults on any obligation to redeem Series B Biohaven Preferred Shares, the redemption amount shall accrue interest on the applicable original issue price at the rate of 18% annually until the redemption price for such unredeemed Series B Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert any or all unredeemed Series B Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date.
    Upon the acquisition of the Series B Biohaven Preferred Shares, beginning on March 31, 2021, we will classify the Series B Biohaven Preferred Shares as available for sale debt securities. We have elected the fair value option to account for our Series B Forwards and will elect the fair value option for the Series B Biohaven Preferred Shares, when acquired. We believe the fair value option most accurately reflects the nature of the Series B Forwards and the associated Series B Biohaven Preferred Shares.

    Tecfidera

    In 2012 and 2013, RPIFT acquired interests in the earn-out payable to the former shareholders of Fumapharm AG. The Fumapharm earn-out primarily represents an indirect interest in Biogen’s sales of Tecfidera, an oral therapeutic for the treatment of relapsing-remitting multiple sclerosis. Our investment in the Tecfidera earn-out was classified as available for sale debt securities.

    This investment was structured in the form of multiple potential milestone payments, of which all were earned as of December 31, 2018. The allocated cost of each milestone was derived using a third-party analysis based on projected sales over time, the future competitive landscape, the strength of the patents underlying the product and the prevailing interest rate environment. The $600.0 million milestone payments that RPIFT was entitled to receive based on sales during the year ended December 31, 2018 were recorded as a $419.5 million realized gain in the consolidated statements of comprehensive income and a $180.5 million reduction of the investment in Tecfidera recorded as available for sale securities at the balance sheet date. As of December 31, 2020 and 2019, we had no available for sale debt securities related to our investment in Tecfidera.
    XML 28 R12.htm IDEA: XBRL DOCUMENT v3.20.4
    Financial Royalty Assets, Net
    		 12 Months Ended
    Dec. 31, 2020
    Receivables [Abstract]  
    Financial Royalty Assets, Net Financial Royalty Assets, Net
    Financial royalty assets consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of those products by unrelated companies.

    The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2020 and December 31, 2019 are as follows (in thousands):
    December 31, 2020Estimated royalty duration (a)Gross carrying valueCumulative allowance for changes in expected cash flows (Note 7)Net carrying value (d)
    Cystic fibrosis franchise2037 (b)$5,274,896 $— $5,274,896 
    Tysabri(c)2,003,797 (112,720)1,891,077 
    Imbruvica2027-20291,406,291 (46,872)1,359,419 
    Xtandi2027-20281,150,335 (145,565)1,004,770 
    Promacta2025-2027686,129 — 686,129 
    Evrysdi2030-2035 (e)675,440 — 675,440 
    Other2020-20393,022,213 (634,950)2,387,263 
    Total$14,219,101 $(940,107)$13,278,994 
    Less: Cumulative allowance for credit losses (Note 7)(323,717)
    Total financial royalty assets, net$12,955,277 
    a)Dates shown represent management’s estimates of when a royalty will substantially end, which may depend on patent expiration dates (which may include patent term extensions) or other factors and may vary by geography. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. There can be no assurances that our royalties will expire when expected.
    b)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on generic entry.
    c)Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
    d)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7—Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.
    e)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
    December 31, 2019Estimated royalty duration (a)Gross carrying valueCumulative allowance for changes in expected cash flows (Note 7)Net carrying value
    Cystic fibrosis franchise (d)2037 (b)$4,639,045 $— $4,639,045 
    Tysabri(c)2,131,272 (71,789)2,059,483 
    Imbruvica2027-20291,332,077 — 1,332,077 
    Xtandi2027-20281,193,918 (332,624)861,294 
    Promacta2025-2027776,555 — 776,555 
    Crysvita2033-2038 (e)321,234 — 321,234 
    Other2019-20391,768,929 (464,005)1,304,924 
    Total$12,163,030 $(868,418)$11,294,612 
    a)Dates shown represent management’s estimates of when a royalty will substantially end, which may depend on patent expiration dates (which may include patent term extensions) or other factors and may vary by geography. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. There can be no assurances that our royalties will expire when expected.
    b)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on generic entry.
    c)Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
    d)The Vertex triple combination therapy, Trikafta, was approved by the FDA in October 2019. Sell-side equity research analysts’ consensus forecasts increased due to expected sales of the newly approved cystic fibrosis franchise product and resulted in a reversal of the entire cumulative allowance for changes in expected cash flows in the fourth quarter of 2019 related to this financial royalty asset.
    e)As of December 31, 2019, the timing of when we expected to reach the royalty cap of 2.5 times our purchase price was 2032.

    Cystic fibrosis franchise payment reduction

    In November 2019, Vertex announced that it reached an agreement with French authorities for a national reimbursement deal for Orkambi. As a result, management expected a reduction to royalty receipts in 2020 from the cystic fibrosis franchise of approximately $35.0 million to $45.0 million, to reflect an adjustment related to prior periods where we collected royalties on French sales of Orkambi at a higher selling price. We recognized a reduction to the current portion of Financial royalty assets of $41.0 million as of December 31, 2019. Upon receipt of the royalty payment in the first quarter of 2020, we did not recognize any material adjustments related to our estimate.
    XML 29 R13.htm IDEA: XBRL DOCUMENT v3.20.4
    Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets
    		 12 Months Ended
    Dec. 31, 2020
    Credit Loss [Abstract]  
    Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets
    The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of Financial royalty assets, net on the consolidated balance sheets and includes the following activities:

    •the movement in the cumulative allowance related to changes in forecasted royalty payments we expect to receive based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts’ consensus forecasts, and
    •the movement in the cumulative allowance for current expected credit losses.

    The periodic movement in the cumulative allowance is presented on the consolidated statements of comprehensive income as the Provision for changes in expected future cash flows from financial royalty assets.

    Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to Retained earnings of $192.7 million to recognize an allowance for current expected credit losses on our portfolio of financial royalty assets. The current period provision for changes in expected cash flows from financial royalty assets reflects the activity for the period that relates to the change in estimates applied to calculate the allowance for credit losses, namely any new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts used in the effective interest model to measure income from our financial royalty assets. Refer to Note 2–Summary of Significant Accounting Policies for further information.
    The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):
    Activity for the year
    Balance at December 31, 2017$(2,045,868)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(284,214)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets341,548 
    Reversal of cumulative allowance (a)5,637 
    Balance at December 31, 2018(1,982,897)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(322,717)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets1,342,038 
    Reversal of cumulative allowance (a)95,158 
    Balance at December 31, 2019(868,418)
    Cumulative adjustment for adoption of ASU 2016-13(192,705)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(645,612)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets570,959 
    Reversal of cumulative allowance (a)2,964 
    Write off of credit loss allowance (b)25,174 
    Current period provision for credit losses (c)(156,186)
    Balance at December 31, 2020$(1,263,824)
    (a)     Relates to amounts reversed out of the allowance at the end of a financial royalty asset’s life to bring the account balance to zero. Reversals solely impact the asset account and allowance account, there is no impact on the consolidated statements of comprehensive income.
    (b)     Relates to amounts reversed out of the credit loss allowance associated with omecamtiv as a result of the write-off of the related financial royalty asset balance of $90.2 million.
    (c)     Primarily related to the allowance for credit losses resulting from increases to our portfolio of financial royalty assets in 2020, predominantly the final tranche
    XML 30 R14.htm IDEA: XBRL DOCUMENT v3.20.4
    Intangible Royalty Assets, Net
    		 12 Months Ended
    Dec. 31, 2020
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Intangible Royalty Assets, Net Intangible Royalty Assets, Net
    The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2020 and 2019 (in thousands).
    As of December 31, 2020CostAccumulated amortizationNet carrying value
    DPP-IV patents$606,216 $577,550 $28,666 
    Total intangible royalty assets$606,216 $577,550 $28,666 
    As of December 31, 2019CostAccumulated amortizationNet carrying value
    DPP-IV patents$606,216 $554,492 $51,724 
    Total intangible royalty assets$606,216 $554,492 $51,724 

    The DPP-IV patents associated with the intangible royalty assets terminate at various dates up to 2022. The weighted average remaining life of the intangible royalty assets is 1.25 years. The projected amortization expense is $23.0 million and $5.7 million in 2021 and 2022, respectively.
    Our revenue is tied to underlying patent protected sales of other DPP-IV products of various licensees. Such revenue from royalty assets is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate our royalty revenue from licensees based on the geography of the underlying sales, as this level of information is not always included in royalty reports provided to us. The marketers paying us royalties on these products do not always provide, and are not necessarily required to provide, the breakdown of product sales by geography. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 97% , 91% and 73% of our revenues from intangible royalty assets in the years ended December 31, 2020, 2019 and 2018, respectively.
    XML 31 R15.htm IDEA: XBRL DOCUMENT v3.20.4
    Non-Consolidated Affiliates
    		 12 Months Ended
    Dec. 31, 2020
    Equity Method Investments and Joint Ventures [Abstract]  
    Non-Consolidated Affiliates Non-Consolidated Affiliates
    The Legacy SLP Interest

    In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) from the Continuing Investors Partnerships for $303.7 million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participated in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also own a non-controlling interest in Old RPI.

    The income allocation from the Legacy SLP Interest is based on an estimate, as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this annual report. Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the year ended December 31, 2020, we received cash distributions of $22.7 million from the Legacy Investors Partnerships and recorded an income allocation of $62.0 million within Equity in (earnings)/loss of non-consolidated affiliates.

    The Avillion Entities

    We account for our partnership interests in Avillion Financing I, LP (“Avillion I”) and BAv Financing II, LP (“Avillion II”, or, together, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the entities. We recorded a loss allocation of $17.6 million, $32.5 million and $7.0 million within Equity in (earnings)/loss of non-consolidated affiliates during the years ended December 31, 2020, 2019 and 2018, respectively.

    On December 19, 2017, the Avillion Entities announced that the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif (bosutinib). Avillion I is eligible to receive fixed payments from Pfizer based on this approval. Subsequent to the asset sale, the only operations of Avillion I are the collection of cash and unwinding of discount on the series of fixed annual payments due from Pfizer. We received distributions of $13.4 million and $14.1 million from Avillion I during the years ended December 31, 2020 and 2019, respectively, in connection with Avillion I’s receipt of the fixed annual payments due under its co-development agreement with Pfizer.

    In March 2017, RPIFT entered into an agreement with Avillion II, amended in 2019, to invest approximately $19.0 million to fund approximately 50% of the costs of a phase II clinical trial for the use of Merck KGaA’s anti-IL 17 nanobody M1095 (the “Merck KGgA Asset”) for the treatment of psoriasis in exchange for certain milestone and royalty payments. We received a distribution of $21.3 million from Avillion II in respect of the Merck KGgA Asset, for which development ceased during the year ended December 31, 2020.

    In May 2018 RPIFT entered into an additional agreement to invest up to $105.0 million in Avillion II over multiple years to fund approximately 44% of the costs of Phase II and III clinical trials to advance Pearl Therapeutics, Inc.’s product PT-027 (the “AZ Asset”) through a global clinical development program for the treatment of asthma in exchange for a series of deferred payments and success-based milestones.

    RPIFT had $28.6 million and $70.8 million of unfunded commitments related to the Avillion Entities as of December 31, 2020 and 2019, respectively. Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments.
    XML 32 R16.htm IDEA: XBRL DOCUMENT v3.20.4
    R&D Funding Expense
    		 12 Months Ended
    Dec. 31, 2020
    Research and Development [Abstract]  
    R&D Funding Expense R&D Funding Expense
    During the year ended December 31, 2020, we did not enter into any new R&D funding arrangements. R&D funding expense incurred in 2020 related to ongoing development stage funding payments, primarily under our co-funding agreement with Sanofi, and upfront funding related to a royalty on an unapproved product that we acquired from BioCryst in the quarter ended December 31, 2020. R&D funding expense in 2019 primarily related to funding agreements with both Sanofi and Pfizer. We completed our funding commitments in the fourth quarter of 2019 under our agreement with Pfizer. R&D funding expense incurred in 2018 related to funding agreements with Sanofi, Pfizer, Immunomedics and Biohaven.

    We recognized $26.3 million of R&D funding expense for the year ended December 31, 2020, of which $18.5 million related to our co-funding agreement with Sanofi. We recognized $83.0 million of R&D funding expense during the year ended December 31, 2019, of which $18.2 million and $62.8 million related to our funding agreements with Sanofi and Pfizer, respectively.

    We recognized $392.6 million of R&D funding expense during the year ended December 31, 2018, of which $6.9 million and $99.3 million related to our funding agreements with Sanofi and Pfizer, respectively. We recognized the $175.0 million and $100.0 million in upfront payments and premiums paid over market value for stock purchases related to our Immunomedics and Biohaven funding agreements, respectively, as R&D funding expense during the year ended December 31, 2018.

    As of December 31, 2020, we have a remaining commitment of $16.6 million related to a R&D funding agreement with Sanofi.
    XML 33 R17.htm IDEA: XBRL DOCUMENT v3.20.4
    Borrowings
    		 12 Months Ended
    Dec. 31, 2020
    Debt Disclosure [Abstract]  
    Borrowings Borrowings
    Our borrowings at December 31, 2020 and 2019 consisted of the following (in thousands):

    Type of BorrowingMaturityInterest rateDecember 31, 2020December 31, 2019
    Senior Unsecured Notes:
    Senior unsecured notes (issued at 99.322% of par)
    		9/20230.75 %$1,000,000 $— 
    Senior unsecured notes (issued at 98.875% of par)
    		9/20251.20 %1,000,000 — 
    Senior unsecured notes (issued at 98.284% of par)
    		9/20271.75 %1,000,000 — 
    Senior unsecured notes (issued at 97.760% of par)
    		9/20302.20 %1,000,000 — 
    Senior unsecured notes (issued at 95.556% of par)
    		9/20403.30 %1,000,000 — 
    Senior unsecured notes (issued at 95.306% of par)
    		9/20503.55 %1,000,000 — 
    Senior Unsecured Revolving Credit Facility— — 
    RPIFT Senior Secured Credit Facilities (1):
    Term Loan B Facility(2)
    LIBOR + 200 bps
    		— 4,123,000
    Term Loan A Facility(2)
    LIBOR + 150 bps
    		— 2,150,000
    Unamortized debt discount and issuance costs(183,416)(34,878)
    Total debt carrying value5,816,584 6,238,122
    Less: Current portion of long-term debt—(281,984)
    Total long-term debt$5,816,584 $5,956,138 
    (1)     The carrying value of our senior secured term loans, including the current portion, approximates its fair value and represented a Level 2 liability within the fair value hierarchy.
    (2)     In February 2020, the outstanding principal amounts of our Prior Credit Facility (as defined below) were repaid in full with net proceeds from our senior secured credit facilities which we subsequently repaid in full in September 2020 with net proceeds from the Notes (as defined below) and available cash on hand.
    Senior Unsecured Notes

    On September 2, 2020, we issued $6 billion of senior unsecured notes (the “Notes”). Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. Interest on each series of the Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, commencing on March 2, 2021. The Notes were issued at a total discount of $149.0 million. In connection with the transaction, we capitalized approximately $40.4 million in debt issuance costs primarily comprised of underwriting fees. The discount and the capitalized debt issuance costs are recorded as a direct deduction from the carrying amount of the Notes on our consolidated balance sheets and are being amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50% as of December 31, 2020, respectively.

    Our Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the Treasury Rate, plus a make-whole premium as defined in the indenture. Our Notes maturing after 2023 also have a call feature, exercisable at our option, to redeem the Notes at par in whole or in part one to six months immediately preceding maturity. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.

    Upon the occurrence of a change of control and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

    We are required to comply with certain covenants under our Notes and, as of December 31, 2020, we were in compliance with all applicable covenants.

    We used the net proceeds from the Notes offering, together with available cash on hand, to repay in full the senior secured credit facilities.

    Senior Unsecured Revolving Credit Facility

    On September 18, 2020, our subsidiary RP Holdings, as borrower, entered into a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) which provides for borrowing capacity of up to $1.5 billion for general corporate purposes. In connection with the transaction, we capitalized approximately $6.1 million in debt issuance costs related to the revolving credit facility which is recorded within Other current assets for the current portion and Other assets for the non-current portion. As of December 31, 2020, there were no outstanding borrowings under the Revolving Credit Facility.

    The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% per annum (“ABR”) or (b) adjusted LIBOR, plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our consolidated leverage ratio. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the ABR, LIBOR and future changes in our consolidated leverage ratio.

    The revolving credit agreement (the “Credit Agreement”) that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated charges, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. As of December 31, 2020, RP Holdings was in compliance with these covenants.
    Senior Secured Credit Facilities

    On February 11, 2020, in connection with the Exchange Offer Transactions (as discussed in Note 1–Organization and Purpose) and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement (the “Senior Secured Credit Agreement”) with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. The senior secured credit facilities contained in the Senior Secured Credit Agreement consisted of a term loan A (“Tranche A-1”) and term loan B (“Tranche B-1”) in the amounts of $3.20 billion and $2.84 billion, respectively. Tranche A-1 had an interest rate of 1.50% above LIBOR and matures in February 2025. Tranche B-1 had an interest rate of 1.75% above LIBOR and matures in February 2027. In September 2020, the Company repaid in whole the outstanding principal amounts of term loans under the senior secured credit facilities governed by the Senior Secured Credit Agreement with net proceeds from the Notes and available cash on hand. Upon refinancing of our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $25.1 million as part of Other non-operating expense/(income), net, which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.

    RPIFT Senior Secured Credit Facilities

    The RPIFT Senior Secured Credit Facilities (the “Prior Credit Facility”) was repaid in full in February 2020 in connection with the Exchange Offer Transactions. We recorded a loss on debt extinguishment of $5.4 million as part of Other non-operating expense/(income), net,. As of December 31, 2019, the Prior Credit Facility included two term loans, Term Loan A and Term Loan B. Tranche A-4 required annual amortization of 5.9% per year and tranche B-6 required annual amortization of 3.2% per year. The Prior Credit Facility was secured by a grant by RPIFT of a security interest in substantially all of its personal property and a grant by RPCT of a security interest in RPIFT’s share (80%) of all amounts on deposit in RPCT’s bank account.

    The Prior Credit Facility contained the following covenants measured quarterly: (i) maximum total leverage ratio of 4:00 to 1:00; (ii) debt coverage ratio of greater than 3.50 to 1.00. RPIFT was in compliance with these covenants at December 31, 2019.

    Principal payments on the Notes

    The future principal payments for our borrowings as of December 31, 2020 over the next five years and thereafter are as follows (in thousands):

    YearPrincipal Payments
    2021$— 
    2022— 
    20231,000,000 
    2024— 
    20251,000,000 
    Thereafter4,000,000 
    Total (1)$6,000,000 
    (1)     Excludes unamortized discount and loan issuance costs on long-term debt of $183.4 million as of December 31, 2020, which are amortized through interest expense over the remaining life of the underlying debt obligations.
    As of December 31, 2020, the fair value of our outstanding Notes was approximately $6.2 billion and represented a Level 2 measurement within the fair value hierarchy.
    XML 34 R18.htm IDEA: XBRL DOCUMENT v3.20.4
    Shareholders' Equity
    		 12 Months Ended
    Dec. 31, 2020
    Equity [Abstract]  
    Shareholders' Equity Shareholders’ Equity
    Capital structure

    Following the completion of our IPO as discussed in Note 1–Organization and Purpose, there have been no material changes in our capital structure, except for the secondary offering that was completed in October 2020, whereby 17,343 thousand of our Class A ordinary shares were offered for sale by certain of the Continuing Investors (the “Selling Shareholders”) at a price of $42.00 per share. We did not receive any proceeds from or pay any underwriting costs associated with the sale of Class A ordinary shares offered by the Selling Shareholders. The shares sold in the offering consisted of (i) 4,137 thousand existing Class A ordinary shares held by the Continuing Investor Partnerships and (ii) 13,206 thousand newly-issued Class A ordinary shares issued in connection with the redemption of 13,206 thousand RP Holdings Class B Interests by the Continuing Investors Partnerships that participated in the secondary offering. As of December 31, 2020, we have outstanding 388,135 thousand Class A ordinary shares and 218,976 thousand Class B ordinary shares.

    In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The purpose of the Class R redeemable shares was to ensure Royalty Pharma Limited had sufficient sterling denominated share capital at the time it was re-registered as a public limited company to Royalty Pharma plc, as required by the U.K. Companies Act. The Class R redeemable shares may be redeemed at the Company’s option in the future. Any such redemption would be at the nominal value of £1 each.

    The RP Holdings Class B Interests are exchangeable on a one-for-one basis for our Class A ordinary shares pursuant to an Exchange Agreement entered into by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings that governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of December 31, 2020, we have outstanding deferred shares of 316,407 thousand.

    Non-controlling interests

    Prior to the Exchange Offer Transactions in February 2020, the only non-controlling interest related to RPSFT, for which the related movements are presented in the historical statements of shareholders’ equity. The net change in the balance of our four non-controlling interests for the year ended December 31, 2020 is as follows (in thousands):

    RPSFTLegacy Investors PartnershipsContinuing Investors Partnerships (1)EPA HoldingsTotal
    December 31, 2019$35,883 $— $— $— $35,883 
    Contributions— 1,165,258 9,418 — 1,174,676 
    Transfer of interests— 1,037,161 — — 1,037,161 
    Distributions(112,339)(594,592)(85,426)— (792,357)
    Net income prior to IPO42,151 102,892 — — 145,043 
    Effect of exchange by Continuing Investors of Class B shares for Class A ordinary shares and reallocation of historical equity— (750)2,433,848 — 2,433,098 
    Issuance of Class A ordinary shares sold in IPO, net of offering costs— — 758,354 — 758,354 
    Other exchanges— — (309,566)(309,566)
    Net income subsequent to IPO46,741 218,137 316,993 — 581,871 
    Other comprehensive income:
    Unrealized gain on available for sale debt securities— 15,015 7,488 — 22,503 
    Reclassification of unrealized gain on available for sale debt securities— (3,612)(6,018)— (9,630)
    December 31, 2020$12,436 $1,939,509 $3,125,091 $— $5,077,036 
    (1)     Related to the Continuing Investors Partnerships’ ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A and Class B Interests as of December 31, 2020.

    RP Holdings Class C Special Interest held by EPA Holdings

    EPA Holdings is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period will be grouped together as separate portfolios (each, a “Portfolio”). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests for which we will issue the same number of Class B ordinary shares, which will be subsequently exchanged for our Class A ordinary shares. We do not currently expect any material Equity Performance Awards to be payable until the mid to late 2020s.

    Dividends

    The holders of Class A ordinary shares are entitled to receive ratably such dividends, if any, as may be approved from time to time by the Board of Directors. Subsequent to our IPO, we declared and paid two quarterly cash dividends for an aggregate amount of $112.5 million, or $0.15 per share during the year ended December 31, 2020 to holders of our Class A ordinary shares. Future dividends are subject to declaration by the Board of Directors.

    2020 Independent Director Equity Incentive Plan

    Our 2020 Independent Director Equity Incentive Plan was approved and became effective on June 15, 2020 whereby 800 thousand Class A ordinary shares were reserved for future issuance to our independent directors. As of December 31, 2020, approximately 675 thousand shares remain reserved for future issuance under the Equity Incentive Plan.

    RSU activity and share-based compensation

    We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year. The estimated fair value of RSUs is based on the closing price of our Class A ordinary shares on the grant date. During the year ended December 31, 2020, we granted approximately 125 thousand RSUs, of which approximately 71 thousand RSUs were vested. No RSUs were cancelled or forfeited during the year.

    We recognized share-based compensation of approximately $5.7 million for the year ended December 31, 2020, which is recorded as part of General and administrative expenses in the consolidated statement of comprehensive income. As of December 31, 2020, the total unrecognized share-based compensation expense related to total outstanding RSUs was less than $1.0 million, which we expect to recognize in the next six months.
    In periods prior to the IPO, we did not have share-based awards or related share-based compensation.
    XML 35 R19.htm IDEA: XBRL DOCUMENT v3.20.4
    Earnings Per Share
    		 12 Months Ended
    Dec. 31, 2020
    Earnings Per Share [Abstract]  
    Earnings Per Share Earnings per Share
    Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares potentially issuable to EPA Holdings, and unvested RSUs issued under our Equity Incentive Plan. We use the “if-converted” method to determine the potentially dilutive effect of our Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.

    Prior to the IPO, our capital structure included predominantly unitholder interests. We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements. Therefore, earnings per share information has not been presented for the years ended December 31, 2019 and 2018.

    Our Class B ordinary shares, Class R redeemable shares, and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares, and deferred shares under the two-class method has not been presented. Our Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because shares of Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. Class B ordinary shares potentially issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact for the year ended December 31, 2020. Class B ordinary shares currently in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive.

    The basic and diluted earnings per share for the year ended December 31, 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares. We have 607,111 thousand fully diluted Class A ordinary shares outstanding as of December 31, 2020. The following table sets forth reconciliations used to compute basic and diluted earnings per Class A ordinary share (in thousands, except per share amounts).
    Year Ended December 31, 2020
    Basic earnings per share:
    Numerator
    Consolidated net income $1,701,954 
    Less: net income attributable to Continuing Investors Partnerships prior to the IPO (1)479,842 
    Less: net income attributable to Continuing Investors Partnerships subsequent to the IPO316,993 
    Less: net income attributable to non-controlling interest - Legacy Investors Partnerships and RPSFT409,921 
    Net income attributable to Royalty Pharma plc$495,198 
    Denominator
    Weighted average Class A ordinary shares outstanding - basic375,444 
    Earnings per Class A ordinary share - basic$1.32 
    Diluted earnings per share:
    Numerator
    Net income attributable to Royalty Pharma plc$495,198 
    Denominator
    Weighted average Class A ordinary shares outstanding - basic375,444 
    Dilutive effect of unvested RSUs11 
    Weighted average Class A ordinary shares outstanding - diluted375,455 
    Earnings per Class A ordinary share - diluted$1.32 

    (1)     Reflected as Net income attributable to controlling interest on the consolidated statements of comprehensive income.
    XML 36 R20.htm IDEA: XBRL DOCUMENT v3.20.4
    Indirect Cash Flow
    		 12 Months Ended
    Dec. 31, 2020
    Supplemental Cash Flow Elements [Abstract]  
    Indirect Cash Flow Indirect Cash Flow
    Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).
    For the Years Ended December 31,
    202020192018
    Cash flow from operating activities:
    Consolidated net income$1,701,954 $2,461,419 $1,517,855 
    Adjustments to reconcile consolidated net income to net cash provided by operating activities:
    Provision for changes in expected cash flows from financial royalty assets230,839 (1,019,321)(57,334)
    Amortization of intangible assets23,058 23,924 33,267 
    Amortization of debt discount and issuance costs11,715 12,790 13,127 
    Realized gain on available for sale debt securities— — (419,481)
    Unrealized loss/(gain) on derivative contracts42,076 39,138 (11,923)
    (Gain)/loss on equity securities(247,073)(155,749)13,939 
    Equity in (earnings)/loss of non-consolidated affiliates(44,459)32,517 7,023 
    Distributions from non-consolidated affiliates42,334 14,059 39,402 
    Loss on extinguishment of debt30,272 — — 
    Share-based compensation5,428 — — 
    Interest income accretion(20,551)— — 
    Unrealized gain on forwards(18,600)— — 
    Impairment charge65,053 — — 
    Loss on derivative financial instruments(34,952)— — 
    Other9,621 (2,122)(7,771)
    (Increase)/decrease in operating assets:
    Financial royalty assets(1,959,975)(1,648,837)(1,524,816)
    Cash collected on financial royalty assets2,121,923 1,934,092 2,052,592 
    Available for sale debt securities— (150,000)(150,000)
    Accrued royalty receivable370 2,471 (27,372)
    Other receivables— 150,000 150,000 
    Other royalty income receivable(770)7,390 (11,099)
    Other current assets(10,278)4,607 (442)
    Other assets45,264 (45,635)— 
    Increase/(decrease) in operating liabilities:
    Accounts payable and accrued expenses(766)6,496 1,350 
    Interest payable42,146 — — 
    Net cash provided by operating activities$2,034,629 $1,667,239 $1,618,317 

    Non-cash investing and financing activities are summarized below (in thousands).
    For the Years Ended December 31,
    202020192018
    Supplemental schedule of non-cash investing / financing activities:
    Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)$303,679 $— $— 
    Settlement of Epizyme forward purchase contract (Note 4)5,700 — — 
    Accrued purchase obligation - Tazverik (Note 17)110,000 — — 
    Repayments of long-term debt by contributions from non-controlling interest (1)1,103,774 — — 
    Milestone payable - Erleada (2)18,600 — — 
    (1) Related to the pro rata portion of RPIFT’s outstanding debt repaid by the Legacy Investors Partnerships
    (2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020.
    XML 37 R21.htm IDEA: XBRL DOCUMENT v3.20.4
    Accumulated Other Comprehensive Income (Loss)
    		 12 Months Ended
    Dec. 31, 2020
    Equity [Abstract]  
    Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)
    Comprehensive income is comprised of net income and other comprehensive income/(loss). We include unrealized gains and losses on available for sale debt securities and unrealized gains/(losses) on the interest rate swaps that were designated as cash flow hedges in other comprehensive income/(loss). Prior to January 1, 2018, unrealized gains and losses on available for sale equity securities were included in accumulated other comprehensive income/(loss). Beginning on January 1, 2018, following the adoption of ASU 2016-01, unrealized gains and losses on equity securities are recognized through earnings.

    Changes in accumulated other comprehensive income/(loss) by component are as follows (in thousands):
    Unrealized gain/(loss) on equity securitiesUnrealized gain/(loss) on available for sale debt securitiesUnrealized gain/(loss) on interest rate swapsTotal Accumulated Other Comprehensive Income/(Loss)
    Balance at December 31, 2017$(2,863)$402,502 $(18,258)$381,381 
    Activity for the year— (402,502)— (402,502)
    Cumulative adjustment for adoption of ASU 2016-012,863 — — 2,863 
    Reclassifications to net income— — 8,003 8,003 
    Balance at December 31, 2018— — (10,255)(10,255)
    Activity for the year— 6,159 — 6,159 
    Reclassifications to net income— — 6,189 6,189 
    Balance at December 31, 2019— 6,159 (4,066)2,093 
    Reclassifications to net income— (10,921)4,066 (6,855)
    Activity for the year— 60,617 — 60,617 
    Reclassifications to non-controlling interest— (24,022)— (24,022)
    Reclassifications from non-controlling interest— 2,562 — 2,562 
    Balance at December 31, 2020$— $34,395 $— $34,395 

    The total reclassification of unrealized gains on available for sale debt securities of $20.6 million in 2020 is presented within interest income on the statement of comprehensive income, including the reclassification of $10.9 million attributable to controlling interest noted in the table above.
    XML 38 R22.htm IDEA: XBRL DOCUMENT v3.20.4
    Related Party Transactions
    		 12 Months Ended
    Dec. 31, 2020
    Related Party Transactions [Abstract]  
    Related Party Transactions Related Party Transactions
    The Manager

    The Manager is the investment manager of Royalty Pharma and its subsidiaries. The Manager is an affiliate of RP Ireland, the administrator of RPIFT and RPI Intermediate FT. The sole member of the Manager, Pablo Legorreta holds an interest in us and serves as our Chief Executive Officer and Chairman of the Board, and as a director on the board of RP Holdings.

    In connection with the Exchange Offer Transactions (discussed in Note 1–Organization and Purpose), the Manager has entered into new management agreements with RPI and its subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the new management agreements, RPI pays quarterly Operating and Personnel Payments in respect of operating and personnel expenses to the Manager or its affiliates equal to 6.5% of the Adjusted Cash Receipts (both, as defined in the New Management Agreement) for such quarter and 0.25% of the GAAP value of our security investments as of the end of such quarter. The Operating and Personnel Payment for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in our income statement, is calculated as the greater of $1 million per quarter and 0.3125% of Royalty Investments (as defined in the New Management Agreement) during the previous twelve calendar months. Operating and Personnel Payments incurred during the year ended December 31, 2020 were $112.5 million.
    Historically, the Manager received operating and personnel payments in equal quarterly installments that increased by 5% annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships. RP Ireland receives an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the Limited Partnership Agreements of the Legacy Investors Partnerships. Operating and personnel payments incurred during years ended December 31, 2019 and 2018 were $60.0 million and $57.2 million, respectively, and were recognized within General and administrative expenses on the consolidated statements of comprehensive income.

    Distribution payable to non-controlling interest

    The Distribution payable to non-controlling interest represents the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPSFT’s non-controlling interest in RPCT. The Distribution payable to non-controlling interest of $126.4 million at December 31, 2020 includes the following: (1) $100.0 million due to the Legacy Investors Partnerships from Old RPI in connection with the Legacy Investors Partnerships’ non-controlling interest in Old RPI that arose in the Reorganization Transactions and (2) $26.3 million due to RPSFT from RPCT in connection with RPSFT’s non-controlling interest in RPCT. The Distribution payable to non-controlling interest of $31.0 million and $44.3 million at December 31, 2019 and 2018, respectively, represents the contractual distribution of cash flows due from RPCT to RPSFT in connection with its non-controlling interest in RPCT.

    Acquisition from Epizyme

    In November 2019, in connection with an equity investment in Epizyme Inc. of $100.0 million made by RPIFT, Pablo Legorreta, our Chief Executive Officer, was appointed as a director of Epizyme, for which he received compensation in cash and shares, all of which will be contributed to the Manager and used to reduce costs and expenses which would otherwise be billed to us or our affiliates.

    Acquisition from Bristol-Myers Squibb

    In November 2017, RPI Acquisitions entered into a purchase agreement with Bristol-Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga, and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”). We agreed to make payments to BMS based on sales of the products over eight quarters beginning with the first quarter of 2018 in exchange for a high single-digit royalty on worldwide sales of the products from 2020 through 2025.

    On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly owned subsidiary of BioPharma Credit PLC (“BPCR”), an affiliate of us. BPCR is a related entity due to the sole member of the investment manager having significant influence over both entities. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement.

    We began making installment payments to BMS during the second quarter of 2018 and completed our funding in the first quarter of 2020. Installment payments made to BMS during the year ended December 31, 2020 and 2019 totaled $24.3 million and $171.0 million, respectively, of which RPI Acquisitions funded $12.1 million and $85.5 million, respectively. Upon transfer of funds from BPCR to RPI Acquisitions to meet the quarterly funding obligation to BMS, RPI Acquisitions derecognized 50% of the financial royalty asset. Cash received from BPCR in respect of each funding obligation equaled the carrying amount of the assigned transfer of interest, therefore no gain or loss was recognized upon the transfer. The financial royalty asset of $150.6 million and $150.3 million included in Financial royalty assets, net on the consolidated balance sheets as of December 31, 2020 and 2019, respectively, represents only our right to the future payment streams acquired from BMS.

    We funded a cumulative amount of $162.4 million, net of the assigned funding obligations. We began to measure this financial royalty asset using the effective interest method once our installment funding obligation was completed and we received our first royalty payment on the asset in the second quarter of 2020.

    Other transactions

    In the year ended December 31, 2020, we reimbursed Pablo Legorreta, our Chief Executive Officer, approximately $1.0 million for the cost of purchasing and donating ventilators to hospitals on our behalf.
    In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 9–Non-Consolidated Affiliates for additional discussion.

    RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnerships, whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3 million is recorded as treasury interests, of which $1.9 million is held by non-controlling interests in the consolidated balance sheet as of December 31, 2020. The total investment of $4.3 million was recorded as treasury interests held by controlling equity in the consolidated balance sheet as of December 31, 2019.

    Based on its ownership percentage of RP Holdings relative to us, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and the ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.
    XML 39 R23.htm IDEA: XBRL DOCUMENT v3.20.4
    Commitments and Contingencies
    		 12 Months Ended
    Dec. 31, 2020
    Commitments and Contingencies Disclosure [Abstract]  
    Commitments and Contingencies Commitments and Contingencies
    In the ordinary course of its business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.

    On August 7, 2020, we entered into a funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, for up to $450.0 million to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones. Biohaven received $150.0 million at closing and will receive $100.0 million upon the start of the oral zavegepant Phase III program. Pursuant to the Series B Biohaven Preferred Share Agreement, we will also provide further support for the ongoing launch of Nurtec ODT with the purchase of committed, non-contingent Commercial Launch Preferred Equity for a total of $200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030.

    In November 2019, RPIFT agreed to pay $330.0 million to purchase Eisai’s royalties on future worldwide sales of Tazverik (tazemetostat), a novel targeted therapy in late-stage clinical development that was approved by the FDA in January 2020 for epithelioid sarcoma, and with the potential to be approved in several cancer indications. Under the terms of its agreement with Eisai, RPIFT acquired Eisai’s future worldwide royalties on net sales by Epizyme of Tazverik outside of Japan, for an upfront payment of $110.0 million plus up to an additional $220.0 million for the remainder of the royalty upon FDA approval of Tazverik for certain indications. The FDA approval of Tazverik in January 2020 triggered our obligation to fund the second $110.0 million tranche in November 2020. In June 2020, the FDA approval of additional indications of Tazverik triggered our obligation to fund the final $110.0 million tranche in November 2021, which is recorded within current liabilities on the consolidated balance sheet at December 31, 2020.

    We have commitments to advance funds to counterparties through our investment in the Avillion Entities and R&D arrangements. Please refer to Notes 9–Non-Consolidated Affiliates and 10–R&D Funding Expense, respectively, for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the management agreement as described in Note 16–Related Party Transactions, which are variable and based on projected cash receipts.
    Legal proceedings

    We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings in our consolidated balance sheets as of December 31, 2020 and 2019. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.
    XML 40 R24.htm IDEA: XBRL DOCUMENT v3.20.4
    Subsequent Events
    		 12 Months Ended
    Dec. 31, 2020
    Subsequent Events [Abstract]  
    Subsequent Events Subsequent EventsIn January 2021, we acquired a royalty interest in seltorexant from Minerva Neurosciences, Inc. for an upfront payment of $60 million and up to $95 million in additional milestone payments, contingent on the achievement of certain clinical, regulatory and commercialization milestones. Seltorexant is currently in Phase III development for the treatment of major depressive disorder (MDD) with insomnia symptoms by Janssen Pharmaceutica, N.V., a subsidiary of Johnson & Johnson.
    XML 41 R25.htm IDEA: XBRL DOCUMENT v3.20.4
    Summary of Significant Accounting Policies (Policies)
    		 12 Months Ended
    Dec. 31, 2020
    Accounting Policies [Abstract]  
    Basis of preparation The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
    Use of estimates
    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.

    The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, the pandemic has not materially impacted our financial performance and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.
    Basis of consolidation
    The consolidated financial statements include the accounts of Royalty Pharma plc and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record Net income attributable to non-controlling interest in our consolidated statements of comprehensive income equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

    Following management’s determination that a high degree of common ownership existed in RPI both before and after the Exchange Date, RPI recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date.
    All intercompany transactions and balances have been eliminated in consolidation.
    Concentrations of credit risk Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2020 and 2019 were held with State Street, Deutsche Bank and Bank of America. Our primary operating accounts significantly exceed the FDIC limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Abbott, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Gilead, Johnson & Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche/ Genentech and Vertex.
    Segment Information Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.
    Royalty assets
    An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.

    In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.
    Financial royalty assets, net Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (“ASC”), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 Imputation of Interest.
    The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty assets is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as Provision for changes in expected future cash flows from financial royalty assets and the carrying value of Financial royalty assets, net is presented net of the cumulative allowance for changes in expected future cash flows.

    The application of the prospective approach to measure financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties.
    The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product and royalty duration, each discussed in further detail below.

    •Analyst coverage. Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to derive annual sales projections for each financial royalty asset by applying the median growth rates calculated from consensus forecasts among sell-side equity research analysts currently reporting on a product to the corresponding periods for which we are entitled to royalties. Growth rates inherent in these forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst estimates are not available for the full term of the royalty, particularly for the later years in a product’s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management’s own expertise. Further, based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms and rates are then applied to the adjusted sales projections to calculate the expected royalty payments over the term of the financial royalty asset’s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.

    •Commercial performance. The approval of a product for use in new indications can extend the date through which we are entitled to royalties on that product. Likewise, for certain royalties, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in sales projections. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts’ forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product’s performance in the market can materially affect our forecast of expected future cash flows over the royalty term.
    •Royalty duration. The duration of a royalty can be based on a number of factors, such as patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product’s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation outcomes. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.

    As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) product growth rates and sales trends in outer years, (2) the geographical allocation of annual sales data from sell-side equity research analysts’ models, (3) the product and pricing mix for franchised products, (4) the strength of patent protection, including anticipated entry of generics and (5) estimates of the duration of the royalty. The most sensitive of these assumptions relates to management’s estimate of the royalty duration in the final years of an asset’s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows.

    A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.

    The current portion of Financial royalty assets, net represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears.

    Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets

    We evaluate financial royalty assets for impairment on an individual basis at each reporting date by comparing the effective interest rate to that of the prior period. If the current period effective interest rate is lower than the prior period, and if the gross cash flows have declined (expected and collected), management records a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset’s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period’s effective interest rate. The amount recognized as provision expense increases the financial royalty asset’s cumulative allowance, which reduces the net carrying value of the financial royalty asset.
    In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. Management also recalculates the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.

    Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the Financial royalty assets, net line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset’s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either Provision for changes in expected cash flows from financial royalty assets or as Income from financial royalty assets on the consolidated statements of comprehensive income.

    Income from financial royalty assets

    We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.

    When royalties continue to be collected for financial royalty assets that have been fully amortized, such income is recognized as Other royalty income.
    Allowance for current expected credit losses On January 1, 2020, we adopted ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of Financial royalty assets, net on the consolidated balance sheets. Any subsequent routine movement in the allowance for credit losses is recorded as part of the Provision for changes in expected future cash flows from financial royalty assets on the consolidated statements of comprehensive income.
    Intangible royalty assets, net Currently, our only intangible royalty assets are the Januvia and Janumet (“DPP-IV”) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, which terminate at various dates until 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10, Property, Plant, and Equipment - Overall. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product’s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty’s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.
    Revenue from intangible royalty assets and Accrued royalty receivable
    We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue on DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts’ projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.

    Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.

    Milestone payments

    Certain acquisition agreements provide for future contingent payments based on the financial performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts’ consensus forecasts. Milestones based on regulatory approval are not reflected in the expected future cash flows until such approval is achieved.

    Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.
    Financial Instruments Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than Financial royalty assets, net are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 3–Fair Value Measurements and Financial Instruments.
    Cash and cash equivalents Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value.
    Equity securities and Available for sale debt securities
    Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities, including our investment in the Biohaven Series A Preferred Shares, are measured at fair value and unrealized gains and losses are included in accumulated other comprehensive income/(loss) (“AOCI”). Unrealized gains and losses are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows.

    A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management’s assessment.

    We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.
    Derivatives All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements. Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of comprehensive income as part of Unrealized gain/(loss) on derivative financial instruments.
    Investments in non-consolidated affiliates
    Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at cost. Subsequently, we recognize through earnings our proportionate share of the investee’s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of these entities one quarter in arrears within Equity in (earnings)/loss of non-consolidated affiliates in the consolidated statements of comprehensive income. The investment is reflected as Investments in non-consolidated affiliates on the consolidated balance sheet.

    We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the “Avillion entities”). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.
    When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets.
    Research and development funding expense
    We enter into transactions where we agree to fund a portion of the research and development (“R&D”) for products undergoing late-stage clinical trials in exchange for future royalties if the products are successfully developed and commercialized. In accordance with ASC 730 Research and Development, we account for the funded amounts as R&D expense when we have the ability to obtain the results of the R&D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval.

    Royalty payments owed to the Company on successfully commercialized products generated from R&D agreements are recognized as Other royalty income in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria (i.e., typically the achievement of agreed upon sales thresholds) for products arising out of our R&D arrangements are also recognized as Other royalty income in the period that the commercial sales threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed and we have no further performance obligations.
    Income taxes
    We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (“the Code”) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.

    While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments.

    Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes.

    We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI.
    We are also subject to the U.K.’s “controlled foreign companies” rules (the “U.K. CFC Rules”). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the “Controlled Foreign Company”) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings), will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes.
    Earnings per share Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares and restricted share units (“RSUs”) issued under our 2020 Independent Director Equity Incentive Plan (“Equity Incentive Plan”). We use the “if-converted” method to determine the potentially dilutive effect of Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.
    Recently adopted and issued accounting standards
    In May 2014, the Financial Accounting Standard Board (“FASB”) issued a new revenue standard under ASC Topic 606 (ASU 2014-09). ASU 2014-09 applies to all contracts with customers. Based on management’s assessment, income from financial royalty assets which are accounted for in accordance with ASC 310, Receivables, is not subject to the application of ASU 2014-09. As a result, management believes that financial royalty assets represent contractual rights and obligations that continue to be within the scope of Topic 310 and therefore specifically exempted from the new revenue standard. The provisions of ASU 2014-09 became effective for us on January 1, 2018, including interim reporting periods. Our revenues are primarily derived from intangible royalty assets, which fall under the sales-based royalties exception in the new standard. Therefore, we did not recognize any adjustment upon adoption of the new revenue standard.

    In January 2016, the FASB issued revised guidance for the accounting and reporting of financial instruments (ASU 2016-01) and in 2018 issued related technical corrections (ASU 2018-03). The new guidance requires that equity investments with readily determinable fair values currently classified as available for sale be measured at fair value with changes in fair value recognized in net income. The new guidance also changed certain disclosure requirements. We adopted ASU 2016-01 as of January 1, 2018 using a modified retrospective approach. We recorded a cumulative-effect adjustment upon adoption that decreased retained earnings by $2.9 million as a result of accumulated other comprehensive income previously recognized on its available for sale equity securities. ASU 2018-03 was also adopted as of January 1, 2018 on a prospective basis and did not result in any additional impact upon adoption.

    In August 2016, the FASB issued revised guidance which makes eight targeted changes to how royalty receipts and cash payments are presented and classified in the Statement of Cash Flows (ASU 2016-15). Among the updates, the standard allows companies to elect the “cumulative earnings” approach or the “nature-of-the-distribution” approach in distinguishing whether distributions received from equity method investees are returns of investment, which should be classified as cash flows from investing activities, and returns on investment, which should be classified as cash flows from operating activities. We made a policy election to use the “cumulative earnings” approach and adopted ASU 2016-15 for the year ended December 31, 2018.
    In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to Retained earnings of $192.7 million to recognize an allowance for current expected credit losses on our financial royalty assets.

    In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.
    Fair value measurements
    The summary below presents information about our assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020 and 2019, and the valuation techniques we utilized to determine such fair value.

    •Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Our Level 1 assets consist of equity securities with readily determinable fair values and money market funds.
    •Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. Our Level 2 assets generally include marketable securities, warrants, derivatives and our interest rate swap contracts, which may be in an asset or liability position.
    •Level 3: Prices or valuation that requires inputs that are both significant to the fair value measurement and unobservable. Our Level 3 assets consist of our investments in the Series A Biohaven Preferred Shares and the Series B Forwards and, historically, our investment in Tecfidera. See Note 5––Available for Sale Debt Securities for a description of our investments in the Biohaven Preferred Shares.

    For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety.
    XML 42 R26.htm IDEA: XBRL DOCUMENT v3.20.4
    Fair Value Measurements and Financial Instruments (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Fair Value Disclosures [Abstract]  
    Schedule of Fair Value Hierarchy
    The following is a summary of the inputs used to value our financial assets and liabilities measured at fair value as of December 31, 2020 and 2019 (in thousands):
    As of December 31, 2020
    Level 1Level 2Level 3Total
    Assets:
    Cash equivalents
    Money market funds$24,302 $— $— $24,302 
    Commercial paper— 77,176 — 77,176 
    Certificates of deposit— 74,502 — 74,502 
    Marketable securities
    Corporate debt securities— 32,754 — 32,754 
    Commercial paper— 444,554 — 444,554 
    Certificates of deposit— 505,971 — 505,971 
    Available for sale debt securities— — 69,984 69,984 
    Total current assets$24,302 $1,134,957 $69,984 $1,229,243 
    Equity securities (1)298,689 — — 298,689 
    Available for sale debt securities— — 144,416 144,416 
    Forwards (2)— — 18,600 18,600 
    Warrants (3)— 5,439 — 5,439 
    Total non-current assets$298,689 $5,439 $163,016 $467,144 
    (1)Upon Gilead’s acquisition of Immunomedics, our investment in Immunomedics common stock was redeemed in full in the fourth quarter of 2020, resulting in a gain of $292.3 million recognized within (Gain)/loss on equity securities in the year ended December 31, 2020.
    (2)The Series B Forwards, recorded within Other assets in the consolidated balance sheet as of December 31, 2020, relate to our obligation to fund the acquisition of the Series B Biohaven Preferred Shares.
    (3)Related to Epizyme transaction as described in Note 4–Derivative Instruments and recorded in the non-current asset portion of Derivative financial instruments in the consolidated balance sheet as of December 31, 2020.

    The net unrealized gain or loss recognized on equity securities still held as of December 31, 2020 was a loss of $45.2 million, a gain of $125.6 million and a loss of $7.8 million for the years ended December 31, 2020, 2019 and 2018, respectively.
    As of December 31, 2019
    Level 1Level 2Level 3Total
    Assets:
    Cash equivalents
    Money market funds$222,326 $— $— $222,326 
    Certificates of deposit— 4,000 — 4,000 
    Marketable securities
    U.S. government securities— 12,877 — 12,877 
    Commercial paper— 21,367 — 21,367 
    Certificates of deposit— 60,211 — 60,211 
    Total current assets$222,326 $98,455 $— $320,781 
    Equity securities380,756 — — 380,756 
    Available for sale debt securities— — 131,280 131,280 
    Warrants (1)— 30,815 — 30,815 
    Forward purchase contract (1)— 11,500 — 11,500 
    Total non-current assets$380,756 $42,315 $131,280 $554,351 
    Liabilities:
    Interest rate swaps— (9,215)— (9,215)
    Total current liabilities$— $(9,215)$— $(9,215)
    Interest rate swaps— (18,902)— (18,902)
    Total non-current liabilities$— $(18,902)$— $(18,902)
    (1)Related to Epizyme warrants and put option as described in Note 4–Derivative Instruments and both recorded in the non-current asset portion of Derivative financial instruments in the consolidated balance sheet as of December 31, 2019.
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation
    The tables presented below summarize the change in the carrying value of Level 3 financial instruments, which relate to our investment in the Series A Biohaven Preferred Shares and the Series B Forwards (in thousands).
    For the years ended
    December 31,
    20202019
    Available for sale debt securities
    Balance at the beginning of the period$131,280 $— 
    Purchases— 125,121 
    Unrealized gains on available for sale debt securities52,725 — 
    Transfer to Level 2(184,005)— 
    Transfer from Level 2 (1)198,526 — 
    Unrealized gains on available for sale debt securities15,874 6,159 
    Balance at the end of the period$214,400 $131,280 
    (1)     Includes $14.5 million of unrealized gains on available for sale debt securities included in other comprehensive income while the instrument was classified as a Level 2 asset.

    For the year ended
    December 31,
    2020
    Forwards
    Balance at the beginning of the period$— 
    Unrealized gains included in earnings (1)18,600 
    Balance at the end of the period$18,600 
    (1)     Recorded within Unrealized gain on forwards on the consolidated statements of comprehensive income.
    Fair Value Disclosure of Asset and Liability Not Measured at Fair Value Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of our financial royalty assets as of December 31, 2020 and 2019 are presented below (in thousands).
    December 31, 2020December 31, 2019
    Fair valueCarrying value, netFair valueCarrying value, net
    Financial royalty assets, net$18,718,179 $12,368,084 $16,501,819 $10,842,052 
    XML 43 R27.htm IDEA: XBRL DOCUMENT v3.20.4
    Derivative Instruments (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Derivative Instruments and Hedging Activities Disclosure [Abstract]  
    Schedule of Notional Values and Fixed Rates The notional values and fixed rates payable on the swap contracts are shown in the table below.
    Notional Value
    (in millions)    		Fixed RateMaturity Date
    $6002.019 %November 9, 2020
    $2502.094 %March 27, 2023
    $5002.029 %March 27, 2023
    $2502.113 %March 27, 2023
    $5002.129 %March 27, 2023
    Summary of Derivatives and Reclassifications
    The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2020, 2019 and 2018 and the line items within the consolidated statements of comprehensive income where the gains/(losses) on these derivatives are recorded (in thousands).
    For the years ended
    December 31,    		Consolidated Statement of Comprehensive Income location
    202020192018
    Derivatives in hedging relationships (1)
    Interest Rate Swaps:
    Amount of loss reclassified from AOCI into income$4,066 $6,189 $8,003 Unrealized loss/(gain) on derivative financial instruments
    Change in fair value of interest rate swaps(73)16,954 (3,357)Unrealized loss/(gain) on derivative financial instruments
    Interest expense/(income)114 (9,565)(9,758)Interest expense
    Derivatives not designated as hedging instruments
    Interest Rate Swaps:
    Change in fair value of interest rate swaps6,908 49,472 (16,569)Unrealized loss/(gain) on derivative financial instruments
    Interest expense/(income)408 (2,681)(440)Interest expense
    Warrant:
    Change in fair value of warrant25,375 (21,977)— Unrealized loss/(gain) on derivative financial instruments
    Forward purchase contract:
    Change in fair value of forward purchase contract5,800 (11,500)— Unrealized loss/(gain) on derivative financial instruments
    (1)     Certain older interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in AOCI have been released into earnings.
    XML 44 R28.htm IDEA: XBRL DOCUMENT v3.20.4
    Available for Sale Debt Securities (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Investments, Debt and Equity Securities [Abstract]  
    Summary of Available for Sale Debt Securities
    A summary of our available for sale debt securities recorded at fair value is shown below as of December 31, 2020 and December 31, 2019 (in thousands):
    CostUnrealized gainsFair Value (1)
    As of December 31, 2020
    Series A Biohaven Preferred Shares$125,121 $89,279 $214,400 
    Total available for sale debt securities$125,121 $89,279 $214,400 
    As of December 31, 2019
    Series A Biohaven Preferred Shares$125,121 $6,159 $131,280 
    Total available for sale debt securities$125,121 $6,159 $131,280 
    (1)As of December 31, 2020, $70.0 million and $144.4 million are recorded as the current and non-current asset portion of Available for sale debt securities, respectively, in the consolidated balance sheet. As of December 31, 2019, the entire balance of the Series A Biohaven Preferred Shares was recorded as a non-current asset.
    XML 45 R29.htm IDEA: XBRL DOCUMENT v3.20.4
    Financial Royalty Assets, Net (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Receivables [Abstract]  
    Summary of Financial Royalty Assets, Net
    The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2020 and December 31, 2019 are as follows (in thousands):
    December 31, 2020Estimated royalty duration (a)Gross carrying valueCumulative allowance for changes in expected cash flows (Note 7)Net carrying value (d)
    Cystic fibrosis franchise2037 (b)$5,274,896 $— $5,274,896 
    Tysabri(c)2,003,797 (112,720)1,891,077 
    Imbruvica2027-20291,406,291 (46,872)1,359,419 
    Xtandi2027-20281,150,335 (145,565)1,004,770 
    Promacta2025-2027686,129 — 686,129 
    Evrysdi2030-2035 (e)675,440 — 675,440 
    Other2020-20393,022,213 (634,950)2,387,263 
    Total$14,219,101 $(940,107)$13,278,994 
    Less: Cumulative allowance for credit losses (Note 7)(323,717)
    Total financial royalty assets, net$12,955,277 
    a)Dates shown represent management’s estimates of when a royalty will substantially end, which may depend on patent expiration dates (which may include patent term extensions) or other factors and may vary by geography. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. There can be no assurances that our royalties will expire when expected.
    b)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on generic entry.
    c)Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
    d)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7—Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.
    e)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
    December 31, 2019Estimated royalty duration (a)Gross carrying valueCumulative allowance for changes in expected cash flows (Note 7)Net carrying value
    Cystic fibrosis franchise (d)2037 (b)$4,639,045 $— $4,639,045 
    Tysabri(c)2,131,272 (71,789)2,059,483 
    Imbruvica2027-20291,332,077 — 1,332,077 
    Xtandi2027-20281,193,918 (332,624)861,294 
    Promacta2025-2027776,555 — 776,555 
    Crysvita2033-2038 (e)321,234 — 321,234 
    Other2019-20391,768,929 (464,005)1,304,924 
    Total$12,163,030 $(868,418)$11,294,612 
    a)Dates shown represent management’s estimates of when a royalty will substantially end, which may depend on patent expiration dates (which may include patent term extensions) or other factors and may vary by geography. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. There can be no assurances that our royalties will expire when expected.
    b)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on generic entry.
    c)Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
    d)The Vertex triple combination therapy, Trikafta, was approved by the FDA in October 2019. Sell-side equity research analysts’ consensus forecasts increased due to expected sales of the newly approved cystic fibrosis franchise product and resulted in a reversal of the entire cumulative allowance for changes in expected cash flows in the fourth quarter of 2019 related to this financial royalty asset.
    e)As of December 31, 2019, the timing of when we expected to reach the royalty cap of 2.5 times our purchase price was 2032.
    XML 46 R30.htm IDEA: XBRL DOCUMENT v3.20.4
    Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Credit Loss [Abstract]  
    Schedule of Cumulative Allowance for Changes in Expected Cash Flows The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):
    Activity for the year
    Balance at December 31, 2017$(2,045,868)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(284,214)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets341,548 
    Reversal of cumulative allowance (a)5,637 
    Balance at December 31, 2018(1,982,897)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(322,717)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets1,342,038 
    Reversal of cumulative allowance (a)95,158 
    Balance at December 31, 2019(868,418)
    Cumulative adjustment for adoption of ASU 2016-13(192,705)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(645,612)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets570,959 
    Reversal of cumulative allowance (a)2,964 
    Write off of credit loss allowance (b)25,174 
    Current period provision for credit losses (c)(156,186)
    Balance at December 31, 2020$(1,263,824)
    (a)     Relates to amounts reversed out of the allowance at the end of a financial royalty asset’s life to bring the account balance to zero. Reversals solely impact the asset account and allowance account, there is no impact on the consolidated statements of comprehensive income.
    (b)     Relates to amounts reversed out of the credit loss allowance associated with omecamtiv as a result of the write-off of the related financial royalty asset balance of $90.2 million.
    (c)     Primarily related to the allowance for credit losses resulting from increases to our portfolio of financial royalty assets in 2020, predominantly the final tranche of Tazverik, zavegepant, and the residual interest in the cystic fibrosis franchise.
    XML 47 R31.htm IDEA: XBRL DOCUMENT v3.20.4
    Intangible Royalty Assets, Net (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Schedule of Intangible Royalty Interests
    The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2020 and 2019 (in thousands).
    As of December 31, 2020CostAccumulated amortizationNet carrying value
    DPP-IV patents$606,216 $577,550 $28,666 
    Total intangible royalty assets$606,216 $577,550 $28,666 
    As of December 31, 2019CostAccumulated amortizationNet carrying value
    DPP-IV patents$606,216 $554,492 $51,724 
    Total intangible royalty assets$606,216 $554,492 $51,724 
    XML 48 R32.htm IDEA: XBRL DOCUMENT v3.20.4
    Borrowings (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Debt Disclosure [Abstract]  
    Schedule of Borrowings
    Our borrowings at December 31, 2020 and 2019 consisted of the following (in thousands):

    Type of BorrowingMaturityInterest rateDecember 31, 2020December 31, 2019
    Senior Unsecured Notes:
    Senior unsecured notes (issued at 99.322% of par)
    		9/20230.75 %$1,000,000 $— 
    Senior unsecured notes (issued at 98.875% of par)
    		9/20251.20 %1,000,000 — 
    Senior unsecured notes (issued at 98.284% of par)
    		9/20271.75 %1,000,000 — 
    Senior unsecured notes (issued at 97.760% of par)
    		9/20302.20 %1,000,000 — 
    Senior unsecured notes (issued at 95.556% of par)
    		9/20403.30 %1,000,000 — 
    Senior unsecured notes (issued at 95.306% of par)
    		9/20503.55 %1,000,000 — 
    Senior Unsecured Revolving Credit Facility— — 
    RPIFT Senior Secured Credit Facilities (1):
    Term Loan B Facility(2)
    LIBOR + 200 bps
    		— 4,123,000
    Term Loan A Facility(2)
    LIBOR + 150 bps
    		— 2,150,000
    Unamortized debt discount and issuance costs(183,416)(34,878)
    Total debt carrying value5,816,584 6,238,122
    Less: Current portion of long-term debt—(281,984)
    Total long-term debt$5,816,584 $5,956,138 
    (1)     The carrying value of our senior secured term loans, including the current portion, approximates its fair value and represented a Level 2 liability within the fair value hierarchy.
    (2)     In February 2020, the outstanding principal amounts of our Prior Credit Facility (as defined below) were repaid in full with net proceeds from our senior secured credit facilities which we subsequently repaid in full in September 2020 with net proceeds from the Notes (as defined below) and available cash on hand.
    Schedule of Repayments of Debt by Year
    The future principal payments for our borrowings as of December 31, 2020 over the next five years and thereafter are as follows (in thousands):

    YearPrincipal Payments
    2021$— 
    2022— 
    20231,000,000 
    2024— 
    20251,000,000 
    Thereafter4,000,000 
    Total (1)$6,000,000 
    (1)     Excludes unamortized discount and loan issuance costs on long-term debt of $183.4 million as of December 31, 2020, which are amortized through interest expense over the remaining life of the underlying debt obligations.
    XML 49 R33.htm IDEA: XBRL DOCUMENT v3.20.4
    Shareholders' Equity (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Equity [Abstract]  
    Schedule of Balance Of Non-controlling Interests The net change in the balance of our four non-controlling interests for the year ended December 31, 2020 is as follows (in thousands):
    RPSFTLegacy Investors PartnershipsContinuing Investors Partnerships (1)EPA HoldingsTotal
    December 31, 2019$35,883 $— $— $— $35,883 
    Contributions— 1,165,258 9,418 — 1,174,676 
    Transfer of interests— 1,037,161 — — 1,037,161 
    Distributions(112,339)(594,592)(85,426)— (792,357)
    Net income prior to IPO42,151 102,892 — — 145,043 
    Effect of exchange by Continuing Investors of Class B shares for Class A ordinary shares and reallocation of historical equity— (750)2,433,848 — 2,433,098 
    Issuance of Class A ordinary shares sold in IPO, net of offering costs— — 758,354 — 758,354 
    Other exchanges— — (309,566)(309,566)
    Net income subsequent to IPO46,741 218,137 316,993 — 581,871 
    Other comprehensive income:
    Unrealized gain on available for sale debt securities— 15,015 7,488 — 22,503 
    Reclassification of unrealized gain on available for sale debt securities— (3,612)(6,018)— (9,630)
    December 31, 2020$12,436 $1,939,509 $3,125,091 $— $5,077,036 
    (1)     Related to the Continuing Investors Partnerships’ ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A and Class B Interests as of December 31, 2020.
    XML 50 R34.htm IDEA: XBRL DOCUMENT v3.20.4
    Earnings Per Share (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Earnings Per Share [Abstract]  
    Schedule of Earnings Per Share, Basic and Diluted The following table sets forth reconciliations used to compute basic and diluted earnings per Class A ordinary share (in thousands, except per share amounts).
    Year Ended December 31, 2020
    Basic earnings per share:
    Numerator
    Consolidated net income $1,701,954 
    Less: net income attributable to Continuing Investors Partnerships prior to the IPO (1)479,842 
    Less: net income attributable to Continuing Investors Partnerships subsequent to the IPO316,993 
    Less: net income attributable to non-controlling interest - Legacy Investors Partnerships and RPSFT409,921 
    Net income attributable to Royalty Pharma plc$495,198 
    Denominator
    Weighted average Class A ordinary shares outstanding - basic375,444 
    Earnings per Class A ordinary share - basic$1.32 
    Diluted earnings per share:
    Numerator
    Net income attributable to Royalty Pharma plc$495,198 
    Denominator
    Weighted average Class A ordinary shares outstanding - basic375,444 
    Dilutive effect of unvested RSUs11 
    Weighted average Class A ordinary shares outstanding - diluted375,455 
    Earnings per Class A ordinary share - diluted$1.32 

    (1)     Reflected as Net income attributable to controlling interest on the consolidated statements of comprehensive income.
    XML 51 R35.htm IDEA: XBRL DOCUMENT v3.20.4
    Indirect Cash Flow (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Supplemental Cash Flow Elements [Abstract]  
    Schedule of Cash Flow, Supplemental Disclosures
    Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).
    For the Years Ended December 31,
    202020192018
    Cash flow from operating activities:
    Consolidated net income$1,701,954 $2,461,419 $1,517,855 
    Adjustments to reconcile consolidated net income to net cash provided by operating activities:
    Provision for changes in expected cash flows from financial royalty assets230,839 (1,019,321)(57,334)
    Amortization of intangible assets23,058 23,924 33,267 
    Amortization of debt discount and issuance costs11,715 12,790 13,127 
    Realized gain on available for sale debt securities— — (419,481)
    Unrealized loss/(gain) on derivative contracts42,076 39,138 (11,923)
    (Gain)/loss on equity securities(247,073)(155,749)13,939 
    Equity in (earnings)/loss of non-consolidated affiliates(44,459)32,517 7,023 
    Distributions from non-consolidated affiliates42,334 14,059 39,402 
    Loss on extinguishment of debt30,272 — — 
    Share-based compensation5,428 — — 
    Interest income accretion(20,551)— — 
    Unrealized gain on forwards(18,600)— — 
    Impairment charge65,053 — — 
    Loss on derivative financial instruments(34,952)— — 
    Other9,621 (2,122)(7,771)
    (Increase)/decrease in operating assets:
    Financial royalty assets(1,959,975)(1,648,837)(1,524,816)
    Cash collected on financial royalty assets2,121,923 1,934,092 2,052,592 
    Available for sale debt securities— (150,000)(150,000)
    Accrued royalty receivable370 2,471 (27,372)
    Other receivables— 150,000 150,000 
    Other royalty income receivable(770)7,390 (11,099)
    Other current assets(10,278)4,607 (442)
    Other assets45,264 (45,635)— 
    Increase/(decrease) in operating liabilities:
    Accounts payable and accrued expenses(766)6,496 1,350 
    Interest payable42,146 — — 
    Net cash provided by operating activities$2,034,629 $1,667,239 $1,618,317 

    Non-cash investing and financing activities are summarized below (in thousands).
    For the Years Ended December 31,
    202020192018
    Supplemental schedule of non-cash investing / financing activities:
    Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)$303,679 $— $— 
    Settlement of Epizyme forward purchase contract (Note 4)5,700 — — 
    Accrued purchase obligation - Tazverik (Note 17)110,000 — — 
    Repayments of long-term debt by contributions from non-controlling interest (1)1,103,774 — — 
    Milestone payable - Erleada (2)18,600 — — 
    (1) Related to the pro rata portion of RPIFT’s outstanding debt repaid by the Legacy Investors Partnerships
    (2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020.
    XML 52 R36.htm IDEA: XBRL DOCUMENT v3.20.4
    Accumulated Other Comprehensive Income (Loss) (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Equity [Abstract]  
    Schedule of Accumulated Other Comprehensive Income (Loss)
    Changes in accumulated other comprehensive income/(loss) by component are as follows (in thousands):
    Unrealized gain/(loss) on equity securitiesUnrealized gain/(loss) on available for sale debt securitiesUnrealized gain/(loss) on interest rate swapsTotal Accumulated Other Comprehensive Income/(Loss)
    Balance at December 31, 2017$(2,863)$402,502 $(18,258)$381,381 
    Activity for the year— (402,502)— (402,502)
    Cumulative adjustment for adoption of ASU 2016-012,863 — — 2,863 
    Reclassifications to net income— — 8,003 8,003 
    Balance at December 31, 2018— — (10,255)(10,255)
    Activity for the year— 6,159 — 6,159 
    Reclassifications to net income— — 6,189 6,189 
    Balance at December 31, 2019— 6,159 (4,066)2,093 
    Reclassifications to net income— (10,921)4,066 (6,855)
    Activity for the year— 60,617 — 60,617 
    Reclassifications to non-controlling interest— (24,022)— (24,022)
    Reclassifications from non-controlling interest— 2,562 — 2,562 
    Balance at December 31, 2020$— $34,395 $— $34,395 
    XML 53 R37.htm IDEA: XBRL DOCUMENT v3.20.4
    Organization and Purpose (Details) - USD ($)
    		 1 Months Ended 12 Months Ended
    Jun. 18, 2020
    Feb. 11, 2020
    Jun. 30, 2020
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Feb. 29, 2020
    Subsidiary, Sale of Stock [Line Items]              
    Repayments of outstanding debt       $ 11,116,196,000 $ 0 $ 0  
    Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1              
    Subsidiary, Sale of Stock [Line Items]              
    Debt issued, amount   $ 3,200,000,000          
    Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1              
    Subsidiary, Sale of Stock [Line Items]              
    Debt issued, amount   2,840,000,000          
    Senior Secured Debt | Old Credit Facility              
    Subsidiary, Sale of Stock [Line Items]              
    Repayments of outstanding debt   $ 6,300,000,000          
    RPCT              
    Subsidiary, Sale of Stock [Line Items]              
    Ownership percentage (as a percent)   66.00%          
    Legacy Investors Partnerships | Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1              
    Subsidiary, Sale of Stock [Line Items]              
    Debt issued, amount   $ 1,300,000,000          
    Legacy Investors Partnerships | Old RPI              
    Subsidiary, Sale of Stock [Line Items]              
    Noncontrolling interest (percentage)             18.00%
    RPSFT | RPCT              
    Subsidiary, Sale of Stock [Line Items]              
    Noncontrolling interest (percentage)   34.00%          
    RPI Intermediate FT | Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1              
    Subsidiary, Sale of Stock [Line Items]              
    Debt issued, amount   $ 6,000,000,000.0          
    RPI Intermediate FT | Senior Secured Debt | RPIFT Senior Secured Credit Facilities              
    Subsidiary, Sale of Stock [Line Items]              
    Repayments of outstanding debt   $ 5,200,000,000          
    Common Class A              
    Subsidiary, Sale of Stock [Line Items]              
    Ownership percentage following IPO     100.00%        
    Exchange Offer Transaction | Old RPI              
    Subsidiary, Sale of Stock [Line Items]              
    Ownership percentage (as a percent)   82.00%          
    Exchange Offer Transaction | Legacy Investors Partnerships              
    Subsidiary, Sale of Stock [Line Items]              
    Exchange offering, ownership percentage   82.00%          
    IPO              
    Subsidiary, Sale of Stock [Line Items]              
    Sale of stock, consideration received $ 1,900,000,000            
    IPO | Common Class A              
    Subsidiary, Sale of Stock [Line Items]              
    Number of shares issued (in shares) 89,334,000            
    Sale of stock, price per share (in dollars per share) $ 28.00            
    IPO - Shares From Company | Common Class A              
    Subsidiary, Sale of Stock [Line Items]              
    Number of shares issued (in shares) 71,652,000            
    IPO - Shares From Selling Shareholders | Common Class A              
    Subsidiary, Sale of Stock [Line Items]              
    Number of shares issued (in shares) 17,682,000            
    Public Stock Offering - Continuing Investors Partnerships Interests | Common Class B              
    Subsidiary, Sale of Stock [Line Items]              
    Number of shares available to convert (in shares)     294,176,000        
    Number of shares converted (in shares)     241,207,000        
    XML 54 R38.htm IDEA: XBRL DOCUMENT v3.20.4
    Summary of Significant Accounting Policies (Details)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    USD ($)
    segment
    Dec. 31, 2019
    USD ($)
    Dec. 31, 2018
    USD ($)
    Jun. 30, 2020
    partnership
    Feb. 29, 2020
    Dec. 31, 2017
    USD ($)
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Number of noncontrolling interests created | partnership       2    
    Cash and cash equivalents $ (1,008,680) $ (246,199)        
    Marketable securities 983,279 94,455        
    Purchases of marketable securities 1,705,283 817,402 $ 0      
    Net cash flow from investing (2,759,320) (2,153,625) 303,424      
    Proceeds from sales and maturities of marketable securities $ 815,440 725,070 0      
    Number of operating segments | segment 1          
    Cumulative adjustment $ 9,895,815 6,141,438 4,552,079     $ 4,460,546
    Revision of Prior Period, Reclassification, Adjustment            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Marketable securities   37,500        
    Purchases of marketable securities   388,000        
    Net cash flow from investing   37,500        
    Proceeds from sales and maturities of marketable securities   350,500        
    RP Holdings            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Noncontrolling interest (percentage) 64.00%          
    Cumulative Effect, Period of Adoption, Adjustment            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Cumulative adjustment   (192,705)       0
    Accumulated Other Comprehensive Income/(Loss)            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Cumulative adjustment $ 34,395 2,093 (10,255)     381,381
    Accumulated Other Comprehensive Income/(Loss) | Cumulative Effect, Period of Adoption, Adjustment            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Cumulative adjustment           2,863
    Retained Earnings            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Cumulative adjustment $ 1,920,635 2,825,212 $ 1,215,953     655,446
    Retained Earnings | Cumulative Effect, Period of Adoption, Adjustment            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Cumulative adjustment   $ (192,705)       $ (2,863)
    Customer Concentration Risk | Current portion of Financial royalty assets | Vertex            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Concentration risk (as a percent) 27.00% 17.00%        
    Legacy Investors Partnerships | Old RPI            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Noncontrolling interest (percentage)         18.00%  
    Continuing Investors Partnerships | RP Holdings            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Noncontrolling interest (percentage) 36.00%          
    XML 55 R39.htm IDEA: XBRL DOCUMENT v3.20.4
    Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Assets:      
    Marketable securities $ 983,279 $ 94,455  
    Available for sale debt securities 69,984 0  
    Equity securities 298,689 380,756  
    Available for sale debt securities 144,416 131,280  
    Liabilities:      
    Interest rate swaps 0 (9,215)  
    Interest rate swaps 0 (18,902)  
    Unrealized gain (loss) on equity securities still held (45,200) 125,600 $ (7,800)
    Immunomedics      
    Liabilities:      
    (Gain)/loss on equity securities 292,300    
    Fair Value, Recurring      
    Assets:      
    Available for sale debt securities 69,984    
    Total current assets 1,229,243 320,781  
    Equity securities 298,689 380,756  
    Available for sale debt securities 144,416 131,280  
    Total non-current assets 467,144 554,351  
    Liabilities:      
    Total current liabilities   (9,215)  
    Total non-current liabilities   (18,902)  
    Fair Value, Recurring | Corporate Debt Securities      
    Assets:      
    Marketable securities 32,754    
    Fair Value, Recurring | Commercial Paper      
    Assets:      
    Marketable securities 444,554 21,367  
    Fair Value, Recurring | Certificates of Deposit      
    Assets:      
    Marketable securities 505,971 60,211  
    Fair Value, Recurring | US Government Debt Securities      
    Assets:      
    Marketable securities   12,877  
    Fair Value, Recurring | Forward Contracts      
    Assets:      
    Derivatives 18,600 11,500  
    Fair Value, Recurring | Warrant      
    Assets:      
    Derivatives 5,439 30,815  
    Fair Value, Recurring | Interest Rate Swap      
    Liabilities:      
    Interest rate swaps   (9,215)  
    Interest rate swaps   (18,902)  
    Level 1 | Fair Value, Recurring      
    Assets:      
    Available for sale debt securities 0    
    Total current assets 24,302 222,326  
    Equity securities 298,689 380,756  
    Available for sale debt securities 0 0  
    Total non-current assets 298,689 380,756  
    Liabilities:      
    Total current liabilities   0  
    Total non-current liabilities   0  
    Level 1 | Fair Value, Recurring | Corporate Debt Securities      
    Assets:      
    Marketable securities 0    
    Level 1 | Fair Value, Recurring | Commercial Paper      
    Assets:      
    Marketable securities 0 0  
    Level 1 | Fair Value, Recurring | Certificates of Deposit      
    Assets:      
    Marketable securities 0 0  
    Level 1 | Fair Value, Recurring | US Government Debt Securities      
    Assets:      
    Marketable securities   0  
    Level 1 | Fair Value, Recurring | Forward Contracts      
    Assets:      
    Derivatives 0 0  
    Level 1 | Fair Value, Recurring | Warrant      
    Assets:      
    Derivatives 0 0  
    Level 1 | Fair Value, Recurring | Interest Rate Swap      
    Liabilities:      
    Interest rate swaps   0  
    Interest rate swaps   0  
    Level 2 | Fair Value, Recurring      
    Assets:      
    Available for sale debt securities 0    
    Total current assets 1,134,957 98,455  
    Equity securities 0 0  
    Available for sale debt securities 0 0  
    Total non-current assets 5,439 42,315  
    Liabilities:      
    Total current liabilities   (9,215)  
    Total non-current liabilities   (18,902)  
    Level 2 | Fair Value, Recurring | Corporate Debt Securities      
    Assets:      
    Marketable securities 32,754    
    Level 2 | Fair Value, Recurring | Commercial Paper      
    Assets:      
    Marketable securities 444,554 21,367  
    Level 2 | Fair Value, Recurring | Certificates of Deposit      
    Assets:      
    Marketable securities 505,971 60,211  
    Level 2 | Fair Value, Recurring | US Government Debt Securities      
    Assets:      
    Marketable securities   12,877  
    Level 2 | Fair Value, Recurring | Forward Contracts      
    Assets:      
    Derivatives 0 11,500  
    Level 2 | Fair Value, Recurring | Warrant      
    Assets:      
    Derivatives 5,439 30,815  
    Level 2 | Fair Value, Recurring | Interest Rate Swap      
    Liabilities:      
    Interest rate swaps   (9,215)  
    Interest rate swaps   (18,902)  
    Level 3 | Fair Value, Recurring      
    Assets:      
    Available for sale debt securities 69,984    
    Total current assets 69,984 0  
    Equity securities 0 0  
    Available for sale debt securities 144,416 131,280  
    Total non-current assets 163,016 131,280  
    Liabilities:      
    Total current liabilities   0  
    Total non-current liabilities   0  
    Level 3 | Fair Value, Recurring | Corporate Debt Securities      
    Assets:      
    Marketable securities 0    
    Level 3 | Fair Value, Recurring | Commercial Paper      
    Assets:      
    Marketable securities 0 0  
    Level 3 | Fair Value, Recurring | Certificates of Deposit      
    Assets:      
    Marketable securities 0 0  
    Level 3 | Fair Value, Recurring | US Government Debt Securities      
    Assets:      
    Marketable securities   0  
    Level 3 | Fair Value, Recurring | Forward Contracts      
    Assets:      
    Derivatives 18,600 0  
    Level 3 | Fair Value, Recurring | Warrant      
    Assets:      
    Derivatives 0 0  
    Level 3 | Fair Value, Recurring | Interest Rate Swap      
    Liabilities:      
    Interest rate swaps   0  
    Interest rate swaps   0  
    Money Market Funds | Fair Value, Recurring      
    Assets:      
    Cash equivalents 24,302 222,326  
    Money Market Funds | Level 1 | Fair Value, Recurring      
    Assets:      
    Cash equivalents 24,302 222,326  
    Money Market Funds | Level 2 | Fair Value, Recurring      
    Assets:      
    Cash equivalents 0 0  
    Money Market Funds | Level 3 | Fair Value, Recurring      
    Assets:      
    Cash equivalents 0 0  
    Commercial Paper | Fair Value, Recurring      
    Assets:      
    Cash equivalents 77,176    
    Commercial Paper | Level 1 | Fair Value, Recurring      
    Assets:      
    Cash equivalents 0    
    Commercial Paper | Level 2 | Fair Value, Recurring      
    Assets:      
    Cash equivalents 77,176    
    Commercial Paper | Level 3 | Fair Value, Recurring      
    Assets:      
    Cash equivalents 0    
    Certificates of Deposit | Fair Value, Recurring      
    Assets:      
    Cash equivalents 74,502 4,000  
    Certificates of Deposit | Level 1 | Fair Value, Recurring      
    Assets:      
    Cash equivalents 0 0  
    Certificates of Deposit | Level 2 | Fair Value, Recurring      
    Assets:      
    Cash equivalents 74,502 4,000  
    Certificates of Deposit | Level 3 | Fair Value, Recurring      
    Assets:      
    Cash equivalents $ 0 $ 0  
    XML 56 R40.htm IDEA: XBRL DOCUMENT v3.20.4
    Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Available-for-sale Securities    
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
    Balance at the beginning of the period $ 131,280 $ 0
    Purchases 0 125,121
    Unrealized gains on available for sale debt securities 52,725 0
    Transfer to Level 2 (184,005) 0
    Transfer from level 2 198,526 0
    Unrealized gains on available for sale debt securities 15,874 6,159
    Balance at the end of the period 214,400 131,280
    Available-for-sale Securities | Level 2    
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
    Unrealized gains on available for sale debt securities 14,500  
    Forward Contracts    
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
    Balance at the beginning of the period 0  
    Unrealized gains on available for sale debt securities 18,600  
    Balance at the end of the period $ 18,600 $ 0
    XML 57 R41.htm IDEA: XBRL DOCUMENT v3.20.4
    Fair Value Measurements and Financial Instruments - Narrative (Details)
    $ / shares in Units, $ in Thousands
    		 12 Months Ended
    Aug. 07, 2020
    USD ($)
    $ / shares
    shares
    Apr. 05, 2019
    USD ($)
    $ / shares
    shares
    Dec. 31, 2020
    USD ($)
    $ / shares
    shares
    Dec. 31, 2019
    USD ($)
    Dec. 31, 2018
    USD ($)
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Available for sale debt securities     $ 214,400 $ 131,280  
    Purchase of warrants     0 $ 125,121 $ 0
    Series A Preferred Stock          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Purchase of warrants   $ 125,000      
    Series B Preferred Shares          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Purchase of warrants $ 200,000   200,000    
    Change Of Control Probability | Level 3 | Valuation Technique, Black-Derman-Troy          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Measurement input, percentage (as a percent)       0  
    Minimum | Likelihood of FDA Approval | Level 3 | Valuation Technique, Black-Derman-Troy          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Measurement input, percentage (as a percent)       0  
    Minimum | Likelihood of FDA Approval At End Of Any Given Quarter By 2024 | Level 3 | Valuation Technique, Black-Derman-Troy          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Measurement input, percentage (as a percent)       0  
    Maximum | Likelihood of FDA Approval | Level 3 | Valuation Technique, Black-Derman-Troy          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Measurement input, percentage (as a percent)       0.86  
    Maximum | Likelihood of FDA Approval At End Of Any Given Quarter By 2024 | Level 3 | Valuation Technique, Black-Derman-Troy          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Measurement input, percentage (as a percent)       0.59  
    Preferred Shares          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Available for sale debt securities     214,400 $ 131,280  
    Preferred Shares | Series A Preferred Stock          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Redemption price, percentage   200.00%      
    Preferred shares, quarterly payments     15,600    
    Preferred shares, fixed payment amount     $ 250,000    
    Preferred shares, weighted average cost of capital     8.30%    
    Available for sale debt securities     $ 214,400    
    Number of shares purchased (in shares) | shares   2,495      
    Price per share (in USD per share) | $ / shares   $ 50,100.00      
    Preferred Shares | Series B Preferred Shares          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Number of shares purchased (in shares) | shares 3,992   3,992    
    Price per share (in USD per share) | $ / shares $ 50,100   $ 50,100    
    Preferred Shares | Redemption, Period One | Series B Preferred Shares          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Redemption price, percentage 180.00%   180.00%    
    Preferred Shares | Maximum | Redemption, Period One          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Redemption price, percentage   200.00%      
    Preferred Shares | Maximum | Redemption, Period One | Series A Preferred Stock          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Redemption price, percentage   200.00%      
    XML 58 R42.htm IDEA: XBRL DOCUMENT v3.20.4
    Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) - Level 3 - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Estimate of Fair Value Measurement    
    Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
    Financial royalty assets, net $ 18,718,179 $ 16,501,819
    Reported Value Measurement    
    Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
    Financial royalty assets, net $ 12,368,084 $ 10,842,052
    XML 59 R43.htm IDEA: XBRL DOCUMENT v3.20.4
    Derivative Instruments - Narrative (Details) - USD ($)
    		 1 Months Ended 12 Months Ended
    Apr. 05, 2019
    Nov. 30, 2019
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Derivative Instruments and Hedging Activities Disclosures [Line Items]          
    Swap termination payments     $ 35,448,000 $ 0 $ 0
    Swap collateral received     45,252,000 360,000 3,467,000
    Unrealized Gain (Loss) on Derivatives     (18,600,000) 0 0
    Derivative liability, current     0 9,215,000  
    Derivative liability, noncurrent     0 18,902,000  
    Other assets     23,158,000 45,635,000  
    Derivative financial instruments     5,439,000 42,315,000  
    Preferred Shares | Series A Preferred Stock          
    Derivative Instruments and Hedging Activities Disclosures [Line Items]          
    Derivative instrument, exercise period (in months) 12 months        
    Additional issuance, purchase price, maximum $ 75,000,000.0        
    Additional issuance, purchase price, minimum $ 25,000,000.0        
    Epizyme Common Stock Warrant          
    Derivative Instruments and Hedging Activities Disclosures [Line Items]          
    Warrants to purchase additional shares (in shares)   2,500,000      
    Equity Investment In Epizyme Inc.          
    Derivative Instruments and Hedging Activities Disclosures [Line Items]          
    Equity securities   $ 100,000,000.0      
    Upfront payment for equity investment   $ 100,000,000.0      
    Equity Investment In Epizyme Inc. | Epizyme Common Stock Warrant          
    Derivative Instruments and Hedging Activities Disclosures [Line Items]          
    Exercise price of warrant (in dollars per share)   $ 20      
    Term of warrant (in years)   3 years      
    Equity Investment In Epizyme Inc. | Put Option          
    Derivative Instruments and Hedging Activities Disclosures [Line Items]          
    Put option, term (in months)   18 months      
    Put option to sell additional common stock   $ 50,000,000.0      
    Put option, selling price, maximum (in dollars per share)   $ 20      
    Interest Rate Swap          
    Derivative Instruments and Hedging Activities Disclosures [Line Items]          
    Unrealized Gain (Loss) on Derivatives     (10,900,000) (72,600,000) $ 11,900,000
    Derivative liability       28,100,000  
    Derivative liability, current       9,200,000  
    Derivative liability, noncurrent       18,900,000  
    Forward Contracts          
    Derivative Instruments and Hedging Activities Disclosures [Line Items]          
    Derivative liability, noncurrent       11,500,000  
    Warrant          
    Derivative Instruments and Hedging Activities Disclosures [Line Items]          
    Unrealized Gain (Loss) on Derivatives     (25,400,000) 22,000,000.0  
    Derivative financial instruments     $ 5,400,000 $ 30,800,000  
    XML 60 R44.htm IDEA: XBRL DOCUMENT v3.20.4
    Derivative Instruments - Schedule of Notional Values and Fixed Rates (Details)
    Dec. 31, 2019
    USD ($)
    Interest Rate Swap, Due November 2020  
    Derivative Instruments and Hedging Activities Disclosures [Line Items]  
    Notional Value (in millions) $ 600,000,000
    Fixed Rate (as a percent) 2.019%
    Interest Rate Swap, Due March 2023 - 1  
    Derivative Instruments and Hedging Activities Disclosures [Line Items]  
    Notional Value (in millions) $ 250,000,000
    Fixed Rate (as a percent) 2.094%
    Interest Rate Swap, Due March 2023 - 2  
    Derivative Instruments and Hedging Activities Disclosures [Line Items]  
    Notional Value (in millions) $ 500,000,000
    Fixed Rate (as a percent) 2.029%
    Interest Rate Swap, Due March 2023 - 3  
    Derivative Instruments and Hedging Activities Disclosures [Line Items]  
    Notional Value (in millions) $ 250,000,000
    Fixed Rate (as a percent) 2.113%
    Interest Rate Swap, Due March 2023 - 4  
    Derivative Instruments and Hedging Activities Disclosures [Line Items]  
    Notional Value (in millions) $ 500,000,000
    Fixed Rate (as a percent) 2.129%
    XML 61 R45.htm IDEA: XBRL DOCUMENT v3.20.4
    Derivative Instruments - Summary of Derivatives and Reclassifications (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Interest Rate Swap | Unrealized loss/(gain) on derivative financial instruments | Designated as Hedging Instrument      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Amount of loss reclassified from AOCI into income $ 4,066 $ 6,189 $ 8,003
    Interest rate swaps (73) 16,954 (3,357)
    Interest Rate Swap | Unrealized loss/(gain) on derivative financial instruments | Not Designated as Hedging Instrument      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Derivatives not designated as hedging instruments 6,908 49,472 (16,569)
    Interest Rate Swap | Interest expense | Designated as Hedging Instrument      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Interest rate swaps 114 (9,565) (9,758)
    Interest Rate Swap | Interest expense | Not Designated as Hedging Instrument      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Derivatives not designated as hedging instruments 408 (2,681) (440)
    Warrant | Unrealized loss/(gain) on derivative financial instruments | Not Designated as Hedging Instrument      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Derivatives not designated as hedging instruments 25,375 (21,977) 0
    Forward Contracts | Unrealized loss/(gain) on derivative financial instruments | Not Designated as Hedging Instrument      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Change in fair value of derivative contracts $ 5,800 $ (11,500) $ 0
    XML 62 R46.htm IDEA: XBRL DOCUMENT v3.20.4
    Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Debt and Equity Securities, FV-NI [Line Items]    
    Cost $ 125,121 $ 125,121
    Unrealized gains 89,279 6,159
    Fair Value 214,400 131,280
    Available for sale debt securities, current 69,984 0
    Available for sale debt securities, noncurrent 144,416 131,280
    Preferred Shares    
    Debt and Equity Securities, FV-NI [Line Items]    
    Cost 125,121 125,121
    Unrealized gains 89,279 6,159
    Fair Value $ 214,400 $ 131,280
    XML 63 R47.htm IDEA: XBRL DOCUMENT v3.20.4
    Available for Sale Debt Securities - Narrative (Details) - USD ($)
    $ / shares in Units, $ in Thousands
    		 12 Months Ended
    Aug. 07, 2020
    Apr. 05, 2019
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Debt and Equity Securities, FV-NI [Line Items]          
    Purchase of available for sale debt securities     $ 0 $ 125,121 $ 0
    Realized gain on available for sale debt securities     0 0 419,481
    Available for sale debt securities     214,400 131,280  
    Royalty Pharma Investment Financial Trust          
    Debt and Equity Securities, FV-NI [Line Items]          
    Potential milestone payments         600,000
    Realized gain on available for sale debt securities         419,500
    Royalty Pharma Investment Financial Trust | Tecfidera          
    Debt and Equity Securities, FV-NI [Line Items]          
    Available for sale debt securities         $ 180,500
    Series A Preferred Stock          
    Debt and Equity Securities, FV-NI [Line Items]          
    Purchase of available for sale debt securities   $ 125,000      
    Series B Preferred Shares          
    Debt and Equity Securities, FV-NI [Line Items]          
    Purchase of available for sale debt securities $ 200,000   200,000    
    Preferred Shares          
    Debt and Equity Securities, FV-NI [Line Items]          
    Available for sale debt securities     214,400 $ 131,280  
    Preferred Shares | Series A Preferred Stock          
    Debt and Equity Securities, FV-NI [Line Items]          
    Number of shares purchased (in shares)   2,495      
    Price per share (in USD per share)   $ 50,100.00      
    Redemption price, percentage   200.00%      
    Redemption default, interest rate   18.00%      
    Available for sale debt securities     $ 214,400    
    Preferred Shares | Series B Preferred Shares          
    Debt and Equity Securities, FV-NI [Line Items]          
    Number of shares purchased (in shares) 3,992   3,992    
    Price per share (in USD per share) $ 50,100   $ 50,100    
    Redemption default, interest rate 18.00%        
    Redemption default, threshold period 1 year        
    Preferred Shares | Redemption, Period One | Series B Preferred Shares          
    Debt and Equity Securities, FV-NI [Line Items]          
    Redemption price, percentage 180.00%   180.00%    
    Preferred Shares | Redemption, Period One | Maximum          
    Debt and Equity Securities, FV-NI [Line Items]          
    Redemption price, percentage   200.00%      
    Preferred Shares | Redemption, Period One | Maximum | Series A Preferred Stock          
    Debt and Equity Securities, FV-NI [Line Items]          
    Redemption price, percentage   200.00%      
    Preferred Shares | Redemption, Period Two | Series A Preferred Stock          
    Debt and Equity Securities, FV-NI [Line Items]          
    Redemption price, percentage   200.00%      
    Preferred Shares | Redemption, Period Two | Series B Preferred Shares          
    Debt and Equity Securities, FV-NI [Line Items]          
    Redemption price, percentage 180.00%        
    XML 64 R48.htm IDEA: XBRL DOCUMENT v3.20.4
    Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Accounts, Notes, Loans and Financing Receivable [Line Items]        
    Gross carrying value $ 14,219,101 $ 12,163,030    
    Cumulative allowance for changes in expected cash flows (940,107)      
    Net carrying value, before cumulative allowance for credit losses 13,278,994      
    Cumulative allowance for credit losses (323,717)      
    Cumulative allowance for changes in expected cash flows (1,263,824) (868,418) $ (1,982,897) $ (2,045,868)
    Net carrying value 12,955,277 11,294,612    
    Cystic fibrosis franchise        
    Accounts, Notes, Loans and Financing Receivable [Line Items]        
    Gross carrying value 5,274,896 4,639,045    
    Cumulative allowance for changes in expected cash flows 0      
    Net carrying value, before cumulative allowance for credit losses 5,274,896      
    Cumulative allowance for changes in expected cash flows   0    
    Net carrying value   4,639,045    
    Tysabri        
    Accounts, Notes, Loans and Financing Receivable [Line Items]        
    Gross carrying value 2,003,797 2,131,272    
    Cumulative allowance for changes in expected cash flows (112,720)      
    Net carrying value, before cumulative allowance for credit losses 1,891,077      
    Cumulative allowance for changes in expected cash flows   (71,789)    
    Net carrying value   2,059,483    
    Imbruvica        
    Accounts, Notes, Loans and Financing Receivable [Line Items]        
    Gross carrying value 1,406,291 1,332,077    
    Cumulative allowance for changes in expected cash flows (46,872)      
    Net carrying value, before cumulative allowance for credit losses 1,359,419      
    Cumulative allowance for changes in expected cash flows   0    
    Net carrying value   1,332,077    
    Xtandi        
    Accounts, Notes, Loans and Financing Receivable [Line Items]        
    Gross carrying value 1,150,335 1,193,918    
    Cumulative allowance for changes in expected cash flows (145,565)      
    Net carrying value, before cumulative allowance for credit losses 1,004,770      
    Cumulative allowance for changes in expected cash flows   (332,624)    
    Net carrying value   861,294    
    Promacta        
    Accounts, Notes, Loans and Financing Receivable [Line Items]        
    Gross carrying value 686,129 776,555    
    Cumulative allowance for changes in expected cash flows 0      
    Net carrying value, before cumulative allowance for credit losses 686,129      
    Cumulative allowance for changes in expected cash flows   0    
    Net carrying value   776,555    
    Evrysdi        
    Accounts, Notes, Loans and Financing Receivable [Line Items]        
    Gross carrying value 675,440      
    Cumulative allowance for changes in expected cash flows 0      
    Net carrying value, before cumulative allowance for credit losses 675,440      
    Aggregate royalty amount when patents cease 1,300,000      
    Crysvita        
    Accounts, Notes, Loans and Financing Receivable [Line Items]        
    Gross carrying value   321,234    
    Cumulative allowance for changes in expected cash flows   0    
    Net carrying value   321,234    
    Other        
    Accounts, Notes, Loans and Financing Receivable [Line Items]        
    Gross carrying value 3,022,213 1,768,929    
    Cumulative allowance for changes in expected cash flows (634,950)      
    Net carrying value, before cumulative allowance for credit losses $ 2,387,263      
    Cumulative allowance for changes in expected cash flows   (464,005)    
    Net carrying value   $ 1,304,924    
    XML 65 R49.htm IDEA: XBRL DOCUMENT v3.20.4
    Financial Royalty Assets, Net - Narrative (Details) - Cystic fibrosis franchise - USD ($)
    $ in Millions
    		 1 Months Ended 12 Months Ended
    Nov. 30, 2019
    Dec. 31, 2019
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Reduction in financial royalty assets   $ 41.0
    Minimum    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Expected reduction in royalty receipts $ 35.0  
    Maximum    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Expected reduction in royalty receipts $ 45.0  
    XML 66 R50.htm IDEA: XBRL DOCUMENT v3.20.4
    Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Financing Receivable, Allowance for Credit Loss [Line Items]        
    Cumulative adjustment to retained earnings $ (9,895,815) $ (6,141,438) $ (4,552,079) $ (4,460,546)
    Retained Earnings        
    Financing Receivable, Allowance for Credit Loss [Line Items]        
    Cumulative adjustment to retained earnings $ (1,920,635) (2,825,212) $ (1,215,953) (655,446)
    Cumulative Effect, Period of Adoption, Adjustment        
    Financing Receivable, Allowance for Credit Loss [Line Items]        
    Cumulative adjustment to retained earnings   192,705   0
    Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings        
    Financing Receivable, Allowance for Credit Loss [Line Items]        
    Cumulative adjustment to retained earnings   $ 192,705   $ 2,863
    XML 67 R51.htm IDEA: XBRL DOCUMENT v3.20.4
    Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Financing Receivable, Allowance for Credit Loss [Line Items]      
    Beginning balance $ (868,418) $ (1,982,897) $ (2,045,868)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets (645,612) (322,717) (284,214)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets 570,959 1,342,038 341,548
    Reversal of cumulative allowance 2,964 95,158 5,637
    Write off of credit loss allowance 25,174    
    Current period provision for credit losses (c) (156,186)    
    Ending balance (1,263,824) (868,418) $ (1,982,897)
    Writeoff related to financial royalty asset 90,200    
    Cumulative Effect, Period of Adoption, Adjustment      
    Financing Receivable, Allowance for Credit Loss [Line Items]      
    Beginning balance $ (192,705)    
    Ending balance   $ (192,705)  
    XML 68 R52.htm IDEA: XBRL DOCUMENT v3.20.4
    Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Finite-Lived Intangible Assets [Line Items]    
    Cost $ 606,216 $ 606,216
    Accumulated amortization 577,550 554,492
    Net carrying value 28,666 51,724
    DPP-IV patents    
    Finite-Lived Intangible Assets [Line Items]    
    Cost 606,216 606,216
    Accumulated amortization 577,550 554,492
    Net carrying value $ 28,666 $ 51,724
    XML 69 R53.htm IDEA: XBRL DOCUMENT v3.20.4
    Intangible Royalty Assets, Net - Narrative (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Revenue Benchmark | Individual Licensees Concentration List      
    Finite-Lived Intangible Assets [Line Items]      
    Individual licensees exceeding 10% or more of revenue (as a percent) 97.00% 91.00% 73.00%
    DPP-IV patents      
    Finite-Lived Intangible Assets [Line Items]      
    Finite lived intangible assets, useful life 1 year 3 months    
    Projected amortization expense, 2021 $ 23,000    
    Projected amortization expense, 2022 $ 5,700    
    XML 70 R54.htm IDEA: XBRL DOCUMENT v3.20.4
    Non-Consolidated Affiliates (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Feb. 11, 2020
    May 31, 2018
    Mar. 31, 2017
    Schedule of Equity Method Investments [Line Items]            
    Investments in non-consolidated affiliates $ 454,936 $ 124,061        
    Distributions from non-consolidated affiliates 15,084 0 $ 0      
    Equity in income (loss) of non-consolidated affiliates 44,459 (32,517) (7,023)      
    Distributions from non-consolidated affiliates 42,334 14,059 39,402      
    Avillion II | Merck Asset - Phase II Clinical Trial            
    Schedule of Equity Method Investments [Line Items]            
    Other commitment   19,000        
    Other commitments, percentage of costs (as a percent)           50.00%
    Avillion II | AZ Asset - Phase II and Phase III Clinical Trial            
    Schedule of Equity Method Investments [Line Items]            
    Other commitment         $ 105,000  
    Other commitments, percentage of costs (as a percent)         44.00%  
    Equity Method Investment, Nonconsolidated Investee or Group of Investees | Legacy Investors Partnerships            
    Schedule of Equity Method Investments [Line Items]            
    Investments in non-consolidated affiliates       $ 303,700    
    Distributions from non-consolidated affiliates 22,700          
    Equity in income (loss) of non-consolidated affiliates 62,000          
    Equity Method Investment, Nonconsolidated Investee or Group of Investees | Avillion Entities            
    Schedule of Equity Method Investments [Line Items]            
    Equity in income (loss) of non-consolidated affiliates (17,600) (32,500) $ (7,000)      
    Equity method investment, unfunded commitments 28,600 70,800        
    Equity Method Investment, Nonconsolidated Investee or Group of Investees | Avillion I            
    Schedule of Equity Method Investments [Line Items]            
    Distributions from non-consolidated affiliates 13,400 $ 14,100        
    Equity Method Investment, Nonconsolidated Investee or Group of Investees | Avillion II            
    Schedule of Equity Method Investments [Line Items]            
    Distributions from non-consolidated affiliates $ 21,300          
    XML 71 R55.htm IDEA: XBRL DOCUMENT v3.20.4
    R&D Funding Expense (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Research and Development Arrangement, Contract to Perform for Others [Line Items]      
    Research and development funding expense $ 26,289 $ 83,036 $ 392,609
    Funding Agreements With Sanofi      
    Research and Development Arrangement, Contract to Perform for Others [Line Items]      
    Research and development funding expense 18,500 18,200 6,900
    Remaining commitment for R&D funding agreement $ 16,600    
    Funding Agreements With Pfizer      
    Research and Development Arrangement, Contract to Perform for Others [Line Items]      
    Research and development funding expense   $ 62,800 99,300
    Funding Agreement With Immunomedics      
    Research and Development Arrangement, Contract to Perform for Others [Line Items]      
    Upfront payment and premium paid     175,000
    Funding Agreement With Biohaven      
    Research and Development Arrangement, Contract to Perform for Others [Line Items]      
    Upfront payment and premium paid     $ 100,000
    XML 72 R56.htm IDEA: XBRL DOCUMENT v3.20.4
    Borrowings - Schedule of Borrowings (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Debt Instrument [Line Items]    
    Less: Current portion of long-term debt $ 0 $ (281,984,000)
    Total long-term debt 5,816,584,000 5,956,138,000
    Unsecured Debt    
    Debt Instrument [Line Items]    
    Unamortized debt discount and issuance costs (183,416,000)  
    Total debt carrying value 5,816,584,000  
    Less: Current portion of long-term debt 0  
    Total long-term debt $ 5,816,584,000  
    Unsecured Debt | Point Seven Five Percent Senior Notes Due 2023    
    Debt Instrument [Line Items]    
    Debt issued as a percent of par value (as a percent) 99.322%  
    Debt instrument, stated rate (as a percent) 0.75%  
    Debt issued, amount $ 1,000,000,000  
    Unsecured Debt | One Point Two Zero Percent Senior Notes Due 2025    
    Debt Instrument [Line Items]    
    Debt issued as a percent of par value (as a percent) 98.875%  
    Debt instrument, stated rate (as a percent) 1.20%  
    Debt issued, amount $ 1,000,000,000  
    Unsecured Debt | One Point Seven Five Percent Senior Notes Due 2027    
    Debt Instrument [Line Items]    
    Debt issued as a percent of par value (as a percent) 98.284%  
    Debt instrument, stated rate (as a percent) 1.75%  
    Debt issued, amount $ 1,000,000,000  
    Unsecured Debt | Two Point Two Zero Percent Senior Notes Due 2030    
    Debt Instrument [Line Items]    
    Debt issued as a percent of par value (as a percent) 97.76%  
    Debt instrument, stated rate (as a percent) 2.20%  
    Debt issued, amount $ 1,000,000,000  
    Unsecured Debt | Three Point Three Zero Percent Senior Notes Due 2040    
    Debt Instrument [Line Items]    
    Debt issued as a percent of par value (as a percent) 95.556%  
    Debt instrument, stated rate (as a percent) 3.30%  
    Debt issued, amount $ 1,000,000,000  
    Unsecured Debt | Three Point Five Five Percent Senior Notes Due 2050    
    Debt Instrument [Line Items]    
    Debt issued as a percent of par value (as a percent) 95.306%  
    Debt instrument, stated rate (as a percent) 3.55%  
    Debt issued, amount $ 1,000,000,000  
    Unsecured Debt | RPIFT Senior Secured Credit Facilities    
    Debt Instrument [Line Items]    
    Debt issued, amount $ 0 0
    Senior Secured Debt    
    Debt Instrument [Line Items]    
    Unamortized debt discount and issuance costs   (34,878,000)
    Total debt carrying value   6,238,122,000
    Less: Current portion of long-term debt   (281,984,000)
    Total long-term debt   5,956,138,000
    Senior Secured Debt | RPIFT Senior Secured Credit Facilities - Tranche B-6    
    Debt Instrument [Line Items]    
    Debt issued, amount   $ 4,123,000,000
    Senior Secured Debt | RPIFT Senior Secured Credit Facilities - Tranche B-6 | London Interbank Offered Rate (LIBOR)    
    Debt Instrument [Line Items]    
    Basis spread on variable rate (percentage)   2.00%
    Senior Secured Debt | RPIFT Senior Secured Credit Facilities - Tranche A-4    
    Debt Instrument [Line Items]    
    Debt issued, amount   $ 2,150,000,000
    Senior Secured Debt | RPIFT Senior Secured Credit Facilities - Tranche A-4 | London Interbank Offered Rate (LIBOR)    
    Debt Instrument [Line Items]    
    Basis spread on variable rate (percentage)   1.50%
    XML 73 R57.htm IDEA: XBRL DOCUMENT v3.20.4
    Borrowings - Narrative (Details)
    		 1 Months Ended 12 Months Ended
    Sep. 18, 2020
    USD ($)
    Sep. 02, 2020
    USD ($)
    Feb. 11, 2020
    USD ($)
    Sep. 30, 2020
    USD ($)
    Feb. 29, 2020
    USD ($)
    Dec. 31, 2020
    USD ($)
    Dec. 31, 2019
    USD ($)
    partnership
    Dec. 31, 2018
    USD ($)
    Debt Instrument [Line Items]                
    Loss on extinguishment of debt           $ 30,272,000 $ 0 $ 0
    Unsecured Debt                
    Debt Instrument [Line Items]                
    Original issue discount           $ 183,416,000    
    Unsecured Debt | The Notes                
    Debt Instrument [Line Items]                
    Debt issued, amount   $ 6,000,000,000            
    Original issue discount   149,000,000.0            
    Debt issuance costs   $ 40,400,000            
    Weighted average coupon rate (as a percent)           2.125%    
    Weighted average effective interest rate (as a percent)           2.50%    
    Unsecured Debt | The Notes | Level 2                
    Debt Instrument [Line Items]                
    Fair value of outstanding Notes           $ 6,200,000,000    
    Unsecured Debt | The Notes | Prior to the applicable par call date                
    Debt Instrument [Line Items]                
    Redemption price (as a percent)   100.00%            
    Unsecured Debt | The Notes | Upon occurrence of a change of control triggering event                
    Debt Instrument [Line Items]                
    Redemption price (as a percent)   101.00%            
    Unsecured Debt | Senior Unsecured Revolving Credit Facility | Revolving Credit Facility                
    Debt Instrument [Line Items]                
    Debt instrument, term 5 years              
    Line of credit, maximum borrowing capacity $ 1,500,000,000              
    Debt issuance costs related to revolving credit facility           6,100,000    
    Maximum consolidated leverage ratio 4.00              
    Maximum consolidated leverage ratio following qualifying material acquisition 4.50              
    Minimum consolidated coverage ratio 2.50              
    Unsecured Debt | Senior Unsecured Revolving Credit Facility | Federal Funds Rate | Revolving Credit Facility                
    Debt Instrument [Line Items]                
    Basis spread on variable rate (percentage) 0.50%              
    Unsecured Debt | Senior Unsecured Revolving Credit Facility | Overnight Bank Funding Rate | Revolving Credit Facility                
    Debt Instrument [Line Items]                
    Basis spread on variable rate (percentage) 0.50%              
    Unsecured Debt | Senior Unsecured Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility                
    Debt Instrument [Line Items]                
    Basis spread on variable rate (percentage) 1.00%              
    Unsecured Debt | RPIFT Senior Secured Credit Facilities                
    Debt Instrument [Line Items]                
    Debt issued, amount           $ 0 0  
    Senior Secured Debt                
    Debt Instrument [Line Items]                
    Original issue discount             $ 34,878,000  
    Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1                
    Debt Instrument [Line Items]                
    Debt issued, amount     $ 3,200,000,000          
    Loss on extinguishment of debt       $ 25,100,000        
    Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1 | London Interbank Offered Rate (LIBOR)                
    Debt Instrument [Line Items]                
    Basis spread on variable rate (percentage)     1.50%          
    Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1                
    Debt Instrument [Line Items]                
    Debt issued, amount     $ 2,840,000,000          
    Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 | London Interbank Offered Rate (LIBOR)                
    Debt Instrument [Line Items]                
    Basis spread on variable rate (percentage)     1.75%          
    Senior Secured Debt | RPIFT Senior Secured Credit Facilities                
    Debt Instrument [Line Items]                
    Loss on extinguishment of debt         $ 5,400,000      
    Number of instruments held | partnership             2  
    Collateral as a percentage of the collection trust account             80.00%  
    Maximum total leverage ratio             4  
    Minimum debt coverage ratio             3.50  
    Senior Secured Debt | RPIFT Senior Secured Credit Facilities - Tranche A-4                
    Debt Instrument [Line Items]                
    Debt issued, amount             $ 2,150,000,000  
    Amortization rate (percentage)             5.90%  
    Senior Secured Debt | RPIFT Senior Secured Credit Facilities - Tranche A-4 | London Interbank Offered Rate (LIBOR)                
    Debt Instrument [Line Items]                
    Basis spread on variable rate (percentage)             1.50%  
    Senior Secured Debt | RPIFT Senior Secured Credit Facilities - Tranche B-6                
    Debt Instrument [Line Items]                
    Debt issued, amount             $ 4,123,000,000  
    Amortization rate (percentage)             3.20%  
    Senior Secured Debt | RPIFT Senior Secured Credit Facilities - Tranche B-6 | London Interbank Offered Rate (LIBOR)                
    Debt Instrument [Line Items]                
    Basis spread on variable rate (percentage)             2.00%  
    XML 74 R58.htm IDEA: XBRL DOCUMENT v3.20.4
    Borrowings - Schedule of Repayments of Debt by Year (Details) - Unsecured Debt - The Notes
    $ in Thousands
    Dec. 31, 2020
    USD ($)
    Debt Instrument [Line Items]  
    2021 $ 0
    2022 0
    2023 1,000,000
    2024 0
    2025 1,000,000
    Thereafter 4,000,000
    Long-term debt, gross 6,000,000
    Unamortized discount and loan issuance costs on long-term debt $ 183,400
    XML 75 R59.htm IDEA: XBRL DOCUMENT v3.20.4
    Shareholders' Equity - Narrative (Details)
    $ / shares in Units, $ in Millions
    		 1 Months Ended 12 Months Ended
    Oct. 31, 2020
    $ / shares
    shares
    Dec. 31, 2020
    USD ($)
    noncontrolling_interest
    £ / shares
    shares
    Dec. 31, 2020
    USD ($)
    noncontrolling_interest
    $ / shares
    shares
    Jun. 15, 2020
    shares
    Dec. 31, 2019
    shares
    Class of Stock [Line Items]          
    Number of noncontrolling interests | noncontrolling_interest   4 4    
    Dividends declared and paid | $     $ 112.5    
    Dividends paid (in dollars per share) | $ / shares     $ 0.15    
    Share based compensation | $     $ 5.7    
    Restricted Stock Units (RSUs)          
    Class of Stock [Line Items]          
    Restricted stock granted during period (in shares)     125,000    
    Restricted stock vested during period (in shares)     71,000    
    Restricted stock units forfeited (in shares)     0    
    Unrecognized share based compensation expense | $   $ 1.0 $ 1.0    
    Unrecognized share based compensation expense, period of recognition     6 months    
    Deferred Shares          
    Class of Stock [Line Items]          
    Shares, outstanding (in shares)   316,407,000 316,407,000   0
    Common Class A          
    Class of Stock [Line Items]          
    Common shares outstanding   388,135,000 388,135,000   0
    Common Class A | Secondary Offering          
    Class of Stock [Line Items]          
    Number of shares issued (in shares) 17,343,000        
    Sale of stock, price per share (in dollars per share) | $ / shares $ 42.00        
    Common Class A | Secondary Offering | Public Stock Offering - Continuing Investors Partnerships Interests          
    Class of Stock [Line Items]          
    Number of shares issued (in shares) 4,137,000        
    Common Class A | Secondary Offering | Continuing Investors Partnerships          
    Class of Stock [Line Items]          
    Number of shares issued (in shares) 13,206,000        
    Common Class A | 2020 Equity Incentive Plan          
    Class of Stock [Line Items]          
    Number of shares authorized under plan (in shares)       800,000  
    Shares reserved for future issuance (in shares)   675,000 675,000    
    Common Class B          
    Class of Stock [Line Items]          
    Common shares outstanding   218,976,000 218,976,000   0
    Common Class B | Secondary Offering | Continuing Investors Partnerships          
    Class of Stock [Line Items]          
    Number of shares issued (in shares) 13,206,000        
    Class R Redeemable Stock          
    Class of Stock [Line Items]          
    Common shares outstanding   50,000 50,000   0
    Shares, outstanding (in shares)   50,000 50,000    
    Redeemable stock, redemption price (in euros per share) | £ / shares   $ 1      
    XML 76 R60.htm IDEA: XBRL DOCUMENT v3.20.4
    Shareholders' Equity - Summary of Noncontrolling Interests (Details) - USD ($)
    $ in Thousands
    		 6 Months Ended 12 Months Ended
    Dec. 31, 2020
    Jun. 17, 2020
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]          
    Beginning balance   $ 6,141,438 $ 6,141,438 $ 4,552,079 $ 4,460,546
    Contributions     1,482,322    
    Transfer of interests     0    
    Distributions     (1,105,765) (880,142) (1,031,823)
    Net income (loss) $ 1,077,069 624,885 1,701,954 2,461,419 1,517,855
    Effect of exchange by Continuing Investors of Class B shares for Class A ordinary shares and reallocation of historical equity     (1)    
    Issuance of Class A ordinary shares sold in IPO, net of offering costs     1,908,744    
    Other exchanges     191    
    Unrealized gain/(loss) on available for sale debt securities     83,120 6,159 (402,502)
    Reclassification of unrealized gain on available for sale debt securities     (20,551) 0 0
    Ending balance $ 9,895,815   $ 9,895,815 6,141,438 4,552,079
    RP Holdings          
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]          
    Noncontrolling interest (percentage) 64.00%   64.00%    
    RP Holdings | Continuing Investors Partnerships          
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]          
    Noncontrolling interest (percentage) 36.00%   36.00%    
    Non-Controlling Interest          
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]          
    Beginning balance   35,883 $ 35,883 63,865 141,203
    Contributions     1,174,676    
    Transfer of interests     1,037,161    
    Distributions     (792,357) (140,866) (217,464)
    Net income (loss) $ 581,871 145,043   112,884 140,126
    Effect of exchange by Continuing Investors of Class B shares for Class A ordinary shares and reallocation of historical equity     2,433,098    
    Issuance of Class A ordinary shares sold in IPO, net of offering costs     758,354    
    Other exchanges     (309,566)    
    Unrealized gain/(loss) on available for sale debt securities     22,503    
    Reclassification of unrealized gain on available for sale debt securities     (9,630)    
    Ending balance 5,077,036   5,077,036 35,883 $ 63,865
    Non-Controlling Interest | RPSFT          
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]          
    Beginning balance   35,883 35,883    
    Distributions     (112,339)    
    Net income (loss) 46,741 42,151      
    Ending balance 12,436   12,436 35,883  
    Non-Controlling Interest | Legacy Investors Partnerships          
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]          
    Beginning balance   0 0    
    Contributions     1,165,258    
    Transfer of interests     1,037,161    
    Distributions     (594,592)    
    Net income (loss) 218,137 102,892      
    Effect of exchange by Continuing Investors of Class B shares for Class A ordinary shares and reallocation of historical equity     (750)    
    Unrealized gain/(loss) on available for sale debt securities     15,015    
    Reclassification of unrealized gain on available for sale debt securities     (3,612)    
    Ending balance 1,939,509   1,939,509 0  
    Non-Controlling Interest | Continuing Investors Partnerships          
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]          
    Beginning balance   0 0    
    Contributions     9,418    
    Distributions     (85,426)    
    Net income (loss) 316,993        
    Effect of exchange by Continuing Investors of Class B shares for Class A ordinary shares and reallocation of historical equity     2,433,848    
    Issuance of Class A ordinary shares sold in IPO, net of offering costs     758,354    
    Other exchanges     (309,566)    
    Unrealized gain/(loss) on available for sale debt securities     7,488    
    Reclassification of unrealized gain on available for sale debt securities     (6,018)    
    Ending balance 3,125,091   3,125,091 0  
    Non-Controlling Interest | EPA Holdings          
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]          
    Beginning balance   $ 0 0    
    Ending balance $ 0   $ 0 $ 0  
    XML 77 R61.htm IDEA: XBRL DOCUMENT v3.20.4
    Earnings Per Share (Details) - USD ($)
    $ / shares in Units, shares in Thousands, $ in Thousands
    		 6 Months Ended 12 Months Ended
    Dec. 31, 2020
    Jun. 17, 2020
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Numerator          
    Net income (loss) $ 1,077,069 $ 624,885 $ 1,701,954 $ 2,461,419 $ 1,517,855
    Less: net income attributable to Continuing Investors Partnerships prior to the IPO     479,842    
    Less: net income attributable to non-controlling interest     726,914 $ 112,884 $ 140,126
    Net income attributable to Royalty Pharma plc     $ 495,198    
    Denominator          
    Weighted average Class A ordinary shares outstanding - basic (in shares) [1]     375,444    
    Earnings per Class A ordinary share - basic (in dollars per share) [1]     $ 1.32    
    Numerator          
    Net income attributable to Royalty Pharma plc     $ 495,198    
    Denominator          
    Dilutive effect of unvested restricted units (in shares)     11    
    Weighted average Class A ordinary shares outstanding - diluted (in shares) [1]     375,455    
    Earnings per Class A ordinary share - diluted (in dollars per share) [1]     $ 1.32    
    Common Class A          
    Denominator          
    Weighted average Class A ordinary shares outstanding - diluted (in shares)     607,111    
    Class B Holders          
    Numerator          
    Less: net income attributable to non-controlling interest     $ 316,993    
    Legacy Investors Partnerships and RPSFT          
    Numerator          
    Less: net income attributable to non-controlling interest     $ 409,921    
    [1] Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020, the period following our initial public offering (see Note 13).
    XML 78 R62.htm IDEA: XBRL DOCUMENT v3.20.4
    Indirect Cash Flow (Details) - USD ($)
    $ in Thousands
    		 6 Months Ended 12 Months Ended
    Dec. 31, 2020
    Jun. 17, 2020
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Supplemental Cash Flow Elements [Abstract]          
    Net income (loss) $ 1,077,069 $ 624,885 $ 1,701,954 $ 2,461,419 $ 1,517,855
    Adjustments to reconcile consolidated net income to net cash provided by operating activities:          
    Provision for changes in expected cash flows from financial royalty assets     230,839 (1,019,321) (57,334)
    Amortization of intangible assets     23,058 23,924 33,267
    Amortization of debt discount and issuance costs     11,715 12,790 13,127
    Realized gain on available for sale debt securities     0 0 (419,481)
    Unrealized loss/(gain) on derivative contracts     42,076 39,138 (11,923)
    (Gain)/loss on equity securities     (247,073) (155,749) 13,939
    Equity in (earnings)/loss of non-consolidated affiliates     (44,459) 32,517 7,023
    Distributions from non-consolidated affiliates     42,334 14,059 39,402
    Loss on extinguishment of debt     30,272 0 0
    Share-based compensation     5,428 0 0
    Interest income accretion     (20,551) 0 0
    Unrealized Gain (Loss) on Derivatives     (18,600) 0 0
    Impairment charge     65,053 0 0
    Loss on derivative financial instruments     (34,952) 0 0
    Other     9,621 (2,122) (7,771)
    (Increase)/decrease in operating assets:          
    Financial royalty assets     (1,959,975) (1,648,837) (1,524,816)
    Cash collected on financial royalty assets     2,121,923 1,934,092 2,052,592
    Available for sale debt securities     0 (150,000) (150,000)
    Accrued royalty receivable     370 2,471 (27,372)
    Other receivables     0 150,000 150,000
    Other royalty income receivable     (770) 7,390 (11,099)
    Other current assets     (10,278) 4,607 (442)
    Other assets     45,264 (45,635) 0
    Increase (Decrease) in Operating Liabilities [Abstract]          
    Accounts payable and accrued expenses     (766) 6,496 1,350
    Interest payable     42,146 0 0
    Net cash provided by operating activities     2,034,629 1,667,239 1,618,317
    Supplemental schedule of non-cash investing / financing activities:          
    Receipt of contribution of investment in Legacy Investors Partnerships     303,679 0 0
    Settlement of Epizyme forward purchase contract     5,700 0 0
    Accrued purchase obligation - Tazverik     110,000 0 0
    Repayments of long-term debt by contributions from non-controlling interest [1]     1,103,774 0 0
    Milestone payable - Erleada [2]     $ 18,600 $ 0 $ 0
    [1] Related to the pro rata portion of RPIFT's outstanding debt repaid by the Legacy Investors Partnerships
    [2] Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020.
    XML 79 R63.htm IDEA: XBRL DOCUMENT v3.20.4
    Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Activity for the year $ 60,617 $ 6,159 $ (402,502)
    Reclassifications to net income (6,855) 6,189 8,003
    Reclassifications to non-controlling interest (24,022)    
    Reclassification of unrealized gain on available for sale debt securities 20,551 0 0
    Interest Income      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Reclassification of unrealized gain on available for sale debt securities 20,600    
    Cumulative Effect, Period of Adoption, Adjustment      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Beginning balance     2,863
    Unrealized gain/(loss) on equity securities      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Beginning balance 0 0 (2,863)
    Activity for the year 0 0 0
    Reclassifications to net income 0 0 0
    Reclassifications to non-controlling interest 0    
    Reclassifications from non-controlling interest 0    
    Ending balance 0 0 0
    Unrealized gain/(loss) on equity securities | Cumulative Effect, Period of Adoption, Adjustment      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Beginning balance     2,863
    Unrealized gain/(loss) on available for sale debt securities      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Beginning balance 6,159 0 402,502
    Activity for the year 60,617 6,159 (402,502)
    Reclassifications to net income (10,921) 0 0
    Reclassifications to non-controlling interest (24,022)    
    Reclassifications from non-controlling interest 2,562    
    Ending balance 34,395 6,159 0
    Unrealized gain/(loss) on available for sale debt securities | Cumulative Effect, Period of Adoption, Adjustment      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Beginning balance     0
    Unrealized gain/(loss) on interest rate swaps      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Beginning balance (4,066) (10,255) (18,258)
    Activity for the year 0 0 0
    Reclassifications to net income 4,066 6,189 8,003
    Reclassifications to non-controlling interest 0    
    Reclassifications from non-controlling interest 0    
    Ending balance 0 (4,066) (10,255)
    Unrealized gain/(loss) on interest rate swaps | Cumulative Effect, Period of Adoption, Adjustment      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Beginning balance     0
    Total Accumulated Other Comprehensive Income/(Loss)      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Beginning balance 2,093 (10,255) 381,381
    Reclassifications from non-controlling interest 2,562    
    Ending balance 34,395 $ 2,093 $ (10,255)
    Reclassification of unrealized gain on available for sale debt securities $ (10,900)    
    XML 80 R64.htm IDEA: XBRL DOCUMENT v3.20.4
    Related Party Transactions (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 08, 2017
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Nov. 30, 2019
    Related Party Transaction [Line Items]          
    Distribution payable to non-controlling interest   $ 126,366 $ 31,041 $ 44,300  
    Investments in non-consolidated affiliates   454,936 124,061    
    Financial royalty asset, net   12,955,277 11,294,612    
    Treasury interests     4,266    
    Equity Investment In Epizyme Inc.          
    Related Party Transaction [Line Items]          
    Investments in non-consolidated affiliates         $ 100,000
    Bristol-Myers Squibb          
    Related Party Transaction [Line Items]          
    Installment payments made during period   24,300 171,000    
    Treasury Stock          
    Related Party Transaction [Line Items]          
    Treasury interests     4,266    
    Payments To Related Party Funded By Acquisitions | Bristol-Myers Squibb          
    Related Party Transaction [Line Items]          
    Installment payments made during period   $ 12,100 85,500    
    The Manager | Operating and Personnel Payments          
    Related Party Transaction [Line Items]          
    Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)   6.50%      
    Quarterly payments to affiliates, percent of security investment (as a percent)   0.25%      
    Amount calculated for operating and personal payment   $ 1,000      
    Percent for calculating operating and personal payment   0.3125%      
    Operating and personnel payments incurred   $ 112,500      
    The Manager | Former Operating and Personnel Payments          
    Related Party Transaction [Line Items]          
    Operating and personnel payments incurred     60,000 $ 57,200  
    Increase in quarterly installment payments (as a percent)   5.00%      
    Affiliated Entity | Royalty Distribution Payable to Legacy Investors Partnerships          
    Related Party Transaction [Line Items]          
    Distribution payable to non-controlling interest   $ 100,000      
    Affiliated Entity | Royalty Distribution Payable to RP Select Finance Trust          
    Related Party Transaction [Line Items]          
    Distribution payable to non-controlling interest   26,300      
    Affiliated Entity | Assignment Agreement - Benefit of Payment Stream | Bristol-Myers Squibb          
    Related Party Transaction [Line Items]          
    Related party, rate (as a percent) 50.00%        
    Affiliated Entity | Assignment Agreement - Funding Obligations | Bristol-Myers Squibb          
    Related Party Transaction [Line Items]          
    Related party, rate (as a percent) 50.00%        
    Financial royalty asset, net   150,600 150,300    
    Cumulative funding amount   $ 162,400      
    Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate          
    Related Party Transaction [Line Items]          
    Number of limited partnership interest acquired (in shares)   27,210      
    Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate | Treasury Stock          
    Related Party Transaction [Line Items]          
    Treasury interests   $ 4,300      
    Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate | Non-Controlling Interest          
    Related Party Transaction [Line Items]          
    Treasury interests   1,900 $ 4,300    
    Pablo Legorreta | Purchasing And Donating Ventilators          
    Related Party Transaction [Line Items]          
    Amount paid to CEO   $ 1,000      
    XML 81 R65.htm IDEA: XBRL DOCUMENT v3.20.4
    Commitments and Contingencies (Details) - USD ($)
    $ in Millions
    		 1 Months Ended
    Aug. 07, 2020
    Nov. 30, 2021
    Nov. 30, 2020
    Jan. 31, 2020
    Nov. 30, 2019
    Funding Agreement With Biohaven Pharmaceuticals          
    Long-term Purchase Commitment [Line Items]          
    Payment for purchase of royalties $ 450.0        
    Purchase commitment, upfront payment 150.0        
    Purchase commitment, additional payments 100.0        
    Purchase commitment, purchase of committed, non-contingent Commercial Launch Preferred Equity payable $ 200.0        
    Purchase Of Eisai Royalties          
    Long-term Purchase Commitment [Line Items]          
    Payment for purchase of royalties         $ 330.0
    Purchase commitment, upfront payment       $ 110.0  
    Purchase commitment, additional payments     $ 110.0 $ 220.0  
    Forecast | Purchase Of Eisai Royalties          
    Long-term Purchase Commitment [Line Items]          
    Purchase commitment, additional payments   $ 110.0      
    XML 82 R66.htm IDEA: XBRL DOCUMENT v3.20.4
    Subsequent Events (Details) - Subsequent Event
    $ in Thousands
    		 1 Months Ended
    Jan. 31, 2021
    USD ($)
    Subsequent Event [Line Items]  
    Payments to acquire royalty interests, upfront payment $ 60,000
    Payments to acquire royalty interests, additional milestone payments $ 95,000
    XML 83 R9999.htm IDEA: XBRL DOCUMENT v3.20.4
    Label Element Value
    Accounting Standards Update [Extensible List] us-gaap_AccountingStandardsUpdateExtensibleList us-gaap:AccountingStandardsUpdate201601Member
    Retained Earnings [Member]  
    Net Income (Loss), Including Portion Attributable to Noncontrolling Interest us-gaap_ProfitLoss $ 495,198,000
    Net Income (Loss), Including Portion Attributable to Noncontrolling Interest us-gaap_ProfitLoss $ 479,842,000
    EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 85 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 87 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 421 460 1 true 153 0 false 8 false false R1.htm 0001001 - Document - Cover Sheet http://royaltypharma.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - Consolidated Balance Sheets Sheet http://royaltypharma.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Consolidated Statements of Comprehensive Income Sheet http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 4 false false R5.htm 1004005 - Statement - Consolidated Statements of Shareholders' Equity Sheet http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity Consolidated Statements of Shareholders' Equity Statements 5 false false R6.htm 1005006 - Statement - Consolidated Statements of Cash Flows Sheet http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101101 - Disclosure - Organization and Purpose Sheet http://royaltypharma.com/role/OrganizationandPurpose Organization and Purpose Notes 7 false false R8.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 2106103 - Disclosure - Fair Value Measurements and Financial Instruments Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments Fair Value Measurements and Financial Instruments Notes 9 false false R10.htm 2112104 - Disclosure - Derivative Instruments Sheet http://royaltypharma.com/role/DerivativeInstruments Derivative Instruments Notes 10 false false R11.htm 2117105 - Disclosure - Available for Sale Debt Securities Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecurities Available for Sale Debt Securities Notes 11 false false R12.htm 2121106 - Disclosure - Financial Royalty Assets, Net Sheet http://royaltypharma.com/role/FinancialRoyaltyAssetsNet Financial Royalty Assets, Net Notes 12 false false R13.htm 2125107 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Notes 13 false false R14.htm 2129108 - Disclosure - Intangible Royalty Assets, Net Sheet http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet Intangible Royalty Assets, Net Notes 14 false false R15.htm 2133109 - Disclosure - Non-Consolidated Affiliates Sheet http://royaltypharma.com/role/NonConsolidatedAffiliates Non-Consolidated Affiliates Notes 15 false false R16.htm 2135110 - Disclosure - R&D Funding Expense Sheet http://royaltypharma.com/role/RDFundingExpense R&D Funding Expense Notes 16 false false R17.htm 2137111 - Disclosure - Borrowings Sheet http://royaltypharma.com/role/Borrowings Borrowings Notes 17 false false R18.htm 2142112 - Disclosure - Shareholders' Equity Sheet http://royaltypharma.com/role/ShareholdersEquity Shareholders' Equity Notes 18 false false R19.htm 2146113 - Disclosure - Earnings Per Share Sheet http://royaltypharma.com/role/EarningsPerShare Earnings Per Share Notes 19 false false R20.htm 2149114 - Disclosure - Indirect Cash Flow Sheet http://royaltypharma.com/role/IndirectCashFlow Indirect Cash Flow Notes 20 false false R21.htm 2152115 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 21 false false R22.htm 2155116 - Disclosure - Related Party Transactions Sheet http://royaltypharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 22 false false R23.htm 2157117 - Disclosure - Commitments and Contingencies Sheet http://royaltypharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 23 false false R24.htm 2159118 - Disclosure - Subsequent Events Sheet http://royaltypharma.com/role/SubsequentEvents Subsequent Events Notes 24 false false R25.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 2307301 - Disclosure - Fair Value Measurements and Financial Instruments (Tables) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables Fair Value Measurements and Financial Instruments (Tables) Tables http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments 26 false false R27.htm 2313302 - Disclosure - Derivative Instruments (Tables) Sheet http://royaltypharma.com/role/DerivativeInstrumentsTables Derivative Instruments (Tables) Tables http://royaltypharma.com/role/DerivativeInstruments 27 false false R28.htm 2318303 - Disclosure - Available for Sale Debt Securities (Tables) Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables Available for Sale Debt Securities (Tables) Tables http://royaltypharma.com/role/AvailableforSaleDebtSecurities 28 false false R29.htm 2322304 - Disclosure - Financial Royalty Assets, Net (Tables) Sheet http://royaltypharma.com/role/FinancialRoyaltyAssetsNetTables Financial Royalty Assets, Net (Tables) Tables http://royaltypharma.com/role/FinancialRoyaltyAssetsNet 29 false false R30.htm 2326305 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables) Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables) Tables http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets 30 false false R31.htm 2330306 - Disclosure - Intangible Royalty Assets, Net (Tables) Sheet http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables Intangible Royalty Assets, Net (Tables) Tables http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet 31 false false R32.htm 2338307 - Disclosure - Borrowings (Tables) Sheet http://royaltypharma.com/role/BorrowingsTables Borrowings (Tables) Tables http://royaltypharma.com/role/Borrowings 32 false false R33.htm 2343308 - Disclosure - Shareholders' Equity (Tables) Sheet http://royaltypharma.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://royaltypharma.com/role/ShareholdersEquity 33 false false R34.htm 2347309 - Disclosure - Earnings Per Share (Tables) Sheet http://royaltypharma.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://royaltypharma.com/role/EarningsPerShare 34 false false R35.htm 2350310 - Disclosure - Indirect Cash Flow (Tables) Sheet http://royaltypharma.com/role/IndirectCashFlowTables Indirect Cash Flow (Tables) Tables http://royaltypharma.com/role/IndirectCashFlow 35 false false R36.htm 2353311 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLoss 36 false false R37.htm 2402401 - Disclosure - Organization and Purpose (Details) Sheet http://royaltypharma.com/role/OrganizationandPurposeDetails Organization and Purpose (Details) Details http://royaltypharma.com/role/OrganizationandPurpose 37 false false R38.htm 2405402 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies 38 false false R39.htm 2408403 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) Details 39 false false R40.htm 2409404 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) Details 40 false false R41.htm 2410405 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails Fair Value Measurements and Financial Instruments - Narrative (Details) Details http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables 41 false false R42.htm 2411406 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) Details 42 false false R43.htm 2414407 - Disclosure - Derivative Instruments - Narrative (Details) Sheet http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails Derivative Instruments - Narrative (Details) Details 43 false false R44.htm 2415408 - Disclosure - Derivative Instruments - Schedule of Notional Values and Fixed Rates (Details) Sheet http://royaltypharma.com/role/DerivativeInstrumentsScheduleofNotionalValuesandFixedRatesDetails Derivative Instruments - Schedule of Notional Values and Fixed Rates (Details) Details 44 false false R45.htm 2416409 - Disclosure - Derivative Instruments - Summary of Derivatives and Reclassifications (Details) Sheet http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails Derivative Instruments - Summary of Derivatives and Reclassifications (Details) Details 45 false false R46.htm 2419410 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) Details 46 false false R47.htm 2420411 - Disclosure - Available for Sale Debt Securities - Narrative (Details) Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails Available for Sale Debt Securities - Narrative (Details) Details 47 false false R48.htm 2423412 - Disclosure - Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details) Sheet http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details) Details 48 false false R49.htm 2424413 - Disclosure - Financial Royalty Assets, Net - Narrative (Details) Sheet http://royaltypharma.com/role/FinancialRoyaltyAssetsNetNarrativeDetails Financial Royalty Assets, Net - Narrative (Details) Details 49 false false R50.htm 2427414 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details) Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details) Details http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables 50 false false R51.htm 2428415 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) Details 51 false false R52.htm 2431416 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) Sheet http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) Details 52 false false R53.htm 2432417 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details) Sheet http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails Intangible Royalty Assets, Net - Narrative (Details) Details 53 false false R54.htm 2434418 - Disclosure - Non-Consolidated Affiliates (Details) Sheet http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails Non-Consolidated Affiliates (Details) Details http://royaltypharma.com/role/NonConsolidatedAffiliates 54 false false R55.htm 2436419 - Disclosure - R&D Funding Expense (Details) Sheet http://royaltypharma.com/role/RDFundingExpenseDetails R&D Funding Expense (Details) Details http://royaltypharma.com/role/RDFundingExpense 55 false false R56.htm 2439420 - Disclosure - Borrowings - Schedule of Borrowings (Details) Sheet http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails Borrowings - Schedule of Borrowings (Details) Details 56 false false R57.htm 2440421 - Disclosure - Borrowings - Narrative (Details) Sheet http://royaltypharma.com/role/BorrowingsNarrativeDetails Borrowings - Narrative (Details) Details 57 false false R58.htm 2441422 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details) Sheet http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails Borrowings - Schedule of Repayments of Debt by Year (Details) Details 58 false false R59.htm 2444423 - Disclosure - Shareholders' Equity - Narrative (Details) Sheet http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity - Narrative (Details) Details 59 false false R60.htm 2445424 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details) Sheet http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails Shareholders' Equity - Summary of Noncontrolling Interests (Details) Details 60 false false R61.htm 2448425 - Disclosure - Earnings Per Share (Details) Sheet http://royaltypharma.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://royaltypharma.com/role/EarningsPerShareTables 61 false false R62.htm 2451426 - Disclosure - Indirect Cash Flow (Details) Sheet http://royaltypharma.com/role/IndirectCashFlowDetails Indirect Cash Flow (Details) Details http://royaltypharma.com/role/IndirectCashFlowTables 62 false false R63.htm 2454427 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossTables 63 false false R64.htm 2456428 - Disclosure - Related Party Transactions (Details) Sheet http://royaltypharma.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://royaltypharma.com/role/RelatedPartyTransactions 64 false false R65.htm 2458429 - Disclosure - Commitments and Contingencies (Details) Sheet http://royaltypharma.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://royaltypharma.com/role/CommitmentsandContingencies 65 false false R66.htm 2460430 - Disclosure - Subsequent Events (Details) Sheet http://royaltypharma.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://royaltypharma.com/role/SubsequentEvents 66 false false R9999.htm Uncategorized Items - rprx-20201231.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - rprx-20201231.htm Cover 67 false false All Reports Book All Reports rprx-20201231.htm rprx-20201231.xsd rprx-20201231_cal.xml rprx-20201231_def.xml rprx-20201231_lab.xml rprx-20201231_pre.xml rprx-20201231ex231.htm rprx-20201231ex311.htm rprx-20201231ex312.htm rprx-20201231ex32.htm rprx-20201231ex42.htm rprx-20201231_g1.jpg rprx-20201231_g2.jpg rprx-20201231_g3.jpg rprx-20201231_g4.jpg http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 90 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rprx-20201231.htm": { "axisCustom": 1, "axisStandard": 42, "contextCount": 421, "dts": { "calculationLink": { "local": [ "rprx-20201231_cal.xml" ] }, "definitionLink": { "local": [ "rprx-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "rprx-20201231.htm" ] }, "labelLink": { "local": [ "rprx-20201231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "rprx-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "rprx-20201231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 722, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 2, "http://royaltypharma.com/20201231": 8, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 14 }, "keyCustom": 113, "keyStandard": 347, "memberCustom": 88, "memberStandard": 57, "nsprefix": "rprx", "nsuri": "http://royaltypharma.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://royaltypharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112104 - Disclosure - Derivative Instruments", "role": "http://royaltypharma.com/role/DerivativeInstruments", "shortName": "Derivative Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - Available for Sale Debt Securities", "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecurities", "shortName": "Available for Sale Debt Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121106 - Disclosure - Financial Royalty Assets, Net", "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsNet", "shortName": "Financial Royalty Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CreditLossFinancialInstrumentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125107 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets", "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CreditLossFinancialInstrumentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129108 - Disclosure - Intangible Royalty Assets, Net", "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet", "shortName": "Intangible Royalty Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133109 - Disclosure - Non-Consolidated Affiliates", "role": "http://royaltypharma.com/role/NonConsolidatedAffiliates", "shortName": "Non-Consolidated Affiliates", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135110 - Disclosure - R&D Funding Expense", "role": "http://royaltypharma.com/role/RDFundingExpense", "shortName": "R&D Funding Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137111 - Disclosure - Borrowings", "role": "http://royaltypharma.com/role/Borrowings", "shortName": "Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142112 - Disclosure - Shareholders' Equity", "role": "http://royaltypharma.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146113 - Disclosure - Earnings Per Share", "role": "http://royaltypharma.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Consolidated Balance Sheets", "role": "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NotesAndLoansReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149114 - Disclosure - Indirect Cash Flow", "role": "http://royaltypharma.com/role/IndirectCashFlow", "shortName": "Indirect Cash Flow", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2152115 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "role": "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLoss", "shortName": "Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2155116 - Disclosure - Related Party Transactions", "role": "http://royaltypharma.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2157117 - Disclosure - Commitments and Contingencies", "role": "http://royaltypharma.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2159118 - Disclosure - Subsequent Events", "role": "http://royaltypharma.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables", "shortName": "Fair Value Measurements and Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313302 - Disclosure - Derivative Instruments (Tables)", "role": "http://royaltypharma.com/role/DerivativeInstrumentsTables", "shortName": "Derivative Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318303 - Disclosure - Available for Sale Debt Securities (Tables)", "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables", "shortName": "Available for Sale Debt Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322304 - Disclosure - Financial Royalty Assets, Net (Tables)", "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetTables", "shortName": "Financial Royalty Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "rprx:DeferredSharesParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:DeferredSharesParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "rprx:DeferredSharesParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:DeferredSharesParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2326305 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)", "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330306 - Disclosure - Intangible Royalty Assets, Net (Tables)", "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables", "shortName": "Intangible Royalty Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338307 - Disclosure - Borrowings (Tables)", "role": "http://royaltypharma.com/role/BorrowingsTables", "shortName": "Borrowings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2343308 - Disclosure - Shareholders' Equity (Tables)", "role": "http://royaltypharma.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347309 - Disclosure - Earnings Per Share (Tables)", "role": "http://royaltypharma.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2350310 - Disclosure - Indirect Cash Flow (Tables)", "role": "http://royaltypharma.com/role/IndirectCashFlowTables", "shortName": "Indirect Cash Flow (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2353311 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfLongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization and Purpose (Details)", "role": "http://royaltypharma.com/role/OrganizationandPurposeDetails", "shortName": "Organization and Purpose (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i691e1e4e3ea64b188975728738a470f0_D20200211-20200211", "decimals": "-8", "lang": "en-US", "name": "us-gaap:RepaymentsOfLongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i713ac149f5944f6caad0e1013f1e9d83_I20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:NumberOfNoncontrollingInterestsCreated", "reportCount": 1, "unique": true, "unitRef": "partnership", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i713ac149f5944f6caad0e1013f1e9d83_I20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:NumberOfNoncontrollingInterestsCreated", "reportCount": 1, "unique": true, "unitRef": "partnership", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TradingSecuritiesDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5f2e70191dc942188065d1acd478a122_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails", "shortName": "Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i2649434135de4ca387dd147c97378bc2_I20181231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "shortName": "Fair Value Measurements and Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i9860996e52a042fbae58aad31310434d_I20191231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i6cfff83bce3946d2a2adba0b55b63a9d_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:FinancingReceivablesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails", "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i6cfff83bce3946d2a2adba0b55b63a9d_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:FinancingReceivablesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:PaymentsToTerminateDerivativeInstruments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - Derivative Instruments - Narrative (Details)", "role": "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "shortName": "Derivative Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "ia6d546e8ed5a437b98d3fed526cd285e_D20190405-20190405", "decimals": null, "lang": "en-US", "name": "rprx:DerivativeInstrumentOptionExercisePeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i51ae16ea8e1044a4b93b43077c3489c0_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - Derivative Instruments - Schedule of Notional Values and Fixed Rates (Details)", "role": "http://royaltypharma.com/role/DerivativeInstrumentsScheduleofNotionalValuesandFixedRatesDetails", "shortName": "Derivative Instruments - Schedule of Notional Values and Fixed Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i51ae16ea8e1044a4b93b43077c3489c0_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i4cf3845d768e450ea98c4b0b78f97f6d_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416409 - Disclosure - Derivative Instruments - Summary of Derivatives and Reclassifications (Details)", "role": "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails", "shortName": "Derivative Instruments - Summary of Derivatives and Reclassifications (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i4cf3845d768e450ea98c4b0b78f97f6d_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419410 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)", "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "shortName": "Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420411 - Disclosure - Available for Sale Debt Securities - Narrative (Details)", "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "shortName": "Available for Sale Debt Securities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5eccbbfaa9a44222a34a1627699c26a1_D20180101-20181231", "decimals": "-5", "lang": "en-US", "name": "rprx:PotentialMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423412 - Disclosure - Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details)", "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails", "shortName": "Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i93afaac8f5524fd395a21fe1c95eccaf_D20190101-20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "rprx:FinancingReceivableIncreaseDecreaseDueIncreaseReductionInRoyaltyReceipts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424413 - Disclosure - Financial Royalty Assets, Net - Narrative (Details)", "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetNarrativeDetails", "shortName": "Financial Royalty Assets, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i93afaac8f5524fd395a21fe1c95eccaf_D20190101-20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "rprx:FinancingReceivableIncreaseDecreaseDueIncreaseReductionInRoyaltyReceipts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "ieff8b4ee23fb4c698ceffdd537a3d5b4_I20171231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Consolidated Statements of Shareholders' Equity", "role": "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "shortName": "Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i07757bb7881947d79d9dd68761b8aa59_I20171231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427414 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details)", "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i3a2e5c6d788b48b487f58e4101218b20_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428415 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)", "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431416 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)", "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails", "shortName": "Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i4b94cf3fce83435eba00a65648ad68df_D20200101-20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432417 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details)", "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "shortName": "Intangible Royalty Assets, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i4b94cf3fce83435eba00a65648ad68df_D20200101-20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434418 - Disclosure - Non-Consolidated Affiliates (Details)", "role": "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "shortName": "Non-Consolidated Affiliates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i72b2facb039e4cdeb98d2009e1cd5eb9_I20191231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherCommitment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436419 - Disclosure - R&D Funding Expense (Details)", "role": "http://royaltypharma.com/role/RDFundingExpenseDetails", "shortName": "R&D Funding Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i27542c60e465408d8465b9c0b5221916_D20200101-20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439420 - Disclosure - Borrowings - Schedule of Borrowings (Details)", "role": "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "shortName": "Borrowings - Schedule of Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "ic6a92595671742b99c81ecc124a84a4b_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440421 - Disclosure - Borrowings - Narrative (Details)", "role": "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "shortName": "Borrowings - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "iff6f087bce404dcbbe7cbec675a24be1_I20200902", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i9eefa75377f54998ab2d03cdd523a29e_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441422 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details)", "role": "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails", "shortName": "Borrowings - Schedule of Repayments of Debt by Year (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i9eefa75377f54998ab2d03cdd523a29e_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:NumberOfNoncontrollingInterests", "reportCount": 1, "unitRef": "noncontrolling_interest", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444423 - Disclosure - Shareholders' Equity - Narrative (Details)", "role": "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "shortName": "Shareholders' Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DividendsCommonStockCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Consolidated Statements of Cash Flows", "role": "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i3a2e5c6d788b48b487f58e4101218b20_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445424 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details)", "role": "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "shortName": "Shareholders' Equity - Summary of Noncontrolling Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i56bdbbbd3da849c8b76d285aca94ec55_D20200618-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "ib2194908ff564e71a16c0a30642bb98c_D20200618-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448425 - Disclosure - Earnings Per Share (Details)", "role": "http://royaltypharma.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "rprx:NetIncomeLossAttributableToParentPriorToOffering", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "ib2194908ff564e71a16c0a30642bb98c_D20200618-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451426 - Disclosure - Indirect Cash Flow (Details)", "role": "http://royaltypharma.com/role/IndirectCashFlowDetails", "shortName": "Indirect Cash Flow (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454427 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "role": "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5af99c5f16c74bb2a8a46bbfcf640416_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456428 - Disclosure - Related Party Transactions (Details)", "role": "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "ib66bd795606545dca8647a6bc9b32251_I20181231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i632b63cab7c847c0979c41a18fce7ca0_D20200807-20200807", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458429 - Disclosure - Commitments and Contingencies (Details)", "role": "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i632b63cab7c847c0979c41a18fce7ca0_D20200807-20200807", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5fdbb087190148219d18802b7f55e2c1_D20210101-20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:PaymentsToAcquireRoyaltyInterestsUpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460430 - Disclosure - Subsequent Events (Details)", "role": "http://royaltypharma.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "i5fdbb087190148219d18802b7f55e2c1_D20210101-20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:PaymentsToAcquireRoyaltyInterestsUpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Purpose", "role": "http://royaltypharma.com/role/OrganizationandPurpose", "shortName": "Organization and Purpose", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106103 - Disclosure - Fair Value Measurements and Financial Instruments", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments", "shortName": "Fair Value Measurements and Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "idfaff1576bd948d1b81c329a01f87ee9_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20201231.htm", "contextRef": "ia450e2cc991e4ed8bf60d642401a5329_D20200618-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - rprx-20201231.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - rprx-20201231.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 153, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r625", "r626", "r627" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "rprx_A2020EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Equity Incentive Plan", "label": "2020 Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan" } } }, "localname": "A2020EquityIncentivePlanMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_AOCIAccumulatedGainLossEquitySecuritiesParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AOCI, Accumulated Gain (Loss), Equity Securities, Parent", "label": "AOCI, Accumulated Gain (Loss), Equity Securities, Parent [Member]", "terseLabel": "Unrealized gain/(loss) on equity securities" } } }, "localname": "AOCIAccumulatedGainLossEquitySecuritiesParentMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AZ Asset - Phase II and Phase III Clinical Trial", "label": "AZ Asset - Phase II and Phase III Clinical Trial [Member]", "terseLabel": "AZ Asset - Phase II and Phase III Clinical Trial" } } }, "localname": "AZAssetPhaseIIAndPhaseIIIClinicalTrialMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_AccruedPurchaseObligationCurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Purchase Obligation, Current", "label": "Accrued Purchase Obligation, Current", "terseLabel": "Accrued purchase obligation" } } }, "localname": "AccruedPurchaseObligationCurrent", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rprx_AccruedPurchaseObligationEquityInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Purchase Obligation, Equity Investment", "label": "Accrued Purchase Obligation, Equity Investment", "terseLabel": "Accrued purchase obligation - Tazverik" } } }, "localname": "AccruedPurchaseObligationEquityInvestment", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_AccruedRoyaltyReceivable": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued Royalty Receivable", "label": "Accrued Royalty Receivable", "terseLabel": "Accrued royalty receivable" } } }, "localname": "AccruedRoyaltyReceivable", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition Of Limited Partnership Interests In Affiliate", "label": "Acquisition Of Limited Partnership Interests In Affiliate [Member]", "terseLabel": "Acquisition Of Limited Partnership Interests In Affiliate" } } }, "localname": "AcquisitionOfLimitedPartnershipInterestsInAffiliateMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_AssetsFairValueDisclosureCurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets, Fair Value Disclosure, Current", "label": "Assets, Fair Value Disclosure, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsFairValueDisclosureCurrent", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "rprx_AssetsFairValueDisclosureNoncurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets, Fair Value Disclosure, Noncurrent", "label": "Assets, Fair Value Disclosure, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsFairValueDisclosureNoncurrent", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "rprx_AssignmentAgreementBenefitOfPaymentStreamMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assignment Agreement - Benefit of Payment Stream", "label": "Assignment Agreement - Benefit of Payment Stream [Member]", "terseLabel": "Assignment Agreement - Benefit of Payment Stream" } } }, "localname": "AssignmentAgreementBenefitOfPaymentStreamMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_AssignmentAgreementFundingObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assignment Agreement - Funding Obligations", "label": "Assignment Agreement - Funding Obligations [Member]", "terseLabel": "Assignment Agreement - Funding Obligations" } } }, "localname": "AssignmentAgreementFundingObligationsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_AvillionEntitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Avillion Entities", "label": "Avillion Entities [Member]", "terseLabel": "Avillion Entities" } } }, "localname": "AvillionEntitiesMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_AvillionIIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Avillion II", "label": "Avillion II [Member]", "terseLabel": "Avillion II" } } }, "localname": "AvillionIIMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_AvillionIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Avillion I", "label": "Avillion I [Member]", "terseLabel": "Avillion I" } } }, "localname": "AvillionIMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_BristolMyersSquibbMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bristol-Myers Squibb", "label": "Bristol-Myers Squibb [Member]", "terseLabel": "Bristol-Myers Squibb" } } }, "localname": "BristolMyersSquibbMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_ChangeOfControlProbabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change Of Control Probability", "label": "Change Of Control Probability [Member]", "terseLabel": "Change Of Control Probability" } } }, "localname": "ChangeOfControlProbabilityMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_ClassBHoldersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class B Holders", "label": "Class B Holders [Member]", "terseLabel": "Class B Holders" } } }, "localname": "ClassBHoldersMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "rprx_ClassRRedeemableStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class R Redeemable Stock", "label": "Class R Redeemable Stock [Member]", "terseLabel": "Class R Redeemable Stock" } } }, "localname": "ClassRRedeemableStockMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_ContinuingInvestorsPartnershipMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continuing Investors Partnership", "label": "Continuing Investors Partnership [Member]", "terseLabel": "Continuing Investors Partnerships" } } }, "localname": "ContinuingInvestorsPartnershipMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "rprx_CrysvitaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Crysvita", "label": "Crysvita [Member]", "terseLabel": "Crysvita" } } }, "localname": "CrysvitaMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_CysticFibrosisFranchiseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cystic Fibrosis Franchise", "label": "Cystic Fibrosis Franchise [Member]", "terseLabel": "Cystic fibrosis franchise" } } }, "localname": "CysticFibrosisFranchiseMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_DPPIVPatentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DPP-IV Patents", "label": "DPP-IV Patents [Member]", "terseLabel": "DPP-IV patents" } } }, "localname": "DPPIVPatentsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "domainItemType" }, "rprx_DebtInstrumentAmortizationRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Rate", "label": "Debt Instrument, Amortization Rate", "terseLabel": "Amortization rate (percentage)" } } }, "localname": "DebtInstrumentAmortizationRate", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio", "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio", "terseLabel": "Maximum consolidated leverage ratio" } } }, "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition", "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition", "terseLabel": "Maximum consolidated leverage ratio following qualifying material acquisition" } } }, "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "rprx_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio", "label": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio", "terseLabel": "Maximum total leverage ratio" } } }, "localname": "DebtInstrumentCovenantTermsMaximumTotalLeverageRatio", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio", "label": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio", "terseLabel": "Minimum consolidated coverage ratio" } } }, "localname": "DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "rprx_DebtInstrumentCovenantTermsMinimumDebtCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Minimum Debt Coverage Ratio", "label": "Debt Instrument, Covenant Terms, Minimum Debt Coverage Ratio", "terseLabel": "Minimum debt coverage ratio" } } }, "localname": "DebtInstrumentCovenantTermsMinimumDebtCoverageRatio", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "rprx_DebtInstrumentIssuanceAsAPercentOfPar": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Issuance As A Percent Of Par", "label": "Debt Instrument, Issuance As A Percent Of Par", "terseLabel": "Debt issued as a percent of par value (as a percent)" } } }, "localname": "DebtInstrumentIssuanceAsAPercentOfPar", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "percentItemType" }, "rprx_DebtInstrumentNumberOfInstrumentsHeld": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Number Of Instruments Held", "label": "Debt Instrument, Number Of Instruments Held", "terseLabel": "Number of instruments held" } } }, "localname": "DebtInstrumentNumberOfInstrumentsHeld", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "integerItemType" }, "rprx_DebtInstrumentTermsCollateralPercentageOfCollectionTrustAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Terms, Collateral, Percentage Of Collection Trust Account", "label": "Debt Instrument, Terms, Collateral, Percentage Of Collection Trust Account", "terseLabel": "Collateral as a percentage of the collection trust account" } } }, "localname": "DebtInstrumentTermsCollateralPercentageOfCollectionTrustAccount", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "rprx_DebtSecuritiesAvailableForSaleAdditionalIssuancePurchasePriceMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Additional Issuance, Purchase Price, Maximum", "label": "Debt Securities, Available-For-Sale, Additional Issuance, Purchase Price, Maximum", "terseLabel": "Additional issuance, purchase price, maximum" } } }, "localname": "DebtSecuritiesAvailableForSaleAdditionalIssuancePurchasePriceMaximum", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_DebtSecuritiesAvailableForSaleAdditionalIssuancePurchasePriceMinimum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Additional Issuance, Purchase Price, Minimum", "label": "Debt Securities, Available-For-Sale, Additional Issuance, Purchase Price, Minimum", "terseLabel": "Additional issuance, purchase price, minimum" } } }, "localname": "DebtSecuritiesAvailableForSaleAdditionalIssuancePurchasePriceMinimum", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_DebtSecuritiesAvailableForSaleFixedPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-Sale, Fixed Payment", "label": "Debt Securities, Available-for-Sale, Fixed Payment", "terseLabel": "Preferred shares, fixed payment amount" } } }, "localname": "DebtSecuritiesAvailableForSaleFixedPayment", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Number Of Shares Purchased", "label": "Debt Securities, Available-For-Sale, Number Of Shares Purchased", "terseLabel": "Number of shares purchased (in shares)" } } }, "localname": "DebtSecuritiesAvailableForSaleNumberOfSharesPurchased", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available For Sale, Policy", "label": "Debt Securities, Available For Sale, Policy [Policy Text Block]", "terseLabel": "Equity securities and Available for sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSalePolicyPolicyTextBlock", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rprx_DebtSecuritiesAvailableForSalePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Price Per Share", "label": "Debt Securities, Available-For-Sale, Price Per Share", "terseLabel": "Price per share (in USD per share)" } } }, "localname": "DebtSecuritiesAvailableForSalePricePerShare", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-Sale, Quarterly Payments", "label": "Debt Securities, Available-for-Sale, Quarterly Payments", "terseLabel": "Preferred shares, quarterly payments" } } }, "localname": "DebtSecuritiesAvailableForSaleQuarterlyPayments", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption Default, Interest Rate", "label": "Debt Securities, Available-For-Sale, Redemption Default, Interest Rate", "terseLabel": "Redemption default, interest rate" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "percentItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption Default, Threshold Period", "label": "Debt Securities, Available-For-Sale, Redemption Default, Threshold Period", "terseLabel": "Redemption default, threshold period" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "durationItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption, Period", "label": "Debt Securities, Available-For-Sale, Redemption, Period [Axis]", "terseLabel": "Debt Securities, Available-For-Sale, Redemption, Period [Axis]" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodAxis", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption, Period", "label": "Debt Securities, Available-For-Sale, Redemption, Period [Domain]", "terseLabel": "Debt Securities, Available-For-Sale, Redemption, Period [Domain]" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodDomain", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption, Period One", "label": "Debt Securities, Available-For-Sale, Redemption, Period One [Member]", "terseLabel": "Redemption, Period One" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption, Period Two", "label": "Debt Securities, Available-For-Sale, Redemption, Period Two [Member]", "terseLabel": "Redemption, Period Two" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption Price, Percentage", "label": "Debt Securities, Available-For-Sale, Redemption Price, Percentage", "terseLabel": "Redemption price, percentage" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPricePercentage", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital", "label": "Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital", "terseLabel": "Preferred shares, weighted average cost of capital" } } }, "localname": "DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "rprx_DeferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares", "label": "Deferred Shares [Member]", "terseLabel": "Deferred Shares", "verboseLabel": "Deferred Shares" } } }, "localname": "DeferredSharesMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_DeferredSharesParOrStatedValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares, Par or Stated Value Per Share", "label": "Deferred Shares, Par or Stated Value Per Share", "terseLabel": "Deferred stock, par value (in dollars per share)" } } }, "localname": "DeferredSharesParOrStatedValuePerShare", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "rprx_DeferredSharesSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares, Shares, Issued", "label": "Deferred Shares, Shares, Issued", "terseLabel": "Deferred stock, issued (in shares)" } } }, "localname": "DeferredSharesSharesIssued", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "rprx_DeferredSharesSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares, Shares, Outstanding", "label": "Deferred Shares, Shares, Outstanding", "terseLabel": "Deferred stock, outstanding (in shares)" } } }, "localname": "DeferredSharesSharesOutstanding", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "rprx_DeferredSharesValueIssued": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Shares, Value, Issued", "label": "Deferred Shares, Value, Issued", "terseLabel": "Deferred shares, $0.000001 par value, 316,407 and 0 issued and outstanding, respectively" } } }, "localname": "DeferredSharesValueIssued", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rprx_DerivativeInstrumentOptionExercisePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Instrument, Option, Exercise Period", "label": "Derivative Instrument, Option, Exercise Period", "terseLabel": "Derivative instrument, exercise period (in months)" } } }, "localname": "DerivativeInstrumentOptionExercisePeriod", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "rprx_EPAHoldingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EPA Holdings", "label": "EPA Holdings [Member]", "terseLabel": "EPA Holdings" } } }, "localname": "EPAHoldingsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "rprx_EpizymeCommonStockWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Epizyme Common Stock Warrant", "label": "Epizyme Common Stock Warrant [Member]", "terseLabel": "Epizyme Common Stock Warrant" } } }, "localname": "EpizymeCommonStockWarrantMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_EpizymeIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Epizyme Inc.", "label": "Epizyme Inc. [Member]", "terseLabel": "Equity Investment In Epizyme Inc." } } }, "localname": "EpizymeIncMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_EquityMethodInvestmentsUnfundedCommitments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investments, Unfunded Commitments", "label": "Equity Method Investments, Unfunded Commitments", "terseLabel": "Equity method investment, unfunded commitments" } } }, "localname": "EquityMethodInvestmentsUnfundedCommitments", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_EquitySecuritiesFVNINoncurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 1.0, "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity Securities, FV-NI, Noncurrent", "label": "Equity Securities, FV-NI, Noncurrent", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFVNINoncurrent", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "rprx_EvrysdiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Evrysdi", "label": "Evrysdi [Member]", "terseLabel": "Evrysdi" } } }, "localname": "EvrysdiMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_ExchangeOfferTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange Offer Transaction", "label": "Exchange Offer Transaction [Member]", "terseLabel": "Exchange Offer Transaction" } } }, "localname": "ExchangeOfferTransactionMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_FinancialAndNonfinancialLiabilitiesFairValueDisclosureCurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial and Nonfinancial Liabilities, Fair Value Disclosure, Current", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure, Current", "negatedTotalLabel": "Total current liabilities" } } }, "localname": "FinancialAndNonfinancialLiabilitiesFairValueDisclosureCurrent", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancialAndNonfinancialLiabilitiesFairValueDisclosureNoncurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial and Nonfinancial Liabilities, Fair Value Disclosure, Noncurrent", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure, Noncurrent", "negatedTotalLabel": "Total non-current liabilities" } } }, "localname": "FinancialAndNonfinancialLiabilitiesFairValueDisclosureNoncurrent", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancialRoyaltyAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Royalty Assets", "label": "Financial Royalty Assets [Member]", "terseLabel": "Financial Royalty Assets" } } }, "localname": "FinancialRoyaltyAssetsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "domainItemType" }, "rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": { "order": 1.0, "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows", "label": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows", "negatedLabel": "Cumulative allowance for changes in expected cash flows" } } }, "localname": "FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": { "order": 1.0, "parentTag": "us-gaap_NotesReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)", "label": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)", "negatedLabel": "Cumulative allowance for credit losses" } } }, "localname": "FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Financial Royalty Asset, Writeoff", "label": "Financing Receivable, Allowance for Credit Loss, Financial Royalty Asset, Writeoff", "terseLabel": "Writeoff related to financial royalty asset" } } }, "localname": "FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense", "label": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense", "terseLabel": "Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets" } } }, "localname": "FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense", "label": "Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense", "negatedTerseLabel": "Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets" } } }, "localname": "FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents", "label": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents", "terseLabel": "Aggregate royalty amount when patents cease" } } }, "localname": "FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableExpectedDecreaseInRoyaltyReceipts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Expected Decrease In Royalty Receipts", "label": "Financing Receivable, Expected Decrease In Royalty Receipts", "terseLabel": "Expected reduction in royalty receipts" } } }, "localname": "FinancingReceivableExpectedDecreaseInRoyaltyReceipts", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableIncreaseDecreaseDueIncreaseReductionInRoyaltyReceipts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Increase (Decrease) Due To Increase (Reduction) In Royalty Receipts", "label": "Financing Receivable, Increase (Decrease) Due Increase (Reduction) In Royalty Receipts", "negatedTerseLabel": "Reduction in financial royalty assets" } } }, "localname": "FinancingReceivableIncreaseDecreaseDueIncreaseReductionInRoyaltyReceipts", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": { "order": 2.0, "parentTag": "us-gaap_NotesReceivableNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows", "label": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows", "totalLabel": "Net carrying value, before cumulative allowance for credit losses" } } }, "localname": "FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivablesFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivables, Fair Value Disclosure", "label": "Financing Receivables, Fair Value Disclosure", "terseLabel": "Financial royalty assets, net" } } }, "localname": "FinancingReceivablesFairValueDisclosure", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FormerOperatingAndPersonnelPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Operating and Personnel Payments", "label": "Former Operating and Personnel Payments [Member]", "terseLabel": "Former Operating and Personnel Payments" } } }, "localname": "FormerOperatingAndPersonnelPaymentsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_FundingAgreementWithBiohavenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Funding Agreement With Biohaven", "label": "Funding Agreement With Biohaven [Member]", "terseLabel": "Funding Agreement With Biohaven" } } }, "localname": "FundingAgreementWithBiohavenMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RDFundingExpenseDetails" ], "xbrltype": "domainItemType" }, "rprx_FundingAgreementWithImmunomedicsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Funding Agreement With Immunomedics", "label": "Funding Agreement With Immunomedics [Member]", "terseLabel": "Funding Agreement With Immunomedics" } } }, "localname": "FundingAgreementWithImmunomedicsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RDFundingExpenseDetails" ], "xbrltype": "domainItemType" }, "rprx_FundingAgreementsWithPfizerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Funding Agreements With Pfizer", "label": "Funding Agreements With Pfizer [Member]", "terseLabel": "Funding Agreements With Pfizer" } } }, "localname": "FundingAgreementsWithPfizerMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RDFundingExpenseDetails" ], "xbrltype": "domainItemType" }, "rprx_FundingAgreementsWithSanofiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Funding Agreements With Sanofi", "label": "Funding Agreements With Sanofi [Member]", "terseLabel": "Funding Agreements With Sanofi" } } }, "localname": "FundingAgreementsWithSanofiMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RDFundingExpenseDetails" ], "xbrltype": "domainItemType" }, "rprx_GainLossOnDerivativeFinancialInstruments": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Derivative Financial Instruments", "label": "Gain (Loss) On Derivative Financial Instruments", "negatedTerseLabel": "Loss on derivative financial instruments" } } }, "localname": "GainLossOnDerivativeFinancialInstruments", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IPOContinuingInvestorsPartnershipsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IPO - Continuing Investors Partnerships", "label": "IPO - Continuing Investors Partnerships [Member]", "terseLabel": "Public Stock Offering - Continuing Investors Partnerships Interests" } } }, "localname": "IPOContinuingInvestorsPartnershipsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_IPOSharesFromCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IPO - Shares From Company", "label": "IPO - Shares From Company [Member]", "terseLabel": "IPO - Shares From Company" } } }, "localname": "IPOSharesFromCompanyMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_IPOSharesFromSellingShareholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IPO - Shares From Selling Shareholders", "label": "IPO - Shares From Selling Shareholders [Member]", "terseLabel": "IPO - Shares From Selling Shareholders" } } }, "localname": "IPOSharesFromSellingShareholdersMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_ImbruvicaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Imbruvica", "label": "Imbruvica [Member]", "terseLabel": "Imbruvica" } } }, "localname": "ImbruvicaMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_ImmunomedicsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Immunomedics", "label": "Immunomedics [Member]", "terseLabel": "Immunomedics" } } }, "localname": "ImmunomedicsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "rprx_IncreaseDecreaseInAccruedRoyaltyReceivable": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Accrued Royalty Receivable", "label": "Increase (Decrease) In Accrued Royalty Receivable", "negatedTerseLabel": "Accrued royalty receivable" } } }, "localname": "IncreaseDecreaseInAccruedRoyaltyReceivable", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Cash Collections On Financing Receivables", "label": "Increase (Decrease) In Cash Collections On Financing Receivables", "terseLabel": "Cash collected on financial royalty assets" } } }, "localname": "IncreaseDecreaseInCashCollectionsOnFinancingReceivables", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Debt Securities, Available For Sale", "label": "Increase (Decrease) In Debt Securities, Available For Sale", "negatedTerseLabel": "Available for sale debt securities" } } }, "localname": "IncreaseDecreaseInDebtSecuritiesAvailableForSale", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Other Royalty Income Receivable", "label": "Increase (Decrease) In Other Royalty Income Receivable", "negatedTerseLabel": "Other royalty income receivable" } } }, "localname": "IncreaseDecreaseInOtherRoyaltyIncomeReceivable", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IndividualLicenseesConcentrationRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Licensees Concentration Risk", "label": "Individual Licensees Concentration Risk [Member]", "terseLabel": "Individual Licensees Concentration List" } } }, "localname": "IndividualLicenseesConcentrationRiskMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_IntangibleRoyaltyAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Royalty Assets", "label": "Intangible Royalty Assets [Member]", "terseLabel": "Intangible Royalty Assets" } } }, "localname": "IntangibleRoyaltyAssetsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "domainItemType" }, "rprx_InterestRateSwapDueMarch20231Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap, Due March 2023 - 1", "label": "Interest Rate Swap, Due March 2023 - 1 [Member]", "terseLabel": "Interest Rate Swap, Due March 2023 - 1" } } }, "localname": "InterestRateSwapDueMarch20231Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsScheduleofNotionalValuesandFixedRatesDetails" ], "xbrltype": "domainItemType" }, "rprx_InterestRateSwapDueMarch20232Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap, Due March 2023 - 2", "label": "Interest Rate Swap, Due March 2023 - 2 [Member]", "terseLabel": "Interest Rate Swap, Due March 2023 - 2" } } }, "localname": "InterestRateSwapDueMarch20232Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsScheduleofNotionalValuesandFixedRatesDetails" ], "xbrltype": "domainItemType" }, "rprx_InterestRateSwapDueMarch20233Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap, Due March 2023 - 3", "label": "Interest Rate Swap, Due March 2023 - 3 [Member]", "terseLabel": "Interest Rate Swap, Due March 2023 - 3" } } }, "localname": "InterestRateSwapDueMarch20233Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsScheduleofNotionalValuesandFixedRatesDetails" ], "xbrltype": "domainItemType" }, "rprx_InterestRateSwapDueMarch20234Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap, Due March 2023 - 4", "label": "Interest Rate Swap, Due March 2023 - 4 [Member]", "terseLabel": "Interest Rate Swap, Due March 2023 - 4" } } }, "localname": "InterestRateSwapDueMarch20234Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsScheduleofNotionalValuesandFixedRatesDetails" ], "xbrltype": "domainItemType" }, "rprx_InterestRateSwapDueNovember2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap, Due November 2020", "label": "Interest Rate Swap, Due November 2020 [Member]", "terseLabel": "Interest Rate Swap, Due November 2020" } } }, "localname": "InterestRateSwapDueNovember2020Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsScheduleofNotionalValuesandFixedRatesDetails" ], "xbrltype": "domainItemType" }, "rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)", "label": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)", "negatedTerseLabel": "Interest income accretion" } } }, "localname": "InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LegacyInvestorsPartnershipsAndRPSFTMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legacy Investors Partnerships and RPSFT", "label": "Legacy Investors Partnerships and RPSFT [Member]", "terseLabel": "Legacy Investors Partnerships and RPSFT" } } }, "localname": "LegacyInvestorsPartnershipsAndRPSFTMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust", "label": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member]", "terseLabel": "RPSFT" } } }, "localname": "LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_LegacyInvestorsPartnershipsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legacy Investors Partnerships", "label": "Legacy Investors Partnerships [Member]", "terseLabel": "Legacy Investors Partnerships" } } }, "localname": "LegacyInvestorsPartnershipsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "rprx_LikelihoodOfFDAApprovalAtEndOfAnyGivenQuarterBy2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Likelihood of FDA Approval At End Of Any Given Quarter By 2024", "label": "Likelihood of FDA Approval At End Of Any Given Quarter By 2024 [Member]", "terseLabel": "Likelihood of FDA Approval At End Of Any Given Quarter By 2024" } } }, "localname": "LikelihoodOfFDAApprovalAtEndOfAnyGivenQuarterBy2024Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_LikelihoodOfFDAApprovalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Likelihood of FDA Approval", "label": "Likelihood of FDA Approval [Member]", "terseLabel": "Likelihood of FDA Approval" } } }, "localname": "LikelihoodOfFDAApprovalMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals", "label": "Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals [Member]", "terseLabel": "Funding Agreement With Biohaven Pharmaceuticals" } } }, "localname": "LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Purchase Commitment, Purchase Of Eisai Royalties", "label": "Long Term Purchase Commitment, Purchase Of Eisai Royalties [Member]", "terseLabel": "Purchase Of Eisai Royalties" } } }, "localname": "LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "rprx_MerckAssetPhaseIIClinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merck Asset - Phase II Clinical Trial", "label": "Merck Asset - Phase II Clinical Trial [Member]", "terseLabel": "Merck Asset - Phase II Clinical Trial" } } }, "localname": "MerckAssetPhaseIIClinicalTrialMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_MilestonePayableCurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payable, Current", "label": "Milestone Payable, Current", "terseLabel": "Milestone payable" } } }, "localname": "MilestonePayableCurrent", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rprx_MilestonePaymentAccruedButNotPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment Accrued But Not Paid", "label": "Milestone Payment Accrued But Not Paid", "terseLabel": "Milestone payable - Erleada" } } }, "localname": "MilestonePaymentAccruedButNotPaid", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_NetIncomeLossAttributableToParentPriorToOffering": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net Income (Loss) Attributable to Parent, Prior To Offering", "label": "Net Income (Loss) Attributable to Parent, Prior To Offering", "terseLabel": "Less: net income attributable to Continuing Investors Partnerships prior to the IPO" } } }, "localname": "NetIncomeLossAttributableToParentPriorToOffering", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "rprx_NoncontrollingInterestIncreaseFromContributions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest, Increase from Contributions", "label": "Noncontrolling Interest, Increase from Contributions", "terseLabel": "Contributions" } } }, "localname": "NoncontrollingInterestIncreaseFromContributions", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_NoncontrollingInterestTransfersOfInterests": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest, Transfers Of Interests", "label": "Noncontrolling Interest, Transfers Of Interests", "terseLabel": "Transfer of interests" } } }, "localname": "NoncontrollingInterestTransfersOfInterests", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_NumberOfNoncontrollingInterests": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Noncontrolling Interests", "label": "Number of Noncontrolling Interests", "terseLabel": "Number of noncontrolling interests" } } }, "localname": "NumberOfNoncontrollingInterests", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "rprx_NumberOfNoncontrollingInterestsCreated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Noncontrolling Interests Created", "label": "Number Of Noncontrolling Interests Created", "terseLabel": "Number of noncontrolling interests created" } } }, "localname": "NumberOfNoncontrollingInterestsCreated", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "rprx_OldCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Old Credit Facility", "label": "Old Credit Facility [Member]", "terseLabel": "Old Credit Facility" } } }, "localname": "OldCreditFacilityMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_OnePointSevenFivePercentSeniorNotesDue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Point Seven Five Percent Senior Notes Due 2027", "label": "One Point Seven Five Percent Senior Notes Due 2027 [Member]", "terseLabel": "One Point Seven Five Percent Senior Notes Due 2027" } } }, "localname": "OnePointSevenFivePercentSeniorNotesDue2027Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Point Two Zero Percent Senior Notes Due 2025", "label": "One Point Two Zero Percent Senior Notes Due 2025 [Member]", "terseLabel": "One Point Two Zero Percent Senior Notes Due 2025" } } }, "localname": "OnePointTwoZeroPercentSeniorNotesDue2025Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_OperatingAndPersonnelPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating and Personnel Payments", "label": "Operating and Personnel Payments [Member]", "terseLabel": "Operating and Personnel Payments" } } }, "localname": "OperatingAndPersonnelPaymentsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_OptionIndexedToIssuersEquityTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option Indexed to Issuer's Equity, Term", "label": "Option Indexed to Issuer's Equity, Term", "terseLabel": "Put option, term (in months)" } } }, "localname": "OptionIndexedToIssuersEquityTerm", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "rprx_OptionIndexedToIssuersEquityValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Option Indexed To Issuers Equity, Value", "label": "Option Indexed To Issuers Equity, Value", "terseLabel": "Put option to sell additional common stock" } } }, "localname": "OptionIndexedToIssuersEquityValue", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_OtherCommitmentsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Commitments, Percentage", "label": "Other Commitments, Percentage", "terseLabel": "Other commitments, percentage of costs (as a percent)" } } }, "localname": "OtherCommitmentsPercentage", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "percentItemType" }, "rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss) Reclassification Adjustment, Attributable From Noncontrolling Interest", "label": "Other Comprehensive Income (Loss) Reclassification Adjustment, Attributable From Noncontrolling Interest", "terseLabel": "Reclassifications from non-controlling interest" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Reclassification Adjustment, Attributable to Noncontrolling Interest", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment, Attributable to Noncontrolling Interest", "negatedTerseLabel": "Reclassifications to non-controlling interest" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "rprx_OtherFinancialRoyaltyAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Financial Royalty Asset", "label": "Other Financial Royalty Asset [Member]", "terseLabel": "Other" } } }, "localname": "OtherFinancialRoyaltyAssetMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_OtherRoyaltyIncomeReceivableCurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Royalty Income Receivable, Current", "label": "Other Royalty Income Receivable, Current", "terseLabel": "Other royalty income receivable" } } }, "localname": "OtherRoyaltyIncomeReceivableCurrent", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rprx_OvernightBankFundingRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Overnight Bank Funding Rate", "label": "Overnight Bank Funding Rate [Member]", "terseLabel": "Overnight Bank Funding Rate" } } }, "localname": "OvernightBankFundingRateMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_PaymentOfDividendsToShareholders": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment Of Dividends To Shareholders", "label": "Payment Of Dividends To Shareholders", "negatedTerseLabel": "Dividends to shareholders" } } }, "localname": "PaymentOfDividendsToShareholders", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForCollateralPostedOnDerivativeInstruments": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Collateral Posted On Derivative Instruments", "label": "Payments For Collateral Posted On Derivative Instruments", "negatedTerseLabel": "Swap collateral posted" } } }, "localname": "PaymentsForCollateralPostedOnDerivativeInstruments", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForDistributionsToShareholdersAndUnitholders": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Distributions To Shareholders and Unitholders", "label": "Payments For Distributions To Shareholders and Unitholders", "negatedLabel": "Distributions to shareholders/unitholders" } } }, "localname": "PaymentsForDistributionsToShareholdersAndUnitholders", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForMilestones": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Milestones", "label": "Payments For Milestones", "negatedTerseLabel": "Milestone payments" } } }, "localname": "PaymentsForMilestones", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForOngoingDevelopmentStageFunding": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Ongoing Development Stage Funding", "label": "Payments For Ongoing Development Stage Funding", "negatedTerseLabel": "Ongoing development-stage funding payments" } } }, "localname": "PaymentsForOngoingDevelopmentStageFunding", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForOperatingCostsAndProfessionalServices": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Operating Costs and Professional Services", "label": "Payments For Operating Costs and Professional Services", "negatedTerseLabel": "Payments for operating and professional costs" } } }, "localname": "PaymentsForOperatingCostsAndProfessionalServices", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForRebates": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Rebates", "label": "Payments For Rebates", "negatedTerseLabel": "Payments for rebates" } } }, "localname": "PaymentsForRebates", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForUpfrontDevelopmentStageFunding": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Upfront Development Stage Funding", "label": "Payments For Upfront Development Stage Funding", "negatedTerseLabel": "Upfront development-stage funding payments" } } }, "localname": "PaymentsForUpfrontDevelopmentStageFunding", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to Acquire Equity Investments, Upfront Payment", "label": "Payments to Acquire Equity Investments, Upfront Payment", "terseLabel": "Upfront payment for equity investment" } } }, "localname": "PaymentsToAcquireEquityInvestmentsUpfrontPayment", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToAcquireEquitySecuritiesFNNI": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Equity Securities, FN-NI", "label": "Payments To Acquire Equity Securities, FN-NI", "negatedTerseLabel": "Purchases of equity securities" } } }, "localname": "PaymentsToAcquireEquitySecuritiesFNNI", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Royalty Interest, Additional Milestone Payments", "label": "Payments To Acquire Royalty Interest, Additional Milestone Payments", "terseLabel": "Payments to acquire royalty interests, additional milestone payments" } } }, "localname": "PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Royalty Interests, Upfront Payment", "label": "Payments To Acquire Royalty Interests, Upfront Payment", "terseLabel": "Payments to acquire royalty interests, upfront payment" } } }, "localname": "PaymentsToAcquireRoyaltyInterestsUpfrontPayment", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToAcquireWarrants": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Warrants", "label": "Payments To Acquire Warrants", "negatedTerseLabel": "Purchase of warrants" } } }, "localname": "PaymentsToAcquireWarrants", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToNoncontrollingInterestsOther": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Noncontrolling Interests, Other", "label": "Payments To Noncontrolling Interests, Other", "negatedTerseLabel": "Distributions to non-controlling interest- other" } } }, "localname": "PaymentsToNoncontrollingInterestsOther", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToRelatedPartyFundedByAcquisitionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payments To Related Party Funded By Acquisitions", "label": "Payments To Related Party Funded By Acquisitions [Member]", "terseLabel": "Payments To Related Party Funded By Acquisitions" } } }, "localname": "PaymentsToRelatedPartyFundedByAcquisitionsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_PaymentsToTerminateDerivativeInstruments": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Terminate Derivative Instruments", "label": "Payments To Terminate Derivative Instruments", "negatedTerseLabel": "Swap termination payments", "verboseLabel": "Swap termination payments" } } }, "localname": "PaymentsToTerminateDerivativeInstruments", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PointSevenFivePercentSeniorNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Point Seven Five Percent Senior Notes Due 2023", "label": "Point Seven Five Percent Senior Notes Due 2023 [Member]", "terseLabel": "Point Seven Five Percent Senior Notes Due 2023" } } }, "localname": "PointSevenFivePercentSeniorNotesDue2023Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_PotentialMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential Milestone Payments", "label": "Potential Milestone Payments", "terseLabel": "Potential milestone payments" } } }, "localname": "PotentialMilestonePayments", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables", "label": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables", "terseLabel": "Other royalty cash collections" } } }, "localname": "ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Cash Collections From Royalties Received On Financing Receivables", "label": "Proceeds From Cash Collections From Royalties Received On Financing Receivables", "terseLabel": "Cash collections from financial royalty assets" } } }, "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Cash Collections From Royalties Received On Intangible Assets", "label": "Proceeds From Cash Collections From Royalties Received On Intangible Assets", "terseLabel": "Cash collections from intangible royalty assets" } } }, "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Collateral Received On Derivative Instruments", "label": "Proceeds From Collateral Received On Derivative Instruments", "terseLabel": "Swap collateral received" } } }, "localname": "ProceedsFromCollateralReceivedOnDerivativeInstruments", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Issuance Of Equity Securities, FN-NI", "label": "Proceeds From Issuance Of Equity Securities, FN-NI", "terseLabel": "Proceeds from equity securities" } } }, "localname": "ProceedsFromIssuanceOfEquitySecuritiesFNNI", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromNoncontrollingInterestsOther": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Noncontrolling Interests, Other", "label": "Proceeds From Noncontrolling Interests, Other", "terseLabel": "Contributions from non-controlling interest- other" } } }, "localname": "ProceedsFromNoncontrollingInterestsOther", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Noncontrolling Interests, Research And Development", "label": "Proceeds From Noncontrolling Interests, Research And Development", "terseLabel": "Contributions from non-controlling interest- R&D" } } }, "localname": "ProceedsFromNoncontrollingInterestsResearchAndDevelopment", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PromactaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promacta", "label": "Promacta [Member]", "terseLabel": "Promacta" } } }, "localname": "PromactaMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_PurchaseCommitmentAdditionalPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase Commitment, Additional Payment", "label": "Purchase Commitment, Additional Payment", "terseLabel": "Purchase commitment, additional payments" } } }, "localname": "PurchaseCommitmentAdditionalPayment", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase Commitment, Committed Non-Contingent Commercial Launch Preferred Equity, Amount", "label": "Purchase Commitment, Committed Non-Contingent Commercial Launch Preferred Equity, Amount", "terseLabel": "Purchase commitment, purchase of committed, non-contingent Commercial Launch Preferred Equity payable" } } }, "localname": "PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PurchaseCommitmentUpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase Commitment, Upfront Payment", "label": "Purchase Commitment, Upfront Payment", "terseLabel": "Purchase commitment, upfront payment" } } }, "localname": "PurchaseCommitmentUpfrontPayment", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PurchasingAndDonatingVentilatorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchasing And Donating Ventilators", "label": "Purchasing And Donating Ventilators [Member]", "terseLabel": "Purchasing And Donating Ventilators" } } }, "localname": "PurchasingAndDonatingVentilatorsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_RPHoldingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RP Holdings", "label": "RP Holdings [Member]", "terseLabel": "RP Holdings" } } }, "localname": "RPHoldingsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "rprx_RPI2019IntermediateFinanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI 2019 Intermediate Finance", "label": "RPI 2019 Intermediate Finance [Member]", "terseLabel": "RPI Intermediate FT" } } }, "localname": "RPI2019IntermediateFinanceMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_RPIFTSeniorSecuredCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPIFT Senior Secured Credit Facilities", "label": "RPIFT Senior Secured Credit Facilities [Member]", "terseLabel": "RPIFT Senior Secured Credit Facilities" } } }, "localname": "RPIFTSeniorSecuredCreditFacilitiesMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_RPIFTSeniorSecuredCreditFacilitiesTrancheA4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPIFT Senior Secured Credit Facilities - Tranche A-4", "label": "RPIFT Senior Secured Credit Facilities - Tranche A-4 [Member]", "terseLabel": "RPIFT Senior Secured Credit Facilities - Tranche A-4" } } }, "localname": "RPIFTSeniorSecuredCreditFacilitiesTrancheA4Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_RPIFTSeniorSecuredCreditFacilitiesTrancheB6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPIFT Senior Secured Credit Facilities - Tranche B-6", "label": "RPIFT Senior Secured Credit Facilities - Tranche B-6 [Member]", "terseLabel": "RPIFT Senior Secured Credit Facilities - Tranche B-6" } } }, "localname": "RPIFTSeniorSecuredCreditFacilitiesTrancheB6Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1", "label": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1 [Member]", "terseLabel": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1" } } }, "localname": "RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1", "label": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 [Member]", "terseLabel": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1" } } }, "localname": "RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_RedeemableStockRedemptionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable Stock, Redemption Price Per Share", "label": "Redeemable Stock, Redemption Price Per Share", "terseLabel": "Redeemable stock, redemption price (in euros per share)" } } }, "localname": "RedeemableStockRedemptionPricePerShare", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "rprx_RelatedPartyTransactionAnnualIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Annual Increase, Percentage", "label": "Related Party Transaction, Annual Increase, Percentage", "terseLabel": "Increase in quarterly installment payments (as a percent)" } } }, "localname": "RelatedPartyTransactionAnnualIncreasePercentage", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rprx_RelatedPartyTransactionCumulativeFundingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Cumulative Funding Amount", "label": "Related Party Transaction, Cumulative Funding Amount", "terseLabel": "Cumulative funding amount" } } }, "localname": "RelatedPartyTransactionCumulativeFundingAmount", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Number of Partnership Interests Acquired", "label": "Related Party Transaction, Number of Partnership Interests Acquired", "terseLabel": "Number of limited partnership interest acquired (in shares)" } } }, "localname": "RelatedPartyTransactionNumberOfPartnershipInterestsAcquired", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Operating and Personal Payment Calculation, Amount", "label": "Related Party Transaction, Operating and Personal Payment Calculation, Amount", "terseLabel": "Amount calculated for operating and personal payment" } } }, "localname": "RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Operating and Personal Payment Calculation, Percent", "label": "Related Party Transaction, Operating and Personal Payment Calculation, Percent", "terseLabel": "Percent for calculating operating and personal payment" } } }, "localname": "RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rprx_RelatedPartyTransactionPaymentsMade": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Payments Made", "label": "Related Party Transaction, Payments Made", "terseLabel": "Installment payments made during period" } } }, "localname": "RelatedPartyTransactionPaymentsMade", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_RelatedPartyTransactionRateAdjustedCashReceipts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Rate, Adjusted Cash Receipts", "label": "Related Party Transaction, Rate, Adjusted Cash Receipts", "terseLabel": "Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)" } } }, "localname": "RelatedPartyTransactionRateAdjustedCashReceipts", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rprx_RelatedPartyTransactionRateValueOfSecurityInvestments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Rate, Value Of Security Investments", "label": "Related Party Transaction, Rate, Value Of Security Investments", "terseLabel": "Quarterly payments to affiliates, percent of security investment (as a percent)" } } }, "localname": "RelatedPartyTransactionRateValueOfSecurityInvestments", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash", "label": "Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash", "terseLabel": "Repayments of long-term debt by contributions from non-controlling interest" } } }, "localname": "RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_RepaymentsOfLongTermDebtScheduledPayments": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments Of Long-term Debt, Scheduled Payments", "label": "Repayments Of Long-term Debt, Scheduled Payments", "negatedTerseLabel": "Scheduled repayments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebtScheduledPayments", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and Development Expense, Upfront Payment and Premium Paid", "label": "Research and Development Expense, Upfront Payment and Premium Paid", "terseLabel": "Upfront payment and premium paid" } } }, "localname": "ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RDFundingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "rprx_ResearchAndDevelopmentRemainingFundingCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Research And Development, Remaining Funding Commitment", "label": "Research And Development, Remaining Funding Commitment", "terseLabel": "Remaining commitment for R&D funding agreement" } } }, "localname": "ResearchAndDevelopmentRemainingFundingCommitment", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RDFundingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "rprx_RoyalPharmacySelectFinanceTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royal Pharmacy Select Finance Trust", "label": "Royal Pharmacy Select Finance Trust [Member]", "terseLabel": "RPSFT" } } }, "localname": "RoyalPharmacySelectFinanceTrustMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Assets, Policy", "label": "Royalty Assets, Policy [Policy Text Block]", "terseLabel": "Royalty assets" } } }, "localname": "RoyaltyAssetsPolicyPolicyTextBlock", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Distribution Payable to Legacy Investors Partnerships", "label": "Royalty Distribution Payable to Legacy Investors Partnerships [Member]", "terseLabel": "Royalty Distribution Payable to Legacy Investors Partnerships" } } }, "localname": "RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Distribution Payable to RP Select Finance Trust", "label": "Royalty Distribution Payable to RP Select Finance Trust [Member]", "terseLabel": "Royalty Distribution Payable to RP Select Finance Trust" } } }, "localname": "RoyaltyDistributionPayableToRPSelectFinanceTrustMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyIncomeOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Income, Other", "label": "Royalty Income, Other [Member]", "terseLabel": "Royalty Income, Other" } } }, "localname": "RoyaltyIncomeOtherMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyPharmaCollectionTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Pharma Collection Trust", "label": "Royalty Pharma Collection Trust [Member]", "terseLabel": "RPCT" } } }, "localname": "RoyaltyPharmaCollectionTrustMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyPharmaInvestmentFinancialTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Pharma Investment Financial Trust", "label": "Royalty Pharma Investment Financial Trust [Member]", "terseLabel": "Royalty Pharma Investment Financial Trust" } } }, "localname": "RoyaltyPharmaInvestmentFinancialTrustMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyPharmaInvestmentsOldRPIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Pharma Investments (Old RPI)", "label": "Royalty Pharma Investments (Old RPI) [Member]", "terseLabel": "Old RPI" } } }, "localname": "RoyaltyPharmaInvestmentsOldRPIMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "rprx_SaleOfStockNumberOfSharesAvailableToConvert": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Number of Shares Available To Convert", "label": "Sale of Stock, Number of Shares Available To Convert", "verboseLabel": "Number of shares available to convert (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesAvailableToConvert", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "sharesItemType" }, "rprx_SaleOfStockNumberOfSharesNotConverted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Number Of Shares Not Converted", "label": "Sale Of Stock, Number Of Shares Not Converted", "terseLabel": "Number of shares converted (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesNotConverted", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "sharesItemType" }, "rprx_SecondaryOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secondary Offering", "label": "Secondary Offering [Member]", "terseLabel": "Secondary Offering" } } }, "localname": "SecondaryOfferingMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_SeniorUnsecuredRevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Revolving Credit Facility", "label": "Senior Unsecured Revolving Credit Facility [Member]", "terseLabel": "Senior Unsecured Revolving Credit Facility" } } }, "localname": "SeniorUnsecuredRevolvingCreditFacilityMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_SettlementsWithEquityMethodInvestments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Settlements With Equity Method Investments", "label": "Settlements With Equity Method Investments", "terseLabel": "Settlement of Epizyme forward purchase contract" } } }, "localname": "SettlementsWithEquityMethodInvestments", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_ShareholdersContributions": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shareholders Contributions", "label": "Shareholders Contributions", "terseLabel": "Shareholders\u2019 contributions" } } }, "localname": "ShareholdersContributions", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rprx_ShareholdersContributionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholders' Contributions", "label": "Shareholders' Contributions [Member]", "terseLabel": "Shareholders\u2019 Contributions" } } }, "localname": "ShareholdersContributionsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "rprx_StockIssuedDuringPeriodSharesIssuedForRegistration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Issued For Registration", "label": "Stock Issued During Period, Shares, Issued For Registration", "terseLabel": "Initial share issuance upon registration of Royalty Pharma plc (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForRegistration", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Issued To Partnerships", "label": "Stock Issued During Period, Shares, Issued To Partnerships", "terseLabel": "Issuance of Class B shares to Continuing Investor Partnerships (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedToPartnerships", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "rprx_StockIssuedDuringPeriodValueIssuedForRegistration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Issued For Registration", "label": "Stock Issued During Period, Value, Issued For Registration", "terseLabel": "Initial share issuance upon registration of Royalty Pharma plc" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForRegistration", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "rprx_StockIssuedDuringPeriodValueIssuedToPartnerships": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Issued To Partnerships", "label": "Stock Issued During Period, Value, Issued To Partnerships", "terseLabel": "Issuance of Class B shares to Continuing Investors Partnerships" } } }, "localname": "StockIssuedDuringPeriodValueIssuedToPartnerships", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockholders' Equity, Shares, Effect Of Exchange And Reallocation", "label": "Stockholders' Equity, Shares, Effect Of Exchange And Reallocation", "terseLabel": "Effect of exchange by Continuing Investors of Class B shares for Class A shares and reallocation of historical equity (in shares)" } } }, "localname": "StockholdersEquitySharesEffectOfExchangeAndReallocation", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "rprx_StockholdersEquityValueEffectOfExchangeAndReallocation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stockholders' Equity, Value, Effect Of Exchange And Reallocation", "label": "Stockholders' Equity, Value, Effect Of Exchange And Reallocation", "terseLabel": "Effect of exchange by Continuing Investors of Class B shares for Class A ordinary shares and reallocation of historical equity" } } }, "localname": "StockholdersEquityValueEffectOfExchangeAndReallocation", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_TecfideraMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tecfidera", "label": "Tecfidera [Member]", "terseLabel": "Tecfidera" } } }, "localname": "TecfideraMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_TheNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Notes", "label": "The Notes [Member]", "terseLabel": "The Notes" } } }, "localname": "TheNotesMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "domainItemType" }, "rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Five Five Percent Senior Notes Due 2050", "label": "Three Point Five Five Percent Senior Notes Due 2050 [Member]", "terseLabel": "Three Point Five Five Percent Senior Notes Due 2050" } } }, "localname": "ThreePointFiveFivePercentSeniorNotesDue2050Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Three Zero Percent Senior Notes Due 2040", "label": "Three Point Three Zero Percent Senior Notes Due 2040 [Member]", "terseLabel": "Three Point Three Zero Percent Senior Notes Due 2040" } } }, "localname": "ThreePointThreeZeroPercentSeniorNotesDue2040Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Two Zero Percent Senior Notes Due 2030", "label": "Two Point Two Zero Percent Senior Notes Due 2030 [Member]", "terseLabel": "Two Point Two Zero Percent Senior Notes Due 2030" } } }, "localname": "TwoPointTwoZeroPercentSeniorNotesDue2030Member", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_TysabriMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tysabri", "label": "Tysabri [Member]", "terseLabel": "Tysabri" } } }, "localname": "TysabriMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_UnitholdersContributionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unitholders Contributions", "label": "Unitholders Contributions [Member]", "terseLabel": "Unitholders\u2019 Contributions" } } }, "localname": "UnitholdersContributionsMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "rprx_ValuationTechniqueBlackDermanTroyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Valuation Technique, Black-Derman-Troy", "label": "Valuation Technique, Black-Derman-Troy [Member]", "terseLabel": "Valuation Technique, Black-Derman-Troy" } } }, "localname": "ValuationTechniqueBlackDermanTroyMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_VertexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vertex", "label": "Vertex [Member]", "terseLabel": "Vertex" } } }, "localname": "VertexMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "rprx_XtandiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xtandi", "label": "Xtandi [Member]", "terseLabel": "Xtandi" } } }, "localname": "XtandiMember", "nsuri": "http://royaltypharma.com/20201231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r343", "r480", "r481", "r484", "r619" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Pablo Legorreta" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r47", "r122" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails", "http://royaltypharma.com/role/RDFundingExpenseDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r132", "r140", "r249", "r364", "r365", "r366", "r382", "r383" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r132", "r140", "r249", "r364", "r365", "r366", "r382", "r383" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r132", "r140", "r249", "r364", "r365", "r366", "r382", "r383" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r208", "r332", "r334", "r595" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_ManagementMember": { "auth_ref": [ "r209", "r483" ], "lang": { "en-us": { "role": { "label": "Management [Member]", "terseLabel": "The Manager" } } }, "localname": "ManagementMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r345", "r347", "r497", "r498", "r499", "r500", "r501", "r502", "r521", "r593", "r596" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r345", "r347", "r497", "r498", "r499", "r500", "r501", "r502", "r521", "r593", "r596" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r208", "r332", "r334", "r595" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r206", "r332", "r333", "r525", "r592", "r594" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r206", "r332", "r333", "r525", "r592", "r594" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r335", "r345", "r347", "r497", "r498", "r499", "r500", "r501", "r502", "r521", "r593", "r596" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r335", "r345", "r347", "r497", "r498", "r499", "r500", "r501", "r502", "r521", "r593", "r596" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails", "http://royaltypharma.com/role/RDFundingExpenseDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r128", "r129", "r130", "r131", "r133", "r134", "r138", "r139", "r140", "r142", "r143", "r144", "r145", "r146", "r164", "r250", "r251", "r367", "r383", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "terseLabel": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r128", "r129", "r130", "r131", "r133", "r134", "r138", "r139", "r140", "r142", "r143", "r144", "r145", "r146", "r164", "r250", "r251", "r367", "r383", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "terseLabel": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Reclassification, Adjustment [Member]", "terseLabel": "Revision of Prior Period, Reclassification, Adjustment" } } }, "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r303", "r346", "r489" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r133", "r134", "r135", "r136", "r246", "r247", "r248", "r249", "r250", "r251", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r382", "r383", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible List]", "terseLabel": "Accounting standards update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "extensibleListItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r55", "r397" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Unrealized gain/(loss) on interest rate swaps" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r49", "r50", "r51", "r55", "r58" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Unrealized gain/(loss) on available for sale debt securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r53", "r54", "r55", "r577", "r604", "r608" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r464", "r465", "r466", "r467", "r468", "r470" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r52", "r55", "r58", "r128", "r129", "r131", "r398", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Total Accumulated Other Comprehensive Income/(Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r367" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r128", "r129", "r131", "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile consolidated net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r349", "r357", "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "auth_ref": [ "r216", "r264" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.", "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of Cumulative Allowance for Changes in Expected Cash Flows" } } }, "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r105", "r475" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r105", "r288", "r293" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r52", "r55", "r58", "r398" ], "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Accumulated Other Comprehensive Income/(Loss)" } } }, "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r105", "r297" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment charge" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r119", "r188", "r198", "r204", "r244", "r391", "r400", "r462", "r545", "r575" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r44", "r119", "r244", "r391", "r400", "r462" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r233" ], "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r231", "r280" ], "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r227", "r232", "r280", "r550" ], "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Available for sale debt securities", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r230", "r280" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 3.0, "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Available for sale debt securities", "verboseLabel": "Available for sale debt securities, current" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r230", "r280" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 2.0, "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Available for sale debt securities", "verboseLabel": "Available for sale debt securities, noncurrent" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableforsaleSecuritiesMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities [Member]", "terseLabel": "Available-for-sale Securities" } } }, "localname": "AvailableforsaleSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r351", "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of preparation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Reported Value Measurement" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r25", "r107" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "negatedTerseLabel": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 1.0, "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r108", "r115" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r101", "r107", "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of year", "periodStartLabel": "Cash and cash equivalents, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r101", "r463" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental schedule of non-cash investing / financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Indirect Cash Flow" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlow" ], "xbrltype": "textBlockItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of Deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r118", "r119", "r150", "r154", "r155", "r158", "r160", "r168", "r169", "r170", "r244", "r462" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/EarningsPerShareDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r330", "r348" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants to purchase additional shares (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r36", "r302", "r554", "r581" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r299", "r300", "r301", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/EarningsPerShareDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends paid (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r128", "r129" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars/pounds per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r320" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common shares outstanding", "verboseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r61", "r63", "r64", "r75", "r562", "r587" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to controlling interest" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r61", "r63", "r74", "r389", "r390", "r406", "r561", "r586" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedTerseLabel": "Less: Other comprehensive income attributable to non-controlling interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r61", "r63", "r73", "r388", "r406", "r560", "r585" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r72", "r84", "r559", "r584" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r177", "r178", "r208", "r460", "r461" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r177", "r178", "r208", "r460", "r461", "r610" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r177", "r178", "r208", "r460", "r461", "r610" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r173", "r573" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r177", "r178", "r208", "r460", "r461" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Individual licensees exceeding 10% or more of revenue (as a percent)", "verboseLabel": "Concentration risk (as a percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r177", "r178", "r208", "r460", "r461" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r115", "r393" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r115", "r399", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Investments in non-consolidated affiliates" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r336", "r344", "r609" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r77" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses, net" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Credit Loss [Abstract]" } } }, "localname": "CreditLossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": { "auth_ref": [ "r252", "r253", "r254", "r257", "r258", "r265", "r267", "r269", "r270", "r271", "r277", "r278", "r279", "r281", "r282", "r283", "r285" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.", "label": "Credit Loss, Financial Instrument [Policy Text Block]", "terseLabel": "Allowance for current expected credit losses" } } }, "localname": "CreditLossFinancialInstrumentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditLossFinancialInstrumentTextBlock": { "auth_ref": [ "r258", "r268", "r269", "r273", "r274", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.", "label": "Credit Loss, Financial Instrument [Text Block]", "terseLabel": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets" } } }, "localname": "CreditLossFinancialInstrumentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r176", "r208" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Borrowings" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/Borrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r11", "r12", "r13", "r546", "r547", "r574" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (percentage)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r13", "r308", "r547", "r574" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "totalLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r474", "r476" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt issued, amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r34", "r311", "r474" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Weighted average effective interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, stated rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Prior to the applicable par call date" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Three [Member]", "terseLabel": "Upon occurrence of a change of control triggering event" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price (as a percent)" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r35", "r123", "r321", "r324", "r325", "r326", "r473", "r474", "r476", "r572" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r473", "r476" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedTerseLabel": "Unamortized debt discount and issuance costs", "terseLabel": "Original issue discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r309", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Unamortized discount and loan issuance costs on long-term debt" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": { "auth_ref": [ "r477" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross", "terseLabel": "Debt issuance costs related to revolving credit facility" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Measurement Input", "terseLabel": "Measurement input, percentage (as a percent)" } } }, "localname": "DebtSecuritiesAvailableForSaleMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r237" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 7.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Gain", "negatedTerseLabel": "Realized gain on available for sale debt securities", "terseLabel": "Realized gain on available for sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Summary of Available for Sale Debt Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt, Weighted Average Interest Rate", "terseLabel": "Weighted average coupon rate (as a percent)" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r45", "r46", "r457" ], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 3.0, "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivatives" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Noncurrent", "terseLabel": "Derivative financial instruments" } } }, "localname": "DerivativeAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsScheduleofNotionalValuesandFixedRatesDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Fixed Rate (as a percent)" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsScheduleofNotionalValuesandFixedRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r415" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Interest rate swaps" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r414", "r416", "r421", "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsScheduleofNotionalValuesandFixedRatesDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsScheduleofNotionalValuesandFixedRatesDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsScheduleofNotionalValuesandFixedRatesDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r420", "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Derivatives not designated as hedging instruments" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r45", "r46", "r457" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 1.0, "parentTag": "rprx_FinancialAndNonfinancialLiabilitiesFairValueDisclosureCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "negatedTerseLabel": "Interest rate swaps", "terseLabel": "Derivative financial instruments", "verboseLabel": "Derivative liability, current" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 1.0, "parentTag": "rprx_FinancialAndNonfinancialLiabilitiesFairValueDisclosureNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "negatedLabel": "Interest rate swaps", "terseLabel": "Derivative financial instruments", "verboseLabel": "Derivative liability, noncurrent" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r409", "r411" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional Value (in millions)" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsScheduleofNotionalValuesandFixedRatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r115", "r125", "r408", "r410", "r412", "r413", "r429" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r327", "r569" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "negatedTerseLabel": "Dividends" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "verboseLabel": "Dividends declared and paid" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r28", "r124", "r481" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Distribution payable to non-controlling interest" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r76", "r138", "r139", "r140", "r141", "r142", "r147", "r150", "r158", "r159", "r160", "r164", "r165", "r563", "r588" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Earnings per Class A ordinary share - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Earnings per Class A ordinary share" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r76", "r138", "r139", "r140", "r141", "r142", "r150", "r158", "r159", "r160", "r164", "r165", "r563", "r588" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Earnings per Class A ordinary share - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted earnings per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r115", "r161", "r162" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r161", "r162", "r163", "r166" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized share based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized share based compensation expense, period of recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r128", "r129", "r131", "r134", "r143", "r146", "r167", "r249", "r320", "r327", "r364", "r365", "r366", "r382", "r383", "r464", "r465", "r466", "r467", "r468", "r470", "r599", "r600", "r601" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r70", "r100", "r105", "r582" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Distributions from non-consolidated affiliates" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/IndirectCashFlowDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "auth_ref": [ "r1", "r119", "r244", "r462" ], "lang": { "en-us": { "role": { "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "auth_ref": [ "r1", "r119", "r244", "r462" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": { "auth_ref": [ "r1", "r119", "r244", "r462" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r26", "r189", "r241" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Investments in non-consolidated affiliates" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Non-Consolidated Affiliates" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliates" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "terseLabel": "(Gain)/loss on equity securities" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r240", "r589" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedTerseLabel": "(Gain)/loss on equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of Fair Value Measurement" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss": { "auth_ref": [ "r447" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income from asset (liability) measured at fair value on recurring basis using unobservable input (level 3) and still held.", "label": "Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)", "terseLabel": "Unrealized gain (loss) on equity securities still held" } } }, "localname": "FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r437", "r438", "r439", "r450" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "auth_ref": [ "r447" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.", "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)", "terseLabel": "Unrealized gains on available for sale debt securities" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r443", "r450" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r443", "r450" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r437", "r450" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r438", "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r437", "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r437", "r438", "r441", "r442", "r452" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]", "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]" } } }, "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value.", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]" } } }, "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value.", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]", "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value" } } }, "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements and Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r336", "r337", "r342", "r344", "r438", "r494" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r336", "r337", "r342", "r344", "r438", "r495" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r438", "r496" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)", "terseLabel": "Unrealized gains on available for sale debt securities" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "auth_ref": [ "r445" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "terseLabel": "Purchases" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r446" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "terseLabel": "Transfer from level 2" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "negatedLabel": "Transfer to Level 2" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r443" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r448", "r452" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r115", "r453", "r456" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FederalFundsPurchasedMember": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Short term borrowing where a bank borrows, at the federal funds rate, from another bank.", "label": "Federal Funds Purchased [Member]", "terseLabel": "Federal Funds Rate" } } }, "localname": "FederalFundsPurchasedMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLoansAndLeasesReceivablePolicy": { "auth_ref": [ "r212", "r217", "r218", "r219", "r220", "r223", "r224", "r225" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for financing receivable.", "label": "Financing Receivable [Policy Text Block]", "terseLabel": "Financial royalty assets, net" } } }, "localname": "FinanceLoansAndLeasesReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Financing Receivable [Member]", "terseLabel": "Current portion of Financial royalty assets" } } }, "localname": "FinanceReceivablesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r234", "r235", "r258", "r264", "r265", "r266", "r273", "r284", "r285", "r286", "r287", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "auth_ref": [ "r213", "r255", "r260", "r263", "r551" ], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails_1": { "order": 1.0, "parentTag": "us-gaap_NotesReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, Allowance for Credit Loss", "negatedLabel": "Cumulative allowance for changes in expected cash flows", "negatedPeriodEndLabel": "Ending balance", "negatedPeriodStartLabel": "Beginning balance" } } }, "localname": "FinancingReceivableAllowanceForCreditLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financing Receivable, Allowance for Credit Loss [Line Items]", "terseLabel": "Financing Receivable, Allowance for Credit Loss [Line Items]" } } }, "localname": "FinancingReceivableAllowanceForCreditLossesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs": { "auth_ref": [ "r215", "r262", "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of writeoff of financing receivable, charged against allowance for credit loss.", "label": "Financing Receivable, Allowance for Credit Loss, Writeoff", "terseLabel": "Write off of credit loss allowance" } } }, "localname": "FinancingReceivableAllowanceForCreditLossesWriteOffs", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal": { "auth_ref": [ "r256", "r259", "r264" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on financing receivable, from change in present value of expected cash flows.", "label": "Financing Receivable, Change in Present Value, Expense (Reversal)", "negatedTerseLabel": "Reversal of cumulative allowance" } } }, "localname": "FinancingReceivableChangeInPresentValueExpenseReversal", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivablesTextBlock": { "auth_ref": [ "r222", "r226" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financing receivable.", "label": "Financing Receivables [Text Block]", "terseLabel": "Financial Royalty Assets, Net" } } }, "localname": "FinancingReceivablesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite lived intangible assets, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r292" ], "calculation": { "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r294" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Projected amortization expense, 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r294" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Projected amortization expense, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r289", "r290", "r292", "r295", "r526", "r530" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r292", "r530" ], "calculation": { "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r289", "r291" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r292", "r526" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net carrying value", "verboseLabel": "Intangible royalty assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing gain (loss) on derivative instruments.", "label": "Gain (Loss) on Derivative Instruments [Member]", "terseLabel": "Unrealized loss/(gain) on derivative financial instruments" } } }, "localname": "GainLossOnDerivativeInstrumentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r414" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedLabel": "Unrealized loss/(gain) on derivative financial instruments", "negatedTerseLabel": "Unrealized loss/(gain) on derivative contracts" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r105", "r312", "r313" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r412", "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r69", "r188", "r197", "r200", "r203", "r205", "r543", "r557", "r566", "r590" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Consolidated net income before tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r70", "r105", "r186", "r241", "r556", "r582" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Equity in (earnings)/loss of non-consolidated affiliates", "verboseLabel": "Equity in income (loss) of non-consolidated affiliates" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/IndirectCashFlowDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r120", "r145", "r146", "r187", "r375", "r384", "r385", "r591" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r65", "r115", "r373", "r374", "r376", "r377", "r378", "r379", "r618" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r104" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInFinanceReceivables": { "auth_ref": [ "r104" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in outstanding loans including accrued interest.", "label": "Increase (Decrease) in Finance Receivables", "negatedTerseLabel": "Financial royalty assets" } } }, "localname": "IncreaseDecreaseInFinanceReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r104" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Interest payable" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Assets [Abstract]", "terseLabel": "(Increase)/decrease in operating assets:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Liabilities [Abstract]", "terseLabel": "Increase (Decrease) in Operating Liabilities [Abstract]" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r104" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedTerseLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r104" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r104" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "Increase (Decrease) in Other Receivables", "negatedTerseLabel": "Other receivables" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r151", "r152", "r153", "r160" ], "calculation": { "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive effect of unvested restricted units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Royalty Assets, Net" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r115", "r291", "r522", "r523", "r524", "r526" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Intangible royalty assets, net" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r67", "r185", "r472", "r475", "r565" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which reported facts about interest income have been included.", "label": "Interest Income [Member]", "terseLabel": "Interest Income" } } }, "localname": "InterestIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r98", "r102", "r109" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "negatedTerseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r8", "r9", "r32" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r80", "r82" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "negatedLabel": "Interest income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r239", "r544", "r568", "r617" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Available for Sale Debt Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r31", "r119", "r199", "r244", "r392", "r400", "r401", "r462" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r119", "r244", "r462", "r549", "r580" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019/unitholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r33", "r119", "r244", "r392", "r400", "r401", "r462" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r13", "r310", "r547", "r576" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total debt carrying value" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedNetLabel": "Less: Current portion of long-term debt", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Fair value of outstanding Notes" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r126", "r306" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r126", "r306" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r126", "r306" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r126", "r306" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r126", "r306" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r126", "r306" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Total long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount", "terseLabel": "Payment for purchase of royalties" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Category of Item Purchased [Axis]", "terseLabel": "Category of Item Purchased [Axis]" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment [Line Items]" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r35", "r307" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r42", "r119", "r244", "r462", "r548", "r579" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Distributions" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Noncontrolling interest (percentage)" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership percentage (as a percent)" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInMinorityInterestRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]", "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]" } } }, "localname": "MovementInMinorityInterestRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r101" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by/(used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r101" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in)/provided by investing activities", "verboseLabel": "Net cash flow from investing" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r101", "r103", "r106" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r59", "r62", "r71", "r106", "r119", "r133", "r138", "r139", "r140", "r141", "r145", "r146", "r156", "r188", "r197", "r200", "r203", "r205", "r244", "r462", "r558", "r583" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to controlling interest" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r59", "r62", "r145", "r146", "r395", "r405" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedTerseLabel": "Less: Net income attributable to non-controlling interest", "terseLabel": "Less: net income attributable to non-controlling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r138", "r139", "r140", "r141", "r147", "r148", "r157", "r160", "r188", "r197", "r200", "r203", "r205" ], "calculation": { "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income attributable to Royalty Pharma plc" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r149", "r157", "r160" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net income attributable to Royalty Pharma plc" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r132", "r133", "r134", "r135", "r136", "r137", "r140", "r164", "r246", "r247", "r248", "r249", "r250", "r251", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r380", "r381", "r382", "r383", "r527", "r528", "r529", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently adopted and issued accounting standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r128", "r129", "r131", "r327", "r386" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-Controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other (income)/expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r4", "r5", "r17", "r210", "r211", "r552" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Financial royalty assets" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "auth_ref": [ "r18" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.", "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Financial royalty assets, net" } } }, "localname": "NotesAndLoansReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableGross": { "auth_ref": [ "r272", "r275", "r276" ], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": { "order": 2.0, "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows", "weight": 1.0 }, "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails_1": { "order": 2.0, "parentTag": "us-gaap_NotesReceivableNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of financing receivable.", "label": "Financing Receivable, before Allowance for Credit Loss", "terseLabel": "Gross carrying value" } } }, "localname": "NotesReceivableGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r18", "r210", "r272" ], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, after Allowance for Credit Loss", "terseLabel": "Financial royalty asset, net", "totalLabel": "Net carrying value" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r188", "r197", "r200", "r203", "r205" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": { "auth_ref": [ "r315", "r433" ], "lang": { "en-us": { "role": { "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.", "label": "Option Indexed to Issuer's Equity, Strike Price", "terseLabel": "Put option, selling price, maximum (in dollars per share)" } } }, "localname": "OptionIndexedToIssuersEquityStrikePrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "auth_ref": [ "r316", "r431", "r432", "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.", "label": "Option Indexed to Issuer's Equity, Type [Axis]", "terseLabel": "Option Indexed to Issuer's Equity, Type [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]", "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r407" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Purpose" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurpose" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Other commitment" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r55", "r66", "r464", "r466", "r470" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Activity for the year" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r53", "r56", "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Amount of loss reclassified from AOCI into income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": { "auth_ref": [ "r48", "r418" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax", "terseLabel": "Reclassification of loss on interest rate swaps" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r60", "r63", "r66", "r72", "r320", "r464", "r469", "r470", "r559", "r584" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive income/(loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income/(loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r53", "r56", "r57", "r238" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "negatedLabel": "Reclassification of unrealized gain on available for sale debt securities", "negatedTerseLabel": "Reclassification of unrealized gain on available for sale debt securities", "verboseLabel": "Reclassification of unrealized gain on available for sale debt securities" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r49", "r53", "r238" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "terseLabel": "Unrealized gains on available for sale debt securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r49", "r53" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gain/(loss) on available for sale debt securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r78" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Cost and Expense, Operating", "terseLabel": "Other operating expenses" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other (income)/expense" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r106" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other non-operating expense/(income), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r93" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchase of treasury interests" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r95" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Debt issuance costs and other" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r85", "r88", "r229" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedTerseLabel": "Purchases of available for sale debt securities", "terseLabel": "Purchase of warrants", "verboseLabel": "Purchase of available for sale debt securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r89" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "negatedTerseLabel": "Investments in non-consolidated affiliates" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireFinanceReceivables": { "auth_ref": [ "r90" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith.", "label": "Payments to Acquire Finance Receivables", "negatedLabel": "Acquisitions of financial royalty assets" } } }, "localname": "PaymentsToAcquireFinanceReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r229" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchases of marketable securities", "terseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r96" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedTerseLabel": "Distributions to non-controlling interest" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r351", "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Shares" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "auth_ref": [ "r87", "r100" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "terseLabel": "Distributions from non-consolidated affiliates" } } }, "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInterestReceived": { "auth_ref": [ "r97" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest received on loans and other debt instruments during the current period.", "label": "Proceeds from Interest Received", "terseLabel": "Interest received" } } }, "localname": "ProceedsFromInterestReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r91" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r92" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sales and maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r85", "r86", "r229" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from available for sale debt securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r59", "r62", "r99", "r119", "r133", "r145", "r146", "r188", "r197", "r200", "r203", "r205", "r244", "r388", "r394", "r396", "r405", "r406", "r462", "r566" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "totalLabel": "Consolidated net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/EarningsPerShareDetails", "http://royaltypharma.com/role/IndirectCashFlowDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForLoanAndLeaseLosses": { "auth_ref": [ "r104", "r214", "r564" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to estimated loss from loan and lease transactions.", "label": "Provision for Loan and Lease Losses", "terseLabel": "Provision for changes in expected cash flows from financial royalty assets" } } }, "localname": "ProvisionForLoanAndLeaseLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForLoanLossesExpensed": { "auth_ref": [ "r261", "r555" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable.", "label": "Financing Receivable, Credit Loss, Expense (Reversal)", "negatedTerseLabel": "Current period provision for credit losses (c)" } } }, "localname": "ProvisionForLoanLossesExpensed", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PutOptionMember": { "auth_ref": [ "r611", "r612", "r613", "r614", "r615", "r616" ], "lang": { "en-us": { "role": { "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option.", "label": "Put Option [Member]", "terseLabel": "Put Option" } } }, "localname": "PutOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r55", "r58", "r66", "r464", "r468", "r470" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Reclassifications to net income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r343", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r480", "r484" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Amount paid to CEO" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r343", "r480", "r481", "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.", "label": "Related Party Transaction, Rate", "terseLabel": "Related party, rate (as a percent)" } } }, "localname": "RelatedPartyTransactionRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party", "terseLabel": "Operating and personnel payments incurred" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r343", "r480", "r484", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r478", "r479", "r481", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r94" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Repayments of long-term debt", "verboseLabel": "Repayments of outstanding debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RDFundingExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r370", "r620" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development funding expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/RDFundingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r115", "r370" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development funding expense" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "terseLabel": "R&D Funding Expense" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RDFundingExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r327", "r367", "r578", "r603", "r608" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r128", "r129", "r131", "r134", "r143", "r146", "r249", "r364", "r365", "r366", "r382", "r383", "r599", "r601" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue from intangible royalty assets and Accrued royalty receivable" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r68", "r119", "r183", "r184", "r196", "r201", "r202", "r206", "r207", "r208", "r244", "r462", "r566" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Sale of stock, consideration received" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "verboseLabel": "Number of shares issued (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.", "label": "Sale of Stock, Percentage of Ownership after Transaction", "terseLabel": "Ownership percentage following IPO" } } }, "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.", "label": "Sale of Stock, Percentage of Ownership before Transaction", "terseLabel": "Exchange offering, ownership percentage" } } }, "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "verboseLabel": "Sale of stock, price per share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r177", "r208" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Summary of Financial Royalty Assets, Net" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r55", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r35", "r123", "r321", "r324", "r325", "r326", "r473", "r474", "r476", "r572" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Borrowings" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r414", "r421", "r427" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Summary of Derivatives and Reclassifications" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r408", "r410", "r411", "r412", "r413", "r417", "r421", "r428", "r430" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Notional Values and Fixed Rates" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r150", "r154", "r158", "r160", "r165" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r1", "r119", "r243", "r244", "r462" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r437", "r438" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value Hierarchy" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on financing receivable.", "label": "Financing Receivable, Allowance for Credit Loss [Table]", "terseLabel": "Financing Receivable, Allowance for Credit Loss [Table]" } } }, "localname": "ScheduleOfFinancingReceivableAllowanceForCreditLossesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r289", "r291", "r526" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r289", "r291" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Royalty Interests" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Repayments of Debt by Year" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r121", "r482", "r484" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/RDFundingExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r37", "r118", "r168", "r169", "r317", "r318", "r319", "r321", "r322", "r323", "r324", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Balance Of Non-controlling Interests" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt and Equity Securities, FV-NI [Line Items]", "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]", "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Senior Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r115", "r190", "r191", "r192", "r193", "r194", "r195", "r207" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Shares" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r104" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Restricted stock units forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted stock granted during period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Restricted stock vested during period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r348", "r352" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r331", "r369" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-based Payments [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Shares, outstanding (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r14", "r15", "r16", "r118", "r119", "r150", "r154", "r155", "r158", "r160", "r168", "r169", "r170", "r244", "r320", "r462" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/EarningsPerShareDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r40", "r128", "r129", "r131", "r134", "r143", "r146", "r167", "r249", "r320", "r327", "r364", "r365", "r366", "r382", "r383", "r464", "r465", "r466", "r467", "r468", "r470", "r599", "r600", "r601" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r128", "r129", "r131", "r167", "r525" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r15", "r16", "r320", "r327" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of Class A ordinary shares sold in initial public offering, net of offering costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r15", "r16", "r320", "r327" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share based compensation and related issuance of Class A ordinary shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r15", "r16", "r320", "r327" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of Class A ordinary shares sold in IPO, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r15", "r16", "r327", "r350", "r356" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation and related issuance of Class A ordinary shares" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Number of shares authorized under plan (in shares)" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r22", "r23", "r119", "r221", "r244", "r462" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019/Unitholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r119", "r128", "r129", "r131", "r134", "r143", "r244", "r249", "r327", "r364", "r365", "r366", "r382", "r383", "r386", "r387", "r404", "r462", "r464", "r465", "r470", "r600", "r601" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "negatedLabel": "Cumulative adjustment to retained earnings", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders\u2019/unitholders\u2019 equity", "verboseLabel": "Cumulative adjustment" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Other exchanges" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOtherShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase (decrease) in shares of stock classified as other.", "label": "Stockholders' Equity, Other Shares", "terseLabel": "Other exchanges (in shares)" } } }, "localname": "StockholdersEquityOtherShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r471", "r488" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r471", "r488" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r471", "r488" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r471", "r488" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r487", "r490" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_TradingSecuritiesDebt": { "auth_ref": [ "r227", "r228" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 2.0, "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Trading", "terseLabel": "Marketable securities" } } }, "localname": "TradingSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransferOfInvestments": { "auth_ref": [ "r110", "r111", "r112" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of investments transferred from the entity's investments in noncash transactions.", "label": "Transfer from Investments", "terseLabel": "Receipt of contribution of investment in Legacy Investors Partnerships" } } }, "localname": "TransferOfInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r234", "r235", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r39", "r328" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock", "verboseLabel": "Treasury Interests" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r39", "r328", "r329" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury interests" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r320", "r327", "r328" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Purchase of treasury interests", "terseLabel": "Treasury interests" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_USGovernmentDebtSecuritiesMember": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by the United States government.", "label": "US Government Debt Securities [Member]", "terseLabel": "US Government Debt Securities" } } }, "localname": "USGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r105" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 8.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "negatedTerseLabel": "Unrealized Gain (Loss) on Derivatives" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts": { "auth_ref": [ "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of open derivatives, commodity, or energy contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives and Commodity Contracts", "terseLabel": "Change in fair value of derivative contracts" } } }, "localname": "UnrealizedGainLossOnDerivativesAndCommodityContracts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r171", "r172", "r174", "r175", "r179", "r180", "r181" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Term of warrant (in years)" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r149", "r160" ], "calculation": { "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average Class A ordinary shares outstanding - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r147", "r160" ], "calculation": { "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average Class A ordinary shares outstanding - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted average Class A ordinary shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b,d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5144-111524" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196816" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "8B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6284393-111563" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r239": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "30", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647444&loc=SL120269210-210444" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "30", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647444&loc=SL120254536-210444" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121648281&loc=SL120267834-210445" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82919204-210446" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL120267845-210446" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919246-210447" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919260-210447" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919269-210447" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919272-210447" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL120267966-210447" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL120267969-210447" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919236-210447" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82922352-210448" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82922355-210448" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121614247&loc=SL120267897-210452" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13A", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121565518&loc=SL120267917-210453" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121565518&loc=SL120269220-210453" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267853-210455" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3C", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267859-210455" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3D", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267862-210455" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r296": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r314": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r369": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759068-111685" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r407": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90198-114008" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519491&loc=d3e90476-114009" }, "r436": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498357-110258" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r486": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r490": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r544": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13(3)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.11)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r568": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611282-123010" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611282-123010" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611282-123010" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611282-123010" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611282-123010" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611282-123010" }, "r617": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r621": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "http://asc.fasb.org/subtopic&trid=2197926" }, "r622": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r623": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r624": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r625": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r626": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r627": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r628": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r629": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r630": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3337-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" } }, "version": "2.1" } ZIP 91 0001802768-21-000006-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001802768-21-000006-xbrl.zip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�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

    T_;4$Y<:W@R0> M6XK'WLVU0EN!UM@ ,1ML(QP0;*X<9E-Q(5AM9+*5P_I,8E^+\Q5%)R"Z!RW[ M8^'-JR%WA0*?CY2*[M+E(2JZ/2HZ]89,L$QP]""TSVUQ+@??_*+ HQ$J,.F\ M7EOG?5T-*B&)BHB*ND)%=^C"$17=&A4M%FWIH()D$N*L:B)F#3XP!\4XH5P) M6C?+J-(1MWW)S_MW1$<7>9XG5W%RO6)&-C<=5:+/N)G/> 3A@L:FO;(W^CKI ME?'H&"FY"L=)G/+:$].9@,AT/PD'3$\>/7=4<]=:&,]+U MTYQZOI3!WN"'*U%7-G;>T6C4V=5FS__O8# ]W,K3#Z-J>C6Z:-4TFX-FD0W3 M9&<\=[ZO\_1@/-PIS_S^8-H^F,RR)#5D5$I4DTSUF3V?+J-%0@\%][=JZ54$+( MU$7>_^,&>#WMYUD8WJ4]_!6"8]B8Y'HROG7%_T.QV MRSUUW]CMVUZ$C5C);9PW3H[LQ6C\IA[8FV]'M5E/CCAL&0[[.+>XJ)28&E4X R+D)3(]1]1IY2I#2_XZL?C_VCVU[4'>]B8>7:,4O]=GPJQ$=+ M\='%^^"D M% &TB;%UZ@:P6DM(: 2304?C;FX&#V4B;B(3D6>9NT>;>.C:T(^+^>DHO7H: MO'BQO?V2N&HIKIK;/<0Y-SD)#1Q3 BPZ@A,E0G(LF2)$BKZLK2O6K\\>!20? M))COSTT@,-\$F$]=AB UXR8X: M)JM'A. 2N!* MU9&PZ".:M75C^\Y=9\H_ M@;G#8+[K:> $YIL$\X(749]75,IET+*T&(#P$(R(P'RQF5<7PAO72I=%=W8# M/K*,PG'EWU$[QBW5,CV&8,=]=66T5.A.H>3H#;+8_.:AH$56)H I*E3_ B-X MQSUDH;.Q5CJMV-JZO-"]H%3$0T'WG98S$;IO&=UG^BR8ET6Q +PH!8A6@X^Y M0!"L.!>X"[IUNU\2/B!\/QA\W^$L"\+W+>-[<5ZA#I%96YT.P2K&O8I@&1HH MJM1CS%8+*];63>SAP1RF9TS/=8#)ML?3NK4]HBREJ*LN;6 M%@EFDG$V@9+>59,D\FJ-9 2%J!5*@8ZWP>9]PU1?6-F-H F%05<&A4%QB/:D(LIX3(.<>O(R^.A0^EE0?Y4K(U"MQW^"I^A;3 M8QS.^@3KODSSR?HV.^1U'1:%G>.OE9'+@AS'O%*H,O39AG=F^M/M< M;']\_D>T3-2SS.!B"("H$MBJET#9XG/24F>9U]:EQ0L;1&E4U$/!]BV/M258 MWS*L#^=AC4E$YHT";J2NL$X6G&@;FA7#>FK:"2Z[&!PE6*^4HT&POEU8;R]H M:QTX*QD+^%!B6[+NP17.03-1__+F#(B*9[JR]7/0-;G2M$P2U'-L>ZY, .>Q_H_+4*2NL,8^-]Z;LQ0_B M<_;T3P9'Z_M&I5<&P^IQ#_Q>;SPZ]'O3PYZ?3/(/3J1=V9C(RO@6+V;'E5_G MF =?6O:5"&LYPHISFRZ2%[(P \E% \@\MC8-"4)Z'3$$F9%7LNIS*_H"-55U M/TA WZMG08"^/J!/G8HLM+,Q2%#66,"2(EB;!$11G&3&\]0JI'C?"-X7CI9; M/%! WZ=?08"^-J 77 IIF= ^"#"JE455!P*",@4$SYF7J*UO>S0K\OO*=:25 M\G%E++8&]2F?CH:YMW^,AL>5F>CH/HL7H_&WDR$26HZ$WI]U$W(1@NL2P9FB M "VV7C&F( LCK?!9.'US>5,*6';8L+CK(;4$X6M!^,R,J,!%8II#-1Q\]?1- MAL"2 9:L1TQ!!6PVQ+5'3!-Z.ZMZ[W*3!>'V.KA=;(O0PMD4+53G/;>RI>K4 M*X503ZHR<6MVE*&+ZO>&$@O=L/S-A?#;SM->K"#H_<_!)*?>8/B/G_;'H[9E M/O7"8?UWRZO5>^FUP_AR[?Z(,!JG/(;I:/]I.Y19352OW62GF>MBT=UQRF%2 M[[=^M41DHY[MLWJTKX[/\U^';^L1OQR^/#G3C6]'2@2W%,%].NM;*(^:N> A MVHB L;"VL[. 1:MB\;FH.$M!&.7Z4MS >.VK86B%8IF/E11NP!DA4N@2*9S9 MNJ>L2$HRD$Y44F"-#Y+2P+/PR?D4&"NSO*22?2VN4_%(I-!]4NAHYH.HX-:H M8,$!TB[*B,WWD94$D!<--H< 6@76[$$IHEI;ETSV4> Y,CCA@GOPSG^L9>1V MR>C8*SNYBI/K%3.JN>F8"WW&S7S&(W"E&Y?VRM[HZ_%@@>/"O#G?^>FESO-- MJ%7ZC,>6N-T<3*;C03@XJ@:=CGJ3#WZG#FTC6%Z>WIL9'@M8WC]-;>35 7/O>$,O)L97=R"TU@@F&B3+=J) MMOF\^N!]J3I2R4X9HP>0[R5PWQJX3P,LPMN8$UK(.E6W"E&",UX!*UQ*IH(. MTJ^M&^GZPERG[)O W6%PW_624@+W+8)[L68T<5\$.K#"^ KPK*OV9A8P:&F< MY+H$T6;A8M7>U]E"W+UT\:JZ'L=S+J;CT=Y>\WH'%:KC/)E2(UJW&M&V!L-1 M&P%ZEKN(K99BJ[G=I"+YR+&25':BC=#3'&S4'DH1G >7O$IZ;5VA[#M%>T4> M)I+OIP.-D'P32#XSGIM)BQ7,4$^SVAS:5Z>B8$6RB,B\B4)A:7M(L<_L^30- M(?E!(/E>6L\(R3> Y,4%0=EIQ6T"S[0 -%4ONV("*"^UT"8U0+>N,]O7U'76 M:0\">J/IASRF'$9G76[U@C--XKF!8?")<>9\@5BZT-%I0WXE$N+ M^^6HC1:H>!<1_=CR$JV:>9C.E4-1'J(K[L-.^79(\RE48JBE&&IN>6CV(6D> M(KA0JN/0>"I@=N"#",)[:0)+U7'@HE^U43?"'12\7%G'@2!\8Q ^=1E,C$64 MXB%55[\5-7EP+C$H60:NJIBOJ58$8*KS'=W"K0NTM!I,%D?\\?MHO-WX?_*O_DX\K#/&L!@V]Y MF%GOTN69F-?_G_^\_\_-QY6+Z:0O=6;MVB51G]=YDOTX?M@8ILW\)>^-]AOE M$[,OQ>QS\\:%$CK8'%L32>LI41K"_\_>NS>W;23MHU^%Y?/N6TX5H<7]DOQ. MJA1?=K6_2')L.3[)/ZX!9B#!I@@N0%J6/_WI[KE@ (*ZV+)%V?1N$EDD@,%, M3T]?GGXZYMQ)N7!SUXNC5( 22:=ANH[TVH5TOY<]_JV;I>ZV]U?=WA;[>.;[ M,6,>NEW<"8.L<+*H!/,M$WD:)*4;QO$V1GAW&_P!.F"[#?Z--OC ,W-9F19) M6CB)*[ WLBAADZ>1DQ1%F <\S9,TV<9-_F.E<6[EE'P^/.Q'""=MDTNR2T3? M7H/UJ,P3SGG@"NR-$F,U7)0X>5:63B(B$;$$0TO!HU^C=)I%R1:%E78AXN_2 M!=EMY\_:SIW'D291+/+ =9(D%\@>ZCEIFG G$)[+0!F'K-S*CNZ[_?Q=>AR[ M_?PY^WE(=QZ492A$XB2P5$Z8I8'#W%0X65C$*?P_CE.^C7OZQ\IZO"K.!%_- M!)\T0G<]PGZJLWI^ZL!V.(?ME7]>\?J##9%L)6CLI5F>X_)W6)P36)NGL#1F M 37Z=:>W;J6W>BSFL5N6C GNL(#%3LC]S&%QQ)U4%+'G9BGSLOC1KUDX]7?= M5;[3#?W-N+)V&_JK;>C.L7 ]X8&A 3X%Y\P)@S)WTKCDCI>RU,T#%I(1XL.. M=G<[^GO=T=^*(&NWH[_6CAZX%B&HY (I*;(\SV%7>P*.:2]RL@#^%Q9YZB;1 MENWJ'RMM\?*N?8D'&_S8-E]"DVYLTE4[U70+U73T=-_V'KB7YD66%TY0^)$3 M)F[LY$G,G1QLC2P->.26,=:>3#TOGH(GL2L_>3#;>'MR$KL-?-<;V"I6C^,B MB)/8B7Q>.&$I4MB[F>^XPN-9EKA^X?O;&++<;>$'E8;8;>$[WL(#]R!Q61&! MIG525F(V,0V=U',S;':>A&&2I6!@;>,V_K$R#SH/)U%-5=NNV+P0/WKN84O= M!3MI>J"6:J>TOD!I/>O54Y2%8%X8.%$L/%!8!7-RI.SS(^%F//1"L"3)<4@S M;^H&ZR&-'>;Z>]G4W\A[V.WGN]_/5@&%Y[.PR!@(4UXZH>M[3NX'S''3Q'.C M(@BC)-A&;/5N,S](/V*WF>]\,P\\BCSP(R]FI<,91O9*QL&W2!*GY%G"X\#E MI=@52]S[SD1)[QR)HFZ7[83-^8]8%[&M:8<7)N"!BZ65U1-+=09?U7U?"Z:49&X91L))\J+ YEZ%DX81"'"9YRPHBLA+LFV,6.YV\0/$*NWV M\MWOY6%Q=>*609Z"EY!$(?@+>>1D?AD[!??=/$$RA=)[]*L_=<,O:=JW2SU\ M;NIAU11GK*5DP[(1K%TUEZ:.^@=K$GY_CL)U-L;SNGDI%FJICLLG]?EY/7^U MK(OW._5T*_74Z]-7%#GV_RX!&6D1MY(MS&4,8N-OD M"QUV6_KK;6FK"W@4NVD1QTZ2,>)KRIW<#3V'AY$;1%$>B(R!]S_UXUT/\(>S ME[]BP=^@Y]F<9EGW&%,%$[(7-=A$6QL4-0\#7PW3.*M/)Q_K#S# M9N32DQEKV\G^I&[@M1@X%=1YHYVL%K"!#UX<3R=SL<0OUF4)CYZ?RBS%CY6; MV-;4Q$@6]0"&5K'9BU4^JXICM68[)7870>Y$"?? 5!',R0KX MEQLD?E2442!\;,\QS=QTFH3KW85WH<[O96O?(]!IMZOO9%=;#H@HB[)P"P=T MLXN Z\))TY@Y@9<%19FE?IG)GE,RVGE5\ M@B^YU5I]?.JVU F#%7T""_I"K>=OEZ]A,0_FS_5*[IN%W.GV6^GVOWHT5QYW MN9\%3H2)(#B8"X?Y4>I$;BS<4GA)[&)W]6F8)E,O6>_AH3?1/5@CGQ?CNMG. M?4#A[.])%7WCI%4+[PL_[9325BBESHD,0YZ[G&6."%CJA"$K'98*X;A!+.(P MS:(P3E IP:I.8_\.,ED[I?"]*(4O=SMW2F&+E,*PAR3/RJQ@"([%:CKFIDZ6 MB-C)TX3%G(5YZ2*MSC1(LBFL\;8KAIUS>G<)P^UP3LYO*]Q.U.3XS[-N75Z*=ME4Q5)P_&!_SON_L+[Y F:B M!M5?())4/!7RO_#WV0I7Y]E'*04OV5(\*TM1[*HQ;W<@]!J_9$&0BX3G3N9C M2#*./8=Y)1P+!>RGJ">YD4>RG8>Z6PBW0:(R3= IGQW948>R4Q%;G(W>JX>&J MAB'0TD\BD?'$R0,AG+!,4OC)\YPT]DN/Q:$;!* >HM"?PL];9$9\5TF]#2TO M-WE*TTDN3JOY'!-Z=3FY%.SS2!U^!$1XP'P1%3%/TC0/\?])&:4B!$T')V'N MNV\/OKBFXXL4WDY_W4I_]9K4E%D1NAY8-2Q)72=,1.0PEH>.8%$SQ/(YSGH!!Z\91&(&]F\9APF*D( ]\/_)HC]^C4;/; MX[?=XQ8A1.JE21(RA^78B"IQN9.F2&%;^LSCI?#=("*^+ QV[7;ZU MNQPL1SB_A?"#,@^+.$L+^ WG49"P@$=Y2+L\V>WR![/+;4_D"#V1(HR3"#9Y MF.1.F#+/R7,>P4^Q%\>B#"(WI>Q6ZDVC9)MV^G>5PQG/0E_ABP@DEAOW0JZ; M )5?E"_V9V1+-_\6XRXB5659$I1<729CG M/DM9&.=Y691QZ(9>C)K_/O->.\U_&\U_TF\5E.4YV&[(",3 AV,"$UJ><,J$ MNQ%G7DH5,][4==-IG*Y'H!X. O,.=_8]A]5W:GVGUN] K>]"<]^;6N_<]B3, M I85@5/F,5CT?IXX+"Z%DX@B=J/ \^*2;P[-[93Z3JGOE/KV3,DN%OOC*O5! ME,:+\B#+R](I!>9<6 #V>L *A^=9*A(>^6F87!6/W:GVVP:6_KED\#CX+Z\^ M_/I_X%]ZR-:]"H&%IQ=4+Y.," MO1)BPHJB/H?17&)R>UXOX7G+>K(\$RTV,IC3!#/8UKJFE@I?5%9XU^A04[ M%4[>"/;>826\X<]L=L$NVT?_[$W$>377(TI\&/+V3-C:&4<3]O+XK_W?3_Z: MO/CW_LO#_7)\].KX]X.G^R?/GDZ> M'QSM'STYV/]]\NH$?G'X[.CDU=KKW'C0^PULLR\9JE1[<)S7#:-M!&I6-/BM M1[].'N:?#;,YIGMO\)5;[,CPT>H<;E'<0;U"W\0[;D[9 MO/I$PO+$:'WX"YAV+QHX"^9+^NMQ^5P? Z_,*?"T:HM9W:X:<0)C^FU&=(SW M:>M].C*V'I\=OOGS[&^PN0[?//.//J'-]S[ZZ^0@/'IW&!T__2,Z_M>?U=') MZP#LMIGX]\O+O]_P10Z.\I'_^N/?;YZ__^O3P<>_3OX*COX%8SV9G1V^._4/ M/[T/CYZ^#_]^ _;B"2\/3_;]XZ?/P OW!,N2%(L",BK%JX+@4$VWZ*1FYD4'R;M4NJ_+R"D,&[JG&*Y](ZWK]F/OO&+ X M#,%6]<(R"&._8#SUXCS+0C_UHI1%(R=4!1IKOOS9]_FL0O8/(OV9S*KS"DTD94E-JCDHW@7J7O@E MJ5XTJ"8S=M%BY@ZOQH7#?]Z ;P06UQE;3BY8.T'X+1E;M;QDH=86KNJ,,8(A MKIK)HA&@XD7;PI=AKJCDDVY:LJ*:54OY3;Q-)3F*]'@-!^1C_!!9='SWEX,7 MQ_23]\M/Q!,)#]A$*MD-%UYX)I;$>C+YSVHN)JA@]M:5];5+>Q,;>AM$XGD] MF]47>@6(6/."#.5E4\\F X'Y=SU#EZ2=_+[D>Y/':J)?OC ?Z F?3D"Z&G"9 ME^++A0E_>KWW?_!LG9[1L.N+N6C:LVJ!-Q@,QTM^V;CN MMKA8EYGO'^A&!D:0<"P;'_#;+1_PV_H#]B9O:/;YJEC2J^6K%M:L;Y*JEH01)D-(J2*)ZN^" M@_D'6#*:E@DF&"8'3_;_A&US5A5G2I\>-*A-X05F HO7P2MM6[&3@+V+FPV75HU\ M52@-"O?4DO\3;3UZ_FKQ@S1+W+DWD=/+["]0<3\&MOH#] M8U3'0GT+=OB4KJ1],Z<#' 9@GM3=Y/&R/A78K' ZL;;@$WF(XU#E7-3PY!?= MS6W]A1M][;C)O84#>B(X[P,"!TG%L MM3RK&Q!7I-RB;SV!!6K@M7YC\_?VMV%VD:%OJ>(9UL*!KBJ6TXF797!6O6@J MN?KXG2O$:&K>!4\^N4(P@@^@&.I5:\]Y7X_]+DY9<7G-!.Z-.#C?@\*0GOZ+ MR:'9R2!OOS_I39#\K+'/PC6)GE4LQ^U^J8_%J=(<\(XHV;,)XQ\J&%^G5N"< M6,"R51@ZQ/V(6J)3*+3ENE%-'BNI^6GMK%8?=,-3FD/>BQ2>%@R4N@ZJI64J MKUE#B"VYGU$$X"_,'/ PME,! H'VF10-^;DE45IC#=\);\_9)3X)_U,OA/3W M6VM4>Y,#$/AR-5?:L(!9R^$R,0/!7$IENCRK&JDV*J6-]";JOF:>+=I3W/VH*AM.5.87U?),F:SFWG7^3AX+\E!> MP,E;X&%LO^/WNWNT)/:4ZU2)XV3TT][)-?SFBP/SJYZJEVLS^/:%&/YFI746 MK87Z)>PM_=M&H.)1HUJ="+[1M4.6LKD,)]C'72&/'3U?FY=$"QD&36(@5)9 F##E]M7@GZ\^BHX8$!G&F-1 M^C/ZKXHBUWQZ<2;FZ+'JDX;TK53,E4S]%+5#0YC!7G3 2@-CJ("IHD$!4:Z6*YA0,U/3P>C,<%@!QR9\4WRL6C*- MN\FE5AO5.[?/O&V(?=QA?*ZW1MMW7%U,$?].A<2 MN$#B-8B42-TKN#3?E+102 K/@NK:BL<^?PATZX_E$.?OX MS?XMI\J00*L+'"\9RD8!VPBQF*_.<]$,H7.<%W$8I@DO19@6299D11X5.4_= MS/?B2(78?4^&V/$'&V[A#^/MK\!"/"ZI<]$+T6!2"_;9<7FL S._T6EER86! M43C^#Q9;/SIYAG7S49"Y2>H*)XO#U DC/W'2P@V=V!-E&?@N$YP]^C5=Y]/X MAS[BV>EI0[;LF)^LU>R5WMK4"!?'+U?-ACNI(-6-[DEZ\D:WN=8;QWTPE']0 MV4:&)MK)E]OR*54,6>J5^DCV%4)WD,"R*I\E#C9'>+QK!P9=6(1AY MY#RNU.WLKD0(R5!!A][K7/LJ>!"UH!S;\G("3@U!E?">"]4(#'] E ;>#!T3 M49#?06&C5I\F'&.JG;W$*59DS#TZZLEH::03Q-K)F*99CP3L*<4SR#H.,B5W MXH7\>#"*:#.,8H>(V+HA[Q 1]_?GRPU%QTNO4T37H2Q&T\.W2_5(>(+2H-,>]FVB[-Z-KMT9,38A#YD2%_Z]KB!S^%( MQ0-*XBN$#%3W8J&875K!27FI0NA=C/)@<(L3.RY_2TO7#1C/"R_'&X1)XF?< M#;$;2QXDPB]R5?MWK8%[6,W!7UM>ZHR=L6P[<_>WRQ<4%_R13=O3\/ 442-Y MQCF8MAY68_NEZZ1I$#J!'WLYR_/<#?P-IBWHLWE]7A7&O$*#R 1%3RPIW$G! M]DK!^\NCB[=ID?(LX\PIHMQW0EXR)TMSSTFB('9##SYF8H,4Z(!*/[&OQ("4 M$N52P T!1213J3-I\^ZD8HNE(CS>?QNRE"=9R)R8A2 5 HE97/!]19"RO"C" M/$G#J]U>K2+L?(G"8;0;SB:*U.&Q\EF'47?\*/C'P60?'3+IBK1=JFTZ^5WY MO?919G^W=X[)]/L&F(R,+-Y.G$4",PBFB><+PRBWW0D6_X\18,D3 MA1>A".K-!?3)B1TXQ!C .:OFMX\)9F'& E$D(LS W V"-!$> Q7NYLSG09[? MI?@BP-@I+JT><-X4AT MZ[W)GG/:]$I"->S@J+@T\ M]\IA@9UVQCX(^2KXE(MJ-C-(:IP2&*58&Z/M:_:/\$K3^$Y&?,0K,!-;[I&C M8-S(&[_ACEZ?FPG%U B:!K.^'O)64%#**IPCR@^'\S^WJ-I-61B4J.79>J$@1<[J2A*AV>!6X1%$24Q]B#<"S8PGN6P*W7MQ6W6 MW',Y!L,*/Q'2G_,"'@D_<)F;"<_?K?E76O/+PS_>IF$,VRK*'?!30RQQDXU_'>)L9MM>93G6RJ/L I)!7,0O6$1A4@3W$ZR,!/ 34* M^F]"76%!C31BP:25<1NIB3-/>"(4V& DS+TTS9(H\=,$_+\P<4OWFLRSD]Y" M>EX*G5\[+G^OYZB!@K M6>@E*#W7:8QZM01S<$XG,J96I1D*#C/F'H<'&IEN\.6I/FD*)@N!1LZK*6&2 M8<'K"?O JAFE1D'D"Y@Z-LB-;S^$_MQXH12P:SR9R6-8?B[: MHJERW!MY_4'\1#CC M:E010R_Z@6.T"DOV]54FZ/C]EBJ\$1T*7#+(]'1-5]^',.4>VNH*0.PXVNH. MIFV;E3_89E;EW+#8FZ#55]03=J&D!@$O''3&,/&CD7+SKK:*D.Q+96HV#1$" M?6"S%2TJ+IR@N-_P3CF;4>BS/1-BNPR-VWQI%-WWH@R>KP(?$=^'R%SX/TT:]I-@U&4C/2TUB>@=V*NDGQ L!FWL1) !J+N!,*H76! M(;FXVD%](1I:PH%8^=SW\SSWW=CWP]PM6 &>?ISZI2]XQERNHG1CTK09XH_# MZYZGQ,/]\<0C B\T$QQ)EDHGRY,,9"2,G-1-4^3(">#W85GF_J-?_73/70_& MH?:6"S_MPFVW4QL9>+HL"9E(>!P&:9@%89FF0>'Z4>1GII)CIS:^H5R\_GB\ M_S9-N)>(7#A!S'PG=)EP,IX$#HM%'..*N4ATF7C3.-H4H#!JXTHLR*A81&Z6 M1'DDW,@OPBS*62&2A(=POI0\R[/=:7(?8G$)ZB(I!2]!("1E#31&" MSF"Q%P6Y5Q3(?YI,XQ$0U/AITDLT:Q()58Q/7Q.$LI!?/ZMG7#1M/_(OS5E] M#<9BX-=8$[GLI0/8 O[VL3J7.>O;A$N#(HQ+W^=9FO$P!968NV[B)L+E298+ MO[A&'&\5+K6D$:G?*JY(!%ZJUSH>%<[LJR*]WC.7I[G]:SC#7CY_^E2;XW^\.*I(OQZHQ,-E$BP=D'O/;'( M2A7Z4@'[5112\![@U6*@@"9'>1#]BGW*86A\O@;?WQ+%5>9EYJ8L%T&)FZ:P?X:L0W_,2 S6Q>I[SCR M-E)U;=( 0QZD*R$SA6B6K#*;;*10ETLEK4\\TD&[>O:^T* MM\UY70U([&YG[/$R2&,11$E:I"'W8\9#$7$_"L(D+_WP1GO^VN.U630?-UMZ M^SI->U+#^R,I^8]KZ)W ??;?PJ)P[J:!X^=% 'YA"GZAB!.P^_P\9%X21F4! M?F$63KUD'1\\L/2N) ^4J"[8I%U%^$Z$'K@(O?8.3^]6A#895D8SDO&_-WDM MM=W0/.G4X1B+;,> (H&^.^%[R,+WEW_T+?77L&RA8SBY\8EZ<5:#8\$QZS*1 M7H!U@DO]N$G^S\3L :K7'RO^NT+2*FGV=I=<9QP8W4P/DP;G.28:VE4!=C78[2KRS)I.SQ/DCKCL M:C#.05H=^*^DLJ,$Y!7'R2AOZA6O164!N'-SG>R879*G+V3D4X6LNJS)R(+, M\?4P0ZSKZ*@[3BMQJA3W@3?A%39URB4DPIY,,+^QIA!Y762&F$Q^!C<#[UXV M#ICBU40Z0H'KX&*6N+4MZLG. MPH9/V;LM*FG<^EMI.?!=@N\:^3TX]@$U\>?D*[^# Z?//7 MQ\-/?UT>?7IV>?CNX/*O\]WBOSZ]__CW MNV>?CMX=!(<5QDC!U@#CP%J*2;<6 M$[T8U[;WN64/G^M'VG^SJ$AXFN=A(((TC,"I9;P47AGQF!=)PI&[ L&RH,#/WT M>G9>VXN&W%0IZ[+9QI!NW^I4LF@JN'R!;8143P+,P!;HI\AK=2,-^!LU@*.- MM$]BQ RWP>N]5WN3?^WOO[ P[[?I37;33-S7E>+7K3@NGVEE\(-+*P8X_<#E M21 XOH\$57$4.2EGW'&S( Z\H RCV!U*ZU9JOY,ST=/](,&C^T;6EV'@$4EN M::L8R=:.>FM7B&B&!G."J-*M=G6^D.$(ZIS&J-B*MI+$[F/?L^,_6V\!48 M[,'F-5)L9#R1@F+'?QX\=;QL F/C JG]*/Y4@;Y7+M/K+&4S)=-5 M7,#:4-6&K@4L62&)\T]J$@E5PZZ?A8PH&%G$54!'%4.[]&0%W1]_%G&5@(C5 M*BHYJT! )M52MJQA+0PUASO-JO>(@\.F,*KZ@]H#[$V>K@QX>\Z62K+M;FYR ME+)(T40/UR8*A4J%19E>1#P% LQ2N%ZB?=@SN?KK5K=LW&I M#&)]2&WH.R2C\^^(:DWQ'4H\I6156Z,_M(Y#U)V*;%X5H6LZ)^3M0C#Q1=IU"^$62'LY8DY$X'Y$V.&4*%??2%3(9+5Z4,M^Z'( M]$S=3-H*IIPUZC=3F0!IM$&!2;H/\N!'4V).F07=/9&LC_,:7J#M8@U&Q4L= M2]\TQ7V&7]92]\AA-6B!:;K/FNE ("8V0:0,&18E4I9B)CMS@DAA['J-H9(@ MG+)D_CO8IM?8. MG0+G8(:<@>F&N3[U;KV$Z<* 5X<+A2O;P>\Z:@:!!ZP\;2E5:L1"@>P["/W: MK.G><]^EX4?G;T?\UGD,9I]QH;DOB*&!O(3)&5P-GR#"4JW8.:H),_'4+$E. M-Y:Y4ALHU>:,-)[IG]8KG)64+KC+0 5\VH;2X&OMJ^]&!F[>:Y0,?4K25XB" MH.Y;FS2-)/\9J"4&DC,!B8+3HNVQ@Q/OI48V$ ME#XAQ V(]O(MITR1K?"59 MPI4#U*W-*5&LVT[>D("RA_7M5]7<#NWON[GG%J4;)HR'851D>9AE"4O3,,FR M4$2:@\W/OGO.UF]LU!Y^>GUQ>/HV%EX4BB)TTC+,G#"*8X<)-W RP8,D*R+F M!L6C7[UTE.7\.V_W.6@P/]:J4I7/XUQ8%?8;]X#53VJP$1(O8(479F64A6$9 M%XQQ5X!_%I2>R'@:Z#+GJY%X\)(%HO$NP&)KQ;P'Q=/XN_XV,$B>)U(=;$\U M]+??#][1Z=L>KY!?>"O$R$*))"BKJ,2>QT_IW*^ D\^^FA>_BT M^'CX#K&HS]YF92K*F,>.YX:N$X8^R#J+"E"F8984L$Y!ZC_Z-1AC@)<&Y%-1 M"$)R!JI!I"1(>^Q?*>%#\VA<"I],7H&#@H$&OXO-""BX>;PR$*ECEH;X32;SSL5RVK&GJ+ KQN$E MCKLNBI4D"6H15@EO=9.Q!QQVJ\PHR[5F#OM MB)(0Q[RLRDIVQV6]19 TCZ"F*'!GCXU*I1V,(/2(X>N1(%#/)9=ASG6=ZF53 M%:-4=>.F]?(YIFE/FSCT$6*D(!G;I)X:1($0C;;\++A(>Y$M^!!.)&U\J]$@:]8B;;'&1O_ M:&Q\<(PUR5.0LB)TD<[%N)/><-/93Q\_1;4LCD86@4X-D M+UHW5L\5[\&RWJ[ KF(_(+.@-2M_K[%;V4V^J!L,E]::/U=M&^S9M543^(2U M9S*3@C\@*.(#[!=4/_*"ONDWI?4&YW =YINI^50R[W;OSC\ MXRT23WA!'#EPJ]P)>1X[>1R73E#PR T+C),(T')I.M(LP*BYV_:&^*82H;A9 ML%L0UDONS_FA.M:/RYUT;):.2RPQ]UQP)\+$"7U1.*%;1DZ:!XG#\R */"]D M69J#=$3N58<@N@VD-F6R]M*.OVR7=G^Q:HHSUDI3[WSLJ+Q7-6\Q8&_'?$U> M](B/6C93*#EE.%=7S.1]3N2PL0EZ0M5\RX01D_"T;XAJJIHKOP/MHP[V<*^F MFW;X,-ZB'+T1UTJ"KHDG2\/ZYO0W>KER5E](Z>E>[]O;%_TC V8>[3P0;JRT MY;]=OFZ1IO! #W#?3/\/>U9T@&F\WV%XN/_6]WU68&PS09Z^L$AS)^,\=Q(N M2L^'I4B\X!I_:\D 5>;<('6G?5-X;N L4W6- M3/I/"6!D%2GK0#_:]7!.H7QCF$RC>J^RE7DM))94R;@1\(62(HRJ*NAE;P?K MYG[Z(6^$1DDI@CGK(53PK; 3]"E;6J&+_R+M5;6DNF3Z*L);NK^SV65;89L\ MF:"V<:\FWG)]<84"6O$;;?[/B,%^5/A1(I(P P?/"]VDS!DVJPYB%C[:JLS-DWJ. M>TY7-"!P4'9U:ZKV_58?/R:5]W7+#+K9>0DS\H0F!W_ZP0Q6+'(_^N,MN 9% ME 7,B5*D+?.*TLD]P9W,S?W(3X+"]]WAAHA9D96A'[HI^!?8@4,$7EAX/"B+ MS'4+-JPR>&X,I\KT)E6U<.TJ?X>6[(JHARQ8.CYRLQR385:U2ZO-)GYA4RQZ M.NYQ3^V^,:ILP$*_2B(DO$;1!M%M[8Y0O9:*DP55K4A&I=;^H/?6M?6).CQ O, MA4!K% W4KM;)>J71\+V,6HQ%?$Q.'-9O#8U!UZ&I*Q%(!)^@EZ)R8?AW(Q"] M\%2LEFT!H_R-S=_3-?1#5TPLAZ>K*6P_095Z]$L8D$M)N0?/GQX\48OPE>J. MMU5OKA]UU^Y4*K;1=3$ZGWS370'"A66,%*P@% M359[Z*MW[3&UV15BE-KO\ M%D7$YJH_TTR&QZ3Q0RCSO*H75,A3@, 0"AK<1^1)-V2'O6KTZ>39J@%A,=6R M!*91:>J+NIEQ%7ZY6KMH4C3>%2;F30VN=T.0:!/!0ZHOF:5K*]PDN,,6C ;> MO1W<8-65[V(QD9!3?2IJV/^+,_P2S:&$])!';\^->F,=36RPQ66#S/PR.F!/ MB $%H?]NW8500W+(Y'?/!%-M-3FXTK#!J/ZBJ$!PEW;C^"FB\# A65$\,%^ MCLX;_??/2L!_ST\%N/Z_-8A2GSF'ES@CKT"+Y/ET\D3,D$1@.OE7A<^;3OY3 MGX$[/9_\+SM?_*+_-IW\7LTPYG@HFN+]=/*B!*EOII.C^@.."1[Z6U734U[6 MH##^.?D7W!.,@D+JK3^1TO'C&/#FN>6/M^,.N:6NINI.4UT K5>8O@&+6ANZ MP37!+2Y;F#S8-B DQ/<'8E*DNIX=LA&#D+PQ ,G( %;NAZ!4O2 M@)4B9GGI97!8C]H]5T 9UXR@#L+H_;AHQ:-W?V#^K\B+S.,\< 38ETZ8N8_KFX[,[JR&8M$ACUFXC@$OFA2)+#+;<'+?7\/;86[I'E"H.2O>GS:@?;FCWKFD/[]\JY#J M&P+_54MU(&TF49 V"-@IF'W#6EEEN=0S\S")MIH:6'/14:6 MPP(M*9*"5MMOA"K"F\@*+VU)58VV@>"R$HYLBR1"]Q/50&.P86#,G.+TMM,V MJ_%!TL12J]Z%TF7W5[EM5(ZB;G2*PN0R>G*[+BT/ CW[2IPJQT^B,FY'M/ 9 M[H5/?QXN8YB:L)>:-V9'&+9&P>0>[K\5N5N$<%@Y>>F[3EBPPLFX%\!/45AZ M20)+4 R#+^3E@X]16DXT6A#80XKHBAK=8O@)?>N9;(+]@2H_JP(^1K)XV*65 MN&@MW67)]J1KST(TT /8'9K$6,.C:B!0,<#C"O36=&*OO4(IXAAA@%3),!MY MB9;J5['@7/6:E<00W&A">8E PWXS;[T4P#7B^L^0[%N7RYDLNZJ8.]:OJ'9% M^\,6R0VWP-'IVS2*PY@%W'&%2)RP#(23Q;QTX@P,Z"A+.(\%XC_%>DY=$7;+ M;+D*:M$$ZV*:JK7BB65=K%0>638M&P]'&&?P^EC3@SBZ7H[:C?=&#T2EI&I, M^S2DW=&P!C;QP&WUBLAWBR)R@L#S<%]$#O-\S\F# &NN8Q[Q_"[8?[ZFI2$K MC]1^D] E?TC4(-()%AFGQUB4>4BNEU(4C3SL" JEH)LZ32:COZ:%H4FOCC M@B$OFP//64INB\U12 K!M<(>,PF2<$)-FN0+I0%(;AC%RD9X'TDH1"?8U*H^1+X?60JT%&3G MK^1(X2A;7@X(XLB3H. L/H_6J#X'M8&G/P@*?62%@(=3;2]SAYA38Z=[7U:8 M=<#WK^==])F(CY Z41 U7"O.J;-"S52I'[ZVKJ]"UZ;=& >_I5>R=5OL0*Z5 MCG)C>DHF= Q]TZ*6#F.WC<#KF]75'^M,9$V/Z4H_N@B M/U3:OTT1H2D"\NY0CK^N?RC?0OR.FW5_SG_'JIOVI9<".1 M>%D2E7$>!]&:T7 O1L$,&TZ=(FQZ@U+N\*;F>+$/"H2(@G:Z7)">(:,"-?_D M,1&5(3V1]67%@JWR[+HF_R1)I#XRF.\W<=H$9QO^D.][O#_>YPOS?XL[VXWVMQ MO /+* _"PG6+@H=I& 8LR=TH!OLH29-")(GP-X&NKK>H!G#*B+M%X'(F_"!, MA9NY//=%D(@LBUCB^EL:J#DY&SVS*=1>@4'%9L5*Q2:H/FL[=A/.$$!O0R(O0W08!"FE#P=DP(SM(-H; P3>2 M.UKG8J6K+6^IW-GN'H9;:FU^SU?@V"ZD 3A"T[K6^*%O.RM^W@TS):=Q_8X; M;?$6QW>.R-:NV6>]$-2L6(%'R4 MV/8:27!-S0PH6$FIL?XZ;%YAI%*E^":EYTA$D0Y;!DW FE[I^(=<-_5PW3QA M^#P#$!R[7T?1I^?+E+51JFRKC.L7YAU00BS@PN:IE,'532)ZGW:Y 8.N[ZGM MFO4;!8_N908I5:>3SBCW&BFS.E^ILP'SS1>T/6XL,@\]L$O%PK)KL/9#AUXV M,6GB 8?E ])%WZS&1YH<&7+O=RNN02Z;3_?U3:F&9,4KN@SJ)MOQ7J91M3VB ML\,.,:M7%?RJMURIA@?FD)9(!C7?:^=4@X20S:FPV^W ,=6*V0P&SH6NOT:) M9PTAG[%X&8MD$!9Q*J96"J4'H.@D@"#D! !3:ZS?:BH-'NPKM6H5LT*Y:BC/ MPY'2'QMNPUM]YN988(7X_-29B7+YOV .R4.$#B,X"/^_X4$ 8WXG"%%X,U,$5"4^P2JC? M?7NFFDQ"5[!A(0CU91KRNHH$SK5VU1L^TJ@+CVG=M-3J9LIO:>2$\ MEM[]!HEI4\NI+E?T/J9\9-A>WM+1_[+'7\W1@9&'@,RQ6>-N1$?%4,T7JZ6F M-0'MIYN780NT1C)+8KE%]U:R!P:^VB=AVI9-=+1>32(\]716@Q6L@]Z"BE=4 M3H,ZLT5]81F&9V^ MZZ^QV@@V$GK+/H V9KK22!;YS61R0^\D]3Y35=$#PM7,+LW79^2@R(J8RA(- M#U3%X9S MH%"3Y/G@[MFHC^#**:VSJ3[B5CY]^$2](5+:HKC<=*1.4N3DR38RT+W%ODBG;X05,@&;] MY7NF5L\"'6(!NK"2O6LVZ/#!MJ!6H$J;2U@KE=1*LFV:C&N.Q%N9A3M[Z[[L MK2>CMO3]6EW*M8,MIO/7>@O3]FLE3@L>9FTY4E349%2UCI6[0\9]KC_K)[H5 ME7K2WN3WZKVX ,TB%8UFI[=09/I\OK(J'H37&Z6:0*P[+:@M@IJ$OJKF M3;TPD[(W^:U6V(;Q%3$Q--&VQCM?_YJ%.5NW=FQ/6=DGRMK G6,UP54MFV^A MZLTQ8Y]R(YBR?@)^EY*_>4H^VZ7D=RGY74K^!G^V-R5_;8I]D"I'YLS<3R.1 M!SP4:9KZKL\25V0\SE@:91MY4*Y+L0^>D[J<(V(R%"$/(R:8%Z=%Z<=)GF1) M7 QJ)W8F]Q>;W"\'0>F]KYT)NS8!8 ?]NPH4M MR*Z[%)I+7@5(#,DC56<$2 M'(]60J7NQ25)#5DUYCH9CE'9RH:"1<;_0%MHJEQ4_(BKAE/PBBM\'EH=.L8_ M+!U1ULY4I:LQ)$:L,W,$ ;;2PK/]<;HW4OI0B!2'@ZU?3U620#5E:RBQUDM3 MD#-=G1L3:BRF)(-NF%+O_ [9C\ VDO8F0SF0?#E4ZZ+#(NB;C[/^P-K [Q7] MOBQ4>;>"]P&[5_I#RFO0I&/4.EM".I:RQKZY=#!3A@!=O7JZ$@:=(0I48-P7 M0R.MY&XWHK &-]Y#-G!I?JL'4Q103IHM.*J(H@OA&+-=.A.V"8G&.@CL^RXL M(ML JV0/>(<5[ZHRK*!5U?9B512[T\$\.W+7O?:'BNMH!UC3-:9/EV.S4DLT ML@VB(.M7KK0UA,X)N,)P5F_5,YLG!S1^U0'9#F:V:GMUM2B4X97FN@)PD%Q; M C>L)Y.X(^DGHR-HXDS$3@"N'3(=$-(:/!%,BI%#H1?-Z,HK@K<@Y2ID:"0T63 RS"P6#04Q4RVF@_: MJQI/98W58KM"'H=.,JW5GIJ/,#C;VP@TMI&RGVEO9\ 1@3W'4:YH-U$(O4L# M6X&Z+G1;G7=12!G&9ZLY>O!JQ(CD0?()<8I:3*:<5+"OL708+,X2O6>8LD-6 M-+5I9[ZFN&VP@$XLZ)(D+"L3V-?\ TK@G%-QA$69I?)99M+U?-E3I3NLZVUN MI;]D'JI9EO6LJO$Z*[IB#>L4=]C\7+UVUC3ZR>A8.V)97R8*)7[2.=#;-72P:N6KF2:_DND\SIW[YW3.C$ANK_*>=_ M)+%!V?$6PXH%EM5-1\YX>;3(0#(&TNP3J,,[#@Q=6S;/6#=FOJ=ZI=(G>&N5 M.).-#$4S,'CPYA42?BZU2U=:B;U*F1.2DD@EE54BL+<]'X2J!JYHOYS7 M"+VIWB/RAGZML)5U4?4.>31[+:NQ7NAXF0RLEFA_"$DE86ZC(HD2T=IE8[O4 M&[QX>U:5R^Y=%M5"4+)41_I[V6M=%MM%Y-5&4M8EIJT5OE6?43IKJ.55EH*; MIW,=^9?=3.S;R/VZ\&$4G*N(66D6'AID4E,56"&/I(6]P*\F:YV #7IJI!ITV M%S(-8L8\:0ODEAT[,7J=6S'0+ =U:9\D78+J0J@]2VMB)[%H?09IO*G,@""= M 5(ZZ[P/_;81IYA(QI';KBX>O%J%/'0KBXH/;D6\N$-*6XEC,$HE4!K/$KUY M#)!>S:L"H)C!F]J(+NJC^/N(%;DQ<8'.^=6WT*UPY)7VANUQ%W?4)\:-5T@P M@O@5: \8M-.-@7[3KA<2*EMX.6Q\?A<]N+^J3&WHY#"&9K_NBHT094\Q(_*9JLJ5BWC2^ M8-8K"M-@Y>Q"(OMN4TE*4&J87=O:JTT8177L@V?2A7Z0753O MX)]ZIIVL"&I[A4VZ(7'RE:ZL !6?;7F MW6]E!>X0!W>G;6!D.\C!#G*P@QSE\.(H#;*LV 0YN!V$8&M,*FSI:9OUVNB0!D=#U@G93_)XN[J>DEQ5N'*\ M&+Y7+VU]9@$F]:T),FJ5/]M?T5$HM!8V57^J(F97:4/4#QEUJ3(_;+K'MQ4"HHP$"9,E3D@:]Y[DHJ9E>] MF"2_X8 NH6?6X/3@7QN!+:)&2Y[66LMV?%;]YU04\)?X5K02+9M0!Z')(FUM MF\@J.<7>7 8,:<9CDSI<54%%X[O.^%['U7\1A'YK-N,A3)R,C.FPU!>5-VN+ M$E//_=35+IARLV"*C*;"[C6M?_I4YY*. 701Q5\;R0XG:5A58-XNO1ND^HW2 MV)OLJ^ICW6]A3!?1_2^::KD4&! ##7'*D,I3[N(N8& E_57+/8R;F+;)ZLB2 MA!U[2#R'NU4UJK?TK'J20T_2Q=$H7J3XK"H=_>2UM-(%U?1<[PO5(_RNK4(V M3(W"F W#QQ12E0YG%USJ%,ZZZT18>T7?ITZ)JNTT.M(=.JN%10,R3+91?!^# MR!4ET;=K$]U]D.A>=AP&X+>-C.3@!KF4^YVT$>5D]2Q'6P>T4B/., 7]8?-I M^;FM>;8E@GJ;A7J@)L(;,5X=M#D>2FJXL^7MXEXKCV:!6,YL/$:A6^ RU?-O#,B.VB5LB$W$YSN4RK. KF1(Z/*SZBB M&L=%$+(9(FPN.YMV5$W*U*9*ODO?QFZ-A+MJ1CT6Y=FCP#C8B96P7>"GG"KL M%1Q:]&SY5H1PPYM;M6\&OKN9\Q99<"0\$8O_X.#2C%>XV5?MY+'8.]V3D-(! MW[V! )!)8%[@DDKPE4?Q_.F^57(H\F?]B:OKJ6/I4ZP;"DC MNBA+\UJO?%\BN@ZV&R13G<)*++4/,08D[9E+*.PFHT0ER_B<+UH;E1B3BT[F MA$E'7,VGVYN,08)".W*]WIL=1I$IUCI9QVZPCC@D<*A;C'6#EB#LU;*A1Y/' MVLJ\P4ARS6[DHR!B5E99 _"$=NRO9P^MHU,@O8# M!"Q+6 X\(I<[4[7PH:+!''&5>L.J=36F*$)!T99KN&KPH [ 0/TM9@)E63H M%-U,9ECFTME6 GEI@9D>^@'2L6"@=C"(B^'V(43=)GGNM$B..1YDI;CLLC@* M6#NZV[?.N#NF[:;?;]0R&LV9/'1;:;\?3U#[M#L%97Q+-OA[,'T#GM"H?X=! MFYC"@6G&ONLAU+4/^,,]/'T;E)Y(&!..FX2A$[*X<-(L"!SN,S?)XL OLO4> M0M]89U$WPN/YY#\,-A^<3ZJ/L^04X/4"977_U6OLZ1P[7C#='NU"(^]"6YT< M2G"S_XL4ULGOLH?FXY-Z 3LB\..??IXU]E=#1B^K< MM2(0U 4I2O.;>GU;JY !-<=>/L:A(:*=F^LE77[0*Z"XLOV!?;WUJ,I"*_?; M%>2Z)0V97R5#7"<:#72#4[";Y^;7LGM![S&RK]]HO[D.!+QNHA%2'I^R6DAG MWA &32D\+X$,Y[@?U(/@"S1*!2.4%"%<\IK)N)^XZHV4F71ME_M^.W1M/'4Y MDO5944[A;19UC>M3M=<@0 1&Z[88'#C8]-L3SZ:!71_%)@/_TDX(@H>P1.DY M5[D)G9H8+.EP!0WO,-O2S --R/=",[QY=6\3!ASM&O*0'!R:!C F!1&:'=7@ MER=C*W+O'<*5!7!/;=II"!;:=+^'-D41ZN^+)]V^>*;WQ1/<$,^[#='I/%W2 MO;]Q0WS%Z?=OME/NNIGO.P6/$R?,W=S)W#ATLM3G?LXX3^)X MB. *_2QF99P%//##-$IS6(^4"9ZQM&!!&0Y=VB>:1U>R M=SI.7>)-::K9(< MT@^5--/Q9[#^36NWIR]>. =_ZNYNNJI0FL+RLUZE84GK[E!Z8_.#)3<$19 K M&S+=N2O@"3*47H=@"ZJ9VE@:Y4-7MVJH(U3]AL((4'H&RY#K52M93%3\'&39 M-\!H'($BVY,0=V(RF1<$Y)YK.]TTK=--;^U"7JL4WDZU:S#S52VV=U#F6T"9 MO1V4>0=EWD&9;_!GBZ',UT&3!P>A%\2")VG,LL(+/;!-O+)(BJP(69GY(HIO M $D>'<>U!^P]H2?M&B=,F;::HLANC['Y@)5G&&92%8.ZE>=D%M=&?DE-28/8 M=3QWNC4!#0D%>F%8>%[,V%QE.)_!R&76V)D#;5I43O;HPOOJH@.X@!:P@+V,1^2C%=B.B1S\EK9NM7; M8KV?A;;O3!=[2K@JG(#$D:L0+5W=R1BE-#!V4_$N_]]1%%DT1&+^H6IJR0:D M/?8K2-C:)34O4*Q)BF#"- BR*5ZF.O^KUP*M.-',%9B S6$2:K07)DM+P8IDQ2JZO&P */F?EJ]90*9-PJ5;%2!]B[J2R M_D@*()#@!M<6!J+@HG9<;%!$]Z!<])<(ME@)TXUCDV,#L[./>"*+::'K\WR+ M$^SK.LWJ;5YVB:5=7K?7%G[_;>J**/=S[I0Y]YTP+#(GS5CA9 '+ N'[22*\ MM;SNEL5?3+TW:VRX2JTYU.%@0&==TLL)J8D'JM?0+Y)V-AZWQAC5%W/*0"K. M=4*SJ+.A9S)80#%Y(\G=I)Z,I -,D0&U'9]EH_8CM#QCI$"J M9WQO\N_Z NY&1._$OX(:S\3;8(\!$R'#$3IUW/3 MEF0R8Z=X1*\4:A0^">-)5L]=0QE9!2D-2' MM9M&_3WH-48I]8[3"8MQ2GE\/< MO&0IK<[S5=.J]D2F/Q6Q/G0#6:.XM?&1==/C*[Z443XPQ_K->@PSS+#:QF)Y M4:;A6+MD]3""?*[Q."DE*7=&;TOWM2+\S;#+&!:E]W-0X*"@+A?*8U/93TD> M88@TNS=XH F6PPITUA+5LU;8#WWW*9UK4]%V:M,<63)-IKJZH/%]2CIMG2VV M!^\=Z86I5=[&3F^64J9@.9/=M1UD4324+L2CMVH6=2MM#ME MM.#FC7V4RG;A5J\8Z?.L]9(R!)Y70!0V;Y]N'),"M"#V.U$ ['=V30=V6&F) MW,S,\\U/ZY&FAGN3P^[]S2TMV+F!F>M"C;6IN*K-%F4FI*>L[X,IDN(,"2 ? M/&);%X=:9[>U(\[7](.90QU,D.F83O-;%JWD[;E4A0WFIIJ3=E4@75ZYFNFJ M!ZL>@XN22(WTY06)QB_-$9I%ZP6J WDPFGTHS;2+)K\ M[IE3U81)&.R+? ?9UQ-DM)ZMB\ PK?10SH(.9%%UL,\' \Y^SJKF3XRL')0)Q_>SV$N#..7^6@K[7M 1^B O MQZ1RY"S;##J(/>-" +I?NK=8"TCW3QZHJY^X.5;JX]U4L]$,7 M!@O7U"FKH8FR(,OTNL"SXZ,R:KLXH,63#[\BUE>'*L'G# \B&%;G*!8=%V75<$G4 MC.@&@Z)0_)3*94,H]G")-Z\P'#G6:,',G%6?]'U5!H#ZBA1G\^J_Y/F@S('+ M9R@%!7HT*E&E[XNG=*]=.R$;@_M$#Y*MYWWM1D-7"RVN!YTG=KF$7/71^H@O M!+INBQ'P9)..I%\>DM@J%M5BU9#>>^ &\-G@U5[I>EMZ(?&GM'!D8).]H!F>B(OS&?"FCPF/KF]306K,1PT6] M3&)?XTS6W9$=D.V&0#9_!V3; =EV0+8;_-E>(-NUP+0!D"TOW$)D+,_#/ Y= M.'""/!$L\'V1Q6 )(^VRD![)N.C@Z-AWU1W4KL*MG[6W#O$HEDT'W]^"H-Z M9<9D1OV\;E[!F*55M+.-+-O(/SI]6P9%&L=!X42E&SEAYI=.5F:NDY0"UB,H MDZ)Q&+0@DZ9ZAXU6_ M534FP>>35Y(>$0[G<&4M-/!Q/3F@LJWKY@*O%09P3+U7RBR3V&: M](T4:_[S,5[^DZDTV3]^1ZY8C\5 \3V-=)L:XAPQ>]@7T#4L4KW[BG?9ME5!_5;.FA:K>LFY8RUU[RRHIFP^U>95F520:EO]%I@TJJ8A_]W MA;W^EHI>=\X5B8+\N\ D-%%#],"[E%8U$%B[U=5S!=C5C& #\H71F5OVPXK7 MS-YULZ*TR<\J7;I4),^* [A[#/8;0>_7M!L9>QIBK#Z(ABK.YK(A5B\#2>E! MM5Y3U6&%FHX2!WC7$A+U#INJ4C/)VXK>>Z^3=7,,H33 66L'F /V=4-COI]JE=8(&"X M(Z>5@0DS4X/QF]2UXL1HI^K(H27"3"V,'//K&F9M) Z3H:U<1"D^HVT,Y_(> M-G>:A&_)NX)P^+M;N^H5T_1 V?;X4!I ]:(ZILO-)]A//1 M;78[P=$9%@FPLE%$(ZTN,?70MK2I[N"$2.X3O$IM-&=JIF33R\&6KQ==;RZ5 MM1I8.\. U 4Q>8[?)A=+XK]$O[^U:A_4BI!,*VHV_0PP&C#E3K^EH1)IIH3M M+ZM&] RC=I.Q4\NS!Y&'N)&4!J$!G-NMWGQEB7@;K)0.&'L%T[(W-1A/DL='F" M9]8C7==/>W^98$\4698*5\19&(9!ED01B_*@".*X+(O@GC8[G1$$^D)8O/62 M"/0?K(0\/= QM=L)&,^_'B ;Y?4@(F3=DLF)#>D)^;79#T9)(2M:'G*VP6:9 M+[3\&OIF$0T/O!I,-N'3E$W6%Q^2UN MQWCHU+ 'O5@84>[9\@MG>S7##7;_$6N3PK>]_#]9@P$HH4-6S]#+O_S1X872 M>-A_&[G,\T(O<80?N4Z8>YZ3Q47FQ%$4)&Z.?='$\%0J M>/>)$5,0]"QHHL M*EWA,IZ6:1R48LUXV$J#]:#O5Z%[TV7X==7!RG*;[,JGCP@\!B_8#CA5\Q+, M%^K@* UGV^:Q D4CQKSD@D1GIPNX[H6%X)GY,)*Q- MK1@YZ>C$"'E7I(V#$\+X^%A^IXXZ1&?4K80:FJAIKTN9KG*S0E7FZ):1,:OR MB% >'Q#4?AP#=@J:2 =#\8T4&,MXY5?J!LMG4MKG7=[JY'T-:=!V]4(Y0T:MS$J&7E$K*/T M',/*UCE)M<[JI.R%(\>*]6BPE]1*3N=.<()U^%L-?-.@Z?A0]^CU/)=1 ^Q^ M9.=X"'S-J#".+;M<36M'VS'IDH,?.GGL_;1Q"O0;T9%CFPC6W/1>D,R Q[Z\ M8U>/16'BO*V;W!">AU1$K]Y<\=%,[;M;UDKRXC\-8\W&#:-PD>29*5H!$?*]G?4Z(40?&<50O":*I, OCJ\Y:I:G8, MH,NC>OW8( N@P73:,,6'1SA\0ED2!-+3CI86R'4!YAT4\Q90S& ,\+6#8NZ@ MF#LHYN#/]D(QKX56#CD%PR3S2Y^%F9N$B1>DJ5\&\#V7Y5GL%?\=P_K-2?1 M73>H\;]D;A$[(2]C)R_RQ/'[-%*"G M,H28V/*UWV_3)ITC\)AV,$?X61XZE\K+(9/,&S_@$F6;G=-SU!*XO8IUD M=E2QA&73\F'QG6BZ@8?4_'(;@L,MG&.C]$5C+02(;+;=FSRO/B)TH!FCQ+&( MEGK,44.JF;JCR3'\2(^K/;%G,XV-7$AKSB5]C6+4/8.-?U;/>#M0DPRVMZPZ M6&K4@9$<.V9(R9]96^\$Z#,$R/!I*OUF<0<-ED>B&I<60Y6U=#+L91:> J9- M=7JJ:$413\)DR_'9>&OIKD=NURN<4H"FB[AQ(#:0CGXGU$4',MNW9!^W"#8@ M!W7"/NX@AC9*X'C_;1[ZL1M&A1.QC#FA"_9QRKS825WF^7G$DZA8@QC&09:! M-^V[01&%(3(.AVGB>UD9!AE+@FS;K6B=%>KU 9"Q<#1*45%W\?RI)&6?HTZW MB&DHT0RF6L4KUE2:G@R_JIL,22$&78"&PW1"3O6R6JZ6J"?(BYR?@MULTR;) M4PZ#[%3QAD=F\#BEH+3W%=& MSQI/YI( #%UP9RP!WSD?72K^>\[]GL%A;R_EG:\B?LDJDZ$-"(O"=&T>R0YL M(];PJ7YZ[_OVHN)#T!XAG#.L+-RB,.1KRN@UM7J2!6VN.7Z-,I,EH5C&5%/6 M4+)CH;1,39>)S@N7/2Y@%R";[V917&! C?BG'59*2P]KO9MXCS[#!IN2)8_^HJ M6?+"?[%0V-)PK5JO+(/Y>U[2-UB])B3;_AI1OF9J@';H1>^5)-\0," M6\(=L&4';-D!6V[P9WN!+=<"58; EHSQ) D"'@5)&!5>*GQ1)!X+RA1^6?B? MVRSS^JA8?QQIZ*4L]WF4B"+DB0OC*++(#YGK^UGNW5<%Z!O1)21Z[I,TQ$QE MAXHFZ3(8B9R&&\T[FTA%F";-"@/Q-N*9CMHGSY],7N)'?;AS_S,P_IN:H:RETYS*LRQKZRKJPPTLF8P%@^&RDPA1Y?UJ0*^XG'=IQ,'6[4E2HL> M7)P1Q'^CV=E[RR?=W#Q7? M,@."SC%^I^IEJ)F$>C\DGI;U%W0CR]HU.2N3*-WT!E.#&8;1&582=1>JU%$6 M)\8^+3DR+8JDA4>)CXDFF#=3:Z#L)B>(>11,XK#)*3D,BE[=C_YAU5QU3%]@ M0TT>F\D]@+EU[ZZX8$&[3&\S'6C5$5DZG,R^;&I*,+19Y?*#+<# MTL1Q7E0+$WRR;,N?'D)=[O4Z<2J1"_D5LJE+(,PF[7S&-P;?WFBJ'-7KM\?; MTFVEON^%W]]P"/=/R_L*;BE4S16&/V5*Z/O8C_>EMI3%SPNA"HH_+IXF*_. MX_^5$ZQZOEZ(AB@3?^P\Z_')ZXNCT[=)R'D&7IA(6(G#QQ R=U,\\O MB]1-BWR8*_T-%$31U=L:\3/INV2X3:$PJ[[,/1#K?#PA\5=*I72\2FT3/XRK3J MUJW3GE8S&@H,\?.&9I_@A)0&=2X5F5W=Q/$QU-':(OG\2B\U'-'UMY.!:0I1 M=9@0^QD:]GCU&\'%7%Y+W'(PNR^NN4 3[5.EF?4\.=#?U@8JV1/12I,-5TG* M5G,,>1H4Z*O7K25L. YU\N#!@KI@<@!_70A2<+#^>!K"H:'*E0_F&"[ 86*+ M^DZ"QS[M?( W6)PO7T-=4)584PL+"N/4/H6"M_>H%S=.JRA+=2!NF(PNN[S4 MF>]V"7KK/"6I^Z4S7Z;XD!%U:;<#,E4676IAEF8YRPKG"#Q4C1$,H>Y1>0489#F 9@AS$W70%Z)G_"XY&E0 MNB'/8Q9GC+LB8HSE69KZ=P'R^NJ.]L%\/_5:WJRXV9PK%E_ M,P$:=.>H2$R"D57"J0#M /81(IT[F-*5_*G3&_6FU=WOUKAFJO%*BL!SIU\[ M3')+%/)+@^Z^BD[CJXO55-=8# *D"OZB 7'6DJMTM2P1Z3$6J&2K,APWKEU' MDF]#UXDJ0*$6+#"RH@60VUGEV2W(0UO4LO.<%%98YV&*507IR+R1@;JNF9X8 MW0(R,FEB!^W@_0G"<:Y-).*.0\8B"H_\A\V)PGT^HI+PH**ZH::+B\+MV!S"=T8]CS4A-FP!;MX"J'&'5D[T*&DL(_4 MHH-TR3GHO;LV1S#-7'$34I$\2@.N(]G\EBLR7V4OCL[JPXTZ:/VK5Q>6-E8Z M&/2JUJ?(&XDSK8&9!LMH62!=ORW%]CW>(4SKV]AQO9]4?(X$JGN6(C6GKHP% M\7@WC5"E<_KRU'$#E8G %3$#,T3SM+F$)F3JV']4QI]Q*8(62,_N&6K!@WM] MQD:H\O.-1*SRF%!<&U=QK';>]L@;48I'WJ5KI8J\G[.Z776Q484UP]"IL@ZM MB<:APXH,MK!JLLDFYS67;]B(95-36-+F8Z&[=H1D$]48 [[B*%]JXZ913"X% MNFOR_K+CIW$%\LO)_RA#]'DCJ^/(NR4S=-7R1WV[-,ORV!=)Z.6B#.%'YA=, M,$]$><)$7+IO#Y"<5IJC\%A0-;/V_WWD1(\FTL^ 6WQ<_CQ?G?-ZJ3X?VJVO MT*/$) 8<[=('/M"*[H4LS]RW(B(G]5$]MTCF-,GA(U#?#/=P_&/;M<'A_MO< M3_S-QEN:<14$0Q8]^]?*,.+4/26[7K\(A8CN[GL?8UGPS <>ZI%K"Y J5%'3T M16?UA;$7%&:O[1I&5=.#853MD-:C;S[_@]A*TVK\]'5SGC(IA%A1M,#T59"1;W'91J!1D M>+YZ4:^V8R*H4OTI3"]%H0.E$W945W>'"(QVB, =(G"'"+S!GRU&!%Z/\!M' M\%T7\MQ:"XBR(^/VCXQ8C@3T5974.0'2\:J>#RX]S\[]+BA+?1+ UV(* _'U;?-., M.#"=SEAG2GQ''T]"_W\(^W81&)0,2^ M(^(X<,*D")TLRH53>&'DYTGF)1D'.SOS]Y)K@C++NA= MW0C-=&3FJU3WVL' M$T)4-J53[K'.\ML&1-);&P2FK)N4/I=!#Q/'70\3M[TXL61ZZ\+1RAB0G\ES M22:=4E"Z79SR, !O(?*][&WH/KIGS,^5CG( &N_K MHG*>@\C^B1+[M-NQ6P+!<0^?Z'/QY?G?;_[RX)^/<+8%?WWZ(SAZ\_SLZ/SP MT_'3?0_N=_'7)QS+W^?#<_'H7W_/_G[W)_SSS#U\Q]\=/2V\O]X\\__Z=!C" M\V'LO[T[>O>R^OO\[_+H71$>[[_U_2!A3+B.*Y+$"<&%=/(BR9PT#TJO=#U6 MLF@(NXG*),G ]LUXF(=EF:=P@5\PF'0_*.-PK0,33ON$YGUR:.M:W$T=V.7 MRI/>#HEX4Z#;J$-]_2MYP4,T^LHXX6&_/S=>*$5:6=4_3U[/9: $ M5NJ_JWI)K+I5(8U5)F-$LJ6\)4F,*'D)LJ7B=982)72VA"WBY"..9TIFKZED M4(**_>8Z.96 ,6/LRZ^@45JUE)==2\[?$,\CO:.YN%2O0>2@5S"J[63KCF3+ M_WGRQU"@UB2)6C5**:N;#;BQKEL6 @'[?1\7*Q7NK'-X 0*>3B>*;M'4X1*" M5O_-EC-?RUG7IE 7Z6V@PU.#:Z#V3Y+9 MAQYO;X3+B<[);I;0^Y!'_T:5)?VDGC\'/V,>\D*4MUJDEZ?]4 MRD!)E)%/:CAFBYP"$H_[_R0(JWDGB[:P!2-*30I-KT$A 5($T9KM3WZK:JQ1 MF\/(D2< #^]777&8]=7?L,3Z JM )+O=&3R@;B1 >#IX##[E1!1EA92&>W ' M,3F"?3J)"+CN_:+^L]\#2+W"_,A3S(^\ZC0P%>G 3FB+IC+1^0WOM/%5'CJ^ MZ?E&Q=7!^3$!5 TM+QGYFY%PJ$D:#6B!.=9C2@=3$'6,O)" .9W,8ACHQM): M220<'M*-6%Y^#DKE2VNN?D 2[P#L.P +#L RPW^;"^ Y=HXV"!NQG,19YE? MYCD/PD D6>P)/RMR3[BL"*+B(<;-S 'U$()FKXHSP5VA/*+O\XP;6HL/]MT'DF7DQ)&( MDS)G4<;1C-@#G]1 MOUG6BY_EE"HG5UM6#9P:#H*LV*(5/^L??OG_V7OSGK:2;7WXJUC1O5*W1'%J M'I+[1J)#TB?GUYA.0CI*_HEJ#";&YM@FA'SZ=]7>'C9@$PPF&*BHF\GVWK6K MZGG64&L(G>%1UYX^[?2J":H^]"Q7?,@VQACD<,V9"K*):S5D-(#_P^3ZXY_EK3%_OJF6P=S98^N8<#(=P7M;50A"*S_CLWLU:6._]9E)NNX#/[99 MHV76KC%KK,S:4K.VUP<;9QD2FV@\8)7$RV=HWCM_7#OT:$ND:#&9' M&22P\9S@8 M[JDWS#H2I28JY!2MB:.\D:+%ELC,RARZU0OYV\L9D\X),I\F7['[Z3??_WCX MO;M[\&E_]\^=D]V]CWCGPS\PIK<'._3M_J?#]W3G .[]XS]?/^[]<_AI[S\' MD\_ O8X_T?>R??B2?_RQ)=H';[Y_^O *QKSSX].?K^"]'T_A.7_L'+[=;W_X MU-TY;*=V!W__:^_E:.<=/OG,>"*48XHD80)QYPQR1"O$J8(%%90JD9X\IWR# M8;H@5^LF:)@0W1*H6*7Z6*CI05)3M!)S%8**@7-%N,-<\L"<3=CQ:-+5J.E' M'/0#4$]AI5_$2C^FK*24#5H)AY*3,7,11SI8X"<:A4A$<&QH'0I(Z+-"2X66 M[@4M&1&U55':(!FG)%H;O0X@;HT7249<:&DM:8E,:8DZ3;%4&$7G*>+,. 3[ MU")L>8@6&RV%*K14:&D-'FT)6O(I6>^2),8'KJDV5(:6;SAX MU3(B8AR@60;0L9VD2%#LO0TI)FW64"H_L@B9%WDH.5E^%*NTAQ"K ME/)KF?Y7];3>9VYBW@B5B*#")&ZQM=%JPV, A=-(%6A1,M:/EG9?-$Q_25UT M+H%602V8_IIII*6)R'*KLJL9UO,A'Y,4((^!;#&C.@IEF2%<8V]P"E(*18C' M#/MB^J\QFF>F/Y6@%G+I$8\D(1ZL0LX$A81+4@8GI>($E R^(=;J8*& >;5@ MYIK@D#P8B<3R:)5SC .B.7PA'FB]2.6UQ''#]!%&NUBD\OJB>6;ZLT0]=YHB MKB*8_A%^,AZG7&#<$(J% \F\AE+Y$21^[P.:IF]5/S>54BY1=0LKN M[&UE"5M[L[8^8T4%=TP@10)'G :/M D811.T=5R[$''1FA\^;&E4AC@)P)4> M+&#O..C,$5.*60K47_'D^U*MN6!W)=@]G6+7:=B1U.6&.X0@#GL .6P\PLP( M:D1DDI(GSQG=4((7Z#Y8Z$9FJ2&1&QD\5\+:J!RC('1I4BHZ5R3NW:.V/9.X M26!/S.)"[SR8-%(U'@^:Q(1HYT8AIA OH2%8DPXM90XI8DE)*$ M,K_$2=!&V.QH=5Q%; B5%C9Q3(8Q24S1'.Z:?5XV;77ME/;>2H1MS+8ZML@8 M[1%)B;+(B8Z*E^#6AP];DW!0D7C8#(Y[8L$,%,PZ*I6$W^,J3K@*=E>"W9GF MX(TC"E.%LF\T!Z8S9(U6*"C'06L@H$_X)\\YYQOBYJI#P>[:8C=R'(E*C@)Z MX4=KL *SG9)$?**:%V-]#6#;,-8IQ=+$))#E\(63B)'AB2"G150QPK)97T3N MPXAUTVC708+(D-)I*VBB&/#D(M$(*QS&2(!2[="#:*X^]<6ME@2H2FEC@?/ M'166T,2LCT90I[PJ&L3:8'>F05 6!";&(>$S=G6(R"HE4%2&BJC!:J?IR7.! MQ891I&#WP6*7)\49EK#B,7"AO$G<:QJM9]P8$4@1N7.M M(G)O'[LSD2NY<3Z"E2Z]3F"T$XUT-MJI<=8P39G(ZO+ZB=Q'D/BQ] M!\"C-80=OI*@^,?@/A2&**ZXED%*+A)QP8@D!8^PVQ.HDC=3(*8+\ZH_> ?+ M M :!5T-)Z2PECDDO.78B!,FJXSI6);UKJO@#ZE@$]TS<4#IQGSYS!- *@%4/. M184TCUJQ8*G#J^O$40"]MH".Q >J21"$B!R3JV-T)L%?9P\X[\V=DZ)$76&HF\P!H6 M+7H:S,)F/!-HW('N<#W_\)6QN>;]RPK%/C**78V7JE#LKZ/8F;9+<""1A8"T MTP)Q+20RFF'$L@LZB*") 6V7;!#&-XQ0A64+RQ:6O1.6O47786'9VV#9AJ-0 M**8HQ;F79&Z_'91"UC&#@@L>.\JM"&2A3Z%0;*'80K&_@F)OT9%;*/96*+9Q MPJHYK#^FR$4,%"NXS3\9I#BU E8O-]'(BBRE9H-R5ECVJA[ER4 F0Z85A]Y! MH=@K/?!=5[,M@[R[03ZH(Y#Y5)'KP(].&[&0K=_([R6'\8Y\__5JS$Y?7_W3 M?MWN]WR1YM>0YA^;GG_+/,'4!B14KH!F@T&&>8\$QMH+R6'=XI/GU.@-J7W(K[$ !9P'L+X&T4#!8)4Q42HM$3Q+&6R*AHD)1$J^"9UR26Q*B'#][5 M>"P+>&\?O.UFI?X8;>01:<88@)<29#31B#M.I4K::E_Z6ST"\-ZV+ZP@>+4( MGHG?D#R D#L4N#"($R:1AA^1C40+Z50BA*^C[EQR&TMNX[KG-A:&NB9#^:9U M3SU--&J%'&>@64B<$*B#$K%H0\S])(PLZ8V/ -/KD=Y8,'U]3#<"R2+5DBF& MDLA=@G+NA [4(>V#TCPR'^GJ[(:"Z;7%]!IE.!9@7QO8#8> LTDE)0F"K%4)3*=03V(SCFA_U_8@=AV/J-EM/]A9J&4]H(K+ TE ?N M;4HV@KYAG,3&^2MV-EMD/6S#\+_94>=;K*/V"M,LQ31?SN3Q.5@)'0/"-H!M M .I$+G!*D'/"2,TTL4Z5,X6'CUA%>*Z9F>MB.)Y\3CEB.-&8I(J[>( M;>@&41#.(D8>-#N4.\@@I[U#V!&N/ E.RG*$_P@02VRBU#ANC.0\6>L24TY' MQ9ABU*HK(O92I;_ ]H:P;=CJ,6(B-=?("<41-P1^2C07)!+.1&="Q-E6UQL2 MXX+:!XO:%!S8Y]+30$ S5LYY13475ALL*':AH'8-4#L3MEP'PL#J!AM<,$ M MU4A[[1&6$J=HF4^Y&/':H?81G-=_L(.![8W #F?7L\,?@V,P^P4%[&$;1>3: M$YTHUKDX"]7.@VU>M/H[))JO33N<*)\$5P%Q:L .S[T+;-0$*>&\%;!N-/<5 M+V=T#QZQ%%O0!!WW%O0#X9P33&,/0D@GD Y7])P5_>!68=OH,!AH-%HXT.HC MZ =!"V29I4@;$R6G5%G!GCP7&YS=.)RO@'9M0:L2URH)IYP4W"2K93",&2YU MPD#EJHC9.\5KLRRP))EA%1(\>,0C5\@:*1#305,J:B, MY(*#86>X8 RK%$W@6!8:_3F"32:+3!04!1RYBSIB4)K7 M3\P^J-/PR^K^PG2CE=3^K1_E7%&!Q>4&'D^EGQM-S)J0]OVM%UR"FJY'X@=; M31='#(DH*A4*%H.MY%-$QGN"L%.$@,;L&$Z+DY_N:Q&@FR#W?A1A*Z1=2'L- M*Q 7TKX^:337*;4D,EE=$83I\\)Y)MX#G) X6T M"VD7TEZ3&5F/'+!"VK=%VC,].U'*J?&YNX>,B O*D<&1HN25]RIJBW,9>B[5 M!N$/IP[]79!VY97_URCG,L+WT/GV_/_@RV3$XSN@S(U/B9X09J<78(,_1?DO MJZ8"_;-YIGF>&\5D?_G=GYV9%;TIJUEX?P2,]&>G&VVH#DS5LV'+^O\>=X:= MBJSZJ?7Z\/"XUS^,H>.'&ZW^\:#5Z7V+P]%A/BGH],Z\#G1V>-C/#];W7ULG M=M@:Q! CO)C?F8Z[W?Q]M)\+]!P/1ONM_Q[;P2@.\GTRM6W ^X?'W1&,,[_1 MMK[83C6(_UF"1644VEHAF12!:RFG#^'(42[;?W[J?CKX!_Y_B7<.PD%[ MVY./'U[2CS]V.-P?QO['0?O@;>?3X:?4/G@OVC^VZ.[>EWP?WM[Z[,'H"(H0 MI(/,?9 214YPC3SQ3!J;0.CI[#>FFQ=+Q]?L!'CHYH4?1-__TH-='UHGG=$^ M;(_;A51UP:>=$="0OPK$\^K__B\0J\,6C#:>+RA]9_A_\GP"O=-H!ZT(9!A: MV]''0P?X8V2C N#F=#;O$:O2=6/5/9CE=W UN,D?K4FR\4:U=0=A33?N+FR- MP;F3WSODVZBY5']T^OOV6^RU_A[$%$$?#JUW^Q9$TKV$!5LW6+RM MUB?DY7AYU/EQ>@AK-8!;C$4ZK&N(0S_HN%I=:/=A,7FEEI!GLTB<#0X MSNH'Z"JPJE-8C;?.A4B&UE%_,%GOM<)_#DQ[U!A"7..DBMH Y:E24)Z=!MZ+&8I*TBM%<0>T= M@J4%/RVA_TY]"95KX:^.=9TN//3;_,P#(( _[+ S?)2= MO2VQN_?^^\[>1[%S -=]\]G;Q+EB 7$B*>**N03#0G< M8 OF=>*,!6=-9('[H+(;#*=J[^C)WM&%?-9I$]'VF\^YJTW]DRV4"R]/C,SA(BLS?R6FVFYY-U1>GZ/HLR+4/3VO M:X_OUP:5:-#Q]>]Y[W5ZQ[9VG#94A;&X%ASD^5&_5O.?5G8!7/O922>,]B=N M^<:GQBY,//N(=:#U'(\6?Z3AK_2@E\3!':DD!*MST]7XNC^862E?(G( @*_( M)ACM4]L]L:?#)_\Z\U"'G=[DZHK"[=?GX2\Q];?_][Z^W. M5NOOOUYK';?K?[U^OMK;V7VZU7K]M;[1>O MM_YJO=N#/^R\;.^]N_ X5Q[TU@!LB9L,M39C0[:M*I@]!0,Z#O*[P#BXG_\6 MS.82UD?3G%_PL<4OUE_/L==8\+@HC:')N< XRPDM)%+C'8G8>B9\+6WA,S%L M9M4NJSYT_H 'KCGCFTU<<\XX\6)\_?'+F]5+YTZIZM>XWI18+7P9;Y*% MKUUV60(O,GZMRU[^&M/7NVH9[)T-UESILC])&_IY;A^Y\-XYP1^U)%NG8(>M M>6X-8LX<+=]T;AI1.E<]9%[O2?LK@M[;(@LKH"SSP(]MUFB9M6O,&BNSMGR* MY#(D-M%XP'"-E\_0O'<^^*33RXR+.DCMZ55VZ(UZMU^K>?952^250:[U(&\5 MO8_YG8^@:-T+.]ROSO:^V6[SD/96:GR4:ZS/-58DE>LH?KI)Q7KO\QV ]6GK MT Z^QE$5/K-T08@U3EZ8_\A+)R^L8Q;"S5M!\BC@7XQ61FZ"MRYY):2EF!D= M1%7>=L[Q[S)U=3*';O5"_O9RQJ1S$A,>1CK"X:N#CP=O]]M_OA3M'^_Y[MZ; MTYT?_^E\VFYWVX>O?WS:_L_![K8GN]OOZ?ETA(\?VAWX'/ZX]Y6U][X(N.>/ MGK"30^2FV+T00?"*0F:4YT/2I26QD?AB.+, M7XV;%E7I*[1T2[3T8TI+^?1)6L90HBDBKCE#)JF @XF&JRQ9P^Y\T6AI0=) M2Z 9Q1 <4]%Z[KDP.E='L8Q;%5P4JM#26M(2F=(25E$:F1P*.F+$DR;(*B-R M\VSK36DYO8 ME)L2IH$*[,"2HPYQ*P,R#"PY#B:ZDE8EDKL.K9\E5YSLZ^UDOR^.R!=Y* D& M,XI5=$F(59AN:1BS*/]=.$R)L9@*S^'3CGKAM3 J\J0\ET4973_"WWW1<-TI M)D3P/B#!G4674%;7K(I3O LTSGXHW M5GHK."+1:$!SP",'DND(;6JD"W0<+W6B=C18++5+B$3O#>?*P M,93@V.MTPY#+@MI5H+;1.40:E<\---)8@L251"'+?$0 7\R83<2XXJ=Z!+"U MFAL<,2RS3ESZY"*@U2A,22*8LU7$_A3LK@2[,XEK@5MY2@(Q;BE@US%D6.(( MF-=8&6F2V*VAQ'UDB7$O^H>'<5#5ZCVR1W%P+5O]JH&5]YF"HH@F*29\5)0G MI8RP% <8+NVL'61>\84 M*,=<<2NB-C: ONRTECQ97KSC:X/=F<0E-GJ-&Y*K[BH"M'AE#/EF1##;$ M>[J&$O>1G;"7W)'EF$ACS'-[<"42Y]IS%P5L9<)3\(%Y4H[7[YR$7C=-=L.C MI 831(Q48+)CH".)$XK8>.54()*6X_5' %OIC-$!Z^!(A%T0G)*.^"0,I\9R MAXL"L2[8G2D0.H&MEF-.-0>]GV/0':S)P:A.@@(!NC\3XIC=I=&$5B1N(\ MA((.G&CE;4\>.T$)SHRI6Q40:=5%$DLV%T)=F<2UWO+ M$LA<9)T"B4L\18XQAZ+V+D9#G6%V#27N@\KZN*2^?NM,T]ZEJ\U>K=7 FE4O MFC\=2USO7(#E'4N_U:H]=%0JY&8LDBQE\IQJR)HMT031O,)LJ;\)F&C MA5IOA5J;X:,4*^P(8I*P', 5D/:!H105Q3QW$,^U=8W>X$(49BW,6ICU5S(K MB8$!.(GSC/$4@TZ4:($]"42J%*[(K.<=?854;X-4FPX_*;C'02(7F4/<4($L MC:"T>L6TC-K;<,D16V'5PJJ%56^157%T3"INK$R$)T^,H-@$DC2GBCO*B[ZZ M;M0ZTU>Q @*5RJ(892ZU+A+2R5$44/JB0[90ZSPO\604 MD_'2NDW[KV^AMIKVL66$#VJ$#^HH8SXWY(IMH].;EO)Y#%'/M^W%KU=B=GSZ MZI_VZW:_YXO@OH;@?M_TX0N&_:@O<6_9$%O"L%;\,;":NNHL_@31XD+VA0R"I,D=741)VL]\$6\#Y\ M\-ZVVZL@>+4(;F3JXR!"B@E)P@3HSDF"^.4,1:7 ^E%2.!O647=>4>+@.ION M6]]LIUN5G@:0M(:PPP$[KI3E_66V_*(LANG"O.H/WL&RG V)GOU6&.J:#/6Q M:=TKG0+Q-*% 34)<^%R%# >4$\H2O(856YV.45(*1(1\X]8I[;W$NTLW(!M7KU,JF /O>. 0*L'\=L$\;=;RU93*2 MW)PJMXV, &PC&-*@@7/E%*9.K".P'\$1_P<[&-C>:-CZC?Q>3O<7:1J@8U(= MK0PN<26"-D+YX)QDA,DD;M@V8!N&_\V..M]B':!7F&8IIO%GZOZR@#FE!#FL M LH%"9%)$B,7?5(@19+@J[,-RIG"VB+6IJB94PS, \]#U(8:(F@"N]\ZKGA: M@0I18'M3V#84!"8$#8DC$W.V5S !:<"+G+U5V,[D M++=4PH(YY"Q)B(,R!(IRHKGDIM71$YP86T,Y^PC.ZU_U!R=V$%I'QP._;X>Q M@EF>^6L;YH_!4PC;F.-HF60X\$2QIM*9:)1TWH3H;GBL5YCG1LSSY4R8?3 & M!^41<<$CK@(H#!J8AWN2&]2["-_*H=W#1RQ7S%AO1= B'(J??",Y?/V@G9$'B='/<%M2ON MQ9,DL3X$HISEF O-M50XLEQEDBJJBIR]4\ V#/-H!/>4420998A+RY CF""F M9=(<.Q)4"7A[!(AU =-HHN2!.2Z\-2H"A2MJN5-*TN( 7P?8-LI',"DIIQ%A MH0&V(EFDG8$=2[W"5+%\>K6&G1"M= MDXN_GJGJ&P756@L48*T0Y\PC4'(#BE@3GB3C2JG%64VEE$^IDE;8]2%6]2WL M>GUV;?2:U%@*8G*;R200CSK':E&%+*$"[!6?(C=/GG.ZP>8<015R+>1:R'7M M"_L6@K/$@?Y74^>_]6QKM.MTF"?+HQ 7$40=;G&^ESC M$83:O@:-;!"'HQ9L^=@:GMBC4@MK81@!=4GG4DDD1AYC<%PG9WFP5,:H"5U5 MX$^#:THSBFLHJ@>OFR=86$0I);/(BX 1)\0A'5P.+B":*NTMYJ0$ =U3]/ZV M!'R9$QIC;A@-DJ>(M5?"\R15BE0$OXK.W@7#J\3PS-B,6@8?0P[? SN3,TV1 MM@* K&1F8Q6BL4^>FPTZYYCD0L)( >^:@'<)[,(#*HY="-(+KE)P021EC"!4 MIBC"#Y$#T*4CO'1&Y>BHOHO:?H74;T MFF0PEMQ:I4$ $V:3D5IF)1J3B/UJ,V,+AF^.X9GH]2DPQ8-"46N)N&()A# ' M-%NM?601S*&X5J+WP;NI)F&XDQ#<[FR_ESC<Y.28.F2_*9R M!E_><*X?U*PFMX\B0/EO/(470";'_",7*<6&2X"0;$F7=< M%4VS4&ZAW+O1-&\[F+80[R\EWF:10ADHR<6 66*YOX] SD>#F'5$NV"IH?Z> M:)HER+6,<.U'^*!.#VXWY.\QE/2]@Y"_DIYR3;GYOND:]V"Q",LJOP/CZ,&X62(@Z!4.1CRD'_A&##,4,"0ZK M:KT@(3M:B=XPF-Y<_RT 7C\)? >1?P6ZUX9NPV484C24&HLBPPIQ:P)RA%$4 M=%#>PN\:1]BB*'>>"0#=PC6,2$=@)Q!L0HVRI2PO"2M8FT/8V\.W-6J?#\[=RU$ M^[")]OY'^A6ZO3[=-C1@J;@T.]S@%_AN6OS7,-AIZ)(W">!-*B0B#N>D$D>R"ZI0"UUEIO[F$U2B+80[3H] M^/T/ZRMT>WVZG:F53@47HXZ(4H41:)@6:2$]REU; W4:# EWG]3*RNWZKY%U MW0C?0^?;\_^#+^=8#V4:>DKTA)LZO0#;Z"G*?UDU'/7/A >MX#CK*/S+[_[L MS*SH35G-PMO8M:,86J-^Z^51Y\?I86R=V,' ]D;#ENWEKLBC5O^HH@X[!-@/ M_:#CX/V=7JO='\46KT0T>38[%&F][@U'@^/#.+D$K-Q^:Y +'8;Z@Z/]>+&M M4^NH/ZANTT^MVYVCZH)/.R/85_X*:]9XLBEEP5-,G_'.%O3)\\ED HU7^*I6 MTMDN##*VAOLQYKG-$[H=?3QT<=!B9*.567QS"ND*.QGQ619T>L>V5K"J/]=O M<8-_/3_[]IH?VO#\@XX_*T1"LBD1H:0+ANM G":>46,QR!$5H_F\33'%.#=& MS#_4TN3L^=I4"-1%E7>BS7(@[/;>QKQC8 O_88>=X?M>W\&T? M!ED!DJ1ZA#T8TA_=OO]Z/X5%-_[[[>FG#^$(!*]L__FI^^G@'_C_)=XY" =M M$! ?/[RD'W_L<+@_C/V/@_;!V\ZGPT^I?>#YS@GHU]9XG2MI$!H0#\D@0YA! MA%,G JP(C;*6_[#F,6QEZ8QRD9\:0%\+='L%2P M]^.3,Y3;)%A*-\7J&9;@*V%B#_!0R85AZV@0AS">C(G8[9^TAL>'AW8 UZI! MLV][7^(40D!ZI["U6M_RSLN8^2M^B]T6FP_ZC=;)?L=G6LOTF=FS?SR -WR+ MPU%^P^2R[^ A8"1;K3\Z_7W[+?9:?P]BBL![H?5NW\( *XILO/6/UK@A_;#U M6W61_C%,1QC^OMDZ"\+&Y,-3?>GT)H(8YO[9^"]9^M9+44W).<$-2]*U1\/X M=/+#L] 9'G7MZ=-.KYK8ZD/G!3%<\]E))XSVLXJYB6M[?GP".K[^^.7-ZJ5S M2D/]FC";G,J%+^--LO"URRY+]";C_%J7O?PUIJ]WU9\.]FIS<,53YH5A(>8J M!](^8V6P3M8+(*&"QFFT@V$K KN$2AHUQ=D9W?2F\]0(P;FJ^KK>,YAE[!4J M2#_&B2%FF:TS84;0>^+E$S3OG0\JT6/9:N9;WVRG6XF?!'@>@@D/=H2#K9/5 MN;G1)KQQV+5(-*KL6PS><$IT;E08B/6!*S!)Z!43 MGRX-VIP:E6-S,BOI'SJC_0M6Y/"L&7G6YJPLTNHR#\,9>9#MQX\GNW^^/]F! M,>[LO>WL_/F>[W[X#]B3+^&^[<.//SS]=/AV_[PS18%ARY^7B3FGWODYKH; '26%4RP<.#LD#F MH_7OXX'?M\-+S(D'F1VS!$G9Y$(":M*&86ZQM#@H)E4P3$83>9KKG+]3MIJN M:6&L91CK74/? JDD@N(64>4<,!;!2$N@+14-8]X!87 M/LC>'W>GX/PJCOL3EOZO_G#XNN>[QR&&U[W=T7X8F9X"[JAZ,4"=_?> M\U18XG8TH5]@!A6"N$V"F&E*DGN*'9]4;_0VDWTFY//7@BM>++(B%PL3@F)#*8<)4$4(SPX$B-H M-D9O""K7R%@K[IRBWA0:6)%V<_)9:FI4,J#-2,40#SJB;/&@1!6U4G*;A"L^ MFX=^NO48[+@[47HN3\)]4251ON[-5GKBJBZ$M@2A[38#I)DU.F$LD#&!(^Z" M1[FH)M)12^T)-E9FO49L@/:S1G9:\=JLM5I3T+Y.:)^I+Y0YS10SR+B8"_[1 M"+B7H,THQJV/A&M!GCR7&T28-0+[@W+*S,\0/9>A%GOA9KEIEU7+P9<5S#F? M6[MF62$W;:*Y\NE9$P%PX\J'/!D;-!4A:0]4()V6D3(,4D 1+NIZ7.OCVBIY M)4N+@6:4MN,!LR042MJ"%6NP0D9PBD#ALT:!!J!2>/*<$KX!BL7]J8=XZVA? M\VR^0OJ%]$LJ="'])NG/='\6L)%*>22)!MU?:88TCPH19;!7,BFJW>)4Z$+Z MCZ=J9*N>\8M?QQ&AP];_+$$RRC%FA6!*&LRC(":D8*11SL+&WC3#M_5V;7'Q%N'??L]RGMR/M) M.S>H\/=>M']LT=V]+W"?-R>YVI_07@8ED>$8M$5;).S@> MCCKI])9J^&F^2E=JTK5_ILF95O%(4;Q5% M\:Y1^^U!G=XN6]%M4J'T5NJV-;=3J8I6JJ(]VI)"W%C%7(J"4<$-MUI3B;E0 M-$;OK)4W:T9=O !SO0#O:9M^/&UO_[/?_O''UYV]-]\_'KSJ?*1O3C\=O/FQ M\^,_!SM[']GNAS?LO!>@#7__=/ :MS^\9#M_OH%[ONKL?/C/P:?M_QRVMW=^ M[!SN?&\?>/%I.S0+HHGVGL>??>!))<=0XMH@;D)$.NF(HK1)2ATDMO(>!C&5 MJJG+1D@US2C0[S+Y#Z\="?X8PB14U)13K)2RD0OB'3'P!R,D6&\L)5J"HNXM M27;.D:0.-E)+#%)& 4DJK)%3'B.+-4A%G+RPO&IB(^<>]@JS,M 4E+K=_SX=M+6[03X!$R6M>K< M=LZXR@=9Z;SG\D+CLSN8X/F;Y^>;(3_0A?9OPQ%\JYOO@2(S[PQN\^)3GSOC MFML.;C(IFM?%U?S"CG"\1.=BI7Y%-,-JGMGMB3X=/_G7V MB+#3FUQ=4;C]^CS\!0VH>OBWNQ^W_MK[V/K[WUMO=[9:?__U8N'&6)VV]O[]LO5BM_UN]Z_7VUM[+[=;KUZWM]HO7F_]U7JW!W_8>=G>>W?A M<:X\Z*U!QW9O,M3+CF9:]_/?@MG\":4L>=R^^,7+]N3/26XN?2L?8O M6(0[V(#SU^#UF2Z3MS<\>[D8AQ+]3&=AAOPZOT)!V=;QE,<=[5SN8= M.U$[[7"_E6"_#UOAN.J!>CRL*]C,+@R7.[0^'E?V66L#?>DWQI5,_(;_?Y[==<^V'R EF[K:%P8O'4$1MPR M#W=D3ZM JGS"\M]CN!)\&8#:T3VMT&>[W:GZO$Q0I1=<:\T"(4ESDWR.[+6< M4\RLY,:05015#HX&WY]N1S=JA$A.0O->]0?O;#>^F3S,W_:T>HY'&R>9Q[F[ MMW6Z\V/G9.?@*]UY\YE3;GPB'A&9R_YRJ9$C6" '?\0^*4UK\E^LL%?;6]-][8].AKT M 975AV#/#495E < N(KJJ@R!%GQ@]L;1_J!__&7_ B[Y9BO#?/9>V.CM8]@" MOK6[O=?Z;0#P^1(!;J/?\XY_%=T =LAI!>F-#/2ZD?%1OY,#,7/,B8>MUH*= MTQEUZ\;P [AE-A\MR*GO\*>C>F>U[&'_&+[=3YR\RH\RQLCCA-6,1L9/UDLD> M)I?M[ASNF+UR^6YPP;-JU76[;F^TAC&VVOU1;(DJJH(\&W\[VZTT[Y16WDBM MV4ZZJ$S=&ZU@VB%]=5I!%;MMN_ZX6[F?CG.\/HCDOK.NT^V,3I$-67F"E_+* M9<* 'Z>JP_2CL)Y5\$-_<%19M7"1:0/VV5C/Z+N9.FM%>F,<-I$_!5L!F"#? M9- 9?KUX]Q9',36"0 -./JR@7Z#Y0&J!FC4PB0K4./3S.JF(<]K_RC?R%XV23"Z M_QYW\L(/004&.\2#$&D='(@Z4\^2YWF07Y,3_PN+6J+!#('('$@&V M<>@DX)@*/["=JXU_=M<, 3@^;R9W"OOKT Z^QA%@*!_X=+)2,Z'\\=[/F[!* M3[DRJYW%+!!,;PJW!IM MIW%<_U68>+E\KVBDRP+="2&YIK!01A@22< D!1GI@C/F9=*\SB-JAK6SR'N\ MJM99,)WL?/D<.,&)28*(=11Q:P2R5@5$.(]::.$X3U7._^:B.D]CM6NZA^/Y M-*J?YFW]Q#,T3U^Y+WI.5AQKL3?,/H)^U3K@C-X)!M!)[98;H_$*T*L5'-OZ MHVO]5[0-4A^>;*]_.O-C;.]-S3Q0;$;9.7'8#[%;&VHKTKR(J32O$+/> 8\> M9KZ9IK0>.QHK1CO)^D.O#RPYC?J8L&?-JQNMZ7UAIJ8N1S:^RF;K_\73Z17[ MU0?A8>N'F[+7Q7$VW9YU<.L&?&8XRF/)(:*>P2IVCF)> MY_SF<.QAP LLW0W@YVJ9)A:Q.ZUNDJUD^'%X!"0&,]3*1Z8@ 7ZCOU^N_%WX M3*5(_<9^KV=VNG"5=E9)K-IN#C$>7G6-\P3:5O?X\*@U/#Z<&=G#5O_HJ#^L M%P7^FD,M:B4O*W:;<*')Q'7&5\DWM [>4IT,=T(,U;]Z4F#SVEJ= MFW#(OCVK[^U'VQWM>QAB]C''4QK/Q^A_8KB,-C^+2M=-A*P:VW M>[70/G--=@#"R\>UOEM/7.?PR/J)*)SMD[%A=Q-@S%6A%_E%3B8B? M7BV1ELW/?[W]9/PKBI6*W.6S6XETN=(0GIT-4N+U1GHQI:X78^HZ8]J"$=KP MQ;@^ZN]_57LOOFLA#=1:HJ("AIQV'S(@>:('*%)ZF1\HO[)\XN>N?_] MO0#N%@'W5^BP48>A"-,L;G 0DL2IR11,QUU%(8G M::PCEGHO(_?)"IO*^M["^K:W/E,E./')(44T0UQ;A:RA8&E'R@,F@D@+]K6^ M>-97F/.NF/-L&DZ.$?C2R8K_6'7)>OF%(Z+6;V^SZO-T2?>RMMQI#\J+=HES M9TV*1,A<;1'SZ!0NJ%PY*E^>MK]\)C$Z9A5!PJ7L]7(>Z0@_L22P=]C!%[(* MUL4F1]^Q1+C@/"6LL;5).Q69L5:GLKZWL;Z@KFJ'0:B!?AI(7E_I&;)1!B0D MZ#C.1$)P?/)\3C7K__W]EL+4UL'DWKWF077MS!CWB\E_KD[/[=0U5Y7'JMQU M9RMFS8GU.-F'ZR]R@8QC/,(9.F[$AU2'B%5XR!>8O(D3=.Z1KNW9[FFV+RN? MRP"HOO9+7G (;+:V9T>IH_U!S.ZBWFA_6%65FI]KY*3O#G_A)\D%P/DJM3H^K)X:UF7GUSQT[G]D.M+D1)GLC+#?' MFR45Y#9204Q)!2FI("45Y K_UB(59&Y*QSU,T5@B0OZ/QQ@A_R&V\B/G/,G# MSF@T/OGT.>XI"\V%%D'2J)V_XZ#Z MT)INJ[_S0\S&6#93WDQLY^0SC&"6XC)Z9P$GT1ELL$GJO7K(_=PC7A=')Q%HZ5RX?96J@$F.6(9:#;"Y\R+FS0O#-TE!N.2IYZ0@7"'W8'$U\GL?KW=I M=-QL,RYTM33S$Z^9@%#[M7YYXL%2\?VPP691TY/XQCQ9L!;KE(! \+73#_(< M7CD!X?M1]*,S[KKFR*OI[APV:BC7B1QQ["!<_!A7#%>?7=SF>1YE;EIPR8UZ MYZ36L+]Q:;SY\N'FL_$T/MH,#FV&^E4Z:>]T'$8/FW]0!34NF]!QA_'\,S:X MM?#]UL0TG SXW.3VQV&,V5RLGR]S=B-L\2QC=49U**3-NZ\66" /\J5K>=6S M(%7CN8/[@]LMN'1MQT+5[*7V.P_O[M3YR?.J"IT< FU-!/@E4FA20"I+F\&O*'YU[;6X0O6K.UF::Q:M6M(ON"ZK M4"-B;GV/>YY&"OQX/,QZ .S]0:@X_+32LZM0X#CXEC7NS(F3LZEFT1.@S3$= M9T4LBWGX-4_*QE@FU*UN9NV%LN1T_<&@BC2>TF$^INSD[E>A[ZM)'>L!O2R, M^[TO_3R6VA*JX\W'W;(V#G6MAM'&TWP\PY5].-R9/.#P^A(>HD)>E7'4*5YW@S6X!I@OLG_H6^=%\ M?C17.?&K+3\=P&;K@QT,;*6O#::Y*F>34-[Y_7XWFTZU2)K;*Q8\YAT>&*/ZE&,3H]R.#_(L#/CJ76W0;T3X(ZI,WX(>/"_ M7O^Q^[9UVHD@?&%1OXV7U(,""J)Q=N):ZQKC!(*5^9W7I3;2JRD/U#*R2L<9 MVQ8AJV4SR7-_V:%RK,^>=- _M=W1Z>2)\_Z9/7'> K"_.XVJ,@M%=NU+/>R# MKIBAY;,Z=3PU5^8<[M?8K"5]K?.#JID_7IL*:>$09WZ%86-%YN5O+;Q&YTQ6 M_%GU>S;HW,H.&+ R>,:?GYIG)W%LVS1+<)PIP .C/*AUTW$^5*4JCS.)NK,A M.3##QEGY^5V5/CK3C7-N4^QV4>:'BHE'634=QLHS4L=RC(;CX(IJ=4 N'P^G M0Z_S?(;-T:3C2I>]\$13,JPX)$>C- R^*G+A*-^X-QK/[YCE\FH IV4*@IW= M <(_'CMA9F;UO+7)"N"EZS.GO!:;Z'*+*FF!V9 W)'!69T[VW?'1K+A7)7 J M7Q-(F3,6['G>W9R<,XTKTIYUZ(9D4R)"21<,UX$X33RCQF*2M(K1S'7H+B@ MO0V3UNUG[.VFJI[S5B_\U1G;RNW^:-+18<_'N$>C.:/;M]_?72.6\_; M7SXS;9ECQJ.4P\.YXQAI+RRBG@L>DF)8A//U_*2D4:EDHE.!:UBO0>%'.G MDZ3&/P$(>GN4.7MP')\\?SG'6&TXM,ZF8HY]-S6Y9 (]S4@9?V:2 @@;"LVA MO4MAL8 MYF6P]VNPXI^?%,W(LS M"LY&JQ='JT#=@YNGLL%N:8,]@D:$B_PU<]'VL^>^KTVN;MJ-=NG'7Y,F5C=N MPBA]2DDSYR,S7 9JJ0W.8B>$D\R:<(,F5E5@XGAW]KZ\K?Q@V;H:SG%J/)#& M5%].8 S[NW^^W=_]\/;@T]X;]I&^Y_FSG[9W\,[V/]WVP7OR:?N/P_.-J>": M=/?/E_S3GR_%IS_;W?9V@,_O'\#WKSL_WIRT/[RG[;U_ON[\^2GMS-HKGGR. M1F&FHD)81(9XS/&PC!@4O&5)*J\T)U53*@7_$W4Q>>]Z[15OO?O3-0G[O.@K MA%<([ZQ3UCE&5>+!2Q2$QSD/7&BF+58<)D&;% *H M>=HRX7GB\ZLI%,*[8\(C4\*CPGD&2X#,9QH;BF.G')O!3/:IOP58ZD7%.TJA'?'A,>FA!>H=!C, M581EL(AKRI&5(2%E0'HE@Z,B.%=FV-"<;F!Q,<]S30GO;$/C"^4Y;J-L1[7Q M$G>6@ Y@'!8\-@Y_#UCYT__SG8W?ZC.R>PID;FA]=L)P?.;'_]_FGORP] ^\G.GSNG'P]V M3CY]V.'P^=0^^/*C_>8SP=;E0HA(P9R"4F()LI[ KT(FR:/7/EP(K,$N^>B5 M\3GX1D1CF5:&66PHL]0E=SZP9K8JK=?-X.N?!*G7,4\?M1!?XZ.:W?RMWB#F&Q6]_Z.1&QREOK])H5M6!J\F6J8D_] M.NFMOD)57NK"),Y]KOS*9LYJ.K2G+5!6)G4NXC@*?GX/TFD4X]EHR<;#5]<, M_2J4N3K9RR/J+UJ7*CAM8*NERRTICF*=?0EO.SH>Y#KW5=SW1;&VXABRQU>" MBN"SDU%*4)425*4$U=Q_ZUN"ZJ<2^IQ$)\13; 41(/VY"=HZC8-56">1 U_M M&I:LF@^'UQ=3D1YN5:JM^5'853'(L:3=[W=#E<1]F8)3U>N WWK1SY+9LI;V M9T[=9>KB]:6[U9M _]H./JKB!5>0HR+D^Q._AB>YT?LZRUOVN)O=%Z M^_?K5WNM.AFBBDG/Z2?]X]%P!&^[J #5F63G*Y16BL21!7-YF7HWU[+;SM:[ M:7AE9A5M]B8/,]>J6YM2-K_><*M+V>S\^$IWMC^>YC+Z-$3'(@0%\9H;W!T%$0!$W.ZF+4F16QR.ZG)A%<:[CC9L$IS -43T'6GVV+0]S&& MX2M0P%_DF'\8K.V^'=?,W>V5/7+)'B'M+Y\QR"R;M$ VY P:S .RRAJ4&&P5 M2HT4DCYYSL6<*"V(FI%Q-SZ56,&!OFCS9K1)WL_\Q9^/-DH9R^60P1:O&O*BZ2%59 MN4K:JPLU55G6M^YB>^?!LC[NQMTT%W*/V9VVL_69 8ZB4QYI*BGBGAIDG<\H M ]AI9H(4^KR&&+C5A!D>5!+<>6>BPS*)8+P,P62-\JP[;:_*+!M7PAIGG-6- MX;Z/R_8,FR7),BK/>UT&.:&W?]*;U'JI4ZRJ7+*K)X_]+ ELD4_LI\][.RE? MFFTJ1:Z5\44W*5M]QM=M7O9JB4D_BZJN)[[N''+A)&698Y;U#CYO3\!4G?Q5 M0BE5QS%O@F%5-RJ"^^@.>LYU<6"I[E+?/3]MULQJN M.S=K%PVPC#TAB(U$1JLCP9Q;[@QHK@PKY1G7QB_336:BMTR OW685=7[;BW4 M!_V';TX^'?[3A?>0'9H#!-ZXWM+[&R_/OU(/Z5\P#\]Z,?) M1IJ/#G'D&'$2 W(N:; _O9,R166,?/)1;]X\/*QG4LB9I^"F9/JOK3VD*I_]VH"EJJ[+FA,A'"0/Y$3 M8QS%TC'/)-8N&J**@O!+Z;#34! \5HQ8K)&23B%N-$8ZBH $XQX+FH2U'.A0 MK$A!F+/1'Z(.< L;ON@ -]WT,QW .ZRC]@0Y'@SBCDG0BF'3*YJ8H2'AE&BE M Y@;YS;-9_8'*^;OH2"KVQQ051XU0%YIS/7F&>$YTR7&Z*EO^LRC(5BG'[Z$:LXP<3T0[$96FG&O.)+5X9%XXRY6G47#)C"5< M*&NYT#:1Y$21X[^4TIH'[XE*QP(E2%/O$4]"(\T]&.56:(Z= ?-1%GM\63E^ M"QN^R/&;;OJ9'"?:1F6L1LG%W+B7!>0HJ3J'JT@ICD&92HX7>[S8XS\KT_&0 M\A!F6>"YN=GI. 5^W!RS:N13)_/TO_1RKGO.$%O0PD=Z=MI*!=3"_;/AY,&B_ESK3#5NSE[HV+NYULS/IMYN8^LX:*W7YNE;ML M:_;D L>6*NR-XT$Q4/J#-U(G'5DTE%TY)VG"\+,6CW_:3N\O&%0S%>GQ)B#M M['WD[3>?=6*6.$>1%U8@;DU$EN0X02FT _W$$5]5 -J\R-33I*.\%9998ZF5 M! &!6=2)8T.,D2EY+GPT("L8SFM,S'B-Y]2/*FM\Y37V)SM;G[W7CDJE$&,6 M(QZ( 8O:8Z1\M)@:IVCT3YXKNBD7KO%&(VVL>[K1JEIXS4U7O5;?TG.L,Y]T MB%[(-;EYZ])4HPPEV'DN06WD'BX?%(Y.8HN#QI'):AOJR3;4\[9A[E@&/UVA MGEG9JC_9J@<>[VY[!KHH:_\ ?73KLV6!N&0T"M8QQ+FGR C0)Y,TADBO8S(\ MU^R80TVU$CE-BESI9GV$69+GVWJG:4$11+P&X&L4DKO\YC!MO>%[9S\EEC9F.0 6D9%.(Z M&&3 GD;$),>E9<*8!&::WB0_ =AO=MH[]-YM@A?UP!_Q7OB:=03J/:R %R@9 M#'H@H119ZG,/1R6XHLR0!#J"V5Q4 K*I"]HS;17OW8YH]WN^;(H?[:W/CAH> M&.5(21H0=\HB'8U +FJ=/ M>"YH[7OQ, O\^KF17-18/D_:Q$X'XJXOGS!=^ MC1*(EW:BOPO!?(6^SP]8+1G7:+"A=9C;0 ]:E9>V9\^F55 :>G1K:SCL MPQ)6'/-;KLU#\;/7[[:WJA_),]B17P9QK.G!7CSJ6IC*JO9/+N,PMS#?N7(9 MXZ[Q1X/^M]P5.A?MRQNGV\IE2W.!EE'6BBJO3G7=-*">5,F;Z:-V6*E8 M(29[W!WE"H 3C\VXT$1^5WZ6V3-LMM[G@F+Y%?CP[-&F!2Y 21O&$>JGU*H< MA,-9G:,A,.+9MO0.AAZ[=9_J[*L:]>&N*3>EKBI&SI^<9D?>>9KU(]NN7V(O MEV#)/C[8N/%[],=5S:?6BT$,G5'KW?%1+AW2VNKUXO?I#GWQ;K9!CRE6BQL;%PYS9C52AF$*M2 ME\.Z&3?LRZE'TGH?CZK?&L5E8JV$OQ# M>/I!)5LGC=#A0>LB%R!TQ]=K +(YG.8MQV,:3DK9U-MU_*0 .-C?U20<]GOQ M=/S8>3 PQMI$:8D#Z:UUO/439;3IYFE47@P]716J^$_E82.G&!"B79T04+R16_K;L;]5M7YL*C*:>?'CMC= M^JQ]5$H(C+ *#/$D*9A.U*&D-.:"& D&2U6\:[&/=5K/N,EX@_@M4U*W8I*, MHUP%;F##>0K?&*LCV1TS]9"NG9)=;9UQU\S;'MJE [D"0UV*Q="I*;LJ])VO MU'>@LM0R %9H$ 'TO8JPSZ\HO'I^Y7()[M'LDI.JE><_:4Z:U8_[7N1;H.!V\N5D.,UQA.)GI MJ[+E(+!'DS/=R8R\[OG-J=8V_N-41*:6692TM&4L%6]?S/8ZXR^9,^=*VV\P M4?.G.G)E 8S)Y#R=C8Y!18-KCJM"K6OK"1)396'ZC$?.C3?1:,-L<";[X4RH MPK-D&IZ]#AF=*R2[4U79KXAJ=\H?@X_5FXPO?,3T]>UD[]T78FR4W 0$*H4% M^B(.6:PMTM)I9J@$7EROCT(K=BV$__5E/?[[_/.-TL44G2UO/L%HLH)^B< MKT!;:BFE)O^$_5',::]$/0-[M'=J.SG^!VP/C%/"0*?89AIQOGCB5YE=UCX2987V<2[XL&8?T&?7C5 \ MPG9JI&ZG5K=3NS#INIW:Q3^;VT[MRO9HYYIE>.8%SVV-*+$<$ZJQ8=$%G9+" M1C*R@%TWP7F_WUT4[9F8%+F;1]G7L](MQHI'SBKO3K32.'8;5)D)4X5UN\B9 M#OGXQ*@S/'N P4[[J$[=:I,.(#E64 6+\FBAG5N0Q1R<)@O(DRTK#*(=(9==9Y+U/( M\G3OY(L-SB5F.:+)E#$IA9R(8/4F'61@@5+%P):_K*_ANL='N161&FVY%)CC MW-;5!R6#%%XG(FA8-8^IWM1%F\KR@5&J?3#&(V9-R@X:CBP#DUMH"0+**^6X MV7K.\+9>OJOC)/]:#/W*4P +Y-"9H_KSAWC+5K(S7;1[_NQ^?MR9C.%);[IU MC_%@SB5.R5I/N9;"VA!\=$Z21$GBJW<9K8_07L6\WU@S%S4W@44O491!()ZC MMBY%A@(-.I]Y839!.T2&C&*P]]U)2!Z1!%SC>IZ0Q M21L?FZ;C'MEGBY.,5=VQ1K[.6"RF8W?_VKWSC,,8^9D?%;'K0I.\#G8CJQ.AJ5Z?$PU[:I3J//@90=GP,;'SLLZ>D# M"#T@FMS1W<,_G]A\X"N5HY0-5O^8$/ '&">?)2NF"_RV'U,$3284'ZK,EIUI M1MZTV7+IPBU-.N 18(R=XWZ[,V<1SLUNCIDFCYA&S:O]:TP,R#(N/CDY>4ED MVP+J& MK:T]OO_NB\/:N8@Y\ICE#N\^(),8_)-% [:FTXZ (43HX@CWH#I5':9Z/T[%> O4>V3/9/2-CLM6U=<.JP78IQ32)58)?2^ M CH^R70YSMPYB[JS<[C#V2G4RFV=!?JD*W;^M,J MH.*R-O]P7 R2*,HE=+R MH-I1+Y\J@91AS, M2>0X\XC3Q%7D,A''2DOGRG3[I95O0$FQ!Y5\/Z-KC*GVC+I[3JV8ZF*+? 9+ M*S3_*N7IK!>Z?724#QFU;:=1'7'-RE3*' 4$:-Q21I%>-B)^E9W]<'$#IAU(G[:9&A M-I@XQ':['R:>E_WT>N+C!LNMU%L KULPJ;\Z/?_ML2D57P]^@AUGK5-.\X"2 M%P'QP"RR7@F$.5C0AB='C3N?\D*8T8P)X37A7$GN")4Q26VCLX'[M%4 ?]KC M3"_]4=S0!)@LGLM2S(/*"U(,2@;)=8BO"!8R#/Y8 M<,IZFHYH^P?M+AIG9Y)YI7>UBN9JS/,ZRXW5YGOMX$)].?GD6VH/C MCCU]VNZ6>U+>=+Y^-XPY2WC M)DN_NVQ8O2V-N-:HEW_'=#W7Z\WULE%S-4?.5AIVW&7E7/HR)15M+RQ8/ZE+ MCXOJJ@NU[8FX<.V"&O95%NS]%+&_H"R4S/;Z(JJ5 GX>V2XKZ-_OG9QOWO&@ MWO_%/ 1/%8B,P"_.(/!NA<"@/I2*TZ*N/>?HB=";T--MR1O]+:K+]E$AIT9)P_UVRPI,:LOZ0U6HU[RN277ZW3LNN3E M.C'=4SN31:]VVM2E;N;@SS:3;4Y';/55U1)_>1E>>5?:E'N,&8]Q2']^J,1K; M;"*M&O!E3:M,RINYIG(IQQPSWME_L3O)-24^_?SKVQY]W?[T[W^^[;?"U_,]]?9^?J--N@OW?(1W>_^U M^0;N_?<5_M3J?-U[\^XGW ?7OQ--VCS;&U=&&@CF DGK N+,6^025XA((@WC M7&EBMY[S!I87*TS>2V_PA8!@98QAKMC[B M+X%X&S@EB'!!$!?:@2YF%?*,>ZF$I67C+-W F#U\''L 2/3Q[,FU/Y_DN.\? MYXXK77J>[]9=7YON5GBQ))R_H%'BXVI$_^37VN!+#K+-?,F+#K(UX[ &\'4 M?+XY/=:,4>P$,B"S$<>LP83ZD'+Z-JP^AWCM=.D@OCC.'8'\<\G55AV>=K'92"^JF]PXT!\#0QW MFB>+J20AYGI.PCJ,)>,V11\K#\NH[299VUFDN35(J<4V*43\1H3N"? M(2JZ@@U5*UWWSM0S8\H0+1A+"B50F1$WU"+-B$2>IB@2EX%;O?7<-(2\6'=T M=86KYNC-Y6AOF07H)H$'P54$>I"6<.R$LR&"&EZ;40^!H\^:458D25,P2":. M$<=$Y&)?#.&49,3&P-O)@F3F^*6G<]1AWE]:^,:1]QT8QA85U3YJ]XX\\6[B$52"04J&>+<(($Z(/O;LCN\HJ6<,)<4YJ1L%16\PHH[(BUF=Y1>4;/[+V+WTRF[,ZF9 MLM$A)CFP.W4<&9,D\H&3F'MX,LFVGG/3X(K6_/ZP^'T=SZ&SN?4IHSP9R;4* M%E[:V]P3)E$J-;ECSV'-^;^&\R<9E,V?'TESYPNG2COE+8H\=_T!10YI%PB* MT01':9("RS+]2LB+)WGJ'(TZ1V-#O ]UCL:*,$]QXI8J"AJ^Y(1KQYA1*:9@ M#?&@Z]T@1Z.&\%\!X:_F;342E#!:.F1MS.@Y'N>;2);SVG#5#;'W1$N.;YI;WXJ-54$RUBC#Q9KBFA M*E LK)5@LZ^5+E\S]OTR]CF3C#BOL<0*3#*50*93AYSV&ND074Q11F=;+'-'.4*UIL%2S)"SUFH@Z\OUPM:]W9R+?/%%/K$71B8C >@X(%.S<<)D) M[XBE(I4-EQM,7M#1IY+%G("2^PU\#YI&'438XJUTR_L4)>.62":,<21BQNR:U=]^QGXOV,%AS>7WS>7GO"M,,\!Q[)'P'B,. MT(Y]/IBX8=8@ M/0-_YNC:1?,0QKA=%\VV$IM-K['3#B][142^TAZDDHI1J(K Q3-*MYZ*A\;*6\0](B7M<1MM:!4Q4C%I)(@D67$:A M2118XABL2T$0>FIK7?P6OSYPS03L=",$H)RLBSI-'AO" F,%.8NU4M"Z7 M*FJ(!.V$4HI)*6[).5,S]B]@['/^ M&*6#QS(?+R2<(AZ30UISA@*WF#/#C#.Z]L<\5'_,GV43].?CKNOCW6O"U?VV MK_Z=^;S='96%,<[T91^O&,K+\Y3HR9JUNP$>]13E3VY[??15ZT,GN#4_ZXKM M/?.""V. 3BT'6T)CPZ(+.B6%C00\6G(?848S)H37A',EN2-4QB2UC C# NV>?3EOL,](3IX0AQ30/=@4/2\'_7[,**+PY,8 MNP6 ,"ML-^1?Y':Q,R@LW#$8=-PG8ZA2V[*,* @T$/Z"^_QTE[>+APA)5?NYQK/Q=H"7 !/+ALQ7AHX85= M?I]^[$0PN4/5G3':?C>_]_8" K[P23%EBI(%RA_5![GK^(4O)[0\ICC!@22/ M>X-V63>F:D#[/3X;=X>OQ.C<7>-NQ'AVBW6#7F[#M\U4!*_$5830 MLXLQ_S//M^26Q)TE ?C,@;X?N04+/T@=.$M!"PKZ/C=;DYL.^S,H.8C( :I] M0S;!*SZUG1-[.MCZ\\Q* #U.IJ0HS'ES5NQ"4:%RQ=[O?]KYI_6I>/OWSON] MG>+M/R^64M.F3+FYWWKUH6CM%ZV_7Q4O]IL?]O_9?;G3>O6R>+W;W&F^V-WY MI_C0@@_V7C5;'Y9PS@J3WNF#9+K)5"\KV50\S#_7PZ%E,G?);B%-O%_YQ13,XE@R2;$E@:H*,:#G:HT\0S:BPF2:L8S4(OXEF[8K<+ MUL.P5)%VP:!P0[ D]FS_6RRUHU?_'8%!\2&"# 7,KLR,2JRW^C:K0#N#01P. M7K8''O2Q43^V8&Y_=7K^VSU;'/L?)A;'-]%\\[G3?/D:QOQ/>Z_UCH*ET?[\ M]>/II]9[>-:[$[COY_Z;=Q2LAT[\^_WIYW_#L:-<[K>^X<]'8)G ,\$R^=%\ M^>ED[\U_CIJM_X#U\8XV7_X%<]R#9W].S9\[9._=%Q4D-3ZW'53,H*PS(><( M1E[X"&+!1B%493^"$(YA)QM]E HO*$L23$C81*4)29((SSEUWF"[540PXXXS M6?9'P.,[WVV[DSY;0%[')0AWQZMF??5OC MN.=2ZN1LSE]RVGBPF 7UDF*IN)[:WG=%\'FMY@AZLIBO>_V\E*W\^V,FXN:[ M+XQR[[T5R*E<9(?H@'1T @EI%&':&*[B>:*\G*C.F$>4;HO;MX]65.5VBL'H MZ"BK[:#9]T;]PI[AID'FIM*(&,RX::I\V^%\W*L]* :'O9,NJ.%96P?5'89\ M&7T\@_\/7@S^>+F50F.H!Z'YCY3F'!\>? M#'O'3ZME+(%ZIF7#3/O9P.^ E1&?3GYY-HFSM[OEHI0WG;?L8KO\ZIQ/H_J.F6UFU-*O\399^MUEPQ*]S3B_UK"7?\?T]4;]O2:[ MVH9=$>Y>(\Q^B<^IL@(VIT3JUO,7O<'R2/;O__IS3K?L;ENES.OONA2O,_S_ M;PG_3\@?Z^1X;:23=?%+[BR69*LD)%72)\NF[+L>]#KM4$SF>PV:6"5?YR$\ M\I82VC:#:!9[YC_ 73#83O%7NY>=D]WB;3^F6+I>/QS:?KP &^N\_&_6JGS1 M&_XN\5"%M91>N63 CK LY/PF(K@63J2(.?^R>^.$IO-&VSF3[J@'ZP;2*HOM MO^R@O3EQT&L:=.,X*,RIM2=@S!][7W=/][Z^PY]:K_A>"XRW-\UO>__N\;V? M!Z=[;]Y_.Q\';;[\*/9^=N!9KT[SO?OM$W_WX]//@Y_[+ MW9//;]ZGO?E.3!;S%#VV2*J@$>>1(R.H0TEC"V0-VTC2UG-"10-^^_TJ,-80 M54/4G4"4]Z.C42>'_-[T>X/!V>2.OR(\)K;LCQJWUL.M6;,I)S1LKH_(F* 0 MI\(BG;Q$3-' C9"8,;7U7)L&51=+1]:P5<-6#5LE;,T@ZRR U<, ^G3.!(XM,12Y0P/E0ML4$L)I[1!/ECD6I*''+3> )L]R# M9G&]_..5N?47)2=?R[];(W*-R!N&R+7%?Q

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�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�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ã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�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end

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